{"idB": "908259_14_item1_p1_s1", "idA": "908259_13_item1_p0_s3", "sentA": "Vascular disruption leads to tumor hypoxia, which refers to the process of starving the tumor of vitally necessary oxygen supply and subsequent tumor cell death.", "sentB": "This deprivation, also known as tumor hypoxia, results in rapid downstream tumor cell death.", "type": 2, "words": ["<tag1>", "Vascular", "disruption", "leads", "to", "tumor", "hypoxia,", "which", "refers", "to", "the", "process", "of", "starving", "the", "tumor", "of", "vitally", "necessary", "oxygen", "supply", "and", "subsequent", "tumor", "cell", "death.", "<tag2>", "This", "deprivation,", "also", "known", "as", "tumor", "hypoxia,", "results", "in", "rapid", "downstream", "tumor", "cell", "death.", "<tag3>"], "wordsA": ["Vascular", "disruption", "leads", "to", "tumor", "hypoxia,", "which", "refers", "to", "the", "process", "of", "starving", "the", "tumor", "of", "vitally", "necessary", "oxygen", "supply", "and", "subsequent", "tumor", "cell", "death."], "wordsB": ["This", "deprivation,", "also", "known", "as", "tumor", "hypoxia,", "results", "in", "rapid", "downstream", "tumor", "cell", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p1_s0", "idA": "908259_13_item1_p0_s4", "sentA": "More specifically, ZYBRESTAT selectively targets the existing abnormal and largely immature vasculature found in most solid tumors and causes endothelial cells that make up the walls of the blood vessels in that vasculature to lose their normally flat shape and to become round, thus blocking the flow of blood to the tumor.", "sentB": "ZYBRESTAT Development Program Our lead compound, ZYBRESTAT , is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in most solid tumors and causes them to swell, obstructing the flow of blood and starving the tumor of vital nutrients including oxygen.", "type": 2, "words": ["<tag1>", "More", "specifically,", "ZYBRESTAT", "selectively", "targets", "the", "existing", "abnormal", "and", "largely", "immature", "vasculature", "found", "in", "most", "solid", "tumors", "and", "causes", "endothelial", "cells", "that", "make", "up", "the", "walls", "of", "the", "blood", "vessels", "in", "that", "vasculature", "to", "lose", "their", "normally", "flat", "shape", "and", "to", "become", "round,", "thus", "blocking", "the", "flow", "of", "blood", "to", "the", "tumor.", "<tag2>", "ZYBRESTAT", "Development", "Program", "Our", "lead", "compound,", "ZYBRESTAT", ",", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen.", "<tag3>"], "wordsA": ["More", "specifically,", "ZYBRESTAT", "selectively", "targets", "the", "existing", "abnormal", "and", "largely", "immature", "vasculature", "found", "in", "most", "solid", "tumors", "and", "causes", "endothelial", "cells", "that", "make", "up", "the", "walls", "of", "the", "blood", "vessels", "in", "that", "vasculature", "to", "lose", "their", "normally", "flat", "shape", "and", "to", "become", "round,", "thus", "blocking", "the", "flow", "of", "blood", "to", "the", "tumor."], "wordsB": ["ZYBRESTAT", "Development", "Program", "Our", "lead", "compound,", "ZYBRESTAT", ",", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p26_s1", "idA": "908259_13_item1_p104_s0", "sentA": "COMPETITION The industry in which we are engaged is characterized by rapidly evolving technology and intense competition.", "sentB": "AML is characterized by the rapid growth of abnormal white blood cells that pollute bone marrow and interfere with the production of normal blood cells.", "type": 2, "words": ["<tag1>", "COMPETITION", "The", "industry", "in", "which", "we", "are", "engaged", "is", "characterized", "by", "rapidly", "evolving", "technology", "and", "intense", "competition.", "<tag2>", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells.", "<tag3>"], "wordsA": ["COMPETITION", "The", "industry", "in", "which", "we", "are", "engaged", "is", "characterized", "by", "rapidly", "evolving", "technology", "and", "intense", "competition."], "wordsB": ["AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p23_s2", "idA": "908259_13_item1_p105_s0", "sentA": "We are aware of a limited number of companies involved in the development of VDAs.", "sentB": "In addition to pursuing development of ZYBRESTAT , we are also pursuing the development of a second product candidate, OXi4503, a novel second-generation, dual-mechanism VDA, which not only has been shown to reduce tumor blood flow but which also forms an antiproliferative metabolite.", "type": 2, "words": ["<tag1>", "We", "are", "aware", "of", "a", "limited", "number", "of", "companies", "involved", "in", "the", "development", "of", "VDAs.", "<tag2>", "In", "addition", "to", "pursuing", "development", "of", "ZYBRESTAT", ",", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel", "second-generation,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "an", "antiproliferative", "metabolite.", "<tag3>"], "wordsA": ["We", "are", "aware", "of", "a", "limited", "number", "of", "companies", "involved", "in", "the", "development", "of", "VDAs."], "wordsB": ["In", "addition", "to", "pursuing", "development", "of", "ZYBRESTAT", ",", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel", "second-generation,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "an", "antiproliferative", "metabolite."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p102_s1", "idA": "908259_13_item1_p105_s1", "sentA": "Such companies include Bionomics, Epicept, Nereus and MediciNova, all of which have VDAs that we believe are at an earlier or similar stage of clinical development than our lead drug candidate, ZYBRESTAT.", "sentB": "Such companies include Bionomics, Epicept, and MediciNova, all of which have VDAs that we believe are at an earlier or similar stage of clinical development than our lead drug candidate, ZYBRESTAT .", "type": 2, "words": ["<tag1>", "Such", "companies", "include", "Bionomics,", "Epicept,", "Nereus", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "ZYBRESTAT.", "<tag2>", "Such", "companies", "include", "Bionomics,", "Epicept,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "ZYBRESTAT", ".", "<tag3>"], "wordsA": ["Such", "companies", "include", "Bionomics,", "Epicept,", "Nereus", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "ZYBRESTAT."], "wordsB": ["Such", "companies", "include", "Bionomics,", "Epicept,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "ZYBRESTAT", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p102_s5", "idA": "908259_13_item1_p106_s3", "sentA": "We rely on outsourcing much of our research, development, preclinical testing and clinical trial activity, although we maintain managerial and quality control over our clinical trials.", "sentB": "We rely on outsourcing for much of our research, development, preclinical testing and clinical trial activity, although we maintain managerial and quality control over our clinical trials.", "type": 2, "words": ["<tag1>", "We", "rely", "on", "outsourcing", "much", "of", "our", "research,", "development,", "preclinical", "testing", "and", "clinical", "trial", "activity,", "although", "we", "maintain", "managerial", "and", "quality", "control", "over", "our", "clinical", "trials.", "<tag2>", "We", "rely", "on", "outsourcing", "for", "much", "of", "our", "research,", "development,", "preclinical", "testing", "and", "clinical", "trial", "activity,", "although", "we", "maintain", "managerial", "and", "quality", "control", "over", "our", "clinical", "trials.", "<tag3>"], "wordsA": ["We", "rely", "on", "outsourcing", "much", "of", "our", "research,", "development,", "preclinical", "testing", "and", "clinical", "trial", "activity,", "although", "we", "maintain", "managerial", "and", "quality", "control", "over", "our", "clinical", "trials."], "wordsB": ["We", "rely", "on", "outsourcing", "for", "much", "of", "our", "research,", "development,", "preclinical", "testing", "and", "clinical", "trial", "activity,", "although", "we", "maintain", "managerial", "and", "quality", "control", "over", "our", "clinical", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p102_s6", "idA": "908259_13_item1_p106_s4", "sentA": "As of March 1, 2013, we had a total of seven full-time employees and approximately three employees working on a part-time basis.", "sentB": "As of March 17, 2014, we had a total of nine full-time employees and one employee working on a part-time basis.", "type": 2, "words": ["<tag1>", "As", "of", "March", "1,", "2013,", "we", "had", "a", "total", "of", "seven", "full-time", "employees", "and", "approximately", "three", "employees", "working", "on", "a", "part-time", "basis.", "<tag2>", "As", "of", "March", "17,", "2014,", "we", "had", "a", "total", "of", "nine", "full-time", "employees", "and", "one", "employee", "working", "on", "a", "part-time", "basis.", "<tag3>"], "wordsA": ["As", "of", "March", "1,", "2013,", "we", "had", "a", "total", "of", "seven", "full-time", "employees", "and", "approximately", "three", "employees", "working", "on", "a", "part-time", "basis."], "wordsB": ["As", "of", "March", "17,", "2014,", "we", "had", "a", "total", "of", "nine", "full-time", "employees", "and", "one", "employee", "working", "on", "a", "part-time", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p2_s0", "idA": "908259_13_item1_p14_s0", "sentA": "Ovarian cancer is the fifth leading cause of cancer-related death among women in the United States.", "sentB": "Ovarian Cancer Ovarian cancer affects approximately 22,000 women in the U.S. each year.", "type": 2, "words": ["<tag1>", "Ovarian", "cancer", "is", "the", "fifth", "leading", "cause", "of", "cancer-related", "death", "among", "women", "in", "the", "United", "States.", "<tag2>", "Ovarian", "Cancer", "Ovarian", "cancer", "affects", "approximately", "22,000", "women", "in", "the", "U.S.", "each", "year.", "<tag3>"], "wordsA": ["Ovarian", "cancer", "is", "the", "fifth", "leading", "cause", "of", "cancer-related", "death", "among", "women", "in", "the", "United", "States."], "wordsB": ["Ovarian", "Cancer", "Ovarian", "cancer", "affects", "approximately", "22,000", "women", "in", "the", "U.S.", "each", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s1", "idA": "908259_13_item1_p16_s2", "sentA": "We believe that combining vascular targeting agents without cytotoxic chemotherapy may be a clinically active yet potentially better tolerated alternative for the treatment of certain advanced ovarian cancer patients.", "sentB": "We believe that using ZYBRESTAT in combination with VOTRIENT (pazopanib) may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "combining", "vascular", "targeting", "agents", "without", "cytotoxic", "chemotherapy", "may", "be", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "certain", "advanced", "ovarian", "cancer", "patients.", "<tag2>", "We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "believe", "that", "combining", "vascular", "targeting", "agents", "without", "cytotoxic", "chemotherapy", "may", "be", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "certain", "advanced", "ovarian", "cancer", "patients."], "wordsB": ["We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p5_s1", "idA": "908259_13_item1_p16_s2", "sentA": "We believe that combining vascular targeting agents without cytotoxic chemotherapy may be a clinically active yet potentially better tolerated alternative for the treatment of certain advanced ovarian cancer patients.", "sentB": "We believe that using ZYBRESTAT in combination with AVASTIN (bevacizumab) may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "combining", "vascular", "targeting", "agents", "without", "cytotoxic", "chemotherapy", "may", "be", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "certain", "advanced", "ovarian", "cancer", "patients.", "<tag2>", "We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "believe", "that", "combining", "vascular", "targeting", "agents", "without", "cytotoxic", "chemotherapy", "may", "be", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "certain", "advanced", "ovarian", "cancer", "patients."], "wordsB": ["We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s0", "idA": "908259_13_item1_p16_s5", "sentA": "We also may have an opportunity to begin a clinical trial in advanced or persistent ovarian cancer with ZYBRESTAT in combination with pazopanib, a small molecule tyrosine kinase inhibitor also targeting VEGF, which is approved for the treatment of renal cell cancer and soft tissue sarcoma and is marketed by GlaxoSmithKline under the name VOTRIENT .", "sentB": "ZYBRESTAT in combination with VOTRIENT (pazopanib) GlaxoSmithKline (GSK) s VOTRIENT (pazopanib) is an anti-angiogenic oral tyrosine kinase inhibitor that is currently FDA-approved for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS), with compelling early clinical data in the treatment of relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "also", "may", "have", "an", "opportunity", "to", "begin", "a", "clinical", "trial", "in", "advanced", "or", "persistent", "ovarian", "cancer", "with", "ZYBRESTAT", "in", "combination", "with", "pazopanib,", "a", "small", "molecule", "tyrosine", "kinase", "inhibitor", "also", "targeting", "VEGF,", "which", "is", "approved", "for", "the", "treatment", "of", "renal", "cell", "cancer", "and", "soft", "tissue", "sarcoma", "and", "is", "marketed", "by", "GlaxoSmithKline", "under", "the", "name", "VOTRIENT", ".", "<tag2>", "ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "also", "may", "have", "an", "opportunity", "to", "begin", "a", "clinical", "trial", "in", "advanced", "or", "persistent", "ovarian", "cancer", "with", "ZYBRESTAT", "in", "combination", "with", "pazopanib,", "a", "small", "molecule", "tyrosine", "kinase", "inhibitor", "also", "targeting", "VEGF,", "which", "is", "approved", "for", "the", "treatment", "of", "renal", "cell", "cancer", "and", "soft", "tissue", "sarcoma", "and", "is", "marketed", "by", "GlaxoSmithKline", "under", "the", "name", "VOTRIENT", "."], "wordsB": ["ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p11_s2", "idA": "908259_13_item1_p16_s7", "sentA": "We also hope to begin a clinical trial in recurrent ovarian cancer, subject to funding, with ZYBRESTAT in combination with paclitaxel.", "sentB": "However, pursuit of this study is dependent upon strategic decisions regarding our future course in ovarian cancer, including planning for potential Phase 3 pivotal studies in combination with Avastin, as well as external support, availability of additional resources and overall corporate priorities.", "type": 2, "words": ["<tag1>", "We", "also", "hope", "to", "begin", "a", "clinical", "trial", "in", "recurrent", "ovarian", "cancer,", "subject", "to", "funding,", "with", "ZYBRESTAT", "in", "combination", "with", "paclitaxel.", "<tag2>", "However,", "pursuit", "of", "this", "study", "is", "dependent", "upon", "strategic", "decisions", "regarding", "our", "future", "course", "in", "ovarian", "cancer,", "including", "planning", "for", "potential", "Phase", "3", "pivotal", "studies", "in", "combination", "with", "Avastin,", "as", "well", "as", "external", "support,", "availability", "of", "additional", "resources", "and", "overall", "corporate", "priorities.", "<tag3>"], "wordsA": ["We", "also", "hope", "to", "begin", "a", "clinical", "trial", "in", "recurrent", "ovarian", "cancer,", "subject", "to", "funding,", "with", "ZYBRESTAT", "in", "combination", "with", "paclitaxel."], "wordsB": ["However,", "pursuit", "of", "this", "study", "is", "dependent", "upon", "strategic", "decisions", "regarding", "our", "future", "course", "in", "ovarian", "cancer,", "including", "planning", "for", "potential", "Phase", "3", "pivotal", "studies", "in", "combination", "with", "Avastin,", "as", "well", "as", "external", "support,", "availability", "of", "additional", "resources", "and", "overall", "corporate", "priorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p14_s3", "idA": "908259_13_item1_p16_s8", "sentA": "We believe that studying ZYBRESTAT in combination with platinum or paclitaxel-based chemotherapy is another potential path forward, since chemotherapy is the current standard of care in this indication.", "sentB": "We believe these trials would be prohibitively expensive for such a rare indication.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "studying", "ZYBRESTAT", "in", "combination", "with", "platinum", "or", "paclitaxel-based", "chemotherapy", "is", "another", "potential", "path", "forward,", "since", "chemotherapy", "is", "the", "current", "standard", "of", "care", "in", "this", "indication.", "<tag2>", "We", "believe", "these", "trials", "would", "be", "prohibitively", "expensive", "for", "such", "a", "rare", "indication.", "<tag3>"], "wordsA": ["We", "believe", "that", "studying", "ZYBRESTAT", "in", "combination", "with", "platinum", "or", "paclitaxel-based", "chemotherapy", "is", "another", "potential", "path", "forward,", "since", "chemotherapy", "is", "the", "current", "standard", "of", "care", "in", "this", "indication."], "wordsB": ["We", "believe", "these", "trials", "would", "be", "prohibitively", "expensive", "for", "such", "a", "rare", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s2", "idA": "908259_13_item1_p17_s0", "sentA": "Patients are treated until disease progression or adverse effects prohibit further therapy.", "sentB": "Patients in both arms were treated until disease progression or adverse effects prohibited further therapy.", "type": 2, "words": ["<tag1>", "Patients", "are", "treated", "until", "disease", "progression", "or", "adverse", "effects", "prohibit", "further", "therapy.", "<tag2>", "Patients", "in", "both", "arms", "were", "treated", "until", "disease", "progression", "or", "adverse", "effects", "prohibited", "further", "therapy.", "<tag3>"], "wordsA": ["Patients", "are", "treated", "until", "disease", "progression", "or", "adverse", "effects", "prohibit", "further", "therapy."], "wordsB": ["Patients", "in", "both", "arms", "were", "treated", "until", "disease", "progression", "or", "adverse", "effects", "prohibited", "further", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p6_s0", "idA": "908259_13_item1_p18_s0", "sentA": "The primary endpoint of the Phase 2 trial is progression-free survival.", "sentB": "The topline results indicated a statistically significant increase in progression-free survival, the primary endpoint of the trial, with a p-value of less than 0.05.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "Phase", "2", "trial", "is", "progression-free", "survival.", "<tag2>", "The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "Phase", "2", "trial", "is", "progression-free", "survival."], "wordsB": ["The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s11", "idA": "908259_13_item1_p18_s0", "sentA": "The primary endpoint of the Phase 2 trial is progression-free survival.", "sentB": "After the tolerability review, it was confirmed that the trial would continue to its pre-specified endpoint, which is based on progression-free survival.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "Phase", "2", "trial", "is", "progression-free", "survival.", "<tag2>", "After", "the", "tolerability", "review,", "it", "was", "confirmed", "that", "the", "trial", "would", "continue", "to", "its", "pre-specified", "endpoint,", "which", "is", "based", "on", "progression-free", "survival.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "Phase", "2", "trial", "is", "progression-free", "survival."], "wordsB": ["After", "the", "tolerability", "review,", "it", "was", "confirmed", "that", "the", "trial", "would", "continue", "to", "its", "pre-specified", "endpoint,", "which", "is", "based", "on", "progression-free", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s4", "idA": "908259_13_item1_p18_s2", "sentA": "If this trial is completed and is clinically successful in terms of slowing tumor progression, we believe that this combination of vascular targeting agents, without the use of cytotoxic chemotherapy agents and their often significant side effects could provide a potentially better tolerated alternative for the treatment of recurrent ovarian cancer patients.", "sentB": "We believe that this combination of vascular targeting agents, without the use of cytotoxic chemotherapy agents and their often significant side effects could provide a potentially better tolerated alternative for the treatment of recurrent ovarian cancer patients.", "type": 2, "words": ["<tag1>", "If", "this", "trial", "is", "completed", "and", "is", "clinically", "successful", "in", "terms", "of", "slowing", "tumor", "progression,", "we", "believe", "that", "this", "combination", "of", "vascular", "targeting", "agents,", "without", "the", "use", "of", "cytotoxic", "chemotherapy", "agents", "and", "their", "often", "significant", "side", "effects", "could", "provide", "a", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "recurrent", "ovarian", "cancer", "patients.", "<tag2>", "We", "believe", "that", "this", "combination", "of", "vascular", "targeting", "agents,", "without", "the", "use", "of", "cytotoxic", "chemotherapy", "agents", "and", "their", "often", "significant", "side", "effects", "could", "provide", "a", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "recurrent", "ovarian", "cancer", "patients.", "<tag3>"], "wordsA": ["If", "this", "trial", "is", "completed", "and", "is", "clinically", "successful", "in", "terms", "of", "slowing", "tumor", "progression,", "we", "believe", "that", "this", "combination", "of", "vascular", "targeting", "agents,", "without", "the", "use", "of", "cytotoxic", "chemotherapy", "agents", "and", "their", "often", "significant", "side", "effects", "could", "provide", "a", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "recurrent", "ovarian", "cancer", "patients."], "wordsB": ["We", "believe", "that", "this", "combination", "of", "vascular", "targeting", "agents,", "without", "the", "use", "of", "cytotoxic", "chemotherapy", "agents", "and", "their", "often", "significant", "side", "effects", "could", "provide", "a", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "recurrent", "ovarian", "cancer", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p31_s0", "idA": "908259_13_item1_p18_s5", "sentA": "While we pay for some costs related to this trial, CTEP bears most of the cost of the trial.", "sentB": "Biological activity associated with OXi4503 includes temporary increases in D-dimer which may be related to anti-leukemic activity of the drug.", "type": 2, "words": ["<tag1>", "While", "we", "pay", "for", "some", "costs", "related", "to", "this", "trial,", "CTEP", "bears", "most", "of", "the", "cost", "of", "the", "trial.", "<tag2>", "Biological", "activity", "associated", "with", "OXi4503", "includes", "temporary", "increases", "in", "D-dimer", "which", "may", "be", "related", "to", "anti-leukemic", "activity", "of", "the", "drug.", "<tag3>"], "wordsA": ["While", "we", "pay", "for", "some", "costs", "related", "to", "this", "trial,", "CTEP", "bears", "most", "of", "the", "cost", "of", "the", "trial."], "wordsB": ["Biological", "activity", "associated", "with", "OXi4503", "includes", "temporary", "increases", "in", "D-dimer", "which", "may", "be", "related", "to", "anti-leukemic", "activity", "of", "the", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p32_s3", "idA": "908259_13_item1_p18_s5", "sentA": "While we pay for some costs related to this trial, CTEP bears most of the cost of the trial.", "sentB": "Based on results to date, an expansion of the study to a second clinical site is planned, with the goal of increasing the rate of enrollment in the trial.", "type": 2, "words": ["<tag1>", "While", "we", "pay", "for", "some", "costs", "related", "to", "this", "trial,", "CTEP", "bears", "most", "of", "the", "cost", "of", "the", "trial.", "<tag2>", "Based", "on", "results", "to", "date,", "an", "expansion", "of", "the", "study", "to", "a", "second", "clinical", "site", "is", "planned,", "with", "the", "goal", "of", "increasing", "the", "rate", "of", "enrollment", "in", "the", "trial.", "<tag3>"], "wordsA": ["While", "we", "pay", "for", "some", "costs", "related", "to", "this", "trial,", "CTEP", "bears", "most", "of", "the", "cost", "of", "the", "trial."], "wordsB": ["Based", "on", "results", "to", "date,", "an", "expansion", "of", "the", "study", "to", "a", "second", "clinical", "site", "is", "planned,", "with", "the", "goal", "of", "increasing", "the", "rate", "of", "enrollment", "in", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s14", "idA": "908259_13_item1_p18_s5", "sentA": "While we pay for some costs related to this trial, CTEP bears most of the cost of the trial.", "sentB": "As CTEP is bearing the majority of the clinical trial costs, our expenses related to this trial were primarily related to manufacturing sufficient quantities of ZYBRESTAT .", "type": 2, "words": ["<tag1>", "While", "we", "pay", "for", "some", "costs", "related", "to", "this", "trial,", "CTEP", "bears", "most", "of", "the", "cost", "of", "the", "trial.", "<tag2>", "As", "CTEP", "is", "bearing", "the", "majority", "of", "the", "clinical", "trial", "costs,", "our", "expenses", "related", "to", "this", "trial", "were", "primarily", "related", "to", "manufacturing", "sufficient", "quantities", "of", "ZYBRESTAT", ".", "<tag3>"], "wordsA": ["While", "we", "pay", "for", "some", "costs", "related", "to", "this", "trial,", "CTEP", "bears", "most", "of", "the", "cost", "of", "the", "trial."], "wordsB": ["As", "CTEP", "is", "bearing", "the", "majority", "of", "the", "clinical", "trial", "costs,", "our", "expenses", "related", "to", "this", "trial", "were", "primarily", "related", "to", "manufacturing", "sufficient", "quantities", "of", "ZYBRESTAT", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s5", "idA": "908259_13_item1_p18_s6", "sentA": "In August, 2012, we announced that a pre-specified interim safety analysis of 25 patients in this trial indicated that only one of these patients had suffered a protocol-specified serious adverse event in the trial to date, and therefore it was recommended that the trial should continue to full enrollment.", "sentB": "In August 2012, we announced that a pre-specified interim safety analysis of 25 patients in this trial indicated that only one of these patients had suffered a protocol-specified serious adverse event in the trial to date, and therefore it was recommended that the trial continue to full enrollment.", "type": 2, "words": ["<tag1>", "In", "August,", "2012,", "we", "announced", "that", "a", "pre-specified", "interim", "safety", "analysis", "of", "25", "patients", "in", "this", "trial", "indicated", "that", "only", "one", "of", "these", "patients", "had", "suffered", "a", "protocol-specified", "serious", "adverse", "event", "in", "the", "trial", "to", "date,", "and", "therefore", "it", "was", "recommended", "that", "the", "trial", "should", "continue", "to", "full", "enrollment.", "<tag2>", "In", "August", "2012,", "we", "announced", "that", "a", "pre-specified", "interim", "safety", "analysis", "of", "25", "patients", "in", "this", "trial", "indicated", "that", "only", "one", "of", "these", "patients", "had", "suffered", "a", "protocol-specified", "serious", "adverse", "event", "in", "the", "trial", "to", "date,", "and", "therefore", "it", "was", "recommended", "that", "the", "trial", "continue", "to", "full", "enrollment.", "<tag3>"], "wordsA": ["In", "August,", "2012,", "we", "announced", "that", "a", "pre-specified", "interim", "safety", "analysis", "of", "25", "patients", "in", "this", "trial", "indicated", "that", "only", "one", "of", "these", "patients", "had", "suffered", "a", "protocol-specified", "serious", "adverse", "event", "in", "the", "trial", "to", "date,", "and", "therefore", "it", "was", "recommended", "that", "the", "trial", "should", "continue", "to", "full", "enrollment."], "wordsB": ["In", "August", "2012,", "we", "announced", "that", "a", "pre-specified", "interim", "safety", "analysis", "of", "25", "patients", "in", "this", "trial", "indicated", "that", "only", "one", "of", "these", "patients", "had", "suffered", "a", "protocol-specified", "serious", "adverse", "event", "in", "the", "trial", "to", "date,", "and", "therefore", "it", "was", "recommended", "that", "the", "trial", "continue", "to", "full", "enrollment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p17_s2", "idA": "908259_13_item1_p18_s8", "sentA": "The results were that there were no additional protocol specified serious adverse events seen during this review, and that the study will continue to full enrollment.", "sentB": "The results were also published in peer- reviewed scientific journals, including, most recently, Thyroid.", "type": 2, "words": ["<tag1>", "The", "results", "were", "that", "there", "were", "no", "additional", "protocol", "specified", "serious", "adverse", "events", "seen", "during", "this", "review,", "and", "that", "the", "study", "will", "continue", "to", "full", "enrollment.", "<tag2>", "The", "results", "were", "also", "published", "in", "peer-", "reviewed", "scientific", "journals,", "including,", "most", "recently,", "Thyroid.", "<tag3>"], "wordsA": ["The", "results", "were", "that", "there", "were", "no", "additional", "protocol", "specified", "serious", "adverse", "events", "seen", "during", "this", "review,", "and", "that", "the", "study", "will", "continue", "to", "full", "enrollment."], "wordsB": ["The", "results", "were", "also", "published", "in", "peer-", "reviewed", "scientific", "journals,", "including,", "most", "recently,", "Thyroid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s7", "idA": "908259_13_item1_p18_s8", "sentA": "The results were that there were no additional protocol specified serious adverse events seen during this review, and that the study will continue to full enrollment.", "sentB": "The results were that there were no additional protocol-specified serious adverse events seen during this review, and that the study would continue to full enrollment.", "type": 2, "words": ["<tag1>", "The", "results", "were", "that", "there", "were", "no", "additional", "protocol", "specified", "serious", "adverse", "events", "seen", "during", "this", "review,", "and", "that", "the", "study", "will", "continue", "to", "full", "enrollment.", "<tag2>", "The", "results", "were", "that", "there", "were", "no", "additional", "protocol-specified", "serious", "adverse", "events", "seen", "during", "this", "review,", "and", "that", "the", "study", "would", "continue", "to", "full", "enrollment.", "<tag3>"], "wordsA": ["The", "results", "were", "that", "there", "were", "no", "additional", "protocol", "specified", "serious", "adverse", "events", "seen", "during", "this", "review,", "and", "that", "the", "study", "will", "continue", "to", "full", "enrollment."], "wordsB": ["The", "results", "were", "that", "there", "were", "no", "additional", "protocol-specified", "serious", "adverse", "events", "seen", "during", "this", "review,", "and", "that", "the", "study", "would", "continue", "to", "full", "enrollment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s9", "idA": "908259_13_item1_p19_s0", "sentA": "We expect that an interim analysis to determine if the trial should continue to full enrollment will be conducted by the second quarter of 2013.", "sentB": "We expect to incur the limited costs in supporting certain resources required by the NHS and the participating institutions during the duration of this trial and the costs of supplying drug for the trial.", "type": 2, "words": ["<tag1>", "We", "expect", "that", "an", "interim", "analysis", "to", "determine", "if", "the", "trial", "should", "continue", "to", "full", "enrollment", "will", "be", "conducted", "by", "the", "second", "quarter", "of", "2013.", "<tag2>", "We", "expect", "to", "incur", "the", "limited", "costs", "in", "supporting", "certain", "resources", "required", "by", "the", "NHS", "and", "the", "participating", "institutions", "during", "the", "duration", "of", "this", "trial", "and", "the", "costs", "of", "supplying", "drug", "for", "the", "trial.", "<tag3>"], "wordsA": ["We", "expect", "that", "an", "interim", "analysis", "to", "determine", "if", "the", "trial", "should", "continue", "to", "full", "enrollment", "will", "be", "conducted", "by", "the", "second", "quarter", "of", "2013."], "wordsB": ["We", "expect", "to", "incur", "the", "limited", "costs", "in", "supporting", "certain", "resources", "required", "by", "the", "NHS", "and", "the", "participating", "institutions", "during", "the", "duration", "of", "this", "trial", "and", "the", "costs", "of", "supplying", "drug", "for", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s8", "idA": "908259_13_item1_p19_s0", "sentA": "We expect that an interim analysis to determine if the trial should continue to full enrollment will be conducted by the second quarter of 2013.", "sentB": "An interim futility analysis of this Phase 2 trial was performed in the second quarter of 2013.", "type": 2, "words": ["<tag1>", "We", "expect", "that", "an", "interim", "analysis", "to", "determine", "if", "the", "trial", "should", "continue", "to", "full", "enrollment", "will", "be", "conducted", "by", "the", "second", "quarter", "of", "2013.", "<tag2>", "An", "interim", "futility", "analysis", "of", "this", "Phase", "2", "trial", "was", "performed", "in", "the", "second", "quarter", "of", "2013.", "<tag3>"], "wordsA": ["We", "expect", "that", "an", "interim", "analysis", "to", "determine", "if", "the", "trial", "should", "continue", "to", "full", "enrollment", "will", "be", "conducted", "by", "the", "second", "quarter", "of", "2013."], "wordsB": ["An", "interim", "futility", "analysis", "of", "this", "Phase", "2", "trial", "was", "performed", "in", "the", "second", "quarter", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s7", "idA": "908259_13_item1_p19_s2", "sentA": "If the study continues after this interim analysis we anticipate that preliminary results of the final data set will be available in the first or second quarter of 2014.", "sentB": "Subject to approval by U.K. health authorities, appropriate funding by NHS with limited support by GlaxoSmithKline and us, and ethics committee approvals, this trial could begin in the second half of 2014.", "type": 2, "words": ["<tag1>", "If", "the", "study", "continues", "after", "this", "interim", "analysis", "we", "anticipate", "that", "preliminary", "results", "of", "the", "final", "data", "set", "will", "be", "available", "in", "the", "first", "or", "second", "quarter", "of", "2014.", "<tag2>", "Subject", "to", "approval", "by", "U.K.", "health", "authorities,", "appropriate", "funding", "by", "NHS", "with", "limited", "support", "by", "GlaxoSmithKline", "and", "us,", "and", "ethics", "committee", "approvals,", "this", "trial", "could", "begin", "in", "the", "second", "half", "of", "2014.", "<tag3>"], "wordsA": ["If", "the", "study", "continues", "after", "this", "interim", "analysis", "we", "anticipate", "that", "preliminary", "results", "of", "the", "final", "data", "set", "will", "be", "available", "in", "the", "first", "or", "second", "quarter", "of", "2014."], "wordsB": ["Subject", "to", "approval", "by", "U.K.", "health", "authorities,", "appropriate", "funding", "by", "NHS", "with", "limited", "support", "by", "GlaxoSmithKline", "and", "us,", "and", "ethics", "committee", "approvals,", "this", "trial", "could", "begin", "in", "the", "second", "half", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s3", "idA": "908259_13_item1_p19_s2", "sentA": "If the study continues after this interim analysis we anticipate that preliminary results of the final data set will be available in the first or second quarter of 2014.", "sentB": "We anticipate that additional data from the completed trial will be available in the second half of 2014 and that the full study results will be submitted for presentation at a future scientific meeting.", "type": 2, "words": ["<tag1>", "If", "the", "study", "continues", "after", "this", "interim", "analysis", "we", "anticipate", "that", "preliminary", "results", "of", "the", "final", "data", "set", "will", "be", "available", "in", "the", "first", "or", "second", "quarter", "of", "2014.", "<tag2>", "We", "anticipate", "that", "additional", "data", "from", "the", "completed", "trial", "will", "be", "available", "in", "the", "second", "half", "of", "2014", "and", "that", "the", "full", "study", "results", "will", "be", "submitted", "for", "presentation", "at", "a", "future", "scientific", "meeting.", "<tag3>"], "wordsA": ["If", "the", "study", "continues", "after", "this", "interim", "analysis", "we", "anticipate", "that", "preliminary", "results", "of", "the", "final", "data", "set", "will", "be", "available", "in", "the", "first", "or", "second", "quarter", "of", "2014."], "wordsB": ["We", "anticipate", "that", "additional", "data", "from", "the", "completed", "trial", "will", "be", "available", "in", "the", "second", "half", "of", "2014", "and", "that", "the", "full", "study", "results", "will", "be", "submitted", "for", "presentation", "at", "a", "future", "scientific", "meeting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p9_s1", "idA": "908259_13_item1_p19_s3", "sentA": "Assuming a positive outcome from these analysis and results, we hope to be able to collaborate with the GOG and Genentech, and also receive guidance from FDA, on the design of a potential pivotal registration trial in this indication that could lead to an NDA filing in the 2016-2017 timeframe.", "sentB": "Depending on the nature of the additional data from the GOG 186I trial, which we anticipate we will obtain in the second half of 2014, we may request an End-of-Phase-2 meeting with the FDA and the Scientific Advice Working Party of the European Medicines Agency (EMA) to seek guidance on the design of one or more possible pivotal registration studies.", "type": 2, "words": ["<tag1>", "Assuming", "a", "positive", "outcome", "from", "these", "analysis", "and", "results,", "we", "hope", "to", "be", "able", "to", "collaborate", "with", "the", "GOG", "and", "Genentech,", "and", "also", "receive", "guidance", "from", "FDA,", "on", "the", "design", "of", "a", "potential", "pivotal", "registration", "trial", "in", "this", "indication", "that", "could", "lead", "to", "an", "NDA", "filing", "in", "the", "2016-2017", "timeframe.", "<tag2>", "Depending", "on", "the", "nature", "of", "the", "additional", "data", "from", "the", "GOG", "186I", "trial,", "which", "we", "anticipate", "we", "will", "obtain", "in", "the", "second", "half", "of", "2014,", "we", "may", "request", "an", "End-of-Phase-2", "meeting", "with", "the", "FDA", "and", "the", "Scientific", "Advice", "Working", "Party", "of", "the", "European", "Medicines", "Agency", "(EMA)", "to", "seek", "guidance", "on", "the", "design", "of", "one", "or", "more", "possible", "pivotal", "registration", "studies.", "<tag3>"], "wordsA": ["Assuming", "a", "positive", "outcome", "from", "these", "analysis", "and", "results,", "we", "hope", "to", "be", "able", "to", "collaborate", "with", "the", "GOG", "and", "Genentech,", "and", "also", "receive", "guidance", "from", "FDA,", "on", "the", "design", "of", "a", "potential", "pivotal", "registration", "trial", "in", "this", "indication", "that", "could", "lead", "to", "an", "NDA", "filing", "in", "the", "2016-2017", "timeframe."], "wordsB": ["Depending", "on", "the", "nature", "of", "the", "additional", "data", "from", "the", "GOG", "186I", "trial,", "which", "we", "anticipate", "we", "will", "obtain", "in", "the", "second", "half", "of", "2014,", "we", "may", "request", "an", "End-of-Phase-2", "meeting", "with", "the", "FDA", "and", "the", "Scientific", "Advice", "Working", "Party", "of", "the", "European", "Medicines", "Agency", "(EMA)", "to", "seek", "guidance", "on", "the", "design", "of", "one", "or", "more", "possible", "pivotal", "registration", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p9_s2", "idA": "908259_13_item1_p19_s4", "sentA": "Planned Clinical Trial in Ovarian Cancer With sufficient funding, we would also like to initiate a Phase 2 study of ZYBRESTAT in combination with weekly paclitaxel in persistent or recurrent ovarian cancer.", "sentB": "Assuming a positive result from the meetings and availability of sufficient funding, we could initiate one or more pivotal registration trials in advanced relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "Planned", "Clinical", "Trial", "in", "Ovarian", "Cancer", "With", "sufficient", "funding,", "we", "would", "also", "like", "to", "initiate", "a", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "persistent", "or", "recurrent", "ovarian", "cancer.", "<tag2>", "Assuming", "a", "positive", "result", "from", "the", "meetings", "and", "availability", "of", "sufficient", "funding,", "we", "could", "initiate", "one", "or", "more", "pivotal", "registration", "trials", "in", "advanced", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Planned", "Clinical", "Trial", "in", "Ovarian", "Cancer", "With", "sufficient", "funding,", "we", "would", "also", "like", "to", "initiate", "a", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "persistent", "or", "recurrent", "ovarian", "cancer."], "wordsB": ["Assuming", "a", "positive", "result", "from", "the", "meetings", "and", "availability", "of", "sufficient", "funding,", "we", "could", "initiate", "one", "or", "more", "pivotal", "registration", "trials", "in", "advanced", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s6", "idA": "908259_13_item1_p19_s6", "sentA": "The primary endpoint would be progression-free survival, with secondary endpoints of safety, overall survival, objective response rate and CA125 response rate.", "sentB": "The primary endpoint of the trial would be progression-free survival (PFS), and secondary endpoints would include safety, overall survival (OS), objective response rate, and CA125 response rate.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "would", "be", "progression-free", "survival,", "with", "secondary", "endpoints", "of", "safety,", "overall", "survival,", "objective", "response", "rate", "and", "CA125", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "the", "trial", "would", "be", "progression-free", "survival", "(PFS),", "and", "secondary", "endpoints", "would", "include", "safety,", "overall", "survival", "(OS),", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "would", "be", "progression-free", "survival,", "with", "secondary", "endpoints", "of", "safety,", "overall", "survival,", "objective", "response", "rate", "and", "CA125", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "the", "trial", "would", "be", "progression-free", "survival", "(PFS),", "and", "secondary", "endpoints", "would", "include", "safety,", "overall", "survival", "(OS),", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p0_s0", "idA": "908259_13_item1_p1_s3", "sentA": "We primarily focus on the development of product candidates for the treatment of rare cancers that will be eligible for orphan drug status and fast track status.", "sentB": "Business Overview We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "type": 2, "words": ["<tag1>", "We", "primarily", "focus", "on", "the", "development", "of", "product", "candidates", "for", "the", "treatment", "of", "rare", "cancers", "that", "will", "be", "eligible", "for", "orphan", "drug", "status", "and", "fast", "track", "status.", "<tag2>", "Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag3>"], "wordsA": ["We", "primarily", "focus", "on", "the", "development", "of", "product", "candidates", "for", "the", "treatment", "of", "rare", "cancers", "that", "will", "be", "eligible", "for", "orphan", "drug", "status", "and", "fast", "track", "status."], "wordsB": ["Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p12_s0", "idA": "908259_13_item1_p21_s0", "sentA": "Background in Ovarian Cancer Clinical Trials On June 15, 2012, British clinical investigators published results from a Phase 1 study in solid tumors in the journal Clinical Cancer Research, using a combination of ZYBRESTAT with bevacizumab, an angiogenesis inhibitor targeting the vascular endothelial growth factor, or VEGF, without cytotoxic chemotherapy.", "sentB": "Background in Ovarian Cancer Clinical Trials On June 15, 2012, British clinical investigators published results from a Phase 1 study in solid tumors in the journal Clinical Cancer Research, using a combination of ZYBRESTAT with AVASTIN (bevacizumab), an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, without cytotoxic chemotherapy.", "type": 2, "words": ["<tag1>", "Background", "in", "Ovarian", "Cancer", "Clinical", "Trials", "On", "June", "15,", "2012,", "British", "clinical", "investigators", "published", "results", "from", "a", "Phase", "1", "study", "in", "solid", "tumors", "in", "the", "journal", "Clinical", "Cancer", "Research,", "using", "a", "combination", "of", "ZYBRESTAT", "with", "bevacizumab,", "an", "angiogenesis", "inhibitor", "targeting", "the", "vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "without", "cytotoxic", "chemotherapy.", "<tag2>", "Background", "in", "Ovarian", "Cancer", "Clinical", "Trials", "On", "June", "15,", "2012,", "British", "clinical", "investigators", "published", "results", "from", "a", "Phase", "1", "study", "in", "solid", "tumors", "in", "the", "journal", "Clinical", "Cancer", "Research,", "using", "a", "combination", "of", "ZYBRESTAT", "with", "AVASTIN", "(bevacizumab),", "an", "anti-vascular", "endothelial", "growth", "factor", "(VEGF)", "monoclonal", "antibody,", "without", "cytotoxic", "chemotherapy.", "<tag3>"], "wordsA": ["Background", "in", "Ovarian", "Cancer", "Clinical", "Trials", "On", "June", "15,", "2012,", "British", "clinical", "investigators", "published", "results", "from", "a", "Phase", "1", "study", "in", "solid", "tumors", "in", "the", "journal", "Clinical", "Cancer", "Research,", "using", "a", "combination", "of", "ZYBRESTAT", "with", "bevacizumab,", "an", "angiogenesis", "inhibitor", "targeting", "the", "vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "without", "cytotoxic", "chemotherapy."], "wordsB": ["Background", "in", "Ovarian", "Cancer", "Clinical", "Trials", "On", "June", "15,", "2012,", "British", "clinical", "investigators", "published", "results", "from", "a", "Phase", "1", "study", "in", "solid", "tumors", "in", "the", "journal", "Clinical", "Cancer", "Research,", "using", "a", "combination", "of", "ZYBRESTAT", "with", "AVASTIN", "(bevacizumab),", "an", "anti-vascular", "endothelial", "growth", "factor", "(VEGF)", "monoclonal", "antibody,", "without", "cytotoxic", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p12_s2", "idA": "908259_13_item1_p21_s2", "sentA": "The investigators also observed that functional imaging of the tumors at baseline and after cycle 1 showed longer profound vascular changes and blood-flow shutdown when bevacizumab was added to the ZYBRESTAT treatment regimen, demonstrating the complementary therapeutic effect of ZYBRESTAT and bevacizumab on the tumor vasculature.", "sentB": "The investigators also observed that functional imaging of the tumors at baseline and after cycle 1 showed longer profound vascular changes and blood-flow shutdown when AVASTIN (bevacizumab) was added to the ZYBRESTAT treatment regimen, demonstrating the complementary therapeutic effect of ZYBRESTAT and AVASTIN (bevacizumab) on the tumor vasculature and serving as the basis for our ongoing Phase 2 clinical trial of ZYBRESTAT in combination with AVASTIN (bevacizumab) in the treatment of advanced ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "investigators", "also", "observed", "that", "functional", "imaging", "of", "the", "tumors", "at", "baseline", "and", "after", "cycle", "1", "showed", "longer", "profound", "vascular", "changes", "and", "blood-flow", "shutdown", "when", "bevacizumab", "was", "added", "to", "the", "ZYBRESTAT", "treatment", "regimen,", "demonstrating", "the", "complementary", "therapeutic", "effect", "of", "ZYBRESTAT", "and", "bevacizumab", "on", "the", "tumor", "vasculature.", "<tag2>", "The", "investigators", "also", "observed", "that", "functional", "imaging", "of", "the", "tumors", "at", "baseline", "and", "after", "cycle", "1", "showed", "longer", "profound", "vascular", "changes", "and", "blood-flow", "shutdown", "when", "AVASTIN", "(bevacizumab)", "was", "added", "to", "the", "ZYBRESTAT", "treatment", "regimen,", "demonstrating", "the", "complementary", "therapeutic", "effect", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "on", "the", "tumor", "vasculature", "and", "serving", "as", "the", "basis", "for", "our", "ongoing", "Phase", "2", "clinical", "trial", "of", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "in", "the", "treatment", "of", "advanced", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "investigators", "also", "observed", "that", "functional", "imaging", "of", "the", "tumors", "at", "baseline", "and", "after", "cycle", "1", "showed", "longer", "profound", "vascular", "changes", "and", "blood-flow", "shutdown", "when", "bevacizumab", "was", "added", "to", "the", "ZYBRESTAT", "treatment", "regimen,", "demonstrating", "the", "complementary", "therapeutic", "effect", "of", "ZYBRESTAT", "and", "bevacizumab", "on", "the", "tumor", "vasculature."], "wordsB": ["The", "investigators", "also", "observed", "that", "functional", "imaging", "of", "the", "tumors", "at", "baseline", "and", "after", "cycle", "1", "showed", "longer", "profound", "vascular", "changes", "and", "blood-flow", "shutdown", "when", "AVASTIN", "(bevacizumab)", "was", "added", "to", "the", "ZYBRESTAT", "treatment", "regimen,", "demonstrating", "the", "complementary", "therapeutic", "effect", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "on", "the", "tumor", "vasculature", "and", "serving", "as", "the", "basis", "for", "our", "ongoing", "Phase", "2", "clinical", "trial", "of", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "in", "the", "treatment", "of", "advanced", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p12_s4", "idA": "908259_13_item1_p21_s5", "sentA": "Final results from a Phase 2 study were published by the Mount Vernon Cancer Centre, in the U. K., in the January 2011 issue of Annals of Oncology, showing a response rate of 25% which represents 11 of 44 patients, in a platinum resistant population and an additional 11%, representing 5 of 44 of patients, with unconfirmed responses on CT, suggesting that randomized trials including ZYBRESTAT with platinum or paclitaxel-based chemotherapy should be performed in patients with advanced ovarian cancer.", "sentB": "Final results from a Phase 2 study conducted by the Mount Vernon Cancer Centre in the United Kingdom were published in the January 2011 issue of Annals of Oncology.", "type": 2, "words": ["<tag1>", "Final", "results", "from", "a", "Phase", "2", "study", "were", "published", "by", "the", "Mount", "Vernon", "Cancer", "Centre,", "in", "the", "U.", "K.,", "in", "the", "January", "2011", "issue", "of", "Annals", "of", "Oncology,", "showing", "a", "response", "rate", "of", "25%", "which", "represents", "11", "of", "44", "patients,", "in", "a", "platinum", "resistant", "population", "and", "an", "additional", "11%,", "representing", "5", "of", "44", "of", "patients,", "with", "unconfirmed", "responses", "on", "CT,", "suggesting", "that", "randomized", "trials", "including", "ZYBRESTAT", "with", "platinum", "or", "paclitaxel-based", "chemotherapy", "should", "be", "performed", "in", "patients", "with", "advanced", "ovarian", "cancer.", "<tag2>", "Final", "results", "from", "a", "Phase", "2", "study", "conducted", "by", "the", "Mount", "Vernon", "Cancer", "Centre", "in", "the", "United", "Kingdom", "were", "published", "in", "the", "January", "2011", "issue", "of", "Annals", "of", "Oncology.", "<tag3>"], "wordsA": ["Final", "results", "from", "a", "Phase", "2", "study", "were", "published", "by", "the", "Mount", "Vernon", "Cancer", "Centre,", "in", "the", "U.", "K.,", "in", "the", "January", "2011", "issue", "of", "Annals", "of", "Oncology,", "showing", "a", "response", "rate", "of", "25%", "which", "represents", "11", "of", "44", "patients,", "in", "a", "platinum", "resistant", "population", "and", "an", "additional", "11%,", "representing", "5", "of", "44", "of", "patients,", "with", "unconfirmed", "responses", "on", "CT,", "suggesting", "that", "randomized", "trials", "including", "ZYBRESTAT", "with", "platinum", "or", "paclitaxel-based", "chemotherapy", "should", "be", "performed", "in", "patients", "with", "advanced", "ovarian", "cancer."], "wordsB": ["Final", "results", "from", "a", "Phase", "2", "study", "conducted", "by", "the", "Mount", "Vernon", "Cancer", "Centre", "in", "the", "United", "Kingdom", "were", "published", "in", "the", "January", "2011", "issue", "of", "Annals", "of", "Oncology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p19_s0", "idA": "908259_13_item1_p23_s1", "sentA": "It is estimated that approximately 800 patients will be diagnosed with ATC in the United States in 2013.", "sentB": "Approximately 14,000 people in the United States are diagnosed with carcinoid tumors each year.", "type": 2, "words": ["<tag1>", "It", "is", "estimated", "that", "approximately", "800", "patients", "will", "be", "diagnosed", "with", "ATC", "in", "the", "United", "States", "in", "2013.", "<tag2>", "Approximately", "14,000", "people", "in", "the", "United", "States", "are", "diagnosed", "with", "carcinoid", "tumors", "each", "year.", "<tag3>"], "wordsA": ["It", "is", "estimated", "that", "approximately", "800", "patients", "will", "be", "diagnosed", "with", "ATC", "in", "the", "United", "States", "in", "2013."], "wordsB": ["Approximately", "14,000", "people", "in", "the", "United", "States", "are", "diagnosed", "with", "carcinoid", "tumors", "each", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p31_s1", "idA": "908259_13_item1_p23_s1", "sentA": "It is estimated that approximately 800 patients will be diagnosed with ATC in the United States in 2013.", "sentB": "It is estimated that an additional 12-15 patients will be required to establish a maximum tolerated dose.", "type": 2, "words": ["<tag1>", "It", "is", "estimated", "that", "approximately", "800", "patients", "will", "be", "diagnosed", "with", "ATC", "in", "the", "United", "States", "in", "2013.", "<tag2>", "It", "is", "estimated", "that", "an", "additional", "12-15", "patients", "will", "be", "required", "to", "establish", "a", "maximum", "tolerated", "dose.", "<tag3>"], "wordsA": ["It", "is", "estimated", "that", "approximately", "800", "patients", "will", "be", "diagnosed", "with", "ATC", "in", "the", "United", "States", "in", "2013."], "wordsB": ["It", "is", "estimated", "that", "an", "additional", "12-15", "patients", "will", "be", "required", "to", "establish", "a", "maximum", "tolerated", "dose."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p17_s1", "idA": "908259_13_item1_p24_s1", "sentA": "We have presented the results of this study at multiple scientific meetings, including the American Society of Clinical Oncology, or ASCO, and the European Society for Medical Oncology, or ESMO, and in scientific journals.", "sentB": "Results from the FACT trial were subsequently presented at the 2010 American Society of Clinical Oncology, or ASCO, meeting and at the 2010 European Society for Medical Oncology, or ESMO, meeting.", "type": 2, "words": ["<tag1>", "We", "have", "presented", "the", "results", "of", "this", "study", "at", "multiple", "scientific", "meetings,", "including", "the", "American", "Society", "of", "Clinical", "Oncology,", "or", "ASCO,", "and", "the", "European", "Society", "for", "Medical", "Oncology,", "or", "ESMO,", "and", "in", "scientific", "journals.", "<tag2>", "Results", "from", "the", "FACT", "trial", "were", "subsequently", "presented", "at", "the", "2010", "American", "Society", "of", "Clinical", "Oncology,", "or", "ASCO,", "meeting", "and", "at", "the", "2010", "European", "Society", "for", "Medical", "Oncology,", "or", "ESMO,", "meeting.", "<tag3>"], "wordsA": ["We", "have", "presented", "the", "results", "of", "this", "study", "at", "multiple", "scientific", "meetings,", "including", "the", "American", "Society", "of", "Clinical", "Oncology,", "or", "ASCO,", "and", "the", "European", "Society", "for", "Medical", "Oncology,", "or", "ESMO,", "and", "in", "scientific", "journals."], "wordsB": ["Results", "from", "the", "FACT", "trial", "were", "subsequently", "presented", "at", "the", "2010", "American", "Society", "of", "Clinical", "Oncology,", "or", "ASCO,", "meeting", "and", "at", "the", "2010", "European", "Society", "for", "Medical", "Oncology,", "or", "ESMO,", "meeting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p14_s2", "idA": "908259_13_item1_p25_s2", "sentA": "While we believe that a positive FACT 2 study would be sufficient to obtain regulatory approval in the United States and in Europe for the treatment of patients with ATC, the required sample size puts this trial beyond our current financial resources.", "sentB": "Based on the results of a Phase 2/3 controlled study in 80 patients with ATC, called the FACT study, comparing standard chemotherapy with and without ZYBRESTAT , the FDA has provided guidance that we would need to conduct one or more large pivotal trials to obtain regulatory approval for ZYBRESTAT in ATC in the United States.", "type": 2, "words": ["<tag1>", "While", "we", "believe", "that", "a", "positive", "FACT", "2", "study", "would", "be", "sufficient", "to", "obtain", "regulatory", "approval", "in", "the", "United", "States", "and", "in", "Europe", "for", "the", "treatment", "of", "patients", "with", "ATC,", "the", "required", "sample", "size", "puts", "this", "trial", "beyond", "our", "current", "financial", "resources.", "<tag2>", "Based", "on", "the", "results", "of", "a", "Phase", "2/3", "controlled", "study", "in", "80", "patients", "with", "ATC,", "called", "the", "FACT", "study,", "comparing", "standard", "chemotherapy", "with", "and", "without", "ZYBRESTAT", ",", "the", "FDA", "has", "provided", "guidance", "that", "we", "would", "need", "to", "conduct", "one", "or", "more", "large", "pivotal", "trials", "to", "obtain", "regulatory", "approval", "for", "ZYBRESTAT", "in", "ATC", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["While", "we", "believe", "that", "a", "positive", "FACT", "2", "study", "would", "be", "sufficient", "to", "obtain", "regulatory", "approval", "in", "the", "United", "States", "and", "in", "Europe", "for", "the", "treatment", "of", "patients", "with", "ATC,", "the", "required", "sample", "size", "puts", "this", "trial", "beyond", "our", "current", "financial", "resources."], "wordsB": ["Based", "on", "the", "results", "of", "a", "Phase", "2/3", "controlled", "study", "in", "80", "patients", "with", "ATC,", "called", "the", "FACT", "study,", "comparing", "standard", "chemotherapy", "with", "and", "without", "ZYBRESTAT", ",", "the", "FDA", "has", "provided", "guidance", "that", "we", "would", "need", "to", "conduct", "one", "or", "more", "large", "pivotal", "trials", "to", "obtain", "regulatory", "approval", "for", "ZYBRESTAT", "in", "ATC", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p15_s0", "idA": "908259_13_item1_p25_s3", "sentA": "At the present time, we believe that pursuing regulatory approval for ZYBRESTAT in ATC in the EU without the requirement for another clinical trial in ATC is the most fiscally feasible path.", "sentB": "The European Union has alternative pathways for potential approval of drugs that are designed to treat life-threatening, extremely rare, orphan diseases such as ATC, without the requirement for large randomized trials.", "type": 2, "words": ["<tag1>", "At", "the", "present", "time,", "we", "believe", "that", "pursuing", "regulatory", "approval", "for", "ZYBRESTAT", "in", "ATC", "in", "the", "EU", "without", "the", "requirement", "for", "another", "clinical", "trial", "in", "ATC", "is", "the", "most", "fiscally", "feasible", "path.", "<tag2>", "The", "European", "Union", "has", "alternative", "pathways", "for", "potential", "approval", "of", "drugs", "that", "are", "designed", "to", "treat", "life-threatening,", "extremely", "rare,", "orphan", "diseases", "such", "as", "ATC,", "without", "the", "requirement", "for", "large", "randomized", "trials.", "<tag3>"], "wordsA": ["At", "the", "present", "time,", "we", "believe", "that", "pursuing", "regulatory", "approval", "for", "ZYBRESTAT", "in", "ATC", "in", "the", "EU", "without", "the", "requirement", "for", "another", "clinical", "trial", "in", "ATC", "is", "the", "most", "fiscally", "feasible", "path."], "wordsB": ["The", "European", "Union", "has", "alternative", "pathways", "for", "potential", "approval", "of", "drugs", "that", "are", "designed", "to", "treat", "life-threatening,", "extremely", "rare,", "orphan", "diseases", "such", "as", "ATC,", "without", "the", "requirement", "for", "large", "randomized", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p15_s1", "idA": "908259_13_item1_p25_s5", "sentA": "European regulations provide that these special marketing approvals may be obtained in the case of therapies for the treatment of life-threatening diseases with orphan designation where there is an unmet medical need.", "sentB": "These include the possibility of a special marketing approval, known as an MAA under exceptional circumstances, in the case of therapies that address urgent, unmet medical needs.", "type": 2, "words": ["<tag1>", "European", "regulations", "provide", "that", "these", "special", "marketing", "approvals", "may", "be", "obtained", "in", "the", "case", "of", "therapies", "for", "the", "treatment", "of", "life-threatening", "diseases", "with", "orphan", "designation", "where", "there", "is", "an", "unmet", "medical", "need.", "<tag2>", "These", "include", "the", "possibility", "of", "a", "special", "marketing", "approval,", "known", "as", "an", "MAA", "under", "exceptional", "circumstances,", "in", "the", "case", "of", "therapies", "that", "address", "urgent,", "unmet", "medical", "needs.", "<tag3>"], "wordsA": ["European", "regulations", "provide", "that", "these", "special", "marketing", "approvals", "may", "be", "obtained", "in", "the", "case", "of", "therapies", "for", "the", "treatment", "of", "life-threatening", "diseases", "with", "orphan", "designation", "where", "there", "is", "an", "unmet", "medical", "need."], "wordsB": ["These", "include", "the", "possibility", "of", "a", "special", "marketing", "approval,", "known", "as", "an", "MAA", "under", "exceptional", "circumstances,", "in", "the", "case", "of", "therapies", "that", "address", "urgent,", "unmet", "medical", "needs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p48_s0", "idA": "908259_13_item1_p26_s0", "sentA": "In December 2011, we established a distribution agreement with Azanta Danmark A/S, or Azanta, to provide access to ZYBRESTAT for the treatment of patients with ATC on a compassionate use basis in certain specified territories.", "sentB": "In December 2011, we established a distribution agreement with a Danish company, Azanta Danmark A/S, or Azanta, to provide access to ZYBRESTAT for the treatment of patients with ATC on a compassionate use basis in certain specified territories.", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "we", "established", "a", "distribution", "agreement", "with", "Azanta", "Danmark", "A/S,", "or", "Azanta,", "to", "provide", "access", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "certain", "specified", "territories.", "<tag2>", "In", "December", "2011,", "we", "established", "a", "distribution", "agreement", "with", "a", "Danish", "company,", "Azanta", "Danmark", "A/S,", "or", "Azanta,", "to", "provide", "access", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "certain", "specified", "territories.", "<tag3>"], "wordsA": ["In", "December", "2011,", "we", "established", "a", "distribution", "agreement", "with", "Azanta", "Danmark", "A/S,", "or", "Azanta,", "to", "provide", "access", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "certain", "specified", "territories."], "wordsB": ["In", "December", "2011,", "we", "established", "a", "distribution", "agreement", "with", "a", "Danish", "company,", "Azanta", "Danmark", "A/S,", "or", "Azanta,", "to", "provide", "access", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "certain", "specified", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p48_s1", "idA": "908259_13_item1_p26_s1", "sentA": "This agreement was expanded to include additional territories in August 2012 on a compassionate use basis.", "sentB": "This agreement was expanded to include additional territories in August 2012 also for treatment on a compassionate use basis.", "type": 2, "words": ["<tag1>", "This", "agreement", "was", "expanded", "to", "include", "additional", "territories", "in", "August", "2012", "on", "a", "compassionate", "use", "basis.", "<tag2>", "This", "agreement", "was", "expanded", "to", "include", "additional", "territories", "in", "August", "2012", "also", "for", "treatment", "on", "a", "compassionate", "use", "basis.", "<tag3>"], "wordsA": ["This", "agreement", "was", "expanded", "to", "include", "additional", "territories", "in", "August", "2012", "on", "a", "compassionate", "use", "basis."], "wordsB": ["This", "agreement", "was", "expanded", "to", "include", "additional", "territories", "in", "August", "2012", "also", "for", "treatment", "on", "a", "compassionate", "use", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p15_s5", "idA": "908259_13_item1_p26_s2", "sentA": "The specified territories include the European Union, including the Nordic countries and Switzerland, Canada, Israel and South Korea.", "sentB": "The unmet medical need of ATC patients in Europe is further addressed by a compassionate use distribution agreement that we entered into in December 2011 with a Danish company, which currently provides access to ZYBRESTAT for the treatment of patients with ATC on a compassionate use basis in the European Union, including the Nordic countries and Switzerland, Canada, Israel and South Korea.", "type": 2, "words": ["<tag1>", "The", "specified", "territories", "include", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "Canada,", "Israel", "and", "South", "Korea.", "<tag2>", "The", "unmet", "medical", "need", "of", "ATC", "patients", "in", "Europe", "is", "further", "addressed", "by", "a", "compassionate", "use", "distribution", "agreement", "that", "we", "entered", "into", "in", "December", "2011", "with", "a", "Danish", "company,", "which", "currently", "provides", "access", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "Canada,", "Israel", "and", "South", "Korea.", "<tag3>"], "wordsA": ["The", "specified", "territories", "include", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "Canada,", "Israel", "and", "South", "Korea."], "wordsB": ["The", "unmet", "medical", "need", "of", "ATC", "patients", "in", "Europe", "is", "further", "addressed", "by", "a", "compassionate", "use", "distribution", "agreement", "that", "we", "entered", "into", "in", "December", "2011", "with", "a", "Danish", "company,", "which", "currently", "provides", "access", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "Canada,", "Israel", "and", "South", "Korea."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p48_s4", "idA": "908259_13_item1_p26_s4", "sentA": "Under the terms of the agreement, we provide ZYBRESTAT to Azanta, and Azanta serves as our exclusive distributor for ZYBRESTAT in the specified territories for this purpose.", "sentB": "Under the terms of the agreement, we provide ZYBRESTAT to the Danish company, and they serve as our exclusive distributor for ZYBRESTAT in the specified territories for this purpose.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "provide", "ZYBRESTAT", "to", "Azanta,", "and", "Azanta", "serves", "as", "our", "exclusive", "distributor", "for", "ZYBRESTAT", "in", "the", "specified", "territories", "for", "this", "purpose.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "provide", "ZYBRESTAT", "to", "the", "Danish", "company,", "and", "they", "serve", "as", "our", "exclusive", "distributor", "for", "ZYBRESTAT", "in", "the", "specified", "territories", "for", "this", "purpose.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "provide", "ZYBRESTAT", "to", "Azanta,", "and", "Azanta", "serves", "as", "our", "exclusive", "distributor", "for", "ZYBRESTAT", "in", "the", "specified", "territories", "for", "this", "purpose."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "provide", "ZYBRESTAT", "to", "the", "Danish", "company,", "and", "they", "serve", "as", "our", "exclusive", "distributor", "for", "ZYBRESTAT", "in", "the", "specified", "territories", "for", "this", "purpose."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p48_s5", "idA": "908259_13_item1_p26_s5", "sentA": "Azanta provides ZYBRESTAT to physicians solely to treat ATC on a compassionate use basis in the specified territories until such time as ZYBRESTAT may obtain marketing approval in that territory.", "sentB": "The Danish company provides ZYBRESTAT to physicians solely to treat ATC on a compassionate use basis in the specified territories until such time as ZYBRESTAT may obtain marketing approval in that territory.", "type": 2, "words": ["<tag1>", "Azanta", "provides", "ZYBRESTAT", "to", "physicians", "solely", "to", "treat", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "specified", "territories", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory.", "<tag2>", "The", "Danish", "company", "provides", "ZYBRESTAT", "to", "physicians", "solely", "to", "treat", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "specified", "territories", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory.", "<tag3>"], "wordsA": ["Azanta", "provides", "ZYBRESTAT", "to", "physicians", "solely", "to", "treat", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "specified", "territories", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory."], "wordsB": ["The", "Danish", "company", "provides", "ZYBRESTAT", "to", "physicians", "solely", "to", "treat", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "specified", "territories", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p49_s0", "idA": "908259_13_item1_p27_s0", "sentA": "Azanta is responsible for all regulatory activities necessary to distribute and sell ZYBRESTAT on a compassionate use basis for the treatment of ATC within the specified territories.", "sentB": "The Danish company is responsible for all regulatory activities necessary to distribute and sell ZYBRESTAT on a compassionate use basis for the treatment of ATC within the specified territories.", "type": 2, "words": ["<tag1>", "Azanta", "is", "responsible", "for", "all", "regulatory", "activities", "necessary", "to", "distribute", "and", "sell", "ZYBRESTAT", "on", "a", "compassionate", "use", "basis", "for", "the", "treatment", "of", "ATC", "within", "the", "specified", "territories.", "<tag2>", "The", "Danish", "company", "is", "responsible", "for", "all", "regulatory", "activities", "necessary", "to", "distribute", "and", "sell", "ZYBRESTAT", "on", "a", "compassionate", "use", "basis", "for", "the", "treatment", "of", "ATC", "within", "the", "specified", "territories.", "<tag3>"], "wordsA": ["Azanta", "is", "responsible", "for", "all", "regulatory", "activities", "necessary", "to", "distribute", "and", "sell", "ZYBRESTAT", "on", "a", "compassionate", "use", "basis", "for", "the", "treatment", "of", "ATC", "within", "the", "specified", "territories."], "wordsB": ["The", "Danish", "company", "is", "responsible", "for", "all", "regulatory", "activities", "necessary", "to", "distribute", "and", "sell", "ZYBRESTAT", "on", "a", "compassionate", "use", "basis", "for", "the", "treatment", "of", "ATC", "within", "the", "specified", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p49_s1", "idA": "908259_13_item1_p27_s1", "sentA": "There is no transfer of ownership of intellectual property rights for ZYBRESTAT to Azanta under the terms of the agreement.", "sentB": "There is no transfer of ownership of intellectual property rights for ZYBRESTAT to the Danish company under the terms of the agreement.", "type": 2, "words": ["<tag1>", "There", "is", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "ZYBRESTAT", "to", "Azanta", "under", "the", "terms", "of", "the", "agreement.", "<tag2>", "There", "is", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "ZYBRESTAT", "to", "the", "Danish", "company", "under", "the", "terms", "of", "the", "agreement.", "<tag3>"], "wordsA": ["There", "is", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "ZYBRESTAT", "to", "Azanta", "under", "the", "terms", "of", "the", "agreement."], "wordsB": ["There", "is", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "ZYBRESTAT", "to", "the", "Danish", "company", "under", "the", "terms", "of", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p59_s3", "idA": "908259_13_item1_p27_s1", "sentA": "There is no transfer of ownership of intellectual property rights for ZYBRESTAT to Azanta under the terms of the agreement.", "sentB": "Milestone payments are due upon initiation of the first clinical trial for a product using Angiogene intellectual property and initiation of the first registration clinical trial for a product using Angiogene intellectual property.", "type": 2, "words": ["<tag1>", "There", "is", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "ZYBRESTAT", "to", "Azanta", "under", "the", "terms", "of", "the", "agreement.", "<tag2>", "Milestone", "payments", "are", "due", "upon", "initiation", "of", "the", "first", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property", "and", "initiation", "of", "the", "first", "registration", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property.", "<tag3>"], "wordsA": ["There", "is", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "ZYBRESTAT", "to", "Azanta", "under", "the", "terms", "of", "the", "agreement."], "wordsB": ["Milestone", "payments", "are", "due", "upon", "initiation", "of", "the", "first", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property", "and", "initiation", "of", "the", "first", "registration", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p16_s0", "idA": "908259_13_item1_p28_s0", "sentA": "Background in ATC In earlier Phase 1 studies of ZYBRESTAT in ATC, clinical investigators observed several objective responses in treatment with ZYBRESTAT, including a complete response lasting more than 13 years, in patients with ATC.", "sentB": "Background in ATC Phase 1 and 2 clinical data that we have gathered thus far suggests that ZYBRESTAT could significantly improve outcomes in patients with ATC.", "type": 2, "words": ["<tag1>", "Background", "in", "ATC", "In", "earlier", "Phase", "1", "studies", "of", "ZYBRESTAT", "in", "ATC,", "clinical", "investigators", "observed", "several", "objective", "responses", "in", "treatment", "with", "ZYBRESTAT,", "including", "a", "complete", "response", "lasting", "more", "than", "13", "years,", "in", "patients", "with", "ATC.", "<tag2>", "Background", "in", "ATC", "Phase", "1", "and", "2", "clinical", "data", "that", "we", "have", "gathered", "thus", "far", "suggests", "that", "ZYBRESTAT", "could", "significantly", "improve", "outcomes", "in", "patients", "with", "ATC.", "<tag3>"], "wordsA": ["Background", "in", "ATC", "In", "earlier", "Phase", "1", "studies", "of", "ZYBRESTAT", "in", "ATC,", "clinical", "investigators", "observed", "several", "objective", "responses", "in", "treatment", "with", "ZYBRESTAT,", "including", "a", "complete", "response", "lasting", "more", "than", "13", "years,", "in", "patients", "with", "ATC."], "wordsB": ["Background", "in", "ATC", "Phase", "1", "and", "2", "clinical", "data", "that", "we", "have", "gathered", "thus", "far", "suggests", "that", "ZYBRESTAT", "could", "significantly", "improve", "outcomes", "in", "patients", "with", "ATC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p16_s1", "idA": "908259_13_item1_p29_s0", "sentA": "We subsequently conducted the FACT (fosbretabulin in anaplastic cancer of the thyroid) trial, a randomized Phase 2/3 study in ATC, which enrolled 80 patients between July 2007 and February 2010.", "sentB": "In a Phase 2/3 clinical trial of ZYBRESTAT in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) in the treatment of ATC, also known as the FACT (Fosbretabulin in Anaplastic Cancer of the Thyroid) trial, conducted between July 2007 and February 2010 in 80 patients at 40 sites in 11 countries, we demonstrated a meaningful, although not statistically significant, improvement in overall survival (OS), the primary endpoint.", "type": 2, "words": ["<tag1>", "We", "subsequently", "conducted", "the", "FACT", "(fosbretabulin", "in", "anaplastic", "cancer", "of", "the", "thyroid)", "trial,", "a", "randomized", "Phase", "2/3", "study", "in", "ATC,", "which", "enrolled", "80", "patients", "between", "July", "2007", "and", "February", "2010.", "<tag2>", "In", "a", "Phase", "2/3", "clinical", "trial", "of", "ZYBRESTAT", "in", "combination", "with", "Paraplatin", "(carboplatin)", "and", "Taxol", "(paclitaxel)", "in", "the", "treatment", "of", "ATC,", "also", "known", "as", "the", "FACT", "(Fosbretabulin", "in", "Anaplastic", "Cancer", "of", "the", "Thyroid)", "trial,", "conducted", "between", "July", "2007", "and", "February", "2010", "in", "80", "patients", "at", "40", "sites", "in", "11", "countries,", "we", "demonstrated", "a", "meaningful,", "although", "not", "statistically", "significant,", "improvement", "in", "overall", "survival", "(OS),", "the", "primary", "endpoint.", "<tag3>"], "wordsA": ["We", "subsequently", "conducted", "the", "FACT", "(fosbretabulin", "in", "anaplastic", "cancer", "of", "the", "thyroid)", "trial,", "a", "randomized", "Phase", "2/3", "study", "in", "ATC,", "which", "enrolled", "80", "patients", "between", "July", "2007", "and", "February", "2010."], "wordsB": ["In", "a", "Phase", "2/3", "clinical", "trial", "of", "ZYBRESTAT", "in", "combination", "with", "Paraplatin", "(carboplatin)", "and", "Taxol", "(paclitaxel)", "in", "the", "treatment", "of", "ATC,", "also", "known", "as", "the", "FACT", "(Fosbretabulin", "in", "Anaplastic", "Cancer", "of", "the", "Thyroid)", "trial,", "conducted", "between", "July", "2007", "and", "February", "2010", "in", "80", "patients", "at", "40", "sites", "in", "11", "countries,", "we", "demonstrated", "a", "meaningful,", "although", "not", "statistically", "significant,", "improvement", "in", "overall", "survival", "(OS),", "the", "primary", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s13", "idA": "908259_13_item1_p30_s0", "sentA": "The trial was originally designed to evaluate ZYBRESTAT in 180 patients as a potential treatment for ATC.", "sentB": "The trial was conducted under cooperative research and development agreements between us and NCI and between NCI and Genentech.", "type": 2, "words": ["<tag1>", "The", "trial", "was", "originally", "designed", "to", "evaluate", "ZYBRESTAT", "in", "180", "patients", "as", "a", "potential", "treatment", "for", "ATC.", "<tag2>", "The", "trial", "was", "conducted", "under", "cooperative", "research", "and", "development", "agreements", "between", "us", "and", "NCI", "and", "between", "NCI", "and", "Genentech.", "<tag3>"], "wordsA": ["The", "trial", "was", "originally", "designed", "to", "evaluate", "ZYBRESTAT", "in", "180", "patients", "as", "a", "potential", "treatment", "for", "ATC."], "wordsB": ["The", "trial", "was", "conducted", "under", "cooperative", "research", "and", "development", "agreements", "between", "us", "and", "NCI", "and", "between", "NCI", "and", "Genentech."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p7_s1", "idA": "908259_13_item1_p31_s0", "sentA": "The primary endpoint for the FACT trial was overall survival.", "sentB": "Secondary endpoints in the study included safety, objective response rate (measured according to RECIST criteria) and overall survival.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "for", "the", "FACT", "trial", "was", "overall", "survival.", "<tag2>", "Secondary", "endpoints", "in", "the", "study", "included", "safety,", "objective", "response", "rate", "(measured", "according", "to", "RECIST", "criteria)", "and", "overall", "survival.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "for", "the", "FACT", "trial", "was", "overall", "survival."], "wordsB": ["Secondary", "endpoints", "in", "the", "study", "included", "safety,", "objective", "response", "rate", "(measured", "according", "to", "RECIST", "criteria)", "and", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p7_s3", "idA": "908259_13_item1_p31_s0", "sentA": "The primary endpoint for the FACT trial was overall survival.", "sentB": "In accordance with the study protocol, all patients will continue to be followed for overall survival.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "for", "the", "FACT", "trial", "was", "overall", "survival.", "<tag2>", "In", "accordance", "with", "the", "study", "protocol,", "all", "patients", "will", "continue", "to", "be", "followed", "for", "overall", "survival.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "for", "the", "FACT", "trial", "was", "overall", "survival."], "wordsB": ["In", "accordance", "with", "the", "study", "protocol,", "all", "patients", "will", "continue", "to", "be", "followed", "for", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p17_s3", "idA": "908259_13_item1_p31_s2", "sentA": "Due to the rarity of the disease and the fact that many of the patients screened for the study did not meet the trial s inclusion criteria or either died or no longer met the trial s inclusion criteria, the enrollment period spanned more than twice the planned 18 month period.", "sentB": "Due to the rarity of the disease and the fact that many of the patients screened for the study either did not meet the trial s inclusion criteria, progressed rapidly or died, we experienced significant difficulties meeting our original 18-month, 180-patient enrollment goal and instead chose to discontinue enrollment after enrolling 80 patients.", "type": 2, "words": ["<tag1>", "Due", "to", "the", "rarity", "of", "the", "disease", "and", "the", "fact", "that", "many", "of", "the", "patients", "screened", "for", "the", "study", "did", "not", "meet", "the", "trial", "s", "inclusion", "criteria", "or", "either", "died", "or", "no", "longer", "met", "the", "trial", "s", "inclusion", "criteria,", "the", "enrollment", "period", "spanned", "more", "than", "twice", "the", "planned", "18", "month", "period.", "<tag2>", "Due", "to", "the", "rarity", "of", "the", "disease", "and", "the", "fact", "that", "many", "of", "the", "patients", "screened", "for", "the", "study", "either", "did", "not", "meet", "the", "trial", "s", "inclusion", "criteria,", "progressed", "rapidly", "or", "died,", "we", "experienced", "significant", "difficulties", "meeting", "our", "original", "18-month,", "180-patient", "enrollment", "goal", "and", "instead", "chose", "to", "discontinue", "enrollment", "after", "enrolling", "80", "patients.", "<tag3>"], "wordsA": ["Due", "to", "the", "rarity", "of", "the", "disease", "and", "the", "fact", "that", "many", "of", "the", "patients", "screened", "for", "the", "study", "did", "not", "meet", "the", "trial", "s", "inclusion", "criteria", "or", "either", "died", "or", "no", "longer", "met", "the", "trial", "s", "inclusion", "criteria,", "the", "enrollment", "period", "spanned", "more", "than", "twice", "the", "planned", "18", "month", "period."], "wordsB": ["Due", "to", "the", "rarity", "of", "the", "disease", "and", "the", "fact", "that", "many", "of", "the", "patients", "screened", "for", "the", "study", "either", "did", "not", "meet", "the", "trial", "s", "inclusion", "criteria,", "progressed", "rapidly", "or", "died,", "we", "experienced", "significant", "difficulties", "meeting", "our", "original", "18-month,", "180-patient", "enrollment", "goal", "and", "instead", "chose", "to", "discontinue", "enrollment", "after", "enrolling", "80", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p16_s2", "idA": "908259_13_item1_p32_s1", "sentA": "Dr. Sosa presented data reflecting a median overall survival, or OS, time of 5.2 months for patients who received ZYBRESTAT and chemotherapy compared with 4.0 months for patients receiving chemotherapy alone.", "sentB": "More specifically, the FACT trial showed a median overall survival, or OS, time of 5.2 months for patients receiving both chemotherapy and ZYBRESTAT compared to 4.0 months for patients receiving chemotherapy alone, equating to a 28% reduction in the risk of death.", "type": 2, "words": ["<tag1>", "Dr.", "Sosa", "presented", "data", "reflecting", "a", "median", "overall", "survival,", "or", "OS,", "time", "of", "5.2", "months", "for", "patients", "who", "received", "ZYBRESTAT", "and", "chemotherapy", "compared", "with", "4.0", "months", "for", "patients", "receiving", "chemotherapy", "alone.", "<tag2>", "More", "specifically,", "the", "FACT", "trial", "showed", "a", "median", "overall", "survival,", "or", "OS,", "time", "of", "5.2", "months", "for", "patients", "receiving", "both", "chemotherapy", "and", "ZYBRESTAT", "compared", "to", "4.0", "months", "for", "patients", "receiving", "chemotherapy", "alone,", "equating", "to", "a", "28%", "reduction", "in", "the", "risk", "of", "death.", "<tag3>"], "wordsA": ["Dr.", "Sosa", "presented", "data", "reflecting", "a", "median", "overall", "survival,", "or", "OS,", "time", "of", "5.2", "months", "for", "patients", "who", "received", "ZYBRESTAT", "and", "chemotherapy", "compared", "with", "4.0", "months", "for", "patients", "receiving", "chemotherapy", "alone."], "wordsB": ["More", "specifically,", "the", "FACT", "trial", "showed", "a", "median", "overall", "survival,", "or", "OS,", "time", "of", "5.2", "months", "for", "patients", "receiving", "both", "chemotherapy", "and", "ZYBRESTAT", "compared", "to", "4.0", "months", "for", "patients", "receiving", "chemotherapy", "alone,", "equating", "to", "a", "28%", "reduction", "in", "the", "risk", "of", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p16_s3", "idA": "908259_13_item1_p32_s4", "sentA": "At one year, the data suggested that the likelihood of being alive was 26% for patients treated with ZYBRESTAT and chemotherapy compared with 9% for patients treated with chemotherapy alone.", "sentB": "Put differently, patients treated with both chemotherapy and ZYBRESTAT had a 48% and 26% likelihood of being alive at six months and one year, respectively, versus only 35% and 9% for patients treated with chemotherapy alone.", "type": 2, "words": ["<tag1>", "At", "one", "year,", "the", "data", "suggested", "that", "the", "likelihood", "of", "being", "alive", "was", "26%", "for", "patients", "treated", "with", "ZYBRESTAT", "and", "chemotherapy", "compared", "with", "9%", "for", "patients", "treated", "with", "chemotherapy", "alone.", "<tag2>", "Put", "differently,", "patients", "treated", "with", "both", "chemotherapy", "and", "ZYBRESTAT", "had", "a", "48%", "and", "26%", "likelihood", "of", "being", "alive", "at", "six", "months", "and", "one", "year,", "respectively,", "versus", "only", "35%", "and", "9%", "for", "patients", "treated", "with", "chemotherapy", "alone.", "<tag3>"], "wordsA": ["At", "one", "year,", "the", "data", "suggested", "that", "the", "likelihood", "of", "being", "alive", "was", "26%", "for", "patients", "treated", "with", "ZYBRESTAT", "and", "chemotherapy", "compared", "with", "9%", "for", "patients", "treated", "with", "chemotherapy", "alone."], "wordsB": ["Put", "differently,", "patients", "treated", "with", "both", "chemotherapy", "and", "ZYBRESTAT", "had", "a", "48%", "and", "26%", "likelihood", "of", "being", "alive", "at", "six", "months", "and", "one", "year,", "respectively,", "versus", "only", "35%", "and", "9%", "for", "patients", "treated", "with", "chemotherapy", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p17_s0", "idA": "908259_13_item1_p33_s0", "sentA": "As in other studies, ZYBRESTAT appeared to be well tolerated.", "sentB": "As in prior studies, ZYBRESTAT appeared to be well tolerated.", "type": 2, "words": ["<tag1>", "As", "in", "other", "studies,", "ZYBRESTAT", "appeared", "to", "be", "well", "tolerated.", "<tag2>", "As", "in", "prior", "studies,", "ZYBRESTAT", "appeared", "to", "be", "well", "tolerated.", "<tag3>"], "wordsA": ["As", "in", "other", "studies,", "ZYBRESTAT", "appeared", "to", "be", "well", "tolerated."], "wordsB": ["As", "in", "prior", "studies,", "ZYBRESTAT", "appeared", "to", "be", "well", "tolerated."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p22_s4", "idA": "908259_13_item1_p33_s0", "sentA": "As in other studies, ZYBRESTAT appeared to be well tolerated.", "sentB": "Treatment with ZYBRESTAT was shown to be well tolerated, with no obvious toxicity and was shown to disrupt tumor vasculature, induce apoptosis (cell death) and inhibit tumor cell proliferation.", "type": 2, "words": ["<tag1>", "As", "in", "other", "studies,", "ZYBRESTAT", "appeared", "to", "be", "well", "tolerated.", "<tag2>", "Treatment", "with", "ZYBRESTAT", "was", "shown", "to", "be", "well", "tolerated,", "with", "no", "obvious", "toxicity", "and", "was", "shown", "to", "disrupt", "tumor", "vasculature,", "induce", "apoptosis", "(cell", "death)", "and", "inhibit", "tumor", "cell", "proliferation.", "<tag3>"], "wordsA": ["As", "in", "other", "studies,", "ZYBRESTAT", "appeared", "to", "be", "well", "tolerated."], "wordsB": ["Treatment", "with", "ZYBRESTAT", "was", "shown", "to", "be", "well", "tolerated,", "with", "no", "obvious", "toxicity", "and", "was", "shown", "to", "disrupt", "tumor", "vasculature,", "induce", "apoptosis", "(cell", "death)", "and", "inhibit", "tumor", "cell", "proliferation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p18_s0", "idA": "908259_13_item1_p34_s0", "sentA": "ZYBRESTAT in Neuroendocrine Tumors with Refractory Carcinoid Syndrome Another indication that we started to pursue in 2012 is the treatment of carcinoid syndrome.", "sentB": "Neuroendocrine Tumors with Carcinoid Syndrome Carcinoid syndrome occurs in a sub-population of patients with neuroendocrine tumors who display an array of symptoms, such as flushing, diarrhea and, less frequently, bronchoconstriction and heart failure.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "in", "Neuroendocrine", "Tumors", "with", "Refractory", "Carcinoid", "Syndrome", "Another", "indication", "that", "we", "started", "to", "pursue", "in", "2012", "is", "the", "treatment", "of", "carcinoid", "syndrome.", "<tag2>", "Neuroendocrine", "Tumors", "with", "Carcinoid", "Syndrome", "Carcinoid", "syndrome", "occurs", "in", "a", "sub-population", "of", "patients", "with", "neuroendocrine", "tumors", "who", "display", "an", "array", "of", "symptoms,", "such", "as", "flushing,", "diarrhea", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag3>"], "wordsA": ["ZYBRESTAT", "in", "Neuroendocrine", "Tumors", "with", "Refractory", "Carcinoid", "Syndrome", "Another", "indication", "that", "we", "started", "to", "pursue", "in", "2012", "is", "the", "treatment", "of", "carcinoid", "syndrome."], "wordsB": ["Neuroendocrine", "Tumors", "with", "Carcinoid", "Syndrome", "Carcinoid", "syndrome", "occurs", "in", "a", "sub-population", "of", "patients", "with", "neuroendocrine", "tumors", "who", "display", "an", "array", "of", "symptoms,", "such", "as", "flushing,", "diarrhea", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p22_s5", "idA": "908259_13_item1_p34_s1", "sentA": "In June 2012, we announced the establishment of an exclusive, worldwide licensing agreement with Angiogene Pharmaceuticals Ltd., a U.K.-based drug development company relative to their VDA program for neuroendocrine cancers, focused specifically on carcinoid syndrome.", "sentB": "In 2012, we announced the establishment of an exclusive, worldwide licensing agreement with Angiogene Pharmaceuticals Ltd., a U.K.-based drug development company that had previously been developing a competing VDA, for intellectual property covering the use of VDAs in treatment of symptoms related to carcinoid syndrome and other neuroendocrine tumors.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "announced", "the", "establishment", "of", "an", "exclusive,", "worldwide", "licensing", "agreement", "with", "Angiogene", "Pharmaceuticals", "Ltd.,", "a", "U.K.-based", "drug", "development", "company", "relative", "to", "their", "VDA", "program", "for", "neuroendocrine", "cancers,", "focused", "specifically", "on", "carcinoid", "syndrome.", "<tag2>", "In", "2012,", "we", "announced", "the", "establishment", "of", "an", "exclusive,", "worldwide", "licensing", "agreement", "with", "Angiogene", "Pharmaceuticals", "Ltd.,", "a", "U.K.-based", "drug", "development", "company", "that", "had", "previously", "been", "developing", "a", "competing", "VDA,", "for", "intellectual", "property", "covering", "the", "use", "of", "VDAs", "in", "treatment", "of", "symptoms", "related", "to", "carcinoid", "syndrome", "and", "other", "neuroendocrine", "tumors.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "announced", "the", "establishment", "of", "an", "exclusive,", "worldwide", "licensing", "agreement", "with", "Angiogene", "Pharmaceuticals", "Ltd.,", "a", "U.K.-based", "drug", "development", "company", "relative", "to", "their", "VDA", "program", "for", "neuroendocrine", "cancers,", "focused", "specifically", "on", "carcinoid", "syndrome."], "wordsB": ["In", "2012,", "we", "announced", "the", "establishment", "of", "an", "exclusive,", "worldwide", "licensing", "agreement", "with", "Angiogene", "Pharmaceuticals", "Ltd.,", "a", "U.K.-based", "drug", "development", "company", "that", "had", "previously", "been", "developing", "a", "competing", "VDA,", "for", "intellectual", "property", "covering", "the", "use", "of", "VDAs", "in", "treatment", "of", "symptoms", "related", "to", "carcinoid", "syndrome", "and", "other", "neuroendocrine", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p59_s0", "idA": "908259_13_item1_p34_s1", "sentA": "In June 2012, we announced the establishment of an exclusive, worldwide licensing agreement with Angiogene Pharmaceuticals Ltd., a U.K.-based drug development company relative to their VDA program for neuroendocrine cancers, focused specifically on carcinoid syndrome.", "sentB": "In June 2012, we secured a royalty-bearing, transferable, worldwide, exclusive license from Angiogene Pharmaceuticals Ltd. to make, have made, use, import, offer for sale, and sell a vascular disrupting agent, such as ZYBRESTAT , for treating neuroendocrine tumors and associated symptoms and syndromes.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "announced", "the", "establishment", "of", "an", "exclusive,", "worldwide", "licensing", "agreement", "with", "Angiogene", "Pharmaceuticals", "Ltd.,", "a", "U.K.-based", "drug", "development", "company", "relative", "to", "their", "VDA", "program", "for", "neuroendocrine", "cancers,", "focused", "specifically", "on", "carcinoid", "syndrome.", "<tag2>", "In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "ZYBRESTAT", ",", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "announced", "the", "establishment", "of", "an", "exclusive,", "worldwide", "licensing", "agreement", "with", "Angiogene", "Pharmaceuticals", "Ltd.,", "a", "U.K.-based", "drug", "development", "company", "relative", "to", "their", "VDA", "program", "for", "neuroendocrine", "cancers,", "focused", "specifically", "on", "carcinoid", "syndrome."], "wordsB": ["In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "ZYBRESTAT", ",", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s1", "idA": "908259_13_item1_p35_s1", "sentA": "Assuming similar incidence rates, this would translate to approximately 25,000-30,000 new cases of NETs annually in the combined markets of Europe and Japan.", "sentB": "All cases of hypertension were managed with antihypertensive treatments, as specified in the study protocol.", "type": 2, "words": ["<tag1>", "Assuming", "similar", "incidence", "rates,", "this", "would", "translate", "to", "approximately", "25,000-30,000", "new", "cases", "of", "NETs", "annually", "in", "the", "combined", "markets", "of", "Europe", "and", "Japan.", "<tag2>", "All", "cases", "of", "hypertension", "were", "managed", "with", "antihypertensive", "treatments,", "as", "specified", "in", "the", "study", "protocol.", "<tag3>"], "wordsA": ["Assuming", "similar", "incidence", "rates,", "this", "would", "translate", "to", "approximately", "25,000-30,000", "new", "cases", "of", "NETs", "annually", "in", "the", "combined", "markets", "of", "Europe", "and", "Japan."], "wordsB": ["All", "cases", "of", "hypertension", "were", "managed", "with", "antihypertensive", "treatments,", "as", "specified", "in", "the", "study", "protocol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p18_s3", "idA": "908259_13_item1_p36_s2", "sentA": "The medical need for additional therapeutic options to control the debilitating symptoms of carcinoid syndrome remains acute and may provide an opportunity for us to utilize our technology and experience in developing VDA drugs for the benefit of those patients.", "sentB": "While drug treatment with somatostatin analogues, such as Sandostatin , helps to control the symptoms of carcinoid syndrome, patients who are or become unresponsive to somatostatin have limited therapeutic options, and we believe that treatment with ZYBRESTAT , resulting in vascular shutdown and tumor necrosis, may improve outcomes for these patients.", "type": 2, "words": ["<tag1>", "The", "medical", "need", "for", "additional", "therapeutic", "options", "to", "control", "the", "debilitating", "symptoms", "of", "carcinoid", "syndrome", "remains", "acute", "and", "may", "provide", "an", "opportunity", "for", "us", "to", "utilize", "our", "technology", "and", "experience", "in", "developing", "VDA", "drugs", "for", "the", "benefit", "of", "those", "patients.", "<tag2>", "While", "drug", "treatment", "with", "somatostatin", "analogues,", "such", "as", "Sandostatin", ",", "helps", "to", "control", "the", "symptoms", "of", "carcinoid", "syndrome,", "patients", "who", "are", "or", "become", "unresponsive", "to", "somatostatin", "have", "limited", "therapeutic", "options,", "and", "we", "believe", "that", "treatment", "with", "ZYBRESTAT", ",", "resulting", "in", "vascular", "shutdown", "and", "tumor", "necrosis,", "may", "improve", "outcomes", "for", "these", "patients.", "<tag3>"], "wordsA": ["The", "medical", "need", "for", "additional", "therapeutic", "options", "to", "control", "the", "debilitating", "symptoms", "of", "carcinoid", "syndrome", "remains", "acute", "and", "may", "provide", "an", "opportunity", "for", "us", "to", "utilize", "our", "technology", "and", "experience", "in", "developing", "VDA", "drugs", "for", "the", "benefit", "of", "those", "patients."], "wordsB": ["While", "drug", "treatment", "with", "somatostatin", "analogues,", "such", "as", "Sandostatin", ",", "helps", "to", "control", "the", "symptoms", "of", "carcinoid", "syndrome,", "patients", "who", "are", "or", "become", "unresponsive", "to", "somatostatin", "have", "limited", "therapeutic", "options,", "and", "we", "believe", "that", "treatment", "with", "ZYBRESTAT", ",", "resulting", "in", "vascular", "shutdown", "and", "tumor", "necrosis,", "may", "improve", "outcomes", "for", "these", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p18_s2", "idA": "908259_13_item1_p36_s3", "sentA": "Given the compelling scientific basis for using a VDA to disrupt blood flow to induce tumor necrosis and reduce production of biologically active mediators, such as serotonin, which are associated with the most severe, debilitating symptoms of this disease, we plan to investigate the effectiveness of ZYBRESTAT in this setting.", "sentB": "These symptoms are caused by overproduction of biologically active substances such as serotonin and kallikrein, which are released directly into systemic circulation, bypassing hepatic degradation.", "type": 2, "words": ["<tag1>", "Given", "the", "compelling", "scientific", "basis", "for", "using", "a", "VDA", "to", "disrupt", "blood", "flow", "to", "induce", "tumor", "necrosis", "and", "reduce", "production", "of", "biologically", "active", "mediators,", "such", "as", "serotonin,", "which", "are", "associated", "with", "the", "most", "severe,", "debilitating", "symptoms", "of", "this", "disease,", "we", "plan", "to", "investigate", "the", "effectiveness", "of", "ZYBRESTAT", "in", "this", "setting.", "<tag2>", "These", "symptoms", "are", "caused", "by", "overproduction", "of", "biologically", "active", "substances", "such", "as", "serotonin", "and", "kallikrein,", "which", "are", "released", "directly", "into", "systemic", "circulation,", "bypassing", "hepatic", "degradation.", "<tag3>"], "wordsA": ["Given", "the", "compelling", "scientific", "basis", "for", "using", "a", "VDA", "to", "disrupt", "blood", "flow", "to", "induce", "tumor", "necrosis", "and", "reduce", "production", "of", "biologically", "active", "mediators,", "such", "as", "serotonin,", "which", "are", "associated", "with", "the", "most", "severe,", "debilitating", "symptoms", "of", "this", "disease,", "we", "plan", "to", "investigate", "the", "effectiveness", "of", "ZYBRESTAT", "in", "this", "setting."], "wordsB": ["These", "symptoms", "are", "caused", "by", "overproduction", "of", "biologically", "active", "substances", "such", "as", "serotonin", "and", "kallikrein,", "which", "are", "released", "directly", "into", "systemic", "circulation,", "bypassing", "hepatic", "degradation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p24_s0", "idA": "908259_13_item1_p37_s1", "sentA": "We believe this unique property may result in enhanced anti-tumor activity in certain tumor types as compared with other VDA drug candidates.", "sentB": "We believe that this dual mechanism differentiates OXi4503 from other VDAs and may result in enhanced anti-tumor activity in certain tumor types as compared with other VDA drug candidates.", "type": 2, "words": ["<tag1>", "We", "believe", "this", "unique", "property", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types", "as", "compared", "with", "other", "VDA", "drug", "candidates.", "<tag2>", "We", "believe", "that", "this", "dual", "mechanism", "differentiates", "OXi4503", "from", "other", "VDAs", "and", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types", "as", "compared", "with", "other", "VDA", "drug", "candidates.", "<tag3>"], "wordsA": ["We", "believe", "this", "unique", "property", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types", "as", "compared", "with", "other", "VDA", "drug", "candidates."], "wordsB": ["We", "believe", "that", "this", "dual", "mechanism", "differentiates", "OXi4503", "from", "other", "VDAs", "and", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types", "as", "compared", "with", "other", "VDA", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p25_s0", "idA": "908259_13_item1_p38_s0", "sentA": "Based on data from preclinical studies, we believe that OXi4503 may have enhanced activity in tumor types with relatively high levels of the enzymes that facilitate the conversion of OXi4503 to the form of chemical that kills tumor cells.", "sentB": "Based on preclinical data, we believe that OXi4503 may be particularly active in hepatocellular carcinoma, melanoma, and leukemias of the myeloid lineage, all of which have relatively high levels of the enzymes that facilitate the conversion of OXi4503 into a chemical that directly kills tumor cells.", "type": 2, "words": ["<tag1>", "Based", "on", "data", "from", "preclinical", "studies,", "we", "believe", "that", "OXi4503", "may", "have", "enhanced", "activity", "in", "tumor", "types", "with", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "to", "the", "form", "of", "chemical", "that", "kills", "tumor", "cells.", "<tag2>", "Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "hepatocellular", "carcinoma,", "melanoma,", "and", "leukemias", "of", "the", "myeloid", "lineage,", "all", "of", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "chemical", "that", "directly", "kills", "tumor", "cells.", "<tag3>"], "wordsA": ["Based", "on", "data", "from", "preclinical", "studies,", "we", "believe", "that", "OXi4503", "may", "have", "enhanced", "activity", "in", "tumor", "types", "with", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "to", "the", "form", "of", "chemical", "that", "kills", "tumor", "cells."], "wordsB": ["Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "hepatocellular", "carcinoma,", "melanoma,", "and", "leukemias", "of", "the", "myeloid", "lineage,", "all", "of", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "chemical", "that", "directly", "kills", "tumor", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p25_s1", "idA": "908259_13_item1_p38_s2", "sentA": "In preclinical studies, OXi4503 has shown potent anti-tumor activity in solid tumors and acute myeloid leukemia models, both as a single agent and in combination with other cancer treatment modalities.", "sentB": "Similar to ZYBRESTAT , OXi4503 has shown potent anti-tumor activity in preclinical studies of solid tumors and acute myelogenous leukemia, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other antiproliferative agents.", "type": 2, "words": ["<tag1>", "In", "preclinical", "studies,", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "solid", "tumors", "and", "acute", "myeloid", "leukemia", "models,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "cancer", "treatment", "modalities.", "<tag2>", "Similar", "to", "ZYBRESTAT", ",", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "acute", "myelogenous", "leukemia,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "antiproliferative", "agents.", "<tag3>"], "wordsA": ["In", "preclinical", "studies,", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "solid", "tumors", "and", "acute", "myeloid", "leukemia", "models,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "cancer", "treatment", "modalities."], "wordsB": ["Similar", "to", "ZYBRESTAT", ",", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "acute", "myelogenous", "leukemia,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "antiproliferative", "agents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p27_s0", "idA": "908259_13_item1_p38_s3", "sentA": "Ongoing Clinical Trial in AML with OXi4503 Based on the results of preclinical studies published in the journal Blood in September 2010 that show OXi4503 has potent activity against AML in animal models, we entered into a clinical trial agreement pursuant to which investigators at the University of Florida initiated an investigator sponsored Phase 1 study of OXi4503 in patients with AML or MDS in May 2011.", "sentB": "OXi4503 has demonstrated potent activity against AML in animal models, and these results were published in the journal Blood in September 2010.", "type": 2, "words": ["<tag1>", "Ongoing", "Clinical", "Trial", "in", "AML", "with", "OXi4503", "Based", "on", "the", "results", "of", "preclinical", "studies", "published", "in", "the", "journal", "Blood", "in", "September", "2010", "that", "show", "OXi4503", "has", "potent", "activity", "against", "AML", "in", "animal", "models,", "we", "entered", "into", "a", "clinical", "trial", "agreement", "pursuant", "to", "which", "investigators", "at", "the", "University", "of", "Florida", "initiated", "an", "investigator", "sponsored", "Phase", "1", "study", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS", "in", "May", "2011.", "<tag2>", "OXi4503", "has", "demonstrated", "potent", "activity", "against", "AML", "in", "animal", "models,", "and", "these", "results", "were", "published", "in", "the", "journal", "Blood", "in", "September", "2010.", "<tag3>"], "wordsA": ["Ongoing", "Clinical", "Trial", "in", "AML", "with", "OXi4503", "Based", "on", "the", "results", "of", "preclinical", "studies", "published", "in", "the", "journal", "Blood", "in", "September", "2010", "that", "show", "OXi4503", "has", "potent", "activity", "against", "AML", "in", "animal", "models,", "we", "entered", "into", "a", "clinical", "trial", "agreement", "pursuant", "to", "which", "investigators", "at", "the", "University", "of", "Florida", "initiated", "an", "investigator", "sponsored", "Phase", "1", "study", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS", "in", "May", "2011."], "wordsB": ["OXi4503", "has", "demonstrated", "potent", "activity", "against", "AML", "in", "animal", "models,", "and", "these", "results", "were", "published", "in", "the", "journal", "Blood", "in", "September", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p27_s1", "idA": "908259_13_item1_p38_s3", "sentA": "Ongoing Clinical Trial in AML with OXi4503 Based on the results of preclinical studies published in the journal Blood in September 2010 that show OXi4503 has potent activity against AML in animal models, we entered into a clinical trial agreement pursuant to which investigators at the University of Florida initiated an investigator sponsored Phase 1 study of OXi4503 in patients with AML or MDS in May 2011.", "sentB": "Shortly thereafter, we entered into a clinical trial agreement with the University of Florida related to an investigator-sponsored Phase 1 study of OXi4503 in up to 36 patients with AML or myelodysplastic syndrome, or MDS, a disorder of the normal blood formation process, which trial was subsequently initiated in May 2011.", "type": 2, "words": ["<tag1>", "Ongoing", "Clinical", "Trial", "in", "AML", "with", "OXi4503", "Based", "on", "the", "results", "of", "preclinical", "studies", "published", "in", "the", "journal", "Blood", "in", "September", "2010", "that", "show", "OXi4503", "has", "potent", "activity", "against", "AML", "in", "animal", "models,", "we", "entered", "into", "a", "clinical", "trial", "agreement", "pursuant", "to", "which", "investigators", "at", "the", "University", "of", "Florida", "initiated", "an", "investigator", "sponsored", "Phase", "1", "study", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS", "in", "May", "2011.", "<tag2>", "Shortly", "thereafter,", "we", "entered", "into", "a", "clinical", "trial", "agreement", "with", "the", "University", "of", "Florida", "related", "to", "an", "investigator-sponsored", "Phase", "1", "study", "of", "OXi4503", "in", "up", "to", "36", "patients", "with", "AML", "or", "myelodysplastic", "syndrome,", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "which", "trial", "was", "subsequently", "initiated", "in", "May", "2011.", "<tag3>"], "wordsA": ["Ongoing", "Clinical", "Trial", "in", "AML", "with", "OXi4503", "Based", "on", "the", "results", "of", "preclinical", "studies", "published", "in", "the", "journal", "Blood", "in", "September", "2010", "that", "show", "OXi4503", "has", "potent", "activity", "against", "AML", "in", "animal", "models,", "we", "entered", "into", "a", "clinical", "trial", "agreement", "pursuant", "to", "which", "investigators", "at", "the", "University", "of", "Florida", "initiated", "an", "investigator", "sponsored", "Phase", "1", "study", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS", "in", "May", "2011."], "wordsB": ["Shortly", "thereafter,", "we", "entered", "into", "a", "clinical", "trial", "agreement", "with", "the", "University", "of", "Florida", "related", "to", "an", "investigator-sponsored", "Phase", "1", "study", "of", "OXi4503", "in", "up", "to", "36", "patients", "with", "AML", "or", "myelodysplastic", "syndrome,", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "which", "trial", "was", "subsequently", "initiated", "in", "May", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p30_s1", "idA": "908259_13_item1_p38_s4", "sentA": "This open-label, dose-escalating study for the treatment of up to 36 patients is being conducted in patients with relapsed or refractory AML and MDS and will evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "sentB": "Accordingly, OXi4503 appears to be well tolerated based on these results to date in patients with relapsed and refractory AML and MDS.", "type": 2, "words": ["<tag1>", "This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "is", "being", "conducted", "in", "patients", "with", "relapsed", "or", "refractory", "AML", "and", "MDS", "and", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag2>", "Accordingly,", "OXi4503", "appears", "to", "be", "well", "tolerated", "based", "on", "these", "results", "to", "date", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS.", "<tag3>"], "wordsA": ["This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "is", "being", "conducted", "in", "patients", "with", "relapsed", "or", "refractory", "AML", "and", "MDS", "and", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "wordsB": ["Accordingly,", "OXi4503", "appears", "to", "be", "well", "tolerated", "based", "on", "these", "results", "to", "date", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p32_s0", "idA": "908259_13_item1_p38_s4", "sentA": "This open-label, dose-escalating study for the treatment of up to 36 patients is being conducted in patients with relapsed or refractory AML and MDS and will evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "sentB": "This open-label, dose-escalating study for the treatment of up to 36 patients will evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "type": 2, "words": ["<tag1>", "This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "is", "being", "conducted", "in", "patients", "with", "relapsed", "or", "refractory", "AML", "and", "MDS", "and", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag2>", "This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag3>"], "wordsA": ["This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "is", "being", "conducted", "in", "patients", "with", "relapsed", "or", "refractory", "AML", "and", "MDS", "and", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "wordsB": ["This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p28_s0", "idA": "908259_13_item1_p38_s6", "sentA": "In December 2012, the investigators at the University of Florida presented data from this Phase 1 study at the 2012 annual meeting of the American Society of Hematology in Atlanta, Georgia.", "sentB": "In December 2012, the investigators at the University of Florida presented compelling initial data from this Phase 1 study at the 2012 annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, indicating that OXi4503 was active, generating responses in patients, and had a manageable safety profile.", "type": 2, "words": ["<tag1>", "In", "December", "2012,", "the", "investigators", "at", "the", "University", "of", "Florida", "presented", "data", "from", "this", "Phase", "1", "study", "at", "the", "2012", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology", "in", "Atlanta,", "Georgia.", "<tag2>", "In", "December", "2012,", "the", "investigators", "at", "the", "University", "of", "Florida", "presented", "compelling", "initial", "data", "from", "this", "Phase", "1", "study", "at", "the", "2012", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology", "(ASH)", "in", "Atlanta,", "Georgia,", "indicating", "that", "OXi4503", "was", "active,", "generating", "responses", "in", "patients,", "and", "had", "a", "manageable", "safety", "profile.", "<tag3>"], "wordsA": ["In", "December", "2012,", "the", "investigators", "at", "the", "University", "of", "Florida", "presented", "data", "from", "this", "Phase", "1", "study", "at", "the", "2012", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology", "in", "Atlanta,", "Georgia."], "wordsB": ["In", "December", "2012,", "the", "investigators", "at", "the", "University", "of", "Florida", "presented", "compelling", "initial", "data", "from", "this", "Phase", "1", "study", "at", "the", "2012", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology", "(ASH)", "in", "Atlanta,", "Georgia,", "indicating", "that", "OXi4503", "was", "active,", "generating", "responses", "in", "patients,", "and", "had", "a", "manageable", "safety", "profile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p29_s1", "idA": "908259_13_item1_p38_s6", "sentA": "In December 2012, the investigators at the University of Florida presented data from this Phase 1 study at the 2012 annual meeting of the American Society of Hematology in Atlanta, Georgia.", "sentB": "Updated data from this trial was presented at the December 2013 annual meeting of ASH in New Orleans, Louisiana.", "type": 2, "words": ["<tag1>", "In", "December", "2012,", "the", "investigators", "at", "the", "University", "of", "Florida", "presented", "data", "from", "this", "Phase", "1", "study", "at", "the", "2012", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology", "in", "Atlanta,", "Georgia.", "<tag2>", "Updated", "data", "from", "this", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana.", "<tag3>"], "wordsA": ["In", "December", "2012,", "the", "investigators", "at", "the", "University", "of", "Florida", "presented", "data", "from", "this", "Phase", "1", "study", "at", "the", "2012", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology", "in", "Atlanta,", "Georgia."], "wordsB": ["Updated", "data", "from", "this", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p29_s0", "idA": "908259_13_item1_p39_s0", "sentA": "Adverse events attributable to OXi4503 infusion included bone pain, fever, anemia and thrombocytopenia.", "sentB": "Adverse events attributable to OXi4503 infusion included bone pain, fever, anemia and thrombocytopenia, as well as hypertension, the latter of which was readily manageable.", "type": 2, "words": ["<tag1>", "Adverse", "events", "attributable", "to", "OXi4503", "infusion", "included", "bone", "pain,", "fever,", "anemia", "and", "thrombocytopenia.", "<tag2>", "Adverse", "events", "attributable", "to", "OXi4503", "infusion", "included", "bone", "pain,", "fever,", "anemia", "and", "thrombocytopenia,", "as", "well", "as", "hypertension,", "the", "latter", "of", "which", "was", "readily", "manageable.", "<tag3>"], "wordsA": ["Adverse", "events", "attributable", "to", "OXi4503", "infusion", "included", "bone", "pain,", "fever,", "anemia", "and", "thrombocytopenia."], "wordsB": ["Adverse", "events", "attributable", "to", "OXi4503", "infusion", "included", "bone", "pain,", "fever,", "anemia", "and", "thrombocytopenia,", "as", "well", "as", "hypertension,", "the", "latter", "of", "which", "was", "readily", "manageable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p30_s0", "idA": "908259_13_item1_p39_s0", "sentA": "Adverse events attributable to OXi4503 infusion included bone pain, fever, anemia and thrombocytopenia.", "sentB": "Side effects included increases in D-dimer, which is a substance in the blood that is released when a blood clot breaks up, bone pain, fever, chills and flu-like symptoms.", "type": 2, "words": ["<tag1>", "Adverse", "events", "attributable", "to", "OXi4503", "infusion", "included", "bone", "pain,", "fever,", "anemia", "and", "thrombocytopenia.", "<tag2>", "Side", "effects", "included", "increases", "in", "D-dimer,", "which", "is", "a", "substance", "in", "the", "blood", "that", "is", "released", "when", "a", "blood", "clot", "breaks", "up,", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms.", "<tag3>"], "wordsA": ["Adverse", "events", "attributable", "to", "OXi4503", "infusion", "included", "bone", "pain,", "fever,", "anemia", "and", "thrombocytopenia."], "wordsB": ["Side", "effects", "included", "increases", "in", "D-dimer,", "which", "is", "a", "substance", "in", "the", "blood", "that", "is", "released", "when", "a", "blood", "clot", "breaks", "up,", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p28_s1", "idA": "908259_13_item1_p39_s1", "sentA": "Hypertension was manageable and plasma LDH and uric acid increased by at least two-fold within hours after OXi4503 infusions, suggesting leukemia cell destruction.", "sentB": "More specifically, results from five initial patients with refractory AML enrolled between May 2011 and August 2012 revealed an increase in plasma LDH and uric acid levels by at least two-fold within hours after OXi4503 infusions, suggesting leukemia cell destruction.", "type": 2, "words": ["<tag1>", "Hypertension", "was", "manageable", "and", "plasma", "LDH", "and", "uric", "acid", "increased", "by", "at", "least", "two-fold", "within", "hours", "after", "OXi4503", "infusions,", "suggesting", "leukemia", "cell", "destruction.", "<tag2>", "More", "specifically,", "results", "from", "five", "initial", "patients", "with", "refractory", "AML", "enrolled", "between", "May", "2011", "and", "August", "2012", "revealed", "an", "increase", "in", "plasma", "LDH", "and", "uric", "acid", "levels", "by", "at", "least", "two-fold", "within", "hours", "after", "OXi4503", "infusions,", "suggesting", "leukemia", "cell", "destruction.", "<tag3>"], "wordsA": ["Hypertension", "was", "manageable", "and", "plasma", "LDH", "and", "uric", "acid", "increased", "by", "at", "least", "two-fold", "within", "hours", "after", "OXi4503", "infusions,", "suggesting", "leukemia", "cell", "destruction."], "wordsB": ["More", "specifically,", "results", "from", "five", "initial", "patients", "with", "refractory", "AML", "enrolled", "between", "May", "2011", "and", "August", "2012", "revealed", "an", "increase", "in", "plasma", "LDH", "and", "uric", "acid", "levels", "by", "at", "least", "two-fold", "within", "hours", "after", "OXi4503", "infusions,", "suggesting", "leukemia", "cell", "destruction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p32_s2", "idA": "908259_13_item1_p39_s3", "sentA": "As of March 1, 2013 a total of 9 patients have been enrolled into this study and no dose-limiting adverse events have been encountered at this point.", "sentB": "As of March 17, 2014, 15 patients have been enrolled into this study, and a maximum tolerated dose has not been observed.", "type": 2, "words": ["<tag1>", "As", "of", "March", "1,", "2013", "a", "total", "of", "9", "patients", "have", "been", "enrolled", "into", "this", "study", "and", "no", "dose-limiting", "adverse", "events", "have", "been", "encountered", "at", "this", "point.", "<tag2>", "As", "of", "March", "17,", "2014,", "15", "patients", "have", "been", "enrolled", "into", "this", "study,", "and", "a", "maximum", "tolerated", "dose", "has", "not", "been", "observed.", "<tag3>"], "wordsA": ["As", "of", "March", "1,", "2013", "a", "total", "of", "9", "patients", "have", "been", "enrolled", "into", "this", "study", "and", "no", "dose-limiting", "adverse", "events", "have", "been", "encountered", "at", "this", "point."], "wordsB": ["As", "of", "March", "17,", "2014,", "15", "patients", "have", "been", "enrolled", "into", "this", "study,", "and", "a", "maximum", "tolerated", "dose", "has", "not", "been", "observed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s10", "idA": "908259_13_item1_p39_s4", "sentA": "The general direction of future development of OXi4503 for hematologic indications will depend on the outcome of the analysis of the study in AML, as well as available financial resources and potential partnering activities.", "sentB": "Since the study had completed patient accrual, the analysis was conducted to review the tolerability of the combination.", "type": 2, "words": ["<tag1>", "The", "general", "direction", "of", "future", "development", "of", "OXi4503", "for", "hematologic", "indications", "will", "depend", "on", "the", "outcome", "of", "the", "analysis", "of", "the", "study", "in", "AML,", "as", "well", "as", "available", "financial", "resources", "and", "potential", "partnering", "activities.", "<tag2>", "Since", "the", "study", "had", "completed", "patient", "accrual,", "the", "analysis", "was", "conducted", "to", "review", "the", "tolerability", "of", "the", "combination.", "<tag3>"], "wordsA": ["The", "general", "direction", "of", "future", "development", "of", "OXi4503", "for", "hematologic", "indications", "will", "depend", "on", "the", "outcome", "of", "the", "analysis", "of", "the", "study", "in", "AML,", "as", "well", "as", "available", "financial", "resources", "and", "potential", "partnering", "activities."], "wordsB": ["Since", "the", "study", "had", "completed", "patient", "accrual,", "the", "analysis", "was", "conducted", "to", "review", "the", "tolerability", "of", "the", "combination."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s4", "idA": "908259_13_item1_p3_s0", "sentA": "We continue to support the ongoing randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab, an anti-VEGF monoclonal antibody, in patients with relapsed ovarian cancer.", "sentB": "The trial design consists of a Phase 1 dose escalation portion with the combination of VOTRIENT and ZYBRESTAT and a randomized Phase 2 portion comparing VOTRIENT alone versus VOTRIENT plus ZYBRESTAT in patients with relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "continue", "to", "support", "the", "ongoing", "randomized", "Phase", "2", "trial", "of", "ZYBRESTAT", "in", "combination", "with", "bevacizumab,", "an", "anti-VEGF", "monoclonal", "antibody,", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag2>", "The", "trial", "design", "consists", "of", "a", "Phase", "1", "dose", "escalation", "portion", "with", "the", "combination", "of", "VOTRIENT", "and", "ZYBRESTAT", "and", "a", "randomized", "Phase", "2", "portion", "comparing", "VOTRIENT", "alone", "versus", "VOTRIENT", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "continue", "to", "support", "the", "ongoing", "randomized", "Phase", "2", "trial", "of", "ZYBRESTAT", "in", "combination", "with", "bevacizumab,", "an", "anti-VEGF", "monoclonal", "antibody,", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "wordsB": ["The", "trial", "design", "consists", "of", "a", "Phase", "1", "dose", "escalation", "portion", "with", "the", "combination", "of", "VOTRIENT", "and", "ZYBRESTAT", "and", "a", "randomized", "Phase", "2", "portion", "comparing", "VOTRIENT", "alone", "versus", "VOTRIENT", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p0_s2", "idA": "908259_13_item1_p3_s1", "sentA": "The trial, which is being conducted by the Gynecologic Oncology Group or GOG, an organization dedicated to clinical research in the field of gynecologic cancer, and is under the sponsorship of the Cancer Therapy Evaluation Program, or CTEP, of the National Cancer Institute, or NCI.", "sentB": "In the United States, we are pursuing collaborations with established pharmaceutical companies with products whose efficacy we believe can be enhanced by the addition of our lead product candidate, ZYBRESTAT , and with non-profit research organizations such as the Gynecologic Oncology Group, or GOG, an organization dedicated to clinical research in the field of gynecologic cancer, for the treatment of advanced ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "trial,", "which", "is", "being", "conducted", "by", "the", "Gynecologic", "Oncology", "Group", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "and", "is", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI.", "<tag2>", "In", "the", "United", "States,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "ZYBRESTAT", ",", "and", "with", "non-profit", "research", "organizations", "such", "as", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "trial,", "which", "is", "being", "conducted", "by", "the", "Gynecologic", "Oncology", "Group", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "and", "is", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI."], "wordsB": ["In", "the", "United", "States,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "ZYBRESTAT", ",", "and", "with", "non-profit", "research", "organizations", "such", "as", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s8", "idA": "908259_13_item1_p3_s1", "sentA": "The trial, which is being conducted by the Gynecologic Oncology Group or GOG, an organization dedicated to clinical research in the field of gynecologic cancer, and is under the sponsorship of the Cancer Therapy Evaluation Program, or CTEP, of the National Cancer Institute, or NCI.", "sentB": "As in the combination therapy trial of ZYBRESTAT with AVASTIN (bevacizumab), which is sponsored and substantially funded by the National Cancer Institute, we believe that the potential collaboration among us, the Christie National Health Service (NHS) Foundation Trust, the Hillingdon Hospital NHS Trust, and GlaxoSmithKline, under the sponsorship and primary funding of our U.K. based collaborators, would help offset costs associated with this trial.", "type": 2, "words": ["<tag1>", "The", "trial,", "which", "is", "being", "conducted", "by", "the", "Gynecologic", "Oncology", "Group", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "and", "is", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI.", "<tag2>", "As", "in", "the", "combination", "therapy", "trial", "of", "ZYBRESTAT", "with", "AVASTIN", "(bevacizumab),", "which", "is", "sponsored", "and", "substantially", "funded", "by", "the", "National", "Cancer", "Institute,", "we", "believe", "that", "the", "potential", "collaboration", "among", "us,", "the", "Christie", "National", "Health", "Service", "(NHS)", "Foundation", "Trust,", "the", "Hillingdon", "Hospital", "NHS", "Trust,", "and", "GlaxoSmithKline,", "under", "the", "sponsorship", "and", "primary", "funding", "of", "our", "U.K.", "based", "collaborators,", "would", "help", "offset", "costs", "associated", "with", "this", "trial.", "<tag3>"], "wordsA": ["The", "trial,", "which", "is", "being", "conducted", "by", "the", "Gynecologic", "Oncology", "Group", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "and", "is", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI."], "wordsB": ["As", "in", "the", "combination", "therapy", "trial", "of", "ZYBRESTAT", "with", "AVASTIN", "(bevacizumab),", "which", "is", "sponsored", "and", "substantially", "funded", "by", "the", "National", "Cancer", "Institute,", "we", "believe", "that", "the", "potential", "collaboration", "among", "us,", "the", "Christie", "National", "Health", "Service", "(NHS)", "Foundation", "Trust,", "the", "Hillingdon", "Hospital", "NHS", "Trust,", "and", "GlaxoSmithKline,", "under", "the", "sponsorship", "and", "primary", "funding", "of", "our", "U.K.", "based", "collaborators,", "would", "help", "offset", "costs", "associated", "with", "this", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p7_s0", "idA": "908259_13_item1_p3_s1", "sentA": "The trial, which is being conducted by the Gynecologic Oncology Group or GOG, an organization dedicated to clinical research in the field of gynecologic cancer, and is under the sponsorship of the Cancer Therapy Evaluation Program, or CTEP, of the National Cancer Institute, or NCI.", "sentB": "The trial enrolled 107 patients at 67 clinical sites in the United States and is being conducted by the GOG under the sponsorship of the Cancer Therapy Evaluation Program, or CTEP, of the National Cancer Institute, or NCI.", "type": 2, "words": ["<tag1>", "The", "trial,", "which", "is", "being", "conducted", "by", "the", "Gynecologic", "Oncology", "Group", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "and", "is", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI.", "<tag2>", "The", "trial", "enrolled", "107", "patients", "at", "67", "clinical", "sites", "in", "the", "United", "States", "and", "is", "being", "conducted", "by", "the", "GOG", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI.", "<tag3>"], "wordsA": ["The", "trial,", "which", "is", "being", "conducted", "by", "the", "Gynecologic", "Oncology", "Group", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "and", "is", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI."], "wordsB": ["The", "trial", "enrolled", "107", "patients", "at", "67", "clinical", "sites", "in", "the", "United", "States", "and", "is", "being", "conducted", "by", "the", "GOG", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p0_s4", "idA": "908259_13_item1_p40_s4", "sentA": "OXi4503 was also observed to be well tolerated in this study.", "sentB": "To date, we have observed ZYBRESTAT to be well tolerated in over 400 patients and to have clinical activity in a variety of indications including ovarian cancer and ATC.", "type": 2, "words": ["<tag1>", "OXi4503", "was", "also", "observed", "to", "be", "well", "tolerated", "in", "this", "study.", "<tag2>", "To", "date,", "we", "have", "observed", "ZYBRESTAT", "to", "be", "well", "tolerated", "in", "over", "400", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer", "and", "ATC.", "<tag3>"], "wordsA": ["OXi4503", "was", "also", "observed", "to", "be", "well", "tolerated", "in", "this", "study."], "wordsB": ["To", "date,", "we", "have", "observed", "ZYBRESTAT", "to", "be", "well", "tolerated", "in", "over", "400", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer", "and", "ATC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p22_s2", "idA": "908259_13_item1_p40_s5", "sentA": "To date, OXi4503 has been observed to have a manageable side-effect profile similar to that of other agents in the VDA class, potential single-agent clinical activity, and effects on tumor blood flow and tumor metabolic activity, as determined with several imaging modalities.", "sentB": "After four weeks, tumor size, serum insulin levels and other efficacy parameters, including apoptosis (cell death), cell proliferation and effects on tumor vasculature, were assessed.", "type": 2, "words": ["<tag1>", "To", "date,", "OXi4503", "has", "been", "observed", "to", "have", "a", "manageable", "side-effect", "profile", "similar", "to", "that", "of", "other", "agents", "in", "the", "VDA", "class,", "potential", "single-agent", "clinical", "activity,", "and", "effects", "on", "tumor", "blood", "flow", "and", "tumor", "metabolic", "activity,", "as", "determined", "with", "several", "imaging", "modalities.", "<tag2>", "After", "four", "weeks,", "tumor", "size,", "serum", "insulin", "levels", "and", "other", "efficacy", "parameters,", "including", "apoptosis", "(cell", "death),", "cell", "proliferation", "and", "effects", "on", "tumor", "vasculature,", "were", "assessed.", "<tag3>"], "wordsA": ["To", "date,", "OXi4503", "has", "been", "observed", "to", "have", "a", "manageable", "side-effect", "profile", "similar", "to", "that", "of", "other", "agents", "in", "the", "VDA", "class,", "potential", "single-agent", "clinical", "activity,", "and", "effects", "on", "tumor", "blood", "flow", "and", "tumor", "metabolic", "activity,", "as", "determined", "with", "several", "imaging", "modalities."], "wordsB": ["After", "four", "weeks,", "tumor", "size,", "serum", "insulin", "levels", "and", "other", "efficacy", "parameters,", "including", "apoptosis", "(cell", "death),", "cell", "proliferation", "and", "effects", "on", "tumor", "vasculature,", "were", "assessed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p23_s0", "idA": "908259_13_item1_p41_s0", "sentA": "conditions that are characterized by abnormal blood vessel growth within the eye that result in loss of vision.", "sentB": "In addition to developing ZYBRESTAT as an intravenously administered therapy for a number of solid tumor indications, we believe that ZYBRESTAT may also be useful as a therapy for a variety of ophthalmological diseases and conditions such as wet age-related macular degeneration (AMD) and diabetic retinopathy that are characterized by abnormal blood vessel growth within the eye that result in loss of vision, many of which are currently treated with anti-vascular endothelial growth factor (VEGF) therapies.", "type": 2, "words": ["<tag1>", "conditions", "that", "are", "characterized", "by", "abnormal", "blood", "vessel", "growth", "within", "the", "eye", "that", "result", "in", "loss", "of", "vision.", "<tag2>", "In", "addition", "to", "developing", "ZYBRESTAT", "as", "an", "intravenously", "administered", "therapy", "for", "a", "number", "of", "solid", "tumor", "indications,", "we", "believe", "that", "ZYBRESTAT", "may", "also", "be", "useful", "as", "a", "therapy", "for", "a", "variety", "of", "ophthalmological", "diseases", "and", "conditions", "such", "as", "wet", "age-related", "macular", "degeneration", "(AMD)", "and", "diabetic", "retinopathy", "that", "are", "characterized", "by", "abnormal", "blood", "vessel", "growth", "within", "the", "eye", "that", "result", "in", "loss", "of", "vision,", "many", "of", "which", "are", "currently", "treated", "with", "anti-vascular", "endothelial", "growth", "factor", "(VEGF)", "therapies.", "<tag3>"], "wordsA": ["conditions", "that", "are", "characterized", "by", "abnormal", "blood", "vessel", "growth", "within", "the", "eye", "that", "result", "in", "loss", "of", "vision."], "wordsB": ["In", "addition", "to", "developing", "ZYBRESTAT", "as", "an", "intravenously", "administered", "therapy", "for", "a", "number", "of", "solid", "tumor", "indications,", "we", "believe", "that", "ZYBRESTAT", "may", "also", "be", "useful", "as", "a", "therapy", "for", "a", "variety", "of", "ophthalmological", "diseases", "and", "conditions", "such", "as", "wet", "age-related", "macular", "degeneration", "(AMD)", "and", "diabetic", "retinopathy", "that", "are", "characterized", "by", "abnormal", "blood", "vessel", "growth", "within", "the", "eye", "that", "result", "in", "loss", "of", "vision,", "many", "of", "which", "are", "currently", "treated", "with", "anti-vascular", "endothelial", "growth", "factor", "(VEGF)", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p23_s1", "idA": "908259_13_item1_p41_s1", "sentA": "While we continue to seek partnership opportunities that will allow us to continue this research, due to financial constraints, we are not actively pursuing development in this area at this time.", "sentB": "While this program is not an immediate priority, we are actively seeking one or more potential development and commercialization partners with expertise in ophthalmology that would allow us to leverage our existing assets and move forward.", "type": 2, "words": ["<tag1>", "While", "we", "continue", "to", "seek", "partnership", "opportunities", "that", "will", "allow", "us", "to", "continue", "this", "research,", "due", "to", "financial", "constraints,", "we", "are", "not", "actively", "pursuing", "development", "in", "this", "area", "at", "this", "time.", "<tag2>", "While", "this", "program", "is", "not", "an", "immediate", "priority,", "we", "are", "actively", "seeking", "one", "or", "more", "potential", "development", "and", "commercialization", "partners", "with", "expertise", "in", "ophthalmology", "that", "would", "allow", "us", "to", "leverage", "our", "existing", "assets", "and", "move", "forward.", "<tag3>"], "wordsA": ["While", "we", "continue", "to", "seek", "partnership", "opportunities", "that", "will", "allow", "us", "to", "continue", "this", "research,", "due", "to", "financial", "constraints,", "we", "are", "not", "actively", "pursuing", "development", "in", "this", "area", "at", "this", "time."], "wordsB": ["While", "this", "program", "is", "not", "an", "immediate", "priority,", "we", "are", "actively", "seeking", "one", "or", "more", "potential", "development", "and", "commercialization", "partners", "with", "expertise", "in", "ophthalmology", "that", "would", "allow", "us", "to", "leverage", "our", "existing", "assets", "and", "move", "forward."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p33_s0", "idA": "908259_13_item1_p46_s0", "sentA": "Complete Company Background We are a Delaware corporation, incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware, with our principal corporate office in the United States at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 (telephone: (650) 635-7000, fax: (650) 635-7001).", "sentB": "We are a Delaware corporation, incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware, with our principal corporate office in the United States at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 (telephone: (650) 635-7000, fax: (650) 635-7001).", "type": 2, "words": ["<tag1>", "Complete", "Company", "Background", "We", "are", "a", "Delaware", "corporation,", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001).", "<tag2>", "We", "are", "a", "Delaware", "corporation,", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001).", "<tag3>"], "wordsA": ["Complete", "Company", "Background", "We", "are", "a", "Delaware", "corporation,", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001)."], "wordsB": ["We", "are", "a", "Delaware", "corporation,", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p34_s0", "idA": "908259_13_item1_p46_s1", "sentA": "Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the Investors section of our web site as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the Securities and Exchange Commission.", "sentB": "Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the Investors Media section of our web site as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the Securities and Exchange Commission.", "type": 2, "words": ["<tag1>", "Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K,", "and", "all", "amendments", "to", "those", "reports,", "are", "available", "to", "you", "free", "of", "charge", "through", "the", "Investors", "section", "of", "our", "web", "site", "as", "soon", "as", "reasonably", "practicable", "after", "such", "materials", "have", "been", "electronically", "filed", "with,", "or", "furnished", "to,", "the", "Securities", "and", "Exchange", "Commission.", "<tag2>", "Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K,", "and", "all", "amendments", "to", "those", "reports,", "are", "available", "to", "you", "free", "of", "charge", "through", "the", "Investors", "Media", "section", "of", "our", "web", "site", "as", "soon", "as", "reasonably", "practicable", "after", "such", "materials", "have", "been", "electronically", "filed", "with,", "or", "furnished", "to,", "the", "Securities", "and", "Exchange", "Commission.", "<tag3>"], "wordsA": ["Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K,", "and", "all", "amendments", "to", "those", "reports,", "are", "available", "to", "you", "free", "of", "charge", "through", "the", "Investors", "section", "of", "our", "web", "site", "as", "soon", "as", "reasonably", "practicable", "after", "such", "materials", "have", "been", "electronically", "filed", "with,", "or", "furnished", "to,", "the", "Securities", "and", "Exchange", "Commission."], "wordsB": ["Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K,", "and", "all", "amendments", "to", "those", "reports,", "are", "available", "to", "you", "free", "of", "charge", "through", "the", "Investors", "Media", "section", "of", "our", "web", "site", "as", "soon", "as", "reasonably", "practicable", "after", "such", "materials", "have", "been", "electronically", "filed", "with,", "or", "furnished", "to,", "the", "Securities", "and", "Exchange", "Commission."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p35_s0", "idA": "908259_13_item1_p46_s2", "sentA": "Information contained on our web site does not form a part of this Form 10-K. Vascular Disrupting Agents: Anti-Vascular Therapeutics that Address a Large Potential Market According to Cancer Research UK, a cancer organization in the United Kingdom, nearly 90% of all cancers, more than 200 types, are solid tumors, which are dependent upon a continually developing vascular supply for their growth and survival.", "sentB": "Information contained on our web site does not form a part of this Form 10-K. Vascular Disrupting Agents: Background According to Cancer Research UK, a non-profit cancer research organization in the United Kingdom, nearly 90% of all cancers are solid tumors that are dependent upon a continually evolving vascular supply for their growth and survival.", "type": 2, "words": ["<tag1>", "Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Form", "10-K.", "Vascular", "Disrupting", "Agents:", "Anti-Vascular", "Therapeutics", "that", "Address", "a", "Large", "Potential", "Market", "According", "to", "Cancer", "Research", "UK,", "a", "cancer", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers,", "more", "than", "200", "types,", "are", "solid", "tumors,", "which", "are", "dependent", "upon", "a", "continually", "developing", "vascular", "supply", "for", "their", "growth", "and", "survival.", "<tag2>", "Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Form", "10-K.", "Vascular", "Disrupting", "Agents:", "Background", "According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "solid", "tumors", "that", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival.", "<tag3>"], "wordsA": ["Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Form", "10-K.", "Vascular", "Disrupting", "Agents:", "Anti-Vascular", "Therapeutics", "that", "Address", "a", "Large", "Potential", "Market", "According", "to", "Cancer", "Research", "UK,", "a", "cancer", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers,", "more", "than", "200", "types,", "are", "solid", "tumors,", "which", "are", "dependent", "upon", "a", "continually", "developing", "vascular", "supply", "for", "their", "growth", "and", "survival."], "wordsB": ["Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Form", "10-K.", "Vascular", "Disrupting", "Agents:", "Background", "According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "solid", "tumors", "that", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p36_s0", "idA": "908259_13_item1_p47_s0", "sentA": "Similarly, in the ophthalmology field, abnormal neovascularization characterizes a variety of ophthalmological diseases and conditions, including corneal neovascularization, central retinal vein occlusion, proliferative diabetic retinopathy, retinopathy of prematurity, sickle cell retinopathy, myopic macular degeneration, or MMD, age-related macular degeneration, or AMD, and neovascular glaucoma.", "sentB": "Similarly, in the ophthalmology field, abnormal neovascularization characterizes a variety of ophthalmological diseases and conditions, including wet age-related macular degeneration, or AMD, and diabetic retinopathy.", "type": 2, "words": ["<tag1>", "Similarly,", "in", "the", "ophthalmology", "field,", "abnormal", "neovascularization", "characterizes", "a", "variety", "of", "ophthalmological", "diseases", "and", "conditions,", "including", "corneal", "neovascularization,", "central", "retinal", "vein", "occlusion,", "proliferative", "diabetic", "retinopathy,", "retinopathy", "of", "prematurity,", "sickle", "cell", "retinopathy,", "myopic", "macular", "degeneration,", "or", "MMD,", "age-related", "macular", "degeneration,", "or", "AMD,", "and", "neovascular", "glaucoma.", "<tag2>", "Similarly,", "in", "the", "ophthalmology", "field,", "abnormal", "neovascularization", "characterizes", "a", "variety", "of", "ophthalmological", "diseases", "and", "conditions,", "including", "wet", "age-related", "macular", "degeneration,", "or", "AMD,", "and", "diabetic", "retinopathy.", "<tag3>"], "wordsA": ["Similarly,", "in", "the", "ophthalmology", "field,", "abnormal", "neovascularization", "characterizes", "a", "variety", "of", "ophthalmological", "diseases", "and", "conditions,", "including", "corneal", "neovascularization,", "central", "retinal", "vein", "occlusion,", "proliferative", "diabetic", "retinopathy,", "retinopathy", "of", "prematurity,", "sickle", "cell", "retinopathy,", "myopic", "macular", "degeneration,", "or", "MMD,", "age-related", "macular", "degeneration,", "or", "AMD,", "and", "neovascular", "glaucoma."], "wordsB": ["Similarly,", "in", "the", "ophthalmology", "field,", "abnormal", "neovascularization", "characterizes", "a", "variety", "of", "ophthalmological", "diseases", "and", "conditions,", "including", "wet", "age-related", "macular", "degeneration,", "or", "AMD,", "and", "diabetic", "retinopathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p37_s0", "idA": "908259_13_item1_p48_s0", "sentA": "Since 2004, multiple drugs that interfere with blood vessel growth or anti-angiogenics (see table below), have been approved for a variety of cancer and ophthalmology indications, and development of approved anti-angiogenic drugs for new indications continues.", "sentB": "Since 2004, a number of anti-angiogenic drugs, which refers to drugs that interfere with blood vessel growth, as described further in the table below, have been approved for a variety of cancer and ophthalmology indications, and development of approved anti-angiogenic drugs for new indications continues.", "type": 2, "words": ["<tag1>", "Since", "2004,", "multiple", "drugs", "that", "interfere", "with", "blood", "vessel", "growth", "or", "anti-angiogenics", "(see", "table", "below),", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "and", "ophthalmology", "indications,", "and", "development", "of", "approved", "anti-angiogenic", "drugs", "for", "new", "indications", "continues.", "<tag2>", "Since", "2004,", "a", "number", "of", "anti-angiogenic", "drugs,", "which", "refers", "to", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "as", "described", "further", "in", "the", "table", "below,", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "and", "ophthalmology", "indications,", "and", "development", "of", "approved", "anti-angiogenic", "drugs", "for", "new", "indications", "continues.", "<tag3>"], "wordsA": ["Since", "2004,", "multiple", "drugs", "that", "interfere", "with", "blood", "vessel", "growth", "or", "anti-angiogenics", "(see", "table", "below),", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "and", "ophthalmology", "indications,", "and", "development", "of", "approved", "anti-angiogenic", "drugs", "for", "new", "indications", "continues."], "wordsB": ["Since", "2004,", "a", "number", "of", "anti-angiogenic", "drugs,", "which", "refers", "to", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "as", "described", "further", "in", "the", "table", "below,", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "and", "ophthalmology", "indications,", "and", "development", "of", "approved", "anti-angiogenic", "drugs", "for", "new", "indications", "continues."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p38_s1", "idA": "908259_13_item1_p48_s2", "sentA": "We believe that our VDA drug candidates are second-generation anti-vascular drugs that differ from and are complementary and non-competitive with anti-angiogenic agents.", "sentB": "Consequently, we believe that our VDA drug candidates are second-generation anti-vascular drugs that are potentially complementary to, rather than directly competitive with, existing anti-angiogenic agents, a stance which is supported by the data we have gathered showing an improvement in patient outcomes when both agents are used in combination.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "our", "VDA", "drug", "candidates", "are", "second-generation", "anti-vascular", "drugs", "that", "differ", "from", "and", "are", "complementary", "and", "non-competitive", "with", "anti-angiogenic", "agents.", "<tag2>", "Consequently,", "we", "believe", "that", "our", "VDA", "drug", "candidates", "are", "second-generation", "anti-vascular", "drugs", "that", "are", "potentially", "complementary", "to,", "rather", "than", "directly", "competitive", "with,", "existing", "anti-angiogenic", "agents,", "a", "stance", "which", "is", "supported", "by", "the", "data", "we", "have", "gathered", "showing", "an", "improvement", "in", "patient", "outcomes", "when", "both", "agents", "are", "used", "in", "combination.", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "VDA", "drug", "candidates", "are", "second-generation", "anti-vascular", "drugs", "that", "differ", "from", "and", "are", "complementary", "and", "non-competitive", "with", "anti-angiogenic", "agents."], "wordsB": ["Consequently,", "we", "believe", "that", "our", "VDA", "drug", "candidates", "are", "second-generation", "anti-vascular", "drugs", "that", "are", "potentially", "complementary", "to,", "rather", "than", "directly", "competitive", "with,", "existing", "anti-angiogenic", "agents,", "a", "stance", "which", "is", "supported", "by", "the", "data", "we", "have", "gathered", "showing", "an", "improvement", "in", "patient", "outcomes", "when", "both", "agents", "are", "used", "in", "combination."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p38_s0", "idA": "908259_13_item1_p48_s3", "sentA": "Similar to anti-angiogenic agents, our VDA drug candidates are anti-vascular drugs that exert therapeutic effects by depriving tumors and in the case of eye disease, ocular lesions of blood supply.", "sentB": "While ZYBRESTAT exerts a therapeutic effect similar to existing anti-angiogenic agents, depriving tumors (or, in the case of eye disease, ocular lesions) of blood supply, its mechanism of action is quite different.", "type": 2, "words": ["<tag1>", "Similar", "to", "anti-angiogenic", "agents,", "our", "VDA", "drug", "candidates", "are", "anti-vascular", "drugs", "that", "exert", "therapeutic", "effects", "by", "depriving", "tumors", "and", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions", "of", "blood", "supply.", "<tag2>", "While", "ZYBRESTAT", "exerts", "a", "therapeutic", "effect", "similar", "to", "existing", "anti-angiogenic", "agents,", "depriving", "tumors", "(or,", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions)", "of", "blood", "supply,", "its", "mechanism", "of", "action", "is", "quite", "different.", "<tag3>"], "wordsA": ["Similar", "to", "anti-angiogenic", "agents,", "our", "VDA", "drug", "candidates", "are", "anti-vascular", "drugs", "that", "exert", "therapeutic", "effects", "by", "depriving", "tumors", "and", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions", "of", "blood", "supply."], "wordsB": ["While", "ZYBRESTAT", "exerts", "a", "therapeutic", "effect", "similar", "to", "existing", "anti-angiogenic", "agents,", "depriving", "tumors", "(or,", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions)", "of", "blood", "supply,", "its", "mechanism", "of", "action", "is", "quite", "different."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p7_s2", "idA": "908259_13_item1_p49_s1", "sentA": "In this article, Professor Kerbel and Dr. Shaked from Sunnybrook Cancer Centre in Canada demonstrated that the combination of ZYBRESTAT and an anti-angiogenic agent, an anti-VEGF-receptor antibody, had synergistic effects on tumors.", "sentB": "The topline results announced in March 2014 indicate that patients receiving the combination of ZYBRESTAT and AVASTIN (bevacizumab) achieved a higher objective response rate than patients receiving AVASTIN (bevacizumab) alone, but that increase was not statistically significant.", "type": 2, "words": ["<tag1>", "In", "this", "article,", "Professor", "Kerbel", "and", "Dr.", "Shaked", "from", "Sunnybrook", "Cancer", "Centre", "in", "Canada", "demonstrated", "that", "the", "combination", "of", "ZYBRESTAT", "and", "an", "anti-angiogenic", "agent,", "an", "anti-VEGF-receptor", "antibody,", "had", "synergistic", "effects", "on", "tumors.", "<tag2>", "The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant.", "<tag3>"], "wordsA": ["In", "this", "article,", "Professor", "Kerbel", "and", "Dr.", "Shaked", "from", "Sunnybrook", "Cancer", "Centre", "in", "Canada", "demonstrated", "that", "the", "combination", "of", "ZYBRESTAT", "and", "an", "anti-angiogenic", "agent,", "an", "anti-VEGF-receptor", "antibody,", "had", "synergistic", "effects", "on", "tumors."], "wordsB": ["The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p40_s2", "idA": "908259_13_item1_p50_s2", "sentA": "Results from initial human clinical studies conducted by us with combinations of ZYBRESTAT and the widely-used anti-angiogenic drug, bevacizumab, provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "sentB": "Results from initial human clinical studies conducted by us with combinations of ZYBRESTAT and AVASTIN (bevacizumab), provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "type": 2, "words": ["<tag1>", "Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "ZYBRESTAT", "and", "the", "widely-used", "anti-angiogenic", "drug,", "bevacizumab,", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag2>", "Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab),", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag3>"], "wordsA": ["Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "ZYBRESTAT", "and", "the", "widely-used", "anti-angiogenic", "drug,", "bevacizumab,", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "wordsB": ["Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab),", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p41_s0", "idA": "908259_13_item1_p51_s0", "sentA": "Chronic-chronic hypertension with long-term use Acute-impairment in wound healing, hemorrhage, hemoptysis, gastrointestinal perforation, proteinuria, nephrotic syndrome, thromboembolic events, etc.", "sentB": "Chronic-chronic hypertension with long- term use; Acute- impairment in wound healing; Hemorrhage, hemoptysis, gastrointestinal perforation, proteinuria, nephrotic syndrome, thromboembolic events, etc.", "type": 2, "words": ["<tag1>", "Chronic-chronic", "hypertension", "with", "long-term", "use", "Acute-impairment", "in", "wound", "healing,", "hemorrhage,", "hemoptysis,", "gastrointestinal", "perforation,", "proteinuria,", "nephrotic", "syndrome,", "thromboembolic", "events,", "etc.", "<tag2>", "Chronic-chronic", "hypertension", "with", "long-", "term", "use;", "Acute-", "impairment", "in", "wound", "healing;", "Hemorrhage,", "hemoptysis,", "gastrointestinal", "perforation,", "proteinuria,", "nephrotic", "syndrome,", "thromboembolic", "events,", "etc.", "<tag3>"], "wordsA": ["Chronic-chronic", "hypertension", "with", "long-term", "use", "Acute-impairment", "in", "wound", "healing,", "hemorrhage,", "hemoptysis,", "gastrointestinal", "perforation,", "proteinuria,", "nephrotic", "syndrome,", "thromboembolic", "events,", "etc."], "wordsB": ["Chronic-chronic", "hypertension", "with", "long-", "term", "use;", "Acute-", "impairment", "in", "wound", "healing;", "Hemorrhage,", "hemoptysis,", "gastrointestinal", "perforation,", "proteinuria,", "nephrotic", "syndrome,", "thromboembolic", "events,", "etc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p42_s0", "idA": "908259_13_item1_p52_s0", "sentA": "Transient and manageable-Mostly hypertension, effectively controlled Non-overlapping with anti-angiogenics No cumulative toxicities alone or in combination We believe our VDA drug candidates act on tumor blood vessels via two complementary mechanisms, tubulin depolymerization and disengagement of the junctional protein VE-cadherin, which cause shape change in tumor vascular endothelial cells, vessel occlusion and collapse, and the subsequent blockage of blood-flow to the tumor, which deprives it of oxygen and nutrients essential for survival.", "sentB": "Mostly hypertension, effectively controlled; Effects on hematopoiesis and white blood cell counts We believe our VDA drug candidates act on tumor blood vessels via two complementary mechanisms, tubulin depolymerization and disengagement of the junctional protein VE-cadherin, which cause shape change in tumor vascular endothelial cells, vessel occlusion and collapse, and the subsequent blockage of blood-flow to the tumor, which deprives it of oxygen and nutrients essential for survival.", "type": 2, "words": ["<tag1>", "Transient", "and", "manageable-Mostly", "hypertension,", "effectively", "controlled", "Non-overlapping", "with", "anti-angiogenics", "No", "cumulative", "toxicities", "alone", "or", "in", "combination", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "shape", "change", "in", "tumor", "vascular", "endothelial", "cells,", "vessel", "occlusion", "and", "collapse,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "it", "of", "oxygen", "and", "nutrients", "essential", "for", "survival.", "<tag2>", "Mostly", "hypertension,", "effectively", "controlled;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "shape", "change", "in", "tumor", "vascular", "endothelial", "cells,", "vessel", "occlusion", "and", "collapse,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "it", "of", "oxygen", "and", "nutrients", "essential", "for", "survival.", "<tag3>"], "wordsA": ["Transient", "and", "manageable-Mostly", "hypertension,", "effectively", "controlled", "Non-overlapping", "with", "anti-angiogenics", "No", "cumulative", "toxicities", "alone", "or", "in", "combination", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "shape", "change", "in", "tumor", "vascular", "endothelial", "cells,", "vessel", "occlusion", "and", "collapse,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "it", "of", "oxygen", "and", "nutrients", "essential", "for", "survival."], "wordsB": ["Mostly", "hypertension,", "effectively", "controlled;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "shape", "change", "in", "tumor", "vascular", "endothelial", "cells,", "vessel", "occlusion", "and", "collapse,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "it", "of", "oxygen", "and", "nutrients", "essential", "for", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p21_s1", "idA": "908259_13_item1_p52_s3", "sentA": "When this occurs, the shape of the cells changes from flat to round, initiating a cascade of events resulting in physical blockage of the blood vessels.", "sentB": "Functional PNETs make hormones that can cause a cascade of disease symptoms, resulting in significant morbidity for the patient.", "type": 2, "words": ["<tag1>", "When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "initiating", "a", "cascade", "of", "events", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels.", "<tag2>", "Functional", "PNETs", "make", "hormones", "that", "can", "cause", "a", "cascade", "of", "disease", "symptoms,", "resulting", "in", "significant", "morbidity", "for", "the", "patient.", "<tag3>"], "wordsA": ["When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "initiating", "a", "cascade", "of", "events", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels."], "wordsB": ["Functional", "PNETs", "make", "hormones", "that", "can", "cause", "a", "cascade", "of", "disease", "symptoms,", "resulting", "in", "significant", "morbidity", "for", "the", "patient."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p43_s0", "idA": "908259_13_item1_p52_s7", "sentA": "The authors of the research article conclude that this effect only occurs in endothelial cells which lack contact with smooth muscle cells, a known feature of abnormal vasculature associated with tumors and other disease processes.", "sentB": "associated with tumors and other disease processes.", "type": 2, "words": ["<tag1>", "The", "authors", "of", "the", "research", "article", "conclude", "that", "this", "effect", "only", "occurs", "in", "endothelial", "cells", "which", "lack", "contact", "with", "smooth", "muscle", "cells,", "a", "known", "feature", "of", "abnormal", "vasculature", "associated", "with", "tumors", "and", "other", "disease", "processes.", "<tag2>", "associated", "with", "tumors", "and", "other", "disease", "processes.", "<tag3>"], "wordsA": ["The", "authors", "of", "the", "research", "article", "conclude", "that", "this", "effect", "only", "occurs", "in", "endothelial", "cells", "which", "lack", "contact", "with", "smooth", "muscle", "cells,", "a", "known", "feature", "of", "abnormal", "vasculature", "associated", "with", "tumors", "and", "other", "disease", "processes."], "wordsB": ["associated", "with", "tumors", "and", "other", "disease", "processes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p2_s1", "idA": "908259_13_item1_p54_s1", "sentA": "Because the half-life of the active form of ZYBRESTAT is relatively short, the effects of ZYBRESTAT on tubulin are reversible, and ZYBRESTAT is typically administered no more frequently than once per week, the side-effects of ZYBRESTAT are typically transient in nature, limited to the period of time following administration when the active form of ZYBRESTAT is in the body in significant concentrations.", "sentB": "This form of cancer begins in the ovaries and often spreads to the rest of the pelvis and abdomen prior to detection, resulting in a relatively poor prognosis.", "type": 2, "words": ["<tag1>", "Because", "the", "half-life", "of", "the", "active", "form", "of", "ZYBRESTAT", "is", "relatively", "short,", "the", "effects", "of", "ZYBRESTAT", "on", "tubulin", "are", "reversible,", "and", "ZYBRESTAT", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "ZYBRESTAT", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "ZYBRESTAT", "is", "in", "the", "body", "in", "significant", "concentrations.", "<tag2>", "This", "form", "of", "cancer", "begins", "in", "the", "ovaries", "and", "often", "spreads", "to", "the", "rest", "of", "the", "pelvis", "and", "abdomen", "prior", "to", "detection,", "resulting", "in", "a", "relatively", "poor", "prognosis.", "<tag3>"], "wordsA": ["Because", "the", "half-life", "of", "the", "active", "form", "of", "ZYBRESTAT", "is", "relatively", "short,", "the", "effects", "of", "ZYBRESTAT", "on", "tubulin", "are", "reversible,", "and", "ZYBRESTAT", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "ZYBRESTAT", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "ZYBRESTAT", "is", "in", "the", "body", "in", "significant", "concentrations."], "wordsB": ["This", "form", "of", "cancer", "begins", "in", "the", "ovaries", "and", "often", "spreads", "to", "the", "rest", "of", "the", "pelvis", "and", "abdomen", "prior", "to", "detection,", "resulting", "in", "a", "relatively", "poor", "prognosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p45_s7", "idA": "908259_13_item1_p55_s0", "sentA": "was less than 3%, a frequency comparable to that reported with approved anti-angiogenic agents such as bevacizumab, sunitinib and sorafenib.", "sentB": "In an analysis undertaken by us, the incidence of serious cardiovascular side-effects such as angina and myocardial ischemia observed across all studies to date (including early studies in which hypertension management and prevention was not employed) was less than 3%, a frequency comparable to that reported with approved anti-angiogenic agents such as bevacizumab, sunitinib and sorafenib.", "type": 2, "words": ["<tag1>", "was", "less", "than", "3%,", "a", "frequency", "comparable", "to", "that", "reported", "with", "approved", "anti-angiogenic", "agents", "such", "as", "bevacizumab,", "sunitinib", "and", "sorafenib.", "<tag2>", "In", "an", "analysis", "undertaken", "by", "us,", "the", "incidence", "of", "serious", "cardiovascular", "side-effects", "such", "as", "angina", "and", "myocardial", "ischemia", "observed", "across", "all", "studies", "to", "date", "(including", "early", "studies", "in", "which", "hypertension", "management", "and", "prevention", "was", "not", "employed)", "was", "less", "than", "3%,", "a", "frequency", "comparable", "to", "that", "reported", "with", "approved", "anti-angiogenic", "agents", "such", "as", "bevacizumab,", "sunitinib", "and", "sorafenib.", "<tag3>"], "wordsA": ["was", "less", "than", "3%,", "a", "frequency", "comparable", "to", "that", "reported", "with", "approved", "anti-angiogenic", "agents", "such", "as", "bevacizumab,", "sunitinib", "and", "sorafenib."], "wordsB": ["In", "an", "analysis", "undertaken", "by", "us,", "the", "incidence", "of", "serious", "cardiovascular", "side-effects", "such", "as", "angina", "and", "myocardial", "ischemia", "observed", "across", "all", "studies", "to", "date", "(including", "early", "studies", "in", "which", "hypertension", "management", "and", "prevention", "was", "not", "employed)", "was", "less", "than", "3%,", "a", "frequency", "comparable", "to", "that", "reported", "with", "approved", "anti-angiogenic", "agents", "such", "as", "bevacizumab,", "sunitinib", "and", "sorafenib."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p46_s1", "idA": "908259_13_item1_p56_s1", "sentA": "Our principal focus is to advance the clinical development of our drug candidates ZYBRESTAT and OXi4503 and to identify new preclinical candidates that are complementary to our VDAs.", "sentB": "Our principal focus is to advance the clinical development and commercialization of our drug candidates ZYBRESTAT and OXi4503 and to identify new preclinical candidates that are complementary to our VDAs.", "type": 2, "words": ["<tag1>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "of", "our", "drug", "candidates", "ZYBRESTAT", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag2>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "ZYBRESTAT", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag3>"], "wordsA": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "of", "our", "drug", "candidates", "ZYBRESTAT", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "wordsB": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "ZYBRESTAT", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p26_s0", "idA": "908259_13_item1_p56_s5", "sentA": "Currently, we have collaborative agreements and arrangements with a number of institutions in the United States and abroad, which we utilize to perform the day-to-day activities associated with drug development.", "sentB": "Our current development program for OXi4503 is as follows: Acute Myelogenous Leukemia, or AML AML is a relatively rare cancer of the myeloid blood cells, with approximately 10,500 new cases each year in the United States and accounting for approximately 1.2% of cancer deaths.", "type": 2, "words": ["<tag1>", "Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "development.", "<tag2>", "Our", "current", "development", "program", "for", "OXi4503", "is", "as", "follows:", "Acute", "Myelogenous", "Leukemia,", "or", "AML", "AML", "is", "a", "relatively", "rare", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "United", "States", "and", "accounting", "for", "approximately", "1.2%", "of", "cancer", "deaths.", "<tag3>"], "wordsA": ["Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "development."], "wordsB": ["Our", "current", "development", "program", "for", "OXi4503", "is", "as", "follows:", "Acute", "Myelogenous", "Leukemia,", "or", "AML", "AML", "is", "a", "relatively", "rare", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "United", "States", "and", "accounting", "for", "approximately", "1.2%", "of", "cancer", "deaths."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p11_s0", "idA": "908259_13_item1_p56_s6", "sentA": "In 2012, collaborations were ongoing with a variety of university and research institutions, including the following:", "sentB": "TAXOL (paclitaxel) is a chemotherapy agent used to treat patients with a variety of solid tumors, including lung, ovarian, breast, head and neck cancers.", "type": 2, "words": ["<tag1>", "In", "2012,", "collaborations", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:", "<tag2>", "TAXOL", "(paclitaxel)", "is", "a", "chemotherapy", "agent", "used", "to", "treat", "patients", "with", "a", "variety", "of", "solid", "tumors,", "including", "lung,", "ovarian,", "breast,", "head", "and", "neck", "cancers.", "<tag3>"], "wordsA": ["In", "2012,", "collaborations", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:"], "wordsB": ["TAXOL", "(paclitaxel)", "is", "a", "chemotherapy", "agent", "used", "to", "treat", "patients", "with", "a", "variety", "of", "solid", "tumors,", "including", "lung,", "ovarian,", "breast,", "head", "and", "neck", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p46_s6", "idA": "908259_13_item1_p56_s6", "sentA": "In 2012, collaborations were ongoing with a variety of university and research institutions, including the following:", "sentB": "In 2013, collaborations and agreements were ongoing with a variety of university and research institutions, including the following:", "type": 2, "words": ["<tag1>", "In", "2012,", "collaborations", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:", "<tag2>", "In", "2013,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:", "<tag3>"], "wordsA": ["In", "2012,", "collaborations", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:"], "wordsB": ["In", "2013,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s12", "idA": "908259_13_item1_p57_s0", "sentA": "Gynecologic Oncology Group, or GOG, and the Cancer Therapy Evaluation Program, or CTEP, of the National Cancer Institute, or NCI.", "sentB": "Importantly, this Phase 2 trial, also known as GOG0186I, was being supported by a variety of collaborators including Genentech / Roche, which manufactures and markets AVASTIN (bevacizumab), as well as the GOG, and its sponsor, the Cancer Therapy Evaluation Program (CTEP) of the NCI.", "type": 2, "words": ["<tag1>", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "and", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI.", "<tag2>", "Importantly,", "this", "Phase", "2", "trial,", "also", "known", "as", "GOG0186I,", "was", "being", "supported", "by", "a", "variety", "of", "collaborators", "including", "Genentech", "/", "Roche,", "which", "manufactures", "and", "markets", "AVASTIN", "(bevacizumab),", "as", "well", "as", "the", "GOG,", "and", "its", "sponsor,", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "NCI.", "<tag3>"], "wordsA": ["Gynecologic", "Oncology", "Group,", "or", "GOG,", "and", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI."], "wordsB": ["Importantly,", "this", "Phase", "2", "trial,", "also", "known", "as", "GOG0186I,", "was", "being", "supported", "by", "a", "variety", "of", "collaborators", "including", "Genentech", "/", "Roche,", "which", "manufactures", "and", "markets", "AVASTIN", "(bevacizumab),", "as", "well", "as", "the", "GOG,", "and", "its", "sponsor,", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "NCI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p50_s0", "idA": "908259_13_item1_p58_s0", "sentA": "University of Florida We have secured a technology license from Arizona State University, or ASU.", "sentB": "We have secured a technology license from Arizona State University, or ASU.", "type": 2, "words": ["<tag1>", "University", "of", "Florida", "We", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU.", "<tag2>", "We", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU.", "<tag3>"], "wordsA": ["University", "of", "Florida", "We", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU."], "wordsB": ["We", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s10", "idA": "908259_13_item1_p5_s0", "sentA": "A Phase 2 study of ZYBRESTAT in combination with weekly paclitaxel in patients with recurrent ovarian cancer.", "sentB": "We also remain interested in a conducting a randomized, two-arm Phase 2 clinical trial, comparing weekly dosing of TAXOL (paclitaxel) with weekly TAXOL (paclitaxel) plus ZYBRESTAT in patients with relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag2>", "We", "also", "remain", "interested", "in", "a", "conducting", "a", "randomized,", "two-arm", "Phase", "2", "clinical", "trial,", "comparing", "weekly", "dosing", "of", "TAXOL", "(paclitaxel)", "with", "weekly", "TAXOL", "(paclitaxel)", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "wordsB": ["We", "also", "remain", "interested", "in", "a", "conducting", "a", "randomized,", "two-arm", "Phase", "2", "clinical", "trial,", "comparing", "weekly", "dosing", "of", "TAXOL", "(paclitaxel)", "with", "weekly", "TAXOL", "(paclitaxel)", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p11_s1", "idA": "908259_13_item1_p5_s0", "sentA": "A Phase 2 study of ZYBRESTAT in combination with weekly paclitaxel in patients with recurrent ovarian cancer.", "sentB": "We believe that using ZYBRESTAT in combination with weekly TAXOL (paclitaxel) may demonstrate how combination therapy with ZYBRESTAT could improve standard of care and improve patient outcomes in certain patients with advanced relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag2>", "We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "weekly", "TAXOL", "(paclitaxel)", "may", "demonstrate", "how", "combination", "therapy", "with", "ZYBRESTAT", "could", "improve", "standard", "of", "care", "and", "improve", "patient", "outcomes", "in", "certain", "patients", "with", "advanced", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "wordsB": ["We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "weekly", "TAXOL", "(paclitaxel)", "may", "demonstrate", "how", "combination", "therapy", "with", "ZYBRESTAT", "could", "improve", "standard", "of", "care", "and", "improve", "patient", "outcomes", "in", "certain", "patients", "with", "advanced", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p12_s3", "idA": "908259_13_item1_p5_s0", "sentA": "A Phase 2 study of ZYBRESTAT in combination with weekly paclitaxel in patients with recurrent ovarian cancer.", "sentB": "Similarly encouraging results have been observed using ZYBRESTAT in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) in patients with platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag2>", "Similarly", "encouraging", "results", "have", "been", "observed", "using", "ZYBRESTAT", "in", "combination", "with", "Paraplatin", "(carboplatin)", "and", "Taxol", "(paclitaxel)", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "wordsB": ["Similarly", "encouraging", "results", "have", "been", "observed", "using", "ZYBRESTAT", "in", "combination", "with", "Paraplatin", "(carboplatin)", "and", "Taxol", "(paclitaxel)", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p13_s0", "idA": "908259_13_item1_p5_s0", "sentA": "A Phase 2 study of ZYBRESTAT in combination with weekly paclitaxel in patients with recurrent ovarian cancer.", "sentB": "outcomes could be substantially improved by using ZYBRESTAT in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) in patients with platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag2>", "outcomes", "could", "be", "substantially", "improved", "by", "using", "ZYBRESTAT", "in", "combination", "with", "Paraplatin", "(carboplatin)", "and", "Taxol", "(paclitaxel)", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "wordsB": ["outcomes", "could", "be", "substantially", "improved", "by", "using", "ZYBRESTAT", "in", "combination", "with", "Paraplatin", "(carboplatin)", "and", "Taxol", "(paclitaxel)", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p20_s0", "idA": "908259_13_item1_p5_s0", "sentA": "A Phase 2 study of ZYBRESTAT in combination with weekly paclitaxel in patients with recurrent ovarian cancer.", "sentB": "A preclinical study of ZYBRESTAT in a transgenic mouse model of pancreatic neuroendocrine tumors (PNETs) was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, in a poster session on October 20, 2013.", "type": 2, "words": ["<tag1>", "A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag2>", "A", "preclinical", "study", "of", "ZYBRESTAT", "in", "a", "transgenic", "mouse", "model", "of", "pancreatic", "neuroendocrine", "tumors", "(PNETs)", "was", "presented", "at", "the", "AACR-NCI-EORTC", "International", "Conference", "on", "Molecular", "Targets", "and", "Cancer", "Therapeutics,", "Boston,", "MA,", "in", "a", "poster", "session", "on", "October", "20,", "2013.", "<tag3>"], "wordsA": ["A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "wordsB": ["A", "preclinical", "study", "of", "ZYBRESTAT", "in", "a", "transgenic", "mouse", "model", "of", "pancreatic", "neuroendocrine", "tumors", "(PNETs)", "was", "presented", "at", "the", "AACR-NCI-EORTC", "International", "Conference", "on", "Molecular", "Targets", "and", "Cancer", "Therapeutics,", "Boston,", "MA,", "in", "a", "poster", "session", "on", "October", "20,", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p22_s7", "idA": "908259_13_item1_p5_s0", "sentA": "A Phase 2 study of ZYBRESTAT in combination with weekly paclitaxel in patients with recurrent ovarian cancer.", "sentB": "Based on the strength of the preclinical data, we are planning to initiate a Phase 2 clinical trial of ZYBRESTAT in patients with recurrent GI-NETs with elevated biomarkers in the second half of 2014.", "type": 2, "words": ["<tag1>", "A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag2>", "Based", "on", "the", "strength", "of", "the", "preclinical", "data,", "we", "are", "planning", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers", "in", "the", "second", "half", "of", "2014.", "<tag3>"], "wordsA": ["A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "wordsB": ["Based", "on", "the", "strength", "of", "the", "preclinical", "data,", "we", "are", "planning", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers", "in", "the", "second", "half", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p9_s0", "idA": "908259_13_item1_p5_s0", "sentA": "A Phase 2 study of ZYBRESTAT in combination with weekly paclitaxel in patients with recurrent ovarian cancer.", "sentB": "Potential Development Pathway in Ovarian Cancer: ZYBRESTAT in combination with AVASTIN (bevacizumab)-Pivotal Trial In light of the top line results from the GOG186I trial which demonstrated a statistically significant increase in progression-free survival from the combination of bevacizumab plus ZYBRESTAT as compared to bevacizumab alone, we are currently evaluating the potential development pathway for ZYBRESTAT in ovarian cancer.", "type": 2, "words": ["<tag1>", "A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag2>", "Potential", "Development", "Pathway", "in", "Ovarian", "Cancer:", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)-Pivotal", "Trial", "In", "light", "of", "the", "top", "line", "results", "from", "the", "GOG186I", "trial", "which", "demonstrated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "from", "the", "combination", "of", "bevacizumab", "plus", "ZYBRESTAT", "as", "compared", "to", "bevacizumab", "alone,", "we", "are", "currently", "evaluating", "the", "potential", "development", "pathway", "for", "ZYBRESTAT", "in", "ovarian", "cancer.", "<tag3>"], "wordsA": ["A", "Phase", "2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "weekly", "paclitaxel", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "wordsB": ["Potential", "Development", "Pathway", "in", "Ovarian", "Cancer:", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)-Pivotal", "Trial", "In", "light", "of", "the", "top", "line", "results", "from", "the", "GOG186I", "trial", "which", "demonstrated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "from", "the", "combination", "of", "bevacizumab", "plus", "ZYBRESTAT", "as", "compared", "to", "bevacizumab", "alone,", "we", "are", "currently", "evaluating", "the", "potential", "development", "pathway", "for", "ZYBRESTAT", "in", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p59_s2", "idA": "908259_13_item1_p60_s1", "sentA": "ASU is entitled to single-digit royalty and milestone payments under the license agreement.", "sentB": "Angiogene is entitled to low single-digit royalty payments and milestone payments under the agreement.", "type": 2, "words": ["<tag1>", "ASU", "is", "entitled", "to", "single-digit", "royalty", "and", "milestone", "payments", "under", "the", "license", "agreement.", "<tag2>", "Angiogene", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "and", "milestone", "payments", "under", "the", "agreement.", "<tag3>"], "wordsA": ["ASU", "is", "entitled", "to", "single-digit", "royalty", "and", "milestone", "payments", "under", "the", "license", "agreement."], "wordsB": ["Angiogene", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "and", "milestone", "payments", "under", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p60_s0", "idA": "908259_13_item1_p61_s0", "sentA": "We bear the costs of preparing, filing, prosecuting and maintaining all patent applications under the ASU license.", "sentB": "We have the sole right to and bear the costs of preparing, filing, prosecuting and maintaining all patent applications under the Angiogene license.", "type": 2, "words": ["<tag1>", "We", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "ASU", "license.", "<tag2>", "We", "have", "the", "sole", "right", "to", "and", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "Angiogene", "license.", "<tag3>"], "wordsA": ["We", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "ASU", "license."], "wordsB": ["We", "have", "the", "sole", "right", "to", "and", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "Angiogene", "license."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p60_s1", "idA": "908259_13_item1_p62_s3", "sentA": "Payments made to ASU to date have amounted to $2,500,000.", "sentB": "Payments to Angiogene, under this license, to date have amounted to $150,000.", "type": 2, "words": ["<tag1>", "Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,500,000.", "<tag2>", "Payments", "to", "Angiogene,", "under", "this", "license,", "to", "date", "have", "amounted", "to", "$150,000.", "<tag3>"], "wordsA": ["Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,500,000."], "wordsB": ["Payments", "to", "Angiogene,", "under", "this", "license,", "to", "date", "have", "amounted", "to", "$150,000."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p0_s6", "idA": "908259_13_item1_p62_s5", "sentA": "Under a sponsored research agreement with Baylor University, we are pursuing discovery and development of additional novel, small-molecule therapeutics for the treatment of cancer, including small-molecule cathepsin-L inhibitors and hypoxia-activated VDAs.", "sentB": "Based on positive preclinical data, we are also pursuing the clinical development of ZYBRESTAT for the treatment of neuroendocrine tumors (NETs), which are tumors that arise from the body s hormonal and nervous systems, produce excessive amounts of biologically active substances, and may cause debilitating symptoms.", "type": 2, "words": ["<tag1>", "Under", "a", "sponsored", "research", "agreement", "with", "Baylor", "University,", "we", "are", "pursuing", "discovery", "and", "development", "of", "additional", "novel,", "small-molecule", "therapeutics", "for", "the", "treatment", "of", "cancer,", "including", "small-molecule", "cathepsin-L", "inhibitors", "and", "hypoxia-activated", "VDAs.", "<tag2>", "Based", "on", "positive", "preclinical", "data,", "we", "are", "also", "pursuing", "the", "clinical", "development", "of", "ZYBRESTAT", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "(NETs),", "which", "are", "tumors", "that", "arise", "from", "the", "body", "s", "hormonal", "and", "nervous", "systems,", "produce", "excessive", "amounts", "of", "biologically", "active", "substances,", "and", "may", "cause", "debilitating", "symptoms.", "<tag3>"], "wordsA": ["Under", "a", "sponsored", "research", "agreement", "with", "Baylor", "University,", "we", "are", "pursuing", "discovery", "and", "development", "of", "additional", "novel,", "small-molecule", "therapeutics", "for", "the", "treatment", "of", "cancer,", "including", "small-molecule", "cathepsin-L", "inhibitors", "and", "hypoxia-activated", "VDAs."], "wordsB": ["Based", "on", "positive", "preclinical", "data,", "we", "are", "also", "pursuing", "the", "clinical", "development", "of", "ZYBRESTAT", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "(NETs),", "which", "are", "tumors", "that", "arise", "from", "the", "body", "s", "hormonal", "and", "nervous", "systems,", "produce", "excessive", "amounts", "of", "biologically", "active", "substances,", "and", "may", "cause", "debilitating", "symptoms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p56_s4", "idA": "908259_13_item1_p65_s0", "sentA": "through use of Baylor s compounds.", "sentB": "The agreement with Baylor stipulates that low-single-digit royalties will be paid by us should sales be generated through use of Baylor s compounds.", "type": 2, "words": ["<tag1>", "through", "use", "of", "Baylor", "s", "compounds.", "<tag2>", "The", "agreement", "with", "Baylor", "stipulates", "that", "low-single-digit", "royalties", "will", "be", "paid", "by", "us", "should", "sales", "be", "generated", "through", "use", "of", "Baylor", "s", "compounds.", "<tag3>"], "wordsA": ["through", "use", "of", "Baylor", "s", "compounds."], "wordsB": ["The", "agreement", "with", "Baylor", "stipulates", "that", "low-single-digit", "royalties", "will", "be", "paid", "by", "us", "should", "sales", "be", "generated", "through", "use", "of", "Baylor", "s", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p60_s2", "idA": "908259_13_item1_p65_s6", "sentA": "The term of the license shall end upon the expiration of the licensed patents.", "sentB": "The term of the royalty payable under the license will expire on the sooner of (i) ten years from the regulatory approval of a product subject to the license or (ii) launch by a third party of a generic version of the vascular disrupting agent.", "type": 2, "words": ["<tag1>", "The", "term", "of", "the", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents.", "<tag2>", "The", "term", "of", "the", "royalty", "payable", "under", "the", "license", "will", "expire", "on", "the", "sooner", "of", "(i)", "ten", "years", "from", "the", "regulatory", "approval", "of", "a", "product", "subject", "to", "the", "license", "or", "(ii)", "launch", "by", "a", "third", "party", "of", "a", "generic", "version", "of", "the", "vascular", "disrupting", "agent.", "<tag3>"], "wordsA": ["The", "term", "of", "the", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents."], "wordsB": ["The", "term", "of", "the", "royalty", "payable", "under", "the", "license", "will", "expire", "on", "the", "sooner", "of", "(i)", "ten", "years", "from", "the", "regulatory", "approval", "of", "a", "product", "subject", "to", "the", "license", "or", "(ii)", "launch", "by", "a", "third", "party", "of", "a", "generic", "version", "of", "the", "vascular", "disrupting", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p60_s3", "idA": "908259_13_item1_p65_s6", "sentA": "The term of the license shall end upon the expiration of the licensed patents.", "sentB": "After the expiry of the royalty term, the license will become fully paid, irrevocable and perpetual.", "type": 2, "words": ["<tag1>", "The", "term", "of", "the", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents.", "<tag2>", "After", "the", "expiry", "of", "the", "royalty", "term,", "the", "license", "will", "become", "fully", "paid,", "irrevocable", "and", "perpetual.", "<tag3>"], "wordsA": ["The", "term", "of", "the", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents."], "wordsB": ["After", "the", "expiry", "of", "the", "royalty", "term,", "the", "license", "will", "become", "fully", "paid,", "irrevocable", "and", "perpetual."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p56_s11", "idA": "908259_13_item1_p65_s7", "sentA": "The latest U.S. patent licensed under this agreement is scheduled to expire in June 2030.", "sentB": "The latest U.S. patent licensed under this agreement is scheduled to expire in November 2030.", "type": 2, "words": ["<tag1>", "The", "latest", "U.S.", "patent", "licensed", "under", "this", "agreement", "is", "scheduled", "to", "expire", "in", "June", "2030.", "<tag2>", "The", "latest", "U.S.", "patent", "licensed", "under", "this", "agreement", "is", "scheduled", "to", "expire", "in", "November", "2030.", "<tag3>"], "wordsA": ["The", "latest", "U.S.", "patent", "licensed", "under", "this", "agreement", "is", "scheduled", "to", "expire", "in", "June", "2030."], "wordsB": ["The", "latest", "U.S.", "patent", "licensed", "under", "this", "agreement", "is", "scheduled", "to", "expire", "in", "November", "2030."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p59_s1", "idA": "908259_13_item1_p65_s9", "sentA": "Under the BMS license, we have the right to grant sublicenses.", "sentB": "Under the Angiogene license, we have the right to grant sublicenses.", "type": 2, "words": ["<tag1>", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses.", "<tag2>", "Under", "the", "Angiogene", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses.", "<tag3>"], "wordsA": ["Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses."], "wordsB": ["Under", "the", "Angiogene", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p60_s4", "idA": "908259_13_item1_p66_s1", "sentA": "Either party may terminate the license upon material default of the other party.", "sentB": "Either party may terminate the license upon material default of the other party, and we may terminate the agreement at will upon sixty days prior notice to Angiogene.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party.", "<tag2>", "Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party,", "and", "we", "may", "terminate", "the", "agreement", "at", "will", "upon", "sixty", "days", "prior", "notice", "to", "Angiogene.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party."], "wordsB": ["Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party,", "and", "we", "may", "terminate", "the", "agreement", "at", "will", "upon", "sixty", "days", "prior", "notice", "to", "Angiogene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s3", "idA": "908259_13_item1_p6_s0", "sentA": "A Phase 1b/2 study of ZYBRESTAT in combination with pazopanib, an antiangiogenic oral tyrosine kinase inhibitor, in recurrent ovarian cancer.", "sentB": "The study is designed as a Phase 1b/2 trial of pazopanib with and without ZYBRESTAT , in advanced recurrent ovarian cancer.", "type": 2, "words": ["<tag1>", "A", "Phase", "1b/2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "pazopanib,", "an", "antiangiogenic", "oral", "tyrosine", "kinase", "inhibitor,", "in", "recurrent", "ovarian", "cancer.", "<tag2>", "The", "study", "is", "designed", "as", "a", "Phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "ZYBRESTAT", ",", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag3>"], "wordsA": ["A", "Phase", "1b/2", "study", "of", "ZYBRESTAT", "in", "combination", "with", "pazopanib,", "an", "antiangiogenic", "oral", "tyrosine", "kinase", "inhibitor,", "in", "recurrent", "ovarian", "cancer."], "wordsB": ["The", "study", "is", "designed", "as", "a", "Phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "ZYBRESTAT", ",", "in", "advanced", "recurrent", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p22_s0", "idA": "908259_13_item1_p70_s0", "sentA": "FDA review and approval of the NDA.", "sentB": "An insulinoma is a PNET that causes the over-secretion of the hormone insulin.", "type": 2, "words": ["<tag1>", "FDA", "review", "and", "approval", "of", "the", "NDA.", "<tag2>", "An", "insulinoma", "is", "a", "PNET", "that", "causes", "the", "over-secretion", "of", "the", "hormone", "insulin.", "<tag3>"], "wordsA": ["FDA", "review", "and", "approval", "of", "the", "NDA."], "wordsB": ["An", "insulinoma", "is", "a", "PNET", "that", "causes", "the", "over-secretion", "of", "the", "hormone", "insulin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p73_s0", "idA": "908259_13_item1_p78_s1", "sentA": "For example, a sponsor may request an SPA of a protocol for a clinical trial that will form the primary basis of an efficacy claim in an NDA.", "sentB": "clinical trial that will form the primary basis of an efficacy claim in an NDA.", "type": 2, "words": ["<tag1>", "For", "example,", "a", "sponsor", "may", "request", "an", "SPA", "of", "a", "protocol", "for", "a", "clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA.", "<tag2>", "clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA.", "<tag3>"], "wordsA": ["For", "example,", "a", "sponsor", "may", "request", "an", "SPA", "of", "a", "protocol", "for", "a", "clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA."], "wordsB": ["clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p15_s3", "idA": "908259_13_item1_p7_s0", "sentA": "To pursue the commercialization of ZYBRESTAT in Europe for the treatment of ATC with a marketing authorization under exceptional or conditional circumstances, as further discussed below.", "sentB": "We intend to address and incorporate this feedback into our potential MAA filing, and we believe that it may be possible that we could obtain an MAA for the use of ZYBRESTAT in the treatment of ATC with the existing clinical data that we have.", "type": 2, "words": ["<tag1>", "To", "pursue", "the", "commercialization", "of", "ZYBRESTAT", "in", "Europe", "for", "the", "treatment", "of", "ATC", "with", "a", "marketing", "authorization", "under", "exceptional", "or", "conditional", "circumstances,", "as", "further", "discussed", "below.", "<tag2>", "We", "intend", "to", "address", "and", "incorporate", "this", "feedback", "into", "our", "potential", "MAA", "filing,", "and", "we", "believe", "that", "it", "may", "be", "possible", "that", "we", "could", "obtain", "an", "MAA", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC", "with", "the", "existing", "clinical", "data", "that", "we", "have.", "<tag3>"], "wordsA": ["To", "pursue", "the", "commercialization", "of", "ZYBRESTAT", "in", "Europe", "for", "the", "treatment", "of", "ATC", "with", "a", "marketing", "authorization", "under", "exceptional", "or", "conditional", "circumstances,", "as", "further", "discussed", "below."], "wordsB": ["We", "intend", "to", "address", "and", "incorporate", "this", "feedback", "into", "our", "potential", "MAA", "filing,", "and", "we", "believe", "that", "it", "may", "be", "possible", "that", "we", "could", "obtain", "an", "MAA", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC", "with", "the", "existing", "clinical", "data", "that", "we", "have."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p93_s5", "idA": "908259_13_item1_p7_s0", "sentA": "To pursue the commercialization of ZYBRESTAT in Europe for the treatment of ATC with a marketing authorization under exceptional or conditional circumstances, as further discussed below.", "sentB": "We are currently pursuing a potential filing for a marketing authorization, or MAA, in the EU with ZYBRESTAT for the treatment of ATC under exceptional circumstances.", "type": 2, "words": ["<tag1>", "To", "pursue", "the", "commercialization", "of", "ZYBRESTAT", "in", "Europe", "for", "the", "treatment", "of", "ATC", "with", "a", "marketing", "authorization", "under", "exceptional", "or", "conditional", "circumstances,", "as", "further", "discussed", "below.", "<tag2>", "We", "are", "currently", "pursuing", "a", "potential", "filing", "for", "a", "marketing", "authorization,", "or", "MAA,", "in", "the", "EU", "with", "ZYBRESTAT", "for", "the", "treatment", "of", "ATC", "under", "exceptional", "circumstances.", "<tag3>"], "wordsA": ["To", "pursue", "the", "commercialization", "of", "ZYBRESTAT", "in", "Europe", "for", "the", "treatment", "of", "ATC", "with", "a", "marketing", "authorization", "under", "exceptional", "or", "conditional", "circumstances,", "as", "further", "discussed", "below."], "wordsB": ["We", "are", "currently", "pursuing", "a", "potential", "filing", "for", "a", "marketing", "authorization,", "or", "MAA,", "in", "the", "EU", "with", "ZYBRESTAT", "for", "the", "treatment", "of", "ATC", "under", "exceptional", "circumstances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p94_s0", "idA": "908259_13_item1_p7_s0", "sentA": "To pursue the commercialization of ZYBRESTAT in Europe for the treatment of ATC with a marketing authorization under exceptional or conditional circumstances, as further discussed below.", "sentB": "We intend to address and incorporate this feedback into our potential MAA filing, and we believe that it is possible that we could obtain an MAA for the use of ZYBRESTAT in the treatment of ATC with the existing clinical data that we have.", "type": 2, "words": ["<tag1>", "To", "pursue", "the", "commercialization", "of", "ZYBRESTAT", "in", "Europe", "for", "the", "treatment", "of", "ATC", "with", "a", "marketing", "authorization", "under", "exceptional", "or", "conditional", "circumstances,", "as", "further", "discussed", "below.", "<tag2>", "We", "intend", "to", "address", "and", "incorporate", "this", "feedback", "into", "our", "potential", "MAA", "filing,", "and", "we", "believe", "that", "it", "is", "possible", "that", "we", "could", "obtain", "an", "MAA", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC", "with", "the", "existing", "clinical", "data", "that", "we", "have.", "<tag3>"], "wordsA": ["To", "pursue", "the", "commercialization", "of", "ZYBRESTAT", "in", "Europe", "for", "the", "treatment", "of", "ATC", "with", "a", "marketing", "authorization", "under", "exceptional", "or", "conditional", "circumstances,", "as", "further", "discussed", "below."], "wordsB": ["We", "intend", "to", "address", "and", "incorporate", "this", "feedback", "into", "our", "potential", "MAA", "filing,", "and", "we", "believe", "that", "it", "is", "possible", "that", "we", "could", "obtain", "an", "MAA", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC", "with", "the", "existing", "clinical", "data", "that", "we", "have."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p74_s1", "idA": "908259_13_item1_p80_s1", "sentA": "IND Safety Reports must be submitted to the FDA, IRBs and the investigators for (a) any suspected adverse reaction that is both serious and unexpected; (b) any findings from epidemiological studies, pooled analysis of multiple studies, or clinical studies (other than those already reported in (a); (c) any findings from animal or in vitro testing, whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug, such as reports of mutagenicity, teratogenicity, or carcinogenicity or reports of significant organ toxicity at or near the expected human exposure; and (d) any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.", "sentB": "IND Safety Reports must be submitted to the FDA, IRBs and the investigators for (a) any suspected adverse reaction that is both serious and unexpected; (b) any findings from epidemiological studies, pooled analysis of multiple studies, or clinical studies (other than those already reported in (a)); (c) any findings from animal or in vitro testing, whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug, such as reports of mutagenicity, teratogenicity, or carcinogenicity or reports of significant organ toxicity at or near the expected human exposure; and (d) any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.", "type": 2, "words": ["<tag1>", "IND", "Safety", "Reports", "must", "be", "submitted", "to", "the", "FDA,", "IRBs", "and", "the", "investigators", "for", "(a)", "any", "suspected", "adverse", "reaction", "that", "is", "both", "serious", "and", "unexpected;", "(b)", "any", "findings", "from", "epidemiological", "studies,", "pooled", "analysis", "of", "multiple", "studies,", "or", "clinical", "studies", "(other", "than", "those", "already", "reported", "in", "(a);", "(c)", "any", "findings", "from", "animal", "or", "in", "vitro", "testing,", "whether", "or", "not", "conducted", "by", "the", "sponsor,", "that", "suggest", "a", "significant", "risk", "in", "humans", "exposed", "to", "the", "drug,", "such", "as", "reports", "of", "mutagenicity,", "teratogenicity,", "or", "carcinogenicity", "or", "reports", "of", "significant", "organ", "toxicity", "at", "or", "near", "the", "expected", "human", "exposure;", "and", "(d)", "any", "clinically", "important", "increase", "in", "the", "rate", "of", "a", "serious", "suspected", "adverse", "reaction", "over", "that", "listed", "in", "the", "protocol", "or", "investigator", "brochure.", "<tag2>", "IND", "Safety", "Reports", "must", "be", "submitted", "to", "the", "FDA,", "IRBs", "and", "the", "investigators", "for", "(a)", "any", "suspected", "adverse", "reaction", "that", "is", "both", "serious", "and", "unexpected;", "(b)", "any", "findings", "from", "epidemiological", "studies,", "pooled", "analysis", "of", "multiple", "studies,", "or", "clinical", "studies", "(other", "than", "those", "already", "reported", "in", "(a));", "(c)", "any", "findings", "from", "animal", "or", "in", "vitro", "testing,", "whether", "or", "not", "conducted", "by", "the", "sponsor,", "that", "suggest", "a", "significant", "risk", "in", "humans", "exposed", "to", "the", "drug,", "such", "as", "reports", "of", "mutagenicity,", "teratogenicity,", "or", "carcinogenicity", "or", "reports", "of", "significant", "organ", "toxicity", "at", "or", "near", "the", "expected", "human", "exposure;", "and", "(d)", "any", "clinically", "important", "increase", "in", "the", "rate", "of", "a", "serious", "suspected", "adverse", "reaction", "over", "that", "listed", "in", "the", "protocol", "or", "investigator", "brochure.", "<tag3>"], "wordsA": ["IND", "Safety", "Reports", "must", "be", "submitted", "to", "the", "FDA,", "IRBs", "and", "the", "investigators", "for", "(a)", "any", "suspected", "adverse", "reaction", "that", "is", "both", "serious", "and", "unexpected;", "(b)", "any", "findings", "from", "epidemiological", "studies,", "pooled", "analysis", "of", "multiple", "studies,", "or", "clinical", "studies", "(other", "than", "those", "already", "reported", "in", "(a);", "(c)", "any", "findings", "from", "animal", "or", "in", "vitro", "testing,", "whether", "or", "not", "conducted", "by", "the", "sponsor,", "that", "suggest", "a", "significant", "risk", "in", "humans", "exposed", "to", "the", "drug,", "such", "as", "reports", "of", "mutagenicity,", "teratogenicity,", "or", "carcinogenicity", "or", "reports", "of", "significant", "organ", "toxicity", "at", "or", "near", "the", "expected", "human", "exposure;", "and", "(d)", "any", "clinically", "important", "increase", "in", "the", "rate", "of", "a", "serious", "suspected", "adverse", "reaction", "over", "that", "listed", "in", "the", "protocol", "or", "investigator", "brochure."], "wordsB": ["IND", "Safety", "Reports", "must", "be", "submitted", "to", "the", "FDA,", "IRBs", "and", "the", "investigators", "for", "(a)", "any", "suspected", "adverse", "reaction", "that", "is", "both", "serious", "and", "unexpected;", "(b)", "any", "findings", "from", "epidemiological", "studies,", "pooled", "analysis", "of", "multiple", "studies,", "or", "clinical", "studies", "(other", "than", "those", "already", "reported", "in", "(a));", "(c)", "any", "findings", "from", "animal", "or", "in", "vitro", "testing,", "whether", "or", "not", "conducted", "by", "the", "sponsor,", "that", "suggest", "a", "significant", "risk", "in", "humans", "exposed", "to", "the", "drug,", "such", "as", "reports", "of", "mutagenicity,", "teratogenicity,", "or", "carcinogenicity", "or", "reports", "of", "significant", "organ", "toxicity", "at", "or", "near", "the", "expected", "human", "exposure;", "and", "(d)", "any", "clinically", "important", "increase", "in", "the", "rate", "of", "a", "serious", "suspected", "adverse", "reaction", "over", "that", "listed", "in", "the", "protocol", "or", "investigator", "brochure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p73_s2", "idA": "908259_13_item1_p83_s0", "sentA": "Once the submission is accepted for filing, the FDA begins an in-depth substantive review.", "sentB": "After receiving the request, the FDA will consider whether the submission is appropriate for an SPA.", "type": 2, "words": ["<tag1>", "Once", "the", "submission", "is", "accepted", "for", "filing,", "the", "FDA", "begins", "an", "in-depth", "substantive", "review.", "<tag2>", "After", "receiving", "the", "request,", "the", "FDA", "will", "consider", "whether", "the", "submission", "is", "appropriate", "for", "an", "SPA.", "<tag3>"], "wordsA": ["Once", "the", "submission", "is", "accepted", "for", "filing,", "the", "FDA", "begins", "an", "in-depth", "substantive", "review."], "wordsB": ["After", "receiving", "the", "request,", "the", "FDA", "will", "consider", "whether", "the", "submission", "is", "appropriate", "for", "an", "SPA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p78_s0", "idA": "908259_13_item1_p83_s1", "sentA": "The FDA may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.", "sentB": "evaluation and recommendation as to whether the application should be approved and under what conditions.", "type": 2, "words": ["<tag1>", "The", "FDA", "may", "refer", "the", "NDA", "to", "an", "advisory", "committee", "for", "review,", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions.", "<tag2>", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions.", "<tag3>"], "wordsA": ["The", "FDA", "may", "refer", "the", "NDA", "to", "an", "advisory", "committee", "for", "review,", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions."], "wordsB": ["evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p78_s2", "idA": "908259_13_item1_p84_s0", "sentA": "criteria are not satisfied or may require additional clinical or other data and information.", "sentB": "The approval process is lengthy and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information.", "type": 2, "words": ["<tag1>", "criteria", "are", "not", "satisfied", "or", "may", "require", "additional", "clinical", "or", "other", "data", "and", "information.", "<tag2>", "The", "approval", "process", "is", "lengthy", "and", "difficult", "and", "the", "FDA", "may", "refuse", "to", "approve", "an", "NDA", "if", "the", "applicable", "regulatory", "criteria", "are", "not", "satisfied", "or", "may", "require", "additional", "clinical", "or", "other", "data", "and", "information.", "<tag3>"], "wordsA": ["criteria", "are", "not", "satisfied", "or", "may", "require", "additional", "clinical", "or", "other", "data", "and", "information."], "wordsB": ["The", "approval", "process", "is", "lengthy", "and", "difficult", "and", "the", "FDA", "may", "refuse", "to", "approve", "an", "NDA", "if", "the", "applicable", "regulatory", "criteria", "are", "not", "satisfied", "or", "may", "require", "additional", "clinical", "or", "other", "data", "and", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p27_s2", "idA": "908259_13_item1_p8_s0", "sentA": "To continue to support the ongoing investigator-sponsored Phase 1 trial of OXi4503 in patients with acute myelogenous leukemia, or AML, or myelodysplastic syndrome, or MDS, being conducted at the University of Florida and with support by The Leukemia Lymphoma Society s Therapy Acceleration Program.", "sentB": "As the University of Florida and a non-profit research organization, the Leukemia Lymphoma Society s Therapy Acceleration Program, are covering the majority of the costs of this trial, our ongoing expenses related to this trial are primarily related to manufacturing sufficient quantities of OXi4503.", "type": 2, "words": ["<tag1>", "To", "continue", "to", "support", "the", "ongoing", "investigator-sponsored", "Phase", "1", "trial", "of", "OXi4503", "in", "patients", "with", "acute", "myelogenous", "leukemia,", "or", "AML,", "or", "myelodysplastic", "syndrome,", "or", "MDS,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program.", "<tag2>", "As", "the", "University", "of", "Florida", "and", "a", "non-profit", "research", "organization,", "the", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program,", "are", "covering", "the", "majority", "of", "the", "costs", "of", "this", "trial,", "our", "ongoing", "expenses", "related", "to", "this", "trial", "are", "primarily", "related", "to", "manufacturing", "sufficient", "quantities", "of", "OXi4503.", "<tag3>"], "wordsA": ["To", "continue", "to", "support", "the", "ongoing", "investigator-sponsored", "Phase", "1", "trial", "of", "OXi4503", "in", "patients", "with", "acute", "myelogenous", "leukemia,", "or", "AML,", "or", "myelodysplastic", "syndrome,", "or", "MDS,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program."], "wordsB": ["As", "the", "University", "of", "Florida", "and", "a", "non-profit", "research", "organization,", "the", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program,", "are", "covering", "the", "majority", "of", "the", "costs", "of", "this", "trial,", "our", "ongoing", "expenses", "related", "to", "this", "trial", "are", "primarily", "related", "to", "manufacturing", "sufficient", "quantities", "of", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p84_s1", "idA": "908259_13_item1_p90_s1", "sentA": "ZYBRESTAT was awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers, acute myelogenous leukemia and ovarian cancer.", "sentB": "ZYBRESTAT was awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers and ovarian cancer.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "acute", "myelogenous", "leukemia", "and", "ovarian", "cancer.", "<tag2>", "ZYBRESTAT", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers", "and", "ovarian", "cancer.", "<tag3>"], "wordsA": ["ZYBRESTAT", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "acute", "myelogenous", "leukemia", "and", "ovarian", "cancer."], "wordsB": ["ZYBRESTAT", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers", "and", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p84_s2", "idA": "908259_13_item1_p90_s1", "sentA": "ZYBRESTAT was awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers, acute myelogenous leukemia and ovarian cancer.", "sentB": "OXi4503 was awarded orphan drug status by the FDA for the treatment of acute myelogenous leukemia.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "acute", "myelogenous", "leukemia", "and", "ovarian", "cancer.", "<tag2>", "OXi4503", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag3>"], "wordsA": ["ZYBRESTAT", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "acute", "myelogenous", "leukemia", "and", "ovarian", "cancer."], "wordsB": ["OXi4503", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p85_s0", "idA": "908259_13_item1_p90_s2", "sentA": "ZYBRESTAT was also awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer.", "sentB": "ZYBRESTAT was also awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer and ovarian cancer.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer.", "<tag2>", "ZYBRESTAT", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer.", "<tag3>"], "wordsA": ["ZYBRESTAT", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer."], "wordsB": ["ZYBRESTAT", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s0", "idA": "908259_13_item1_p92_s0", "sentA": "Fast Track designation applies to the combination of the product and the specific indication for which it is being studied.", "sentB": "Consistent with prior clinical experience with ZYBRESTAT , patients in the combination arm experienced a higher incidence of hypertension compared to the control arm.", "type": 2, "words": ["<tag1>", "Fast", "Track", "designation", "applies", "to", "the", "combination", "of", "the", "product", "and", "the", "specific", "indication", "for", "which", "it", "is", "being", "studied.", "<tag2>", "Consistent", "with", "prior", "clinical", "experience", "with", "ZYBRESTAT", ",", "patients", "in", "the", "combination", "arm", "experienced", "a", "higher", "incidence", "of", "hypertension", "compared", "to", "the", "control", "arm.", "<tag3>"], "wordsA": ["Fast", "Track", "designation", "applies", "to", "the", "combination", "of", "the", "product", "and", "the", "specific", "indication", "for", "which", "it", "is", "being", "studied."], "wordsB": ["Consistent", "with", "prior", "clinical", "experience", "with", "ZYBRESTAT", ",", "patients", "in", "the", "combination", "arm", "experienced", "a", "higher", "incidence", "of", "hypertension", "compared", "to", "the", "control", "arm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p20_s1", "idA": "908259_13_item1_p93_s2", "sentA": "The FDA has granted Fast Track designation to ZYBRESTAT for the treatment of regionally advanced and/or metastatic ATC.", "sentB": "This placebo-controlled preclinical study was designed to evaluate the activity of systemic administration of ZYBRESTAT for the treatment of functional insulinomas in a transgenic mouse model of PNETs.", "type": 2, "words": ["<tag1>", "The", "FDA", "has", "granted", "Fast", "Track", "designation", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "regionally", "advanced", "and/or", "metastatic", "ATC.", "<tag2>", "This", "placebo-controlled", "preclinical", "study", "was", "designed", "to", "evaluate", "the", "activity", "of", "systemic", "administration", "of", "ZYBRESTAT", "for", "the", "treatment", "of", "functional", "insulinomas", "in", "a", "transgenic", "mouse", "model", "of", "PNETs.", "<tag3>"], "wordsA": ["The", "FDA", "has", "granted", "Fast", "Track", "designation", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "regionally", "advanced", "and/or", "metastatic", "ATC."], "wordsB": ["This", "placebo-controlled", "preclinical", "study", "was", "designed", "to", "evaluate", "the", "activity", "of", "systemic", "administration", "of", "ZYBRESTAT", "for", "the", "treatment", "of", "functional", "insulinomas", "in", "a", "transgenic", "mouse", "model", "of", "PNETs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p14_s1", "idA": "908259_13_item1_p98_s3", "sentA": "We are evaluating the potential benefits of seeking approval under exceptional circumstances for the use of ZYBRESTAT in ATC.", "sentB": "Due to an unmet need in the treatment of ATC and the small size of the indication, we have been granted an orphan drug designation by both the FDA and European Medicines Agency (EMA) for the use of ZYBRESTAT in the treatment of ATC.", "type": 2, "words": ["<tag1>", "We", "are", "evaluating", "the", "potential", "benefits", "of", "seeking", "approval", "under", "exceptional", "circumstances", "for", "the", "use", "of", "ZYBRESTAT", "in", "ATC.", "<tag2>", "Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "ATC", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "by", "both", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA)", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC.", "<tag3>"], "wordsA": ["We", "are", "evaluating", "the", "potential", "benefits", "of", "seeking", "approval", "under", "exceptional", "circumstances", "for", "the", "use", "of", "ZYBRESTAT", "in", "ATC."], "wordsB": ["Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "ATC", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "by", "both", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA)", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p15_s2", "idA": "908259_13_item1_p98_s3", "sentA": "We are evaluating the potential benefits of seeking approval under exceptional circumstances for the use of ZYBRESTAT in ATC.", "sentB": "We received feedback from the Scientific Advice Working Party, or SAWP, of the EMA, in July 2013, two reviewing countries in March 2013, and from two more countries in February 2014, on our plan to submit an MAA for ZYBRESTAT in ATC.", "type": 2, "words": ["<tag1>", "We", "are", "evaluating", "the", "potential", "benefits", "of", "seeking", "approval", "under", "exceptional", "circumstances", "for", "the", "use", "of", "ZYBRESTAT", "in", "ATC.", "<tag2>", "We", "received", "feedback", "from", "the", "Scientific", "Advice", "Working", "Party,", "or", "SAWP,", "of", "the", "EMA,", "in", "July", "2013,", "two", "reviewing", "countries", "in", "March", "2013,", "and", "from", "two", "more", "countries", "in", "February", "2014,", "on", "our", "plan", "to", "submit", "an", "MAA", "for", "ZYBRESTAT", "in", "ATC.", "<tag3>"], "wordsA": ["We", "are", "evaluating", "the", "potential", "benefits", "of", "seeking", "approval", "under", "exceptional", "circumstances", "for", "the", "use", "of", "ZYBRESTAT", "in", "ATC."], "wordsB": ["We", "received", "feedback", "from", "the", "Scientific", "Advice", "Working", "Party,", "or", "SAWP,", "of", "the", "EMA,", "in", "July", "2013,", "two", "reviewing", "countries", "in", "March", "2013,", "and", "from", "two", "more", "countries", "in", "February", "2014,", "on", "our", "plan", "to", "submit", "an", "MAA", "for", "ZYBRESTAT", "in", "ATC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p93_s4", "idA": "908259_13_item1_p98_s4", "sentA": "We cannot assure you that this pathway will be acceptable for marketing approval in Europe.", "sentB": "We cannot assure you that we will receive this approval for marketing in Europe.", "type": 2, "words": ["<tag1>", "We", "cannot", "assure", "you", "that", "this", "pathway", "will", "be", "acceptable", "for", "marketing", "approval", "in", "Europe.", "<tag2>", "We", "cannot", "assure", "you", "that", "we", "will", "receive", "this", "approval", "for", "marketing", "in", "Europe.", "<tag3>"], "wordsA": ["We", "cannot", "assure", "you", "that", "this", "pathway", "will", "be", "acceptable", "for", "marketing", "approval", "in", "Europe."], "wordsB": ["We", "cannot", "assure", "you", "that", "we", "will", "receive", "this", "approval", "for", "marketing", "in", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p95_s2", "idA": "908259_13_item1_p99_s0", "sentA": "including the European Union, Canada and Japan.", "sentB": "As of March 17, 2014, we were the exclusive licensee, sole assignee or co-assignee of twenty-nine (29) granted U.S. patents, seven (7) pending U.S. patent applications, two (2) pending Patent Cooperation Treaty international patent applications and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "type": 2, "words": ["<tag1>", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag2>", "As", "of", "March", "17,", "2014,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-nine", "(29)", "granted", "U.S.", "patents,", "seven", "(7)", "pending", "U.S.", "patent", "applications,", "two", "(2)", "pending", "Patent", "Cooperation", "Treaty", "international", "patent", "applications", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag3>"], "wordsA": ["including", "the", "European", "Union,", "Canada", "and", "Japan."], "wordsB": ["As", "of", "March", "17,", "2014,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-nine", "(29)", "granted", "U.S.", "patents,", "seven", "(7)", "pending", "U.S.", "patent", "applications,", "two", "(2)", "pending", "Patent", "Cooperation", "Treaty", "international", "patent", "applications", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p15_s4", "idA": "908259_13_item1_p9_s1", "sentA": "We currently have orphan drug status in the United States and in the European Union for ZYBRESTAT for the treatment of ATC, medullary thyroid cancer, Stage IV papillary thyroid cancer, and Stage IV follicular thyroid cancer, and for ZYBRETSTAT in the United States for the treatment of ovarian cancer.", "sentB": "If we are successful in obtaining an MAA for ZYBRESTAT in the treatment of ATC, we believe that this could lead to similar authorizations in other countries such as Japan, South Korea, China, or Canada (but not in the United States).", "type": 2, "words": ["<tag1>", "We", "currently", "have", "orphan", "drug", "status", "in", "the", "United", "States", "and", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ATC,", "medullary", "thyroid", "cancer,", "Stage", "IV", "papillary", "thyroid", "cancer,", "and", "Stage", "IV", "follicular", "thyroid", "cancer,", "and", "for", "ZYBRETSTAT", "in", "the", "United", "States", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "If", "we", "are", "successful", "in", "obtaining", "an", "MAA", "for", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC,", "we", "believe", "that", "this", "could", "lead", "to", "similar", "authorizations", "in", "other", "countries", "such", "as", "Japan,", "South", "Korea,", "China,", "or", "Canada", "(but", "not", "in", "the", "United", "States).", "<tag3>"], "wordsA": ["We", "currently", "have", "orphan", "drug", "status", "in", "the", "United", "States", "and", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ATC,", "medullary", "thyroid", "cancer,", "Stage", "IV", "papillary", "thyroid", "cancer,", "and", "Stage", "IV", "follicular", "thyroid", "cancer,", "and", "for", "ZYBRETSTAT", "in", "the", "United", "States", "for", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["If", "we", "are", "successful", "in", "obtaining", "an", "MAA", "for", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC,", "we", "believe", "that", "this", "could", "lead", "to", "similar", "authorizations", "in", "other", "countries", "such", "as", "Japan,", "South", "Korea,", "China,", "or", "Canada", "(but", "not", "in", "the", "United", "States)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p94_s1", "idA": "908259_13_item1_p9_s1", "sentA": "We currently have orphan drug status in the United States and in the European Union for ZYBRESTAT for the treatment of ATC, medullary thyroid cancer, Stage IV papillary thyroid cancer, and Stage IV follicular thyroid cancer, and for ZYBRETSTAT in the United States for the treatment of ovarian cancer.", "sentB": "If we are successful in obtaining an MAA for ZYBRESTAT in the treatment of ATC, we believe that this could lead to similar authorizations in other countries such as Japan, South Korea, China, or Canada (but not in the United States).", "type": 2, "words": ["<tag1>", "We", "currently", "have", "orphan", "drug", "status", "in", "the", "United", "States", "and", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ATC,", "medullary", "thyroid", "cancer,", "Stage", "IV", "papillary", "thyroid", "cancer,", "and", "Stage", "IV", "follicular", "thyroid", "cancer,", "and", "for", "ZYBRETSTAT", "in", "the", "United", "States", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "If", "we", "are", "successful", "in", "obtaining", "an", "MAA", "for", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC,", "we", "believe", "that", "this", "could", "lead", "to", "similar", "authorizations", "in", "other", "countries", "such", "as", "Japan,", "South", "Korea,", "China,", "or", "Canada", "(but", "not", "in", "the", "United", "States).", "<tag3>"], "wordsA": ["We", "currently", "have", "orphan", "drug", "status", "in", "the", "United", "States", "and", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ATC,", "medullary", "thyroid", "cancer,", "Stage", "IV", "papillary", "thyroid", "cancer,", "and", "Stage", "IV", "follicular", "thyroid", "cancer,", "and", "for", "ZYBRETSTAT", "in", "the", "United", "States", "for", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["If", "we", "are", "successful", "in", "obtaining", "an", "MAA", "for", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC,", "we", "believe", "that", "this", "could", "lead", "to", "similar", "authorizations", "in", "other", "countries", "such", "as", "Japan,", "South", "Korea,", "China,", "or", "Canada", "(but", "not", "in", "the", "United", "States)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p0_s3", "idA": "908259_13_item1_p9_s2", "sentA": "We have applied for orphan drug status in the European Union for ZYBRESTAT for the treatment of ovarian cancer.", "sentB": "In the European Union, we are primarily focused on pursuing registration for ZYBRESTAT for anaplastic thyroid cancer (ATC), a rare and highly aggressive cancer, through the European Union s exceptional circumstances marketing authorization process.", "type": 2, "words": ["<tag1>", "We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "In", "the", "European", "Union,", "we", "are", "primarily", "focused", "on", "pursuing", "registration", "for", "ZYBRESTAT", "for", "anaplastic", "thyroid", "cancer", "(ATC),", "a", "rare", "and", "highly", "aggressive", "cancer,", "through", "the", "European", "Union", "s", "exceptional", "circumstances", "marketing", "authorization", "process.", "<tag3>"], "wordsA": ["We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["In", "the", "European", "Union,", "we", "are", "primarily", "focused", "on", "pursuing", "registration", "for", "ZYBRESTAT", "for", "anaplastic", "thyroid", "cancer", "(ATC),", "a", "rare", "and", "highly", "aggressive", "cancer,", "through", "the", "European", "Union", "s", "exceptional", "circumstances", "marketing", "authorization", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p0_s5", "idA": "908259_13_item1_p9_s2", "sentA": "We have applied for orphan drug status in the European Union for ZYBRESTAT for the treatment of ovarian cancer.", "sentB": "We have been granted orphan drug designation for ovarian cancer and ATC in the United States and the European Union.", "type": 2, "words": ["<tag1>", "We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "ovarian", "cancer", "and", "ATC", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag3>"], "wordsA": ["We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "ovarian", "cancer", "and", "ATC", "in", "the", "United", "States", "and", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p22_s1", "idA": "908259_13_item1_p9_s2", "sentA": "We have applied for orphan drug status in the European Union for ZYBRESTAT for the treatment of ovarian cancer.", "sentB": "The animals in the treatment group received ZYBRESTAT three times per week for four weeks, and the animals in the control group received a placebo at the same schedule.", "type": 2, "words": ["<tag1>", "We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "The", "animals", "in", "the", "treatment", "group", "received", "ZYBRESTAT", "three", "times", "per", "week", "for", "four", "weeks,", "and", "the", "animals", "in", "the", "control", "group", "received", "a", "placebo", "at", "the", "same", "schedule.", "<tag3>"], "wordsA": ["We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["The", "animals", "in", "the", "treatment", "group", "received", "ZYBRESTAT", "three", "times", "per", "week", "for", "four", "weeks,", "and", "the", "animals", "in", "the", "control", "group", "received", "a", "placebo", "at", "the", "same", "schedule."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p3_s0", "idA": "908259_13_item1_p9_s2", "sentA": "We have applied for orphan drug status in the European Union for ZYBRESTAT for the treatment of ovarian cancer.", "sentB": "There are relatively few cancer therapies that have been approved for the treatment of ovarian cancer, including carboplatin and cisplatin, gemcitabine, doxorubicin, and paclitaxel and also in the European Union, bevacizumab.", "type": 2, "words": ["<tag1>", "We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer,", "including", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "and", "paclitaxel", "and", "also", "in", "the", "European", "Union,", "bevacizumab.", "<tag3>"], "wordsA": ["We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer,", "including", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "and", "paclitaxel", "and", "also", "in", "the", "European", "Union,", "bevacizumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p4_s0", "idA": "908259_13_item1_p9_s2", "sentA": "We have applied for orphan drug status in the European Union for ZYBRESTAT for the treatment of ovarian cancer.", "sentB": "Due to the unmet need in the treatment of ovarian cancer and the small size of the indication, we have been granted an orphan drug designation in both the U.S. and Europe for the use of ZYBRESTAT in the treatment of ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p5_s0", "idA": "908259_13_item1_p9_s2", "sentA": "We have applied for orphan drug status in the European Union for ZYBRESTAT for the treatment of ovarian cancer.", "sentB": "Genentech / Roche s AVASTIN (bevacizumab) is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody that is currently FDA-approved for the treatment of a variety of solid tumor indications, but not including ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "Genentech", "/", "Roche", "s", "AVASTIN", "(bevacizumab)", "is", "an", "anti-vascular", "endothelial", "growth", "factor", "(VEGF)", "monoclonal", "antibody", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "a", "variety", "of", "solid", "tumor", "indications,", "but", "not", "including", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "have", "applied", "for", "orphan", "drug", "status", "in", "the", "European", "Union", "for", "ZYBRESTAT", "for", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["Genentech", "/", "Roche", "s", "AVASTIN", "(bevacizumab)", "is", "an", "anti-vascular", "endothelial", "growth", "factor", "(VEGF)", "monoclonal", "antibody", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "a", "variety", "of", "solid", "tumor", "indications,", "but", "not", "including", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p26_s2", "idA": "908259_13_item1_p9_s3", "sentA": "We also have orphan drug status in the United States for our product candidate OXi4503 for the treatment of AML.", "sentB": "Due to an unmet need in the treatment of AML and the small size of the indication, we have been granted orphan drug designation in the United States for the use of OXi4503 in the treatment of AML.", "type": 2, "words": ["<tag1>", "We", "also", "have", "orphan", "drug", "status", "in", "the", "United", "States", "for", "our", "product", "candidate", "OXi4503", "for", "the", "treatment", "of", "AML.", "<tag2>", "Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "AML", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "orphan", "drug", "designation", "in", "the", "United", "States", "for", "the", "use", "of", "OXi4503", "in", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["We", "also", "have", "orphan", "drug", "status", "in", "the", "United", "States", "for", "our", "product", "candidate", "OXi4503", "for", "the", "treatment", "of", "AML."], "wordsB": ["Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "AML", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "orphan", "drug", "designation", "in", "the", "United", "States", "for", "the", "use", "of", "OXi4503", "in", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p0_s0", "idA": "908259_14_item1_p0_s0", "sentA": "Business Overview We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "type": 2, "words": ["<tag1>", "Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag3>"], "wordsA": ["Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p0_s6", "idA": "908259_14_item1_p0_s2", "sentA": "In the United States, we are pursuing collaborations with established pharmaceutical companies with products whose efficacy we believe can be enhanced by the addition of our lead product candidate, ZYBRESTAT , and with non-profit research organizations such as the Gynecologic Oncology Group, or GOG, an organization dedicated to clinical research in the field of gynecologic cancer, for the treatment of advanced ovarian cancer.", "sentB": "In the United States and Europe, we are pursuing collaborations with established pharmaceutical companies with products whose efficacy we believe can be enhanced by the addition of our lead product candidate, fosbretabulin, and with non-profit research organizations such as The Christie Hospital NHS Foundation Trust (UK), an international leader in cancer research and development, and the Gynecologic Oncology Group, or GOG, now part of NRG Oncology (NCI), an organization dedicated to clinical research in the field of gynecologic cancer, for the treatment of advanced ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "ZYBRESTAT", ",", "and", "with", "non-profit", "research", "organizations", "such", "as", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer.", "<tag2>", "In", "the", "United", "States", "and", "Europe,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "fosbretabulin,", "and", "with", "non-profit", "research", "organizations", "such", "as", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "(UK),", "an", "international", "leader", "in", "cancer", "research", "and", "development,", "and", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "now", "part", "of", "NRG", "Oncology", "(NCI),", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "ZYBRESTAT", ",", "and", "with", "non-profit", "research", "organizations", "such", "as", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer."], "wordsB": ["In", "the", "United", "States", "and", "Europe,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "fosbretabulin,", "and", "with", "non-profit", "research", "organizations", "such", "as", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "(UK),", "an", "international", "leader", "in", "cancer", "research", "and", "development,", "and", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "now", "part", "of", "NRG", "Oncology", "(NCI),", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p0_s4", "idA": "908259_14_item1_p0_s4", "sentA": "To date, we have observed ZYBRESTAT to be well tolerated in over 400 patients and to have clinical activity in a variety of indications including ovarian cancer and ATC.", "sentB": "To date, we have observed fosbretabulin to be well tolerated in over 450 patients and to have clinical activity in a variety of indications including ovarian cancer.", "type": 2, "words": ["<tag1>", "To", "date,", "we", "have", "observed", "ZYBRESTAT", "to", "be", "well", "tolerated", "in", "over", "400", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer", "and", "ATC.", "<tag2>", "To", "date,", "we", "have", "observed", "fosbretabulin", "to", "be", "well", "tolerated", "in", "over", "450", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer.", "<tag3>"], "wordsA": ["To", "date,", "we", "have", "observed", "ZYBRESTAT", "to", "be", "well", "tolerated", "in", "over", "400", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer", "and", "ATC."], "wordsB": ["To", "date,", "we", "have", "observed", "fosbretabulin", "to", "be", "well", "tolerated", "in", "over", "450", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p0_s3", "idA": "908259_14_item1_p0_s5", "sentA": "We have been granted orphan drug designation for ovarian cancer and ATC in the United States and the European Union.", "sentB": "We have been granted orphan drug designation for fosbretabulin in the treatment of ovarian cancer in the United States and the European Union, and for OXi4503 in the treatment of AML in the United States.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "ovarian", "cancer", "and", "ATC", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "ovarian", "cancer", "and", "ATC", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p24_s3", "idA": "908259_14_item1_p0_s5", "sentA": "We have been granted orphan drug designation for ovarian cancer and ATC in the United States and the European Union.", "sentB": "We intend to seek orphan drug designation in the EU.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "ovarian", "cancer", "and", "ATC", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "We", "intend", "to", "seek", "orphan", "drug", "designation", "in", "the", "EU.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "ovarian", "cancer", "and", "ATC", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["We", "intend", "to", "seek", "orphan", "drug", "designation", "in", "the", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p94_s1", "idA": "908259_14_item1_p102_s1", "sentA": "Such companies include Bionomics, Epicept, and MediciNova, all of which have VDAs that we believe are at an earlier or similar stage of clinical development than our lead drug candidate, ZYBRESTAT .", "sentB": "Such companies include Bionomics, Immune Pharmaceuticals, and MediciNova, all of which have VDAs that we believe are at an earlier or similar stage of clinical development than our lead drug candidate, fosbretabulin.", "type": 2, "words": ["<tag1>", "Such", "companies", "include", "Bionomics,", "Epicept,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "ZYBRESTAT", ".", "<tag2>", "Such", "companies", "include", "Bionomics,", "Immune", "Pharmaceuticals,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "fosbretabulin.", "<tag3>"], "wordsA": ["Such", "companies", "include", "Bionomics,", "Epicept,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "ZYBRESTAT", "."], "wordsB": ["Such", "companies", "include", "Bionomics,", "Immune", "Pharmaceuticals,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "fosbretabulin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s8", "idA": "908259_14_item1_p102_s4", "sentA": "EMPLOYEES We expect to continue to maintain a relatively small number of executives and other employees.", "sentB": "Although the subgroup included a relatively small number of patients, these findings suggest that adding fosbretabulin to AVASTIN (bevacizumab) has a potentially greater effect in this difficult-to-treat patient group than for platinum-sensitive patients.", "type": 2, "words": ["<tag1>", "EMPLOYEES", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees.", "<tag2>", "Although", "the", "subgroup", "included", "a", "relatively", "small", "number", "of", "patients,", "these", "findings", "suggest", "that", "adding", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "has", "a", "potentially", "greater", "effect", "in", "this", "difficult-to-treat", "patient", "group", "than", "for", "platinum-sensitive", "patients.", "<tag3>"], "wordsA": ["EMPLOYEES", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees."], "wordsB": ["Although", "the", "subgroup", "included", "a", "relatively", "small", "number", "of", "patients,", "these", "findings", "suggest", "that", "adding", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "has", "a", "potentially", "greater", "effect", "in", "this", "difficult-to-treat", "patient", "group", "than", "for", "platinum-sensitive", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p94_s6", "idA": "908259_14_item1_p102_s6", "sentA": "As of March 17, 2014, we had a total of nine full-time employees and one employee working on a part-time basis.", "sentB": "As of March 25, 2015, we had a total of 13 full-time employees and 1 employee working on a part-time basis.", "type": 2, "words": ["<tag1>", "As", "of", "March", "17,", "2014,", "we", "had", "a", "total", "of", "nine", "full-time", "employees", "and", "one", "employee", "working", "on", "a", "part-time", "basis.", "<tag2>", "As", "of", "March", "25,", "2015,", "we", "had", "a", "total", "of", "13", "full-time", "employees", "and", "1", "employee", "working", "on", "a", "part-time", "basis.", "<tag3>"], "wordsA": ["As", "of", "March", "17,", "2014,", "we", "had", "a", "total", "of", "nine", "full-time", "employees", "and", "one", "employee", "working", "on", "a", "part-time", "basis."], "wordsB": ["As", "of", "March", "25,", "2015,", "we", "had", "a", "total", "of", "13", "full-time", "employees", "and", "1", "employee", "working", "on", "a", "part-time", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p10_s0", "idA": "908259_14_item1_p10_s0", "sentA": "ZYBRESTAT in combination with VOTRIENT (pazopanib) GlaxoSmithKline (GSK) s VOTRIENT (pazopanib) is an anti-angiogenic oral tyrosine kinase inhibitor that is currently FDA-approved for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS), with compelling early clinical data in the treatment of relapsed ovarian cancer.", "sentB": "AVASTIN (bevacizumab) is approved in the US in combination with chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) for the treatment of women with platinum-resistant recurrent ovarian cancer, based on results from the Phase III AURELIA trial, the approval of which was based on progression free survival.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer.", "<tag2>", "AVASTIN", "(bevacizumab)", "is", "approved", "in", "the", "US", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "recurrent", "ovarian", "cancer,", "based", "on", "results", "from", "the", "Phase", "III", "AURELIA", "trial,", "the", "approval", "of", "which", "was", "based", "on", "progression", "free", "survival.", "<tag3>"], "wordsA": ["ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer."], "wordsB": ["AVASTIN", "(bevacizumab)", "is", "approved", "in", "the", "US", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "recurrent", "ovarian", "cancer,", "based", "on", "results", "from", "the", "Phase", "III", "AURELIA", "trial,", "the", "approval", "of", "which", "was", "based", "on", "progression", "free", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s0", "idA": "908259_14_item1_p10_s0", "sentA": "ZYBRESTAT in combination with VOTRIENT (pazopanib) GlaxoSmithKline (GSK) s VOTRIENT (pazopanib) is an anti-angiogenic oral tyrosine kinase inhibitor that is currently FDA-approved for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS), with compelling early clinical data in the treatment of relapsed ovarian cancer.", "sentB": "Fosbretabulin in combination with VOTRIENT (pazopanib) GlaxoSmithKline (GSK) s VOTRIENT (pazopanib) is an anti-angiogenic oral tyrosine kinase inhibitor that is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS), with compelling early clinical data in the treatment of relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer.", "<tag2>", "Fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer."], "wordsB": ["Fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s1", "idA": "908259_14_item1_p10_s1", "sentA": "We believe that using ZYBRESTAT in combination with VOTRIENT (pazopanib) may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "We believe that using fosbretabulin in combination with VOTRIENT (pazopanib) may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p0_s2", "idA": "908259_14_item1_p10_s10", "sentA": "We also remain interested in a conducting a randomized, two-arm Phase 2 clinical trial, comparing weekly dosing of TAXOL (paclitaxel) with weekly TAXOL (paclitaxel) plus ZYBRESTAT in patients with relapsed ovarian cancer.", "sentB": "Our lead compound, fosbretabulin tromethamine, or fosbretabulin, is being tested in two indications, recurrent ovarian cancer and gastrointestinal neuroendocrine tumors, or GI-NETs, and our second compound, OXi4503, is currently being tested in patients with relapsed or refractory acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).", "type": 2, "words": ["<tag1>", "We", "also", "remain", "interested", "in", "a", "conducting", "a", "randomized,", "two-arm", "Phase", "2", "clinical", "trial,", "comparing", "weekly", "dosing", "of", "TAXOL", "(paclitaxel)", "with", "weekly", "TAXOL", "(paclitaxel)", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag2>", "Our", "lead", "compound,", "fosbretabulin", "tromethamine,", "or", "fosbretabulin,", "is", "being", "tested", "in", "two", "indications,", "recurrent", "ovarian", "cancer", "and", "gastrointestinal", "neuroendocrine", "tumors,", "or", "GI-NETs,", "and", "our", "second", "compound,", "OXi4503,", "is", "currently", "being", "tested", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myelogenous", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag3>"], "wordsA": ["We", "also", "remain", "interested", "in", "a", "conducting", "a", "randomized,", "two-arm", "Phase", "2", "clinical", "trial,", "comparing", "weekly", "dosing", "of", "TAXOL", "(paclitaxel)", "with", "weekly", "TAXOL", "(paclitaxel)", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "wordsB": ["Our", "lead", "compound,", "fosbretabulin", "tromethamine,", "or", "fosbretabulin,", "is", "being", "tested", "in", "two", "indications,", "recurrent", "ovarian", "cancer", "and", "gastrointestinal", "neuroendocrine", "tumors,", "or", "GI-NETs,", "and", "our", "second", "compound,", "OXi4503,", "is", "currently", "being", "tested", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myelogenous", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p21_s2", "idA": "908259_14_item1_p10_s10", "sentA": "We also remain interested in a conducting a randomized, two-arm Phase 2 clinical trial, comparing weekly dosing of TAXOL (paclitaxel) with weekly TAXOL (paclitaxel) plus ZYBRESTAT in patients with relapsed ovarian cancer.", "sentB": "Although this pathway continues to remain open to us, our near term priorities for fosbretabulin are focused on our development programs in ovarian cancer and completing our Phase 2 clinical trial in GI-NETs.", "type": 2, "words": ["<tag1>", "We", "also", "remain", "interested", "in", "a", "conducting", "a", "randomized,", "two-arm", "Phase", "2", "clinical", "trial,", "comparing", "weekly", "dosing", "of", "TAXOL", "(paclitaxel)", "with", "weekly", "TAXOL", "(paclitaxel)", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag2>", "Although", "this", "pathway", "continues", "to", "remain", "open", "to", "us,", "our", "near", "term", "priorities", "for", "fosbretabulin", "are", "focused", "on", "our", "development", "programs", "in", "ovarian", "cancer", "and", "completing", "our", "Phase", "2", "clinical", "trial", "in", "GI-NETs.", "<tag3>"], "wordsA": ["We", "also", "remain", "interested", "in", "a", "conducting", "a", "randomized,", "two-arm", "Phase", "2", "clinical", "trial,", "comparing", "weekly", "dosing", "of", "TAXOL", "(paclitaxel)", "with", "weekly", "TAXOL", "(paclitaxel)", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "wordsB": ["Although", "this", "pathway", "continues", "to", "remain", "open", "to", "us,", "our", "near", "term", "priorities", "for", "fosbretabulin", "are", "focused", "on", "our", "development", "programs", "in", "ovarian", "cancer", "and", "completing", "our", "Phase", "2", "clinical", "trial", "in", "GI-NETs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s2", "idA": "908259_14_item1_p10_s3", "sentA": "The study is designed as a Phase 1b/2 trial of pazopanib with and without ZYBRESTAT , in advanced recurrent ovarian cancer.", "sentB": "In October 2014, the first patient was enrolled in a Phase 1b/2 trial of VOTRIENT (pazopanib) with and without fosbretabulin, in advanced recurrent ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "study", "is", "designed", "as", "a", "Phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "ZYBRESTAT", ",", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag2>", "In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "Phase", "1b/2", "trial", "of", "VOTRIENT", "(pazopanib)", "with", "and", "without", "fosbretabulin,", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "study", "is", "designed", "as", "a", "Phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "ZYBRESTAT", ",", "in", "advanced", "recurrent", "ovarian", "cancer."], "wordsB": ["In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "Phase", "1b/2", "trial", "of", "VOTRIENT", "(pazopanib)", "with", "and", "without", "fosbretabulin,", "in", "advanced", "recurrent", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p6_s2", "idA": "908259_14_item1_p10_s3", "sentA": "The study is designed as a Phase 1b/2 trial of pazopanib with and without ZYBRESTAT , in advanced recurrent ovarian cancer.", "sentB": "This belief is supported by the recently completed Phase 2 trial with this combination in recurrent ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "study", "is", "designed", "as", "a", "Phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "ZYBRESTAT", ",", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag2>", "This", "belief", "is", "supported", "by", "the", "recently", "completed", "Phase", "2", "trial", "with", "this", "combination", "in", "recurrent", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "study", "is", "designed", "as", "a", "Phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "ZYBRESTAT", ",", "in", "advanced", "recurrent", "ovarian", "cancer."], "wordsB": ["This", "belief", "is", "supported", "by", "the", "recently", "completed", "Phase", "2", "trial", "with", "this", "combination", "in", "recurrent", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s4", "idA": "908259_14_item1_p10_s4", "sentA": "The trial design consists of a Phase 1 dose escalation portion with the combination of VOTRIENT and ZYBRESTAT and a randomized Phase 2 portion comparing VOTRIENT alone versus VOTRIENT plus ZYBRESTAT in patients with relapsed ovarian cancer.", "sentB": "The trial design consists of a Phase 1b dose escalation portion with the combination of VOTRIENT (pazopanib) and fosbretabulin and a randomized Phase 2 portion comparing VOTRIENT (pazopanib) alone versus VOTRIENT (pazopanib) plus fosbretabulin in patients with relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "trial", "design", "consists", "of", "a", "Phase", "1", "dose", "escalation", "portion", "with", "the", "combination", "of", "VOTRIENT", "and", "ZYBRESTAT", "and", "a", "randomized", "Phase", "2", "portion", "comparing", "VOTRIENT", "alone", "versus", "VOTRIENT", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag2>", "The", "trial", "design", "consists", "of", "a", "Phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "VOTRIENT", "(pazopanib)", "and", "fosbretabulin", "and", "a", "randomized", "Phase", "2", "portion", "comparing", "VOTRIENT", "(pazopanib)", "alone", "versus", "VOTRIENT", "(pazopanib)", "plus", "fosbretabulin", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "trial", "design", "consists", "of", "a", "Phase", "1", "dose", "escalation", "portion", "with", "the", "combination", "of", "VOTRIENT", "and", "ZYBRESTAT", "and", "a", "randomized", "Phase", "2", "portion", "comparing", "VOTRIENT", "alone", "versus", "VOTRIENT", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "wordsB": ["The", "trial", "design", "consists", "of", "a", "Phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "VOTRIENT", "(pazopanib)", "and", "fosbretabulin", "and", "a", "randomized", "Phase", "2", "portion", "comparing", "VOTRIENT", "(pazopanib)", "alone", "versus", "VOTRIENT", "(pazopanib)", "plus", "fosbretabulin", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s5", "idA": "908259_14_item1_p10_s5", "sentA": "The study may enroll approximately 120 patients at sites in the U.K.", "sentB": "The study is expected to enroll approximately 128 patients at sites in the U.K.", "type": 2, "words": ["<tag1>", "The", "study", "may", "enroll", "approximately", "120", "patients", "at", "sites", "in", "the", "U.K.", "<tag2>", "The", "study", "is", "expected", "to", "enroll", "approximately", "128", "patients", "at", "sites", "in", "the", "U.K.", "<tag3>"], "wordsA": ["The", "study", "may", "enroll", "approximately", "120", "patients", "at", "sites", "in", "the", "U.K."], "wordsB": ["The", "study", "is", "expected", "to", "enroll", "approximately", "128", "patients", "at", "sites", "in", "the", "U.K."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s6", "idA": "908259_14_item1_p10_s6", "sentA": "The primary endpoint of the trial would be progression-free survival (PFS), and secondary endpoints would include safety, overall survival (OS), objective response rate, and CA125 response rate.", "sentB": "The primary endpoint of the trial is progression-free survival, and secondary endpoints include safety, overall survival, objective response rate, and CA125 response rate.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "trial", "would", "be", "progression-free", "survival", "(PFS),", "and", "secondary", "endpoints", "would", "include", "safety,", "overall", "survival", "(OS),", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "the", "trial", "is", "progression-free", "survival,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "trial", "would", "be", "progression-free", "survival", "(PFS),", "and", "secondary", "endpoints", "would", "include", "safety,", "overall", "survival", "(OS),", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "the", "trial", "is", "progression-free", "survival,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p16_s4", "idA": "908259_14_item1_p10_s6", "sentA": "The primary endpoint of the trial would be progression-free survival (PFS), and secondary endpoints would include safety, overall survival (OS), objective response rate, and CA125 response rate.", "sentB": "The primary endpoint of the trial is a reduction in biomarkers and secondary endpoints include symptom control and changes in quality of life as assessed by validated measures.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "trial", "would", "be", "progression-free", "survival", "(PFS),", "and", "secondary", "endpoints", "would", "include", "safety,", "overall", "survival", "(OS),", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "the", "trial", "is", "a", "reduction", "in", "biomarkers", "and", "secondary", "endpoints", "include", "symptom", "control", "and", "changes", "in", "quality", "of", "life", "as", "assessed", "by", "validated", "measures.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "trial", "would", "be", "progression-free", "survival", "(PFS),", "and", "secondary", "endpoints", "would", "include", "safety,", "overall", "survival", "(OS),", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "the", "trial", "is", "a", "reduction", "in", "biomarkers", "and", "secondary", "endpoints", "include", "symptom", "control", "and", "changes", "in", "quality", "of", "life", "as", "assessed", "by", "validated", "measures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s7", "idA": "908259_14_item1_p10_s8", "sentA": "As in the combination therapy trial of ZYBRESTAT with AVASTIN (bevacizumab), which is sponsored and substantially funded by the National Cancer Institute, we believe that the potential collaboration among us, the Christie National Health Service (NHS) Foundation Trust, the Hillingdon Hospital NHS Trust, and GlaxoSmithKline, under the sponsorship and primary funding of our U.K. based collaborators, would help offset costs associated with this trial.", "sentB": "As in the combination therapy trial of fosbretabulin with AVASTIN (bevacizumab), which was sponsored and substantially funded by the National Cancer Institute, we believe that the cooperative relationship among the participants in this trial, with VOTRIENT (pazopanib) supplied by GSK and fosbretabulin supplied by us, will minimize our costs associated with this trial.", "type": 2, "words": ["<tag1>", "As", "in", "the", "combination", "therapy", "trial", "of", "ZYBRESTAT", "with", "AVASTIN", "(bevacizumab),", "which", "is", "sponsored", "and", "substantially", "funded", "by", "the", "National", "Cancer", "Institute,", "we", "believe", "that", "the", "potential", "collaboration", "among", "us,", "the", "Christie", "National", "Health", "Service", "(NHS)", "Foundation", "Trust,", "the", "Hillingdon", "Hospital", "NHS", "Trust,", "and", "GlaxoSmithKline,", "under", "the", "sponsorship", "and", "primary", "funding", "of", "our", "U.K.", "based", "collaborators,", "would", "help", "offset", "costs", "associated", "with", "this", "trial.", "<tag2>", "As", "in", "the", "combination", "therapy", "trial", "of", "fosbretabulin", "with", "AVASTIN", "(bevacizumab),", "which", "was", "sponsored", "and", "substantially", "funded", "by", "the", "National", "Cancer", "Institute,", "we", "believe", "that", "the", "cooperative", "relationship", "among", "the", "participants", "in", "this", "trial,", "with", "VOTRIENT", "(pazopanib)", "supplied", "by", "GSK", "and", "fosbretabulin", "supplied", "by", "us,", "will", "minimize", "our", "costs", "associated", "with", "this", "trial.", "<tag3>"], "wordsA": ["As", "in", "the", "combination", "therapy", "trial", "of", "ZYBRESTAT", "with", "AVASTIN", "(bevacizumab),", "which", "is", "sponsored", "and", "substantially", "funded", "by", "the", "National", "Cancer", "Institute,", "we", "believe", "that", "the", "potential", "collaboration", "among", "us,", "the", "Christie", "National", "Health", "Service", "(NHS)", "Foundation", "Trust,", "the", "Hillingdon", "Hospital", "NHS", "Trust,", "and", "GlaxoSmithKline,", "under", "the", "sponsorship", "and", "primary", "funding", "of", "our", "U.K.", "based", "collaborators,", "would", "help", "offset", "costs", "associated", "with", "this", "trial."], "wordsB": ["As", "in", "the", "combination", "therapy", "trial", "of", "fosbretabulin", "with", "AVASTIN", "(bevacizumab),", "which", "was", "sponsored", "and", "substantially", "funded", "by", "the", "National", "Cancer", "Institute,", "we", "believe", "that", "the", "cooperative", "relationship", "among", "the", "participants", "in", "this", "trial,", "with", "VOTRIENT", "(pazopanib)", "supplied", "by", "GSK", "and", "fosbretabulin", "supplied", "by", "us,", "will", "minimize", "our", "costs", "associated", "with", "this", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s8", "idA": "908259_14_item1_p10_s9", "sentA": "We expect to incur the limited costs in supporting certain resources required by the NHS and the participating institutions during the duration of this trial and the costs of supplying drug for the trial.", "sentB": "We will incur limited costs as required by the U.K. s National Health Service (NHS) and the participating institutions for the duration of this trial and the costs of supplying fosbretabulin for the trial.", "type": 2, "words": ["<tag1>", "We", "expect", "to", "incur", "the", "limited", "costs", "in", "supporting", "certain", "resources", "required", "by", "the", "NHS", "and", "the", "participating", "institutions", "during", "the", "duration", "of", "this", "trial", "and", "the", "costs", "of", "supplying", "drug", "for", "the", "trial.", "<tag2>", "We", "will", "incur", "limited", "costs", "as", "required", "by", "the", "U.K.", "s", "National", "Health", "Service", "(NHS)", "and", "the", "participating", "institutions", "for", "the", "duration", "of", "this", "trial", "and", "the", "costs", "of", "supplying", "fosbretabulin", "for", "the", "trial.", "<tag3>"], "wordsA": ["We", "expect", "to", "incur", "the", "limited", "costs", "in", "supporting", "certain", "resources", "required", "by", "the", "NHS", "and", "the", "participating", "institutions", "during", "the", "duration", "of", "this", "trial", "and", "the", "costs", "of", "supplying", "drug", "for", "the", "trial."], "wordsB": ["We", "will", "incur", "limited", "costs", "as", "required", "by", "the", "U.K.", "s", "National", "Health", "Service", "(NHS)", "and", "the", "participating", "institutions", "for", "the", "duration", "of", "this", "trial", "and", "the", "costs", "of", "supplying", "fosbretabulin", "for", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p12_s3", "idA": "908259_14_item1_p12_s4", "sentA": "Final results from a Phase 2 study conducted by the Mount Vernon Cancer Centre in the United Kingdom were published in the January 2011 issue of Annals of Oncology.", "sentB": "The study is sponsored by The Christie Hospital NHS Foundation Trust and coordinated by the Manchester Academic Health Science Centre, Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).", "type": 2, "words": ["<tag1>", "Final", "results", "from", "a", "Phase", "2", "study", "conducted", "by", "the", "Mount", "Vernon", "Cancer", "Centre", "in", "the", "United", "Kingdom", "were", "published", "in", "the", "January", "2011", "issue", "of", "Annals", "of", "Oncology.", "<tag2>", "The", "study", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "and", "coordinated", "by", "the", "Manchester", "Academic", "Health", "Science", "Centre,", "Trials", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust).", "<tag3>"], "wordsA": ["Final", "results", "from", "a", "Phase", "2", "study", "conducted", "by", "the", "Mount", "Vernon", "Cancer", "Centre", "in", "the", "United", "Kingdom", "were", "published", "in", "the", "January", "2011", "issue", "of", "Annals", "of", "Oncology."], "wordsB": ["The", "study", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "and", "coordinated", "by", "the", "Manchester", "Academic", "Health", "Science", "Centre,", "Trials", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p21_s0", "idA": "908259_14_item1_p14_s0", "sentA": "Anaplastic Thyroid Cancer, or ATC Anaplastic thyroid cancer (ATC) is a rare, but particularly aggressive form of thyroid cancer that is resistant to mainstream cancer therapies and that has a particularly grim prognosis, with a median survival from diagnosis of three to four months and a one-year survival rate of less than 10%.", "sentB": "Anaplastic Thyroid Cancer, or ATC At this time our main focus with fosbretabulin is pursuing our programs in ovarian cancer and GI-NETs.", "type": 2, "words": ["<tag1>", "Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "Anaplastic", "thyroid", "cancer", "(ATC)", "is", "a", "rare,", "but", "particularly", "aggressive", "form", "of", "thyroid", "cancer", "that", "is", "resistant", "to", "mainstream", "cancer", "therapies", "and", "that", "has", "a", "particularly", "grim", "prognosis,", "with", "a", "median", "survival", "from", "diagnosis", "of", "three", "to", "four", "months", "and", "a", "one-year", "survival", "rate", "of", "less", "than", "10%.", "<tag2>", "Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "At", "this", "time", "our", "main", "focus", "with", "fosbretabulin", "is", "pursuing", "our", "programs", "in", "ovarian", "cancer", "and", "GI-NETs.", "<tag3>"], "wordsA": ["Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "Anaplastic", "thyroid", "cancer", "(ATC)", "is", "a", "rare,", "but", "particularly", "aggressive", "form", "of", "thyroid", "cancer", "that", "is", "resistant", "to", "mainstream", "cancer", "therapies", "and", "that", "has", "a", "particularly", "grim", "prognosis,", "with", "a", "median", "survival", "from", "diagnosis", "of", "three", "to", "four", "months", "and", "a", "one-year", "survival", "rate", "of", "less", "than", "10%."], "wordsB": ["Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "At", "this", "time", "our", "main", "focus", "with", "fosbretabulin", "is", "pursuing", "our", "programs", "in", "ovarian", "cancer", "and", "GI-NETs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p21_s1", "idA": "908259_14_item1_p15_s1", "sentA": "These include the possibility of a special marketing approval, known as an MAA under exceptional circumstances, in the case of therapies that address urgent, unmet medical needs.", "sentB": "While we have had discussions with the European regulatory agencies regarding the potential to submit a special marketing approval known as an MAA in the European Union for ATC under the exceptional circumstances pathway, and have received useful feedback, given our current priorities and resources, we have decided not to actively pursue such a filing at this time.", "type": 2, "words": ["<tag1>", "These", "include", "the", "possibility", "of", "a", "special", "marketing", "approval,", "known", "as", "an", "MAA", "under", "exceptional", "circumstances,", "in", "the", "case", "of", "therapies", "that", "address", "urgent,", "unmet", "medical", "needs.", "<tag2>", "While", "we", "have", "had", "discussions", "with", "the", "European", "regulatory", "agencies", "regarding", "the", "potential", "to", "submit", "a", "special", "marketing", "approval", "known", "as", "an", "MAA", "in", "the", "European", "Union", "for", "ATC", "under", "the", "exceptional", "circumstances", "pathway,", "and", "have", "received", "useful", "feedback,", "given", "our", "current", "priorities", "and", "resources,", "we", "have", "decided", "not", "to", "actively", "pursue", "such", "a", "filing", "at", "this", "time.", "<tag3>"], "wordsA": ["These", "include", "the", "possibility", "of", "a", "special", "marketing", "approval,", "known", "as", "an", "MAA", "under", "exceptional", "circumstances,", "in", "the", "case", "of", "therapies", "that", "address", "urgent,", "unmet", "medical", "needs."], "wordsB": ["While", "we", "have", "had", "discussions", "with", "the", "European", "regulatory", "agencies", "regarding", "the", "potential", "to", "submit", "a", "special", "marketing", "approval", "known", "as", "an", "MAA", "in", "the", "European", "Union", "for", "ATC", "under", "the", "exceptional", "circumstances", "pathway,", "and", "have", "received", "useful", "feedback,", "given", "our", "current", "priorities", "and", "resources,", "we", "have", "decided", "not", "to", "actively", "pursue", "such", "a", "filing", "at", "this", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s4", "idA": "908259_14_item1_p16_s2", "sentA": "More specifically, the FACT trial showed a median overall survival, or OS, time of 5.2 months for patients receiving both chemotherapy and ZYBRESTAT compared to 4.0 months for patients receiving chemotherapy alone, equating to a 28% reduction in the risk of death.", "sentB": "Median PFS was 7.3 months for AVASTIN (bevacizumab) plus fosbretabulin (n=54), compared to 4.8 months with AVASTIN (bevacizumab) alone (n= 53).", "type": 2, "words": ["<tag1>", "More", "specifically,", "the", "FACT", "trial", "showed", "a", "median", "overall", "survival,", "or", "OS,", "time", "of", "5.2", "months", "for", "patients", "receiving", "both", "chemotherapy", "and", "ZYBRESTAT", "compared", "to", "4.0", "months", "for", "patients", "receiving", "chemotherapy", "alone,", "equating", "to", "a", "28%", "reduction", "in", "the", "risk", "of", "death.", "<tag2>", "Median", "PFS", "was", "7.3", "months", "for", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin", "(n=54),", "compared", "to", "4.8", "months", "with", "AVASTIN", "(bevacizumab)", "alone", "(n=", "53).", "<tag3>"], "wordsA": ["More", "specifically,", "the", "FACT", "trial", "showed", "a", "median", "overall", "survival,", "or", "OS,", "time", "of", "5.2", "months", "for", "patients", "receiving", "both", "chemotherapy", "and", "ZYBRESTAT", "compared", "to", "4.0", "months", "for", "patients", "receiving", "chemotherapy", "alone,", "equating", "to", "a", "28%", "reduction", "in", "the", "risk", "of", "death."], "wordsB": ["Median", "PFS", "was", "7.3", "months", "for", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin", "(n=54),", "compared", "to", "4.8", "months", "with", "AVASTIN", "(bevacizumab)", "alone", "(n=", "53)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p6_s3", "idA": "908259_14_item1_p17_s1", "sentA": "Results from the FACT trial were subsequently presented at the 2010 American Society of Clinical Oncology, or ASCO, meeting and at the 2010 European Society for Medical Oncology, or ESMO, meeting.", "sentB": "In November 2014, the positive study results from the Phase 2 GOG-0186I clinical trial were presented at the 15th Biennial International Gynecologic Cancer Society (IGCS) conference in Melbourne, Australia.", "type": 2, "words": ["<tag1>", "Results", "from", "the", "FACT", "trial", "were", "subsequently", "presented", "at", "the", "2010", "American", "Society", "of", "Clinical", "Oncology,", "or", "ASCO,", "meeting", "and", "at", "the", "2010", "European", "Society", "for", "Medical", "Oncology,", "or", "ESMO,", "meeting.", "<tag2>", "In", "November", "2014,", "the", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "were", "presented", "at", "the", "15th", "Biennial", "International", "Gynecologic", "Cancer", "Society", "(IGCS)", "conference", "in", "Melbourne,", "Australia.", "<tag3>"], "wordsA": ["Results", "from", "the", "FACT", "trial", "were", "subsequently", "presented", "at", "the", "2010", "American", "Society", "of", "Clinical", "Oncology,", "or", "ASCO,", "meeting", "and", "at", "the", "2010", "European", "Society", "for", "Medical", "Oncology,", "or", "ESMO,", "meeting."], "wordsB": ["In", "November", "2014,", "the", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "were", "presented", "at", "the", "15th", "Biennial", "International", "Gynecologic", "Cancer", "Society", "(IGCS)", "conference", "in", "Melbourne,", "Australia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p14_s0", "idA": "908259_14_item1_p18_s0", "sentA": "Neuroendocrine Tumors with Carcinoid Syndrome Carcinoid syndrome occurs in a sub-population of patients with neuroendocrine tumors who display an array of symptoms, such as flushing, diarrhea and, less frequently, bronchoconstriction and heart failure.", "sentB": "These tumors can produce increased amounts of materials including peptides, many of which are biologically active and can, in around 10 -20% of patients, result in debilitating symptoms including flushing, diarrhea, weight loss and, less frequently, bronchoconstriction and heart failure.", "type": 2, "words": ["<tag1>", "Neuroendocrine", "Tumors", "with", "Carcinoid", "Syndrome", "Carcinoid", "syndrome", "occurs", "in", "a", "sub-population", "of", "patients", "with", "neuroendocrine", "tumors", "who", "display", "an", "array", "of", "symptoms,", "such", "as", "flushing,", "diarrhea", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag2>", "These", "tumors", "can", "produce", "increased", "amounts", "of", "materials", "including", "peptides,", "many", "of", "which", "are", "biologically", "active", "and", "can,", "in", "around", "10", "-20%", "of", "patients,", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag3>"], "wordsA": ["Neuroendocrine", "Tumors", "with", "Carcinoid", "Syndrome", "Carcinoid", "syndrome", "occurs", "in", "a", "sub-population", "of", "patients", "with", "neuroendocrine", "tumors", "who", "display", "an", "array", "of", "symptoms,", "such", "as", "flushing,", "diarrhea", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "wordsB": ["These", "tumors", "can", "produce", "increased", "amounts", "of", "materials", "including", "peptides,", "many", "of", "which", "are", "biologically", "active", "and", "can,", "in", "around", "10", "-20%", "of", "patients,", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p14_s1", "idA": "908259_14_item1_p18_s2", "sentA": "These symptoms are caused by overproduction of biologically active substances such as serotonin and kallikrein, which are released directly into systemic circulation, bypassing hepatic degradation.", "sentB": "These particular symptoms are caused by overproduction of biologically active substances such as serotonin and kallikrein, which are released directly into systemic circulation, bypassing hepatic degradation.", "type": 2, "words": ["<tag1>", "These", "symptoms", "are", "caused", "by", "overproduction", "of", "biologically", "active", "substances", "such", "as", "serotonin", "and", "kallikrein,", "which", "are", "released", "directly", "into", "systemic", "circulation,", "bypassing", "hepatic", "degradation.", "<tag2>", "These", "particular", "symptoms", "are", "caused", "by", "overproduction", "of", "biologically", "active", "substances", "such", "as", "serotonin", "and", "kallikrein,", "which", "are", "released", "directly", "into", "systemic", "circulation,", "bypassing", "hepatic", "degradation.", "<tag3>"], "wordsA": ["These", "symptoms", "are", "caused", "by", "overproduction", "of", "biologically", "active", "substances", "such", "as", "serotonin", "and", "kallikrein,", "which", "are", "released", "directly", "into", "systemic", "circulation,", "bypassing", "hepatic", "degradation."], "wordsB": ["These", "particular", "symptoms", "are", "caused", "by", "overproduction", "of", "biologically", "active", "substances", "such", "as", "serotonin", "and", "kallikrein,", "which", "are", "released", "directly", "into", "systemic", "circulation,", "bypassing", "hepatic", "degradation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p15_s0", "idA": "908259_14_item1_p18_s3", "sentA": "While drug treatment with somatostatin analogues, such as Sandostatin , helps to control the symptoms of carcinoid syndrome, patients who are or become unresponsive to somatostatin have limited therapeutic options, and we believe that treatment with ZYBRESTAT , resulting in vascular shutdown and tumor necrosis, may improve outcomes for these patients.", "sentB": "While drug treatment with somatostatin analogs, such as Sandostatin , helps to control the symptoms, patients who are or become unresponsive to somatostatin or its analogs have limited therapeutic options.", "type": 2, "words": ["<tag1>", "While", "drug", "treatment", "with", "somatostatin", "analogues,", "such", "as", "Sandostatin", ",", "helps", "to", "control", "the", "symptoms", "of", "carcinoid", "syndrome,", "patients", "who", "are", "or", "become", "unresponsive", "to", "somatostatin", "have", "limited", "therapeutic", "options,", "and", "we", "believe", "that", "treatment", "with", "ZYBRESTAT", ",", "resulting", "in", "vascular", "shutdown", "and", "tumor", "necrosis,", "may", "improve", "outcomes", "for", "these", "patients.", "<tag2>", "While", "drug", "treatment", "with", "somatostatin", "analogs,", "such", "as", "Sandostatin", ",", "helps", "to", "control", "the", "symptoms,", "patients", "who", "are", "or", "become", "unresponsive", "to", "somatostatin", "or", "its", "analogs", "have", "limited", "therapeutic", "options.", "<tag3>"], "wordsA": ["While", "drug", "treatment", "with", "somatostatin", "analogues,", "such", "as", "Sandostatin", ",", "helps", "to", "control", "the", "symptoms", "of", "carcinoid", "syndrome,", "patients", "who", "are", "or", "become", "unresponsive", "to", "somatostatin", "have", "limited", "therapeutic", "options,", "and", "we", "believe", "that", "treatment", "with", "ZYBRESTAT", ",", "resulting", "in", "vascular", "shutdown", "and", "tumor", "necrosis,", "may", "improve", "outcomes", "for", "these", "patients."], "wordsB": ["While", "drug", "treatment", "with", "somatostatin", "analogs,", "such", "as", "Sandostatin", ",", "helps", "to", "control", "the", "symptoms,", "patients", "who", "are", "or", "become", "unresponsive", "to", "somatostatin", "or", "its", "analogs", "have", "limited", "therapeutic", "options."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p13_s1", "idA": "908259_14_item1_p19_s0", "sentA": "Approximately 14,000 people in the United States are diagnosed with carcinoid tumors each year.", "sentB": "Since patients with NETs can have prolonged survival rates of over 5 years, it is estimated that the prevalence is much higher, approximating 100,000 people in the US.", "type": 2, "words": ["<tag1>", "Approximately", "14,000", "people", "in", "the", "United", "States", "are", "diagnosed", "with", "carcinoid", "tumors", "each", "year.", "<tag2>", "Since", "patients", "with", "NETs", "can", "have", "prolonged", "survival", "rates", "of", "over", "5", "years,", "it", "is", "estimated", "that", "the", "prevalence", "is", "much", "higher,", "approximating", "100,000", "people", "in", "the", "US.", "<tag3>"], "wordsA": ["Approximately", "14,000", "people", "in", "the", "United", "States", "are", "diagnosed", "with", "carcinoid", "tumors", "each", "year."], "wordsB": ["Since", "patients", "with", "NETs", "can", "have", "prolonged", "survival", "rates", "of", "over", "5", "years,", "it", "is", "estimated", "that", "the", "prevalence", "is", "much", "higher,", "approximating", "100,000", "people", "in", "the", "US."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p1_s0", "idA": "908259_14_item1_p1_s0", "sentA": "ZYBRESTAT Development Program Our lead compound, ZYBRESTAT , is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in most solid tumors and causes them to swell, obstructing the flow of blood and starving the tumor of vital nutrients including oxygen.", "sentB": "Fosbretabulin Development Program Fosbretabulin is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in most solid tumors and causes them to swell, obstructing the flow of blood and starving the tumor of vital nutrients including oxygen.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "Development", "Program", "Our", "lead", "compound,", "ZYBRESTAT", ",", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen.", "<tag2>", "Fosbretabulin", "Development", "Program", "Fosbretabulin", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen.", "<tag3>"], "wordsA": ["ZYBRESTAT", "Development", "Program", "Our", "lead", "compound,", "ZYBRESTAT", ",", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen."], "wordsB": ["Fosbretabulin", "Development", "Program", "Fosbretabulin", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p17_s0", "idA": "908259_14_item1_p20_s0", "sentA": "A preclinical study of ZYBRESTAT in a transgenic mouse model of pancreatic neuroendocrine tumors (PNETs) was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, in a poster session on October 20, 2013.", "sentB": "Background A preclinical study of fosbretabulin in a transgenic mouse model of pancreatic neuroendocrine tumors, or PNETs, was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, in a poster session on October 20, 2013.", "type": 2, "words": ["<tag1>", "A", "preclinical", "study", "of", "ZYBRESTAT", "in", "a", "transgenic", "mouse", "model", "of", "pancreatic", "neuroendocrine", "tumors", "(PNETs)", "was", "presented", "at", "the", "AACR-NCI-EORTC", "International", "Conference", "on", "Molecular", "Targets", "and", "Cancer", "Therapeutics,", "Boston,", "MA,", "in", "a", "poster", "session", "on", "October", "20,", "2013.", "<tag2>", "Background", "A", "preclinical", "study", "of", "fosbretabulin", "in", "a", "transgenic", "mouse", "model", "of", "pancreatic", "neuroendocrine", "tumors,", "or", "PNETs,", "was", "presented", "at", "the", "AACR-NCI-EORTC", "International", "Conference", "on", "Molecular", "Targets", "and", "Cancer", "Therapeutics,", "Boston,", "MA,", "in", "a", "poster", "session", "on", "October", "20,", "2013.", "<tag3>"], "wordsA": ["A", "preclinical", "study", "of", "ZYBRESTAT", "in", "a", "transgenic", "mouse", "model", "of", "pancreatic", "neuroendocrine", "tumors", "(PNETs)", "was", "presented", "at", "the", "AACR-NCI-EORTC", "International", "Conference", "on", "Molecular", "Targets", "and", "Cancer", "Therapeutics,", "Boston,", "MA,", "in", "a", "poster", "session", "on", "October", "20,", "2013."], "wordsB": ["Background", "A", "preclinical", "study", "of", "fosbretabulin", "in", "a", "transgenic", "mouse", "model", "of", "pancreatic", "neuroendocrine", "tumors,", "or", "PNETs,", "was", "presented", "at", "the", "AACR-NCI-EORTC", "International", "Conference", "on", "Molecular", "Targets", "and", "Cancer", "Therapeutics,", "Boston,", "MA,", "in", "a", "poster", "session", "on", "October", "20,", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p17_s1", "idA": "908259_14_item1_p20_s1", "sentA": "This placebo-controlled preclinical study was designed to evaluate the activity of systemic administration of ZYBRESTAT for the treatment of functional insulinomas in a transgenic mouse model of PNETs.", "sentB": "This placebo-controlled preclinical study was designed to evaluate the activity of systemic administration of fosbretabulin for the treatment of functional insulinomas in a transgenic mouse model of PNETs.", "type": 2, "words": ["<tag1>", "This", "placebo-controlled", "preclinical", "study", "was", "designed", "to", "evaluate", "the", "activity", "of", "systemic", "administration", "of", "ZYBRESTAT", "for", "the", "treatment", "of", "functional", "insulinomas", "in", "a", "transgenic", "mouse", "model", "of", "PNETs.", "<tag2>", "This", "placebo-controlled", "preclinical", "study", "was", "designed", "to", "evaluate", "the", "activity", "of", "systemic", "administration", "of", "fosbretabulin", "for", "the", "treatment", "of", "functional", "insulinomas", "in", "a", "transgenic", "mouse", "model", "of", "PNETs.", "<tag3>"], "wordsA": ["This", "placebo-controlled", "preclinical", "study", "was", "designed", "to", "evaluate", "the", "activity", "of", "systemic", "administration", "of", "ZYBRESTAT", "for", "the", "treatment", "of", "functional", "insulinomas", "in", "a", "transgenic", "mouse", "model", "of", "PNETs."], "wordsB": ["This", "placebo-controlled", "preclinical", "study", "was", "designed", "to", "evaluate", "the", "activity", "of", "systemic", "administration", "of", "fosbretabulin", "for", "the", "treatment", "of", "functional", "insulinomas", "in", "a", "transgenic", "mouse", "model", "of", "PNETs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p19_s1", "idA": "908259_14_item1_p22_s1", "sentA": "The animals in the treatment group received ZYBRESTAT three times per week for four weeks, and the animals in the control group received a placebo at the same schedule.", "sentB": "The animals in the treatment group received fosbretabulin three times per week for four weeks, and the animals in the control group received a placebo at the same schedule.", "type": 2, "words": ["<tag1>", "The", "animals", "in", "the", "treatment", "group", "received", "ZYBRESTAT", "three", "times", "per", "week", "for", "four", "weeks,", "and", "the", "animals", "in", "the", "control", "group", "received", "a", "placebo", "at", "the", "same", "schedule.", "<tag2>", "The", "animals", "in", "the", "treatment", "group", "received", "fosbretabulin", "three", "times", "per", "week", "for", "four", "weeks,", "and", "the", "animals", "in", "the", "control", "group", "received", "a", "placebo", "at", "the", "same", "schedule.", "<tag3>"], "wordsA": ["The", "animals", "in", "the", "treatment", "group", "received", "ZYBRESTAT", "three", "times", "per", "week", "for", "four", "weeks,", "and", "the", "animals", "in", "the", "control", "group", "received", "a", "placebo", "at", "the", "same", "schedule."], "wordsB": ["The", "animals", "in", "the", "treatment", "group", "received", "fosbretabulin", "three", "times", "per", "week", "for", "four", "weeks,", "and", "the", "animals", "in", "the", "control", "group", "received", "a", "placebo", "at", "the", "same", "schedule."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p19_s3", "idA": "908259_14_item1_p22_s3", "sentA": "Treatment with ZYBRESTAT in this animal model resulted in a significant and sustained decrease in circulating insulin of more than 90% over four weeks following a single dose of ZYBRESTAT and was accompanied by a significantly reduced tumor size of greater than 80% in the treated group compared to the placebo treated group.", "sentB": "Treatment with fosbretabulin in this animal model resulted in a significant and sustained decrease in circulating insulin of more than 90% over four weeks of treatment with fosbretabulin.", "type": 2, "words": ["<tag1>", "Treatment", "with", "ZYBRESTAT", "in", "this", "animal", "model", "resulted", "in", "a", "significant", "and", "sustained", "decrease", "in", "circulating", "insulin", "of", "more", "than", "90%", "over", "four", "weeks", "following", "a", "single", "dose", "of", "ZYBRESTAT", "and", "was", "accompanied", "by", "a", "significantly", "reduced", "tumor", "size", "of", "greater", "than", "80%", "in", "the", "treated", "group", "compared", "to", "the", "placebo", "treated", "group.", "<tag2>", "Treatment", "with", "fosbretabulin", "in", "this", "animal", "model", "resulted", "in", "a", "significant", "and", "sustained", "decrease", "in", "circulating", "insulin", "of", "more", "than", "90%", "over", "four", "weeks", "of", "treatment", "with", "fosbretabulin.", "<tag3>"], "wordsA": ["Treatment", "with", "ZYBRESTAT", "in", "this", "animal", "model", "resulted", "in", "a", "significant", "and", "sustained", "decrease", "in", "circulating", "insulin", "of", "more", "than", "90%", "over", "four", "weeks", "following", "a", "single", "dose", "of", "ZYBRESTAT", "and", "was", "accompanied", "by", "a", "significantly", "reduced", "tumor", "size", "of", "greater", "than", "80%", "in", "the", "treated", "group", "compared", "to", "the", "placebo", "treated", "group."], "wordsB": ["Treatment", "with", "fosbretabulin", "in", "this", "animal", "model", "resulted", "in", "a", "significant", "and", "sustained", "decrease", "in", "circulating", "insulin", "of", "more", "than", "90%", "over", "four", "weeks", "of", "treatment", "with", "fosbretabulin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p20_s0", "idA": "908259_14_item1_p22_s4", "sentA": "Treatment with ZYBRESTAT was shown to be well tolerated, with no obvious toxicity and was shown to disrupt tumor vasculature, induce apoptosis (cell death) and inhibit tumor cell proliferation.", "sentB": "Treatment with fosbretabulin was not shown to be associated with any obvious toxicity, and was shown to disrupt tumor vasculature, induce apoptosis and inhibit tumor cell proliferation.", "type": 2, "words": ["<tag1>", "Treatment", "with", "ZYBRESTAT", "was", "shown", "to", "be", "well", "tolerated,", "with", "no", "obvious", "toxicity", "and", "was", "shown", "to", "disrupt", "tumor", "vasculature,", "induce", "apoptosis", "(cell", "death)", "and", "inhibit", "tumor", "cell", "proliferation.", "<tag2>", "Treatment", "with", "fosbretabulin", "was", "not", "shown", "to", "be", "associated", "with", "any", "obvious", "toxicity,", "and", "was", "shown", "to", "disrupt", "tumor", "vasculature,", "induce", "apoptosis", "and", "inhibit", "tumor", "cell", "proliferation.", "<tag3>"], "wordsA": ["Treatment", "with", "ZYBRESTAT", "was", "shown", "to", "be", "well", "tolerated,", "with", "no", "obvious", "toxicity", "and", "was", "shown", "to", "disrupt", "tumor", "vasculature,", "induce", "apoptosis", "(cell", "death)", "and", "inhibit", "tumor", "cell", "proliferation."], "wordsB": ["Treatment", "with", "fosbretabulin", "was", "not", "shown", "to", "be", "associated", "with", "any", "obvious", "toxicity,", "and", "was", "shown", "to", "disrupt", "tumor", "vasculature,", "induce", "apoptosis", "and", "inhibit", "tumor", "cell", "proliferation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p16_s2", "idA": "908259_14_item1_p22_s7", "sentA": "Based on the strength of the preclinical data, we are planning to initiate a Phase 2 clinical trial of ZYBRESTAT in patients with recurrent GI-NETs with elevated biomarkers in the second half of 2014.", "sentB": "In September 2014, we enrolled the first patient in a Phase 2 monotherapy clinical trial of fosbretabulin in patients with GI-NETs with elevated biomarkers.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "strength", "of", "the", "preclinical", "data,", "we", "are", "planning", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers", "in", "the", "second", "half", "of", "2014.", "<tag2>", "In", "September", "2014,", "we", "enrolled", "the", "first", "patient", "in", "a", "Phase", "2", "monotherapy", "clinical", "trial", "of", "fosbretabulin", "in", "patients", "with", "GI-NETs", "with", "elevated", "biomarkers.", "<tag3>"], "wordsA": ["Based", "on", "the", "strength", "of", "the", "preclinical", "data,", "we", "are", "planning", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers", "in", "the", "second", "half", "of", "2014."], "wordsB": ["In", "September", "2014,", "we", "enrolled", "the", "first", "patient", "in", "a", "Phase", "2", "monotherapy", "clinical", "trial", "of", "fosbretabulin", "in", "patients", "with", "GI-NETs", "with", "elevated", "biomarkers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p25_s3", "idA": "908259_14_item1_p22_s7", "sentA": "Based on the strength of the preclinical data, we are planning to initiate a Phase 2 clinical trial of ZYBRESTAT in patients with recurrent GI-NETs with elevated biomarkers in the second half of 2014.", "sentB": "In an effort to increase enrollment at a faster rate, we are planning to close this trial and initiate our own sponsored clinical trial with additional sites as described below.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "strength", "of", "the", "preclinical", "data,", "we", "are", "planning", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers", "in", "the", "second", "half", "of", "2014.", "<tag2>", "In", "an", "effort", "to", "increase", "enrollment", "at", "a", "faster", "rate,", "we", "are", "planning", "to", "close", "this", "trial", "and", "initiate", "our", "own", "sponsored", "clinical", "trial", "with", "additional", "sites", "as", "described", "below.", "<tag3>"], "wordsA": ["Based", "on", "the", "strength", "of", "the", "preclinical", "data,", "we", "are", "planning", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers", "in", "the", "second", "half", "of", "2014."], "wordsB": ["In", "an", "effort", "to", "increase", "enrollment", "at", "a", "faster", "rate,", "we", "are", "planning", "to", "close", "this", "trial", "and", "initiate", "our", "own", "sponsored", "clinical", "trial", "with", "additional", "sites", "as", "described", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p21_s3", "idA": "908259_14_item1_p23_s2", "sentA": "In addition to pursuing development of ZYBRESTAT , we are also pursuing the development of a second product candidate, OXi4503, a novel second-generation, dual-mechanism VDA, which not only has been shown to reduce tumor blood flow but which also forms an antiproliferative metabolite.", "sentB": "In addition to pursuing development of fosbretabulin, we are also pursuing the development of a second product candidate, OXi4503, a novel, dual-mechanism VDA, which not only has been shown to reduce tumor blood flow but which also forms a potentially antiproliferative metabolite.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "pursuing", "development", "of", "ZYBRESTAT", ",", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel", "second-generation,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "an", "antiproliferative", "metabolite.", "<tag2>", "In", "addition", "to", "pursuing", "development", "of", "fosbretabulin,", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "a", "potentially", "antiproliferative", "metabolite.", "<tag3>"], "wordsA": ["In", "addition", "to", "pursuing", "development", "of", "ZYBRESTAT", ",", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel", "second-generation,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "an", "antiproliferative", "metabolite."], "wordsB": ["In", "addition", "to", "pursuing", "development", "of", "fosbretabulin,", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "a", "potentially", "antiproliferative", "metabolite."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p23_s1", "idA": "908259_14_item1_p25_s1", "sentA": "Similar to ZYBRESTAT , OXi4503 has shown potent anti-tumor activity in preclinical studies of solid tumors and acute myelogenous leukemia, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other antiproliferative agents.", "sentB": "Similar to fosbretabulin, OXi4503 has shown potent anti- tumor activity in preclinical studies of solid tumors and AML, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other antiproliferative agents.", "type": 2, "words": ["<tag1>", "Similar", "to", "ZYBRESTAT", ",", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "acute", "myelogenous", "leukemia,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "antiproliferative", "agents.", "<tag2>", "Similar", "to", "fosbretabulin,", "OXi4503", "has", "shown", "potent", "anti-", "tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "antiproliferative", "agents.", "<tag3>"], "wordsA": ["Similar", "to", "ZYBRESTAT", ",", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "acute", "myelogenous", "leukemia,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "antiproliferative", "agents."], "wordsB": ["Similar", "to", "fosbretabulin,", "OXi4503", "has", "shown", "potent", "anti-", "tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "antiproliferative", "agents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p25_s0", "idA": "908259_14_item1_p27_s1", "sentA": "Shortly thereafter, we entered into a clinical trial agreement with the University of Florida related to an investigator-sponsored Phase 1 study of OXi4503 in up to 36 patients with AML or myelodysplastic syndrome, or MDS, a disorder of the normal blood formation process, which trial was subsequently initiated in May 2011.", "sentB": "OXi4503 Investigator Sponsored Trial OXi4503 has been under development in an ongoing investigator-sponsored Phase 1 trial of OXi4503 in patients with AML or MDS, a disorder of the normal blood formation process, being conducted at the University of Florida and with support by The Leukemia Lymphoma Society s Therapy Acceleration Program.", "type": 2, "words": ["<tag1>", "Shortly", "thereafter,", "we", "entered", "into", "a", "clinical", "trial", "agreement", "with", "the", "University", "of", "Florida", "related", "to", "an", "investigator-sponsored", "Phase", "1", "study", "of", "OXi4503", "in", "up", "to", "36", "patients", "with", "AML", "or", "myelodysplastic", "syndrome,", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "which", "trial", "was", "subsequently", "initiated", "in", "May", "2011.", "<tag2>", "OXi4503", "Investigator", "Sponsored", "Trial", "OXi4503", "has", "been", "under", "development", "in", "an", "ongoing", "investigator-sponsored", "Phase", "1", "trial", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program.", "<tag3>"], "wordsA": ["Shortly", "thereafter,", "we", "entered", "into", "a", "clinical", "trial", "agreement", "with", "the", "University", "of", "Florida", "related", "to", "an", "investigator-sponsored", "Phase", "1", "study", "of", "OXi4503", "in", "up", "to", "36", "patients", "with", "AML", "or", "myelodysplastic", "syndrome,", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "which", "trial", "was", "subsequently", "initiated", "in", "May", "2011."], "wordsB": ["OXi4503", "Investigator", "Sponsored", "Trial", "OXi4503", "has", "been", "under", "development", "in", "an", "ongoing", "investigator-sponsored", "Phase", "1", "trial", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p16_s6", "idA": "908259_14_item1_p29_s1", "sentA": "Updated data from this trial was presented at the December 2013 annual meeting of ASH in New Orleans, Louisiana.", "sentB": "We also believe that there is the potential to receive interim data from this clinical trial by the end of 2015.", "type": 2, "words": ["<tag1>", "Updated", "data", "from", "this", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana.", "<tag2>", "We", "also", "believe", "that", "there", "is", "the", "potential", "to", "receive", "interim", "data", "from", "this", "clinical", "trial", "by", "the", "end", "of", "2015.", "<tag3>"], "wordsA": ["Updated", "data", "from", "this", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana."], "wordsB": ["We", "also", "believe", "that", "there", "is", "the", "potential", "to", "receive", "interim", "data", "from", "this", "clinical", "trial", "by", "the", "end", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p27_s0", "idA": "908259_14_item1_p29_s1", "sentA": "Updated data from this trial was presented at the December 2013 annual meeting of ASH in New Orleans, Louisiana.", "sentB": "Background Updated data from the investigator trial was presented at the December 2013 annual meeting of ASH in New Orleans, Louisiana.", "type": 2, "words": ["<tag1>", "Updated", "data", "from", "this", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana.", "<tag2>", "Background", "Updated", "data", "from", "the", "investigator", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana.", "<tag3>"], "wordsA": ["Updated", "data", "from", "this", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana."], "wordsB": ["Background", "Updated", "data", "from", "the", "investigator", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p28_s0", "idA": "908259_14_item1_p29_s2", "sentA": "Among the first 13 patients treated at the two lowest dose levels, two patients have shown stable disease, one patient had a partial remission and one patient achieved a complete bone marrow response.", "sentB": "Among the first 13 patients treated at the two lowest dose levels, two patients showed stable disease, one patient had a partial remission and one patient achieved a complete bone marrow response.", "type": 2, "words": ["<tag1>", "Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "have", "shown", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response.", "<tag2>", "Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "showed", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response.", "<tag3>"], "wordsA": ["Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "have", "shown", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response."], "wordsB": ["Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "showed", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p2_s2", "idA": "908259_14_item1_p2_s2", "sentA": "In fact, more than 60% of women diagnosed with ovarian cancer are in stage III or IV, making it difficult to treat and often fatal, with a five-year survival rate of 47% a rate which is largely unchanged since the 1990s.", "sentB": "In fact, more than 60% of women diagnosed with ovarian cancer are in stage III or IV, making ovarian cancer difficult to treat and often fatal, with a five-year survival rate of approximately 45% a rate which is largely unchanged since the 1990s.", "type": 2, "words": ["<tag1>", "In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "it", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "47%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s.", "<tag2>", "In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "ovarian", "cancer", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "approximately", "45%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s.", "<tag3>"], "wordsA": ["In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "it", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "47%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s."], "wordsB": ["In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "ovarian", "cancer", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "approximately", "45%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p25_s1", "idA": "908259_14_item1_p32_s0", "sentA": "This open-label, dose-escalating study for the treatment of up to 36 patients will evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "sentB": "This open-label, dose-escalating study was intended to treat up to 36 patients and evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "type": 2, "words": ["<tag1>", "This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag2>", "This", "open-label,", "dose-escalating", "study", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag3>"], "wordsA": ["This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "wordsB": ["This", "open-label,", "dose-escalating", "study", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p26_s0", "idA": "908259_14_item1_p32_s0", "sentA": "This open-label, dose-escalating study for the treatment of up to 36 patients will evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "sentB": "In 2015 we intend to close the investigator sponsored Phase 1 trial of OXi4503 in patients with AML or MDS and initiate our own Phase 1/2 trial which will initially be an open-label, dose-escalating study intended to treat up to an additional 20 patients, at 3-6 sites and evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "type": 2, "words": ["<tag1>", "This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag2>", "In", "2015", "we", "intend", "to", "close", "the", "investigator", "sponsored", "Phase", "1", "trial", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS", "and", "initiate", "our", "own", "Phase", "1/2", "trial", "which", "will", "initially", "be", "an", "open-label,", "dose-escalating", "study", "intended", "to", "treat", "up", "to", "an", "additional", "20", "patients,", "at", "3-6", "sites", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag3>"], "wordsA": ["This", "open-label,", "dose-escalating", "study", "for", "the", "treatment", "of", "up", "to", "36", "patients", "will", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "wordsB": ["In", "2015", "we", "intend", "to", "close", "the", "investigator", "sponsored", "Phase", "1", "trial", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS", "and", "initiate", "our", "own", "Phase", "1/2", "trial", "which", "will", "initially", "be", "an", "open-label,", "dose-escalating", "study", "intended", "to", "treat", "up", "to", "an", "additional", "20", "patients,", "at", "3-6", "sites", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p25_s2", "idA": "908259_14_item1_p32_s2", "sentA": "As of March 17, 2014, 15 patients have been enrolled into this study, and a maximum tolerated dose has not been observed.", "sentB": "As of March 18, 2015, 16 patients have been enrolled into this study, and a maximum tolerated dose had not been observed.", "type": 2, "words": ["<tag1>", "As", "of", "March", "17,", "2014,", "15", "patients", "have", "been", "enrolled", "into", "this", "study,", "and", "a", "maximum", "tolerated", "dose", "has", "not", "been", "observed.", "<tag2>", "As", "of", "March", "18,", "2015,", "16", "patients", "have", "been", "enrolled", "into", "this", "study,", "and", "a", "maximum", "tolerated", "dose", "had", "not", "been", "observed.", "<tag3>"], "wordsA": ["As", "of", "March", "17,", "2014,", "15", "patients", "have", "been", "enrolled", "into", "this", "study,", "and", "a", "maximum", "tolerated", "dose", "has", "not", "been", "observed."], "wordsB": ["As", "of", "March", "18,", "2015,", "16", "patients", "have", "been", "enrolled", "into", "this", "study,", "and", "a", "maximum", "tolerated", "dose", "had", "not", "been", "observed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p54_s0", "idA": "908259_14_item1_p33_s0", "sentA": "We are a Delaware corporation, incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware, with our principal corporate office in the United States at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 (telephone: (650) 635-7000, fax: (650) 635-7001).", "sentB": "We are a Delaware corporation, originally incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware, with our principal corporate office in the United States at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 (telephone: (650) 635-7000, fax: (650) 635-7001).", "type": 2, "words": ["<tag1>", "We", "are", "a", "Delaware", "corporation,", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001).", "<tag2>", "We", "are", "a", "Delaware", "corporation,", "originally", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001).", "<tag3>"], "wordsA": ["We", "are", "a", "Delaware", "corporation,", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001)."], "wordsB": ["We", "are", "a", "Delaware", "corporation,", "originally", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p31_s0", "idA": "908259_14_item1_p35_s0", "sentA": "Information contained on our web site does not form a part of this Form 10-K. Vascular Disrupting Agents: Background According to Cancer Research UK, a non-profit cancer research organization in the United Kingdom, nearly 90% of all cancers are solid tumors that are dependent upon a continually evolving vascular supply for their growth and survival.", "sentB": "According to Cancer Research UK, a non-profit cancer research organization in the United Kingdom, nearly 90% of all cancers are solid tumors that are dependent upon a continually evolving vascular supply for their growth and survival.", "type": 2, "words": ["<tag1>", "Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Form", "10-K.", "Vascular", "Disrupting", "Agents:", "Background", "According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "solid", "tumors", "that", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival.", "<tag2>", "According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "solid", "tumors", "that", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival.", "<tag3>"], "wordsA": ["Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Form", "10-K.", "Vascular", "Disrupting", "Agents:", "Background", "According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "solid", "tumors", "that", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival."], "wordsB": ["According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "solid", "tumors", "that", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p34_s0", "idA": "908259_14_item1_p38_s0", "sentA": "While ZYBRESTAT exerts a therapeutic effect similar to existing anti-angiogenic agents, depriving tumors (or, in the case of eye disease, ocular lesions) of blood supply, its mechanism of action is quite different.", "sentB": "While fosbretabulin exerts a therapeutic effect similar to existing anti-angiogenic agents, depriving tumors (or, in the case of eye disease, ocular lesions) of blood supply, its mechanism of action is quite different.", "type": 2, "words": ["<tag1>", "While", "ZYBRESTAT", "exerts", "a", "therapeutic", "effect", "similar", "to", "existing", "anti-angiogenic", "agents,", "depriving", "tumors", "(or,", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions)", "of", "blood", "supply,", "its", "mechanism", "of", "action", "is", "quite", "different.", "<tag2>", "While", "fosbretabulin", "exerts", "a", "therapeutic", "effect", "similar", "to", "existing", "anti-angiogenic", "agents,", "depriving", "tumors", "(or,", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions)", "of", "blood", "supply,", "its", "mechanism", "of", "action", "is", "quite", "different.", "<tag3>"], "wordsA": ["While", "ZYBRESTAT", "exerts", "a", "therapeutic", "effect", "similar", "to", "existing", "anti-angiogenic", "agents,", "depriving", "tumors", "(or,", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions)", "of", "blood", "supply,", "its", "mechanism", "of", "action", "is", "quite", "different."], "wordsB": ["While", "fosbretabulin", "exerts", "a", "therapeutic", "effect", "similar", "to", "existing", "anti-angiogenic", "agents,", "depriving", "tumors", "(or,", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions)", "of", "blood", "supply,", "its", "mechanism", "of", "action", "is", "quite", "different."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p4_s0", "idA": "908259_14_item1_p3_s0", "sentA": "There are relatively few cancer therapies that have been approved for the treatment of ovarian cancer, including carboplatin and cisplatin, gemcitabine, doxorubicin, and paclitaxel and also in the European Union, bevacizumab.", "sentB": "There are relatively few cancer therapies that have been approved for the treatment of ovarian cancer including platinum-resistant cancer.", "type": 2, "words": ["<tag1>", "There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer,", "including", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "and", "paclitaxel", "and", "also", "in", "the", "European", "Union,", "bevacizumab.", "<tag2>", "There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "including", "platinum-resistant", "cancer.", "<tag3>"], "wordsA": ["There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer,", "including", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "and", "paclitaxel", "and", "also", "in", "the", "European", "Union,", "bevacizumab."], "wordsB": ["There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "including", "platinum-resistant", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p4_s1", "idA": "908259_14_item1_p3_s0", "sentA": "There are relatively few cancer therapies that have been approved for the treatment of ovarian cancer, including carboplatin and cisplatin, gemcitabine, doxorubicin, and paclitaxel and also in the European Union, bevacizumab.", "sentB": "Approved drugs include carboplatin and cisplatin, gemcitabine, doxorubicin, paclitaxel and bevacizumab.", "type": 2, "words": ["<tag1>", "There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer,", "including", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "and", "paclitaxel", "and", "also", "in", "the", "European", "Union,", "bevacizumab.", "<tag2>", "Approved", "drugs", "include", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "bevacizumab.", "<tag3>"], "wordsA": ["There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer,", "including", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "and", "paclitaxel", "and", "also", "in", "the", "European", "Union,", "bevacizumab."], "wordsB": ["Approved", "drugs", "include", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "bevacizumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p4_s2", "idA": "908259_14_item1_p3_s1", "sentA": "Many patients eventually become resistant to platinum-based therapies, and new agents are needed.", "sentB": "Many patients eventually become resistant to platinum-based therapies, and new treatment agents are needed.", "type": 2, "words": ["<tag1>", "Many", "patients", "eventually", "become", "resistant", "to", "platinum-based", "therapies,", "and", "new", "agents", "are", "needed.", "<tag2>", "Many", "patients", "eventually", "become", "resistant", "to", "platinum-based", "therapies,", "and", "new", "treatment", "agents", "are", "needed.", "<tag3>"], "wordsA": ["Many", "patients", "eventually", "become", "resistant", "to", "platinum-based", "therapies,", "and", "new", "agents", "are", "needed."], "wordsB": ["Many", "patients", "eventually", "become", "resistant", "to", "platinum-based", "therapies,", "and", "new", "treatment", "agents", "are", "needed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p35_s2", "idA": "908259_14_item1_p40_s2", "sentA": "Results from initial human clinical studies conducted by us with combinations of ZYBRESTAT and AVASTIN (bevacizumab), provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "sentB": "Results from initial human clinical studies conducted by us with combinations of fosbretabulin and AVASTIN (bevacizumab), provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "type": 2, "words": ["<tag1>", "Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab),", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag2>", "Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "fosbretabulin", "and", "AVASTIN", "(bevacizumab),", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag3>"], "wordsA": ["Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab),", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "wordsB": ["Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "fosbretabulin", "and", "AVASTIN", "(bevacizumab),", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p37_s2", "idA": "908259_14_item1_p42_s2", "sentA": "By binding to the tubulin, ZYBRESTAT is able to collapse the structural framework that maintains the cells flat shape.", "sentB": "By binding to the tubulin, fosbretabulin is able to collapse the structural framework that maintains the cells flat shape.", "type": 2, "words": ["<tag1>", "By", "binding", "to", "the", "tubulin,", "ZYBRESTAT", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "maintains", "the", "cells", "flat", "shape.", "<tag2>", "By", "binding", "to", "the", "tubulin,", "fosbretabulin", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "maintains", "the", "cells", "flat", "shape.", "<tag3>"], "wordsA": ["By", "binding", "to", "the", "tubulin,", "ZYBRESTAT", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "maintains", "the", "cells", "flat", "shape."], "wordsB": ["By", "binding", "to", "the", "tubulin,", "fosbretabulin", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "maintains", "the", "cells", "flat", "shape."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p37_s5", "idA": "908259_14_item1_p42_s5", "sentA": "The consequence of the blockage is extensive tumor cell death, as demonstrated in animal studies and suggested in imaging studies of human patients treated with ZYBRESTAT and OXi4503.", "sentB": "The consequence of the blockage is extensive tumor cell death, as demonstrated in animal studies and suggested in imaging studies of human patients treated with fosbretabulin and OXi4503.", "type": 2, "words": ["<tag1>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "ZYBRESTAT", "and", "OXi4503.", "<tag2>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "fosbretabulin", "and", "OXi4503.", "<tag3>"], "wordsA": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "ZYBRESTAT", "and", "OXi4503."], "wordsB": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "fosbretabulin", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p37_s6", "idA": "908259_14_item1_p42_s6", "sentA": "Preclinical research, published in the November 2005 issue of the Journal of Clinical Investigation, showed that ZYBRESTAT also disrupts the molecular engagement of VE-cadherin, a junctional protein important for endothelial cell survival and function.", "sentB": "Preclinical research, published in the November 2005 issue of the Journal of Clinical Investigation, showed that fosbretabulin also disrupts the molecular engagement of VE-cadherin, a junctional protein important for endothelial cell survival and function.", "type": 2, "words": ["<tag1>", "Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "ZYBRESTAT", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function.", "<tag2>", "Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "fosbretabulin", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function.", "<tag3>"], "wordsA": ["Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "ZYBRESTAT", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function."], "wordsB": ["Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "fosbretabulin", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p37_s7", "idA": "908259_14_item1_p43_s0", "sentA": "associated with tumors and other disease processes.", "sentB": "The authors of the research article conclude that this effect only occurs in endothelial cells which lack contact with smooth muscle cells, a known feature of abnormal vasculature associated with tumors and other disease processes.", "type": 2, "words": ["<tag1>", "associated", "with", "tumors", "and", "other", "disease", "processes.", "<tag2>", "The", "authors", "of", "the", "research", "article", "conclude", "that", "this", "effect", "only", "occurs", "in", "endothelial", "cells", "which", "lack", "contact", "with", "smooth", "muscle", "cells,", "a", "known", "feature", "of", "abnormal", "vasculature", "associated", "with", "tumors", "and", "other", "disease", "processes.", "<tag3>"], "wordsA": ["associated", "with", "tumors", "and", "other", "disease", "processes."], "wordsB": ["The", "authors", "of", "the", "research", "article", "conclude", "that", "this", "effect", "only", "occurs", "in", "endothelial", "cells", "which", "lack", "contact", "with", "smooth", "muscle", "cells,", "a", "known", "feature", "of", "abnormal", "vasculature", "associated", "with", "tumors", "and", "other", "disease", "processes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p39_s0", "idA": "908259_14_item1_p45_s0", "sentA": "Preclinical and clinical study results indicate that ZYBRESTAT exerts anti-vascular effects rapidly, within hours of administration, and the half-life of the active form of ZYBRESTAT in humans is approximately four hours.", "sentB": "Preclinical and clinical study results indicate that fosbretabulin exerts anti-vascular effects rapidly, within hours of administration, and the half-life of the active form of fosbretabulin in humans is approximately four hours.", "type": 2, "words": ["<tag1>", "Preclinical", "and", "clinical", "study", "results", "indicate", "that", "ZYBRESTAT", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "ZYBRESTAT", "in", "humans", "is", "approximately", "four", "hours.", "<tag2>", "Preclinical", "and", "clinical", "study", "results", "indicate", "that", "fosbretabulin", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "in", "humans", "is", "approximately", "four", "hours.", "<tag3>"], "wordsA": ["Preclinical", "and", "clinical", "study", "results", "indicate", "that", "ZYBRESTAT", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "ZYBRESTAT", "in", "humans", "is", "approximately", "four", "hours."], "wordsB": ["Preclinical", "and", "clinical", "study", "results", "indicate", "that", "fosbretabulin", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "in", "humans", "is", "approximately", "four", "hours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p39_s1", "idA": "908259_14_item1_p45_s1", "sentA": "Because the half-life of the active form of ZYBRESTAT is relatively short, the effects of ZYBRESTAT on tubulin are reversible, and ZYBRESTAT is typically administered no more frequently than once per week, the side-effects of ZYBRESTAT are typically transient in nature, limited to the period of time following administration when the active form of ZYBRESTAT is in the body in significant concentrations.", "sentB": "Because the half-life of the active form of fosbretabulin is relatively short, the effects of fosbretabulin on tubulin are reversible, and fosbretabulin is typically administered no more frequently than once per week, the side-effects of fosbretabulin are typically transient in nature, limited to the period of time following administration when the active form of fosbretabulin is in the body in significant concentrations.", "type": 2, "words": ["<tag1>", "Because", "the", "half-life", "of", "the", "active", "form", "of", "ZYBRESTAT", "is", "relatively", "short,", "the", "effects", "of", "ZYBRESTAT", "on", "tubulin", "are", "reversible,", "and", "ZYBRESTAT", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "ZYBRESTAT", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "ZYBRESTAT", "is", "in", "the", "body", "in", "significant", "concentrations.", "<tag2>", "Because", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "is", "relatively", "short,", "the", "effects", "of", "fosbretabulin", "on", "tubulin", "are", "reversible,", "and", "fosbretabulin", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "fosbretabulin", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "fosbretabulin", "is", "in", "the", "body", "in", "significant", "concentrations.", "<tag3>"], "wordsA": ["Because", "the", "half-life", "of", "the", "active", "form", "of", "ZYBRESTAT", "is", "relatively", "short,", "the", "effects", "of", "ZYBRESTAT", "on", "tubulin", "are", "reversible,", "and", "ZYBRESTAT", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "ZYBRESTAT", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "ZYBRESTAT", "is", "in", "the", "body", "in", "significant", "concentrations."], "wordsB": ["Because", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "is", "relatively", "short,", "the", "effects", "of", "fosbretabulin", "on", "tubulin", "are", "reversible,", "and", "fosbretabulin", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "fosbretabulin", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "fosbretabulin", "is", "in", "the", "body", "in", "significant", "concentrations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p39_s3", "idA": "908259_14_item1_p45_s3", "sentA": "In contrast with anti-angiogenic agents, which can cause a variety of chronic side-effects, side-effects associated with ZYBRESTAT are typically transient and manageable.", "sentB": "In contrast with anti-angiogenic agents, which can cause a variety of chronic side-effects, side-effects associated with fosbretabulin are typically transient and manageable.", "type": 2, "words": ["<tag1>", "In", "contrast", "with", "anti-angiogenic", "agents,", "which", "can", "cause", "a", "variety", "of", "chronic", "side-effects,", "side-effects", "associated", "with", "ZYBRESTAT", "are", "typically", "transient", "and", "manageable.", "<tag2>", "In", "contrast", "with", "anti-angiogenic", "agents,", "which", "can", "cause", "a", "variety", "of", "chronic", "side-effects,", "side-effects", "associated", "with", "fosbretabulin", "are", "typically", "transient", "and", "manageable.", "<tag3>"], "wordsA": ["In", "contrast", "with", "anti-angiogenic", "agents,", "which", "can", "cause", "a", "variety", "of", "chronic", "side-effects,", "side-effects", "associated", "with", "ZYBRESTAT", "are", "typically", "transient", "and", "manageable."], "wordsB": ["In", "contrast", "with", "anti-angiogenic", "agents,", "which", "can", "cause", "a", "variety", "of", "chronic", "side-effects,", "side-effects", "associated", "with", "fosbretabulin", "are", "typically", "transient", "and", "manageable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p40_s0", "idA": "908259_14_item1_p45_s4", "sentA": "The most frequent ZYBRESTAT side-effects include infusion-related side effects such as nausea, vomiting, headache and fatigue, and tumor pain, which is consistent with the drug s mechanism-of-action.", "sentB": "effects include infusion-related side effects such as nausea, vomiting, headache and fatigue, and tumor pain, which is consistent with the drug s mechanism-of-action.", "type": 2, "words": ["<tag1>", "The", "most", "frequent", "ZYBRESTAT", "side-effects", "include", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action.", "<tag2>", "effects", "include", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action.", "<tag3>"], "wordsA": ["The", "most", "frequent", "ZYBRESTAT", "side-effects", "include", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action."], "wordsB": ["effects", "include", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p40_s1", "idA": "908259_14_item1_p45_s5", "sentA": "Like approved anti-angiogenic drugs, ZYBRESTAT also exhibits cardiovascular effects, which in the majority of patients are mild and transient in nature.", "sentB": "Like approved anti-angiogenic drugs, fosbretabulin also exhibits cardiovascular effects, which in the majority of patients are mild and transient in nature.", "type": 2, "words": ["<tag1>", "Like", "approved", "anti-angiogenic", "drugs,", "ZYBRESTAT", "also", "exhibits", "cardiovascular", "effects,", "which", "in", "the", "majority", "of", "patients", "are", "mild", "and", "transient", "in", "nature.", "<tag2>", "Like", "approved", "anti-angiogenic", "drugs,", "fosbretabulin", "also", "exhibits", "cardiovascular", "effects,", "which", "in", "the", "majority", "of", "patients", "are", "mild", "and", "transient", "in", "nature.", "<tag3>"], "wordsA": ["Like", "approved", "anti-angiogenic", "drugs,", "ZYBRESTAT", "also", "exhibits", "cardiovascular", "effects,", "which", "in", "the", "majority", "of", "patients", "are", "mild", "and", "transient", "in", "nature."], "wordsB": ["Like", "approved", "anti-angiogenic", "drugs,", "fosbretabulin", "also", "exhibits", "cardiovascular", "effects,", "which", "in", "the", "majority", "of", "patients", "are", "mild", "and", "transient", "in", "nature."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p40_s2", "idA": "908259_14_item1_p45_s6", "sentA": "Approximately 10-20% of patients treated with ZYBRESTAT experience clinically-significant and transient hypertension that can be readily managed and prevented after initial occurrence with straightforward oral anti-hypertensive therapy.", "sentB": "Approximately 10-20% of patients treated with fosbretabulin experience clinically-significant and transient hypertension that can be readily managed and prevented after initial occurrence with straightforward oral anti-hypertensive therapy.", "type": 2, "words": ["<tag1>", "Approximately", "10-20%", "of", "patients", "treated", "with", "ZYBRESTAT", "experience", "clinically-significant", "and", "transient", "hypertension", "that", "can", "be", "readily", "managed", "and", "prevented", "after", "initial", "occurrence", "with", "straightforward", "oral", "anti-hypertensive", "therapy.", "<tag2>", "Approximately", "10-20%", "of", "patients", "treated", "with", "fosbretabulin", "experience", "clinically-significant", "and", "transient", "hypertension", "that", "can", "be", "readily", "managed", "and", "prevented", "after", "initial", "occurrence", "with", "straightforward", "oral", "anti-hypertensive", "therapy.", "<tag3>"], "wordsA": ["Approximately", "10-20%", "of", "patients", "treated", "with", "ZYBRESTAT", "experience", "clinically-significant", "and", "transient", "hypertension", "that", "can", "be", "readily", "managed", "and", "prevented", "after", "initial", "occurrence", "with", "straightforward", "oral", "anti-hypertensive", "therapy."], "wordsB": ["Approximately", "10-20%", "of", "patients", "treated", "with", "fosbretabulin", "experience", "clinically-significant", "and", "transient", "hypertension", "that", "can", "be", "readily", "managed", "and", "prevented", "after", "initial", "occurrence", "with", "straightforward", "oral", "anti-hypertensive", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p41_s0", "idA": "908259_14_item1_p46_s0", "sentA": "Our strategy is to develop innovative therapeutics for oncology and to leverage our drug candidates and technology in the field of ophthalmology.", "sentB": "Our strategy is to develop innovative therapeutics for oncology.", "type": 2, "words": ["<tag1>", "Our", "strategy", "is", "to", "develop", "innovative", "therapeutics", "for", "oncology", "and", "to", "leverage", "our", "drug", "candidates", "and", "technology", "in", "the", "field", "of", "ophthalmology.", "<tag2>", "Our", "strategy", "is", "to", "develop", "innovative", "therapeutics", "for", "oncology.", "<tag3>"], "wordsA": ["Our", "strategy", "is", "to", "develop", "innovative", "therapeutics", "for", "oncology", "and", "to", "leverage", "our", "drug", "candidates", "and", "technology", "in", "the", "field", "of", "ophthalmology."], "wordsB": ["Our", "strategy", "is", "to", "develop", "innovative", "therapeutics", "for", "oncology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p41_s1", "idA": "908259_14_item1_p46_s1", "sentA": "Our principal focus is to advance the clinical development and commercialization of our drug candidates ZYBRESTAT and OXi4503 and to identify new preclinical candidates that are complementary to our VDAs.", "sentB": "Our principal focus is to advance the clinical development and commercialization of our drug candidates fosbretabulin and OXi4503 and to identify new preclinical candidates that are complementary to our VDAs.", "type": 2, "words": ["<tag1>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "ZYBRESTAT", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag2>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "fosbretabulin", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag3>"], "wordsA": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "ZYBRESTAT", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "wordsB": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "fosbretabulin", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p41_s6", "idA": "908259_14_item1_p46_s6", "sentA": "In 2013, collaborations and agreements were ongoing with a variety of university and research institutions, including the following:", "sentB": "In 2014, collaborations and agreements were ongoing with a variety of university and research institutions, including the following:", "type": 2, "words": ["<tag1>", "In", "2013,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:", "<tag2>", "In", "2014,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:", "<tag3>"], "wordsA": ["In", "2013,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:"], "wordsB": ["In", "2014,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p42_s0", "idA": "908259_14_item1_p48_s0", "sentA": "In December 2011, we established a distribution agreement with a Danish company, Azanta Danmark A/S, or Azanta, to provide access to ZYBRESTAT for the treatment of patients with ATC on a compassionate use basis in certain specified territories.", "sentB": "In December 2011, we established a distribution agreement with a Danish company, Azanta Danmark A/S, or Azanta, to provide access to fosbretabulin for the treatment of patients with ATC on a compassionate use basis in certain specified territories, which was expanded to include additional territories in August 2012.", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "we", "established", "a", "distribution", "agreement", "with", "a", "Danish", "company,", "Azanta", "Danmark", "A/S,", "or", "Azanta,", "to", "provide", "access", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "certain", "specified", "territories.", "<tag2>", "In", "December", "2011,", "we", "established", "a", "distribution", "agreement", "with", "a", "Danish", "company,", "Azanta", "Danmark", "A/S,", "or", "Azanta,", "to", "provide", "access", "to", "fosbretabulin", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "certain", "specified", "territories,", "which", "was", "expanded", "to", "include", "additional", "territories", "in", "August", "2012.", "<tag3>"], "wordsA": ["In", "December", "2011,", "we", "established", "a", "distribution", "agreement", "with", "a", "Danish", "company,", "Azanta", "Danmark", "A/S,", "or", "Azanta,", "to", "provide", "access", "to", "ZYBRESTAT", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "certain", "specified", "territories."], "wordsB": ["In", "December", "2011,", "we", "established", "a", "distribution", "agreement", "with", "a", "Danish", "company,", "Azanta", "Danmark", "A/S,", "or", "Azanta,", "to", "provide", "access", "to", "fosbretabulin", "for", "the", "treatment", "of", "patients", "with", "ATC", "on", "a", "compassionate", "use", "basis", "in", "certain", "specified", "territories,", "which", "was", "expanded", "to", "include", "additional", "territories", "in", "August", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p42_s1", "idA": "908259_14_item1_p48_s1", "sentA": "This agreement was expanded to include additional territories in August 2012 also for treatment on a compassionate use basis.", "sentB": "This agreement was terminated effective December 31, 2014.", "type": 2, "words": ["<tag1>", "This", "agreement", "was", "expanded", "to", "include", "additional", "territories", "in", "August", "2012", "also", "for", "treatment", "on", "a", "compassionate", "use", "basis.", "<tag2>", "This", "agreement", "was", "terminated", "effective", "December", "31,", "2014.", "<tag3>"], "wordsA": ["This", "agreement", "was", "expanded", "to", "include", "additional", "territories", "in", "August", "2012", "also", "for", "treatment", "on", "a", "compassionate", "use", "basis."], "wordsB": ["This", "agreement", "was", "terminated", "effective", "December", "31,", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p42_s2", "idA": "908259_14_item1_p48_s2", "sentA": "The specified territories include the European Union, including the Nordic countries and Switzerland, Canada, Israel and South Korea.", "sentB": "The specified territories included the European Union, including the Nordic countries and Switzerland, Canada, Israel and South Korea.", "type": 2, "words": ["<tag1>", "The", "specified", "territories", "include", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "Canada,", "Israel", "and", "South", "Korea.", "<tag2>", "The", "specified", "territories", "included", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "Canada,", "Israel", "and", "South", "Korea.", "<tag3>"], "wordsA": ["The", "specified", "territories", "include", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "Canada,", "Israel", "and", "South", "Korea."], "wordsB": ["The", "specified", "territories", "included", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "Canada,", "Israel", "and", "South", "Korea."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p42_s3", "idA": "908259_14_item1_p48_s3", "sentA": "This program, which is managed by Azanta , provides a regulatory mechanism to allow healthcare professionals in the specified territories to prescribe ZYBRESTAT to individual ATC patients while it is still in development.", "sentB": "This program, which was managed by Azanta, provided a regulatory mechanism to allow healthcare professionals in the specified territories to prescribe fosbretabulin to individual ATC patients while it is still in development.", "type": 2, "words": ["<tag1>", "This", "program,", "which", "is", "managed", "by", "Azanta", ",", "provides", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "the", "specified", "territories", "to", "prescribe", "ZYBRESTAT", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development.", "<tag2>", "This", "program,", "which", "was", "managed", "by", "Azanta,", "provided", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "the", "specified", "territories", "to", "prescribe", "fosbretabulin", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development.", "<tag3>"], "wordsA": ["This", "program,", "which", "is", "managed", "by", "Azanta", ",", "provides", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "the", "specified", "territories", "to", "prescribe", "ZYBRESTAT", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development."], "wordsB": ["This", "program,", "which", "was", "managed", "by", "Azanta,", "provided", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "the", "specified", "territories", "to", "prescribe", "fosbretabulin", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p42_s4", "idA": "908259_14_item1_p48_s4", "sentA": "Under the terms of the agreement, we provide ZYBRESTAT to the Danish company, and they serve as our exclusive distributor for ZYBRESTAT in the specified territories for this purpose.", "sentB": "Under the terms of the agreement, we provided fosbretabulin to the Danish company, and they served as our exclusive distributor for fosbretabulin in the specified territories for this purpose.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "provide", "ZYBRESTAT", "to", "the", "Danish", "company,", "and", "they", "serve", "as", "our", "exclusive", "distributor", "for", "ZYBRESTAT", "in", "the", "specified", "territories", "for", "this", "purpose.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "provided", "fosbretabulin", "to", "the", "Danish", "company,", "and", "they", "served", "as", "our", "exclusive", "distributor", "for", "fosbretabulin", "in", "the", "specified", "territories", "for", "this", "purpose.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "provide", "ZYBRESTAT", "to", "the", "Danish", "company,", "and", "they", "serve", "as", "our", "exclusive", "distributor", "for", "ZYBRESTAT", "in", "the", "specified", "territories", "for", "this", "purpose."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "provided", "fosbretabulin", "to", "the", "Danish", "company,", "and", "they", "served", "as", "our", "exclusive", "distributor", "for", "fosbretabulin", "in", "the", "specified", "territories", "for", "this", "purpose."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p42_s5", "idA": "908259_14_item1_p48_s5", "sentA": "The Danish company provides ZYBRESTAT to physicians solely to treat ATC on a compassionate use basis in the specified territories until such time as ZYBRESTAT may obtain marketing approval in that territory.", "sentB": "The Danish company provided fosbretabulin to physicians solely to treat ATC on a compassionate use basis in the specified territories until such time as fosbretabulin may have obtained marketing approval in that territory.", "type": 2, "words": ["<tag1>", "The", "Danish", "company", "provides", "ZYBRESTAT", "to", "physicians", "solely", "to", "treat", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "specified", "territories", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory.", "<tag2>", "The", "Danish", "company", "provided", "fosbretabulin", "to", "physicians", "solely", "to", "treat", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "specified", "territories", "until", "such", "time", "as", "fosbretabulin", "may", "have", "obtained", "marketing", "approval", "in", "that", "territory.", "<tag3>"], "wordsA": ["The", "Danish", "company", "provides", "ZYBRESTAT", "to", "physicians", "solely", "to", "treat", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "specified", "territories", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory."], "wordsB": ["The", "Danish", "company", "provided", "fosbretabulin", "to", "physicians", "solely", "to", "treat", "ATC", "on", "a", "compassionate", "use", "basis", "in", "the", "specified", "territories", "until", "such", "time", "as", "fosbretabulin", "may", "have", "obtained", "marketing", "approval", "in", "that", "territory."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p42_s6", "idA": "908259_14_item1_p49_s0", "sentA": "The Danish company is responsible for all regulatory activities necessary to distribute and sell ZYBRESTAT on a compassionate use basis for the treatment of ATC within the specified territories.", "sentB": "The Danish company was responsible for all regulatory activities necessary to distribute and sell fosbretabulin on a compassionate use basis for the treatment of ATC within the specified territories.", "type": 2, "words": ["<tag1>", "The", "Danish", "company", "is", "responsible", "for", "all", "regulatory", "activities", "necessary", "to", "distribute", "and", "sell", "ZYBRESTAT", "on", "a", "compassionate", "use", "basis", "for", "the", "treatment", "of", "ATC", "within", "the", "specified", "territories.", "<tag2>", "The", "Danish", "company", "was", "responsible", "for", "all", "regulatory", "activities", "necessary", "to", "distribute", "and", "sell", "fosbretabulin", "on", "a", "compassionate", "use", "basis", "for", "the", "treatment", "of", "ATC", "within", "the", "specified", "territories.", "<tag3>"], "wordsA": ["The", "Danish", "company", "is", "responsible", "for", "all", "regulatory", "activities", "necessary", "to", "distribute", "and", "sell", "ZYBRESTAT", "on", "a", "compassionate", "use", "basis", "for", "the", "treatment", "of", "ATC", "within", "the", "specified", "territories."], "wordsB": ["The", "Danish", "company", "was", "responsible", "for", "all", "regulatory", "activities", "necessary", "to", "distribute", "and", "sell", "fosbretabulin", "on", "a", "compassionate", "use", "basis", "for", "the", "treatment", "of", "ATC", "within", "the", "specified", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p42_s7", "idA": "908259_14_item1_p49_s1", "sentA": "There is no transfer of ownership of intellectual property rights for ZYBRESTAT to the Danish company under the terms of the agreement.", "sentB": "There was no transfer of ownership of intellectual property rights for fosbretabulin to the Danish company under the terms of the agreement.", "type": 2, "words": ["<tag1>", "There", "is", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "ZYBRESTAT", "to", "the", "Danish", "company", "under", "the", "terms", "of", "the", "agreement.", "<tag2>", "There", "was", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "fosbretabulin", "to", "the", "Danish", "company", "under", "the", "terms", "of", "the", "agreement.", "<tag3>"], "wordsA": ["There", "is", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "ZYBRESTAT", "to", "the", "Danish", "company", "under", "the", "terms", "of", "the", "agreement."], "wordsB": ["There", "was", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "fosbretabulin", "to", "the", "Danish", "company", "under", "the", "terms", "of", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p5_s0", "idA": "908259_14_item1_p4_s0", "sentA": "Due to the unmet need in the treatment of ovarian cancer and the small size of the indication, we have been granted an orphan drug designation in both the U.S. and Europe for the use of ZYBRESTAT in the treatment of ovarian cancer.", "sentB": "Due to the unmet need in the treatment of ovarian cancer and the small patient size of the indication in terms of number of patients, we have been granted an orphan drug designation in both the U.S. and Europe for the use of fosbretabulin in the treatment of ovarian cancer.", "type": 2, "words": ["<tag1>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "patient", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "use", "of", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "use", "of", "ZYBRESTAT", "in", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "patient", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "use", "of", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p43_s1", "idA": "908259_14_item1_p50_s1", "sentA": "The ASU license is an exclusive, world-wide, royalty-bearing license for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, ZYBRESTAT and OXi4503.", "sentB": "The ASU license is an exclusive, world-wide, royalty-bearing license for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, fosbretabulin and OXi4503.", "type": 2, "words": ["<tag1>", "The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "ZYBRESTAT", "and", "OXi4503.", "<tag2>", "The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "fosbretabulin", "and", "OXi4503.", "<tag3>"], "wordsA": ["The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "ZYBRESTAT", "and", "OXi4503."], "wordsB": ["The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "fosbretabulin", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p47_s3", "idA": "908259_14_item1_p54_s3", "sentA": "Payments made to ASU to date have amounted to $2,500,000.", "sentB": "Payments made to ASU to date have amounted to $2,600,000.", "type": 2, "words": ["<tag1>", "Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,500,000.", "<tag2>", "Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,600,000.", "<tag3>"], "wordsA": ["Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,500,000."], "wordsB": ["Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,600,000."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p49_s1", "idA": "908259_14_item1_p56_s1", "sentA": "We believe that our hypoxia-activated VDAs could serve as line-extension products to ZYBRESTAT and/or OXi4503.", "sentB": "We believe that our hypoxia-activated VDAs could serve as line-extension products to fosbretabulin and/or OXi4503.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "ZYBRESTAT", "and/or", "OXi4503.", "<tag2>", "We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "fosbretabulin", "and/or", "OXi4503.", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "ZYBRESTAT", "and/or", "OXi4503."], "wordsB": ["We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "fosbretabulin", "and/or", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p49_s12", "idA": "908259_14_item1_p57_s0", "sentA": "We also have an exclusive, world-wide, royalty-bearing license from Bristol-Myers Squibb, or BMS, for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, ZYBRESTAT .", "sentB": "We also have an exclusive, world-wide, royalty-bearing license from Bristol-Myers Squibb, or BMS, for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, fosbretabulin.", "type": 2, "words": ["<tag1>", "We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "ZYBRESTAT", ".", "<tag2>", "We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "fosbretabulin.", "<tag3>"], "wordsA": ["We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "ZYBRESTAT", "."], "wordsB": ["We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "fosbretabulin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p49_s14", "idA": "908259_14_item1_p57_s2", "sentA": "Under the license agreement, BMS is entitled to low-single-digit royalty payments for all commercial sales plus any remuneration OXiGENE receives for sale of ZYBRESTAT under named patient or compassionate use programs.", "sentB": "Under the license agreement, BMS is entitled to low-single-digit royalty payments for all commercial sales plus any remuneration OXiGENE receives for sale of fosbretabulin under named patient or compassionate use programs.", "type": 2, "words": ["<tag1>", "Under", "the", "license", "agreement,", "BMS", "is", "entitled", "to", "low-single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "OXiGENE", "receives", "for", "sale", "of", "ZYBRESTAT", "under", "named", "patient", "or", "compassionate", "use", "programs.", "<tag2>", "Under", "the", "license", "agreement,", "BMS", "is", "entitled", "to", "low-single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "OXiGENE", "receives", "for", "sale", "of", "fosbretabulin", "under", "named", "patient", "or", "compassionate", "use", "programs.", "<tag3>"], "wordsA": ["Under", "the", "license", "agreement,", "BMS", "is", "entitled", "to", "low-single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "OXiGENE", "receives", "for", "sale", "of", "ZYBRESTAT", "under", "named", "patient", "or", "compassionate", "use", "programs."], "wordsB": ["Under", "the", "license", "agreement,", "BMS", "is", "entitled", "to", "low-single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "OXiGENE", "receives", "for", "sale", "of", "fosbretabulin", "under", "named", "patient", "or", "compassionate", "use", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p51_s0", "idA": "908259_14_item1_p59_s0", "sentA": "In June 2012, we secured a royalty-bearing, transferable, worldwide, exclusive license from Angiogene Pharmaceuticals Ltd. to make, have made, use, import, offer for sale, and sell a vascular disrupting agent, such as ZYBRESTAT , for treating neuroendocrine tumors and associated symptoms and syndromes.", "sentB": "In June 2012, we secured a royalty-bearing, transferable, worldwide, exclusive license from Angiogene Pharmaceuticals Ltd. to make, have made, use, import, offer for sale, and sell a vascular disrupting agent, such as fosbretabulin, for treating neuroendocrine tumors and associated symptoms and syndromes.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "ZYBRESTAT", ",", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes.", "<tag2>", "In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "fosbretabulin,", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "ZYBRESTAT", ",", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes."], "wordsB": ["In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "fosbretabulin,", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p53_s0", "idA": "908259_14_item1_p59_s3", "sentA": "Milestone payments are due upon initiation of the first clinical trial for a product using Angiogene intellectual property and initiation of the first registration clinical trial for a product using Angiogene intellectual property.", "sentB": "for a product using Angiogene intellectual property.", "type": 2, "words": ["<tag1>", "Milestone", "payments", "are", "due", "upon", "initiation", "of", "the", "first", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property", "and", "initiation", "of", "the", "first", "registration", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property.", "<tag2>", "for", "a", "product", "using", "Angiogene", "intellectual", "property.", "<tag3>"], "wordsA": ["Milestone", "payments", "are", "due", "upon", "initiation", "of", "the", "first", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property", "and", "initiation", "of", "the", "first", "registration", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property."], "wordsB": ["for", "a", "product", "using", "Angiogene", "intellectual", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p6_s0", "idA": "908259_14_item1_p5_s0", "sentA": "Genentech / Roche s AVASTIN (bevacizumab) is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody that is currently FDA-approved for the treatment of a variety of solid tumor indications, but not including ovarian cancer.", "sentB": "Fosbretabulin in combination with AVASTIN (bevacizumab) Completed Phase 2 Trial Genentech / Roche s AVASTIN (bevacizumab) is an anti-vascular endothelial growth factor, or VEGF, monoclonal antibody.", "type": 2, "words": ["<tag1>", "Genentech", "/", "Roche", "s", "AVASTIN", "(bevacizumab)", "is", "an", "anti-vascular", "endothelial", "growth", "factor", "(VEGF)", "monoclonal", "antibody", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "a", "variety", "of", "solid", "tumor", "indications,", "but", "not", "including", "ovarian", "cancer.", "<tag2>", "Fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "Completed", "Phase", "2", "Trial", "Genentech", "/", "Roche", "s", "AVASTIN", "(bevacizumab)", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody.", "<tag3>"], "wordsA": ["Genentech", "/", "Roche", "s", "AVASTIN", "(bevacizumab)", "is", "an", "anti-vascular", "endothelial", "growth", "factor", "(VEGF)", "monoclonal", "antibody", "that", "is", "currently", "FDA-approved", "for", "the", "treatment", "of", "a", "variety", "of", "solid", "tumor", "indications,", "but", "not", "including", "ovarian", "cancer."], "wordsB": ["Fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "Completed", "Phase", "2", "Trial", "Genentech", "/", "Roche", "s", "AVASTIN", "(bevacizumab)", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p11_s0", "idA": "908259_14_item1_p5_s1", "sentA": "We believe that using ZYBRESTAT in combination with AVASTIN (bevacizumab) may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "AVASTIN (bevacizumab) is also approved in the EU in combination with different chemotherapy regimens for platinum-resistant and platinum-sensitive ovarian cancer, the approval of which was based on progression free survival.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "AVASTIN", "(bevacizumab)", "is", "also", "approved", "in", "the", "EU", "in", "combination", "with", "different", "chemotherapy", "regimens", "for", "platinum-resistant", "and", "platinum-sensitive", "ovarian", "cancer,", "the", "approval", "of", "which", "was", "based", "on", "progression", "free", "survival.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["AVASTIN", "(bevacizumab)", "is", "also", "approved", "in", "the", "EU", "in", "combination", "with", "different", "chemotherapy", "regimens", "for", "platinum-resistant", "and", "platinum-sensitive", "ovarian", "cancer,", "the", "approval", "of", "which", "was", "based", "on", "progression", "free", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p6_s1", "idA": "908259_14_item1_p5_s1", "sentA": "We believe that using ZYBRESTAT in combination with AVASTIN (bevacizumab) may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "We believe that using fosbretabulin in combination with AVASTIN (bevacizumab) may provide an equally effective yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "an", "equally", "effective", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "an", "equally", "effective", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p53_s2", "idA": "908259_14_item1_p60_s1", "sentA": "Payments to Angiogene, under this license, to date have amounted to $150,000.", "sentB": "Payments to Angiogene under this license to date have amounted to $300,000.", "type": 2, "words": ["<tag1>", "Payments", "to", "Angiogene,", "under", "this", "license,", "to", "date", "have", "amounted", "to", "$150,000.", "<tag2>", "Payments", "to", "Angiogene", "under", "this", "license", "to", "date", "have", "amounted", "to", "$300,000.", "<tag3>"], "wordsA": ["Payments", "to", "Angiogene,", "under", "this", "license,", "to", "date", "have", "amounted", "to", "$150,000."], "wordsB": ["Payments", "to", "Angiogene", "under", "this", "license", "to", "date", "have", "amounted", "to", "$300,000."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p54_s2", "idA": "908259_14_item1_p61_s0", "sentA": "REGULATORY MATTERS Government Regulation and Product Approval Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing.", "sentB": "Information contained on our web site does not form a part of this Annual Report on Form 10-K. REGULATORY MATTERS Government Regulation and Product Approval Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing.", "type": 2, "words": ["<tag1>", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag2>", "Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag3>"], "wordsA": ["REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "wordsB": ["Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p16_s3", "idA": "908259_14_item1_p61_s1", "sentA": "Our drugs must be approved by FDA through the new drug application, or NDA, process before they may be legally marketed in the United States.", "sentB": "This trial is designed to enroll 20 GI-NET patients with increased biomarker levels at five sites in the United States.", "type": 2, "words": ["<tag1>", "Our", "drugs", "must", "be", "approved", "by", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States.", "<tag2>", "This", "trial", "is", "designed", "to", "enroll", "20", "GI-NET", "patients", "with", "increased", "biomarker", "levels", "at", "five", "sites", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Our", "drugs", "must", "be", "approved", "by", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States."], "wordsB": ["This", "trial", "is", "designed", "to", "enroll", "20", "GI-NET", "patients", "with", "increased", "biomarker", "levels", "at", "five", "sites", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p35_s3", "idA": "908259_14_item1_p6_s0", "sentA": "The topline results indicated a statistically significant increase in progression-free survival, the primary endpoint of the trial, with a p-value of less than 0.05.", "sentB": "Additionally, positive study results from the Phase 2 GOG-0186I clinical trial indicated a statistically significant increase in PFS with the combination of fosbretabulin and bevacizumab.", "type": 2, "words": ["<tag1>", "The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05.", "<tag2>", "Additionally,", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "with", "the", "combination", "of", "fosbretabulin", "and", "bevacizumab.", "<tag3>"], "wordsA": ["The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05."], "wordsB": ["Additionally,", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "with", "the", "combination", "of", "fosbretabulin", "and", "bevacizumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s2", "idA": "908259_14_item1_p6_s0", "sentA": "The topline results indicated a statistically significant increase in progression-free survival, the primary endpoint of the trial, with a p-value of less than 0.05.", "sentB": "The results indicated a statistically significant increase in progression-free survival (PFS) in the combination arm, which was the primary endpoint of the trial, with a p-value of 0.049 (pre-specified analysis using a one-sided test; 10% level of significance).", "type": 2, "words": ["<tag1>", "The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05.", "<tag2>", "The", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "(PFS)", "in", "the", "combination", "arm,", "which", "was", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "0.049", "(pre-specified", "analysis", "using", "a", "one-sided", "test;", "10%", "level", "of", "significance).", "<tag3>"], "wordsA": ["The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05."], "wordsB": ["The", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "(PFS)", "in", "the", "combination", "arm,", "which", "was", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "0.049", "(pre-specified", "analysis", "using", "a", "one-sided", "test;", "10%", "level", "of", "significance)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s7", "idA": "908259_14_item1_p6_s0", "sentA": "The topline results indicated a statistically significant increase in progression-free survival, the primary endpoint of the trial, with a p-value of less than 0.05.", "sentB": "Among the 27 patients who were platinum-resistant, median PFS was 6.7 months for those receiving AVASTIN (bevacizumab) and fosbretabulin compared to 3.4 months for those receiving AVASTIN (bevacizumab) alone, with a p-value of 0.01.", "type": 2, "words": ["<tag1>", "The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05.", "<tag2>", "Among", "the", "27", "patients", "who", "were", "platinum-resistant,", "median", "PFS", "was", "6.7", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "and", "fosbretabulin", "compared", "to", "3.4", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "with", "a", "p-value", "of", "0.01.", "<tag3>"], "wordsA": ["The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05."], "wordsB": ["Among", "the", "27", "patients", "who", "were", "platinum-resistant,", "median", "PFS", "was", "6.7", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "and", "fosbretabulin", "compared", "to", "3.4", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "with", "a", "p-value", "of", "0.01."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p9_s2", "idA": "908259_14_item1_p6_s0", "sentA": "The topline results indicated a statistically significant increase in progression-free survival, the primary endpoint of the trial, with a p-value of less than 0.05.", "sentB": "A preliminary analysis after 33 events did not demonstrate a statistically significant difference in OS between the study arms.", "type": 2, "words": ["<tag1>", "The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05.", "<tag2>", "A", "preliminary", "analysis", "after", "33", "events", "did", "not", "demonstrate", "a", "statistically", "significant", "difference", "in", "OS", "between", "the", "study", "arms.", "<tag3>"], "wordsA": ["The", "topline", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival,", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "less", "than", "0.05."], "wordsB": ["A", "preliminary", "analysis", "after", "33", "events", "did", "not", "demonstrate", "a", "statistically", "significant", "difference", "in", "OS", "between", "the", "study", "arms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p11_s4", "idA": "908259_14_item1_p72_s0", "sentA": "During the development of a new drug, sponsors may, under certain circumstances request a special protocol assessment, or SPA, from the FDA.", "sentB": "Depending on the feedback from the FDA, we may file a special protocol assessment (SPA) relating to the development of fosbretabulin in this indication during the third quarter of 2015.", "type": 2, "words": ["<tag1>", "During", "the", "development", "of", "a", "new", "drug,", "sponsors", "may,", "under", "certain", "circumstances", "request", "a", "special", "protocol", "assessment,", "or", "SPA,", "from", "the", "FDA.", "<tag2>", "Depending", "on", "the", "feedback", "from", "the", "FDA,", "we", "may", "file", "a", "special", "protocol", "assessment", "(SPA)", "relating", "to", "the", "development", "of", "fosbretabulin", "in", "this", "indication", "during", "the", "third", "quarter", "of", "2015.", "<tag3>"], "wordsA": ["During", "the", "development", "of", "a", "new", "drug,", "sponsors", "may,", "under", "certain", "circumstances", "request", "a", "special", "protocol", "assessment,", "or", "SPA,", "from", "the", "FDA."], "wordsB": ["Depending", "on", "the", "feedback", "from", "the", "FDA,", "we", "may", "file", "a", "special", "protocol", "assessment", "(SPA)", "relating", "to", "the", "development", "of", "fosbretabulin", "in", "this", "indication", "during", "the", "third", "quarter", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p65_s1", "idA": "908259_14_item1_p73_s0", "sentA": "clinical trial that will form the primary basis of an efficacy claim in an NDA.", "sentB": "For example, a sponsor may request an SPA of a protocol for a clinical trial that will form the primary basis of an efficacy claim in an NDA.", "type": 2, "words": ["<tag1>", "clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA.", "<tag2>", "For", "example,", "a", "sponsor", "may", "request", "an", "SPA", "of", "a", "protocol", "for", "a", "clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA.", "<tag3>"], "wordsA": ["clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA."], "wordsB": ["For", "example,", "a", "sponsor", "may", "request", "an", "SPA", "of", "a", "protocol", "for", "a", "clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p66_s0", "idA": "908259_14_item1_p73_s6", "sentA": "If the sponsor and the FDA reach agreement regarding the protocol, the agreement will be documented and made part of the administrative record.", "sentB": "agreement will be documented and made part of the administrative record.", "type": 2, "words": ["<tag1>", "If", "the", "sponsor", "and", "the", "FDA", "reach", "agreement", "regarding", "the", "protocol,", "the", "agreement", "will", "be", "documented", "and", "made", "part", "of", "the", "administrative", "record.", "<tag2>", "agreement", "will", "be", "documented", "and", "made", "part", "of", "the", "administrative", "record.", "<tag3>"], "wordsA": ["If", "the", "sponsor", "and", "the", "FDA", "reach", "agreement", "regarding", "the", "protocol,", "the", "agreement", "will", "be", "documented", "and", "made", "part", "of", "the", "administrative", "record."], "wordsB": ["agreement", "will", "be", "documented", "and", "made", "part", "of", "the", "administrative", "record."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p70_s1", "idA": "908259_14_item1_p78_s0", "sentA": "evaluation and recommendation as to whether the application should be approved and under what conditions.", "sentB": "The FDA may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.", "type": 2, "words": ["<tag1>", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions.", "<tag2>", "The", "FDA", "may", "refer", "the", "NDA", "to", "an", "advisory", "committee", "for", "review,", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions.", "<tag3>"], "wordsA": ["evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions."], "wordsB": ["The", "FDA", "may", "refer", "the", "NDA", "to", "an", "advisory", "committee", "for", "review,", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p71_s0", "idA": "908259_14_item1_p78_s5", "sentA": "The FDA may issue a complete response letter, which may require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the NDA.", "sentB": "require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the NDA.", "type": 2, "words": ["<tag1>", "The", "FDA", "may", "issue", "a", "complete", "response", "letter,", "which", "may", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA.", "<tag2>", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA.", "<tag3>"], "wordsA": ["The", "FDA", "may", "issue", "a", "complete", "response", "letter,", "which", "may", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA."], "wordsB": ["require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s0", "idA": "908259_14_item1_p7_s0", "sentA": "The trial enrolled 107 patients at 67 clinical sites in the United States and is being conducted by the GOG under the sponsorship of the Cancer Therapy Evaluation Program, or CTEP, of the National Cancer Institute, or NCI.", "sentB": "The GOG-0186I clinical trial was conducted by the GOG, now part of NRG Oncology, under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and was a randomized, two-arm Phase 2 trial evaluating AVASTIN (bevacizumab) alone, as compared to AVASTIN (bevacizumab) plus fosbretabulin, in patients with recurrent ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "trial", "enrolled", "107", "patients", "at", "67", "clinical", "sites", "in", "the", "United", "States", "and", "is", "being", "conducted", "by", "the", "GOG", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI.", "<tag2>", "The", "GOG-0186I", "clinical", "trial", "was", "conducted", "by", "the", "GOG,", "now", "part", "of", "NRG", "Oncology,", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "National", "Cancer", "Institute", "(NCI)", "and", "was", "a", "randomized,", "two-arm", "Phase", "2", "trial", "evaluating", "AVASTIN", "(bevacizumab)", "alone,", "as", "compared", "to", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin,", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "trial", "enrolled", "107", "patients", "at", "67", "clinical", "sites", "in", "the", "United", "States", "and", "is", "being", "conducted", "by", "the", "GOG", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI."], "wordsB": ["The", "GOG-0186I", "clinical", "trial", "was", "conducted", "by", "the", "GOG,", "now", "part", "of", "NRG", "Oncology,", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "National", "Cancer", "Institute", "(NCI)", "and", "was", "a", "randomized,", "two-arm", "Phase", "2", "trial", "evaluating", "AVASTIN", "(bevacizumab)", "alone,", "as", "compared", "to", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin,", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s1", "idA": "908259_14_item1_p7_s0", "sentA": "The trial enrolled 107 patients at 67 clinical sites in the United States and is being conducted by the GOG under the sponsorship of the Cancer Therapy Evaluation Program, or CTEP, of the National Cancer Institute, or NCI.", "sentB": "The trial enrolled a total of 107 patients with both platinum-sensitive and platinum-resistant recurrent ovarian cancer at 67 clinical sites in the United States.", "type": 2, "words": ["<tag1>", "The", "trial", "enrolled", "107", "patients", "at", "67", "clinical", "sites", "in", "the", "United", "States", "and", "is", "being", "conducted", "by", "the", "GOG", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI.", "<tag2>", "The", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["The", "trial", "enrolled", "107", "patients", "at", "67", "clinical", "sites", "in", "the", "United", "States", "and", "is", "being", "conducted", "by", "the", "GOG", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program,", "or", "CTEP,", "of", "the", "National", "Cancer", "Institute,", "or", "NCI."], "wordsB": ["The", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s13", "idA": "908259_14_item1_p7_s1", "sentA": "Secondary endpoints in the study included safety, objective response rate (measured according to RECIST criteria) and overall survival.", "sentB": "Additional secondary endpoints in the study included safety and overall survival.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "in", "the", "study", "included", "safety,", "objective", "response", "rate", "(measured", "according", "to", "RECIST", "criteria)", "and", "overall", "survival.", "<tag2>", "Additional", "secondary", "endpoints", "in", "the", "study", "included", "safety", "and", "overall", "survival.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "in", "the", "study", "included", "safety,", "objective", "response", "rate", "(measured", "according", "to", "RECIST", "criteria)", "and", "overall", "survival."], "wordsB": ["Additional", "secondary", "endpoints", "in", "the", "study", "included", "safety", "and", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s10", "idA": "908259_14_item1_p7_s2", "sentA": "The topline results announced in March 2014 indicate that patients receiving the combination of ZYBRESTAT and AVASTIN (bevacizumab) achieved a higher objective response rate than patients receiving AVASTIN (bevacizumab) alone, but that increase was not statistically significant.", "sentB": "In the study, patients with measurable disease who received the combination of fosbretabulin and AVASTIN (bevacizumab) also achieved a higher objective response rate, or ORR, a secondary endpoint in the study, measured according to RECIST criteria.", "type": 2, "words": ["<tag1>", "The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant.", "<tag2>", "In", "the", "study,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "fosbretabulin", "and", "AVASTIN", "(bevacizumab)", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "study,", "measured", "according", "to", "RECIST", "criteria.", "<tag3>"], "wordsA": ["The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant."], "wordsB": ["In", "the", "study,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "fosbretabulin", "and", "AVASTIN", "(bevacizumab)", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "study,", "measured", "according", "to", "RECIST", "criteria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s11", "idA": "908259_14_item1_p7_s2", "sentA": "The topline results announced in March 2014 indicate that patients receiving the combination of ZYBRESTAT and AVASTIN (bevacizumab) achieved a higher objective response rate than patients receiving AVASTIN (bevacizumab) alone, but that increase was not statistically significant.", "sentB": "Although not a statistically significant result, patients receiving the combination had an ORR of 35.7% (n=42; CI 90% 23.5 ~ 49.5%) compared to 28.2 percent for patients on AVASTIN (bevacizumab) alone (n=39; CI 90% 16.7 ~ 42.3%).", "type": 2, "words": ["<tag1>", "The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant.", "<tag2>", "Although", "not", "a", "statistically", "significant", "result,", "patients", "receiving", "the", "combination", "had", "an", "ORR", "of", "35.7%", "(n=42;", "CI", "90%", "23.5", "~", "49.5%)", "compared", "to", "28.2", "percent", "for", "patients", "on", "AVASTIN", "(bevacizumab)", "alone", "(n=39;", "CI", "90%", "16.7", "~", "42.3%).", "<tag3>"], "wordsA": ["The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant."], "wordsB": ["Although", "not", "a", "statistically", "significant", "result,", "patients", "receiving", "the", "combination", "had", "an", "ORR", "of", "35.7%", "(n=42;", "CI", "90%", "23.5", "~", "49.5%)", "compared", "to", "28.2", "percent", "for", "patients", "on", "AVASTIN", "(bevacizumab)", "alone", "(n=39;", "CI", "90%", "16.7", "~", "42.3%)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s6", "idA": "908259_14_item1_p7_s2", "sentA": "The topline results announced in March 2014 indicate that patients receiving the combination of ZYBRESTAT and AVASTIN (bevacizumab) achieved a higher objective response rate than patients receiving AVASTIN (bevacizumab) alone, but that increase was not statistically significant.", "sentB": "In a post-hoc subgroup analysis presented at the IGCS conference, data showed that patients who were platinum-resistant also had a statistically significant improvement in PFS with the combination.", "type": 2, "words": ["<tag1>", "The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant.", "<tag2>", "In", "a", "post-hoc", "subgroup", "analysis", "presented", "at", "the", "IGCS", "conference,", "data", "showed", "that", "patients", "who", "were", "platinum-resistant", "also", "had", "a", "statistically", "significant", "improvement", "in", "PFS", "with", "the", "combination.", "<tag3>"], "wordsA": ["The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant."], "wordsB": ["In", "a", "post-hoc", "subgroup", "analysis", "presented", "at", "the", "IGCS", "conference,", "data", "showed", "that", "patients", "who", "were", "platinum-resistant", "also", "had", "a", "statistically", "significant", "improvement", "in", "PFS", "with", "the", "combination."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s9", "idA": "908259_14_item1_p7_s2", "sentA": "The topline results announced in March 2014 indicate that patients receiving the combination of ZYBRESTAT and AVASTIN (bevacizumab) achieved a higher objective response rate than patients receiving AVASTIN (bevacizumab) alone, but that increase was not statistically significant.", "sentB": "Also in the post-hoc subgroup analysis, while not statistically significant, among the 80 patients who were platinum-sensitive, median PFS was 7.6 months for those receiving AVASTIN (bevacizumab) and fosbretabulin compared to 6.1 months for those receiving AVASTIN (bevacizumab) alone, with a p-value of 0.139 and a hazard ratio of 0.67.", "type": 2, "words": ["<tag1>", "The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant.", "<tag2>", "Also", "in", "the", "post-hoc", "subgroup", "analysis,", "while", "not", "statistically", "significant,", "among", "the", "80", "patients", "who", "were", "platinum-sensitive,", "median", "PFS", "was", "7.6", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "and", "fosbretabulin", "compared", "to", "6.1", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67.", "<tag3>"], "wordsA": ["The", "topline", "results", "announced", "in", "March", "2014", "indicate", "that", "patients", "receiving", "the", "combination", "of", "ZYBRESTAT", "and", "AVASTIN", "(bevacizumab)", "achieved", "a", "higher", "objective", "response", "rate", "than", "patients", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "but", "that", "increase", "was", "not", "statistically", "significant."], "wordsB": ["Also", "in", "the", "post-hoc", "subgroup", "analysis,", "while", "not", "statistically", "significant,", "among", "the", "80", "patients", "who", "were", "platinum-sensitive,", "median", "PFS", "was", "7.6", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "and", "fosbretabulin", "compared", "to", "6.1", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p9_s1", "idA": "908259_14_item1_p7_s3", "sentA": "In accordance with the study protocol, all patients will continue to be followed for overall survival.", "sentB": "Patients continue to be followed for overall survival (OS).", "type": 2, "words": ["<tag1>", "In", "accordance", "with", "the", "study", "protocol,", "all", "patients", "will", "continue", "to", "be", "followed", "for", "overall", "survival.", "<tag2>", "Patients", "continue", "to", "be", "followed", "for", "overall", "survival", "(OS).", "<tag3>"], "wordsA": ["In", "accordance", "with", "the", "study", "protocol,", "all", "patients", "will", "continue", "to", "be", "followed", "for", "overall", "survival."], "wordsB": ["Patients", "continue", "to", "be", "followed", "for", "overall", "survival", "(OS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p77_s1", "idA": "908259_14_item1_p84_s1", "sentA": "ZYBRESTAT was awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers and ovarian cancer.", "sentB": "Fosbretabulin was awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers and ovarian cancer.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers", "and", "ovarian", "cancer.", "<tag2>", "Fosbretabulin", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers", "and", "ovarian", "cancer.", "<tag3>"], "wordsA": ["ZYBRESTAT", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers", "and", "ovarian", "cancer."], "wordsB": ["Fosbretabulin", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers", "and", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p77_s3", "idA": "908259_14_item1_p85_s0", "sentA": "ZYBRESTAT was also awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer and ovarian cancer.", "sentB": "Fosbretabulin was also awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer and ovarian cancer.", "type": 2, "words": ["<tag1>", "ZYBRESTAT", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer.", "<tag2>", "Fosbretabulin", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer.", "<tag3>"], "wordsA": ["ZYBRESTAT", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer."], "wordsB": ["Fosbretabulin", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p79_s0", "idA": "908259_14_item1_p86_s1", "sentA": "Even if a drug qualifies for one or more of these programs, we cannot be sure that the FDA will not later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened.", "sentB": "will not later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened.", "type": 2, "words": ["<tag1>", "Even", "if", "a", "drug", "qualifies", "for", "one", "or", "more", "of", "these", "programs,", "we", "cannot", "be", "sure", "that", "the", "FDA", "will", "not", "later", "decide", "that", "the", "drug", "no", "longer", "meets", "the", "conditions", "for", "qualification", "or", "that", "the", "time", "period", "for", "FDA", "review", "or", "approval", "will", "be", "shortened.", "<tag2>", "will", "not", "later", "decide", "that", "the", "drug", "no", "longer", "meets", "the", "conditions", "for", "qualification", "or", "that", "the", "time", "period", "for", "FDA", "review", "or", "approval", "will", "be", "shortened.", "<tag3>"], "wordsA": ["Even", "if", "a", "drug", "qualifies", "for", "one", "or", "more", "of", "these", "programs,", "we", "cannot", "be", "sure", "that", "the", "FDA", "will", "not", "later", "decide", "that", "the", "drug", "no", "longer", "meets", "the", "conditions", "for", "qualification", "or", "that", "the", "time", "period", "for", "FDA", "review", "or", "approval", "will", "be", "shortened."], "wordsB": ["will", "not", "later", "decide", "that", "the", "drug", "no", "longer", "meets", "the", "conditions", "for", "qualification", "or", "that", "the", "time", "period", "for", "FDA", "review", "or", "approval", "will", "be", "shortened."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p8_s1", "idA": "908259_14_item1_p8_s0", "sentA": "Consistent with prior clinical experience with ZYBRESTAT , patients in the combination arm experienced a higher incidence of hypertension compared to the control arm.", "sentB": "Consistent with prior clinical experience with fosbretabulin, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (10 cases for AVASTIN (bevacizumab) as compared to 17 for the combination).", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "ZYBRESTAT", ",", "patients", "in", "the", "combination", "arm", "experienced", "a", "higher", "incidence", "of", "hypertension", "compared", "to", "the", "control", "arm.", "<tag2>", "Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination).", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "ZYBRESTAT", ",", "patients", "in", "the", "combination", "arm", "experienced", "a", "higher", "incidence", "of", "hypertension", "compared", "to", "the", "control", "arm."], "wordsB": ["Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p8_s0", "idA": "908259_14_item1_p8_s1", "sentA": "All cases of hypertension were managed with antihypertensive treatments, as specified in the study protocol.", "sentB": "All adverse events in the study were manageable, with one Grade 4 event occurring in each treatment arm.", "type": 2, "words": ["<tag1>", "All", "cases", "of", "hypertension", "were", "managed", "with", "antihypertensive", "treatments,", "as", "specified", "in", "the", "study", "protocol.", "<tag2>", "All", "adverse", "events", "in", "the", "study", "were", "manageable,", "with", "one", "Grade", "4", "event", "occurring", "in", "each", "treatment", "arm.", "<tag3>"], "wordsA": ["All", "cases", "of", "hypertension", "were", "managed", "with", "antihypertensive", "treatments,", "as", "specified", "in", "the", "study", "protocol."], "wordsB": ["All", "adverse", "events", "in", "the", "study", "were", "manageable,", "with", "one", "Grade", "4", "event", "occurring", "in", "each", "treatment", "arm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p16_s5", "idA": "908259_14_item1_p8_s11", "sentA": "After the tolerability review, it was confirmed that the trial would continue to its pre-specified endpoint, which is based on progression-free survival.", "sentB": "We estimate that the trial will complete enrollment by the end of 2015.", "type": 2, "words": ["<tag1>", "After", "the", "tolerability", "review,", "it", "was", "confirmed", "that", "the", "trial", "would", "continue", "to", "its", "pre-specified", "endpoint,", "which", "is", "based", "on", "progression-free", "survival.", "<tag2>", "We", "estimate", "that", "the", "trial", "will", "complete", "enrollment", "by", "the", "end", "of", "2015.", "<tag3>"], "wordsA": ["After", "the", "tolerability", "review,", "it", "was", "confirmed", "that", "the", "trial", "would", "continue", "to", "its", "pre-specified", "endpoint,", "which", "is", "based", "on", "progression-free", "survival."], "wordsB": ["We", "estimate", "that", "the", "trial", "will", "complete", "enrollment", "by", "the", "end", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p34_s2", "idA": "908259_14_item1_p8_s12", "sentA": "Importantly, this Phase 2 trial, also known as GOG0186I, was being supported by a variety of collaborators including Genentech / Roche, which manufactures and markets AVASTIN (bevacizumab), as well as the GOG, and its sponsor, the Cancer Therapy Evaluation Program (CTEP) of the NCI.", "sentB": "Several preclinical studies, as well as the results of the Phase 2 GOG-0186I clinical trial, have confirmed the potential of this approach.", "type": 2, "words": ["<tag1>", "Importantly,", "this", "Phase", "2", "trial,", "also", "known", "as", "GOG0186I,", "was", "being", "supported", "by", "a", "variety", "of", "collaborators", "including", "Genentech", "/", "Roche,", "which", "manufactures", "and", "markets", "AVASTIN", "(bevacizumab),", "as", "well", "as", "the", "GOG,", "and", "its", "sponsor,", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "NCI.", "<tag2>", "Several", "preclinical", "studies,", "as", "well", "as", "the", "results", "of", "the", "Phase", "2", "GOG-0186I", "clinical", "trial,", "have", "confirmed", "the", "potential", "of", "this", "approach.", "<tag3>"], "wordsA": ["Importantly,", "this", "Phase", "2", "trial,", "also", "known", "as", "GOG0186I,", "was", "being", "supported", "by", "a", "variety", "of", "collaborators", "including", "Genentech", "/", "Roche,", "which", "manufactures", "and", "markets", "AVASTIN", "(bevacizumab),", "as", "well", "as", "the", "GOG,", "and", "its", "sponsor,", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "NCI."], "wordsB": ["Several", "preclinical", "studies,", "as", "well", "as", "the", "results", "of", "the", "Phase", "2", "GOG-0186I", "clinical", "trial,", "have", "confirmed", "the", "potential", "of", "this", "approach."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p11_s2", "idA": "908259_14_item1_p8_s4", "sentA": "We believe that this combination of vascular targeting agents, without the use of cytotoxic chemotherapy agents and their often significant side effects could provide a potentially better tolerated alternative for the treatment of recurrent ovarian cancer patients.", "sentB": "The subgroup analysis in platinum-resistant patients from the GOG-0186I trial suggests that adding fosbretabulin to AVASTIN (bevacizumab) has a potentially greater effect in this difficult-to-treat patient group than for platinum-sensitive patients, and therefore we currently plan to focus our potential development pathway on platinum-resistant ovarian cancer patients.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "this", "combination", "of", "vascular", "targeting", "agents,", "without", "the", "use", "of", "cytotoxic", "chemotherapy", "agents", "and", "their", "often", "significant", "side", "effects", "could", "provide", "a", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "recurrent", "ovarian", "cancer", "patients.", "<tag2>", "The", "subgroup", "analysis", "in", "platinum-resistant", "patients", "from", "the", "GOG-0186I", "trial", "suggests", "that", "adding", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "has", "a", "potentially", "greater", "effect", "in", "this", "difficult-to-treat", "patient", "group", "than", "for", "platinum-sensitive", "patients,", "and", "therefore", "we", "currently", "plan", "to", "focus", "our", "potential", "development", "pathway", "on", "platinum-resistant", "ovarian", "cancer", "patients.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "combination", "of", "vascular", "targeting", "agents,", "without", "the", "use", "of", "cytotoxic", "chemotherapy", "agents", "and", "their", "often", "significant", "side", "effects", "could", "provide", "a", "potentially", "better", "tolerated", "alternative", "for", "the", "treatment", "of", "recurrent", "ovarian", "cancer", "patients."], "wordsB": ["The", "subgroup", "analysis", "in", "platinum-resistant", "patients", "from", "the", "GOG-0186I", "trial", "suggests", "that", "adding", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "has", "a", "potentially", "greater", "effect", "in", "this", "difficult-to-treat", "patient", "group", "than", "for", "platinum-sensitive", "patients,", "and", "therefore", "we", "currently", "plan", "to", "focus", "our", "potential", "development", "pathway", "on", "platinum-resistant", "ovarian", "cancer", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p11_s3", "idA": "908259_14_item1_p8_s8", "sentA": "An interim futility analysis of this Phase 2 trial was performed in the second quarter of 2013.", "sentB": "We are also conducting discussions regarding our development pathway in ovarian cancer with leading experts in this indication and anticipate discussions with regulatory agencies in the second quarter of 2015 to determine a possible path forward for fosbretabulin in platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "An", "interim", "futility", "analysis", "of", "this", "Phase", "2", "trial", "was", "performed", "in", "the", "second", "quarter", "of", "2013.", "<tag2>", "We", "are", "also", "conducting", "discussions", "regarding", "our", "development", "pathway", "in", "ovarian", "cancer", "with", "leading", "experts", "in", "this", "indication", "and", "anticipate", "discussions", "with", "regulatory", "agencies", "in", "the", "second", "quarter", "of", "2015", "to", "determine", "a", "possible", "path", "forward", "for", "fosbretabulin", "in", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["An", "interim", "futility", "analysis", "of", "this", "Phase", "2", "trial", "was", "performed", "in", "the", "second", "quarter", "of", "2013."], "wordsB": ["We", "are", "also", "conducting", "discussions", "regarding", "our", "development", "pathway", "in", "ovarian", "cancer", "with", "leading", "experts", "in", "this", "indication", "and", "anticipate", "discussions", "with", "regulatory", "agencies", "in", "the", "second", "quarter", "of", "2015", "to", "determine", "a", "possible", "path", "forward", "for", "fosbretabulin", "in", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p9_s4", "idA": "908259_14_item1_p8_s8", "sentA": "An interim futility analysis of this Phase 2 trial was performed in the second quarter of 2013.", "sentB": "Further analysis of this secondary endpoint will be conducted as the data matures.", "type": 2, "words": ["<tag1>", "An", "interim", "futility", "analysis", "of", "this", "Phase", "2", "trial", "was", "performed", "in", "the", "second", "quarter", "of", "2013.", "<tag2>", "Further", "analysis", "of", "this", "secondary", "endpoint", "will", "be", "conducted", "as", "the", "data", "matures.", "<tag3>"], "wordsA": ["An", "interim", "futility", "analysis", "of", "this", "Phase", "2", "trial", "was", "performed", "in", "the", "second", "quarter", "of", "2013."], "wordsB": ["Further", "analysis", "of", "this", "secondary", "endpoint", "will", "be", "conducted", "as", "the", "data", "matures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p85_s3", "idA": "908259_14_item1_p91_s3", "sentA": "Based on these requirements, the centralized procedure would be used for OXiGENE products for ATC or for ovarian cancer indications.", "sentB": "Based on these requirements, the centralized procedure would be used for our two current product candidates, fosbretabulin and OXi4503.", "type": 2, "words": ["<tag1>", "Based", "on", "these", "requirements,", "the", "centralized", "procedure", "would", "be", "used", "for", "OXiGENE", "products", "for", "ATC", "or", "for", "ovarian", "cancer", "indications.", "<tag2>", "Based", "on", "these", "requirements,", "the", "centralized", "procedure", "would", "be", "used", "for", "our", "two", "current", "product", "candidates,", "fosbretabulin", "and", "OXi4503.", "<tag3>"], "wordsA": ["Based", "on", "these", "requirements,", "the", "centralized", "procedure", "would", "be", "used", "for", "OXiGENE", "products", "for", "ATC", "or", "for", "ovarian", "cancer", "indications."], "wordsB": ["Based", "on", "these", "requirements,", "the", "centralized", "procedure", "would", "be", "used", "for", "our", "two", "current", "product", "candidates,", "fosbretabulin", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p87_s3", "idA": "908259_14_item1_p93_s3", "sentA": "We are evaluating the potential benefits of seeking approval under exceptional circumstances for the use of ZYBRESTAT in ATC.", "sentB": "We have evaluated the potential benefits of seeking approval under exceptional circumstances for the use of fosbretabulin in ATC.", "type": 2, "words": ["<tag1>", "We", "are", "evaluating", "the", "potential", "benefits", "of", "seeking", "approval", "under", "exceptional", "circumstances", "for", "the", "use", "of", "ZYBRESTAT", "in", "ATC.", "<tag2>", "We", "have", "evaluated", "the", "potential", "benefits", "of", "seeking", "approval", "under", "exceptional", "circumstances", "for", "the", "use", "of", "fosbretabulin", "in", "ATC.", "<tag3>"], "wordsA": ["We", "are", "evaluating", "the", "potential", "benefits", "of", "seeking", "approval", "under", "exceptional", "circumstances", "for", "the", "use", "of", "ZYBRESTAT", "in", "ATC."], "wordsB": ["We", "have", "evaluated", "the", "potential", "benefits", "of", "seeking", "approval", "under", "exceptional", "circumstances", "for", "the", "use", "of", "fosbretabulin", "in", "ATC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p87_s7", "idA": "908259_14_item1_p95_s2", "sentA": "As of March 17, 2014, we were the exclusive licensee, sole assignee or co-assignee of twenty-nine (29) granted U.S. patents, seven (7) pending U.S. patent applications, two (2) pending Patent Cooperation Treaty international patent applications and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "sentB": "As of March 18, 2015, we were the exclusive licensee, sole assignee or co-assignee of twenty-seven (27) granted U.S. patents, six (6) pending U.S. patent applications, and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "type": 2, "words": ["<tag1>", "As", "of", "March", "17,", "2014,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-nine", "(29)", "granted", "U.S.", "patents,", "seven", "(7)", "pending", "U.S.", "patent", "applications,", "two", "(2)", "pending", "Patent", "Cooperation", "Treaty", "international", "patent", "applications", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag2>", "As", "of", "March", "18,", "2015,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-seven", "(27)", "granted", "U.S.", "patents,", "six", "(6)", "pending", "U.S.", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag3>"], "wordsA": ["As", "of", "March", "17,", "2014,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-nine", "(29)", "granted", "U.S.", "patents,", "seven", "(7)", "pending", "U.S.", "patent", "applications,", "two", "(2)", "pending", "Patent", "Cooperation", "Treaty", "international", "patent", "applications", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "wordsB": ["As", "of", "March", "18,", "2015,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-seven", "(27)", "granted", "U.S.", "patents,", "six", "(6)", "pending", "U.S.", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p88_s0", "idA": "908259_14_item1_p95_s4", "sentA": "There can be no assurance that any of these patent applications will result in the grant of a patent either in the United States or elsewhere, or that any patents granted will be valid and enforceable, or will provide a competitive advantage or will afford protection against competitors with similar technologies.", "sentB": "patent applications will result in the grant of a patent either in the United States or elsewhere, or that any patents granted will be valid and enforceable, or will provide a competitive advantage or will afford protection against competitors with similar technologies.", "type": 2, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "any", "of", "these", "patent", "applications", "will", "result", "in", "the", "grant", "of", "a", "patent", "either", "in", "the", "United", "States", "or", "elsewhere,", "or", "that", "any", "patents", "granted", "will", "be", "valid", "and", "enforceable,", "or", "will", "provide", "a", "competitive", "advantage", "or", "will", "afford", "protection", "against", "competitors", "with", "similar", "technologies.", "<tag2>", "patent", "applications", "will", "result", "in", "the", "grant", "of", "a", "patent", "either", "in", "the", "United", "States", "or", "elsewhere,", "or", "that", "any", "patents", "granted", "will", "be", "valid", "and", "enforceable,", "or", "will", "provide", "a", "competitive", "advantage", "or", "will", "afford", "protection", "against", "competitors", "with", "similar", "technologies.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "any", "of", "these", "patent", "applications", "will", "result", "in", "the", "grant", "of", "a", "patent", "either", "in", "the", "United", "States", "or", "elsewhere,", "or", "that", "any", "patents", "granted", "will", "be", "valid", "and", "enforceable,", "or", "will", "provide", "a", "competitive", "advantage", "or", "will", "afford", "protection", "against", "competitors", "with", "similar", "technologies."], "wordsB": ["patent", "applications", "will", "result", "in", "the", "grant", "of", "a", "patent", "either", "in", "the", "United", "States", "or", "elsewhere,", "or", "that", "any", "patents", "granted", "will", "be", "valid", "and", "enforceable,", "or", "will", "provide", "a", "competitive", "advantage", "or", "will", "afford", "protection", "against", "competitors", "with", "similar", "technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p88_s3", "idA": "908259_14_item1_p95_s7", "sentA": "We consider the following U.S. patents owned by or exclusively licensed to us to be particularly important to the protection of our most advanced product candidates.", "sentB": "We consider the following U.S. patents and applications owned by or exclusively licensed to us to be particularly important to the protection of our most advanced product candidates.", "type": 2, "words": ["<tag1>", "We", "consider", "the", "following", "U.S.", "patents", "owned", "by", "or", "exclusively", "licensed", "to", "us", "to", "be", "particularly", "important", "to", "the", "protection", "of", "our", "most", "advanced", "product", "candidates.", "<tag2>", "We", "consider", "the", "following", "U.S.", "patents", "and", "applications", "owned", "by", "or", "exclusively", "licensed", "to", "us", "to", "be", "particularly", "important", "to", "the", "protection", "of", "our", "most", "advanced", "product", "candidates.", "<tag3>"], "wordsA": ["We", "consider", "the", "following", "U.S.", "patents", "owned", "by", "or", "exclusively", "licensed", "to", "us", "to", "be", "particularly", "important", "to", "the", "protection", "of", "our", "most", "advanced", "product", "candidates."], "wordsB": ["We", "consider", "the", "following", "U.S.", "patents", "and", "applications", "owned", "by", "or", "exclusively", "licensed", "to", "us", "to", "be", "particularly", "important", "to", "the", "protection", "of", "our", "most", "advanced", "product", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p89_s0", "idA": "908259_14_item1_p96_s0", "sentA": "In addition to these patents, for some of our product candidates, we have patents and/or applications that cover a particular form or composition, use for a particular indication, use as part of combination therapy or method of preparation or use, as well as other pending patent applications.", "sentB": "**** Patent filed, awaiting grant In addition to these patents, for some of our product candidates, we have patents and/or applications that cover a particular form or composition, use for a particular indication, use as part of combination therapy or method of preparation or use, as well as other pending patent applications.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications.", "<tag2>", "****", "Patent", "filed,", "awaiting", "grant", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications.", "<tag3>"], "wordsA": ["In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications."], "wordsB": ["****", "Patent", "filed,", "awaiting", "grant", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p91_s0", "idA": "908259_14_item1_p98_s0", "sentA": "The patent term restoration period is generally one-half of the time between the effective date of an investigational new drug application, or IND, and the submission date of a new drug application, or NDA, plus the time between the submission date and approval date of an NDA.", "sentB": "The patent term restoration period is generally one-half of the time between the effective date of an investigational new drug application, or IND, and the submission date of an NDA, plus the time between the submission date and approval date of an NDA.", "type": 2, "words": ["<tag1>", "The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "of", "the", "time", "between", "the", "effective", "date", "of", "an", "investigational", "new", "drug", "application,", "or", "IND,", "and", "the", "submission", "date", "of", "a", "new", "drug", "application,", "or", "NDA,", "plus", "the", "time", "between", "the", "submission", "date", "and", "approval", "date", "of", "an", "NDA.", "<tag2>", "The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "of", "the", "time", "between", "the", "effective", "date", "of", "an", "investigational", "new", "drug", "application,", "or", "IND,", "and", "the", "submission", "date", "of", "an", "NDA,", "plus", "the", "time", "between", "the", "submission", "date", "and", "approval", "date", "of", "an", "NDA.", "<tag3>"], "wordsA": ["The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "of", "the", "time", "between", "the", "effective", "date", "of", "an", "investigational", "new", "drug", "application,", "or", "IND,", "and", "the", "submission", "date", "of", "a", "new", "drug", "application,", "or", "NDA,", "plus", "the", "time", "between", "the", "submission", "date", "and", "approval", "date", "of", "an", "NDA."], "wordsB": ["The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "of", "the", "time", "between", "the", "effective", "date", "of", "an", "investigational", "new", "drug", "application,", "or", "IND,", "and", "the", "submission", "date", "of", "an", "NDA,", "plus", "the", "time", "between", "the", "submission", "date", "and", "approval", "date", "of", "an", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p11_s1", "idA": "908259_14_item1_p9_s0", "sentA": "Potential Development Pathway in Ovarian Cancer: ZYBRESTAT in combination with AVASTIN (bevacizumab)-Pivotal Trial In light of the top line results from the GOG186I trial which demonstrated a statistically significant increase in progression-free survival from the combination of bevacizumab plus ZYBRESTAT as compared to bevacizumab alone, we are currently evaluating the potential development pathway for ZYBRESTAT in ovarian cancer.", "sentB": "Our current clinical development plan in ovarian cancer is as follows: Fosbretabulin in combination with AVASTIN (bevacizumab) Potential Future Development In light of the results from the GOG-0186I trial, which demonstrated a prospectively defined statistically significant increase in progression-free survival from the combination of AVASTIN (bevacizumab) plus fosbretabulin as compared to AVASTIN (bevacizumab) alone, we are currently evaluating the potential development pathway, including the potential for a pivotal phase 3 clinical trial, for fosbretabulin in ovarian cancer.", "type": 2, "words": ["<tag1>", "Potential", "Development", "Pathway", "in", "Ovarian", "Cancer:", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)-Pivotal", "Trial", "In", "light", "of", "the", "top", "line", "results", "from", "the", "GOG186I", "trial", "which", "demonstrated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "from", "the", "combination", "of", "bevacizumab", "plus", "ZYBRESTAT", "as", "compared", "to", "bevacizumab", "alone,", "we", "are", "currently", "evaluating", "the", "potential", "development", "pathway", "for", "ZYBRESTAT", "in", "ovarian", "cancer.", "<tag2>", "Our", "current", "clinical", "development", "plan", "in", "ovarian", "cancer", "is", "as", "follows:", "Fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "Potential", "Future", "Development", "In", "light", "of", "the", "results", "from", "the", "GOG-0186I", "trial,", "which", "demonstrated", "a", "prospectively", "defined", "statistically", "significant", "increase", "in", "progression-free", "survival", "from", "the", "combination", "of", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin", "as", "compared", "to", "AVASTIN", "(bevacizumab)", "alone,", "we", "are", "currently", "evaluating", "the", "potential", "development", "pathway,", "including", "the", "potential", "for", "a", "pivotal", "phase", "3", "clinical", "trial,", "for", "fosbretabulin", "in", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Potential", "Development", "Pathway", "in", "Ovarian", "Cancer:", "ZYBRESTAT", "in", "combination", "with", "AVASTIN", "(bevacizumab)-Pivotal", "Trial", "In", "light", "of", "the", "top", "line", "results", "from", "the", "GOG186I", "trial", "which", "demonstrated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "from", "the", "combination", "of", "bevacizumab", "plus", "ZYBRESTAT", "as", "compared", "to", "bevacizumab", "alone,", "we", "are", "currently", "evaluating", "the", "potential", "development", "pathway", "for", "ZYBRESTAT", "in", "ovarian", "cancer."], "wordsB": ["Our", "current", "clinical", "development", "plan", "in", "ovarian", "cancer", "is", "as", "follows:", "Fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "Potential", "Future", "Development", "In", "light", "of", "the", "results", "from", "the", "GOG-0186I", "trial,", "which", "demonstrated", "a", "prospectively", "defined", "statistically", "significant", "increase", "in", "progression-free", "survival", "from", "the", "combination", "of", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin", "as", "compared", "to", "AVASTIN", "(bevacizumab)", "alone,", "we", "are", "currently", "evaluating", "the", "potential", "development", "pathway,", "including", "the", "potential", "for", "a", "pivotal", "phase", "3", "clinical", "trial,", "for", "fosbretabulin", "in", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p0_s0", "idA": "908259_15_item1_p0_s0", "sentA": "We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "Business Overview We are a biopharmaceutical company focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "type": 2, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p7_s1", "idA": "908259_15_item1_p0_s0", "sentA": "We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "Our primary focus for 2016 will be the development of CA4P for platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "Our", "primary", "focus", "for", "2016", "will", "be", "the", "development", "of", "CA4P", "for", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["Our", "primary", "focus", "for", "2016", "will", "be", "the", "development", "of", "CA4P", "for", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p2_s7", "idA": "908259_15_item1_p0_s1", "sentA": "We have two clinical stage product candidates that are currently being developed in three potential oncology indications.", "sentB": "We are currently developing two clinical stage investigational drugs, both VDAs CA4P and OXi4503.", "type": 2, "words": ["<tag1>", "We", "have", "two", "clinical", "stage", "product", "candidates", "that", "are", "currently", "being", "developed", "in", "three", "potential", "oncology", "indications.", "<tag2>", "We", "are", "currently", "developing", "two", "clinical", "stage", "investigational", "drugs,", "both", "VDAs", "CA4P", "and", "OXi4503.", "<tag3>"], "wordsA": ["We", "have", "two", "clinical", "stage", "product", "candidates", "that", "are", "currently", "being", "developed", "in", "three", "potential", "oncology", "indications."], "wordsB": ["We", "are", "currently", "developing", "two", "clinical", "stage", "investigational", "drugs,", "both", "VDAs", "CA4P", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p3_s4", "idA": "908259_15_item1_p0_s2", "sentA": "Our lead compound, fosbretabulin tromethamine, or fosbretabulin, is being tested in two indications, recurrent ovarian cancer and gastrointestinal neuroendocrine tumors, or GI-NETs, and our second compound, OXi4503, is currently being tested in patients with relapsed or refractory acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).", "sentB": "Our second compound, OXi4503, is being studied in combination with cytarabine in a phase 1/2 clinical trial in the United States in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).", "type": 2, "words": ["<tag1>", "Our", "lead", "compound,", "fosbretabulin", "tromethamine,", "or", "fosbretabulin,", "is", "being", "tested", "in", "two", "indications,", "recurrent", "ovarian", "cancer", "and", "gastrointestinal", "neuroendocrine", "tumors,", "or", "GI-NETs,", "and", "our", "second", "compound,", "OXi4503,", "is", "currently", "being", "tested", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myelogenous", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag2>", "Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "a", "phase", "1/2", "clinical", "trial", "in", "the", "United", "States", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag3>"], "wordsA": ["Our", "lead", "compound,", "fosbretabulin", "tromethamine,", "or", "fosbretabulin,", "is", "being", "tested", "in", "two", "indications,", "recurrent", "ovarian", "cancer", "and", "gastrointestinal", "neuroendocrine", "tumors,", "or", "GI-NETs,", "and", "our", "second", "compound,", "OXi4503,", "is", "currently", "being", "tested", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myelogenous", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "wordsB": ["Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "a", "phase", "1/2", "clinical", "trial", "in", "the", "United", "States", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p102_s0", "idA": "908259_15_item1_p0_s3", "sentA": "We have been granted orphan drug designation for fosbretabulin in the treatment of ovarian cancer in the United States and the European Union, and for OXi4503 in the treatment of AML in the United States.", "sentB": "Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States.", "<tag2>", "Historically,", "products", "launched", "in", "the", "European", "Union", "do", "not", "follow", "price", "structures", "of", "the", "United", "States", "and", "generally", "tend", "to", "be", "significantly", "lower.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States."], "wordsB": ["Historically,", "products", "launched", "in", "the", "European", "Union", "do", "not", "follow", "price", "structures", "of", "the", "United", "States", "and", "generally", "tend", "to", "be", "significantly", "lower."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s6", "idA": "908259_15_item1_p0_s3", "sentA": "We have been granted orphan drug designation for fosbretabulin in the treatment of ovarian cancer in the United States and the European Union, and for OXi4503 in the treatment of AML in the United States.", "sentB": "Pazopanib is also approved for ovarian and other cancers in the European Union, and was initially developed by GlaxoSmithKline, then sold to Novartis in 2015.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States.", "<tag2>", "Pazopanib", "is", "also", "approved", "for", "ovarian", "and", "other", "cancers", "in", "the", "European", "Union,", "and", "was", "initially", "developed", "by", "GlaxoSmithKline,", "then", "sold", "to", "Novartis", "in", "2015.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States."], "wordsB": ["Pazopanib", "is", "also", "approved", "for", "ovarian", "and", "other", "cancers", "in", "the", "European", "Union,", "and", "was", "initially", "developed", "by", "GlaxoSmithKline,", "then", "sold", "to", "Novartis", "in", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p25_s0", "idA": "908259_15_item1_p0_s3", "sentA": "We have been granted orphan drug designation for fosbretabulin in the treatment of ovarian cancer in the United States and the European Union, and for OXi4503 in the treatment of AML in the United States.", "sentB": "We have been granted orphan drug designation for CA4P for the treatment of neuroendocrine tumors in the United States and the European Union.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States.", "<tag2>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States."], "wordsB": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "the", "United", "States", "and", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p3_s5", "idA": "908259_15_item1_p0_s3", "sentA": "We have been granted orphan drug designation for fosbretabulin in the treatment of ovarian cancer in the United States and the European Union, and for OXi4503 in the treatment of AML in the United States.", "sentB": "We have been granted orphan drug designation for CA4P for the treatment of ovarian cancer in the United States and the European Union, and for OXi4503 for the treatment of AML in the United States and the European Union.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States.", "<tag2>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "for", "the", "treatment", "of", "AML", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "in", "the", "treatment", "of", "AML", "in", "the", "United", "States."], "wordsB": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "for", "the", "treatment", "of", "AML", "in", "the", "United", "States", "and", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p3_s6", "idA": "908259_15_item1_p0_s4", "sentA": "To date, we have observed fosbretabulin to be well tolerated in over 450 patients and to have clinical activity in a variety of indications including ovarian cancer.", "sentB": "To date, we have observed CA4P to be well tolerated in over 450 patients and to have clinical activity in a variety of indications in addition to ovarian cancer.", "type": 2, "words": ["<tag1>", "To", "date,", "we", "have", "observed", "fosbretabulin", "to", "be", "well", "tolerated", "in", "over", "450", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer.", "<tag2>", "To", "date,", "we", "have", "observed", "CA4P", "to", "be", "well", "tolerated", "in", "over", "450", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "in", "addition", "to", "ovarian", "cancer.", "<tag3>"], "wordsA": ["To", "date,", "we", "have", "observed", "fosbretabulin", "to", "be", "well", "tolerated", "in", "over", "450", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer."], "wordsB": ["To", "date,", "we", "have", "observed", "CA4P", "to", "be", "well", "tolerated", "in", "over", "450", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "in", "addition", "to", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p3_s1", "idA": "908259_15_item1_p0_s6", "sentA": "In the United States and Europe, we are pursuing collaborations with established pharmaceutical companies with products whose efficacy we believe can be enhanced by the addition of our lead product candidate, fosbretabulin, and with non-profit research organizations such as The Christie Hospital NHS Foundation Trust (UK), an international leader in cancer research and development, and the Gynecologic Oncology Group, or GOG, now part of NRG Oncology (NCI), an organization dedicated to clinical research in the field of gynecologic cancer, for the treatment of advanced ovarian cancer.", "sentB": "The largest clinical trial of CA4P conducted to date was a recent phase 2 clinical trial in recurrent ovarian cancer sponsored by the Gynecologic Oncology Group, or GOG, which was completed in 2014 and met its primary endpoint by demonstrating an improvement in progression-free survival for the patients who received CA4P. This trial, referred to as GOG-0186I, compared treatment with CA4P plus bevacizumab to treatment with bevacizumab alone.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States", "and", "Europe,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "fosbretabulin,", "and", "with", "non-profit", "research", "organizations", "such", "as", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "(UK),", "an", "international", "leader", "in", "cancer", "research", "and", "development,", "and", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "now", "part", "of", "NRG", "Oncology", "(NCI),", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer.", "<tag2>", "The", "largest", "clinical", "trial", "of", "CA4P", "conducted", "to", "date", "was", "a", "recent", "phase", "2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "sponsored", "by", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "which", "was", "completed", "in", "2014", "and", "met", "its", "primary", "endpoint", "by", "demonstrating", "an", "improvement", "in", "progression-free", "survival", "for", "the", "patients", "who", "received", "CA4P.", "This", "trial,", "referred", "to", "as", "GOG-0186I,", "compared", "treatment", "with", "CA4P", "plus", "bevacizumab", "to", "treatment", "with", "bevacizumab", "alone.", "<tag3>"], "wordsA": ["In", "the", "United", "States", "and", "Europe,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "fosbretabulin,", "and", "with", "non-profit", "research", "organizations", "such", "as", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "(UK),", "an", "international", "leader", "in", "cancer", "research", "and", "development,", "and", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "now", "part", "of", "NRG", "Oncology", "(NCI),", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer."], "wordsB": ["The", "largest", "clinical", "trial", "of", "CA4P", "conducted", "to", "date", "was", "a", "recent", "phase", "2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "sponsored", "by", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "which", "was", "completed", "in", "2014", "and", "met", "its", "primary", "endpoint", "by", "demonstrating", "an", "improvement", "in", "progression-free", "survival", "for", "the", "patients", "who", "received", "CA4P.", "This", "trial,", "referred", "to", "as", "GOG-0186I,", "compared", "treatment", "with", "CA4P", "plus", "bevacizumab", "to", "treatment", "with", "bevacizumab", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p17_s0", "idA": "908259_15_item1_p10_s0", "sentA": "AVASTIN (bevacizumab) is approved in the US in combination with chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) for the treatment of women with platinum-resistant recurrent ovarian cancer, based on results from the Phase III AURELIA trial, the approval of which was based on progression free survival.", "sentB": "The approval of bevacizumab in the U.S. in combination with chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) for the treatment of women with platinum-resistant ovarian cancer was based on results from the phase 3 AURELIA trial, which had a primary endpoint of PFS.", "type": 2, "words": ["<tag1>", "AVASTIN", "(bevacizumab)", "is", "approved", "in", "the", "US", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "recurrent", "ovarian", "cancer,", "based", "on", "results", "from", "the", "Phase", "III", "AURELIA", "trial,", "the", "approval", "of", "which", "was", "based", "on", "progression", "free", "survival.", "<tag2>", "The", "approval", "of", "bevacizumab", "in", "the", "U.S.", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "ovarian", "cancer", "was", "based", "on", "results", "from", "the", "phase", "3", "AURELIA", "trial,", "which", "had", "a", "primary", "endpoint", "of", "PFS.", "<tag3>"], "wordsA": ["AVASTIN", "(bevacizumab)", "is", "approved", "in", "the", "US", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "recurrent", "ovarian", "cancer,", "based", "on", "results", "from", "the", "Phase", "III", "AURELIA", "trial,", "the", "approval", "of", "which", "was", "based", "on", "progression", "free", "survival."], "wordsB": ["The", "approval", "of", "bevacizumab", "in", "the", "U.S.", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "ovarian", "cancer", "was", "based", "on", "results", "from", "the", "phase", "3", "AURELIA", "trial,", "which", "had", "a", "primary", "endpoint", "of", "PFS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p17_s1", "idA": "908259_15_item1_p11_s0", "sentA": "AVASTIN (bevacizumab) is also approved in the EU in combination with different chemotherapy regimens for platinum-resistant and platinum-sensitive ovarian cancer, the approval of which was based on progression free survival.", "sentB": "Bevacizumab is also approved in the EU in combination with different chemotherapy regimens for platinum-resistant and platinum-sensitive ovarian cancer, and the EU approvals were also based on PFS.", "type": 2, "words": ["<tag1>", "AVASTIN", "(bevacizumab)", "is", "also", "approved", "in", "the", "EU", "in", "combination", "with", "different", "chemotherapy", "regimens", "for", "platinum-resistant", "and", "platinum-sensitive", "ovarian", "cancer,", "the", "approval", "of", "which", "was", "based", "on", "progression", "free", "survival.", "<tag2>", "Bevacizumab", "is", "also", "approved", "in", "the", "EU", "in", "combination", "with", "different", "chemotherapy", "regimens", "for", "platinum-resistant", "and", "platinum-sensitive", "ovarian", "cancer,", "and", "the", "EU", "approvals", "were", "also", "based", "on", "PFS.", "<tag3>"], "wordsA": ["AVASTIN", "(bevacizumab)", "is", "also", "approved", "in", "the", "EU", "in", "combination", "with", "different", "chemotherapy", "regimens", "for", "platinum-resistant", "and", "platinum-sensitive", "ovarian", "cancer,", "the", "approval", "of", "which", "was", "based", "on", "progression", "free", "survival."], "wordsB": ["Bevacizumab", "is", "also", "approved", "in", "the", "EU", "in", "combination", "with", "different", "chemotherapy", "regimens", "for", "platinum-resistant", "and", "platinum-sensitive", "ovarian", "cancer,", "and", "the", "EU", "approvals", "were", "also", "based", "on", "PFS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s5", "idA": "908259_15_item1_p12_s0", "sentA": "Fosbretabulin in combination with VOTRIENT (pazopanib) GlaxoSmithKline (GSK) s VOTRIENT (pazopanib) is an anti-angiogenic oral tyrosine kinase inhibitor that is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS), with compelling early clinical data in the treatment of relapsed ovarian cancer.", "sentB": "CA4P in Combination with Pazopanib Ongoing Phase 1b Clinical Trial moving into Phase 2 Pazopanib is an anti-angiogenic oral tyrosine kinase inhibitor that is currently approved by the FDA for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS).", "type": 2, "words": ["<tag1>", "Fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer.", "<tag2>", "CA4P", "in", "Combination", "with", "Pazopanib", "Ongoing", "Phase", "1b", "Clinical", "Trial", "moving", "into", "Phase", "2", "Pazopanib", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "FDA", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS).", "<tag3>"], "wordsA": ["Fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "GlaxoSmithKline", "(GSK)", "s", "VOTRIENT", "(pazopanib)", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS),", "with", "compelling", "early", "clinical", "data", "in", "the", "treatment", "of", "relapsed", "ovarian", "cancer."], "wordsB": ["CA4P", "in", "Combination", "with", "Pazopanib", "Ongoing", "Phase", "1b", "Clinical", "Trial", "moving", "into", "Phase", "2", "Pazopanib", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "FDA", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p18_s0", "idA": "908259_15_item1_p12_s1", "sentA": "We believe that using fosbretabulin in combination with VOTRIENT (pazopanib) may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "The current standard of care for platinum-resistant ovarian cancer is treatment with bevacizumab and chemotherapy.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s7", "idA": "908259_15_item1_p12_s1", "sentA": "We believe that using fosbretabulin in combination with VOTRIENT (pazopanib) may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "We believe that using CA4P in combination with pazopanib may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "We", "believe", "that", "using", "CA4P", "in", "combination", "with", "pazopanib", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "VOTRIENT", "(pazopanib)", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["We", "believe", "that", "using", "CA4P", "in", "combination", "with", "pazopanib", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s8", "idA": "908259_15_item1_p12_s2", "sentA": "In October 2014, the first patient was enrolled in a Phase 1b/2 trial of VOTRIENT (pazopanib) with and without fosbretabulin, in advanced recurrent ovarian cancer.", "sentB": "In October 2014, the first patient was enrolled in a phase 1b/2 trial of pazopanib with and without CA4P in advanced recurrent ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "Phase", "1b/2", "trial", "of", "VOTRIENT", "(pazopanib)", "with", "and", "without", "fosbretabulin,", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag2>", "In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "CA4P", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "Phase", "1b/2", "trial", "of", "VOTRIENT", "(pazopanib)", "with", "and", "without", "fosbretabulin,", "in", "advanced", "recurrent", "ovarian", "cancer."], "wordsB": ["In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "CA4P", "in", "advanced", "recurrent", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p20_s0", "idA": "908259_15_item1_p12_s3", "sentA": "The study is sponsored by The Christie Hospital NHS Foundation Trust and coordinated by the Manchester Academic Health Science Centre, Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).", "sentB": "Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).", "type": 2, "words": ["<tag1>", "The", "study", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "and", "coordinated", "by", "the", "Manchester", "Academic", "Health", "Science", "Centre,", "Trials", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust).", "<tag2>", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust).", "<tag3>"], "wordsA": ["The", "study", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "and", "coordinated", "by", "the", "Manchester", "Academic", "Health", "Science", "Centre,", "Trials", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust)."], "wordsB": ["Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p3_s3", "idA": "908259_15_item1_p12_s3", "sentA": "The study is sponsored by The Christie Hospital NHS Foundation Trust and coordinated by the Manchester Academic Health Science Centre, Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).", "sentB": "CA4P is also being studied in combination with pazopanib (Votrient ) in an on-going phase 1b/2 clinical trial in recurrent ovarian cancer that is sponsored by The Christie Hospital NHS Foundation Trust in the United Kingdom.", "type": 2, "words": ["<tag1>", "The", "study", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "and", "coordinated", "by", "the", "Manchester", "Academic", "Health", "Science", "Centre,", "Trials", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust).", "<tag2>", "CA4P", "is", "also", "being", "studied", "in", "combination", "with", "pazopanib", "(Votrient", ")", "in", "an", "on-going", "phase", "1b/2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "that", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "in", "the", "United", "Kingdom.", "<tag3>"], "wordsA": ["The", "study", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "and", "coordinated", "by", "the", "Manchester", "Academic", "Health", "Science", "Centre,", "Trials", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust)."], "wordsB": ["CA4P", "is", "also", "being", "studied", "in", "combination", "with", "pazopanib", "(Votrient", ")", "in", "an", "on-going", "phase", "1b/2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "that", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "in", "the", "United", "Kingdom."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p21_s0", "idA": "908259_15_item1_p12_s4", "sentA": "The trial design consists of a Phase 1b dose escalation portion with the combination of VOTRIENT (pazopanib) and fosbretabulin and a randomized Phase 2 portion comparing VOTRIENT (pazopanib) alone versus VOTRIENT (pazopanib) plus fosbretabulin in patients with relapsed ovarian cancer.", "sentB": "The trial design consists of a phase 1b dose escalation portion with the combination of pazopanib and CA4P, which has been completed, and then a randomized phase 2 portion comparing pazopanib alone versus pazopanib plus CA4P in patients with relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "trial", "design", "consists", "of", "a", "Phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "VOTRIENT", "(pazopanib)", "and", "fosbretabulin", "and", "a", "randomized", "Phase", "2", "portion", "comparing", "VOTRIENT", "(pazopanib)", "alone", "versus", "VOTRIENT", "(pazopanib)", "plus", "fosbretabulin", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag2>", "The", "trial", "design", "consists", "of", "a", "phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "pazopanib", "and", "CA4P,", "which", "has", "been", "completed,", "and", "then", "a", "randomized", "phase", "2", "portion", "comparing", "pazopanib", "alone", "versus", "pazopanib", "plus", "CA4P", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "trial", "design", "consists", "of", "a", "Phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "VOTRIENT", "(pazopanib)", "and", "fosbretabulin", "and", "a", "randomized", "Phase", "2", "portion", "comparing", "VOTRIENT", "(pazopanib)", "alone", "versus", "VOTRIENT", "(pazopanib)", "plus", "fosbretabulin", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "wordsB": ["The", "trial", "design", "consists", "of", "a", "phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "pazopanib", "and", "CA4P,", "which", "has", "been", "completed,", "and", "then", "a", "randomized", "phase", "2", "portion", "comparing", "pazopanib", "alone", "versus", "pazopanib", "plus", "CA4P", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p21_s1", "idA": "908259_15_item1_p12_s5", "sentA": "The study is expected to enroll approximately 128 patients at sites in the U.K.", "sentB": "The clinical trial is expected to enroll approximately 128 patients at sites in the U.K.", "type": 2, "words": ["<tag1>", "The", "study", "is", "expected", "to", "enroll", "approximately", "128", "patients", "at", "sites", "in", "the", "U.K.", "<tag2>", "The", "clinical", "trial", "is", "expected", "to", "enroll", "approximately", "128", "patients", "at", "sites", "in", "the", "U.K.", "<tag3>"], "wordsA": ["The", "study", "is", "expected", "to", "enroll", "approximately", "128", "patients", "at", "sites", "in", "the", "U.K."], "wordsB": ["The", "clinical", "trial", "is", "expected", "to", "enroll", "approximately", "128", "patients", "at", "sites", "in", "the", "U.K."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p21_s3", "idA": "908259_15_item1_p12_s5", "sentA": "The study is expected to enroll approximately 128 patients at sites in the U.K.", "sentB": "The phase 2 portion is expected to begin enrolling patients in the second quarter of 2016.", "type": 2, "words": ["<tag1>", "The", "study", "is", "expected", "to", "enroll", "approximately", "128", "patients", "at", "sites", "in", "the", "U.K.", "<tag2>", "The", "phase", "2", "portion", "is", "expected", "to", "begin", "enrolling", "patients", "in", "the", "second", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["The", "study", "is", "expected", "to", "enroll", "approximately", "128", "patients", "at", "sites", "in", "the", "U.K."], "wordsB": ["The", "phase", "2", "portion", "is", "expected", "to", "begin", "enrolling", "patients", "in", "the", "second", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s2", "idA": "908259_15_item1_p12_s6", "sentA": "The primary endpoint of the trial is progression-free survival, and secondary endpoints include safety, overall survival, objective response rate, and CA125 response rate.", "sentB": "The primary endpoint of our phase 2/3 clinical trial will be PFS, and we will also evaluate overall response rate, overall survival and other parameters.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "trial", "is", "progression-free", "survival,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "our", "phase", "2/3", "clinical", "trial", "will", "be", "PFS,", "and", "we", "will", "also", "evaluate", "overall", "response", "rate,", "overall", "survival", "and", "other", "parameters.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "trial", "is", "progression-free", "survival,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "our", "phase", "2/3", "clinical", "trial", "will", "be", "PFS,", "and", "we", "will", "also", "evaluate", "overall", "response", "rate,", "overall", "survival", "and", "other", "parameters."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p21_s2", "idA": "908259_15_item1_p12_s6", "sentA": "The primary endpoint of the trial is progression-free survival, and secondary endpoints include safety, overall survival, objective response rate, and CA125 response rate.", "sentB": "The primary endpoint of the trial is PFS, and secondary endpoints include safety, overall survival, objective response rate, and CA125 response rate.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "trial", "is", "progression-free", "survival,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "the", "trial", "is", "PFS,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "trial", "is", "progression-free", "survival,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "the", "trial", "is", "PFS,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p22_s1", "idA": "908259_15_item1_p13_s1", "sentA": "Since patients with NETs can have prolonged survival rates of over 5 years, it is estimated that the prevalence is much higher, approximating 100,000 people in the US.", "sentB": "Since patients with NETs can have prolonged survival rates of over 5 years, it is estimated that the overall prevalence is much higher, approximating 100,000 patients in the U.S.", "type": 2, "words": ["<tag1>", "Since", "patients", "with", "NETs", "can", "have", "prolonged", "survival", "rates", "of", "over", "5", "years,", "it", "is", "estimated", "that", "the", "prevalence", "is", "much", "higher,", "approximating", "100,000", "people", "in", "the", "US.", "<tag2>", "Since", "patients", "with", "NETs", "can", "have", "prolonged", "survival", "rates", "of", "over", "5", "years,", "it", "is", "estimated", "that", "the", "overall", "prevalence", "is", "much", "higher,", "approximating", "100,000", "patients", "in", "the", "U.S.", "<tag3>"], "wordsA": ["Since", "patients", "with", "NETs", "can", "have", "prolonged", "survival", "rates", "of", "over", "5", "years,", "it", "is", "estimated", "that", "the", "prevalence", "is", "much", "higher,", "approximating", "100,000", "people", "in", "the", "US."], "wordsB": ["Since", "patients", "with", "NETs", "can", "have", "prolonged", "survival", "rates", "of", "over", "5", "years,", "it", "is", "estimated", "that", "the", "overall", "prevalence", "is", "much", "higher,", "approximating", "100,000", "patients", "in", "the", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p23_s0", "idA": "908259_15_item1_p14_s0", "sentA": "These tumors can produce increased amounts of materials including peptides, many of which are biologically active and can, in around 10 -20% of patients, result in debilitating symptoms including flushing, diarrhea, weight loss and, less frequently, bronchoconstriction and heart failure.", "sentB": "These tumors can produce increased amounts of vasoactive substances including hormones, many of which are biologically active and can result in debilitating symptoms including flushing, diarrhea, weight loss and, less frequently, bronchoconstriction and heart failure.", "type": 2, "words": ["<tag1>", "These", "tumors", "can", "produce", "increased", "amounts", "of", "materials", "including", "peptides,", "many", "of", "which", "are", "biologically", "active", "and", "can,", "in", "around", "10", "-20%", "of", "patients,", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag2>", "These", "tumors", "can", "produce", "increased", "amounts", "of", "vasoactive", "substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag3>"], "wordsA": ["These", "tumors", "can", "produce", "increased", "amounts", "of", "materials", "including", "peptides,", "many", "of", "which", "are", "biologically", "active", "and", "can,", "in", "around", "10", "-20%", "of", "patients,", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "wordsB": ["These", "tumors", "can", "produce", "increased", "amounts", "of", "vasoactive", "substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p23_s1", "idA": "908259_15_item1_p16_s0", "sentA": "It is our belief, based on the available preclinical data, that by reducing blood flow to the tumors using fosbretabulin, we may be able to reduce the production of tumor-derived materials, including these biologically active substances.", "sentB": "It is our belief, based on the available preclinical data, that by reducing blood flow to these highly vascular tumors using CA4P, we may be able to reduce the production of tumor-derived substances, including the biologically active hormones.", "type": 2, "words": ["<tag1>", "It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "the", "tumors", "using", "fosbretabulin,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "materials,", "including", "these", "biologically", "active", "substances.", "<tag2>", "It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "these", "highly", "vascular", "tumors", "using", "CA4P,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "substances,", "including", "the", "biologically", "active", "hormones.", "<tag3>"], "wordsA": ["It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "the", "tumors", "using", "fosbretabulin,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "materials,", "including", "these", "biologically", "active", "substances."], "wordsB": ["It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "these", "highly", "vascular", "tumors", "using", "CA4P,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "substances,", "including", "the", "biologically", "active", "hormones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p24_s0", "idA": "908259_15_item1_p16_s2", "sentA": "In September 2014, we enrolled the first patient in a Phase 2 monotherapy clinical trial of fosbretabulin in patients with GI-NETs with elevated biomarkers.", "sentB": "We are completing a phase 2 monotherapy clinical trial of CA4P in 18 patients with gastrointestinal or pancreatic NETs and elevated biomarkers.", "type": 2, "words": ["<tag1>", "In", "September", "2014,", "we", "enrolled", "the", "first", "patient", "in", "a", "Phase", "2", "monotherapy", "clinical", "trial", "of", "fosbretabulin", "in", "patients", "with", "GI-NETs", "with", "elevated", "biomarkers.", "<tag2>", "We", "are", "completing", "a", "phase", "2", "monotherapy", "clinical", "trial", "of", "CA4P", "in", "18", "patients", "with", "gastrointestinal", "or", "pancreatic", "NETs", "and", "elevated", "biomarkers.", "<tag3>"], "wordsA": ["In", "September", "2014,", "we", "enrolled", "the", "first", "patient", "in", "a", "Phase", "2", "monotherapy", "clinical", "trial", "of", "fosbretabulin", "in", "patients", "with", "GI-NETs", "with", "elevated", "biomarkers."], "wordsB": ["We", "are", "completing", "a", "phase", "2", "monotherapy", "clinical", "trial", "of", "CA4P", "in", "18", "patients", "with", "gastrointestinal", "or", "pancreatic", "NETs", "and", "elevated", "biomarkers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s0", "idA": "908259_15_item1_p16_s3", "sentA": "This trial is designed to enroll 20 GI-NET patients with increased biomarker levels at five sites in the United States.", "sentB": "The clinical trial is designed with two stages in the first stage we plan to enroll up to 80 patients and conduct regular interim analyses in order to verify efficacy and confirm powering assumptions for the second stage.", "type": 2, "words": ["<tag1>", "This", "trial", "is", "designed", "to", "enroll", "20", "GI-NET", "patients", "with", "increased", "biomarker", "levels", "at", "five", "sites", "in", "the", "United", "States.", "<tag2>", "The", "clinical", "trial", "is", "designed", "with", "two", "stages", "in", "the", "first", "stage", "we", "plan", "to", "enroll", "up", "to", "80", "patients", "and", "conduct", "regular", "interim", "analyses", "in", "order", "to", "verify", "efficacy", "and", "confirm", "powering", "assumptions", "for", "the", "second", "stage.", "<tag3>"], "wordsA": ["This", "trial", "is", "designed", "to", "enroll", "20", "GI-NET", "patients", "with", "increased", "biomarker", "levels", "at", "five", "sites", "in", "the", "United", "States."], "wordsB": ["The", "clinical", "trial", "is", "designed", "with", "two", "stages", "in", "the", "first", "stage", "we", "plan", "to", "enroll", "up", "to", "80", "patients", "and", "conduct", "regular", "interim", "analyses", "in", "order", "to", "verify", "efficacy", "and", "confirm", "powering", "assumptions", "for", "the", "second", "stage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p24_s1", "idA": "908259_15_item1_p16_s4", "sentA": "The primary endpoint of the trial is a reduction in biomarkers and secondary endpoints include symptom control and changes in quality of life as assessed by validated measures.", "sentB": "The primary endpoint of the trial is a reduction in biomarkers, and secondary endpoints include symptom control and changes in quality of life as assessed by validated measures.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "trial", "is", "a", "reduction", "in", "biomarkers", "and", "secondary", "endpoints", "include", "symptom", "control", "and", "changes", "in", "quality", "of", "life", "as", "assessed", "by", "validated", "measures.", "<tag2>", "The", "primary", "endpoint", "of", "the", "trial", "is", "a", "reduction", "in", "biomarkers,", "and", "secondary", "endpoints", "include", "symptom", "control", "and", "changes", "in", "quality", "of", "life", "as", "assessed", "by", "validated", "measures.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "trial", "is", "a", "reduction", "in", "biomarkers", "and", "secondary", "endpoints", "include", "symptom", "control", "and", "changes", "in", "quality", "of", "life", "as", "assessed", "by", "validated", "measures."], "wordsB": ["The", "primary", "endpoint", "of", "the", "trial", "is", "a", "reduction", "in", "biomarkers,", "and", "secondary", "endpoints", "include", "symptom", "control", "and", "changes", "in", "quality", "of", "life", "as", "assessed", "by", "validated", "measures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p24_s2", "idA": "908259_15_item1_p16_s5", "sentA": "We estimate that the trial will complete enrollment by the end of 2015.", "sentB": "We estimate that initial data from the trial will be available by the third quarter of 2016.", "type": 2, "words": ["<tag1>", "We", "estimate", "that", "the", "trial", "will", "complete", "enrollment", "by", "the", "end", "of", "2015.", "<tag2>", "We", "estimate", "that", "initial", "data", "from", "the", "trial", "will", "be", "available", "by", "the", "third", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["We", "estimate", "that", "the", "trial", "will", "complete", "enrollment", "by", "the", "end", "of", "2015."], "wordsB": ["We", "estimate", "that", "initial", "data", "from", "the", "trial", "will", "be", "available", "by", "the", "third", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p4_s0", "idA": "908259_15_item1_p1_s0", "sentA": "Fosbretabulin Development Program Fosbretabulin is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in most solid tumors and causes them to swell, obstructing the flow of blood and starving the tumor of vital nutrients including oxygen.", "sentB": "CA4P Development Program CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in most solid tumors.", "type": 2, "words": ["<tag1>", "Fosbretabulin", "Development", "Program", "Fosbretabulin", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen.", "<tag2>", "CA4P", "Development", "Program", "CA4P", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors.", "<tag3>"], "wordsA": ["Fosbretabulin", "Development", "Program", "Fosbretabulin", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen."], "wordsB": ["CA4P", "Development", "Program", "CA4P", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p5_s0", "idA": "908259_15_item1_p1_s0", "sentA": "Fosbretabulin Development Program Fosbretabulin is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in most solid tumors and causes them to swell, obstructing the flow of blood and starving the tumor of vital nutrients including oxygen.", "sentB": "which obstructs the flow of blood to the tumor and starves the tumor of vital nutrients including oxygen.", "type": 2, "words": ["<tag1>", "Fosbretabulin", "Development", "Program", "Fosbretabulin", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen.", "<tag2>", "which", "obstructs", "the", "flow", "of", "blood", "to", "the", "tumor", "and", "starves", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen.", "<tag3>"], "wordsA": ["Fosbretabulin", "Development", "Program", "Fosbretabulin", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen."], "wordsB": ["which", "obstructs", "the", "flow", "of", "blood", "to", "the", "tumor", "and", "starves", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p3_s0", "idA": "908259_15_item1_p1_s1", "sentA": "This deprivation, also known as tumor hypoxia, results in rapid downstream tumor cell death.", "sentB": "Our lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT .", "type": 2, "words": ["<tag1>", "This", "deprivation,", "also", "known", "as", "tumor", "hypoxia,", "results", "in", "rapid", "downstream", "tumor", "cell", "death.", "<tag2>", "Our", "lead", "compound", "is", "CA4P,", "which", "is", "also", "known", "as", "combretastatin", "A4-phosphate,", "fosbretabulin", "tromethamine,", "fosbretabulin", "and", "ZYBRESTAT", ".", "<tag3>"], "wordsA": ["This", "deprivation,", "also", "known", "as", "tumor", "hypoxia,", "results", "in", "rapid", "downstream", "tumor", "cell", "death."], "wordsB": ["Our", "lead", "compound", "is", "CA4P,", "which", "is", "also", "known", "as", "combretastatin", "A4-phosphate,", "fosbretabulin", "tromethamine,", "fosbretabulin", "and", "ZYBRESTAT", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p27_s0", "idA": "908259_15_item1_p21_s0", "sentA": "Anaplastic Thyroid Cancer, or ATC At this time our main focus with fosbretabulin is pursuing our programs in ovarian cancer and GI-NETs.", "sentB": "Anaplastic Thyroid Cancer, or ATC We have previously conducted a randomized, controlled clinical trial in ATC.", "type": 2, "words": ["<tag1>", "Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "At", "this", "time", "our", "main", "focus", "with", "fosbretabulin", "is", "pursuing", "our", "programs", "in", "ovarian", "cancer", "and", "GI-NETs.", "<tag2>", "Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "We", "have", "previously", "conducted", "a", "randomized,", "controlled", "clinical", "trial", "in", "ATC.", "<tag3>"], "wordsA": ["Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "At", "this", "time", "our", "main", "focus", "with", "fosbretabulin", "is", "pursuing", "our", "programs", "in", "ovarian", "cancer", "and", "GI-NETs."], "wordsB": ["Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "We", "have", "previously", "conducted", "a", "randomized,", "controlled", "clinical", "trial", "in", "ATC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p26_s2", "idA": "908259_15_item1_p21_s2", "sentA": "Although this pathway continues to remain open to us, our near term priorities for fosbretabulin are focused on our development programs in ovarian cancer and completing our Phase 2 clinical trial in GI-NETs.", "sentB": "However, we currently do not plan to initiate a GBM clinical trial in the near term in order to conserve current resources.", "type": 2, "words": ["<tag1>", "Although", "this", "pathway", "continues", "to", "remain", "open", "to", "us,", "our", "near", "term", "priorities", "for", "fosbretabulin", "are", "focused", "on", "our", "development", "programs", "in", "ovarian", "cancer", "and", "completing", "our", "Phase", "2", "clinical", "trial", "in", "GI-NETs.", "<tag2>", "However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources.", "<tag3>"], "wordsA": ["Although", "this", "pathway", "continues", "to", "remain", "open", "to", "us,", "our", "near", "term", "priorities", "for", "fosbretabulin", "are", "focused", "on", "our", "development", "programs", "in", "ovarian", "cancer", "and", "completing", "our", "Phase", "2", "clinical", "trial", "in", "GI-NETs."], "wordsB": ["However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p30_s4", "idA": "908259_15_item1_p21_s3", "sentA": "In addition to pursuing development of fosbretabulin, we are also pursuing the development of a second product candidate, OXi4503, a novel, dual-mechanism VDA, which not only has been shown to reduce tumor blood flow but which also forms a potentially antiproliferative metabolite.", "sentB": "In addition to pursuing development of CA4P, we are also pursuing the development of a second product candidate, OXi4503, a novel, dual-mechanism VDA, which not only has been shown to reduce tumor blood flow but which also forms a potentially anti-proliferative metabolite.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "pursuing", "development", "of", "fosbretabulin,", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "a", "potentially", "antiproliferative", "metabolite.", "<tag2>", "In", "addition", "to", "pursuing", "development", "of", "CA4P,", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "a", "potentially", "anti-proliferative", "metabolite.", "<tag3>"], "wordsA": ["In", "addition", "to", "pursuing", "development", "of", "fosbretabulin,", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "a", "potentially", "antiproliferative", "metabolite."], "wordsB": ["In", "addition", "to", "pursuing", "development", "of", "CA4P,", "we", "are", "also", "pursuing", "the", "development", "of", "a", "second", "product", "candidate,", "OXi4503,", "a", "novel,", "dual-mechanism", "VDA,", "which", "not", "only", "has", "been", "shown", "to", "reduce", "tumor", "blood", "flow", "but", "which", "also", "forms", "a", "potentially", "anti-proliferative", "metabolite."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p30_s5", "idA": "908259_15_item1_p22_s0", "sentA": "We believe that this dual mechanism differentiates OXi4503 from other VDAs and may result in enhanced anti-tumor activity in certain tumor types as compared with other VDA drug candidates.", "sentB": "We believe that this dual mechanism of OXi4503 may result in enhanced anti-tumor activity in certain tumor types.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "this", "dual", "mechanism", "differentiates", "OXi4503", "from", "other", "VDAs", "and", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types", "as", "compared", "with", "other", "VDA", "drug", "candidates.", "<tag2>", "We", "believe", "that", "this", "dual", "mechanism", "of", "OXi4503", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "dual", "mechanism", "differentiates", "OXi4503", "from", "other", "VDAs", "and", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types", "as", "compared", "with", "other", "VDA", "drug", "candidates."], "wordsB": ["We", "believe", "that", "this", "dual", "mechanism", "of", "OXi4503", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p31_s0", "idA": "908259_15_item1_p23_s0", "sentA": "Based on preclinical data, we believe that OXi4503 may be particularly active in hepatocellular carcinoma, melanoma, and leukemias of the myeloid lineage, all of which have relatively high levels of the enzymes that facilitate the conversion of OXi4503 into a chemical that directly kills tumor cells.", "sentB": "Based on preclinical data, we believe that OXi4503 may be particularly active in hepatocellular carcinoma, melanoma, and leukemias of the myeloid lineage, all of which have relatively high levels of the enzymes that facilitate the conversion of OXi4503 into a metabolite that directly kills tumor cells.", "type": 2, "words": ["<tag1>", "Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "hepatocellular", "carcinoma,", "melanoma,", "and", "leukemias", "of", "the", "myeloid", "lineage,", "all", "of", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "chemical", "that", "directly", "kills", "tumor", "cells.", "<tag2>", "Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "hepatocellular", "carcinoma,", "melanoma,", "and", "leukemias", "of", "the", "myeloid", "lineage,", "all", "of", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "metabolite", "that", "directly", "kills", "tumor", "cells.", "<tag3>"], "wordsA": ["Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "hepatocellular", "carcinoma,", "melanoma,", "and", "leukemias", "of", "the", "myeloid", "lineage,", "all", "of", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "chemical", "that", "directly", "kills", "tumor", "cells."], "wordsB": ["Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "hepatocellular", "carcinoma,", "melanoma,", "and", "leukemias", "of", "the", "myeloid", "lineage,", "all", "of", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "metabolite", "that", "directly", "kills", "tumor", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p31_s1", "idA": "908259_15_item1_p23_s1", "sentA": "Similar to fosbretabulin, OXi4503 has shown potent anti- tumor activity in preclinical studies of solid tumors and AML, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other antiproliferative agents.", "sentB": "Similar to CA4P, OXi4503 has shown potent anti-tumor activity in preclinical studies of solid tumors and AML, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other anti-proliferative agents.", "type": 2, "words": ["<tag1>", "Similar", "to", "fosbretabulin,", "OXi4503", "has", "shown", "potent", "anti-", "tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "antiproliferative", "agents.", "<tag2>", "Similar", "to", "CA4P,", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents.", "<tag3>"], "wordsA": ["Similar", "to", "fosbretabulin,", "OXi4503", "has", "shown", "potent", "anti-", "tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "antiproliferative", "agents."], "wordsB": ["Similar", "to", "CA4P,", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p32_s0", "idA": "908259_15_item1_p24_s0", "sentA": "Our current development program for OXi4503 is as follows: Acute Myelogenous Leukemia, or AML AML is a relatively rare cancer of the myeloid blood cells, with approximately 10,500 new cases each year in the United States and accounting for approximately 1.2% of cancer deaths.", "sentB": "Acute Myeloid Leukemia AML is a relatively rare cancer of the myeloid blood cells, with approximately 10,500 new cases each year in the United States and accounting for approximately 1.2% of cancer deaths.", "type": 2, "words": ["<tag1>", "Our", "current", "development", "program", "for", "OXi4503", "is", "as", "follows:", "Acute", "Myelogenous", "Leukemia,", "or", "AML", "AML", "is", "a", "relatively", "rare", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "United", "States", "and", "accounting", "for", "approximately", "1.2%", "of", "cancer", "deaths.", "<tag2>", "Acute", "Myeloid", "Leukemia", "AML", "is", "a", "relatively", "rare", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "United", "States", "and", "accounting", "for", "approximately", "1.2%", "of", "cancer", "deaths.", "<tag3>"], "wordsA": ["Our", "current", "development", "program", "for", "OXi4503", "is", "as", "follows:", "Acute", "Myelogenous", "Leukemia,", "or", "AML", "AML", "is", "a", "relatively", "rare", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "United", "States", "and", "accounting", "for", "approximately", "1.2%", "of", "cancer", "deaths."], "wordsB": ["Acute", "Myeloid", "Leukemia", "AML", "is", "a", "relatively", "rare", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "United", "States", "and", "accounting", "for", "approximately", "1.2%", "of", "cancer", "deaths."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p2_s0", "idA": "908259_15_item1_p24_s1", "sentA": "AML is characterized by the rapid growth of abnormal white blood cells that pollute bone marrow and interfere with the production of normal blood cells.", "sentB": "Bevacizumab and other AA drugs work by preventing the growth of new blood vessels which can supply nutrients to tumor cells.", "type": 2, "words": ["<tag1>", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells.", "<tag2>", "Bevacizumab", "and", "other", "AA", "drugs", "work", "by", "preventing", "the", "growth", "of", "new", "blood", "vessels", "which", "can", "supply", "nutrients", "to", "tumor", "cells.", "<tag3>"], "wordsA": ["AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells."], "wordsB": ["Bevacizumab", "and", "other", "AA", "drugs", "work", "by", "preventing", "the", "growth", "of", "new", "blood", "vessels", "which", "can", "supply", "nutrients", "to", "tumor", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p32_s2", "idA": "908259_15_item1_p24_s2", "sentA": "Due to an unmet need in the treatment of AML and the small size of the indication, we have been granted orphan drug designation in the United States for the use of OXi4503 in the treatment of AML.", "sentB": "Due to an unmet need in the treatment of AML and the small size of the indication, we have been granted orphan drug designation in the United States and European Union for the use of OXi4503 for the treatment of AML.", "type": 2, "words": ["<tag1>", "Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "AML", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "orphan", "drug", "designation", "in", "the", "United", "States", "for", "the", "use", "of", "OXi4503", "in", "the", "treatment", "of", "AML.", "<tag2>", "Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "AML", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "orphan", "drug", "designation", "in", "the", "United", "States", "and", "European", "Union", "for", "the", "use", "of", "OXi4503", "for", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "AML", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "orphan", "drug", "designation", "in", "the", "United", "States", "for", "the", "use", "of", "OXi4503", "in", "the", "treatment", "of", "AML."], "wordsB": ["Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "AML", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "orphan", "drug", "designation", "in", "the", "United", "States", "and", "European", "Union", "for", "the", "use", "of", "OXi4503", "for", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p33_s4", "idA": "908259_15_item1_p24_s2", "sentA": "Due to an unmet need in the treatment of AML and the small size of the indication, we have been granted orphan drug designation in the United States for the use of OXi4503 in the treatment of AML.", "sentB": "In December 2015, we moved this clinical trial into its second stage, whereby OXi4503 is being used in combination with cytarabine, an FDA-approved drug for the treatment of AML.", "type": 2, "words": ["<tag1>", "Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "AML", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "orphan", "drug", "designation", "in", "the", "United", "States", "for", "the", "use", "of", "OXi4503", "in", "the", "treatment", "of", "AML.", "<tag2>", "In", "December", "2015,", "we", "moved", "this", "clinical", "trial", "into", "its", "second", "stage,", "whereby", "OXi4503", "is", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["Due", "to", "an", "unmet", "need", "in", "the", "treatment", "of", "AML", "and", "the", "small", "size", "of", "the", "indication,", "we", "have", "been", "granted", "orphan", "drug", "designation", "in", "the", "United", "States", "for", "the", "use", "of", "OXi4503", "in", "the", "treatment", "of", "AML."], "wordsB": ["In", "December", "2015,", "we", "moved", "this", "clinical", "trial", "into", "its", "second", "stage,", "whereby", "OXi4503", "is", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p90_s2", "idA": "908259_15_item1_p24_s3", "sentA": "We intend to seek orphan drug designation in the EU.", "sentB": "A company whose application for orphan drug designation in the European Union is approved is eligible to receive, among other benefits, regulatory assistance in preparing the marketing application, protocol assistance and reduced application fees.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "seek", "orphan", "drug", "designation", "in", "the", "EU.", "<tag2>", "A", "company", "whose", "application", "for", "orphan", "drug", "designation", "in", "the", "European", "Union", "is", "approved", "is", "eligible", "to", "receive,", "among", "other", "benefits,", "regulatory", "assistance", "in", "preparing", "the", "marketing", "application,", "protocol", "assistance", "and", "reduced", "application", "fees.", "<tag3>"], "wordsA": ["We", "intend", "to", "seek", "orphan", "drug", "designation", "in", "the", "EU."], "wordsB": ["A", "company", "whose", "application", "for", "orphan", "drug", "designation", "in", "the", "European", "Union", "is", "approved", "is", "eligible", "to", "receive,", "among", "other", "benefits,", "regulatory", "assistance", "in", "preparing", "the", "marketing", "application,", "protocol", "assistance", "and", "reduced", "application", "fees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p33_s0", "idA": "908259_15_item1_p25_s0", "sentA": "OXi4503 Investigator Sponsored Trial OXi4503 has been under development in an ongoing investigator-sponsored Phase 1 trial of OXi4503 in patients with AML or MDS, a disorder of the normal blood formation process, being conducted at the University of Florida and with support by The Leukemia Lymphoma Society s Therapy Acceleration Program.", "sentB": "Prior to October 2015, OXi4503 had been in development in an investigator-sponsored phase 1 clinical trial of patients with AML or MDS, a disorder of the normal blood formation process, being conducted at the University of Florida and with support by The Leukemia Lymphoma Society s Therapy Acceleration Program.", "type": 2, "words": ["<tag1>", "OXi4503", "Investigator", "Sponsored", "Trial", "OXi4503", "has", "been", "under", "development", "in", "an", "ongoing", "investigator-sponsored", "Phase", "1", "trial", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program.", "<tag2>", "Prior", "to", "October", "2015,", "OXi4503", "had", "been", "in", "development", "in", "an", "investigator-sponsored", "phase", "1", "clinical", "trial", "of", "patients", "with", "AML", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program.", "<tag3>"], "wordsA": ["OXi4503", "Investigator", "Sponsored", "Trial", "OXi4503", "has", "been", "under", "development", "in", "an", "ongoing", "investigator-sponsored", "Phase", "1", "trial", "of", "OXi4503", "in", "patients", "with", "AML", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program."], "wordsB": ["Prior", "to", "October", "2015,", "OXi4503", "had", "been", "in", "development", "in", "an", "investigator-sponsored", "phase", "1", "clinical", "trial", "of", "patients", "with", "AML", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p33_s1", "idA": "908259_15_item1_p25_s1", "sentA": "This open-label, dose-escalating study was intended to treat up to 36 patients and evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "sentB": "This open-label, dose-escalating clinical trial was intended to treat up to 36 patients and evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "type": 2, "words": ["<tag1>", "This", "open-label,", "dose-escalating", "study", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag2>", "This", "open-label,", "dose-escalating", "clinical", "trial", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag3>"], "wordsA": ["This", "open-label,", "dose-escalating", "study", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "wordsB": ["This", "open-label,", "dose-escalating", "clinical", "trial", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p33_s2", "idA": "908259_15_item1_p25_s2", "sentA": "As of March 18, 2015, 16 patients have been enrolled into this study, and a maximum tolerated dose had not been observed.", "sentB": "Through October 2015, 18 patients had been enrolled into this clinical trial and a maximum tolerated dose had not been observed.", "type": 2, "words": ["<tag1>", "As", "of", "March", "18,", "2015,", "16", "patients", "have", "been", "enrolled", "into", "this", "study,", "and", "a", "maximum", "tolerated", "dose", "had", "not", "been", "observed.", "<tag2>", "Through", "October", "2015,", "18", "patients", "had", "been", "enrolled", "into", "this", "clinical", "trial", "and", "a", "maximum", "tolerated", "dose", "had", "not", "been", "observed.", "<tag3>"], "wordsA": ["As", "of", "March", "18,", "2015,", "16", "patients", "have", "been", "enrolled", "into", "this", "study,", "and", "a", "maximum", "tolerated", "dose", "had", "not", "been", "observed."], "wordsB": ["Through", "October", "2015,", "18", "patients", "had", "been", "enrolled", "into", "this", "clinical", "trial", "and", "a", "maximum", "tolerated", "dose", "had", "not", "been", "observed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p34_s0", "idA": "908259_15_item1_p27_s0", "sentA": "Background Updated data from the investigator trial was presented at the December 2013 annual meeting of ASH in New Orleans, Louisiana.", "sentB": "Data from the investigator-sponsored trial was presented at the December 2013 annual meeting of the American Society of Hematology, or ASH, in New Orleans, Louisiana.", "type": 2, "words": ["<tag1>", "Background", "Updated", "data", "from", "the", "investigator", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana.", "<tag2>", "Data", "from", "the", "investigator-sponsored", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH,", "in", "New", "Orleans,", "Louisiana.", "<tag3>"], "wordsA": ["Background", "Updated", "data", "from", "the", "investigator", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "ASH", "in", "New", "Orleans,", "Louisiana."], "wordsB": ["Data", "from", "the", "investigator-sponsored", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH,", "in", "New", "Orleans,", "Louisiana."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p35_s0", "idA": "908259_15_item1_p29_s0", "sentA": "Side effects included increases in D-dimer, which is a substance in the blood that is released when a blood clot breaks up, bone pain, fever, chills and flu-like symptoms.", "sentB": "that is released when a blood clot breaks up), bone pain, fever, chills and flu-like symptoms.", "type": 2, "words": ["<tag1>", "Side", "effects", "included", "increases", "in", "D-dimer,", "which", "is", "a", "substance", "in", "the", "blood", "that", "is", "released", "when", "a", "blood", "clot", "breaks", "up,", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms.", "<tag2>", "that", "is", "released", "when", "a", "blood", "clot", "breaks", "up),", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms.", "<tag3>"], "wordsA": ["Side", "effects", "included", "increases", "in", "D-dimer,", "which", "is", "a", "substance", "in", "the", "blood", "that", "is", "released", "when", "a", "blood", "clot", "breaks", "up,", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms."], "wordsB": ["that", "is", "released", "when", "a", "blood", "clot", "breaks", "up),", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p35_s1", "idA": "908259_15_item1_p29_s1", "sentA": "Accordingly, OXi4503 appears to be well tolerated based on these results to date in patients with relapsed and refractory AML and MDS.", "sentB": "Accordingly, OXi4503 appears to be reasonably well-tolerated based on these results to date in patients with relapsed and refractory AML and MDS.", "type": 2, "words": ["<tag1>", "Accordingly,", "OXi4503", "appears", "to", "be", "well", "tolerated", "based", "on", "these", "results", "to", "date", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS.", "<tag2>", "Accordingly,", "OXi4503", "appears", "to", "be", "reasonably", "well-tolerated", "based", "on", "these", "results", "to", "date", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS.", "<tag3>"], "wordsA": ["Accordingly,", "OXi4503", "appears", "to", "be", "well", "tolerated", "based", "on", "these", "results", "to", "date", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS."], "wordsB": ["Accordingly,", "OXi4503", "appears", "to", "be", "reasonably", "well-tolerated", "based", "on", "these", "results", "to", "date", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p1_s1", "idA": "908259_15_item1_p2_s0", "sentA": "Ovarian Cancer Ovarian cancer affects approximately 22,000 women in the U.S. each year.", "sentB": "There are over 12 AAs approved in the U.S. for over 15 different oncology indications, and according to Datamonitor, 2015 sales for AAs are estimated to exceed $10 billion.", "type": 2, "words": ["<tag1>", "Ovarian", "Cancer", "Ovarian", "cancer", "affects", "approximately", "22,000", "women", "in", "the", "U.S.", "each", "year.", "<tag2>", "There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications,", "and", "according", "to", "Datamonitor,", "2015", "sales", "for", "AAs", "are", "estimated", "to", "exceed", "$10", "billion.", "<tag3>"], "wordsA": ["Ovarian", "Cancer", "Ovarian", "cancer", "affects", "approximately", "22,000", "women", "in", "the", "U.S.", "each", "year."], "wordsB": ["There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications,", "and", "according", "to", "Datamonitor,", "2015", "sales", "for", "AAs", "are", "estimated", "to", "exceed", "$10", "billion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p22_s0", "idA": "908259_15_item1_p2_s0", "sentA": "Ovarian Cancer Ovarian cancer affects approximately 22,000 women in the U.S. each year.", "sentB": "Approximately 14,000 patients in the U.S. are diagnosed with neuroendocrine tumors, or NETs, each year.", "type": 2, "words": ["<tag1>", "Ovarian", "Cancer", "Ovarian", "cancer", "affects", "approximately", "22,000", "women", "in", "the", "U.S.", "each", "year.", "<tag2>", "Approximately", "14,000", "patients", "in", "the", "U.S.", "are", "diagnosed", "with", "neuroendocrine", "tumors,", "or", "NETs,", "each", "year.", "<tag3>"], "wordsA": ["Ovarian", "Cancer", "Ovarian", "cancer", "affects", "approximately", "22,000", "women", "in", "the", "U.S.", "each", "year."], "wordsB": ["Approximately", "14,000", "patients", "in", "the", "U.S.", "are", "diagnosed", "with", "neuroendocrine", "tumors,", "or", "NETs,", "each", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p8_s0", "idA": "908259_15_item1_p2_s0", "sentA": "Ovarian Cancer Ovarian cancer affects approximately 22,000 women in the U.S. each year.", "sentB": "Ovarian Cancer Approximately 22,000 women in the U.S. are diagnosed with ovarian cancer each year.", "type": 2, "words": ["<tag1>", "Ovarian", "Cancer", "Ovarian", "cancer", "affects", "approximately", "22,000", "women", "in", "the", "U.S.", "each", "year.", "<tag2>", "Ovarian", "Cancer", "Approximately", "22,000", "women", "in", "the", "U.S.", "are", "diagnosed", "with", "ovarian", "cancer", "each", "year.", "<tag3>"], "wordsA": ["Ovarian", "Cancer", "Ovarian", "cancer", "affects", "approximately", "22,000", "women", "in", "the", "U.S.", "each", "year."], "wordsB": ["Ovarian", "Cancer", "Approximately", "22,000", "women", "in", "the", "U.S.", "are", "diagnosed", "with", "ovarian", "cancer", "each", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p8_s2", "idA": "908259_15_item1_p2_s2", "sentA": "In fact, more than 60% of women diagnosed with ovarian cancer are in stage III or IV, making ovarian cancer difficult to treat and often fatal, with a five-year survival rate of approximately 45% a rate which is largely unchanged since the 1990s.", "sentB": "More than 60% of women diagnosed with ovarian cancer are in stage III or IV, making ovarian cancer difficult to treat and often fatal, with a five-year survival rate of approximately 45% a rate which is largely unchanged since the 1990s.", "type": 2, "words": ["<tag1>", "In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "ovarian", "cancer", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "approximately", "45%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s.", "<tag2>", "More", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "ovarian", "cancer", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "approximately", "45%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s.", "<tag3>"], "wordsA": ["In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "ovarian", "cancer", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "approximately", "45%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s."], "wordsB": ["More", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "ovarian", "cancer", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "approximately", "45%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p37_s2", "idA": "908259_15_item1_p33_s0", "sentA": "Since 2004, a number of anti-angiogenic drugs, which refers to drugs that interfere with blood vessel growth, as described further in the table below, have been approved for a variety of cancer and ophthalmology indications, and development of approved anti-angiogenic drugs for new indications continues.", "sentB": "AAs are drugs that interfere with tumor blood vessel growth, as described further in the table below, and since 2004, a number have been approved for a variety of cancer indications.", "type": 2, "words": ["<tag1>", "Since", "2004,", "a", "number", "of", "anti-angiogenic", "drugs,", "which", "refers", "to", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "as", "described", "further", "in", "the", "table", "below,", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "and", "ophthalmology", "indications,", "and", "development", "of", "approved", "anti-angiogenic", "drugs", "for", "new", "indications", "continues.", "<tag2>", "AAs", "are", "drugs", "that", "interfere", "with", "tumor", "blood", "vessel", "growth,", "as", "described", "further", "in", "the", "table", "below,", "and", "since", "2004,", "a", "number", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "indications.", "<tag3>"], "wordsA": ["Since", "2004,", "a", "number", "of", "anti-angiogenic", "drugs,", "which", "refers", "to", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "as", "described", "further", "in", "the", "table", "below,", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "and", "ophthalmology", "indications,", "and", "development", "of", "approved", "anti-angiogenic", "drugs", "for", "new", "indications", "continues."], "wordsB": ["AAs", "are", "drugs", "that", "interfere", "with", "tumor", "blood", "vessel", "growth,", "as", "described", "further", "in", "the", "table", "below,", "and", "since", "2004,", "a", "number", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p38_s1", "idA": "908259_15_item1_p33_s0", "sentA": "Since 2004, a number of anti-angiogenic drugs, which refers to drugs that interfere with blood vessel growth, as described further in the table below, have been approved for a variety of cancer and ophthalmology indications, and development of approved anti-angiogenic drugs for new indications continues.", "sentB": "Although a number of VDAs have been in clinical development, to date none have been approved.", "type": 2, "words": ["<tag1>", "Since", "2004,", "a", "number", "of", "anti-angiogenic", "drugs,", "which", "refers", "to", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "as", "described", "further", "in", "the", "table", "below,", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "and", "ophthalmology", "indications,", "and", "development", "of", "approved", "anti-angiogenic", "drugs", "for", "new", "indications", "continues.", "<tag2>", "Although", "a", "number", "of", "VDAs", "have", "been", "in", "clinical", "development,", "to", "date", "none", "have", "been", "approved.", "<tag3>"], "wordsA": ["Since", "2004,", "a", "number", "of", "anti-angiogenic", "drugs,", "which", "refers", "to", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "as", "described", "further", "in", "the", "table", "below,", "have", "been", "approved", "for", "a", "variety", "of", "cancer", "and", "ophthalmology", "indications,", "and", "development", "of", "approved", "anti-angiogenic", "drugs", "for", "new", "indications", "continues."], "wordsB": ["Although", "a", "number", "of", "VDAs", "have", "been", "in", "clinical", "development,", "to", "date", "none", "have", "been", "approved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p37_s3", "idA": "908259_15_item1_p33_s1", "sentA": "Physician adoption of these first-generation anti-vascular drugs has been rapid and continues to accelerate.", "sentB": "Development of AAs for new indications continues, and physician adoption of AAs has been rapid.", "type": 2, "words": ["<tag1>", "Physician", "adoption", "of", "these", "first-generation", "anti-vascular", "drugs", "has", "been", "rapid", "and", "continues", "to", "accelerate.", "<tag2>", "Development", "of", "AAs", "for", "new", "indications", "continues,", "and", "physician", "adoption", "of", "AAs", "has", "been", "rapid.", "<tag3>"], "wordsA": ["Physician", "adoption", "of", "these", "first-generation", "anti-vascular", "drugs", "has", "been", "rapid", "and", "continues", "to", "accelerate."], "wordsB": ["Development", "of", "AAs", "for", "new", "indications", "continues,", "and", "physician", "adoption", "of", "AAs", "has", "been", "rapid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p39_s0", "idA": "908259_15_item1_p34_s0", "sentA": "While fosbretabulin exerts a therapeutic effect similar to existing anti-angiogenic agents, depriving tumors (or, in the case of eye disease, ocular lesions) of blood supply, its mechanism of action is quite different.", "sentB": "While VDAs such as CA4P deprive tumors of blood supply, as do AAs, the mechanism of action of VDAs is quite different than that of AAs.", "type": 2, "words": ["<tag1>", "While", "fosbretabulin", "exerts", "a", "therapeutic", "effect", "similar", "to", "existing", "anti-angiogenic", "agents,", "depriving", "tumors", "(or,", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions)", "of", "blood", "supply,", "its", "mechanism", "of", "action", "is", "quite", "different.", "<tag2>", "While", "VDAs", "such", "as", "CA4P", "deprive", "tumors", "of", "blood", "supply,", "as", "do", "AAs,", "the", "mechanism", "of", "action", "of", "VDAs", "is", "quite", "different", "than", "that", "of", "AAs.", "<tag3>"], "wordsA": ["While", "fosbretabulin", "exerts", "a", "therapeutic", "effect", "similar", "to", "existing", "anti-angiogenic", "agents,", "depriving", "tumors", "(or,", "in", "the", "case", "of", "eye", "disease,", "ocular", "lesions)", "of", "blood", "supply,", "its", "mechanism", "of", "action", "is", "quite", "different."], "wordsB": ["While", "VDAs", "such", "as", "CA4P", "deprive", "tumors", "of", "blood", "supply,", "as", "do", "AAs,", "the", "mechanism", "of", "action", "of", "VDAs", "is", "quite", "different", "than", "that", "of", "AAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p39_s6", "idA": "908259_15_item1_p34_s1", "sentA": "Consequently, we believe that our VDA drug candidates are second-generation anti-vascular drugs that are potentially complementary to, rather than directly competitive with, existing anti-angiogenic agents, a stance which is supported by the data we have gathered showing an improvement in patient outcomes when both agents are used in combination.", "sentB": "Our belief in the synergy of CA4P and AAs is supported by the data we have gathered showing an improvement in certain patient outcomes when both agents are used in combination.", "type": 2, "words": ["<tag1>", "Consequently,", "we", "believe", "that", "our", "VDA", "drug", "candidates", "are", "second-generation", "anti-vascular", "drugs", "that", "are", "potentially", "complementary", "to,", "rather", "than", "directly", "competitive", "with,", "existing", "anti-angiogenic", "agents,", "a", "stance", "which", "is", "supported", "by", "the", "data", "we", "have", "gathered", "showing", "an", "improvement", "in", "patient", "outcomes", "when", "both", "agents", "are", "used", "in", "combination.", "<tag2>", "Our", "belief", "in", "the", "synergy", "of", "CA4P", "and", "AAs", "is", "supported", "by", "the", "data", "we", "have", "gathered", "showing", "an", "improvement", "in", "certain", "patient", "outcomes", "when", "both", "agents", "are", "used", "in", "combination.", "<tag3>"], "wordsA": ["Consequently,", "we", "believe", "that", "our", "VDA", "drug", "candidates", "are", "second-generation", "anti-vascular", "drugs", "that", "are", "potentially", "complementary", "to,", "rather", "than", "directly", "competitive", "with,", "existing", "anti-angiogenic", "agents,", "a", "stance", "which", "is", "supported", "by", "the", "data", "we", "have", "gathered", "showing", "an", "improvement", "in", "patient", "outcomes", "when", "both", "agents", "are", "used", "in", "combination."], "wordsB": ["Our", "belief", "in", "the", "synergy", "of", "CA4P", "and", "AAs", "is", "supported", "by", "the", "data", "we", "have", "gathered", "showing", "an", "improvement", "in", "certain", "patient", "outcomes", "when", "both", "agents", "are", "used", "in", "combination."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p3_s2", "idA": "908259_15_item1_p34_s2", "sentA": "Several preclinical studies, as well as the results of the Phase 2 GOG-0186I clinical trial, have confirmed the potential of this approach.", "sentB": "Based on the positive results of this clinical trial, we plan to initiate a phase 2/3 clinical trial in platinum-resistant ovarian cancer, which will compare treatment with CA4P, bevacizumab and chemotherapy to treatment with bevacizumab and chemotherapy.", "type": 2, "words": ["<tag1>", "Several", "preclinical", "studies,", "as", "well", "as", "the", "results", "of", "the", "Phase", "2", "GOG-0186I", "clinical", "trial,", "have", "confirmed", "the", "potential", "of", "this", "approach.", "<tag2>", "Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "plan", "to", "initiate", "a", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag3>"], "wordsA": ["Several", "preclinical", "studies,", "as", "well", "as", "the", "results", "of", "the", "Phase", "2", "GOG-0186I", "clinical", "trial,", "have", "confirmed", "the", "potential", "of", "this", "approach."], "wordsB": ["Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "plan", "to", "initiate", "a", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p40_s2", "idA": "908259_15_item1_p35_s2", "sentA": "Results from initial human clinical studies conducted by us with combinations of fosbretabulin and AVASTIN (bevacizumab), provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "sentB": "Results from initial human clinical trials conducted by us with combinations of CA4P and bevacizumab provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "type": 2, "words": ["<tag1>", "Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "fosbretabulin", "and", "AVASTIN", "(bevacizumab),", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag2>", "Results", "from", "initial", "human", "clinical", "trials", "conducted", "by", "us", "with", "combinations", "of", "CA4P", "and", "bevacizumab", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag3>"], "wordsA": ["Results", "from", "initial", "human", "clinical", "studies", "conducted", "by", "us", "with", "combinations", "of", "fosbretabulin", "and", "AVASTIN", "(bevacizumab),", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "wordsB": ["Results", "from", "initial", "human", "clinical", "trials", "conducted", "by", "us", "with", "combinations", "of", "CA4P", "and", "bevacizumab", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p17_s2", "idA": "908259_15_item1_p35_s3", "sentA": "Additionally, positive study results from the Phase 2 GOG-0186I clinical trial indicated a statistically significant increase in PFS with the combination of fosbretabulin and bevacizumab.", "sentB": "CA4P in Combination with Bevacizumab and Physician s Choice Chemotherapy Phase 2/3 Clinical Trial Planned Based on the positive overall results from the GOG-0186I clinical trial in recurrent ovarian cancer and also the statistically significant results among the subgroup of platinum-resistant patients, we plan to initiate the FOCUS Study, a phase 2/3 clinical trial of CA4P seeking to demonstrate whether CA4P improves the current standard of care for platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "Additionally,", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "with", "the", "combination", "of", "fosbretabulin", "and", "bevacizumab.", "<tag2>", "CA4P", "in", "Combination", "with", "Bevacizumab", "and", "Physician", "s", "Choice", "Chemotherapy", "Phase", "2/3", "Clinical", "Trial", "Planned", "Based", "on", "the", "positive", "overall", "results", "from", "the", "GOG-0186I", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "and", "also", "the", "statistically", "significant", "results", "among", "the", "subgroup", "of", "platinum-resistant", "patients,", "we", "plan", "to", "initiate", "the", "FOCUS", "Study,", "a", "phase", "2/3", "clinical", "trial", "of", "CA4P", "seeking", "to", "demonstrate", "whether", "CA4P", "improves", "the", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Additionally,", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "with", "the", "combination", "of", "fosbretabulin", "and", "bevacizumab."], "wordsB": ["CA4P", "in", "Combination", "with", "Bevacizumab", "and", "Physician", "s", "Choice", "Chemotherapy", "Phase", "2/3", "Clinical", "Trial", "Planned", "Based", "on", "the", "positive", "overall", "results", "from", "the", "GOG-0186I", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "and", "also", "the", "statistically", "significant", "results", "among", "the", "subgroup", "of", "platinum-resistant", "patients,", "we", "plan", "to", "initiate", "the", "FOCUS", "Study,", "a", "phase", "2/3", "clinical", "trial", "of", "CA4P", "seeking", "to", "demonstrate", "whether", "CA4P", "improves", "the", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p40_s3", "idA": "908259_15_item1_p35_s3", "sentA": "Additionally, positive study results from the Phase 2 GOG-0186I clinical trial indicated a statistically significant increase in PFS with the combination of fosbretabulin and bevacizumab.", "sentB": "Additionally, positive study results from the phase 2 GOG-0186I clinical trial indicated a statistically significant increase in PFS in patients with platinum-resistant recurrent ovarian cancer with the combination of CA4P and bevacizumab.", "type": 2, "words": ["<tag1>", "Additionally,", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "with", "the", "combination", "of", "fosbretabulin", "and", "bevacizumab.", "<tag2>", "Additionally,", "positive", "study", "results", "from", "the", "phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "in", "patients", "with", "platinum-resistant", "recurrent", "ovarian", "cancer", "with", "the", "combination", "of", "CA4P", "and", "bevacizumab.", "<tag3>"], "wordsA": ["Additionally,", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "with", "the", "combination", "of", "fosbretabulin", "and", "bevacizumab."], "wordsB": ["Additionally,", "positive", "study", "results", "from", "the", "phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "in", "patients", "with", "platinum-resistant", "recurrent", "ovarian", "cancer", "with", "the", "combination", "of", "CA4P", "and", "bevacizumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p41_s0", "idA": "908259_15_item1_p36_s0", "sentA": "Chronic-chronic hypertension with long- term use; Acute- impairment in wound healing; Hemorrhage, hemoptysis, gastrointestinal perforation, proteinuria, nephrotic syndrome, thromboembolic events, etc.", "sentB": "Chronic hypertension with long-term use; Acute-impairment in wound healing; Hemorrhage, hemoptysis, gastrointestinal perforation, proteinuria, nephrotic syndrome, thromboembolic events, etc.", "type": 2, "words": ["<tag1>", "Chronic-chronic", "hypertension", "with", "long-", "term", "use;", "Acute-", "impairment", "in", "wound", "healing;", "Hemorrhage,", "hemoptysis,", "gastrointestinal", "perforation,", "proteinuria,", "nephrotic", "syndrome,", "thromboembolic", "events,", "etc.", "<tag2>", "Chronic", "hypertension", "with", "long-term", "use;", "Acute-impairment", "in", "wound", "healing;", "Hemorrhage,", "hemoptysis,", "gastrointestinal", "perforation,", "proteinuria,", "nephrotic", "syndrome,", "thromboembolic", "events,", "etc.", "<tag3>"], "wordsA": ["Chronic-chronic", "hypertension", "with", "long-", "term", "use;", "Acute-", "impairment", "in", "wound", "healing;", "Hemorrhage,", "hemoptysis,", "gastrointestinal", "perforation,", "proteinuria,", "nephrotic", "syndrome,", "thromboembolic", "events,", "etc."], "wordsB": ["Chronic", "hypertension", "with", "long-term", "use;", "Acute-impairment", "in", "wound", "healing;", "Hemorrhage,", "hemoptysis,", "gastrointestinal", "perforation,", "proteinuria,", "nephrotic", "syndrome,", "thromboembolic", "events,", "etc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p42_s0", "idA": "908259_15_item1_p37_s0", "sentA": "Mostly hypertension, effectively controlled; Effects on hematopoiesis and white blood cell counts We believe our VDA drug candidates act on tumor blood vessels via two complementary mechanisms, tubulin depolymerization and disengagement of the junctional protein VE-cadherin, which cause shape change in tumor vascular endothelial cells, vessel occlusion and collapse, and the subsequent blockage of blood-flow to the tumor, which deprives it of oxygen and nutrients essential for survival.", "sentB": "Transient acute blood pressure increases; Tumor pain, nausea, vomiting, headache, fatigue; Effects on hematopoiesis and white blood cell counts; In AML similar to solid tumors with more pronounced effects on coagulation and hematopoiesis We believe our VDA drug candidates act on tumor blood vessels via two complementary mechanisms, tubulin depolymerization and disengagement of the junctional protein VE-cadherin, which cause a change in the shape of tumor vascular endothelial cells, tumor vessel occlusion and collapse, and the subsequent blockage of blood-flow to the tumor, which deprives the tumor of oxygen and nutrients essential for survival.", "type": 2, "words": ["<tag1>", "Mostly", "hypertension,", "effectively", "controlled;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "shape", "change", "in", "tumor", "vascular", "endothelial", "cells,", "vessel", "occlusion", "and", "collapse,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "it", "of", "oxygen", "and", "nutrients", "essential", "for", "survival.", "<tag2>", "Transient", "acute", "blood", "pressure", "increases;", "Tumor", "pain,", "nausea,", "vomiting,", "headache,", "fatigue;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts;", "In", "AML", "similar", "to", "solid", "tumors", "with", "more", "pronounced", "effects", "on", "coagulation", "and", "hematopoiesis", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "a", "change", "in", "the", "shape", "of", "tumor", "vascular", "endothelial", "cells,", "tumor", "vessel", "occlusion", "and", "collapse,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "the", "tumor", "of", "oxygen", "and", "nutrients", "essential", "for", "survival.", "<tag3>"], "wordsA": ["Mostly", "hypertension,", "effectively", "controlled;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "shape", "change", "in", "tumor", "vascular", "endothelial", "cells,", "vessel", "occlusion", "and", "collapse,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "it", "of", "oxygen", "and", "nutrients", "essential", "for", "survival."], "wordsB": ["Transient", "acute", "blood", "pressure", "increases;", "Tumor", "pain,", "nausea,", "vomiting,", "headache,", "fatigue;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts;", "In", "AML", "similar", "to", "solid", "tumors", "with", "more", "pronounced", "effects", "on", "coagulation", "and", "hematopoiesis", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "a", "change", "in", "the", "shape", "of", "tumor", "vascular", "endothelial", "cells,", "tumor", "vessel", "occlusion", "and", "collapse,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "the", "tumor", "of", "oxygen", "and", "nutrients", "essential", "for", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p39_s3", "idA": "908259_15_item1_p37_s1", "sentA": "In vitro studies have demonstrated that our VDA drug candidates act in a reversible fashion on a protein called tubulin inside newly-formed and growing endothelial cells, such as the vascular endothelial cells comprising tumor vasculature.", "sentB": "We believe that our VDA drug candidates and approved AAs are complementary to each other in that one agent destroys existing tumor vasculature and the other prevents new tumor vasculature from forming.", "type": 2, "words": ["<tag1>", "In", "vitro", "studies", "have", "demonstrated", "that", "our", "VDA", "drug", "candidates", "act", "in", "a", "reversible", "fashion", "on", "a", "protein", "called", "tubulin", "inside", "newly-formed", "and", "growing", "endothelial", "cells,", "such", "as", "the", "vascular", "endothelial", "cells", "comprising", "tumor", "vasculature.", "<tag2>", "We", "believe", "that", "our", "VDA", "drug", "candidates", "and", "approved", "AAs", "are", "complementary", "to", "each", "other", "in", "that", "one", "agent", "destroys", "existing", "tumor", "vasculature", "and", "the", "other", "prevents", "new", "tumor", "vasculature", "from", "forming.", "<tag3>"], "wordsA": ["In", "vitro", "studies", "have", "demonstrated", "that", "our", "VDA", "drug", "candidates", "act", "in", "a", "reversible", "fashion", "on", "a", "protein", "called", "tubulin", "inside", "newly-formed", "and", "growing", "endothelial", "cells,", "such", "as", "the", "vascular", "endothelial", "cells", "comprising", "tumor", "vasculature."], "wordsB": ["We", "believe", "that", "our", "VDA", "drug", "candidates", "and", "approved", "AAs", "are", "complementary", "to", "each", "other", "in", "that", "one", "agent", "destroys", "existing", "tumor", "vasculature", "and", "the", "other", "prevents", "new", "tumor", "vasculature", "from", "forming."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p43_s0", "idA": "908259_15_item1_p37_s2", "sentA": "By binding to the tubulin, fosbretabulin is able to collapse the structural framework that maintains the cells flat shape.", "sentB": "By binding to the tubulin, CA4P is able to collapse the structural framework that normally maintains the cells flat shape.", "type": 2, "words": ["<tag1>", "By", "binding", "to", "the", "tubulin,", "fosbretabulin", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "maintains", "the", "cells", "flat", "shape.", "<tag2>", "By", "binding", "to", "the", "tubulin,", "CA4P", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape.", "<tag3>"], "wordsA": ["By", "binding", "to", "the", "tubulin,", "fosbretabulin", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "maintains", "the", "cells", "flat", "shape."], "wordsB": ["By", "binding", "to", "the", "tubulin,", "CA4P", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p38_s0", "idA": "908259_15_item1_p37_s3", "sentA": "When this occurs, the shape of the cells changes from flat to round, initiating a cascade of events resulting in physical blockage of the blood vessels.", "sentB": "VDAs are drugs that interfere with existing tumor blood vessels.", "type": 2, "words": ["<tag1>", "When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "initiating", "a", "cascade", "of", "events", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels.", "<tag2>", "VDAs", "are", "drugs", "that", "interfere", "with", "existing", "tumor", "blood", "vessels.", "<tag3>"], "wordsA": ["When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "initiating", "a", "cascade", "of", "events", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels."], "wordsB": ["VDAs", "are", "drugs", "that", "interfere", "with", "existing", "tumor", "blood", "vessels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p43_s3", "idA": "908259_15_item1_p37_s5", "sentA": "The consequence of the blockage is extensive tumor cell death, as demonstrated in animal studies and suggested in imaging studies of human patients treated with fosbretabulin and OXi4503.", "sentB": "The consequence of the blockage is extensive tumor cell death, as demonstrated in animal studies and suggested in imaging studies of human patients treated with CA4P and OXi4503.", "type": 2, "words": ["<tag1>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "fosbretabulin", "and", "OXi4503.", "<tag2>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "CA4P", "and", "OXi4503.", "<tag3>"], "wordsA": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "fosbretabulin", "and", "OXi4503."], "wordsB": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "CA4P", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p43_s4", "idA": "908259_15_item1_p37_s6", "sentA": "Preclinical research, published in the November 2005 issue of the Journal of Clinical Investigation, showed that fosbretabulin also disrupts the molecular engagement of VE-cadherin, a junctional protein important for endothelial cell survival and function.", "sentB": "Preclinical research, published in the November 2005 issue of the Journal of Clinical Investigation, showed that CA4P also disrupts the molecular engagement of VE-cadherin, a junctional protein important for endothelial cell survival and function.", "type": 2, "words": ["<tag1>", "Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "fosbretabulin", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function.", "<tag2>", "Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "CA4P", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function.", "<tag3>"], "wordsA": ["Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "fosbretabulin", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function."], "wordsB": ["Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "CA4P", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p45_s0", "idA": "908259_15_item1_p39_s0", "sentA": "Preclinical and clinical study results indicate that fosbretabulin exerts anti-vascular effects rapidly, within hours of administration, and the half-life of the active form of fosbretabulin in humans is approximately four hours.", "sentB": "Preclinical and clinical study results indicate that CA4P exerts anti-vascular effects rapidly, within hours of administration, and the half-life of the active form of CA4P in humans is approximately four hours.", "type": 2, "words": ["<tag1>", "Preclinical", "and", "clinical", "study", "results", "indicate", "that", "fosbretabulin", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "in", "humans", "is", "approximately", "four", "hours.", "<tag2>", "Preclinical", "and", "clinical", "study", "results", "indicate", "that", "CA4P", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "in", "humans", "is", "approximately", "four", "hours.", "<tag3>"], "wordsA": ["Preclinical", "and", "clinical", "study", "results", "indicate", "that", "fosbretabulin", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "in", "humans", "is", "approximately", "four", "hours."], "wordsB": ["Preclinical", "and", "clinical", "study", "results", "indicate", "that", "CA4P", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "in", "humans", "is", "approximately", "four", "hours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p45_s1", "idA": "908259_15_item1_p39_s1", "sentA": "Because the half-life of the active form of fosbretabulin is relatively short, the effects of fosbretabulin on tubulin are reversible, and fosbretabulin is typically administered no more frequently than once per week, the side-effects of fosbretabulin are typically transient in nature, limited to the period of time following administration when the active form of fosbretabulin is in the body in significant concentrations.", "sentB": "In part because the half-life of the active form of CA4P is relatively short, the effects of CA4P on tubulin are reversible, and CA4P is typically administered no more frequently than once per week.", "type": 2, "words": ["<tag1>", "Because", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "is", "relatively", "short,", "the", "effects", "of", "fosbretabulin", "on", "tubulin", "are", "reversible,", "and", "fosbretabulin", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "fosbretabulin", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "fosbretabulin", "is", "in", "the", "body", "in", "significant", "concentrations.", "<tag2>", "In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week.", "<tag3>"], "wordsA": ["Because", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "is", "relatively", "short,", "the", "effects", "of", "fosbretabulin", "on", "tubulin", "are", "reversible,", "and", "fosbretabulin", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "fosbretabulin", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "fosbretabulin", "is", "in", "the", "body", "in", "significant", "concentrations."], "wordsB": ["In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p46_s0", "idA": "908259_15_item1_p39_s1", "sentA": "Because the half-life of the active form of fosbretabulin is relatively short, the effects of fosbretabulin on tubulin are reversible, and fosbretabulin is typically administered no more frequently than once per week, the side-effects of fosbretabulin are typically transient in nature, limited to the period of time following administration when the active form of fosbretabulin is in the body in significant concentrations.", "sentB": "The side-effects of CA4P are typically transient in nature, limited to the period of time following administration when the active form of CA4P is in the body in significant concentrations.", "type": 2, "words": ["<tag1>", "Because", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "is", "relatively", "short,", "the", "effects", "of", "fosbretabulin", "on", "tubulin", "are", "reversible,", "and", "fosbretabulin", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "fosbretabulin", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "fosbretabulin", "is", "in", "the", "body", "in", "significant", "concentrations.", "<tag2>", "The", "side-effects", "of", "CA4P", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "CA4P", "is", "in", "the", "body", "in", "significant", "concentrations.", "<tag3>"], "wordsA": ["Because", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "is", "relatively", "short,", "the", "effects", "of", "fosbretabulin", "on", "tubulin", "are", "reversible,", "and", "fosbretabulin", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week,", "the", "side-effects", "of", "fosbretabulin", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "fosbretabulin", "is", "in", "the", "body", "in", "significant", "concentrations."], "wordsB": ["The", "side-effects", "of", "CA4P", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "CA4P", "is", "in", "the", "body", "in", "significant", "concentrations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p46_s1", "idA": "908259_15_item1_p39_s2", "sentA": "This contrasts with drugs that interfere with blood vessel growth, known as anti-angiogenic agents, which are typically administered on a chronic basis so as to constantly maintain levels of drug in the body, exert their tumor blood-vessel growth inhibiting effects over days to weeks, and as a result can cause a variety of chronic side-effects that are not limited to the immediate period following administration.", "sentB": "This contrasts with AAs, which are typically administered on a chronic basis so as to constantly maintain levels of drug in the body.", "type": 2, "words": ["<tag1>", "This", "contrasts", "with", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "known", "as", "anti-angiogenic", "agents,", "which", "are", "typically", "administered", "on", "a", "chronic", "basis", "so", "as", "to", "constantly", "maintain", "levels", "of", "drug", "in", "the", "body,", "exert", "their", "tumor", "blood-vessel", "growth", "inhibiting", "effects", "over", "days", "to", "weeks,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration.", "<tag2>", "This", "contrasts", "with", "AAs,", "which", "are", "typically", "administered", "on", "a", "chronic", "basis", "so", "as", "to", "constantly", "maintain", "levels", "of", "drug", "in", "the", "body.", "<tag3>"], "wordsA": ["This", "contrasts", "with", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "known", "as", "anti-angiogenic", "agents,", "which", "are", "typically", "administered", "on", "a", "chronic", "basis", "so", "as", "to", "constantly", "maintain", "levels", "of", "drug", "in", "the", "body,", "exert", "their", "tumor", "blood-vessel", "growth", "inhibiting", "effects", "over", "days", "to", "weeks,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration."], "wordsB": ["This", "contrasts", "with", "AAs,", "which", "are", "typically", "administered", "on", "a", "chronic", "basis", "so", "as", "to", "constantly", "maintain", "levels", "of", "drug", "in", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p47_s0", "idA": "908259_15_item1_p39_s2", "sentA": "This contrasts with drugs that interfere with blood vessel growth, known as anti-angiogenic agents, which are typically administered on a chronic basis so as to constantly maintain levels of drug in the body, exert their tumor blood-vessel growth inhibiting effects over days to weeks, and as a result can cause a variety of chronic side-effects that are not limited to the immediate period following administration.", "sentB": "Currently approved AAs generally exert their tumor blood-vessel growth inhibiting effects over days to weeks to months, and as a result can cause a variety of chronic side-effects that are not limited to the immediate period following administration.", "type": 2, "words": ["<tag1>", "This", "contrasts", "with", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "known", "as", "anti-angiogenic", "agents,", "which", "are", "typically", "administered", "on", "a", "chronic", "basis", "so", "as", "to", "constantly", "maintain", "levels", "of", "drug", "in", "the", "body,", "exert", "their", "tumor", "blood-vessel", "growth", "inhibiting", "effects", "over", "days", "to", "weeks,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration.", "<tag2>", "Currently", "approved", "AAs", "generally", "exert", "their", "tumor", "blood-vessel", "growth", "inhibiting", "effects", "over", "days", "to", "weeks", "to", "months,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration.", "<tag3>"], "wordsA": ["This", "contrasts", "with", "drugs", "that", "interfere", "with", "blood", "vessel", "growth,", "known", "as", "anti-angiogenic", "agents,", "which", "are", "typically", "administered", "on", "a", "chronic", "basis", "so", "as", "to", "constantly", "maintain", "levels", "of", "drug", "in", "the", "body,", "exert", "their", "tumor", "blood-vessel", "growth", "inhibiting", "effects", "over", "days", "to", "weeks,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration."], "wordsB": ["Currently", "approved", "AAs", "generally", "exert", "their", "tumor", "blood-vessel", "growth", "inhibiting", "effects", "over", "days", "to", "weeks", "to", "months,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p48_s0", "idA": "908259_15_item1_p39_s3", "sentA": "In contrast with anti-angiogenic agents, which can cause a variety of chronic side-effects, side-effects associated with fosbretabulin are typically transient and manageable.", "sentB": "Side-effects associated with CA4P are generally transient and manageable.", "type": 2, "words": ["<tag1>", "In", "contrast", "with", "anti-angiogenic", "agents,", "which", "can", "cause", "a", "variety", "of", "chronic", "side-effects,", "side-effects", "associated", "with", "fosbretabulin", "are", "typically", "transient", "and", "manageable.", "<tag2>", "Side-effects", "associated", "with", "CA4P", "are", "generally", "transient", "and", "manageable.", "<tag3>"], "wordsA": ["In", "contrast", "with", "anti-angiogenic", "agents,", "which", "can", "cause", "a", "variety", "of", "chronic", "side-effects,", "side-effects", "associated", "with", "fosbretabulin", "are", "typically", "transient", "and", "manageable."], "wordsB": ["Side-effects", "associated", "with", "CA4P", "are", "generally", "transient", "and", "manageable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p9_s1", "idA": "908259_15_item1_p3_s1", "sentA": "Patients are said to have platinum-resistant disease if the disease worsens within six months of completing platinum-based chemotherapy.", "sentB": "Patients are said to have platinum-resistant disease if the disease progresses within six months of completing platinum-based chemotherapy.", "type": 2, "words": ["<tag1>", "Patients", "are", "said", "to", "have", "platinum-resistant", "disease", "if", "the", "disease", "worsens", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy.", "<tag2>", "Patients", "are", "said", "to", "have", "platinum-resistant", "disease", "if", "the", "disease", "progresses", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy.", "<tag3>"], "wordsA": ["Patients", "are", "said", "to", "have", "platinum-resistant", "disease", "if", "the", "disease", "worsens", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy."], "wordsB": ["Patients", "are", "said", "to", "have", "platinum-resistant", "disease", "if", "the", "disease", "progresses", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p27_s1", "idA": "908259_15_item1_p3_s2", "sentA": "One quarter of those who relapse after initial treatment, or more than 4,300 women, will have platinum-resistant cancer, the most difficult-to-treat form of the disease.", "sentB": "ATC is one of the most aggressive tumors known and has very few treatment options.", "type": 2, "words": ["<tag1>", "One", "quarter", "of", "those", "who", "relapse", "after", "initial", "treatment,", "or", "more", "than", "4,300", "women,", "will", "have", "platinum-resistant", "cancer,", "the", "most", "difficult-to-treat", "form", "of", "the", "disease.", "<tag2>", "ATC", "is", "one", "of", "the", "most", "aggressive", "tumors", "known", "and", "has", "very", "few", "treatment", "options.", "<tag3>"], "wordsA": ["One", "quarter", "of", "those", "who", "relapse", "after", "initial", "treatment,", "or", "more", "than", "4,300", "women,", "will", "have", "platinum-resistant", "cancer,", "the", "most", "difficult-to-treat", "form", "of", "the", "disease."], "wordsB": ["ATC", "is", "one", "of", "the", "most", "aggressive", "tumors", "known", "and", "has", "very", "few", "treatment", "options."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p48_s1", "idA": "908259_15_item1_p40_s0", "sentA": "effects include infusion-related side effects such as nausea, vomiting, headache and fatigue, and tumor pain, which is consistent with the drug s mechanism-of-action.", "sentB": "The most frequent CA4P side-effects include acute blood pressure increases, infusion-related side effects such as nausea, vomiting, headache and fatigue, and tumor pain, which is consistent with the drug s mechanism-of-action.", "type": 2, "words": ["<tag1>", "effects", "include", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action.", "<tag2>", "The", "most", "frequent", "CA4P", "side-effects", "include", "acute", "blood", "pressure", "increases,", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action.", "<tag3>"], "wordsA": ["effects", "include", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action."], "wordsB": ["The", "most", "frequent", "CA4P", "side-effects", "include", "acute", "blood", "pressure", "increases,", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p48_s2", "idA": "908259_15_item1_p40_s2", "sentA": "Approximately 10-20% of patients treated with fosbretabulin experience clinically-significant and transient hypertension that can be readily managed and prevented after initial occurrence with straightforward oral anti-hypertensive therapy.", "sentB": "Approximately 10-20% of patients treated with CA4P experience clinically-significant acute blood pressure increases, which are often manageable by controlling underlying hypertension or treating with short-acting anti-hypertensives prior to CA4P infusion.", "type": 2, "words": ["<tag1>", "Approximately", "10-20%", "of", "patients", "treated", "with", "fosbretabulin", "experience", "clinically-significant", "and", "transient", "hypertension", "that", "can", "be", "readily", "managed", "and", "prevented", "after", "initial", "occurrence", "with", "straightforward", "oral", "anti-hypertensive", "therapy.", "<tag2>", "Approximately", "10-20%", "of", "patients", "treated", "with", "CA4P", "experience", "clinically-significant", "acute", "blood", "pressure", "increases,", "which", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion.", "<tag3>"], "wordsA": ["Approximately", "10-20%", "of", "patients", "treated", "with", "fosbretabulin", "experience", "clinically-significant", "and", "transient", "hypertension", "that", "can", "be", "readily", "managed", "and", "prevented", "after", "initial", "occurrence", "with", "straightforward", "oral", "anti-hypertensive", "therapy."], "wordsB": ["Approximately", "10-20%", "of", "patients", "treated", "with", "CA4P", "experience", "clinically-significant", "acute", "blood", "pressure", "increases,", "which", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p49_s0", "idA": "908259_15_item1_p40_s3", "sentA": "In an analysis undertaken by us, the incidence of serious cardiovascular side-effects such as angina and myocardial ischemia observed across all studies to date (including early studies in which hypertension management and prevention was not employed) was less than 3%, a frequency comparable to that reported with approved anti-angiogenic agents such as bevacizumab, sunitinib and sorafenib.", "sentB": "The incidence of serious cardiovascular side-effects such as angina and myocardial ischemia observed across all studies to date (including early studies in which hypertension management and prevention was not employed) was less than 3%, a frequency comparable to that reported with approved anti-angiogenic agents such as bevacizumab, sunitinib and sorafenib.", "type": 2, "words": ["<tag1>", "In", "an", "analysis", "undertaken", "by", "us,", "the", "incidence", "of", "serious", "cardiovascular", "side-effects", "such", "as", "angina", "and", "myocardial", "ischemia", "observed", "across", "all", "studies", "to", "date", "(including", "early", "studies", "in", "which", "hypertension", "management", "and", "prevention", "was", "not", "employed)", "was", "less", "than", "3%,", "a", "frequency", "comparable", "to", "that", "reported", "with", "approved", "anti-angiogenic", "agents", "such", "as", "bevacizumab,", "sunitinib", "and", "sorafenib.", "<tag2>", "The", "incidence", "of", "serious", "cardiovascular", "side-effects", "such", "as", "angina", "and", "myocardial", "ischemia", "observed", "across", "all", "studies", "to", "date", "(including", "early", "studies", "in", "which", "hypertension", "management", "and", "prevention", "was", "not", "employed)", "was", "less", "than", "3%,", "a", "frequency", "comparable", "to", "that", "reported", "with", "approved", "anti-angiogenic", "agents", "such", "as", "bevacizumab,", "sunitinib", "and", "sorafenib.", "<tag3>"], "wordsA": ["In", "an", "analysis", "undertaken", "by", "us,", "the", "incidence", "of", "serious", "cardiovascular", "side-effects", "such", "as", "angina", "and", "myocardial", "ischemia", "observed", "across", "all", "studies", "to", "date", "(including", "early", "studies", "in", "which", "hypertension", "management", "and", "prevention", "was", "not", "employed)", "was", "less", "than", "3%,", "a", "frequency", "comparable", "to", "that", "reported", "with", "approved", "anti-angiogenic", "agents", "such", "as", "bevacizumab,", "sunitinib", "and", "sorafenib."], "wordsB": ["The", "incidence", "of", "serious", "cardiovascular", "side-effects", "such", "as", "angina", "and", "myocardial", "ischemia", "observed", "across", "all", "studies", "to", "date", "(including", "early", "studies", "in", "which", "hypertension", "management", "and", "prevention", "was", "not", "employed)", "was", "less", "than", "3%,", "a", "frequency", "comparable", "to", "that", "reported", "with", "approved", "anti-angiogenic", "agents", "such", "as", "bevacizumab,", "sunitinib", "and", "sorafenib."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p50_s0", "idA": "908259_15_item1_p41_s0", "sentA": "Our strategy is to develop innovative therapeutics for oncology.", "sentB": "Our strategy is to develop innovative therapeutics for oncology, with a larger goal of ultimately transforming vascular targeted therapies to include VDAs in order to improve patient outcomes.", "type": 2, "words": ["<tag1>", "Our", "strategy", "is", "to", "develop", "innovative", "therapeutics", "for", "oncology.", "<tag2>", "Our", "strategy", "is", "to", "develop", "innovative", "therapeutics", "for", "oncology,", "with", "a", "larger", "goal", "of", "ultimately", "transforming", "vascular", "targeted", "therapies", "to", "include", "VDAs", "in", "order", "to", "improve", "patient", "outcomes.", "<tag3>"], "wordsA": ["Our", "strategy", "is", "to", "develop", "innovative", "therapeutics", "for", "oncology."], "wordsB": ["Our", "strategy", "is", "to", "develop", "innovative", "therapeutics", "for", "oncology,", "with", "a", "larger", "goal", "of", "ultimately", "transforming", "vascular", "targeted", "therapies", "to", "include", "VDAs", "in", "order", "to", "improve", "patient", "outcomes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p50_s1", "idA": "908259_15_item1_p41_s1", "sentA": "Our principal focus is to advance the clinical development and commercialization of our drug candidates fosbretabulin and OXi4503 and to identify new preclinical candidates that are complementary to our VDAs.", "sentB": "Our principal focus is to advance the clinical development of our drug candidates, CA4P and OXi4503, and to identify new preclinical candidates that are complementary to our VDAs.", "type": 2, "words": ["<tag1>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "fosbretabulin", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag2>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "of", "our", "drug", "candidates,", "CA4P", "and", "OXi4503,", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag3>"], "wordsA": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "fosbretabulin", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "wordsB": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "of", "our", "drug", "candidates,", "CA4P", "and", "OXi4503,", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p50_s2", "idA": "908259_15_item1_p41_s2", "sentA": "To advance our strategy, we have established relationships with universities, research organizations and other institutions in these fields.", "sentB": "To help advance our strategy, we have established relationships with universities, research organizations and other institutions in these fields.", "type": 2, "words": ["<tag1>", "To", "advance", "our", "strategy,", "we", "have", "established", "relationships", "with", "universities,", "research", "organizations", "and", "other", "institutions", "in", "these", "fields.", "<tag2>", "To", "help", "advance", "our", "strategy,", "we", "have", "established", "relationships", "with", "universities,", "research", "organizations", "and", "other", "institutions", "in", "these", "fields.", "<tag3>"], "wordsA": ["To", "advance", "our", "strategy,", "we", "have", "established", "relationships", "with", "universities,", "research", "organizations", "and", "other", "institutions", "in", "these", "fields."], "wordsB": ["To", "help", "advance", "our", "strategy,", "we", "have", "established", "relationships", "with", "universities,", "research", "organizations", "and", "other", "institutions", "in", "these", "fields."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p39_s4", "idA": "908259_15_item1_p41_s3", "sentA": "We intend to continue to rely on these relationships, rather than expand our in-house research and development staff.", "sentB": "We intend for substantially all of our future CA4P development to be focused on this combination, rather than pursuing CA4P approval as a single therapy.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "continue", "to", "rely", "on", "these", "relationships,", "rather", "than", "expand", "our", "in-house", "research", "and", "development", "staff.", "<tag2>", "We", "intend", "for", "substantially", "all", "of", "our", "future", "CA4P", "development", "to", "be", "focused", "on", "this", "combination,", "rather", "than", "pursuing", "CA4P", "approval", "as", "a", "single", "therapy.", "<tag3>"], "wordsA": ["We", "intend", "to", "continue", "to", "rely", "on", "these", "relationships,", "rather", "than", "expand", "our", "in-house", "research", "and", "development", "staff."], "wordsB": ["We", "intend", "for", "substantially", "all", "of", "our", "future", "CA4P", "development", "to", "be", "focused", "on", "this", "combination,", "rather", "than", "pursuing", "CA4P", "approval", "as", "a", "single", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p50_s5", "idA": "908259_15_item1_p41_s5", "sentA": "Currently, we have collaborative agreements and arrangements with a number of institutions in the United States and abroad, which we utilize to perform the day-to-day activities associated with drug development.", "sentB": "Currently, we have collaborative agreements and arrangements with a number of institutions in the United States and abroad, which we utilize to perform the day-to-day activities associated with drug discovery and/or development.", "type": 2, "words": ["<tag1>", "Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "development.", "<tag2>", "Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "discovery", "and/or", "development.", "<tag3>"], "wordsA": ["Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "development."], "wordsB": ["Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "discovery", "and/or", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p50_s6", "idA": "908259_15_item1_p41_s6", "sentA": "In 2014, collaborations and agreements were ongoing with a variety of university and research institutions, including the following:", "sentB": "In 2015, collaborations and agreements were ongoing with a variety of universities and research institutions, including the following:", "type": 2, "words": ["<tag1>", "In", "2014,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:", "<tag2>", "In", "2015,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "universities", "and", "research", "institutions,", "including", "the", "following:", "<tag3>"], "wordsA": ["In", "2014,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:"], "wordsB": ["In", "2015,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "universities", "and", "research", "institutions,", "including", "the", "following:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p98_s0", "idA": "908259_15_item1_p42_s7", "sentA": "There was no transfer of ownership of intellectual property rights for fosbretabulin to the Danish company under the terms of the agreement.", "sentB": "The ACA also made changes to the drug coverage requirements under the Medicare Part D program.", "type": 2, "words": ["<tag1>", "There", "was", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "fosbretabulin", "to", "the", "Danish", "company", "under", "the", "terms", "of", "the", "agreement.", "<tag2>", "The", "ACA", "also", "made", "changes", "to", "the", "drug", "coverage", "requirements", "under", "the", "Medicare", "Part", "D", "program.", "<tag3>"], "wordsA": ["There", "was", "no", "transfer", "of", "ownership", "of", "intellectual", "property", "rights", "for", "fosbretabulin", "to", "the", "Danish", "company", "under", "the", "terms", "of", "the", "agreement."], "wordsB": ["The", "ACA", "also", "made", "changes", "to", "the", "drug", "coverage", "requirements", "under", "the", "Medicare", "Part", "D", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p51_s0", "idA": "908259_15_item1_p43_s0", "sentA": "We have secured a technology license from Arizona State University, or ASU.", "sentB": "For rights to CA4P, we have secured a technology license from Arizona State University, or ASU.", "type": 2, "words": ["<tag1>", "We", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU.", "<tag2>", "For", "rights", "to", "CA4P,", "we", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU.", "<tag3>"], "wordsA": ["We", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU."], "wordsB": ["For", "rights", "to", "CA4P,", "we", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p51_s1", "idA": "908259_15_item1_p43_s1", "sentA": "The ASU license is an exclusive, world-wide, royalty-bearing license for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, fosbretabulin and OXi4503.", "sentB": "The ASU license is an exclusive, world-wide, royalty-bearing license for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, CA4P and OXi4503.", "type": 2, "words": ["<tag1>", "The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "fosbretabulin", "and", "OXi4503.", "<tag2>", "The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P", "and", "OXi4503.", "<tag3>"], "wordsA": ["The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "fosbretabulin", "and", "OXi4503."], "wordsB": ["The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p55_s5", "idA": "908259_15_item1_p47_s1", "sentA": "Either party may terminate the license agreement upon material default or bankruptcy of the other party.", "sentB": "Either party may terminate the ASU license agreement upon material default or bankruptcy of the other party.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "license", "agreement", "upon", "material", "default", "or", "bankruptcy", "of", "the", "other", "party.", "<tag2>", "Either", "party", "may", "terminate", "the", "ASU", "license", "agreement", "upon", "material", "default", "or", "bankruptcy", "of", "the", "other", "party.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "license", "agreement", "upon", "material", "default", "or", "bankruptcy", "of", "the", "other", "party."], "wordsB": ["Either", "party", "may", "terminate", "the", "ASU", "license", "agreement", "upon", "material", "default", "or", "bankruptcy", "of", "the", "other", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p55_s6", "idA": "908259_15_item1_p47_s2", "sentA": "In addition, we may terminate the agreement by either (i) determining that filing for regulatory approval is not warranted by the clinical testing date or (ii) by providing two months written notice of our intent to terminate the agreement.", "sentB": "In addition, we may terminate the agreement by either (i) determining that filing for regulatory approval is not warranted or economically feasible by the clinical testing date or (ii) by providing two months written notice of our intent to terminate the agreement.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "may", "terminate", "the", "agreement", "by", "either", "(i)", "determining", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "by", "the", "clinical", "testing", "date", "or", "(ii)", "by", "providing", "two", "months", "written", "notice", "of", "our", "intent", "to", "terminate", "the", "agreement.", "<tag2>", "In", "addition,", "we", "may", "terminate", "the", "agreement", "by", "either", "(i)", "determining", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "or", "economically", "feasible", "by", "the", "clinical", "testing", "date", "or", "(ii)", "by", "providing", "two", "months", "written", "notice", "of", "our", "intent", "to", "terminate", "the", "agreement.", "<tag3>"], "wordsA": ["In", "addition,", "we", "may", "terminate", "the", "agreement", "by", "either", "(i)", "determining", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "by", "the", "clinical", "testing", "date", "or", "(ii)", "by", "providing", "two", "months", "written", "notice", "of", "our", "intent", "to", "terminate", "the", "agreement."], "wordsB": ["In", "addition,", "we", "may", "terminate", "the", "agreement", "by", "either", "(i)", "determining", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "or", "economically", "feasible", "by", "the", "clinical", "testing", "date", "or", "(ii)", "by", "providing", "two", "months", "written", "notice", "of", "our", "intent", "to", "terminate", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p55_s3", "idA": "908259_15_item1_p47_s3", "sentA": "Payments made to ASU to date have amounted to $2,600,000.", "sentB": "Payments made to ASU to date have amounted to $2,700,000.", "type": 2, "words": ["<tag1>", "Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,600,000.", "<tag2>", "Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,700,000.", "<tag3>"], "wordsA": ["Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,600,000."], "wordsB": ["Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,700,000."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p0_s2", "idA": "908259_15_item1_p48_s0", "sentA": "Cathepsin-L is an enzyme involved in protein degradation and has been shown to be closely involved in the processes of angiogenesis and metastasis.", "sentB": "Treatment with VDAs has been shown to lead to significant central tumor necrosis, which refers to the death of cancer cells.", "type": 2, "words": ["<tag1>", "Cathepsin-L", "is", "an", "enzyme", "involved", "in", "protein", "degradation", "and", "has", "been", "shown", "to", "be", "closely", "involved", "in", "the", "processes", "of", "angiogenesis", "and", "metastasis.", "<tag2>", "Treatment", "with", "VDAs", "has", "been", "shown", "to", "lead", "to", "significant", "central", "tumor", "necrosis,", "which", "refers", "to", "the", "death", "of", "cancer", "cells.", "<tag3>"], "wordsA": ["Cathepsin-L", "is", "an", "enzyme", "involved", "in", "protein", "degradation", "and", "has", "been", "shown", "to", "be", "closely", "involved", "in", "the", "processes", "of", "angiogenesis", "and", "metastasis."], "wordsB": ["Treatment", "with", "VDAs", "has", "been", "shown", "to", "lead", "to", "significant", "central", "tumor", "necrosis,", "which", "refers", "to", "the", "death", "of", "cancer", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p39_s5", "idA": "908259_15_item1_p49_s0", "sentA": "Small molecule inhibitors may have the potential to slow tumor growth and metastasis in a manner we believe could be complementary with our VDA therapeutics.", "sentB": "We believe our VDAs are a second generation of VTTs that have the potential to improve upon the efficacy of AAs, the first generation of VTTs.", "type": 2, "words": ["<tag1>", "Small", "molecule", "inhibitors", "may", "have", "the", "potential", "to", "slow", "tumor", "growth", "and", "metastasis", "in", "a", "manner", "we", "believe", "could", "be", "complementary", "with", "our", "VDA", "therapeutics.", "<tag2>", "We", "believe", "our", "VDAs", "are", "a", "second", "generation", "of", "VTTs", "that", "have", "the", "potential", "to", "improve", "upon", "the", "efficacy", "of", "AAs,", "the", "first", "generation", "of", "VTTs.", "<tag3>"], "wordsA": ["Small", "molecule", "inhibitors", "may", "have", "the", "potential", "to", "slow", "tumor", "growth", "and", "metastasis", "in", "a", "manner", "we", "believe", "could", "be", "complementary", "with", "our", "VDA", "therapeutics."], "wordsB": ["We", "believe", "our", "VDAs", "are", "a", "second", "generation", "of", "VTTs", "that", "have", "the", "potential", "to", "improve", "upon", "the", "efficacy", "of", "AAs,", "the", "first", "generation", "of", "VTTs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p58_s12", "idA": "908259_15_item1_p49_s12", "sentA": "We also have an exclusive, world-wide, royalty-bearing license from Bristol-Myers Squibb, or BMS, for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, fosbretabulin.", "sentB": "We also have an exclusive, world-wide, royalty-bearing license from Bristol-Myers Squibb, or BMS, for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, CA4P. Under the BMS license, we have the right to grant sublicenses, and BMS is entitled to low single-digit royalty payments for all commercial sales plus any remuneration we receive for sale of CA4P under named patient or compassionate use programs.", "type": 2, "words": ["<tag1>", "We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "fosbretabulin.", "<tag2>", "We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs.", "<tag3>"], "wordsA": ["We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "fosbretabulin."], "wordsB": ["We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p58_s13", "idA": "908259_15_item1_p49_s15", "sentA": "All licensing fees and milestone payments under the license agreement, in the aggregate amount of $1,080,000, have been paid.", "sentB": "All licensing fees and milestone payments under the BMS license, in the aggregate amount of $1,080,000, have been paid.", "type": 2, "words": ["<tag1>", "All", "licensing", "fees", "and", "milestone", "payments", "under", "the", "license", "agreement,", "in", "the", "aggregate", "amount", "of", "$1,080,000,", "have", "been", "paid.", "<tag2>", "All", "licensing", "fees", "and", "milestone", "payments", "under", "the", "BMS", "license,", "in", "the", "aggregate", "amount", "of", "$1,080,000,", "have", "been", "paid.", "<tag3>"], "wordsA": ["All", "licensing", "fees", "and", "milestone", "payments", "under", "the", "license", "agreement,", "in", "the", "aggregate", "amount", "of", "$1,080,000,", "have", "been", "paid."], "wordsB": ["All", "licensing", "fees", "and", "milestone", "payments", "under", "the", "BMS", "license,", "in", "the", "aggregate", "amount", "of", "$1,080,000,", "have", "been", "paid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p93_s1", "idA": "908259_15_item1_p49_s6", "sentA": "We are not required to pay Baylor for use of Baylor s compounds other than pursuant to this royalty arrangement.", "sentB": "Under Part D (the Medicare prescription drug benefit), Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs not covered under Medicare Part B. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs.", "type": 2, "words": ["<tag1>", "We", "are", "not", "required", "to", "pay", "Baylor", "for", "use", "of", "Baylor", "s", "compounds", "other", "than", "pursuant", "to", "this", "royalty", "arrangement.", "<tag2>", "Under", "Part", "D", "(the", "Medicare", "prescription", "drug", "benefit),", "Medicare", "beneficiaries", "may", "enroll", "in", "prescription", "drug", "plans", "offered", "by", "private", "entities", "that", "provide", "coverage", "of", "outpatient", "prescription", "drugs", "not", "covered", "under", "Medicare", "Part", "B.", "Part", "D", "prescription", "drug", "plan", "sponsors", "are", "not", "required", "to", "pay", "for", "all", "covered", "Part", "D", "drugs.", "<tag3>"], "wordsA": ["We", "are", "not", "required", "to", "pay", "Baylor", "for", "use", "of", "Baylor", "s", "compounds", "other", "than", "pursuant", "to", "this", "royalty", "arrangement."], "wordsB": ["Under", "Part", "D", "(the", "Medicare", "prescription", "drug", "benefit),", "Medicare", "beneficiaries", "may", "enroll", "in", "prescription", "drug", "plans", "offered", "by", "private", "entities", "that", "provide", "coverage", "of", "outpatient", "prescription", "drugs", "not", "covered", "under", "Medicare", "Part", "B.", "Part", "D", "prescription", "drug", "plan", "sponsors", "are", "not", "required", "to", "pay", "for", "all", "covered", "Part", "D", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p95_s0", "idA": "908259_15_item1_p49_s7", "sentA": "We are entitled to file, prosecute and maintain patent applications on products for which we have a license under this agreement.", "sentB": "In general, government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "file,", "prosecute", "and", "maintain", "patent", "applications", "on", "products", "for", "which", "we", "have", "a", "license", "under", "this", "agreement.", "<tag2>", "In", "general,", "government", "payment", "for", "some", "of", "the", "costs", "of", "prescription", "drugs", "may", "increase", "demand", "for", "products", "for", "which", "we", "receive", "marketing", "approval.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "file,", "prosecute", "and", "maintain", "patent", "applications", "on", "products", "for", "which", "we", "have", "a", "license", "under", "this", "agreement."], "wordsB": ["In", "general,", "government", "payment", "for", "some", "of", "the", "costs", "of", "prescription", "drugs", "may", "increase", "demand", "for", "products", "for", "which", "we", "receive", "marketing", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p10_s1", "idA": "908259_15_item1_p4_s1", "sentA": "Approved drugs include carboplatin and cisplatin, gemcitabine, doxorubicin, paclitaxel and bevacizumab.", "sentB": "Approved drugs include bevacizumab, carboplatin and cisplatin, gemcitabine, doxorubicin, paclitaxel and olaparib.", "type": 2, "words": ["<tag1>", "Approved", "drugs", "include", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "bevacizumab.", "<tag2>", "Approved", "drugs", "include", "bevacizumab,", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "olaparib.", "<tag3>"], "wordsA": ["Approved", "drugs", "include", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "bevacizumab."], "wordsB": ["Approved", "drugs", "include", "bevacizumab,", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "olaparib."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p59_s0", "idA": "908259_15_item1_p50_s0", "sentA": "We bear the costs of preparing, filing, prosecuting and maintaining all patent applications under the BMS license and have a right, but not a duty, of enforcing patents covered by the license.", "sentB": "preparing, filing, prosecuting and maintaining all patent applications under the BMS license and have a right, but not a duty, of enforcing patents covered by the license.", "type": 2, "words": ["<tag1>", "We", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license.", "<tag2>", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license.", "<tag3>"], "wordsA": ["We", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license."], "wordsB": ["preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p59_s1", "idA": "908259_15_item1_p50_s1", "sentA": "Either party may terminate the license upon material default of the other party.", "sentB": "Either party may terminate the BMS license upon material default of the other party.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party.", "<tag2>", "Either", "party", "may", "terminate", "the", "BMS", "license", "upon", "material", "default", "of", "the", "other", "party.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party."], "wordsB": ["Either", "party", "may", "terminate", "the", "BMS", "license", "upon", "material", "default", "of", "the", "other", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p59_s2", "idA": "908259_15_item1_p50_s2", "sentA": "The term of the license shall end upon the expiration of the licensed patents.", "sentB": "The term of the BMS license shall end upon the expiration of the licensed patents.", "type": 2, "words": ["<tag1>", "The", "term", "of", "the", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents.", "<tag2>", "The", "term", "of", "the", "BMS", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents.", "<tag3>"], "wordsA": ["The", "term", "of", "the", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents."], "wordsB": ["The", "term", "of", "the", "BMS", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p59_s3", "idA": "908259_15_item1_p50_s3", "sentA": "The latest United States patent licensed under this agreement is scheduled to expire in December 2021, excluding a patent term extension available under the Hatch-Waxman Act.", "sentB": "The latest United States patent licensed under the BMS license is scheduled to expire in December 2021, excluding a patent term extension available under the Hatch-Waxman Act.", "type": 2, "words": ["<tag1>", "The", "latest", "United", "States", "patent", "licensed", "under", "this", "agreement", "is", "scheduled", "to", "expire", "in", "December", "2021,", "excluding", "a", "patent", "term", "extension", "available", "under", "the", "Hatch-Waxman", "Act.", "<tag2>", "The", "latest", "United", "States", "patent", "licensed", "under", "the", "BMS", "license", "is", "scheduled", "to", "expire", "in", "December", "2021,", "excluding", "a", "patent", "term", "extension", "available", "under", "the", "Hatch-Waxman", "Act.", "<tag3>"], "wordsA": ["The", "latest", "United", "States", "patent", "licensed", "under", "this", "agreement", "is", "scheduled", "to", "expire", "in", "December", "2021,", "excluding", "a", "patent", "term", "extension", "available", "under", "the", "Hatch-Waxman", "Act."], "wordsB": ["The", "latest", "United", "States", "patent", "licensed", "under", "the", "BMS", "license", "is", "scheduled", "to", "expire", "in", "December", "2021,", "excluding", "a", "patent", "term", "extension", "available", "under", "the", "Hatch-Waxman", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p60_s0", "idA": "908259_15_item1_p51_s0", "sentA": "In June 2012, we secured a royalty-bearing, transferable, worldwide, exclusive license from Angiogene Pharmaceuticals Ltd. to make, have made, use, import, offer for sale, and sell a vascular disrupting agent, such as fosbretabulin, for treating neuroendocrine tumors and associated symptoms and syndromes.", "sentB": "In June 2012, we secured a royalty-bearing, transferable, worldwide, exclusive license from Angiogene Pharmaceuticals Ltd., or Angiogene, to make, have made, use, import, offer for sale, and sell a vascular disrupting agent, such as CA4P, for treating neuroendocrine tumors and associated symptoms and syndromes.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "fosbretabulin,", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes.", "<tag2>", "In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.,", "or", "Angiogene,", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "CA4P,", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "fosbretabulin,", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes."], "wordsB": ["In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.,", "or", "Angiogene,", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "CA4P,", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p60_s3", "idA": "908259_15_item1_p53_s0", "sentA": "for a product using Angiogene intellectual property.", "sentB": "Milestone payments are due upon initiation of the first clinical trial for a product using Angiogene intellectual property and initiation of the first registration clinical trial for a product using Angiogene intellectual property.", "type": 2, "words": ["<tag1>", "for", "a", "product", "using", "Angiogene", "intellectual", "property.", "<tag2>", "Milestone", "payments", "are", "due", "upon", "initiation", "of", "the", "first", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property", "and", "initiation", "of", "the", "first", "registration", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property.", "<tag3>"], "wordsA": ["for", "a", "product", "using", "Angiogene", "intellectual", "property."], "wordsB": ["Milestone", "payments", "are", "due", "upon", "initiation", "of", "the", "first", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property", "and", "initiation", "of", "the", "first", "registration", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p61_s1", "idA": "908259_15_item1_p53_s2", "sentA": "Payments to Angiogene under this license to date have amounted to $300,000.", "sentB": "Payments to Angiogene under this license to date have amounted to $375,000.", "type": 2, "words": ["<tag1>", "Payments", "to", "Angiogene", "under", "this", "license", "to", "date", "have", "amounted", "to", "$300,000.", "<tag2>", "Payments", "to", "Angiogene", "under", "this", "license", "to", "date", "have", "amounted", "to", "$375,000.", "<tag3>"], "wordsA": ["Payments", "to", "Angiogene", "under", "this", "license", "to", "date", "have", "amounted", "to", "$300,000."], "wordsB": ["Payments", "to", "Angiogene", "under", "this", "license", "to", "date", "have", "amounted", "to", "$375,000."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p62_s2", "idA": "908259_15_item1_p54_s2", "sentA": "Information contained on our web site does not form a part of this Annual Report on Form 10-K. REGULATORY MATTERS Government Regulation and Product Approval Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing.", "sentB": "Information contained on, or that can be accessed through, our web site is not and shall not be deemed to be a part of this Annual Report on Form 10-K. REGULATORY MATTERS Government Regulation and Product Approval Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing.", "type": 2, "words": ["<tag1>", "Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag2>", "Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "web", "site", "is", "not", "and", "shall", "not", "be", "deemed", "to", "be", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag3>"], "wordsA": ["Information", "contained", "on", "our", "web", "site", "does", "not", "form", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "wordsB": ["Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "web", "site", "is", "not", "and", "shall", "not", "be", "deemed", "to", "be", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p100_s0", "idA": "908259_15_item1_p54_s3", "sentA": "Our drugs must be approved by FDA through the new drug application, or NDA, process before they may be legally marketed in the United States.", "sentB": "In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed.", "type": 2, "words": ["<tag1>", "Our", "drugs", "must", "be", "approved", "by", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States.", "<tag2>", "In", "addition,", "in", "some", "foreign", "countries,", "the", "proposed", "pricing", "for", "a", "drug", "must", "be", "approved", "before", "it", "may", "be", "lawfully", "marketed.", "<tag3>"], "wordsA": ["Our", "drugs", "must", "be", "approved", "by", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States."], "wordsB": ["In", "addition,", "in", "some", "foreign", "countries,", "the", "proposed", "pricing", "for", "a", "drug", "must", "be", "approved", "before", "it", "may", "be", "lawfully", "marketed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p62_s3", "idA": "908259_15_item1_p54_s3", "sentA": "Our drugs must be approved by FDA through the new drug application, or NDA, process before they may be legally marketed in the United States.", "sentB": "Our drug candidates must be approved by the FDA through the New Drug Application, or NDA, process before they may be legally marketed in the United States.", "type": 2, "words": ["<tag1>", "Our", "drugs", "must", "be", "approved", "by", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States.", "<tag2>", "Our", "drug", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "the", "New", "Drug", "Application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Our", "drugs", "must", "be", "approved", "by", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States."], "wordsB": ["Our", "drug", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "the", "New", "Drug", "Application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p96_s2", "idA": "908259_15_item1_p54_s3", "sentA": "Our drugs must be approved by FDA through the new drug application, or NDA, process before they may be legally marketed in the United States.", "sentB": "The ACA also expanded coverage for the uninsured through the new health insurance exchanges and a significant increase in the number of individuals eligible for Medicaid coverage.", "type": 2, "words": ["<tag1>", "Our", "drugs", "must", "be", "approved", "by", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States.", "<tag2>", "The", "ACA", "also", "expanded", "coverage", "for", "the", "uninsured", "through", "the", "new", "health", "insurance", "exchanges", "and", "a", "significant", "increase", "in", "the", "number", "of", "individuals", "eligible", "for", "Medicaid", "coverage.", "<tag3>"], "wordsA": ["Our", "drugs", "must", "be", "approved", "by", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process", "before", "they", "may", "be", "legally", "marketed", "in", "the", "United", "States."], "wordsB": ["The", "ACA", "also", "expanded", "coverage", "for", "the", "uninsured", "through", "the", "new", "health", "insurance", "exchanges", "and", "a", "significant", "increase", "in", "the", "number", "of", "individuals", "eligible", "for", "Medicaid", "coverage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p39_s1", "idA": "908259_15_item1_p55_s4", "sentA": "Any agency or judicial enforcement action could have a material adverse effect on us.", "sentB": "VDAs such as CA4P have a direct effect on existing tumor blood vessels, and act by rapidly obstructing the blood supply to cancer tumors.", "type": 2, "words": ["<tag1>", "Any", "agency", "or", "judicial", "enforcement", "action", "could", "have", "a", "material", "adverse", "effect", "on", "us.", "<tag2>", "VDAs", "such", "as", "CA4P", "have", "a", "direct", "effect", "on", "existing", "tumor", "blood", "vessels,", "and", "act", "by", "rapidly", "obstructing", "the", "blood", "supply", "to", "cancer", "tumors.", "<tag3>"], "wordsA": ["Any", "agency", "or", "judicial", "enforcement", "action", "could", "have", "a", "material", "adverse", "effect", "on", "us."], "wordsB": ["VDAs", "such", "as", "CA4P", "have", "a", "direct", "effect", "on", "existing", "tumor", "blood", "vessels,", "and", "act", "by", "rapidly", "obstructing", "the", "blood", "supply", "to", "cancer", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p99_s2", "idA": "908259_15_item1_p55_s4", "sentA": "Any agency or judicial enforcement action could have a material adverse effect on us.", "sentB": "It is possible that the adoption of other legislative or regulatory proposals could have a material adverse effect on our business, financial condition and results of operations.", "type": 2, "words": ["<tag1>", "Any", "agency", "or", "judicial", "enforcement", "action", "could", "have", "a", "material", "adverse", "effect", "on", "us.", "<tag2>", "It", "is", "possible", "that", "the", "adoption", "of", "other", "legislative", "or", "regulatory", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations.", "<tag3>"], "wordsA": ["Any", "agency", "or", "judicial", "enforcement", "action", "could", "have", "a", "material", "adverse", "effect", "on", "us."], "wordsB": ["It", "is", "possible", "that", "the", "adoption", "of", "other", "legislative", "or", "regulatory", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p67_s3", "idA": "908259_15_item1_p59_s3", "sentA": "Clinical holds also may be imposed by the FDA at any time before or during studies due to safety concerns or non-compliance.", "sentB": "Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or non-compliance.", "type": 2, "words": ["<tag1>", "Clinical", "holds", "also", "may", "be", "imposed", "by", "the", "FDA", "at", "any", "time", "before", "or", "during", "studies", "due", "to", "safety", "concerns", "or", "non-compliance.", "<tag2>", "Clinical", "holds", "also", "may", "be", "imposed", "by", "the", "FDA", "at", "any", "time", "before", "or", "during", "clinical", "trials", "due", "to", "safety", "concerns", "or", "non-compliance.", "<tag3>"], "wordsA": ["Clinical", "holds", "also", "may", "be", "imposed", "by", "the", "FDA", "at", "any", "time", "before", "or", "during", "studies", "due", "to", "safety", "concerns", "or", "non-compliance."], "wordsB": ["Clinical", "holds", "also", "may", "be", "imposed", "by", "the", "FDA", "at", "any", "time", "before", "or", "during", "clinical", "trials", "due", "to", "safety", "concerns", "or", "non-compliance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p11_s0", "idA": "908259_15_item1_p5_s0", "sentA": "Due to the unmet need in the treatment of ovarian cancer and the small patient size of the indication in terms of number of patients, we have been granted an orphan drug designation in both the U.S. and Europe for the use of fosbretabulin in the treatment of ovarian cancer.", "sentB": "Due to the unmet need in the treatment of ovarian cancer and the small size of the indication in terms of number of patients, we have been granted an orphan drug designation in both the U.S. and the European Union for the use of CA4P in the treatment of ovarian cancer.", "type": 2, "words": ["<tag1>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "patient", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "use", "of", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "patient", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "use", "of", "fosbretabulin", "in", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p67_s4", "idA": "908259_15_item1_p60_s0", "sentA": "All clinical trials must be conducted under the supervision of qualified investigators in accordance with Good Clinical Practice regulations.", "sentB": "All clinical trials must be conducted under the supervision of qualified investigators in accordance with GCP regulations.", "type": 2, "words": ["<tag1>", "All", "clinical", "trials", "must", "be", "conducted", "under", "the", "supervision", "of", "qualified", "investigators", "in", "accordance", "with", "Good", "Clinical", "Practice", "regulations.", "<tag2>", "All", "clinical", "trials", "must", "be", "conducted", "under", "the", "supervision", "of", "qualified", "investigators", "in", "accordance", "with", "GCP", "regulations.", "<tag3>"], "wordsA": ["All", "clinical", "trials", "must", "be", "conducted", "under", "the", "supervision", "of", "qualified", "investigators", "in", "accordance", "with", "Good", "Clinical", "Practice", "regulations."], "wordsB": ["All", "clinical", "trials", "must", "be", "conducted", "under", "the", "supervision", "of", "qualified", "investigators", "in", "accordance", "with", "GCP", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p67_s8", "idA": "908259_15_item1_p60_s4", "sentA": "The IRB also approves the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative and must monitor the study until completed.", "sentB": "The IRB also approves the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative and must monitor the clinical trial until completed.", "type": 2, "words": ["<tag1>", "The", "IRB", "also", "approves", "the", "information", "regarding", "the", "trial", "and", "the", "consent", "form", "that", "must", "be", "provided", "to", "each", "trial", "subject", "or", "his", "or", "her", "legal", "representative", "and", "must", "monitor", "the", "study", "until", "completed.", "<tag2>", "The", "IRB", "also", "approves", "the", "information", "regarding", "the", "trial", "and", "the", "consent", "form", "that", "must", "be", "provided", "to", "each", "trial", "subject", "or", "his", "or", "her", "legal", "representative", "and", "must", "monitor", "the", "clinical", "trial", "until", "completed.", "<tag3>"], "wordsA": ["The", "IRB", "also", "approves", "the", "information", "regarding", "the", "trial", "and", "the", "consent", "form", "that", "must", "be", "provided", "to", "each", "trial", "subject", "or", "his", "or", "her", "legal", "representative", "and", "must", "monitor", "the", "study", "until", "completed."], "wordsB": ["The", "IRB", "also", "approves", "the", "information", "regarding", "the", "trial", "and", "the", "consent", "form", "that", "must", "be", "provided", "to", "each", "trial", "subject", "or", "his", "or", "her", "legal", "representative", "and", "must", "monitor", "the", "clinical", "trial", "until", "completed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p96_s4", "idA": "908259_15_item1_p60_s4", "sentA": "The IRB also approves the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative and must monitor the study until completed.", "sentB": "Because of the significant increase in the number of individuals covered and the expansion of the coverage that must be provided to them, commercial insurers and government programs have increased their emphasis on cost controls to reduce overall spending.", "type": 2, "words": ["<tag1>", "The", "IRB", "also", "approves", "the", "information", "regarding", "the", "trial", "and", "the", "consent", "form", "that", "must", "be", "provided", "to", "each", "trial", "subject", "or", "his", "or", "her", "legal", "representative", "and", "must", "monitor", "the", "study", "until", "completed.", "<tag2>", "Because", "of", "the", "significant", "increase", "in", "the", "number", "of", "individuals", "covered", "and", "the", "expansion", "of", "the", "coverage", "that", "must", "be", "provided", "to", "them,", "commercial", "insurers", "and", "government", "programs", "have", "increased", "their", "emphasis", "on", "cost", "controls", "to", "reduce", "overall", "spending.", "<tag3>"], "wordsA": ["The", "IRB", "also", "approves", "the", "information", "regarding", "the", "trial", "and", "the", "consent", "form", "that", "must", "be", "provided", "to", "each", "trial", "subject", "or", "his", "or", "her", "legal", "representative", "and", "must", "monitor", "the", "study", "until", "completed."], "wordsB": ["Because", "of", "the", "significant", "increase", "in", "the", "number", "of", "individuals", "covered", "and", "the", "expansion", "of", "the", "coverage", "that", "must", "be", "provided", "to", "them,", "commercial", "insurers", "and", "government", "programs", "have", "increased", "their", "emphasis", "on", "cost", "controls", "to", "reduce", "overall", "spending."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p67_s10", "idA": "908259_15_item1_p60_s6", "sentA": "Protocols detail, among other things, the objectives of the study, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and efficacy in Phase 2 and 3 clinical trials.", "sentB": "Protocols detail, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and efficacy in Phase 2 and 3 clinical trials.", "type": 2, "words": ["<tag1>", "Protocols", "detail,", "among", "other", "things,", "the", "objectives", "of", "the", "study,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "subject", "safety", "and", "efficacy", "in", "Phase", "2", "and", "3", "clinical", "trials.", "<tag2>", "Protocols", "detail,", "among", "other", "things,", "the", "objectives", "of", "the", "clinical", "trial,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "subject", "safety", "and", "efficacy", "in", "Phase", "2", "and", "3", "clinical", "trials.", "<tag3>"], "wordsA": ["Protocols", "detail,", "among", "other", "things,", "the", "objectives", "of", "the", "study,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "subject", "safety", "and", "efficacy", "in", "Phase", "2", "and", "3", "clinical", "trials."], "wordsB": ["Protocols", "detail,", "among", "other", "things,", "the", "objectives", "of", "the", "clinical", "trial,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "subject", "safety", "and", "efficacy", "in", "Phase", "2", "and", "3", "clinical", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p70_s0", "idA": "908259_15_item1_p63_s0", "sentA": "Phase 2: Involves studies in a limited patient population to identify possible adverse effects and safety risks, to evaluate preliminary efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.", "sentB": "Phase 2: Involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to evaluate preliminary efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.", "type": 2, "words": ["<tag1>", "Phase", "2:", "Involves", "studies", "in", "a", "limited", "patient", "population", "to", "identify", "possible", "adverse", "effects", "and", "safety", "risks,", "to", "evaluate", "preliminary", "efficacy", "of", "the", "product", "for", "specific", "targeted", "diseases", "and", "to", "determine", "dosage", "tolerance", "and", "optimal", "dosage.", "<tag2>", "Phase", "2:", "Involves", "clinical", "trials", "in", "a", "limited", "patient", "population", "to", "identify", "possible", "adverse", "effects", "and", "safety", "risks,", "to", "evaluate", "preliminary", "efficacy", "of", "the", "product", "for", "specific", "targeted", "diseases", "and", "to", "determine", "dosage", "tolerance", "and", "optimal", "dosage.", "<tag3>"], "wordsA": ["Phase", "2:", "Involves", "studies", "in", "a", "limited", "patient", "population", "to", "identify", "possible", "adverse", "effects", "and", "safety", "risks,", "to", "evaluate", "preliminary", "efficacy", "of", "the", "product", "for", "specific", "targeted", "diseases", "and", "to", "determine", "dosage", "tolerance", "and", "optimal", "dosage."], "wordsB": ["Phase", "2:", "Involves", "clinical", "trials", "in", "a", "limited", "patient", "population", "to", "identify", "possible", "adverse", "effects", "and", "safety", "risks,", "to", "evaluate", "preliminary", "efficacy", "of", "the", "product", "for", "specific", "targeted", "diseases", "and", "to", "determine", "dosage", "tolerance", "and", "optimal", "dosage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p71_s0", "idA": "908259_15_item1_p64_s0", "sentA": "Phase 3: Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites.", "sentB": "Phase 3: Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites.", "type": 2, "words": ["<tag1>", "Phase", "3:", "Clinical", "trials", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "study", "sites.", "<tag2>", "Phase", "3:", "Clinical", "trials", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "trial", "sites.", "<tag3>"], "wordsA": ["Phase", "3:", "Clinical", "trials", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "study", "sites."], "wordsB": ["Phase", "3:", "Clinical", "trials", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "trial", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p72_s2", "idA": "908259_15_item1_p65_s2", "sentA": "The request, which must be made prior to commencing the trial, must include the proposed protocol and protocol-specific questions that the sponsor would like the FDA to answer regarding the protocol design, study goals and data analysis for the proposed investigation.", "sentB": "The request, which must be made prior to commencing the trial, must include the proposed protocol and protocol-specific questions that the sponsor would like the FDA to answer regarding the protocol design, clinical trial goals and data analysis for the proposed investigation.", "type": 2, "words": ["<tag1>", "The", "request,", "which", "must", "be", "made", "prior", "to", "commencing", "the", "trial,", "must", "include", "the", "proposed", "protocol", "and", "protocol-specific", "questions", "that", "the", "sponsor", "would", "like", "the", "FDA", "to", "answer", "regarding", "the", "protocol", "design,", "study", "goals", "and", "data", "analysis", "for", "the", "proposed", "investigation.", "<tag2>", "The", "request,", "which", "must", "be", "made", "prior", "to", "commencing", "the", "trial,", "must", "include", "the", "proposed", "protocol", "and", "protocol-specific", "questions", "that", "the", "sponsor", "would", "like", "the", "FDA", "to", "answer", "regarding", "the", "protocol", "design,", "clinical", "trial", "goals", "and", "data", "analysis", "for", "the", "proposed", "investigation.", "<tag3>"], "wordsA": ["The", "request,", "which", "must", "be", "made", "prior", "to", "commencing", "the", "trial,", "must", "include", "the", "proposed", "protocol", "and", "protocol-specific", "questions", "that", "the", "sponsor", "would", "like", "the", "FDA", "to", "answer", "regarding", "the", "protocol", "design,", "study", "goals", "and", "data", "analysis", "for", "the", "proposed", "investigation."], "wordsB": ["The", "request,", "which", "must", "be", "made", "prior", "to", "commencing", "the", "trial,", "must", "include", "the", "proposed", "protocol", "and", "protocol-specific", "questions", "that", "the", "sponsor", "would", "like", "the", "FDA", "to", "answer", "regarding", "the", "protocol", "design,", "clinical", "trial", "goals", "and", "data", "analysis", "for", "the", "proposed", "investigation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p72_s7", "idA": "908259_15_item1_p66_s0", "sentA": "agreement will be documented and made part of the administrative record.", "sentB": "If the sponsor and the FDA reach agreement regarding the protocol, the agreement will be documented and made part of the administrative record.", "type": 2, "words": ["<tag1>", "agreement", "will", "be", "documented", "and", "made", "part", "of", "the", "administrative", "record.", "<tag2>", "If", "the", "sponsor", "and", "the", "FDA", "reach", "agreement", "regarding", "the", "protocol,", "the", "agreement", "will", "be", "documented", "and", "made", "part", "of", "the", "administrative", "record.", "<tag3>"], "wordsA": ["agreement", "will", "be", "documented", "and", "made", "part", "of", "the", "administrative", "record."], "wordsB": ["If", "the", "sponsor", "and", "the", "FDA", "reach", "agreement", "regarding", "the", "protocol,", "the", "agreement", "will", "be", "documented", "and", "made", "part", "of", "the", "administrative", "record."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s3", "idA": "908259_15_item1_p67_s0", "sentA": "Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA.", "sentB": "If results from the second stage of the clinical study meet the primary endpoint, we intend to submit a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA.", "type": 2, "words": ["<tag1>", "Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "trials", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA.", "<tag2>", "If", "results", "from", "the", "second", "stage", "of", "the", "clinical", "study", "meet", "the", "primary", "endpoint,", "we", "intend", "to", "submit", "a", "New", "Drug", "Application,", "or", "NDA,", "to", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA.", "<tag3>"], "wordsA": ["Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "trials", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA."], "wordsB": ["If", "results", "from", "the", "second", "stage", "of", "the", "clinical", "study", "meet", "the", "primary", "endpoint,", "we", "intend", "to", "submit", "a", "New", "Drug", "Application,", "or", "NDA,", "to", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p12_s0", "idA": "908259_15_item1_p6_s0", "sentA": "Fosbretabulin in combination with AVASTIN (bevacizumab) Completed Phase 2 Trial Genentech / Roche s AVASTIN (bevacizumab) is an anti-vascular endothelial growth factor, or VEGF, monoclonal antibody.", "sentB": "CA4P in Combination with Bevacizumab Completed Phase 2 Clinical Trial with Positive Results Genentech s bevacizumab is an anti-vascular endothelial growth factor, or VEGF, monoclonal antibody which has been approved for the treatment of ovarian cancer in the United States and elsewhere.", "type": 2, "words": ["<tag1>", "Fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "Completed", "Phase", "2", "Trial", "Genentech", "/", "Roche", "s", "AVASTIN", "(bevacizumab)", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody.", "<tag2>", "CA4P", "in", "Combination", "with", "Bevacizumab", "Completed", "Phase", "2", "Clinical", "Trial", "with", "Positive", "Results", "Genentech", "s", "bevacizumab", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody", "which", "has", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "elsewhere.", "<tag3>"], "wordsA": ["Fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "Completed", "Phase", "2", "Trial", "Genentech", "/", "Roche", "s", "AVASTIN", "(bevacizumab)", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody."], "wordsB": ["CA4P", "in", "Combination", "with", "Bevacizumab", "Completed", "Phase", "2", "Clinical", "Trial", "with", "Positive", "Results", "Genentech", "s", "bevacizumab", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody", "which", "has", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "elsewhere."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p26_s1", "idA": "908259_15_item1_p6_s1", "sentA": "We believe that using fosbretabulin in combination with AVASTIN (bevacizumab) may provide an equally effective yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "If funds become available for us to initiate and complete a clinical trial in GBM, we expect that we would pursue such a trial, with a similar two-stage phase 2/3 design in combination with bevacizumab as we are pursuing in platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "an", "equally", "effective", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "If", "funds", "become", "available", "for", "us", "to", "initiate", "and", "complete", "a", "clinical", "trial", "in", "GBM,", "we", "expect", "that", "we", "would", "pursue", "such", "a", "trial,", "with", "a", "similar", "two-stage", "phase", "2/3", "design", "in", "combination", "with", "bevacizumab", "as", "we", "are", "pursuing", "in", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "an", "equally", "effective", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["If", "funds", "become", "available", "for", "us", "to", "initiate", "and", "complete", "a", "clinical", "trial", "in", "GBM,", "we", "expect", "that", "we", "would", "pursue", "such", "a", "trial,", "with", "a", "similar", "two-stage", "phase", "2/3", "design", "in", "combination", "with", "bevacizumab", "as", "we", "are", "pursuing", "in", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p38_s2", "idA": "908259_15_item1_p6_s1", "sentA": "We believe that using fosbretabulin in combination with AVASTIN (bevacizumab) may provide an equally effective yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "We believe that the historical focus on development of VDAs as a single agent, rather than as an agent for use in combination with an AA, is the primary reason that VDA development to date has generally not been successful.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "an", "equally", "effective", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "We", "believe", "that", "the", "historical", "focus", "on", "development", "of", "VDAs", "as", "a", "single", "agent,", "rather", "than", "as", "an", "agent", "for", "use", "in", "combination", "with", "an", "AA,", "is", "the", "primary", "reason", "that", "VDA", "development", "to", "date", "has", "generally", "not", "been", "successful.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "fosbretabulin", "in", "combination", "with", "AVASTIN", "(bevacizumab)", "may", "provide", "an", "equally", "effective", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["We", "believe", "that", "the", "historical", "focus", "on", "development", "of", "VDAs", "as", "a", "single", "agent,", "rather", "than", "as", "an", "agent", "for", "use", "in", "combination", "with", "an", "AA,", "is", "the", "primary", "reason", "that", "VDA", "development", "to", "date", "has", "generally", "not", "been", "successful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p2_s5", "idA": "908259_15_item1_p6_s2", "sentA": "This belief is supported by the recently completed Phase 2 trial with this combination in recurrent ovarian cancer.", "sentB": "Our belief is supported by both clinical and preclinical studies, which demonstrate an increased benefit in terms of progression-free survival from treatment with our VDA, known as CA4P, when it is used in combination with approved AAs.", "type": 2, "words": ["<tag1>", "This", "belief", "is", "supported", "by", "the", "recently", "completed", "Phase", "2", "trial", "with", "this", "combination", "in", "recurrent", "ovarian", "cancer.", "<tag2>", "Our", "belief", "is", "supported", "by", "both", "clinical", "and", "preclinical", "studies,", "which", "demonstrate", "an", "increased", "benefit", "in", "terms", "of", "progression-free", "survival", "from", "treatment", "with", "our", "VDA,", "known", "as", "CA4P,", "when", "it", "is", "used", "in", "combination", "with", "approved", "AAs.", "<tag3>"], "wordsA": ["This", "belief", "is", "supported", "by", "the", "recently", "completed", "Phase", "2", "trial", "with", "this", "combination", "in", "recurrent", "ovarian", "cancer."], "wordsB": ["Our", "belief", "is", "supported", "by", "both", "clinical", "and", "preclinical", "studies,", "which", "demonstrate", "an", "increased", "benefit", "in", "terms", "of", "progression-free", "survival", "from", "treatment", "with", "our", "VDA,", "known", "as", "CA4P,", "when", "it", "is", "used", "in", "combination", "with", "approved", "AAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p76_s5", "idA": "908259_15_item1_p70_s5", "sentA": "Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.", "sentB": "Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data.", "type": 2, "words": ["<tag1>", "Data", "obtained", "from", "clinical", "trials", "are", "not", "always", "conclusive", "and", "the", "FDA", "may", "interpret", "data", "differently", "than", "we", "interpret", "the", "same", "data.", "<tag2>", "Data", "obtained", "from", "clinical", "trials", "are", "not", "always", "conclusive,", "and", "the", "FDA", "may", "interpret", "data", "differently", "than", "we", "interpret", "the", "same", "data.", "<tag3>"], "wordsA": ["Data", "obtained", "from", "clinical", "trials", "are", "not", "always", "conclusive", "and", "the", "FDA", "may", "interpret", "data", "differently", "than", "we", "interpret", "the", "same", "data."], "wordsB": ["Data", "obtained", "from", "clinical", "trials", "are", "not", "always", "conclusive,", "and", "the", "FDA", "may", "interpret", "data", "differently", "than", "we", "interpret", "the", "same", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p76_s6", "idA": "908259_15_item1_p71_s0", "sentA": "require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the NDA.", "sentB": "The FDA may issue a complete response letter, which may require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the NDA.", "type": 2, "words": ["<tag1>", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA.", "<tag2>", "The", "FDA", "may", "issue", "a", "complete", "response", "letter,", "which", "may", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA.", "<tag3>"], "wordsA": ["require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA."], "wordsB": ["The", "FDA", "may", "issue", "a", "complete", "response", "letter,", "which", "may", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p90_s3", "idA": "908259_15_item1_p77_s0", "sentA": "In the European Union and Japan, orphan drug exclusivity regulations provide for 10 years of marketing exclusivity for orphan drugs that are approved for the treatment of rare diseases or conditions.", "sentB": "Orphan drugs in the European Union also enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication, unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan designated product.", "type": 2, "words": ["<tag1>", "In", "the", "European", "Union", "and", "Japan,", "orphan", "drug", "exclusivity", "regulations", "provide", "for", "10", "years", "of", "marketing", "exclusivity", "for", "orphan", "drugs", "that", "are", "approved", "for", "the", "treatment", "of", "rare", "diseases", "or", "conditions.", "<tag2>", "Orphan", "drugs", "in", "the", "European", "Union", "also", "enjoy", "economic", "and", "marketing", "benefits,", "including", "up", "to", "ten", "years", "of", "market", "exclusivity", "for", "the", "approved", "indication,", "unless", "another", "applicant", "can", "show", "that", "its", "product", "is", "safer,", "more", "effective", "or", "otherwise", "clinically", "superior", "to", "the", "orphan", "designated", "product.", "<tag3>"], "wordsA": ["In", "the", "European", "Union", "and", "Japan,", "orphan", "drug", "exclusivity", "regulations", "provide", "for", "10", "years", "of", "marketing", "exclusivity", "for", "orphan", "drugs", "that", "are", "approved", "for", "the", "treatment", "of", "rare", "diseases", "or", "conditions."], "wordsB": ["Orphan", "drugs", "in", "the", "European", "Union", "also", "enjoy", "economic", "and", "marketing", "benefits,", "including", "up", "to", "ten", "years", "of", "market", "exclusivity", "for", "the", "approved", "indication,", "unless", "another", "applicant", "can", "show", "that", "its", "product", "is", "safer,", "more", "effective", "or", "otherwise", "clinically", "superior", "to", "the", "orphan", "designated", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p83_s0", "idA": "908259_15_item1_p77_s1", "sentA": "Fosbretabulin was awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers and ovarian cancer.", "sentB": "CA4P has been awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers, ovarian cancer and neuroendocrine tumors.", "type": 2, "words": ["<tag1>", "Fosbretabulin", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers", "and", "ovarian", "cancer.", "<tag2>", "CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer", "and", "neuroendocrine", "tumors.", "<tag3>"], "wordsA": ["Fosbretabulin", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers", "and", "ovarian", "cancer."], "wordsB": ["CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer", "and", "neuroendocrine", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p83_s1", "idA": "908259_15_item1_p77_s2", "sentA": "OXi4503 was awarded orphan drug status by the FDA for the treatment of acute myelogenous leukemia.", "sentB": "OXi4503 has been awarded orphan drug status by the FDA for the treatment of acute myelogenous leukemia.", "type": 2, "words": ["<tag1>", "OXi4503", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag2>", "OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag3>"], "wordsA": ["OXi4503", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "wordsB": ["OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p83_s3", "idA": "908259_15_item1_p77_s2", "sentA": "OXi4503 was awarded orphan drug status by the FDA for the treatment of acute myelogenous leukemia.", "sentB": "OXi4503 has been awarded orphan drug status by the European Commission in the European Union for the treatment of acute myelogenous leukemia.", "type": 2, "words": ["<tag1>", "OXi4503", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag2>", "OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag3>"], "wordsA": ["OXi4503", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "wordsB": ["OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p83_s2", "idA": "908259_15_item1_p77_s3", "sentA": "Fosbretabulin was also awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer and ovarian cancer.", "sentB": "CA4P has also been awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer, ovarian cancer and gastro-entero-pancreatic neuroendocrine tumors.", "type": 2, "words": ["<tag1>", "Fosbretabulin", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer.", "<tag2>", "CA4P", "has", "also", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer,", "ovarian", "cancer", "and", "gastro-entero-pancreatic", "neuroendocrine", "tumors.", "<tag3>"], "wordsA": ["Fosbretabulin", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer."], "wordsB": ["CA4P", "has", "also", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer,", "ovarian", "cancer", "and", "gastro-entero-pancreatic", "neuroendocrine", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p90_s0", "idA": "908259_15_item1_p77_s3", "sentA": "Fosbretabulin was also awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer and ovarian cancer.", "sentB": "As in the United States, the European Medicines Agency, or EMA, may grant orphan drug status for specific indications if the request is made before an MAA is made.", "type": 2, "words": ["<tag1>", "Fosbretabulin", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer.", "<tag2>", "As", "in", "the", "United", "States,", "the", "European", "Medicines", "Agency,", "or", "EMA,", "may", "grant", "orphan", "drug", "status", "for", "specific", "indications", "if", "the", "request", "is", "made", "before", "an", "MAA", "is", "made.", "<tag3>"], "wordsA": ["Fosbretabulin", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer."], "wordsB": ["As", "in", "the", "United", "States,", "the", "European", "Medicines", "Agency,", "or", "EMA,", "may", "grant", "orphan", "drug", "status", "for", "specific", "indications", "if", "the", "request", "is", "made", "before", "an", "MAA", "is", "made."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p90_s1", "idA": "908259_15_item1_p77_s3", "sentA": "Fosbretabulin was also awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer and ovarian cancer.", "sentB": "The EMA considers an orphan medicinal product to be one that affects less than five of every 10,000 people in the European Union.", "type": 2, "words": ["<tag1>", "Fosbretabulin", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer.", "<tag2>", "The", "EMA", "considers", "an", "orphan", "medicinal", "product", "to", "be", "one", "that", "affects", "less", "than", "five", "of", "every", "10,000", "people", "in", "the", "European", "Union.", "<tag3>"], "wordsA": ["Fosbretabulin", "was", "also", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer", "and", "ovarian", "cancer."], "wordsB": ["The", "EMA", "considers", "an", "orphan", "medicinal", "product", "to", "be", "one", "that", "affects", "less", "than", "five", "of", "every", "10,000", "people", "in", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p84_s0", "idA": "908259_15_item1_p78_s0", "sentA": "Expedited Review and Approval The FDA has various programs, including Fast Track, priority review, and accelerated approval, which are intended to expedite or simplify the process for reviewing drugs, and/or provide for approval on the basis of surrogate endpoints.", "sentB": "Expedited Review and Approval The FDA has various programs, including Fast Track, priority review, accelerated approval and breakthrough therapy, which are intended to expedite or simplify the process for reviewing drugs, and/or provide for approval on the basis of surrogate endpoints.", "type": 2, "words": ["<tag1>", "Expedited", "Review", "and", "Approval", "The", "FDA", "has", "various", "programs,", "including", "Fast", "Track,", "priority", "review,", "and", "accelerated", "approval,", "which", "are", "intended", "to", "expedite", "or", "simplify", "the", "process", "for", "reviewing", "drugs,", "and/or", "provide", "for", "approval", "on", "the", "basis", "of", "surrogate", "endpoints.", "<tag2>", "Expedited", "Review", "and", "Approval", "The", "FDA", "has", "various", "programs,", "including", "Fast", "Track,", "priority", "review,", "accelerated", "approval", "and", "breakthrough", "therapy,", "which", "are", "intended", "to", "expedite", "or", "simplify", "the", "process", "for", "reviewing", "drugs,", "and/or", "provide", "for", "approval", "on", "the", "basis", "of", "surrogate", "endpoints.", "<tag3>"], "wordsA": ["Expedited", "Review", "and", "Approval", "The", "FDA", "has", "various", "programs,", "including", "Fast", "Track,", "priority", "review,", "and", "accelerated", "approval,", "which", "are", "intended", "to", "expedite", "or", "simplify", "the", "process", "for", "reviewing", "drugs,", "and/or", "provide", "for", "approval", "on", "the", "basis", "of", "surrogate", "endpoints."], "wordsB": ["Expedited", "Review", "and", "Approval", "The", "FDA", "has", "various", "programs,", "including", "Fast", "Track,", "priority", "review,", "accelerated", "approval", "and", "breakthrough", "therapy,", "which", "are", "intended", "to", "expedite", "or", "simplify", "the", "process", "for", "reviewing", "drugs,", "and/or", "provide", "for", "approval", "on", "the", "basis", "of", "surrogate", "endpoints."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p84_s1", "idA": "908259_15_item1_p79_s0", "sentA": "will not later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened.", "sentB": "Even if a drug qualifies for one or more of these programs, the FDA may subsequently decide the drug no longer meets the conditions for qualification or the FDA may not shorten the review or approval time period.", "type": 2, "words": ["<tag1>", "will", "not", "later", "decide", "that", "the", "drug", "no", "longer", "meets", "the", "conditions", "for", "qualification", "or", "that", "the", "time", "period", "for", "FDA", "review", "or", "approval", "will", "be", "shortened.", "<tag2>", "Even", "if", "a", "drug", "qualifies", "for", "one", "or", "more", "of", "these", "programs,", "the", "FDA", "may", "subsequently", "decide", "the", "drug", "no", "longer", "meets", "the", "conditions", "for", "qualification", "or", "the", "FDA", "may", "not", "shorten", "the", "review", "or", "approval", "time", "period.", "<tag3>"], "wordsA": ["will", "not", "later", "decide", "that", "the", "drug", "no", "longer", "meets", "the", "conditions", "for", "qualification", "or", "that", "the", "time", "period", "for", "FDA", "review", "or", "approval", "will", "be", "shortened."], "wordsB": ["Even", "if", "a", "drug", "qualifies", "for", "one", "or", "more", "of", "these", "programs,", "the", "FDA", "may", "subsequently", "decide", "the", "drug", "no", "longer", "meets", "the", "conditions", "for", "qualification", "or", "the", "FDA", "may", "not", "shorten", "the", "review", "or", "approval", "time", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p13_s0", "idA": "908259_15_item1_p7_s0", "sentA": "The GOG-0186I clinical trial was conducted by the GOG, now part of NRG Oncology, under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and was a randomized, two-arm Phase 2 trial evaluating AVASTIN (bevacizumab) alone, as compared to AVASTIN (bevacizumab) plus fosbretabulin, in patients with recurrent ovarian cancer.", "sentB": "The GOG-0186I clinical trial was conducted by the GOG, now part of NRG Oncology, under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), and was a randomized, two-arm phase 2 clinical trial evaluating CA4P plus bevacizumab compared to bevacizumab alone in patients with recurrent ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "GOG-0186I", "clinical", "trial", "was", "conducted", "by", "the", "GOG,", "now", "part", "of", "NRG", "Oncology,", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "National", "Cancer", "Institute", "(NCI)", "and", "was", "a", "randomized,", "two-arm", "Phase", "2", "trial", "evaluating", "AVASTIN", "(bevacizumab)", "alone,", "as", "compared", "to", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin,", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag2>", "The", "GOG-0186I", "clinical", "trial", "was", "conducted", "by", "the", "GOG,", "now", "part", "of", "NRG", "Oncology,", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "National", "Cancer", "Institute", "(NCI),", "and", "was", "a", "randomized,", "two-arm", "phase", "2", "clinical", "trial", "evaluating", "CA4P", "plus", "bevacizumab", "compared", "to", "bevacizumab", "alone", "in", "patients", "with", "recurrent", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "GOG-0186I", "clinical", "trial", "was", "conducted", "by", "the", "GOG,", "now", "part", "of", "NRG", "Oncology,", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "National", "Cancer", "Institute", "(NCI)", "and", "was", "a", "randomized,", "two-arm", "Phase", "2", "trial", "evaluating", "AVASTIN", "(bevacizumab)", "alone,", "as", "compared", "to", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin,", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "wordsB": ["The", "GOG-0186I", "clinical", "trial", "was", "conducted", "by", "the", "GOG,", "now", "part", "of", "NRG", "Oncology,", "under", "the", "sponsorship", "of", "the", "Cancer", "Therapy", "Evaluation", "Program", "(CTEP)", "of", "the", "National", "Cancer", "Institute", "(NCI),", "and", "was", "a", "randomized,", "two-arm", "phase", "2", "clinical", "trial", "evaluating", "CA4P", "plus", "bevacizumab", "compared", "to", "bevacizumab", "alone", "in", "patients", "with", "recurrent", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p13_s1", "idA": "908259_15_item1_p7_s1", "sentA": "The trial enrolled a total of 107 patients with both platinum-sensitive and platinum-resistant recurrent ovarian cancer at 67 clinical sites in the United States.", "sentB": "The GOG-0186I clinical trial enrolled a total of 107 patients with both platinum-sensitive and platinum-resistant recurrent ovarian cancer at 67 clinical sites in the United States.", "type": 2, "words": ["<tag1>", "The", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States.", "<tag2>", "The", "GOG-0186I", "clinical", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["The", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States."], "wordsB": ["The", "GOG-0186I", "clinical", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p14_s1", "idA": "908259_15_item1_p7_s10", "sentA": "In the study, patients with measurable disease who received the combination of fosbretabulin and AVASTIN (bevacizumab) also achieved a higher objective response rate, or ORR, a secondary endpoint in the study, measured according to RECIST criteria.", "sentB": "In the clinical trial, patients with measurable disease who received the combination of CA4P and bevacizumab also achieved a higher objective response rate, or ORR, a secondary endpoint in the clinical trial, measured according to RECIST criteria.", "type": 2, "words": ["<tag1>", "In", "the", "study,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "fosbretabulin", "and", "AVASTIN", "(bevacizumab)", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "study,", "measured", "according", "to", "RECIST", "criteria.", "<tag2>", "In", "the", "clinical", "trial,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria.", "<tag3>"], "wordsA": ["In", "the", "study,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "fosbretabulin", "and", "AVASTIN", "(bevacizumab)", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "study,", "measured", "according", "to", "RECIST", "criteria."], "wordsB": ["In", "the", "clinical", "trial,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p14_s2", "idA": "908259_15_item1_p7_s11", "sentA": "Although not a statistically significant result, patients receiving the combination had an ORR of 35.7% (n=42; CI 90% 23.5 ~ 49.5%) compared to 28.2 percent for patients on AVASTIN (bevacizumab) alone (n=39; CI 90% 16.7 ~ 42.3%).", "sentB": "Although not a statistically significant result, patients receiving the combination had an ORR of 35.7% (n=42; CI 90% 23.5 ~ 49.5%) compared to 28.2% for patients on bevacizumab alone (n=39; CI 90% 16.7 ~ 42.3%).", "type": 2, "words": ["<tag1>", "Although", "not", "a", "statistically", "significant", "result,", "patients", "receiving", "the", "combination", "had", "an", "ORR", "of", "35.7%", "(n=42;", "CI", "90%", "23.5", "~", "49.5%)", "compared", "to", "28.2", "percent", "for", "patients", "on", "AVASTIN", "(bevacizumab)", "alone", "(n=39;", "CI", "90%", "16.7", "~", "42.3%).", "<tag2>", "Although", "not", "a", "statistically", "significant", "result,", "patients", "receiving", "the", "combination", "had", "an", "ORR", "of", "35.7%", "(n=42;", "CI", "90%", "23.5", "~", "49.5%)", "compared", "to", "28.2%", "for", "patients", "on", "bevacizumab", "alone", "(n=39;", "CI", "90%", "16.7", "~", "42.3%).", "<tag3>"], "wordsA": ["Although", "not", "a", "statistically", "significant", "result,", "patients", "receiving", "the", "combination", "had", "an", "ORR", "of", "35.7%", "(n=42;", "CI", "90%", "23.5", "~", "49.5%)", "compared", "to", "28.2", "percent", "for", "patients", "on", "AVASTIN", "(bevacizumab)", "alone", "(n=39;", "CI", "90%", "16.7", "~", "42.3%)."], "wordsB": ["Although", "not", "a", "statistically", "significant", "result,", "patients", "receiving", "the", "combination", "had", "an", "ORR", "of", "35.7%", "(n=42;", "CI", "90%", "23.5", "~", "49.5%)", "compared", "to", "28.2%", "for", "patients", "on", "bevacizumab", "alone", "(n=39;", "CI", "90%", "16.7", "~", "42.3%)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p14_s3", "idA": "908259_15_item1_p7_s12", "sentA": "In the small subgroup of platinum-resistant patients, the addition of fosbretabulin to AVASTIN (bevacizumab) treatment increased ORR to 40.0 percent (n=10) compared to 12.5 percent (n=8) for AVASTIN (bevacizumab) alone.", "sentB": "In the subgroup of platinum-resistant patients, the addition of CA4P to bevacizumab increased ORR to 40.0% (n=10) compared to 12.5% (n=8) for bevacizumab alone.", "type": 2, "words": ["<tag1>", "In", "the", "small", "subgroup", "of", "platinum-resistant", "patients,", "the", "addition", "of", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "treatment", "increased", "ORR", "to", "40.0", "percent", "(n=10)", "compared", "to", "12.5", "percent", "(n=8)", "for", "AVASTIN", "(bevacizumab)", "alone.", "<tag2>", "In", "the", "subgroup", "of", "platinum-resistant", "patients,", "the", "addition", "of", "CA4P", "to", "bevacizumab", "increased", "ORR", "to", "40.0%", "(n=10)", "compared", "to", "12.5%", "(n=8)", "for", "bevacizumab", "alone.", "<tag3>"], "wordsA": ["In", "the", "small", "subgroup", "of", "platinum-resistant", "patients,", "the", "addition", "of", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "treatment", "increased", "ORR", "to", "40.0", "percent", "(n=10)", "compared", "to", "12.5", "percent", "(n=8)", "for", "AVASTIN", "(bevacizumab)", "alone."], "wordsB": ["In", "the", "subgroup", "of", "platinum-resistant", "patients,", "the", "addition", "of", "CA4P", "to", "bevacizumab", "increased", "ORR", "to", "40.0%", "(n=10)", "compared", "to", "12.5%", "(n=8)", "for", "bevacizumab", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p14_s4", "idA": "908259_15_item1_p7_s13", "sentA": "Additional secondary endpoints in the study included safety and overall survival.", "sentB": "Additional secondary endpoints in the clinical trial included safety and overall survival.", "type": 2, "words": ["<tag1>", "Additional", "secondary", "endpoints", "in", "the", "study", "included", "safety", "and", "overall", "survival.", "<tag2>", "Additional", "secondary", "endpoints", "in", "the", "clinical", "trial", "included", "safety", "and", "overall", "survival.", "<tag3>"], "wordsA": ["Additional", "secondary", "endpoints", "in", "the", "study", "included", "safety", "and", "overall", "survival."], "wordsB": ["Additional", "secondary", "endpoints", "in", "the", "clinical", "trial", "included", "safety", "and", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p13_s4", "idA": "908259_15_item1_p7_s4", "sentA": "Median PFS was 7.3 months for AVASTIN (bevacizumab) plus fosbretabulin (n=54), compared to 4.8 months with AVASTIN (bevacizumab) alone (n= 53).", "sentB": "Median PFS was 7.3 months for CA4P plus bevacizumab (n=54), compared to 4.8 months for bevacizumab alone (n= 53).", "type": 2, "words": ["<tag1>", "Median", "PFS", "was", "7.3", "months", "for", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin", "(n=54),", "compared", "to", "4.8", "months", "with", "AVASTIN", "(bevacizumab)", "alone", "(n=", "53).", "<tag2>", "Median", "PFS", "was", "7.3", "months", "for", "CA4P", "plus", "bevacizumab", "(n=54),", "compared", "to", "4.8", "months", "for", "bevacizumab", "alone", "(n=", "53).", "<tag3>"], "wordsA": ["Median", "PFS", "was", "7.3", "months", "for", "AVASTIN", "(bevacizumab)", "plus", "fosbretabulin", "(n=54),", "compared", "to", "4.8", "months", "with", "AVASTIN", "(bevacizumab)", "alone", "(n=", "53)."], "wordsB": ["Median", "PFS", "was", "7.3", "months", "for", "CA4P", "plus", "bevacizumab", "(n=54),", "compared", "to", "4.8", "months", "for", "bevacizumab", "alone", "(n=", "53)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p13_s6", "idA": "908259_15_item1_p7_s6", "sentA": "In a post-hoc subgroup analysis presented at the IGCS conference, data showed that patients who were platinum-resistant also had a statistically significant improvement in PFS with the combination.", "sentB": "In a post-hoc subgroup analysis, data showed that patients who were platinum-resistant had an even greater improvement in PFS with the combination.", "type": 2, "words": ["<tag1>", "In", "a", "post-hoc", "subgroup", "analysis", "presented", "at", "the", "IGCS", "conference,", "data", "showed", "that", "patients", "who", "were", "platinum-resistant", "also", "had", "a", "statistically", "significant", "improvement", "in", "PFS", "with", "the", "combination.", "<tag2>", "In", "a", "post-hoc", "subgroup", "analysis,", "data", "showed", "that", "patients", "who", "were", "platinum-resistant", "had", "an", "even", "greater", "improvement", "in", "PFS", "with", "the", "combination.", "<tag3>"], "wordsA": ["In", "a", "post-hoc", "subgroup", "analysis", "presented", "at", "the", "IGCS", "conference,", "data", "showed", "that", "patients", "who", "were", "platinum-resistant", "also", "had", "a", "statistically", "significant", "improvement", "in", "PFS", "with", "the", "combination."], "wordsB": ["In", "a", "post-hoc", "subgroup", "analysis,", "data", "showed", "that", "patients", "who", "were", "platinum-resistant", "had", "an", "even", "greater", "improvement", "in", "PFS", "with", "the", "combination."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p13_s7", "idA": "908259_15_item1_p7_s7", "sentA": "Among the 27 patients who were platinum-resistant, median PFS was 6.7 months for those receiving AVASTIN (bevacizumab) and fosbretabulin compared to 3.4 months for those receiving AVASTIN (bevacizumab) alone, with a p-value of 0.01.", "sentB": "Among the 27 patients who were platinum-resistant, median PFS was 6.7 months for those receiving CA4P plus bevacizumab compared to 3.4 months for those receiving bevacizumab alone, and the results were statistically significant with a p-value of 0.01 and a hazard ratio of 0.57.", "type": 2, "words": ["<tag1>", "Among", "the", "27", "patients", "who", "were", "platinum-resistant,", "median", "PFS", "was", "6.7", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "and", "fosbretabulin", "compared", "to", "3.4", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "with", "a", "p-value", "of", "0.01.", "<tag2>", "Among", "the", "27", "patients", "who", "were", "platinum-resistant,", "median", "PFS", "was", "6.7", "months", "for", "those", "receiving", "CA4P", "plus", "bevacizumab", "compared", "to", "3.4", "months", "for", "those", "receiving", "bevacizumab", "alone,", "and", "the", "results", "were", "statistically", "significant", "with", "a", "p-value", "of", "0.01", "and", "a", "hazard", "ratio", "of", "0.57.", "<tag3>"], "wordsA": ["Among", "the", "27", "patients", "who", "were", "platinum-resistant,", "median", "PFS", "was", "6.7", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "and", "fosbretabulin", "compared", "to", "3.4", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "with", "a", "p-value", "of", "0.01."], "wordsB": ["Among", "the", "27", "patients", "who", "were", "platinum-resistant,", "median", "PFS", "was", "6.7", "months", "for", "those", "receiving", "CA4P", "plus", "bevacizumab", "compared", "to", "3.4", "months", "for", "those", "receiving", "bevacizumab", "alone,", "and", "the", "results", "were", "statistically", "significant", "with", "a", "p-value", "of", "0.01", "and", "a", "hazard", "ratio", "of", "0.57."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p13_s8", "idA": "908259_15_item1_p7_s8", "sentA": "Although the subgroup included a relatively small number of patients, these findings suggest that adding fosbretabulin to AVASTIN (bevacizumab) has a potentially greater effect in this difficult-to-treat patient group than for platinum-sensitive patients.", "sentB": "These findings suggest that adding CA4P to bevacizumab has a greater effect in the difficult-to-treat platinum-resistant patient group than it does for platinum-sensitive patients.", "type": 2, "words": ["<tag1>", "Although", "the", "subgroup", "included", "a", "relatively", "small", "number", "of", "patients,", "these", "findings", "suggest", "that", "adding", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "has", "a", "potentially", "greater", "effect", "in", "this", "difficult-to-treat", "patient", "group", "than", "for", "platinum-sensitive", "patients.", "<tag2>", "These", "findings", "suggest", "that", "adding", "CA4P", "to", "bevacizumab", "has", "a", "greater", "effect", "in", "the", "difficult-to-treat", "platinum-resistant", "patient", "group", "than", "it", "does", "for", "platinum-sensitive", "patients.", "<tag3>"], "wordsA": ["Although", "the", "subgroup", "included", "a", "relatively", "small", "number", "of", "patients,", "these", "findings", "suggest", "that", "adding", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "has", "a", "potentially", "greater", "effect", "in", "this", "difficult-to-treat", "patient", "group", "than", "for", "platinum-sensitive", "patients."], "wordsB": ["These", "findings", "suggest", "that", "adding", "CA4P", "to", "bevacizumab", "has", "a", "greater", "effect", "in", "the", "difficult-to-treat", "platinum-resistant", "patient", "group", "than", "it", "does", "for", "platinum-sensitive", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p14_s0", "idA": "908259_15_item1_p7_s9", "sentA": "Also in the post-hoc subgroup analysis, while not statistically significant, among the 80 patients who were platinum-sensitive, median PFS was 7.6 months for those receiving AVASTIN (bevacizumab) and fosbretabulin compared to 6.1 months for those receiving AVASTIN (bevacizumab) alone, with a p-value of 0.139 and a hazard ratio of 0.67.", "sentB": "CA4P plus bevacizumab compared to 6.1 months for those receiving bevacizumab alone, although the results were not statistically significant, with a p-value of 0.139 and a hazard ratio of 0.67.", "type": 2, "words": ["<tag1>", "Also", "in", "the", "post-hoc", "subgroup", "analysis,", "while", "not", "statistically", "significant,", "among", "the", "80", "patients", "who", "were", "platinum-sensitive,", "median", "PFS", "was", "7.6", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "and", "fosbretabulin", "compared", "to", "6.1", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67.", "<tag2>", "CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67.", "<tag3>"], "wordsA": ["Also", "in", "the", "post-hoc", "subgroup", "analysis,", "while", "not", "statistically", "significant,", "among", "the", "80", "patients", "who", "were", "platinum-sensitive,", "median", "PFS", "was", "7.6", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "and", "fosbretabulin", "compared", "to", "6.1", "months", "for", "those", "receiving", "AVASTIN", "(bevacizumab)", "alone,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67."], "wordsB": ["CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p101_s0", "idA": "908259_15_item1_p83_s0", "sentA": "Foreign Regulation Before our products can be marketed outside of the United States, they are subject to regulatory approval similar to that required in the United States, although the requirements governing the conduct of clinical trials, including additional clinical trials that may be required, product licensing, pricing and reimbursement vary widely from country to country.", "sentB": "The requirements governing drug pricing vary widely from country to country.", "type": 2, "words": ["<tag1>", "Foreign", "Regulation", "Before", "our", "products", "can", "be", "marketed", "outside", "of", "the", "United", "States,", "they", "are", "subject", "to", "regulatory", "approval", "similar", "to", "that", "required", "in", "the", "United", "States,", "although", "the", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "including", "additional", "clinical", "trials", "that", "may", "be", "required,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "widely", "from", "country", "to", "country.", "<tag2>", "The", "requirements", "governing", "drug", "pricing", "vary", "widely", "from", "country", "to", "country.", "<tag3>"], "wordsA": ["Foreign", "Regulation", "Before", "our", "products", "can", "be", "marketed", "outside", "of", "the", "United", "States,", "they", "are", "subject", "to", "regulatory", "approval", "similar", "to", "that", "required", "in", "the", "United", "States,", "although", "the", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "including", "additional", "clinical", "trials", "that", "may", "be", "required,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "widely", "from", "country", "to", "country."], "wordsB": ["The", "requirements", "governing", "drug", "pricing", "vary", "widely", "from", "country", "to", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p87_s0", "idA": "908259_15_item1_p83_s0", "sentA": "Foreign Regulation Before our products can be marketed outside of the United States, they are subject to regulatory approval similar to that required in the United States, although the requirements governing the conduct of clinical trials, including additional clinical trials that may be required, product licensing, pricing and reimbursement vary widely from country to country.", "sentB": "In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products.", "type": 2, "words": ["<tag1>", "Foreign", "Regulation", "Before", "our", "products", "can", "be", "marketed", "outside", "of", "the", "United", "States,", "they", "are", "subject", "to", "regulatory", "approval", "similar", "to", "that", "required", "in", "the", "United", "States,", "although", "the", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "including", "additional", "clinical", "trials", "that", "may", "be", "required,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "widely", "from", "country", "to", "country.", "<tag2>", "In", "addition", "to", "regulations", "in", "the", "United", "States,", "we", "will", "be", "subject", "to", "a", "variety", "of", "foreign", "regulations", "governing", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "products.", "<tag3>"], "wordsA": ["Foreign", "Regulation", "Before", "our", "products", "can", "be", "marketed", "outside", "of", "the", "United", "States,", "they", "are", "subject", "to", "regulatory", "approval", "similar", "to", "that", "required", "in", "the", "United", "States,", "although", "the", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "including", "additional", "clinical", "trials", "that", "may", "be", "required,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "widely", "from", "country", "to", "country."], "wordsB": ["In", "addition", "to", "regulations", "in", "the", "United", "States,", "we", "will", "be", "subject", "to", "a", "variety", "of", "foreign", "regulations", "governing", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p87_s3", "idA": "908259_15_item1_p83_s0", "sentA": "Foreign Regulation Before our products can be marketed outside of the United States, they are subject to regulatory approval similar to that required in the United States, although the requirements governing the conduct of clinical trials, including additional clinical trials that may be required, product licensing, pricing and reimbursement vary widely from country to country.", "sentB": "The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.", "type": 2, "words": ["<tag1>", "Foreign", "Regulation", "Before", "our", "products", "can", "be", "marketed", "outside", "of", "the", "United", "States,", "they", "are", "subject", "to", "regulatory", "approval", "similar", "to", "that", "required", "in", "the", "United", "States,", "although", "the", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "including", "additional", "clinical", "trials", "that", "may", "be", "required,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "widely", "from", "country", "to", "country.", "<tag2>", "The", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "greatly", "from", "country", "to", "country.", "<tag3>"], "wordsA": ["Foreign", "Regulation", "Before", "our", "products", "can", "be", "marketed", "outside", "of", "the", "United", "States,", "they", "are", "subject", "to", "regulatory", "approval", "similar", "to", "that", "required", "in", "the", "United", "States,", "although", "the", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "including", "additional", "clinical", "trials", "that", "may", "be", "required,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "widely", "from", "country", "to", "country."], "wordsB": ["The", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "greatly", "from", "country", "to", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p87_s1", "idA": "908259_15_item1_p83_s1", "sentA": "No action can be taken to market any product in a country until an appropriate application has been approved by the regulatory authorities in that country.", "sentB": "Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of any product candidate in those countries.", "type": 2, "words": ["<tag1>", "No", "action", "can", "be", "taken", "to", "market", "any", "product", "in", "a", "country", "until", "an", "appropriate", "application", "has", "been", "approved", "by", "the", "regulatory", "authorities", "in", "that", "country.", "<tag2>", "Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "clinical", "trials", "or", "marketing", "of", "any", "product", "candidate", "in", "those", "countries.", "<tag3>"], "wordsA": ["No", "action", "can", "be", "taken", "to", "market", "any", "product", "in", "a", "country", "until", "an", "appropriate", "application", "has", "been", "approved", "by", "the", "regulatory", "authorities", "in", "that", "country."], "wordsB": ["Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "clinical", "trials", "or", "marketing", "of", "any", "product", "candidate", "in", "those", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p87_s2", "idA": "908259_15_item1_p84_s0", "sentA": "The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval.", "sentB": "The approval process varies from country to country and the time may be longer or shorter than that required for FDA approval.", "type": 2, "words": ["<tag1>", "The", "current", "approval", "process", "varies", "from", "country", "to", "country,", "and", "the", "time", "spent", "in", "gaining", "approval", "varies", "from", "that", "required", "for", "FDA", "approval.", "<tag2>", "The", "approval", "process", "varies", "from", "country", "to", "country", "and", "the", "time", "may", "be", "longer", "or", "shorter", "than", "that", "required", "for", "FDA", "approval.", "<tag3>"], "wordsA": ["The", "current", "approval", "process", "varies", "from", "country", "to", "country,", "and", "the", "time", "spent", "in", "gaining", "approval", "varies", "from", "that", "required", "for", "FDA", "approval."], "wordsB": ["The", "approval", "process", "varies", "from", "country", "to", "country", "and", "the", "time", "may", "be", "longer", "or", "shorter", "than", "that", "required", "for", "FDA", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p88_s1", "idA": "908259_15_item1_p85_s1", "sentA": "The centralized procedure is mandatory for the approval of biotechnology products and provides for the grant of a single marketing authorization that is valid in all European Union members states.", "sentB": "The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and optional for those medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states.", "type": 2, "words": ["<tag1>", "The", "centralized", "procedure", "is", "mandatory", "for", "the", "approval", "of", "biotechnology", "products", "and", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "in", "all", "European", "Union", "members", "states.", "<tag2>", "The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag3>"], "wordsA": ["The", "centralized", "procedure", "is", "mandatory", "for", "the", "approval", "of", "biotechnology", "products", "and", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "in", "all", "European", "Union", "members", "states."], "wordsB": ["The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p89_s0", "idA": "908259_15_item1_p85_s1", "sentA": "The centralized procedure is mandatory for the approval of biotechnology products and provides for the grant of a single marketing authorization that is valid in all European Union members states.", "sentB": "Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states.", "type": 2, "words": ["<tag1>", "The", "centralized", "procedure", "is", "mandatory", "for", "the", "approval", "of", "biotechnology", "products", "and", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "in", "all", "European", "Union", "members", "states.", "<tag2>", "Under", "this", "procedure,", "the", "holder", "of", "a", "national", "marketing", "authorization", "may", "submit", "an", "application", "to", "the", "remaining", "member", "states.", "<tag3>"], "wordsA": ["The", "centralized", "procedure", "is", "mandatory", "for", "the", "approval", "of", "biotechnology", "products", "and", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "in", "all", "European", "Union", "members", "states."], "wordsB": ["Under", "this", "procedure,", "the", "holder", "of", "a", "national", "marketing", "authorization", "may", "submit", "an", "application", "to", "the", "remaining", "member", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p99_s0", "idA": "908259_15_item1_p86_s1", "sentA": "These pathways are available for drugs to treat serious or debilitating diseases and/or orphan drugs.", "sentB": "At the present time, Medicare is prohibited from negotiating directly with pharmaceutical companies for drugs.", "type": 2, "words": ["<tag1>", "These", "pathways", "are", "available", "for", "drugs", "to", "treat", "serious", "or", "debilitating", "diseases", "and/or", "orphan", "drugs.", "<tag2>", "At", "the", "present", "time,", "Medicare", "is", "prohibited", "from", "negotiating", "directly", "with", "pharmaceutical", "companies", "for", "drugs.", "<tag3>"], "wordsA": ["These", "pathways", "are", "available", "for", "drugs", "to", "treat", "serious", "or", "debilitating", "diseases", "and/or", "orphan", "drugs."], "wordsB": ["At", "the", "present", "time,", "Medicare", "is", "prohibited", "from", "negotiating", "directly", "with", "pharmaceutical", "companies", "for", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p103_s2", "idA": "908259_15_item1_p87_s7", "sentA": "As of March 18, 2015, we were the exclusive licensee, sole assignee or co-assignee of twenty-seven (27) granted U.S. patents, six (6) pending U.S. patent applications, and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "sentB": "As of March 23, 2016, we were the exclusive licensee, sole assignee or co-assignee of thirty (30) granted U.S. patents, two (2) pending U.S. patent applications, and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "type": 2, "words": ["<tag1>", "As", "of", "March", "18,", "2015,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-seven", "(27)", "granted", "U.S.", "patents,", "six", "(6)", "pending", "U.S.", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag2>", "As", "of", "March", "23,", "2016,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "thirty", "(30)", "granted", "U.S.", "patents,", "two", "(2)", "pending", "U.S.", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag3>"], "wordsA": ["As", "of", "March", "18,", "2015,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-seven", "(27)", "granted", "U.S.", "patents,", "six", "(6)", "pending", "U.S.", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "wordsB": ["As", "of", "March", "23,", "2016,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "thirty", "(30)", "granted", "U.S.", "patents,", "two", "(2)", "pending", "U.S.", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p103_s4", "idA": "908259_15_item1_p88_s0", "sentA": "patent applications will result in the grant of a patent either in the United States or elsewhere, or that any patents granted will be valid and enforceable, or will provide a competitive advantage or will afford protection against competitors with similar technologies.", "sentB": "There can be no assurance that any of these patent applications will result in the grant of a patent either in the United States or elsewhere, or that any patents granted will be valid and enforceable, or will provide a competitive advantage or will afford protection against competitors with similar technologies.", "type": 2, "words": ["<tag1>", "patent", "applications", "will", "result", "in", "the", "grant", "of", "a", "patent", "either", "in", "the", "United", "States", "or", "elsewhere,", "or", "that", "any", "patents", "granted", "will", "be", "valid", "and", "enforceable,", "or", "will", "provide", "a", "competitive", "advantage", "or", "will", "afford", "protection", "against", "competitors", "with", "similar", "technologies.", "<tag2>", "There", "can", "be", "no", "assurance", "that", "any", "of", "these", "patent", "applications", "will", "result", "in", "the", "grant", "of", "a", "patent", "either", "in", "the", "United", "States", "or", "elsewhere,", "or", "that", "any", "patents", "granted", "will", "be", "valid", "and", "enforceable,", "or", "will", "provide", "a", "competitive", "advantage", "or", "will", "afford", "protection", "against", "competitors", "with", "similar", "technologies.", "<tag3>"], "wordsA": ["patent", "applications", "will", "result", "in", "the", "grant", "of", "a", "patent", "either", "in", "the", "United", "States", "or", "elsewhere,", "or", "that", "any", "patents", "granted", "will", "be", "valid", "and", "enforceable,", "or", "will", "provide", "a", "competitive", "advantage", "or", "will", "afford", "protection", "against", "competitors", "with", "similar", "technologies."], "wordsB": ["There", "can", "be", "no", "assurance", "that", "any", "of", "these", "patent", "applications", "will", "result", "in", "the", "grant", "of", "a", "patent", "either", "in", "the", "United", "States", "or", "elsewhere,", "or", "that", "any", "patents", "granted", "will", "be", "valid", "and", "enforceable,", "or", "will", "provide", "a", "competitive", "advantage", "or", "will", "afford", "protection", "against", "competitors", "with", "similar", "technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p104_s0", "idA": "908259_15_item1_p89_s0", "sentA": "**** Patent filed, awaiting grant In addition to these patents, for some of our product candidates, we have patents and/or applications that cover a particular form or composition, use for a particular indication, use as part of combination therapy or method of preparation or use, as well as other pending patent applications.", "sentB": "In-licensed from Angiogene Pharmaceuticals Ltd.; patent filed, awaiting grant In addition to these patents, for some of our product candidates, we have patents and/or applications that cover a particular form or composition, use for a particular indication, use as part of combination therapy or method of preparation or use, as well as other pending patent applications.", "type": 2, "words": ["<tag1>", "****", "Patent", "filed,", "awaiting", "grant", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications.", "<tag2>", "In-licensed", "from", "Angiogene", "Pharmaceuticals", "Ltd.;", "patent", "filed,", "awaiting", "grant", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications.", "<tag3>"], "wordsA": ["****", "Patent", "filed,", "awaiting", "grant", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications."], "wordsB": ["In-licensed", "from", "Angiogene", "Pharmaceuticals", "Ltd.;", "patent", "filed,", "awaiting", "grant", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p15_s0", "idA": "908259_15_item1_p8_s0", "sentA": "All adverse events in the study were manageable, with one Grade 4 event occurring in each treatment arm.", "sentB": "All adverse events in the clinical trial were manageable, with one Grade 4 event occurring in each treatment arm.", "type": 2, "words": ["<tag1>", "All", "adverse", "events", "in", "the", "study", "were", "manageable,", "with", "one", "Grade", "4", "event", "occurring", "in", "each", "treatment", "arm.", "<tag2>", "All", "adverse", "events", "in", "the", "clinical", "trial", "were", "manageable,", "with", "one", "Grade", "4", "event", "occurring", "in", "each", "treatment", "arm.", "<tag3>"], "wordsA": ["All", "adverse", "events", "in", "the", "study", "were", "manageable,", "with", "one", "Grade", "4", "event", "occurring", "in", "each", "treatment", "arm."], "wordsB": ["All", "adverse", "events", "in", "the", "clinical", "trial", "were", "manageable,", "with", "one", "Grade", "4", "event", "occurring", "in", "each", "treatment", "arm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p15_s1", "idA": "908259_15_item1_p8_s1", "sentA": "Consistent with prior clinical experience with fosbretabulin, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (10 cases for AVASTIN (bevacizumab) as compared to 17 for the combination).", "sentB": "Consistent with prior clinical experience with CA4P, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (18 cases for the combination compared to 10 cases for bevacizumab alone).", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination).", "<tag2>", "Consistent", "with", "prior", "clinical", "experience", "with", "CA4P,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(18", "cases", "for", "the", "combination", "compared", "to", "10", "cases", "for", "bevacizumab", "alone).", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination)."], "wordsB": ["Consistent", "with", "prior", "clinical", "experience", "with", "CA4P,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(18", "cases", "for", "the", "combination", "compared", "to", "10", "cases", "for", "bevacizumab", "alone)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p27_s2", "idA": "908259_15_item1_p8_s1", "sentA": "Consistent with prior clinical experience with fosbretabulin, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (10 cases for AVASTIN (bevacizumab) as compared to 17 for the combination).", "sentB": "Results of the FACT Study, which combined CA4P with chemotherapy and which, in 2010, we terminated early (after 75 patients were enrolled) due to slow enrollment, showed a numerical improvement in overall survival for the CA4P group (5.2 months) compared to the control group (4.0 months), although the results were not statistically significant.", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination).", "<tag2>", "Results", "of", "the", "FACT", "Study,", "which", "combined", "CA4P", "with", "chemotherapy", "and", "which,", "in", "2010,", "we", "terminated", "early", "(after", "75", "patients", "were", "enrolled)", "due", "to", "slow", "enrollment,", "showed", "a", "numerical", "improvement", "in", "overall", "survival", "for", "the", "CA4P", "group", "(5.2", "months)", "compared", "to", "the", "control", "group", "(4.0", "months),", "although", "the", "results", "were", "not", "statistically", "significant.", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination)."], "wordsB": ["Results", "of", "the", "FACT", "Study,", "which", "combined", "CA4P", "with", "chemotherapy", "and", "which,", "in", "2010,", "we", "terminated", "early", "(after", "75", "patients", "were", "enrolled)", "due", "to", "slow", "enrollment,", "showed", "a", "numerical", "improvement", "in", "overall", "survival", "for", "the", "CA4P", "group", "(5.2", "months)", "compared", "to", "the", "control", "group", "(4.0", "months),", "although", "the", "results", "were", "not", "statistically", "significant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p28_s0", "idA": "908259_15_item1_p8_s1", "sentA": "Consistent with prior clinical experience with fosbretabulin, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (10 cases for AVASTIN (bevacizumab) as compared to 17 for the combination).", "sentB": "improvement in overall response rate for the CA4P group (20.0%) compared to the control group (16.0%), although these results were not statistically significant either.", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination).", "<tag2>", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(20.0%)", "compared", "to", "the", "control", "group", "(16.0%),", "although", "these", "results", "were", "not", "statistically", "significant", "either.", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination)."], "wordsB": ["improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(20.0%)", "compared", "to", "the", "control", "group", "(16.0%),", "although", "these", "results", "were", "not", "statistically", "significant", "either."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p28_s1", "idA": "908259_15_item1_p8_s1", "sentA": "Consistent with prior clinical experience with fosbretabulin, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (10 cases for AVASTIN (bevacizumab) as compared to 17 for the combination).", "sentB": "We believe the numerical improvements shown for the CA4P group compared to the control group provide supportive evidence for the potential benefit of CA4P against this tumor type, and for the overall potential of CA4P against other highly vascular solid tumors.", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination).", "<tag2>", "We", "believe", "the", "numerical", "improvements", "shown", "for", "the", "CA4P", "group", "compared", "to", "the", "control", "group", "provide", "supportive", "evidence", "for", "the", "potential", "benefit", "of", "CA4P", "against", "this", "tumor", "type,", "and", "for", "the", "overall", "potential", "of", "CA4P", "against", "other", "highly", "vascular", "solid", "tumors.", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination)."], "wordsB": ["We", "believe", "the", "numerical", "improvements", "shown", "for", "the", "CA4P", "group", "compared", "to", "the", "control", "group", "provide", "supportive", "evidence", "for", "the", "potential", "benefit", "of", "CA4P", "against", "this", "tumor", "type,", "and", "for", "the", "overall", "potential", "of", "CA4P", "against", "other", "highly", "vascular", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p30_s1", "idA": "908259_15_item1_p8_s1", "sentA": "Consistent with prior clinical experience with fosbretabulin, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (10 cases for AVASTIN (bevacizumab) as compared to 17 for the combination).", "sentB": "Results of the FALCON Study, completed in 2011, which enrolled 63 patients and combined CA4P with both bevacizumab and chemotherapy, showed a numerical improvement in overall response rate for the CA4P group (56.3%) compared to the control group (35.5%), although the results were not statistically significant.", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination).", "<tag2>", "Results", "of", "the", "FALCON", "Study,", "completed", "in", "2011,", "which", "enrolled", "63", "patients", "and", "combined", "CA4P", "with", "both", "bevacizumab", "and", "chemotherapy,", "showed", "a", "numerical", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(56.3%)", "compared", "to", "the", "control", "group", "(35.5%),", "although", "the", "results", "were", "not", "statistically", "significant.", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination)."], "wordsB": ["Results", "of", "the", "FALCON", "Study,", "completed", "in", "2011,", "which", "enrolled", "63", "patients", "and", "combined", "CA4P", "with", "both", "bevacizumab", "and", "chemotherapy,", "showed", "a", "numerical", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(56.3%)", "compared", "to", "the", "control", "group", "(35.5%),", "although", "the", "results", "were", "not", "statistically", "significant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p30_s3", "idA": "908259_15_item1_p8_s1", "sentA": "Consistent with prior clinical experience with fosbretabulin, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (10 cases for AVASTIN (bevacizumab) as compared to 17 for the combination).", "sentB": "However, we believe the numerical improvements in response rates shown for the CA4P group compared to the control group provide supportive evidence for the potential benefit of CA4P against this tumor type, and for the overall potential of CA4P against other highly vascular solid tumors.", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination).", "<tag2>", "However,", "we", "believe", "the", "numerical", "improvements", "in", "response", "rates", "shown", "for", "the", "CA4P", "group", "compared", "to", "the", "control", "group", "provide", "supportive", "evidence", "for", "the", "potential", "benefit", "of", "CA4P", "against", "this", "tumor", "type,", "and", "for", "the", "overall", "potential", "of", "CA4P", "against", "other", "highly", "vascular", "solid", "tumors.", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "fosbretabulin,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(10", "cases", "for", "AVASTIN", "(bevacizumab)", "as", "compared", "to", "17", "for", "the", "combination)."], "wordsB": ["However,", "we", "believe", "the", "numerical", "improvements", "in", "response", "rates", "shown", "for", "the", "CA4P", "group", "compared", "to", "the", "control", "group", "provide", "supportive", "evidence", "for", "the", "potential", "benefit", "of", "CA4P", "against", "this", "tumor", "type,", "and", "for", "the", "overall", "potential", "of", "CA4P", "against", "other", "highly", "vascular", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p106_s0", "idA": "908259_15_item1_p91_s0", "sentA": "The patent term restoration period is generally one-half of the time between the effective date of an investigational new drug application, or IND, and the submission date of an NDA, plus the time between the submission date and approval date of an NDA.", "sentB": "The patent term restoration period is generally one-half of the time between the effective date of an investigational new drug application, or IND, and the submission date of a new drug application, or NDA, plus the time between the submission date and approval date of an NDA.", "type": 2, "words": ["<tag1>", "The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "of", "the", "time", "between", "the", "effective", "date", "of", "an", "investigational", "new", "drug", "application,", "or", "IND,", "and", "the", "submission", "date", "of", "an", "NDA,", "plus", "the", "time", "between", "the", "submission", "date", "and", "approval", "date", "of", "an", "NDA.", "<tag2>", "The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "of", "the", "time", "between", "the", "effective", "date", "of", "an", "investigational", "new", "drug", "application,", "or", "IND,", "and", "the", "submission", "date", "of", "a", "new", "drug", "application,", "or", "NDA,", "plus", "the", "time", "between", "the", "submission", "date", "and", "approval", "date", "of", "an", "NDA.", "<tag3>"], "wordsA": ["The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "of", "the", "time", "between", "the", "effective", "date", "of", "an", "investigational", "new", "drug", "application,", "or", "IND,", "and", "the", "submission", "date", "of", "an", "NDA,", "plus", "the", "time", "between", "the", "submission", "date", "and", "approval", "date", "of", "an", "NDA."], "wordsB": ["The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "of", "the", "time", "between", "the", "effective", "date", "of", "an", "investigational", "new", "drug", "application,", "or", "IND,", "and", "the", "submission", "date", "of", "a", "new", "drug", "application,", "or", "NDA,", "plus", "the", "time", "between", "the", "submission", "date", "and", "approval", "date", "of", "an", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p109_s0", "idA": "908259_15_item1_p94_s0", "sentA": "We are aware of a limited number of companies involved in the development of VDAs.", "sentB": "We are aware of a limited number of companies currently or previously involved in the development of VDAs.", "type": 2, "words": ["<tag1>", "We", "are", "aware", "of", "a", "limited", "number", "of", "companies", "involved", "in", "the", "development", "of", "VDAs.", "<tag2>", "We", "are", "aware", "of", "a", "limited", "number", "of", "companies", "currently", "or", "previously", "involved", "in", "the", "development", "of", "VDAs.", "<tag3>"], "wordsA": ["We", "are", "aware", "of", "a", "limited", "number", "of", "companies", "involved", "in", "the", "development", "of", "VDAs."], "wordsB": ["We", "are", "aware", "of", "a", "limited", "number", "of", "companies", "currently", "or", "previously", "involved", "in", "the", "development", "of", "VDAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p2_s1", "idA": "908259_15_item1_p94_s0", "sentA": "We are aware of a limited number of companies involved in the development of VDAs.", "sentB": "We are seeking to realize the full potential of VTTs in oncology by using the combination of VDAs and AAs to treat cancer tumors.", "type": 2, "words": ["<tag1>", "We", "are", "aware", "of", "a", "limited", "number", "of", "companies", "involved", "in", "the", "development", "of", "VDAs.", "<tag2>", "We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer", "tumors.", "<tag3>"], "wordsA": ["We", "are", "aware", "of", "a", "limited", "number", "of", "companies", "involved", "in", "the", "development", "of", "VDAs."], "wordsB": ["We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p109_s1", "idA": "908259_15_item1_p94_s1", "sentA": "Such companies include Bionomics, Immune Pharmaceuticals, and MediciNova, all of which have VDAs that we believe are at an earlier or similar stage of clinical development than our lead drug candidate, fosbretabulin.", "sentB": "Such companies include Bionomics, Angiogene, Immune Pharmaceuticals, and MediciNova, all of which have VDAs that we believe are at an earlier stage of clinical development than our lead drug candidate, CA4P.", "type": 2, "words": ["<tag1>", "Such", "companies", "include", "Bionomics,", "Immune", "Pharmaceuticals,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "fosbretabulin.", "<tag2>", "Such", "companies", "include", "Bionomics,", "Angiogene,", "Immune", "Pharmaceuticals,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "CA4P.", "<tag3>"], "wordsA": ["Such", "companies", "include", "Bionomics,", "Immune", "Pharmaceuticals,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "or", "similar", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "fosbretabulin."], "wordsB": ["Such", "companies", "include", "Bionomics,", "Angiogene,", "Immune", "Pharmaceuticals,", "and", "MediciNova,", "all", "of", "which", "have", "VDAs", "that", "we", "believe", "are", "at", "an", "earlier", "stage", "of", "clinical", "development", "than", "our", "lead", "drug", "candidate,", "CA4P."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p101_s3", "idA": "908259_15_item1_p94_s2", "sentA": "We expect that, if any of our products gain regulatory approval for sale, they will compete primarily on the basis of product efficacy, safety, patient convenience, reliability, price and patent protection.", "sentB": "There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.", "type": 2, "words": ["<tag1>", "We", "expect", "that,", "if", "any", "of", "our", "products", "gain", "regulatory", "approval", "for", "sale,", "they", "will", "compete", "primarily", "on", "the", "basis", "of", "product", "efficacy,", "safety,", "patient", "convenience,", "reliability,", "price", "and", "patent", "protection.", "<tag2>", "There", "can", "be", "no", "assurance", "that", "any", "country", "that", "has", "price", "controls", "or", "reimbursement", "limitations", "for", "pharmaceutical", "products", "will", "allow", "favorable", "reimbursement", "and", "pricing", "arrangements", "for", "any", "of", "our", "products.", "<tag3>"], "wordsA": ["We", "expect", "that,", "if", "any", "of", "our", "products", "gain", "regulatory", "approval", "for", "sale,", "they", "will", "compete", "primarily", "on", "the", "basis", "of", "product", "efficacy,", "safety,", "patient", "convenience,", "reliability,", "price", "and", "patent", "protection."], "wordsB": ["There", "can", "be", "no", "assurance", "that", "any", "country", "that", "has", "price", "controls", "or", "reimbursement", "limitations", "for", "pharmaceutical", "products", "will", "allow", "favorable", "reimbursement", "and", "pricing", "arrangements", "for", "any", "of", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s4", "idA": "908259_15_item1_p94_s4", "sentA": "EMPLOYEES We expect to continue to maintain a relatively small number of executives and other employees.", "sentB": "We expect to begin enrolling patients into this clinical trial during the second quarter of 2016.", "type": 2, "words": ["<tag1>", "EMPLOYEES", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees.", "<tag2>", "We", "expect", "to", "begin", "enrolling", "patients", "into", "this", "clinical", "trial", "during", "the", "second", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["EMPLOYEES", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees."], "wordsB": ["We", "expect", "to", "begin", "enrolling", "patients", "into", "this", "clinical", "trial", "during", "the", "second", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p98_s3", "idA": "908259_15_item1_p94_s4", "sentA": "EMPLOYEES We expect to continue to maintain a relatively small number of executives and other employees.", "sentB": "We expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of health care costs, including the cost of prescription drugs, while at the same time increasing access to health care services.", "type": 2, "words": ["<tag1>", "EMPLOYEES", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees.", "<tag2>", "We", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "health", "care", "costs,", "including", "the", "cost", "of", "prescription", "drugs,", "while", "at", "the", "same", "time", "increasing", "access", "to", "health", "care", "services.", "<tag3>"], "wordsA": ["EMPLOYEES", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees."], "wordsB": ["We", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "health", "care", "costs,", "including", "the", "cost", "of", "prescription", "drugs,", "while", "at", "the", "same", "time", "increasing", "access", "to", "health", "care", "services."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p2_s6", "idA": "908259_15_item1_p94_s5", "sentA": "We rely on outsourcing for much of our research, development, preclinical testing and clinical trial activity, although we maintain managerial and quality control over our clinical trials.", "sentB": "Historically, however, the majority of our clinical trials have used VDAs as a single agent.", "type": 2, "words": ["<tag1>", "We", "rely", "on", "outsourcing", "for", "much", "of", "our", "research,", "development,", "preclinical", "testing", "and", "clinical", "trial", "activity,", "although", "we", "maintain", "managerial", "and", "quality", "control", "over", "our", "clinical", "trials.", "<tag2>", "Historically,", "however,", "the", "majority", "of", "our", "clinical", "trials", "have", "used", "VDAs", "as", "a", "single", "agent.", "<tag3>"], "wordsA": ["We", "rely", "on", "outsourcing", "for", "much", "of", "our", "research,", "development,", "preclinical", "testing", "and", "clinical", "trial", "activity,", "although", "we", "maintain", "managerial", "and", "quality", "control", "over", "our", "clinical", "trials."], "wordsB": ["Historically,", "however,", "the", "majority", "of", "our", "clinical", "trials", "have", "used", "VDAs", "as", "a", "single", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p109_s6", "idA": "908259_15_item1_p94_s6", "sentA": "As of March 25, 2015, we had a total of 13 full-time employees and 1 employee working on a part-time basis.", "sentB": "As of March 23, 2016, we had a total of 15 full-time employees.", "type": 2, "words": ["<tag1>", "As", "of", "March", "25,", "2015,", "we", "had", "a", "total", "of", "13", "full-time", "employees", "and", "1", "employee", "working", "on", "a", "part-time", "basis.", "<tag2>", "As", "of", "March", "23,", "2016,", "we", "had", "a", "total", "of", "15", "full-time", "employees.", "<tag3>"], "wordsA": ["As", "of", "March", "25,", "2015,", "we", "had", "a", "total", "of", "13", "full-time", "employees", "and", "1", "employee", "working", "on", "a", "part-time", "basis."], "wordsB": ["As", "of", "March", "23,", "2016,", "we", "had", "a", "total", "of", "15", "full-time", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p16_s0", "idA": "908259_15_item1_p9_s0", "sentA": "All cases of hypertension were managed with antihypertensive treatments, as specified in the study protocol.", "sentB": "All cases of hypertension were managed with anti-hypertensive treatments, as specified in the clinical trial protocol.", "type": 2, "words": ["<tag1>", "All", "cases", "of", "hypertension", "were", "managed", "with", "antihypertensive", "treatments,", "as", "specified", "in", "the", "study", "protocol.", "<tag2>", "All", "cases", "of", "hypertension", "were", "managed", "with", "anti-hypertensive", "treatments,", "as", "specified", "in", "the", "clinical", "trial", "protocol.", "<tag3>"], "wordsA": ["All", "cases", "of", "hypertension", "were", "managed", "with", "antihypertensive", "treatments,", "as", "specified", "in", "the", "study", "protocol."], "wordsB": ["All", "cases", "of", "hypertension", "were", "managed", "with", "anti-hypertensive", "treatments,", "as", "specified", "in", "the", "clinical", "trial", "protocol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p16_s2", "idA": "908259_15_item1_p9_s2", "sentA": "A preliminary analysis after 33 events did not demonstrate a statistically significant difference in OS between the study arms.", "sentB": "A preliminary analysis after 33 events did not demonstrate a statistically significant difference in OS between the clinical trial arms; however, these OS data were not sufficiently mature to yield any meaningful conclusions.", "type": 2, "words": ["<tag1>", "A", "preliminary", "analysis", "after", "33", "events", "did", "not", "demonstrate", "a", "statistically", "significant", "difference", "in", "OS", "between", "the", "study", "arms.", "<tag2>", "A", "preliminary", "analysis", "after", "33", "events", "did", "not", "demonstrate", "a", "statistically", "significant", "difference", "in", "OS", "between", "the", "clinical", "trial", "arms;", "however,", "these", "OS", "data", "were", "not", "sufficiently", "mature", "to", "yield", "any", "meaningful", "conclusions.", "<tag3>"], "wordsA": ["A", "preliminary", "analysis", "after", "33", "events", "did", "not", "demonstrate", "a", "statistically", "significant", "difference", "in", "OS", "between", "the", "study", "arms."], "wordsB": ["A", "preliminary", "analysis", "after", "33", "events", "did", "not", "demonstrate", "a", "statistically", "significant", "difference", "in", "OS", "between", "the", "clinical", "trial", "arms;", "however,", "these", "OS", "data", "were", "not", "sufficiently", "mature", "to", "yield", "any", "meaningful", "conclusions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p16_s3", "idA": "908259_15_item1_p9_s4", "sentA": "Further analysis of this secondary endpoint will be conducted as the data matures.", "sentB": "Further analyses of this secondary endpoint will be conducted as the data matures.", "type": 2, "words": ["<tag1>", "Further", "analysis", "of", "this", "secondary", "endpoint", "will", "be", "conducted", "as", "the", "data", "matures.", "<tag2>", "Further", "analyses", "of", "this", "secondary", "endpoint", "will", "be", "conducted", "as", "the", "data", "matures.", "<tag3>"], "wordsA": ["Further", "analysis", "of", "this", "secondary", "endpoint", "will", "be", "conducted", "as", "the", "data", "matures."], "wordsB": ["Further", "analyses", "of", "this", "secondary", "endpoint", "will", "be", "conducted", "as", "the", "data", "matures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s8", "idA": "908259_16_item1_p0_s0", "sentA": "Business Overview We are a biopharmaceutical company focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "Interestingly, our VDAs have consistently shown a stronger treatment effect in larger tumors than in smaller tumors, which is in contrast to the majority of conventional therapies currently used for the treatment of cancer.", "type": 2, "words": ["<tag1>", "Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "Interestingly,", "our", "VDAs", "have", "consistently", "shown", "a", "stronger", "treatment", "effect", "in", "larger", "tumors", "than", "in", "smaller", "tumors,", "which", "is", "in", "contrast", "to", "the", "majority", "of", "conventional", "therapies", "currently", "used", "for", "the", "treatment", "of", "cancer.", "<tag3>"], "wordsA": ["Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["Interestingly,", "our", "VDAs", "have", "consistently", "shown", "a", "stronger", "treatment", "effect", "in", "larger", "tumors", "than", "in", "smaller", "tumors,", "which", "is", "in", "contrast", "to", "the", "majority", "of", "conventional", "therapies", "currently", "used", "for", "the", "treatment", "of", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s10", "idA": "908259_16_item1_p0_s1", "sentA": "VDAs selectively target the vasculature of cancer tumors and obstruct a tumor s blood supply without disrupting the blood supply to normal tissues.", "sentB": "The proportion of the tumor s blood vessels that are inside the tumor increases as the size of the tumor increases, based on volume-to-surface area ratios, allowing our drug candidates to occlude a greater percentage of a larger tumor s overall blood supply.", "type": 2, "words": ["<tag1>", "VDAs", "selectively", "target", "the", "vasculature", "of", "cancer", "tumors", "and", "obstruct", "a", "tumor", "s", "blood", "supply", "without", "disrupting", "the", "blood", "supply", "to", "normal", "tissues.", "<tag2>", "The", "proportion", "of", "the", "tumor", "s", "blood", "vessels", "that", "are", "inside", "the", "tumor", "increases", "as", "the", "size", "of", "the", "tumor", "increases,", "based", "on", "volume-to-surface", "area", "ratios,", "allowing", "our", "drug", "candidates", "to", "occlude", "a", "greater", "percentage", "of", "a", "larger", "tumor", "s", "overall", "blood", "supply.", "<tag3>"], "wordsA": ["VDAs", "selectively", "target", "the", "vasculature", "of", "cancer", "tumors", "and", "obstruct", "a", "tumor", "s", "blood", "supply", "without", "disrupting", "the", "blood", "supply", "to", "normal", "tissues."], "wordsB": ["The", "proportion", "of", "the", "tumor", "s", "blood", "vessels", "that", "are", "inside", "the", "tumor", "increases", "as", "the", "size", "of", "the", "tumor", "increases,", "based", "on", "volume-to-surface", "area", "ratios,", "allowing", "our", "drug", "candidates", "to", "occlude", "a", "greater", "percentage", "of", "a", "larger", "tumor", "s", "overall", "blood", "supply."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p0_s2", "idA": "908259_16_item1_p0_s2", "sentA": "Treatment with VDAs has been shown to lead to significant central tumor necrosis, which refers to the death of cancer cells.", "sentB": "Treatment with VDAs has been shown to lead to rapid and significant death of cancer cells within tumors.", "type": 2, "words": ["<tag1>", "Treatment", "with", "VDAs", "has", "been", "shown", "to", "lead", "to", "significant", "central", "tumor", "necrosis,", "which", "refers", "to", "the", "death", "of", "cancer", "cells.", "<tag2>", "Treatment", "with", "VDAs", "has", "been", "shown", "to", "lead", "to", "rapid", "and", "significant", "death", "of", "cancer", "cells", "within", "tumors.", "<tag3>"], "wordsA": ["Treatment", "with", "VDAs", "has", "been", "shown", "to", "lead", "to", "significant", "central", "tumor", "necrosis,", "which", "refers", "to", "the", "death", "of", "cancer", "cells."], "wordsB": ["Treatment", "with", "VDAs", "has", "been", "shown", "to", "lead", "to", "rapid", "and", "significant", "death", "of", "cancer", "cells", "within", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p20_s3", "idA": "908259_16_item1_p102_s0", "sentA": "Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.", "sentB": "The FOCUS Study is currently enrolling patients in the United States and western Europe, with the first interim analysis expected in April 2017.", "type": 2, "words": ["<tag1>", "Historically,", "products", "launched", "in", "the", "European", "Union", "do", "not", "follow", "price", "structures", "of", "the", "United", "States", "and", "generally", "tend", "to", "be", "significantly", "lower.", "<tag2>", "The", "FOCUS", "Study", "is", "currently", "enrolling", "patients", "in", "the", "United", "States", "and", "western", "Europe,", "with", "the", "first", "interim", "analysis", "expected", "in", "April", "2017.", "<tag3>"], "wordsA": ["Historically,", "products", "launched", "in", "the", "European", "Union", "do", "not", "follow", "price", "structures", "of", "the", "United", "States", "and", "generally", "tend", "to", "be", "significantly", "lower."], "wordsB": ["The", "FOCUS", "Study", "is", "currently", "enrolling", "patients", "in", "the", "United", "States", "and", "western", "Europe,", "with", "the", "first", "interim", "analysis", "expected", "in", "April", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p117_s2", "idA": "908259_16_item1_p103_s2", "sentA": "As of March 23, 2016, we were the exclusive licensee, sole assignee or co-assignee of thirty (30) granted U.S. patents, two (2) pending U.S. patent applications, and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "sentB": "As of March 30, 2017, we were the exclusive licensee, sole assignee or co-assignee of twenty-one granted U.S. patents, one pending U.S. patent application, and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "type": 2, "words": ["<tag1>", "As", "of", "March", "23,", "2016,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "thirty", "(30)", "granted", "U.S.", "patents,", "two", "(2)", "pending", "U.S.", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag2>", "As", "of", "March", "30,", "2017,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-one", "granted", "U.S.", "patents,", "one", "pending", "U.S.", "patent", "application,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag3>"], "wordsA": ["As", "of", "March", "23,", "2016,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "thirty", "(30)", "granted", "U.S.", "patents,", "two", "(2)", "pending", "U.S.", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "wordsB": ["As", "of", "March", "30,", "2017,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-one", "granted", "U.S.", "patents,", "one", "pending", "U.S.", "patent", "application,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p119_s0", "idA": "908259_16_item1_p104_s0", "sentA": "In-licensed from Angiogene Pharmaceuticals Ltd.; patent filed, awaiting grant In addition to these patents, for some of our product candidates, we have patents and/or applications that cover a particular form or composition, use for a particular indication, use as part of combination therapy or method of preparation or use, as well as other pending patent applications.", "sentB": "In-licensed from Arizona State University In addition to these patents, for some of our product candidates, we have patents and/or applications that cover a particular form or composition, use for a particular indication, use as part of combination therapy or method of preparation or use, as well as other pending patent applications.", "type": 2, "words": ["<tag1>", "In-licensed", "from", "Angiogene", "Pharmaceuticals", "Ltd.;", "patent", "filed,", "awaiting", "grant", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications.", "<tag2>", "In-licensed", "from", "Arizona", "State", "University", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications.", "<tag3>"], "wordsA": ["In-licensed", "from", "Angiogene", "Pharmaceuticals", "Ltd.;", "patent", "filed,", "awaiting", "grant", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications."], "wordsB": ["In-licensed", "from", "Arizona", "State", "University", "In", "addition", "to", "these", "patents,", "for", "some", "of", "our", "product", "candidates,", "we", "have", "patents", "and/or", "applications", "that", "cover", "a", "particular", "form", "or", "composition,", "use", "for", "a", "particular", "indication,", "use", "as", "part", "of", "combination", "therapy", "or", "method", "of", "preparation", "or", "use,", "as", "well", "as", "other", "pending", "patent", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p126_s5", "idA": "908259_16_item1_p109_s6", "sentA": "As of March 23, 2016, we had a total of 15 full-time employees.", "sentB": "As of March 30, 2017, we had a total of 16 full-time employees.", "type": 2, "words": ["<tag1>", "As", "of", "March", "23,", "2016,", "we", "had", "a", "total", "of", "15", "full-time", "employees.", "<tag2>", "As", "of", "March", "30,", "2017,", "we", "had", "a", "total", "of", "16", "full-time", "employees.", "<tag3>"], "wordsA": ["As", "of", "March", "23,", "2016,", "we", "had", "a", "total", "of", "15", "full-time", "employees."], "wordsB": ["As", "of", "March", "30,", "2017,", "we", "had", "a", "total", "of", "16", "full-time", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p12_s0", "idA": "908259_16_item1_p10_s0", "sentA": "There are relatively few cancer therapies that have been approved for the treatment of ovarian cancer including platinum-resistant cancer.", "sentB": "There are relatively few treatments that have been approved for ovarian cancer, and fewer for platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "including", "platinum-resistant", "cancer.", "<tag2>", "There", "are", "relatively", "few", "treatments", "that", "have", "been", "approved", "for", "ovarian", "cancer,", "and", "fewer", "for", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "including", "platinum-resistant", "cancer."], "wordsB": ["There", "are", "relatively", "few", "treatments", "that", "have", "been", "approved", "for", "ovarian", "cancer,", "and", "fewer", "for", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p12_s1", "idA": "908259_16_item1_p10_s1", "sentA": "Approved drugs include bevacizumab, carboplatin and cisplatin, gemcitabine, doxorubicin, paclitaxel and olaparib.", "sentB": "Approved drugs for ovarian cancer include bevacizumab, carboplatin and cisplatin, gemcitabine, doxorubicin, paclitaxel and olaparib.", "type": 2, "words": ["<tag1>", "Approved", "drugs", "include", "bevacizumab,", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "olaparib.", "<tag2>", "Approved", "drugs", "for", "ovarian", "cancer", "include", "bevacizumab,", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "olaparib.", "<tag3>"], "wordsA": ["Approved", "drugs", "include", "bevacizumab,", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "olaparib."], "wordsB": ["Approved", "drugs", "for", "ovarian", "cancer", "include", "bevacizumab,", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "paclitaxel", "and", "olaparib."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p13_s0", "idA": "908259_16_item1_p11_s0", "sentA": "Due to the unmet need in the treatment of ovarian cancer and the small size of the indication in terms of number of patients, we have been granted an orphan drug designation in both the U.S. and the European Union for the use of CA4P in the treatment of ovarian cancer.", "sentB": "CA4P has been granted Fast Track designation in the U.S. for treatment of platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "CA4P", "has", "been", "granted", "Fast", "Track", "designation", "in", "the", "U.S.", "for", "treatment", "of", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["CA4P", "has", "been", "granted", "Fast", "Track", "designation", "in", "the", "U.S.", "for", "treatment", "of", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p13_s1", "idA": "908259_16_item1_p11_s0", "sentA": "Due to the unmet need in the treatment of ovarian cancer and the small size of the indication in terms of number of patients, we have been granted an orphan drug designation in both the U.S. and the European Union for the use of CA4P in the treatment of ovarian cancer.", "sentB": "CA4P has also been granted orphan drug designation in both the U.S. and the European Union for the treatment of ovarian cancer.", "type": 2, "words": ["<tag1>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "CA4P", "has", "also", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["CA4P", "has", "also", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p33_s0", "idA": "908259_16_item1_p11_s0", "sentA": "Due to the unmet need in the treatment of ovarian cancer and the small size of the indication in terms of number of patients, we have been granted an orphan drug designation in both the U.S. and the European Union for the use of CA4P in the treatment of ovarian cancer.", "sentB": "Combination with Immune Oncology Agents Preclinical Research Over the last several years, there have been considerable advances in cancer immunotherapy, which makes use of the immune system to treat cancer.", "type": 2, "words": ["<tag1>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "Combination", "with", "Immune", "Oncology", "Agents", "Preclinical", "Research", "Over", "the", "last", "several", "years,", "there", "have", "been", "considerable", "advances", "in", "cancer", "immunotherapy,", "which", "makes", "use", "of", "the", "immune", "system", "to", "treat", "cancer.", "<tag3>"], "wordsA": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["Combination", "with", "Immune", "Oncology", "Agents", "Preclinical", "Research", "Over", "the", "last", "several", "years,", "there", "have", "been", "considerable", "advances", "in", "cancer", "immunotherapy,", "which", "makes", "use", "of", "the", "immune", "system", "to", "treat", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p36_s1", "idA": "908259_16_item1_p11_s0", "sentA": "Due to the unmet need in the treatment of ovarian cancer and the small size of the indication in terms of number of patients, we have been granted an orphan drug designation in both the U.S. and the European Union for the use of CA4P in the treatment of ovarian cancer.", "sentB": "OXi4503 has been granted orphan drug designation in both the U.S. and the European Union for the treatment of AML.", "type": 2, "words": ["<tag1>", "Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer.", "<tag2>", "OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["Due", "to", "the", "unmet", "need", "in", "the", "treatment", "of", "ovarian", "cancer", "and", "the", "small", "size", "of", "the", "indication", "in", "terms", "of", "number", "of", "patients,", "we", "have", "been", "granted", "an", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "use", "of", "CA4P", "in", "the", "treatment", "of", "ovarian", "cancer."], "wordsB": ["OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p14_s0", "idA": "908259_16_item1_p12_s0", "sentA": "CA4P in Combination with Bevacizumab Completed Phase 2 Clinical Trial with Positive Results Genentech s bevacizumab is an anti-vascular endothelial growth factor, or VEGF, monoclonal antibody which has been approved for the treatment of ovarian cancer in the United States and elsewhere.", "sentB": "Genentech s bevacizumab is an anti-vascular endothelial growth factor, or VEGF, monoclonal antibody which has been approved for the treatment of ovarian cancer in the United States and elsewhere.", "type": 2, "words": ["<tag1>", "CA4P", "in", "Combination", "with", "Bevacizumab", "Completed", "Phase", "2", "Clinical", "Trial", "with", "Positive", "Results", "Genentech", "s", "bevacizumab", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody", "which", "has", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "elsewhere.", "<tag2>", "Genentech", "s", "bevacizumab", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody", "which", "has", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "elsewhere.", "<tag3>"], "wordsA": ["CA4P", "in", "Combination", "with", "Bevacizumab", "Completed", "Phase", "2", "Clinical", "Trial", "with", "Positive", "Results", "Genentech", "s", "bevacizumab", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody", "which", "has", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "elsewhere."], "wordsB": ["Genentech", "s", "bevacizumab", "is", "an", "anti-vascular", "endothelial", "growth", "factor,", "or", "VEGF,", "monoclonal", "antibody", "which", "has", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "elsewhere."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p15_s1", "idA": "908259_16_item1_p13_s1", "sentA": "The GOG-0186I clinical trial enrolled a total of 107 patients with both platinum-sensitive and platinum-resistant recurrent ovarian cancer at 67 clinical sites in the United States.", "sentB": "The GOG-0186I clinical trial enrolled a total of 107 patients with recurrent ovarian cancer at 67 clinical sites in the United States.", "type": 2, "words": ["<tag1>", "The", "GOG-0186I", "clinical", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States.", "<tag2>", "The", "GOG-0186I", "clinical", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["The", "GOG-0186I", "clinical", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States."], "wordsB": ["The", "GOG-0186I", "clinical", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p16_s0", "idA": "908259_16_item1_p13_s1", "sentA": "The GOG-0186I clinical trial enrolled a total of 107 patients with both platinum-sensitive and platinum-resistant recurrent ovarian cancer at 67 clinical sites in the United States.", "sentB": "The GOG-0186I Study included 81 patients (75.7% of study patients) with recurrent ovarian cancer that was deemed measurable , as defined by RECIST criteria, and 26 patients (24.3%) deemed non-measurable.", "type": 2, "words": ["<tag1>", "The", "GOG-0186I", "clinical", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States.", "<tag2>", "The", "GOG-0186I", "Study", "included", "81", "patients", "(75.7%", "of", "study", "patients)", "with", "recurrent", "ovarian", "cancer", "that", "was", "deemed", "measurable", ",", "as", "defined", "by", "RECIST", "criteria,", "and", "26", "patients", "(24.3%)", "deemed", "non-measurable.", "<tag3>"], "wordsA": ["The", "GOG-0186I", "clinical", "trial", "enrolled", "a", "total", "of", "107", "patients", "with", "both", "platinum-sensitive", "and", "platinum-resistant", "recurrent", "ovarian", "cancer", "at", "67", "clinical", "sites", "in", "the", "United", "States."], "wordsB": ["The", "GOG-0186I", "Study", "included", "81", "patients", "(75.7%", "of", "study", "patients)", "with", "recurrent", "ovarian", "cancer", "that", "was", "deemed", "measurable", ",", "as", "defined", "by", "RECIST", "criteria,", "and", "26", "patients", "(24.3%)", "deemed", "non-measurable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p24_s3", "idA": "908259_16_item1_p13_s2", "sentA": "The results indicated a statistically significant increase in progression-free survival (PFS) in the combination arm, which was the primary endpoint of the trial, with a p-value of 0.049 (pre-specified analysis using a one-sided test; 10% level of significance).", "sentB": "A statistically significant mean change in biomarkers from baseline, the primary endpoint of the study, was not achieved due to the small sample size along with a high intra-and inter-patient variability observed in the biomarkers.", "type": 2, "words": ["<tag1>", "The", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "(PFS)", "in", "the", "combination", "arm,", "which", "was", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "0.049", "(pre-specified", "analysis", "using", "a", "one-sided", "test;", "10%", "level", "of", "significance).", "<tag2>", "A", "statistically", "significant", "mean", "change", "in", "biomarkers", "from", "baseline,", "the", "primary", "endpoint", "of", "the", "study,", "was", "not", "achieved", "due", "to", "the", "small", "sample", "size", "along", "with", "a", "high", "intra-and", "inter-patient", "variability", "observed", "in", "the", "biomarkers.", "<tag3>"], "wordsA": ["The", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "(PFS)", "in", "the", "combination", "arm,", "which", "was", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "0.049", "(pre-specified", "analysis", "using", "a", "one-sided", "test;", "10%", "level", "of", "significance)."], "wordsB": ["A", "statistically", "significant", "mean", "change", "in", "biomarkers", "from", "baseline,", "the", "primary", "endpoint", "of", "the", "study,", "was", "not", "achieved", "due", "to", "the", "small", "sample", "size", "along", "with", "a", "high", "intra-and", "inter-patient", "variability", "observed", "in", "the", "biomarkers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p43_s1", "idA": "908259_16_item1_p13_s2", "sentA": "The results indicated a statistically significant increase in progression-free survival (PFS) in the combination arm, which was the primary endpoint of the trial, with a p-value of 0.049 (pre-specified analysis using a one-sided test; 10% level of significance).", "sentB": "The adverse event profile remains similar to that seen in the monotherapy portion of the trial, with coagulopathies and hematological adverse events the most significant events.", "type": 2, "words": ["<tag1>", "The", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "(PFS)", "in", "the", "combination", "arm,", "which", "was", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "0.049", "(pre-specified", "analysis", "using", "a", "one-sided", "test;", "10%", "level", "of", "significance).", "<tag2>", "The", "adverse", "event", "profile", "remains", "similar", "to", "that", "seen", "in", "the", "monotherapy", "portion", "of", "the", "trial,", "with", "coagulopathies", "and", "hematological", "adverse", "events", "the", "most", "significant", "events.", "<tag3>"], "wordsA": ["The", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "(PFS)", "in", "the", "combination", "arm,", "which", "was", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "0.049", "(pre-specified", "analysis", "using", "a", "one-sided", "test;", "10%", "level", "of", "significance)."], "wordsB": ["The", "adverse", "event", "profile", "remains", "similar", "to", "that", "seen", "in", "the", "monotherapy", "portion", "of", "the", "trial,", "with", "coagulopathies", "and", "hematological", "adverse", "events", "the", "most", "significant", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p15_s9", "idA": "908259_16_item1_p14_s0", "sentA": "CA4P plus bevacizumab compared to 6.1 months for those receiving bevacizumab alone, although the results were not statistically significant, with a p-value of 0.139 and a hazard ratio of 0.67.", "sentB": "Although the results were stronger for the platinum-resistant patients, the 80 patients who were platinum-sensitive still showed a numerical improvement in PFS for the combination therapy, with a median PFS of 7.6 months for those receiving CA4P plus bevacizumab compared to 6.1 months for those receiving bevacizumab alone, although the results were not statistically significant, with a p-value of 0.139 and a hazard ratio of 0.67.", "type": 2, "words": ["<tag1>", "CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67.", "<tag2>", "Although", "the", "results", "were", "stronger", "for", "the", "platinum-resistant", "patients,", "the", "80", "patients", "who", "were", "platinum-sensitive", "still", "showed", "a", "numerical", "improvement", "in", "PFS", "for", "the", "combination", "therapy,", "with", "a", "median", "PFS", "of", "7.6", "months", "for", "those", "receiving", "CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67.", "<tag3>"], "wordsA": ["CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67."], "wordsB": ["Although", "the", "results", "were", "stronger", "for", "the", "platinum-resistant", "patients,", "the", "80", "patients", "who", "were", "platinum-sensitive", "still", "showed", "a", "numerical", "improvement", "in", "PFS", "for", "the", "combination", "therapy,", "with", "a", "median", "PFS", "of", "7.6", "months", "for", "those", "receiving", "CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p16_s5", "idA": "908259_16_item1_p14_s0", "sentA": "CA4P plus bevacizumab compared to 6.1 months for those receiving bevacizumab alone, although the results were not statistically significant, with a p-value of 0.139 and a hazard ratio of 0.67.", "sentB": "More importantly, patients with measurable disease treated with CA4P had a 5.6 month improvement in median OS (26.8 vs. 21.2 months; 22% reduction in the risk of death; HR=0.78, not statistically significant), and a 3.7 month improvement in progression free survival (PFS) (9.8 vs. 6.1 months; HR=0.60, p=0.027) compared to control patients with measurable disease.", "type": 2, "words": ["<tag1>", "CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67.", "<tag2>", "More", "importantly,", "patients", "with", "measurable", "disease", "treated", "with", "CA4P", "had", "a", "5.6", "month", "improvement", "in", "median", "OS", "(26.8", "vs.", "21.2", "months;", "22%", "reduction", "in", "the", "risk", "of", "death;", "HR=0.78,", "not", "statistically", "significant),", "and", "a", "3.7", "month", "improvement", "in", "progression", "free", "survival", "(PFS)", "(9.8", "vs.", "6.1", "months;", "HR=0.60,", "p=0.027)", "compared", "to", "control", "patients", "with", "measurable", "disease.", "<tag3>"], "wordsA": ["CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67."], "wordsB": ["More", "importantly,", "patients", "with", "measurable", "disease", "treated", "with", "CA4P", "had", "a", "5.6", "month", "improvement", "in", "median", "OS", "(26.8", "vs.", "21.2", "months;", "22%", "reduction", "in", "the", "risk", "of", "death;", "HR=0.78,", "not", "statistically", "significant),", "and", "a", "3.7", "month", "improvement", "in", "progression", "free", "survival", "(PFS)", "(9.8", "vs.", "6.1", "months;", "HR=0.60,", "p=0.027)", "compared", "to", "control", "patients", "with", "measurable", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p16_s2", "idA": "908259_16_item1_p14_s1", "sentA": "In the clinical trial, patients with measurable disease who received the combination of CA4P and bevacizumab also achieved a higher objective response rate, or ORR, a secondary endpoint in the clinical trial, measured according to RECIST criteria.", "sentB": "Patients with measurable disease who received the combination of CA4P and bevacizumab achieved a higher objective response rate, or ORR, a secondary endpoint in the clinical trial, measured according to RECIST criteria.", "type": 2, "words": ["<tag1>", "In", "the", "clinical", "trial,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria.", "<tag2>", "Patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria.", "<tag3>"], "wordsA": ["In", "the", "clinical", "trial,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria."], "wordsB": ["Patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p34_s4", "idA": "908259_16_item1_p14_s1", "sentA": "In the clinical trial, patients with measurable disease who received the combination of CA4P and bevacizumab also achieved a higher objective response rate, or ORR, a secondary endpoint in the clinical trial, measured according to RECIST criteria.", "sentB": "In this study, 7 of 8 mice receiving a combination of CA4P and an anti-CTLA4 antibody experienced complete remission of their tumors, compared to 1 of 8 in the CA4P monotherapy arm and 2 of 8 in the anti-CTLA4 antibody monotherapy arm.", "type": 2, "words": ["<tag1>", "In", "the", "clinical", "trial,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria.", "<tag2>", "In", "this", "study,", "7", "of", "8", "mice", "receiving", "a", "combination", "of", "CA4P", "and", "an", "anti-CTLA4", "antibody", "experienced", "complete", "remission", "of", "their", "tumors,", "compared", "to", "1", "of", "8", "in", "the", "CA4P", "monotherapy", "arm", "and", "2", "of", "8", "in", "the", "anti-CTLA4", "antibody", "monotherapy", "arm.", "<tag3>"], "wordsA": ["In", "the", "clinical", "trial,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria."], "wordsB": ["In", "this", "study,", "7", "of", "8", "mice", "receiving", "a", "combination", "of", "CA4P", "and", "an", "anti-CTLA4", "antibody", "experienced", "complete", "remission", "of", "their", "tumors,", "compared", "to", "1", "of", "8", "in", "the", "CA4P", "monotherapy", "arm", "and", "2", "of", "8", "in", "the", "anti-CTLA4", "antibody", "monotherapy", "arm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p15_s10", "idA": "908259_16_item1_p15_s1", "sentA": "Consistent with prior clinical experience with CA4P, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (18 cases for the combination compared to 10 cases for bevacizumab alone).", "sentB": "Based on the final dataset as of November 2015, the median overall survival (OS) for the GOG-0186I Study in the intent-to-treat (ITT) group was 3.2 months longer for the CA4P-treated patients compared to the control patients (25.2 vs. 22.0 months, respectively; HR=0.83, p=NS).", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "CA4P,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(18", "cases", "for", "the", "combination", "compared", "to", "10", "cases", "for", "bevacizumab", "alone).", "<tag2>", "Based", "on", "the", "final", "dataset", "as", "of", "November", "2015,", "the", "median", "overall", "survival", "(OS)", "for", "the", "GOG-0186I", "Study", "in", "the", "intent-to-treat", "(ITT)", "group", "was", "3.2", "months", "longer", "for", "the", "CA4P-treated", "patients", "compared", "to", "the", "control", "patients", "(25.2", "vs.", "22.0", "months,", "respectively;", "HR=0.83,", "p=NS).", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "CA4P,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(18", "cases", "for", "the", "combination", "compared", "to", "10", "cases", "for", "bevacizumab", "alone)."], "wordsB": ["Based", "on", "the", "final", "dataset", "as", "of", "November", "2015,", "the", "median", "overall", "survival", "(OS)", "for", "the", "GOG-0186I", "Study", "in", "the", "intent-to-treat", "(ITT)", "group", "was", "3.2", "months", "longer", "for", "the", "CA4P-treated", "patients", "compared", "to", "the", "control", "patients", "(25.2", "vs.", "22.0", "months,", "respectively;", "HR=0.83,", "p=NS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p17_s1", "idA": "908259_16_item1_p15_s1", "sentA": "Consistent with prior clinical experience with CA4P, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (18 cases for the combination compared to 10 cases for bevacizumab alone).", "sentB": "Consistent with prior clinical experience with CA4P, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (17 events for the combination compared to 10 events for bevacizumab alone).", "type": 2, "words": ["<tag1>", "Consistent", "with", "prior", "clinical", "experience", "with", "CA4P,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(18", "cases", "for", "the", "combination", "compared", "to", "10", "cases", "for", "bevacizumab", "alone).", "<tag2>", "Consistent", "with", "prior", "clinical", "experience", "with", "CA4P,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(17", "events", "for", "the", "combination", "compared", "to", "10", "events", "for", "bevacizumab", "alone).", "<tag3>"], "wordsA": ["Consistent", "with", "prior", "clinical", "experience", "with", "CA4P,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(18", "cases", "for", "the", "combination", "compared", "to", "10", "cases", "for", "bevacizumab", "alone)."], "wordsB": ["Consistent", "with", "prior", "clinical", "experience", "with", "CA4P,", "patients", "in", "the", "combination", "arm", "experienced", "an", "increased", "incidence", "of", "Grade", "3", "hypertension", "compared", "to", "the", "control", "arm", "(17", "events", "for", "the", "combination", "compared", "to", "10", "events", "for", "bevacizumab", "alone)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p24_s1", "idA": "908259_16_item1_p15_s2", "sentA": "One patient on the combination regimen had a Grade 3 thromboembolic event.", "sentB": "One patient (6%) experienced significant symptomatic improvement as measured by ECOG Status and had a partial response per investigator-assessed RECIST criteria, and an additional 7 patients (39%) had stable disease.", "type": 2, "words": ["<tag1>", "One", "patient", "on", "the", "combination", "regimen", "had", "a", "Grade", "3", "thromboembolic", "event.", "<tag2>", "One", "patient", "(6%)", "experienced", "significant", "symptomatic", "improvement", "as", "measured", "by", "ECOG", "Status", "and", "had", "a", "partial", "response", "per", "investigator-assessed", "RECIST", "criteria,", "and", "an", "additional", "7", "patients", "(39%)", "had", "stable", "disease.", "<tag3>"], "wordsA": ["One", "patient", "on", "the", "combination", "regimen", "had", "a", "Grade", "3", "thromboembolic", "event."], "wordsB": ["One", "patient", "(6%)", "experienced", "significant", "symptomatic", "improvement", "as", "measured", "by", "ECOG", "Status", "and", "had", "a", "partial", "response", "per", "investigator-assessed", "RECIST", "criteria,", "and", "an", "additional", "7", "patients", "(39%)", "had", "stable", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p12_s3", "idA": "908259_16_item1_p17_s0", "sentA": "The approval of bevacizumab in the U.S. in combination with chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) for the treatment of women with platinum-resistant ovarian cancer was based on results from the phase 3 AURELIA trial, which had a primary endpoint of PFS.", "sentB": "In December 2014, the FDA approved bevacizumab in combination with chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) for the treatment of women with platinum-resistant ovarian cancer, based on results from the phase 3 AURELIA trial, which had a primary endpoint of PFS, or progression-free survival.", "type": 2, "words": ["<tag1>", "The", "approval", "of", "bevacizumab", "in", "the", "U.S.", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "ovarian", "cancer", "was", "based", "on", "results", "from", "the", "phase", "3", "AURELIA", "trial,", "which", "had", "a", "primary", "endpoint", "of", "PFS.", "<tag2>", "In", "December", "2014,", "the", "FDA", "approved", "bevacizumab", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "ovarian", "cancer,", "based", "on", "results", "from", "the", "phase", "3", "AURELIA", "trial,", "which", "had", "a", "primary", "endpoint", "of", "PFS,", "or", "progression-free", "survival.", "<tag3>"], "wordsA": ["The", "approval", "of", "bevacizumab", "in", "the", "U.S.", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "ovarian", "cancer", "was", "based", "on", "results", "from", "the", "phase", "3", "AURELIA", "trial,", "which", "had", "a", "primary", "endpoint", "of", "PFS."], "wordsB": ["In", "December", "2014,", "the", "FDA", "approved", "bevacizumab", "in", "combination", "with", "chemotherapy", "(paclitaxel,", "pegylated", "liposomal", "doxorubicin,", "or", "topotecan)", "for", "the", "treatment", "of", "women", "with", "platinum-resistant", "ovarian", "cancer,", "based", "on", "results", "from", "the", "phase", "3", "AURELIA", "trial,", "which", "had", "a", "primary", "endpoint", "of", "PFS,", "or", "progression-free", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p19_s0", "idA": "908259_16_item1_p17_s2", "sentA": "CA4P in Combination with Bevacizumab and Physician s Choice Chemotherapy Phase 2/3 Clinical Trial Planned Based on the positive overall results from the GOG-0186I clinical trial in recurrent ovarian cancer and also the statistically significant results among the subgroup of platinum-resistant patients, we plan to initiate the FOCUS Study, a phase 2/3 clinical trial of CA4P seeking to demonstrate whether CA4P improves the current standard of care for platinum-resistant ovarian cancer.", "sentB": "CA4P in Combination with Bevacizumab and Physician s Choice Chemotherapy Phase 2/3 FOCUS Study Based on the positive overall results from the GOG-0186I clinical trial in recurrent ovarian cancer, including the stronger results among the subgroup of platinum-resistant patients and among the patients with measurable disease, we initiated the FOCUS Clinical Study in June 2016.", "type": 2, "words": ["<tag1>", "CA4P", "in", "Combination", "with", "Bevacizumab", "and", "Physician", "s", "Choice", "Chemotherapy", "Phase", "2/3", "Clinical", "Trial", "Planned", "Based", "on", "the", "positive", "overall", "results", "from", "the", "GOG-0186I", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "and", "also", "the", "statistically", "significant", "results", "among", "the", "subgroup", "of", "platinum-resistant", "patients,", "we", "plan", "to", "initiate", "the", "FOCUS", "Study,", "a", "phase", "2/3", "clinical", "trial", "of", "CA4P", "seeking", "to", "demonstrate", "whether", "CA4P", "improves", "the", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer.", "<tag2>", "CA4P", "in", "Combination", "with", "Bevacizumab", "and", "Physician", "s", "Choice", "Chemotherapy", "Phase", "2/3", "FOCUS", "Study", "Based", "on", "the", "positive", "overall", "results", "from", "the", "GOG-0186I", "clinical", "trial", "in", "recurrent", "ovarian", "cancer,", "including", "the", "stronger", "results", "among", "the", "subgroup", "of", "platinum-resistant", "patients", "and", "among", "the", "patients", "with", "measurable", "disease,", "we", "initiated", "the", "FOCUS", "Clinical", "Study", "in", "June", "2016.", "<tag3>"], "wordsA": ["CA4P", "in", "Combination", "with", "Bevacizumab", "and", "Physician", "s", "Choice", "Chemotherapy", "Phase", "2/3", "Clinical", "Trial", "Planned", "Based", "on", "the", "positive", "overall", "results", "from", "the", "GOG-0186I", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "and", "also", "the", "statistically", "significant", "results", "among", "the", "subgroup", "of", "platinum-resistant", "patients,", "we", "plan", "to", "initiate", "the", "FOCUS", "Study,", "a", "phase", "2/3", "clinical", "trial", "of", "CA4P", "seeking", "to", "demonstrate", "whether", "CA4P", "improves", "the", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer."], "wordsB": ["CA4P", "in", "Combination", "with", "Bevacizumab", "and", "Physician", "s", "Choice", "Chemotherapy", "Phase", "2/3", "FOCUS", "Study", "Based", "on", "the", "positive", "overall", "results", "from", "the", "GOG-0186I", "clinical", "trial", "in", "recurrent", "ovarian", "cancer,", "including", "the", "stronger", "results", "among", "the", "subgroup", "of", "platinum-resistant", "patients", "and", "among", "the", "patients", "with", "measurable", "disease,", "we", "initiated", "the", "FOCUS", "Clinical", "Study", "in", "June", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p19_s1", "idA": "908259_16_item1_p18_s0", "sentA": "The current standard of care for platinum-resistant ovarian cancer is treatment with bevacizumab and chemotherapy.", "sentB": "FOCUS is a phase 2/3 clinical trial of CA4P seeking to demonstrate whether CA4P improves upon the current standard of care for platinum-resistant ovarian cancer the current standard of care being treatment with both bevacizumab and chemotherapy.", "type": 2, "words": ["<tag1>", "The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag2>", "FOCUS", "is", "a", "phase", "2/3", "clinical", "trial", "of", "CA4P", "seeking", "to", "demonstrate", "whether", "CA4P", "improves", "upon", "the", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "the", "current", "standard", "of", "care", "being", "treatment", "with", "both", "bevacizumab", "and", "chemotherapy.", "<tag3>"], "wordsA": ["The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "wordsB": ["FOCUS", "is", "a", "phase", "2/3", "clinical", "trial", "of", "CA4P", "seeking", "to", "demonstrate", "whether", "CA4P", "improves", "upon", "the", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "the", "current", "standard", "of", "care", "being", "treatment", "with", "both", "bevacizumab", "and", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p19_s5", "idA": "908259_16_item1_p18_s0", "sentA": "The current standard of care for platinum-resistant ovarian cancer is treatment with bevacizumab and chemotherapy.", "sentB": "In FOCUS, we are enrolling platinum-resistant ovarian cancer patients with measurable disease, and randomizing them on a 1:1 basis into either the treatment group or the control group.", "type": 2, "words": ["<tag1>", "The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag2>", "In", "FOCUS,", "we", "are", "enrolling", "platinum-resistant", "ovarian", "cancer", "patients", "with", "measurable", "disease,", "and", "randomizing", "them", "on", "a", "1:1", "basis", "into", "either", "the", "treatment", "group", "or", "the", "control", "group.", "<tag3>"], "wordsA": ["The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "wordsB": ["In", "FOCUS,", "we", "are", "enrolling", "platinum-resistant", "ovarian", "cancer", "patients", "with", "measurable", "disease,", "and", "randomizing", "them", "on", "a", "1:1", "basis", "into", "either", "the", "treatment", "group", "or", "the", "control", "group."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p6_s0", "idA": "908259_16_item1_p18_s0", "sentA": "The current standard of care for platinum-resistant ovarian cancer is treatment with bevacizumab and chemotherapy.", "sentB": "(PCC) to treatment with bevacizumab and PCC.", "type": 2, "words": ["<tag1>", "The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag2>", "(PCC)", "to", "treatment", "with", "bevacizumab", "and", "PCC.", "<tag3>"], "wordsA": ["The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "wordsB": ["(PCC)", "to", "treatment", "with", "bevacizumab", "and", "PCC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p20_s0", "idA": "908259_16_item1_p19_s0", "sentA": "The clinical trial is designed with two stages in the first stage we plan to enroll up to 80 patients and conduct regular interim analyses in order to verify efficacy and confirm powering assumptions for the second stage.", "sentB": "The clinical trial is designed in two sequential stages in the first stage we are enrolling up to 80 patients and conducting interim analyses after 20, 40, 60 and 80 patients have been treated for approximately three months.", "type": 2, "words": ["<tag1>", "The", "clinical", "trial", "is", "designed", "with", "two", "stages", "in", "the", "first", "stage", "we", "plan", "to", "enroll", "up", "to", "80", "patients", "and", "conduct", "regular", "interim", "analyses", "in", "order", "to", "verify", "efficacy", "and", "confirm", "powering", "assumptions", "for", "the", "second", "stage.", "<tag2>", "The", "clinical", "trial", "is", "designed", "in", "two", "sequential", "stages", "in", "the", "first", "stage", "we", "are", "enrolling", "up", "to", "80", "patients", "and", "conducting", "interim", "analyses", "after", "20,", "40,", "60", "and", "80", "patients", "have", "been", "treated", "for", "approximately", "three", "months.", "<tag3>"], "wordsA": ["The", "clinical", "trial", "is", "designed", "with", "two", "stages", "in", "the", "first", "stage", "we", "plan", "to", "enroll", "up", "to", "80", "patients", "and", "conduct", "regular", "interim", "analyses", "in", "order", "to", "verify", "efficacy", "and", "confirm", "powering", "assumptions", "for", "the", "second", "stage."], "wordsB": ["The", "clinical", "trial", "is", "designed", "in", "two", "sequential", "stages", "in", "the", "first", "stage", "we", "are", "enrolling", "up", "to", "80", "patients", "and", "conducting", "interim", "analyses", "after", "20,", "40,", "60", "and", "80", "patients", "have", "been", "treated", "for", "approximately", "three", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p20_s1", "idA": "908259_16_item1_p19_s0", "sentA": "The clinical trial is designed with two stages in the first stage we plan to enroll up to 80 patients and conduct regular interim analyses in order to verify efficacy and confirm powering assumptions for the second stage.", "sentB": "The goal of the first stage is to verify efficacy seen in the GOG-0186I Study, confirm the safety of the treatment regimen in this population, and to confirm powering assumptions for the second stage.", "type": 2, "words": ["<tag1>", "The", "clinical", "trial", "is", "designed", "with", "two", "stages", "in", "the", "first", "stage", "we", "plan", "to", "enroll", "up", "to", "80", "patients", "and", "conduct", "regular", "interim", "analyses", "in", "order", "to", "verify", "efficacy", "and", "confirm", "powering", "assumptions", "for", "the", "second", "stage.", "<tag2>", "The", "goal", "of", "the", "first", "stage", "is", "to", "verify", "efficacy", "seen", "in", "the", "GOG-0186I", "Study,", "confirm", "the", "safety", "of", "the", "treatment", "regimen", "in", "this", "population,", "and", "to", "confirm", "powering", "assumptions", "for", "the", "second", "stage.", "<tag3>"], "wordsA": ["The", "clinical", "trial", "is", "designed", "with", "two", "stages", "in", "the", "first", "stage", "we", "plan", "to", "enroll", "up", "to", "80", "patients", "and", "conduct", "regular", "interim", "analyses", "in", "order", "to", "verify", "efficacy", "and", "confirm", "powering", "assumptions", "for", "the", "second", "stage."], "wordsB": ["The", "goal", "of", "the", "first", "stage", "is", "to", "verify", "efficacy", "seen", "in", "the", "GOG-0186I", "Study,", "confirm", "the", "safety", "of", "the", "treatment", "regimen", "in", "this", "population,", "and", "to", "confirm", "powering", "assumptions", "for", "the", "second", "stage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p20_s2", "idA": "908259_16_item1_p19_s1", "sentA": "In the second stage, we plan to enroll up to 356 additional patients and do not plan to conduct any interim analyses.", "sentB": "In the second stage, which is designed to support registration of CA4P in the United States and elsewhere, we plan to enroll up to 356 additional patients.", "type": 2, "words": ["<tag1>", "In", "the", "second", "stage,", "we", "plan", "to", "enroll", "up", "to", "356", "additional", "patients", "and", "do", "not", "plan", "to", "conduct", "any", "interim", "analyses.", "<tag2>", "In", "the", "second", "stage,", "which", "is", "designed", "to", "support", "registration", "of", "CA4P", "in", "the", "United", "States", "and", "elsewhere,", "we", "plan", "to", "enroll", "up", "to", "356", "additional", "patients.", "<tag3>"], "wordsA": ["In", "the", "second", "stage,", "we", "plan", "to", "enroll", "up", "to", "356", "additional", "patients", "and", "do", "not", "plan", "to", "conduct", "any", "interim", "analyses."], "wordsB": ["In", "the", "second", "stage,", "which", "is", "designed", "to", "support", "registration", "of", "CA4P", "in", "the", "United", "States", "and", "elsewhere,", "we", "plan", "to", "enroll", "up", "to", "356", "additional", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p19_s3", "idA": "908259_16_item1_p19_s3", "sentA": "If results from the second stage of the clinical study meet the primary endpoint, we intend to submit a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA.", "sentB": "If results from the second stage of the clinical study meet the primary endpoint, we plan to submit a New Drug Application, or NDA, to the FDA.", "type": 2, "words": ["<tag1>", "If", "results", "from", "the", "second", "stage", "of", "the", "clinical", "study", "meet", "the", "primary", "endpoint,", "we", "intend", "to", "submit", "a", "New", "Drug", "Application,", "or", "NDA,", "to", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA.", "<tag2>", "If", "results", "from", "the", "second", "stage", "of", "the", "clinical", "study", "meet", "the", "primary", "endpoint,", "we", "plan", "to", "submit", "a", "New", "Drug", "Application,", "or", "NDA,", "to", "the", "FDA.", "<tag3>"], "wordsA": ["If", "results", "from", "the", "second", "stage", "of", "the", "clinical", "study", "meet", "the", "primary", "endpoint,", "we", "intend", "to", "submit", "a", "New", "Drug", "Application,", "or", "NDA,", "to", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA."], "wordsB": ["If", "results", "from", "the", "second", "stage", "of", "the", "clinical", "study", "meet", "the", "primary", "endpoint,", "we", "plan", "to", "submit", "a", "New", "Drug", "Application,", "or", "NDA,", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p6_s4", "idA": "908259_16_item1_p19_s3", "sentA": "If results from the second stage of the clinical study meet the primary endpoint, we intend to submit a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA.", "sentB": "Companies with Fast Track designation are able to benefit from more frequent meetings and communications with the United States Food and Drug Administration, or the FDA, regarding development plans to support product registration, and may also be eligible for priority review of New Drug Applications, which shortens FDA s standard review timeline.", "type": 2, "words": ["<tag1>", "If", "results", "from", "the", "second", "stage", "of", "the", "clinical", "study", "meet", "the", "primary", "endpoint,", "we", "intend", "to", "submit", "a", "New", "Drug", "Application,", "or", "NDA,", "to", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA.", "<tag2>", "Companies", "with", "Fast", "Track", "designation", "are", "able", "to", "benefit", "from", "more", "frequent", "meetings", "and", "communications", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "the", "FDA,", "regarding", "development", "plans", "to", "support", "product", "registration,", "and", "may", "also", "be", "eligible", "for", "priority", "review", "of", "New", "Drug", "Applications,", "which", "shortens", "FDA", "s", "standard", "review", "timeline.", "<tag3>"], "wordsA": ["If", "results", "from", "the", "second", "stage", "of", "the", "clinical", "study", "meet", "the", "primary", "endpoint,", "we", "intend", "to", "submit", "a", "New", "Drug", "Application,", "or", "NDA,", "to", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA."], "wordsB": ["Companies", "with", "Fast", "Track", "designation", "are", "able", "to", "benefit", "from", "more", "frequent", "meetings", "and", "communications", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "the", "FDA,", "regarding", "development", "plans", "to", "support", "product", "registration,", "and", "may", "also", "be", "eligible", "for", "priority", "review", "of", "New", "Drug", "Applications,", "which", "shortens", "FDA", "s", "standard", "review", "timeline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p21_s0", "idA": "908259_16_item1_p19_s5", "sentA": "CA4P in Combination with Pazopanib Ongoing Phase 1b Clinical Trial moving into Phase 2 Pazopanib is an anti-angiogenic oral tyrosine kinase inhibitor that is currently approved by the FDA for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS).", "sentB": "CA4P in Combination with Pazopanib Ongoing Phase 2 Clinical Trial Pazopanib is an anti-angiogenic oral tyrosine kinase inhibitor that is currently approved by the FDA for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS).", "type": 2, "words": ["<tag1>", "CA4P", "in", "Combination", "with", "Pazopanib", "Ongoing", "Phase", "1b", "Clinical", "Trial", "moving", "into", "Phase", "2", "Pazopanib", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "FDA", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS).", "<tag2>", "CA4P", "in", "Combination", "with", "Pazopanib", "Ongoing", "Phase", "2", "Clinical", "Trial", "Pazopanib", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "FDA", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS).", "<tag3>"], "wordsA": ["CA4P", "in", "Combination", "with", "Pazopanib", "Ongoing", "Phase", "1b", "Clinical", "Trial", "moving", "into", "Phase", "2", "Pazopanib", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "FDA", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS)."], "wordsB": ["CA4P", "in", "Combination", "with", "Pazopanib", "Ongoing", "Phase", "2", "Clinical", "Trial", "Pazopanib", "is", "an", "anti-angiogenic", "oral", "tyrosine", "kinase", "inhibitor", "that", "is", "currently", "approved", "by", "the", "FDA", "for", "the", "treatment", "of", "renal", "cell", "carcinoma", "(RCC)", "and", "soft", "tissue", "sarcoma", "(STS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p25_s2", "idA": "908259_16_item1_p19_s7", "sentA": "We believe that using CA4P in combination with pazopanib may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "Based on the evidence of efficacy observed in this trial, plus an understanding of the benefits of VTT combination therapy, a lead investigator in this trial is sponsoring and funding a 20 patient study in NETs using CA4P in combination with everolimus (AFINITOR , marketed by Novartis), an anti-angiogenic agent which is already approved and commonly used in this indication.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "CA4P", "in", "combination", "with", "pazopanib", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "Based", "on", "the", "evidence", "of", "efficacy", "observed", "in", "this", "trial,", "plus", "an", "understanding", "of", "the", "benefits", "of", "VTT", "combination", "therapy,", "a", "lead", "investigator", "in", "this", "trial", "is", "sponsoring", "and", "funding", "a", "20", "patient", "study", "in", "NETs", "using", "CA4P", "in", "combination", "with", "everolimus", "(AFINITOR", ",", "marketed", "by", "Novartis),", "an", "anti-angiogenic", "agent", "which", "is", "already", "approved", "and", "commonly", "used", "in", "this", "indication.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "CA4P", "in", "combination", "with", "pazopanib", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["Based", "on", "the", "evidence", "of", "efficacy", "observed", "in", "this", "trial,", "plus", "an", "understanding", "of", "the", "benefits", "of", "VTT", "combination", "therapy,", "a", "lead", "investigator", "in", "this", "trial", "is", "sponsoring", "and", "funding", "a", "20", "patient", "study", "in", "NETs", "using", "CA4P", "in", "combination", "with", "everolimus", "(AFINITOR", ",", "marketed", "by", "Novartis),", "an", "anti-angiogenic", "agent", "which", "is", "already", "approved", "and", "commonly", "used", "in", "this", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p21_s5", "idA": "908259_16_item1_p19_s8", "sentA": "In October 2014, the first patient was enrolled in a phase 1b/2 trial of pazopanib with and without CA4P in advanced recurrent ovarian cancer.", "sentB": "In October 2014, the first patient was enrolled in the phase 1b portion of the trial, with the goal of finding an appropriate combination dose of CA4P and pazopanib for the phase 2 portion of the trial.", "type": 2, "words": ["<tag1>", "In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "CA4P", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag2>", "In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "the", "phase", "1b", "portion", "of", "the", "trial,", "with", "the", "goal", "of", "finding", "an", "appropriate", "combination", "dose", "of", "CA4P", "and", "pazopanib", "for", "the", "phase", "2", "portion", "of", "the", "trial.", "<tag3>"], "wordsA": ["In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "CA4P", "in", "advanced", "recurrent", "ovarian", "cancer."], "wordsB": ["In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "the", "phase", "1b", "portion", "of", "the", "trial,", "with", "the", "goal", "of", "finding", "an", "appropriate", "combination", "dose", "of", "CA4P", "and", "pazopanib", "for", "the", "phase", "2", "portion", "of", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p21_s6", "idA": "908259_16_item1_p19_s8", "sentA": "In October 2014, the first patient was enrolled in a phase 1b/2 trial of pazopanib with and without CA4P in advanced recurrent ovarian cancer.", "sentB": "Following the investigators identification of an appropriate dose combination, in July 2016 the first patient was enrolled in the phase 2 portion of the trial.", "type": 2, "words": ["<tag1>", "In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "CA4P", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag2>", "Following", "the", "investigators", "identification", "of", "an", "appropriate", "dose", "combination,", "in", "July", "2016", "the", "first", "patient", "was", "enrolled", "in", "the", "phase", "2", "portion", "of", "the", "trial.", "<tag3>"], "wordsA": ["In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "CA4P", "in", "advanced", "recurrent", "ovarian", "cancer."], "wordsB": ["Following", "the", "investigators", "identification", "of", "an", "appropriate", "dose", "combination,", "in", "July", "2016", "the", "first", "patient", "was", "enrolled", "in", "the", "phase", "2", "portion", "of", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p1_s1", "idA": "908259_16_item1_p1_s1", "sentA": "There are over 12 AAs approved in the U.S. for over 15 different oncology indications, and according to Datamonitor, 2015 sales for AAs are estimated to exceed $10 billion.", "sentB": "There are over 12 AAs approved in the U.S. for over 15 different oncology indications.", "type": 2, "words": ["<tag1>", "There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications,", "and", "according", "to", "Datamonitor,", "2015", "sales", "for", "AAs", "are", "estimated", "to", "exceed", "$10", "billion.", "<tag2>", "There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications.", "<tag3>"], "wordsA": ["There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications,", "and", "according", "to", "Datamonitor,", "2015", "sales", "for", "AAs", "are", "estimated", "to", "exceed", "$10", "billion."], "wordsB": ["There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p1_s2", "idA": "908259_16_item1_p1_s1", "sentA": "There are over 12 AAs approved in the U.S. for over 15 different oncology indications, and according to Datamonitor, 2015 sales for AAs are estimated to exceed $10 billion.", "sentB": "According to Datamonitor, 2015 sales for AAs were estimated to exceed $10 billion.", "type": 2, "words": ["<tag1>", "There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications,", "and", "according", "to", "Datamonitor,", "2015", "sales", "for", "AAs", "are", "estimated", "to", "exceed", "$10", "billion.", "<tag2>", "According", "to", "Datamonitor,", "2015", "sales", "for", "AAs", "were", "estimated", "to", "exceed", "$10", "billion.", "<tag3>"], "wordsA": ["There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications,", "and", "according", "to", "Datamonitor,", "2015", "sales", "for", "AAs", "are", "estimated", "to", "exceed", "$10", "billion."], "wordsB": ["According", "to", "Datamonitor,", "2015", "sales", "for", "AAs", "were", "estimated", "to", "exceed", "$10", "billion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p1_s3", "idA": "908259_16_item1_p1_s2", "sentA": "Genentech s bevacizumab (Avastin ) has the greatest market share in the class, with 2015 estimated sales of approximately $6.7 billion.", "sentB": "Genentech s bevacizumab (Avastin ) had the greatest market share, with 2015 estimated sales of approximately $6.7 billion.", "type": 2, "words": ["<tag1>", "Genentech", "s", "bevacizumab", "(Avastin", ")", "has", "the", "greatest", "market", "share", "in", "the", "class,", "with", "2015", "estimated", "sales", "of", "approximately", "$6.7", "billion.", "<tag2>", "Genentech", "s", "bevacizumab", "(Avastin", ")", "had", "the", "greatest", "market", "share,", "with", "2015", "estimated", "sales", "of", "approximately", "$6.7", "billion.", "<tag3>"], "wordsA": ["Genentech", "s", "bevacizumab", "(Avastin", ")", "has", "the", "greatest", "market", "share", "in", "the", "class,", "with", "2015", "estimated", "sales", "of", "approximately", "$6.7", "billion."], "wordsB": ["Genentech", "s", "bevacizumab", "(Avastin", ")", "had", "the", "greatest", "market", "share,", "with", "2015", "estimated", "sales", "of", "approximately", "$6.7", "billion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p21_s4", "idA": "908259_16_item1_p20_s0", "sentA": "Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).", "sentB": "We are incurring limited costs for this trial, which is sponsored by The Christie Hospital NHS Foundation Trust and coordinated by the Manchester Academic Health Science Centre, Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).", "type": 2, "words": ["<tag1>", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust).", "<tag2>", "We", "are", "incurring", "limited", "costs", "for", "this", "trial,", "which", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "and", "coordinated", "by", "the", "Manchester", "Academic", "Health", "Science", "Centre,", "Trials", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust).", "<tag3>"], "wordsA": ["Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust)."], "wordsB": ["We", "are", "incurring", "limited", "costs", "for", "this", "trial,", "which", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "and", "coordinated", "by", "the", "Manchester", "Academic", "Health", "Science", "Centre,", "Trials", "Coordination", "Unit,", "or", "MAHSC-CTU,", "with", "additional", "support", "from", "The", "University", "of", "Manchester,", "the", "Royal", "Marsden", "NHS", "Foundation", "Trust", "and", "Mount", "Vernon", "Cancer", "Centre", "(part", "of", "the", "East", "and", "North", "Hertfordshire", "NHS", "Trust)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p21_s3", "idA": "908259_16_item1_p21_s0", "sentA": "The trial design consists of a phase 1b dose escalation portion with the combination of pazopanib and CA4P, which has been completed, and then a randomized phase 2 portion comparing pazopanib alone versus pazopanib plus CA4P in patients with relapsed ovarian cancer.", "sentB": "The PAZOFOS trial in advanced recurrent ovarian cancer patients consists of a 12 patient phase 1b dose escalation portion with the combination of pazopanib and CA4P, which has been completed, followed by a 120 patient randomized phase 2 portion comparing pazopanib plus CA4P to pazopanib alone in patients with relapsed ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "trial", "design", "consists", "of", "a", "phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "pazopanib", "and", "CA4P,", "which", "has", "been", "completed,", "and", "then", "a", "randomized", "phase", "2", "portion", "comparing", "pazopanib", "alone", "versus", "pazopanib", "plus", "CA4P", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag2>", "The", "PAZOFOS", "trial", "in", "advanced", "recurrent", "ovarian", "cancer", "patients", "consists", "of", "a", "12", "patient", "phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "pazopanib", "and", "CA4P,", "which", "has", "been", "completed,", "followed", "by", "a", "120", "patient", "randomized", "phase", "2", "portion", "comparing", "pazopanib", "plus", "CA4P", "to", "pazopanib", "alone", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "trial", "design", "consists", "of", "a", "phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "pazopanib", "and", "CA4P,", "which", "has", "been", "completed,", "and", "then", "a", "randomized", "phase", "2", "portion", "comparing", "pazopanib", "alone", "versus", "pazopanib", "plus", "CA4P", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "wordsB": ["The", "PAZOFOS", "trial", "in", "advanced", "recurrent", "ovarian", "cancer", "patients", "consists", "of", "a", "12", "patient", "phase", "1b", "dose", "escalation", "portion", "with", "the", "combination", "of", "pazopanib", "and", "CA4P,", "which", "has", "been", "completed,", "followed", "by", "a", "120", "patient", "randomized", "phase", "2", "portion", "comparing", "pazopanib", "plus", "CA4P", "to", "pazopanib", "alone", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p19_s2", "idA": "908259_16_item1_p21_s2", "sentA": "The primary endpoint of the trial is PFS, and secondary endpoints include safety, overall survival, objective response rate, and CA125 response rate.", "sentB": "The primary endpoint of FOCUS is PFS, and secondary endpoints include ORR, OS and safety.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "trial", "is", "PFS,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "FOCUS", "is", "PFS,", "and", "secondary", "endpoints", "include", "ORR,", "OS", "and", "safety.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "trial", "is", "PFS,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "FOCUS", "is", "PFS,", "and", "secondary", "endpoints", "include", "ORR,", "OS", "and", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p21_s7", "idA": "908259_16_item1_p21_s2", "sentA": "The primary endpoint of the trial is PFS, and secondary endpoints include safety, overall survival, objective response rate, and CA125 response rate.", "sentB": "The primary endpoint of the trial is PFS, and secondary endpoints include ORR, OS and safety.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "trial", "is", "PFS,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "the", "trial", "is", "PFS,", "and", "secondary", "endpoints", "include", "ORR,", "OS", "and", "safety.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "trial", "is", "PFS,", "and", "secondary", "endpoints", "include", "safety,", "overall", "survival,", "objective", "response", "rate,", "and", "CA125", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "the", "trial", "is", "PFS,", "and", "secondary", "endpoints", "include", "ORR,", "OS", "and", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p23_s0", "idA": "908259_16_item1_p23_s0", "sentA": "These tumors can produce increased amounts of vasoactive substances including hormones, many of which are biologically active and can result in debilitating symptoms including flushing, diarrhea, weight loss and, less frequently, bronchoconstriction and heart failure.", "sentB": "substances including hormones, many of which are biologically active and can result in debilitating symptoms including flushing, diarrhea, weight loss and, less frequently, bronchoconstriction and heart failure.", "type": 2, "words": ["<tag1>", "These", "tumors", "can", "produce", "increased", "amounts", "of", "vasoactive", "substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag2>", "substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag3>"], "wordsA": ["These", "tumors", "can", "produce", "increased", "amounts", "of", "vasoactive", "substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "wordsB": ["substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p23_s1", "idA": "908259_16_item1_p23_s1", "sentA": "It is our belief, based on the available preclinical data, that by reducing blood flow to these highly vascular tumors using CA4P, we may be able to reduce the production of tumor-derived substances, including the biologically active hormones.", "sentB": "It is our belief, based on the available preclinical data, that by reducing blood flow to these tumors using CA4P, we may be able to reduce the production of tumor-derived substances, including the biologically active hormones.", "type": 2, "words": ["<tag1>", "It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "these", "highly", "vascular", "tumors", "using", "CA4P,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "substances,", "including", "the", "biologically", "active", "hormones.", "<tag2>", "It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "these", "tumors", "using", "CA4P,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "substances,", "including", "the", "biologically", "active", "hormones.", "<tag3>"], "wordsA": ["It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "these", "highly", "vascular", "tumors", "using", "CA4P,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "substances,", "including", "the", "biologically", "active", "hormones."], "wordsB": ["It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "these", "tumors", "using", "CA4P,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "substances,", "including", "the", "biologically", "active", "hormones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p44_s1", "idA": "908259_16_item1_p24_s2", "sentA": "We estimate that initial data from the trial will be available by the third quarter of 2016.", "sentB": "In March 2017 we announced preliminary data from the third cohort, which enrolled 4 patients at a dose of 6.25 mg/m 2 of OXi4503 in combination with the same intermediate dose of cytarabine.", "type": 2, "words": ["<tag1>", "We", "estimate", "that", "initial", "data", "from", "the", "trial", "will", "be", "available", "by", "the", "third", "quarter", "of", "2016.", "<tag2>", "In", "March", "2017", "we", "announced", "preliminary", "data", "from", "the", "third", "cohort,", "which", "enrolled", "4", "patients", "at", "a", "dose", "of", "6.25", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine.", "<tag3>"], "wordsA": ["We", "estimate", "that", "initial", "data", "from", "the", "trial", "will", "be", "available", "by", "the", "third", "quarter", "of", "2016."], "wordsB": ["In", "March", "2017", "we", "announced", "preliminary", "data", "from", "the", "third", "cohort,", "which", "enrolled", "4", "patients", "at", "a", "dose", "of", "6.25", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p26_s0", "idA": "908259_16_item1_p25_s0", "sentA": "We have been granted orphan drug designation for CA4P for the treatment of neuroendocrine tumors in the United States and the European Union.", "sentB": "CA4P has been granted orphan drug designation for the treatment of neuroendocrine tumors in both the U.S. and the European Union.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "CA4P", "has", "been", "granted", "orphan", "drug", "designation", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "both", "the", "U.S.", "and", "the", "European", "Union.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["CA4P", "has", "been", "granted", "orphan", "drug", "designation", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "both", "the", "U.S.", "and", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p28_s0", "idA": "908259_16_item1_p25_s0", "sentA": "We have been granted orphan drug designation for CA4P for the treatment of neuroendocrine tumors in the United States and the European Union.", "sentB": "CA4P has been granted orphan drug designation for the treatment of glioma in the United States.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "CA4P", "has", "been", "granted", "orphan", "drug", "designation", "for", "the", "treatment", "of", "glioma", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["CA4P", "has", "been", "granted", "orphan", "drug", "designation", "for", "the", "treatment", "of", "glioma", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p6_s3", "idA": "908259_16_item1_p25_s0", "sentA": "We have been granted orphan drug designation for CA4P for the treatment of neuroendocrine tumors in the United States and the European Union.", "sentB": "In 2016, we received Fast Track designation for CA4P for the treatment of platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "In", "2016,", "we", "received", "Fast", "Track", "designation", "for", "CA4P", "for", "the", "treatment", "of", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "neuroendocrine", "tumors", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["In", "2016,", "we", "received", "Fast", "Track", "designation", "for", "CA4P", "for", "the", "treatment", "of", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p25_s1", "idA": "908259_16_item1_p26_s0", "sentA": "rapid enrollment would be expected in clinical trials for this indication.", "sentB": "The partial response and stable disease analyses, as well as other measures from the trial, suggest that CA4P monotherapy has activity in this indication.", "type": 2, "words": ["<tag1>", "rapid", "enrollment", "would", "be", "expected", "in", "clinical", "trials", "for", "this", "indication.", "<tag2>", "The", "partial", "response", "and", "stable", "disease", "analyses,", "as", "well", "as", "other", "measures", "from", "the", "trial,", "suggest", "that", "CA4P", "monotherapy", "has", "activity", "in", "this", "indication.", "<tag3>"], "wordsA": ["rapid", "enrollment", "would", "be", "expected", "in", "clinical", "trials", "for", "this", "indication."], "wordsB": ["The", "partial", "response", "and", "stable", "disease", "analyses,", "as", "well", "as", "other", "measures", "from", "the", "trial,", "suggest", "that", "CA4P", "monotherapy", "has", "activity", "in", "this", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p28_s1", "idA": "908259_16_item1_p26_s1", "sentA": "If funds become available for us to initiate and complete a clinical trial in GBM, we expect that we would pursue such a trial, with a similar two-stage phase 2/3 design in combination with bevacizumab as we are pursuing in platinum-resistant ovarian cancer.", "sentB": "If funds become available for us to initiate and complete a clinical trial in GBM, we expect that we would pursue a trial.", "type": 2, "words": ["<tag1>", "If", "funds", "become", "available", "for", "us", "to", "initiate", "and", "complete", "a", "clinical", "trial", "in", "GBM,", "we", "expect", "that", "we", "would", "pursue", "such", "a", "trial,", "with", "a", "similar", "two-stage", "phase", "2/3", "design", "in", "combination", "with", "bevacizumab", "as", "we", "are", "pursuing", "in", "platinum-resistant", "ovarian", "cancer.", "<tag2>", "If", "funds", "become", "available", "for", "us", "to", "initiate", "and", "complete", "a", "clinical", "trial", "in", "GBM,", "we", "expect", "that", "we", "would", "pursue", "a", "trial.", "<tag3>"], "wordsA": ["If", "funds", "become", "available", "for", "us", "to", "initiate", "and", "complete", "a", "clinical", "trial", "in", "GBM,", "we", "expect", "that", "we", "would", "pursue", "such", "a", "trial,", "with", "a", "similar", "two-stage", "phase", "2/3", "design", "in", "combination", "with", "bevacizumab", "as", "we", "are", "pursuing", "in", "platinum-resistant", "ovarian", "cancer."], "wordsB": ["If", "funds", "become", "available", "for", "us", "to", "initiate", "and", "complete", "a", "clinical", "trial", "in", "GBM,", "we", "expect", "that", "we", "would", "pursue", "a", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p29_s2", "idA": "908259_16_item1_p27_s2", "sentA": "Results of the FACT Study, which combined CA4P with chemotherapy and which, in 2010, we terminated early (after 75 patients were enrolled) due to slow enrollment, showed a numerical improvement in overall survival for the CA4P group (5.2 months) compared to the control group (4.0 months), although the results were not statistically significant.", "sentB": "Results of the FACT Study, which combined CA4P with chemotherapy and which, in 2010, we terminated early (after 80 patients were enrolled) due to slow enrollment, showed a numerical improvement in OS for the CA4P group (5.2 months) compared to the control group (4.0 months), although the results were not statistically significant.", "type": 2, "words": ["<tag1>", "Results", "of", "the", "FACT", "Study,", "which", "combined", "CA4P", "with", "chemotherapy", "and", "which,", "in", "2010,", "we", "terminated", "early", "(after", "75", "patients", "were", "enrolled)", "due", "to", "slow", "enrollment,", "showed", "a", "numerical", "improvement", "in", "overall", "survival", "for", "the", "CA4P", "group", "(5.2", "months)", "compared", "to", "the", "control", "group", "(4.0", "months),", "although", "the", "results", "were", "not", "statistically", "significant.", "<tag2>", "Results", "of", "the", "FACT", "Study,", "which", "combined", "CA4P", "with", "chemotherapy", "and", "which,", "in", "2010,", "we", "terminated", "early", "(after", "80", "patients", "were", "enrolled)", "due", "to", "slow", "enrollment,", "showed", "a", "numerical", "improvement", "in", "OS", "for", "the", "CA4P", "group", "(5.2", "months)", "compared", "to", "the", "control", "group", "(4.0", "months),", "although", "the", "results", "were", "not", "statistically", "significant.", "<tag3>"], "wordsA": ["Results", "of", "the", "FACT", "Study,", "which", "combined", "CA4P", "with", "chemotherapy", "and", "which,", "in", "2010,", "we", "terminated", "early", "(after", "75", "patients", "were", "enrolled)", "due", "to", "slow", "enrollment,", "showed", "a", "numerical", "improvement", "in", "overall", "survival", "for", "the", "CA4P", "group", "(5.2", "months)", "compared", "to", "the", "control", "group", "(4.0", "months),", "although", "the", "results", "were", "not", "statistically", "significant."], "wordsB": ["Results", "of", "the", "FACT", "Study,", "which", "combined", "CA4P", "with", "chemotherapy", "and", "which,", "in", "2010,", "we", "terminated", "early", "(after", "80", "patients", "were", "enrolled)", "due", "to", "slow", "enrollment,", "showed", "a", "numerical", "improvement", "in", "OS", "for", "the", "CA4P", "group", "(5.2", "months)", "compared", "to", "the", "control", "group", "(4.0", "months),", "although", "the", "results", "were", "not", "statistically", "significant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p19_s6", "idA": "908259_16_item1_p28_s0", "sentA": "improvement in overall response rate for the CA4P group (20.0%) compared to the control group (16.0%), although these results were not statistically significant either.", "sentB": "The treatment group receives CA4P, bevacizumab and PCC, while the control group receives only bevacizumab and PCC.", "type": 2, "words": ["<tag1>", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(20.0%)", "compared", "to", "the", "control", "group", "(16.0%),", "although", "these", "results", "were", "not", "statistically", "significant", "either.", "<tag2>", "The", "treatment", "group", "receives", "CA4P,", "bevacizumab", "and", "PCC,", "while", "the", "control", "group", "receives", "only", "bevacizumab", "and", "PCC.", "<tag3>"], "wordsA": ["improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(20.0%)", "compared", "to", "the", "control", "group", "(16.0%),", "although", "these", "results", "were", "not", "statistically", "significant", "either."], "wordsB": ["The", "treatment", "group", "receives", "CA4P,", "bevacizumab", "and", "PCC,", "while", "the", "control", "group", "receives", "only", "bevacizumab", "and", "PCC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p29_s3", "idA": "908259_16_item1_p28_s0", "sentA": "improvement in overall response rate for the CA4P group (20.0%) compared to the control group (16.0%), although these results were not statistically significant either.", "sentB": "Results also showed an improvement in ORR for the CA4P group (20.0%) compared to the control group (16.0%), although these results were not statistically significant.", "type": 2, "words": ["<tag1>", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(20.0%)", "compared", "to", "the", "control", "group", "(16.0%),", "although", "these", "results", "were", "not", "statistically", "significant", "either.", "<tag2>", "Results", "also", "showed", "an", "improvement", "in", "ORR", "for", "the", "CA4P", "group", "(20.0%)", "compared", "to", "the", "control", "group", "(16.0%),", "although", "these", "results", "were", "not", "statistically", "significant.", "<tag3>"], "wordsA": ["improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(20.0%)", "compared", "to", "the", "control", "group", "(16.0%),", "although", "these", "results", "were", "not", "statistically", "significant", "either."], "wordsB": ["Results", "also", "showed", "an", "improvement", "in", "ORR", "for", "the", "CA4P", "group", "(20.0%)", "compared", "to", "the", "control", "group", "(16.0%),", "although", "these", "results", "were", "not", "statistically", "significant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s0", "idA": "908259_16_item1_p2_s0", "sentA": "Bevacizumab and other AA drugs work by preventing the growth of new blood vessels which can supply nutrients to tumor cells.", "sentB": "Bevacizumab and other AA drugs work by preventing angiogenesis, or the growth of new blood vessels.", "type": 2, "words": ["<tag1>", "Bevacizumab", "and", "other", "AA", "drugs", "work", "by", "preventing", "the", "growth", "of", "new", "blood", "vessels", "which", "can", "supply", "nutrients", "to", "tumor", "cells.", "<tag2>", "Bevacizumab", "and", "other", "AA", "drugs", "work", "by", "preventing", "angiogenesis,", "or", "the", "growth", "of", "new", "blood", "vessels.", "<tag3>"], "wordsA": ["Bevacizumab", "and", "other", "AA", "drugs", "work", "by", "preventing", "the", "growth", "of", "new", "blood", "vessels", "which", "can", "supply", "nutrients", "to", "tumor", "cells."], "wordsB": ["Bevacizumab", "and", "other", "AA", "drugs", "work", "by", "preventing", "angiogenesis,", "or", "the", "growth", "of", "new", "blood", "vessels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s9", "idA": "908259_16_item1_p2_s0", "sentA": "Bevacizumab and other AA drugs work by preventing the growth of new blood vessels which can supply nutrients to tumor cells.", "sentB": "The greater effect of our VDAs on larger tumors occurs because these larger tumors have a greater proportion of tumor cells which depend upon the tumor vasculature for their supply of oxygen and nutrients, and a smaller proportion of tumor cells that have exposure to the tumor rim, where normal tissue blood vessels can supply oxygen and nutrients to the tumor cells.", "type": 2, "words": ["<tag1>", "Bevacizumab", "and", "other", "AA", "drugs", "work", "by", "preventing", "the", "growth", "of", "new", "blood", "vessels", "which", "can", "supply", "nutrients", "to", "tumor", "cells.", "<tag2>", "The", "greater", "effect", "of", "our", "VDAs", "on", "larger", "tumors", "occurs", "because", "these", "larger", "tumors", "have", "a", "greater", "proportion", "of", "tumor", "cells", "which", "depend", "upon", "the", "tumor", "vasculature", "for", "their", "supply", "of", "oxygen", "and", "nutrients,", "and", "a", "smaller", "proportion", "of", "tumor", "cells", "that", "have", "exposure", "to", "the", "tumor", "rim,", "where", "normal", "tissue", "blood", "vessels", "can", "supply", "oxygen", "and", "nutrients", "to", "the", "tumor", "cells.", "<tag3>"], "wordsA": ["Bevacizumab", "and", "other", "AA", "drugs", "work", "by", "preventing", "the", "growth", "of", "new", "blood", "vessels", "which", "can", "supply", "nutrients", "to", "tumor", "cells."], "wordsB": ["The", "greater", "effect", "of", "our", "VDAs", "on", "larger", "tumors", "occurs", "because", "these", "larger", "tumors", "have", "a", "greater", "proportion", "of", "tumor", "cells", "which", "depend", "upon", "the", "tumor", "vasculature", "for", "their", "supply", "of", "oxygen", "and", "nutrients,", "and", "a", "smaller", "proportion", "of", "tumor", "cells", "that", "have", "exposure", "to", "the", "tumor", "rim,", "where", "normal", "tissue", "blood", "vessels", "can", "supply", "oxygen", "and", "nutrients", "to", "the", "tumor", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s1", "idA": "908259_16_item1_p2_s1", "sentA": "We are seeking to realize the full potential of VTTs in oncology by using the combination of VDAs and AAs to treat cancer tumors.", "sentB": "We are seeking to realize the full potential of VTTs in oncology by using the combination of VDAs and AAs to treat cancer.", "type": 2, "words": ["<tag1>", "We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer", "tumors.", "<tag2>", "We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer.", "<tag3>"], "wordsA": ["We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer", "tumors."], "wordsB": ["We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s2", "idA": "908259_16_item1_p2_s2", "sentA": "When VDAs and AAs are used in combination, our VDAs have been shown to directly cut off the blood supply to the interior of the tumor, while the AA inhibits angiogenesis, which is the process by which new blood vessels form and re-vascularize the tumor.", "sentB": "Our VDAs have been shown to rapidly cut off the blood supply to the tumor, which causes necrosis, or death, of the cancer cells in the interior of the tumor.", "type": 2, "words": ["<tag1>", "When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor.", "<tag2>", "Our", "VDAs", "have", "been", "shown", "to", "rapidly", "cut", "off", "the", "blood", "supply", "to", "the", "tumor,", "which", "causes", "necrosis,", "or", "death,", "of", "the", "cancer", "cells", "in", "the", "interior", "of", "the", "tumor.", "<tag3>"], "wordsA": ["When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor."], "wordsB": ["Our", "VDAs", "have", "been", "shown", "to", "rapidly", "cut", "off", "the", "blood", "supply", "to", "the", "tumor,", "which", "causes", "necrosis,", "or", "death,", "of", "the", "cancer", "cells", "in", "the", "interior", "of", "the", "tumor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s3", "idA": "908259_16_item1_p2_s2", "sentA": "When VDAs and AAs are used in combination, our VDAs have been shown to directly cut off the blood supply to the interior of the tumor, while the AA inhibits angiogenesis, which is the process by which new blood vessels form and re-vascularize the tumor.", "sentB": "Conversely, AAs inhibit angiogenesis, which is the process by which new tumor blood vessels form.", "type": 2, "words": ["<tag1>", "When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor.", "<tag2>", "Conversely,", "AAs", "inhibit", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "tumor", "blood", "vessels", "form.", "<tag3>"], "wordsA": ["When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor."], "wordsB": ["Conversely,", "AAs", "inhibit", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "tumor", "blood", "vessels", "form."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s4", "idA": "908259_16_item1_p2_s2", "sentA": "When VDAs and AAs are used in combination, our VDAs have been shown to directly cut off the blood supply to the interior of the tumor, while the AA inhibits angiogenesis, which is the process by which new blood vessels form and re-vascularize the tumor.", "sentB": "If a VDA were given in the absence of an AA, angiogenesis would allow new blood vessels to re-vascularize the tumor, including the interior where the VDA had caused tumor cell necrosis.", "type": 2, "words": ["<tag1>", "When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor.", "<tag2>", "If", "a", "VDA", "were", "given", "in", "the", "absence", "of", "an", "AA,", "angiogenesis", "would", "allow", "new", "blood", "vessels", "to", "re-vascularize", "the", "tumor,", "including", "the", "interior", "where", "the", "VDA", "had", "caused", "tumor", "cell", "necrosis.", "<tag3>"], "wordsA": ["When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor."], "wordsB": ["If", "a", "VDA", "were", "given", "in", "the", "absence", "of", "an", "AA,", "angiogenesis", "would", "allow", "new", "blood", "vessels", "to", "re-vascularize", "the", "tumor,", "including", "the", "interior", "where", "the", "VDA", "had", "caused", "tumor", "cell", "necrosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p3_s0", "idA": "908259_16_item1_p2_s2", "sentA": "When VDAs and AAs are used in combination, our VDAs have been shown to directly cut off the blood supply to the interior of the tumor, while the AA inhibits angiogenesis, which is the process by which new blood vessels form and re-vascularize the tumor.", "sentB": "The tumor cell necrosis caused by CA4P is greatest in the interior of the tumor, because cancer cells in the interior are fully reliant on the tumor vasculature for their blood supply.", "type": 2, "words": ["<tag1>", "When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor.", "<tag2>", "The", "tumor", "cell", "necrosis", "caused", "by", "CA4P", "is", "greatest", "in", "the", "interior", "of", "the", "tumor,", "because", "cancer", "cells", "in", "the", "interior", "are", "fully", "reliant", "on", "the", "tumor", "vasculature", "for", "their", "blood", "supply.", "<tag3>"], "wordsA": ["When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor."], "wordsB": ["The", "tumor", "cell", "necrosis", "caused", "by", "CA4P", "is", "greatest", "in", "the", "interior", "of", "the", "tumor,", "because", "cancer", "cells", "in", "the", "interior", "are", "fully", "reliant", "on", "the", "tumor", "vasculature", "for", "their", "blood", "supply."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s5", "idA": "908259_16_item1_p2_s3", "sentA": "Our current VDA development plans are focused on this combination, in which the mechanism of action of each drug complements that of the other disrupting tumor blood supply in two different ways instead of just one.", "sentB": "Our current VDA development plans are focused on the combination of VDAs and AAs because the mechanism of action of each drug complements that of the other disrupting tumor blood supply in two different ways instead of just one.", "type": 2, "words": ["<tag1>", "Our", "current", "VDA", "development", "plans", "are", "focused", "on", "this", "combination,", "in", "which", "the", "mechanism", "of", "action", "of", "each", "drug", "complements", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one.", "<tag2>", "Our", "current", "VDA", "development", "plans", "are", "focused", "on", "the", "combination", "of", "VDAs", "and", "AAs", "because", "the", "mechanism", "of", "action", "of", "each", "drug", "complements", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one.", "<tag3>"], "wordsA": ["Our", "current", "VDA", "development", "plans", "are", "focused", "on", "this", "combination,", "in", "which", "the", "mechanism", "of", "action", "of", "each", "drug", "complements", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one."], "wordsB": ["Our", "current", "VDA", "development", "plans", "are", "focused", "on", "the", "combination", "of", "VDAs", "and", "AAs", "because", "the", "mechanism", "of", "action", "of", "each", "drug", "complements", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s6", "idA": "908259_16_item1_p2_s4", "sentA": "We believe that the indirect inhibition on angiogenesis (provided by the AA) combined with the direct effect on established tumor blood vessels (provided by the VDA) would result in a significantly greater benefit to patients than the anti-vascular effect of either drug alone.", "sentB": "We believe that our VDA s direct effect on established tumor blood vessels combined with the AA s prevention of new blood vessel formation results in a significantly greater benefit to patients than either drug alone.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "the", "indirect", "inhibition", "on", "angiogenesis", "(provided", "by", "the", "AA)", "combined", "with", "the", "direct", "effect", "on", "established", "tumor", "blood", "vessels", "(provided", "by", "the", "VDA)", "would", "result", "in", "a", "significantly", "greater", "benefit", "to", "patients", "than", "the", "anti-vascular", "effect", "of", "either", "drug", "alone.", "<tag2>", "We", "believe", "that", "our", "VDA", "s", "direct", "effect", "on", "established", "tumor", "blood", "vessels", "combined", "with", "the", "AA", "s", "prevention", "of", "new", "blood", "vessel", "formation", "results", "in", "a", "significantly", "greater", "benefit", "to", "patients", "than", "either", "drug", "alone.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "indirect", "inhibition", "on", "angiogenesis", "(provided", "by", "the", "AA)", "combined", "with", "the", "direct", "effect", "on", "established", "tumor", "blood", "vessels", "(provided", "by", "the", "VDA)", "would", "result", "in", "a", "significantly", "greater", "benefit", "to", "patients", "than", "the", "anti-vascular", "effect", "of", "either", "drug", "alone."], "wordsB": ["We", "believe", "that", "our", "VDA", "s", "direct", "effect", "on", "established", "tumor", "blood", "vessels", "combined", "with", "the", "AA", "s", "prevention", "of", "new", "blood", "vessel", "formation", "results", "in", "a", "significantly", "greater", "benefit", "to", "patients", "than", "either", "drug", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p4_s0", "idA": "908259_16_item1_p2_s7", "sentA": "We are currently developing two clinical stage investigational drugs, both VDAs CA4P and OXi4503.", "sentB": "We are currently developing two clinical stage investigational drugs, which are both VDAs CA4P and OXi4503.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "developing", "two", "clinical", "stage", "investigational", "drugs,", "both", "VDAs", "CA4P", "and", "OXi4503.", "<tag2>", "We", "are", "currently", "developing", "two", "clinical", "stage", "investigational", "drugs,", "which", "are", "both", "VDAs", "CA4P", "and", "OXi4503.", "<tag3>"], "wordsA": ["We", "are", "currently", "developing", "two", "clinical", "stage", "investigational", "drugs,", "both", "VDAs", "CA4P", "and", "OXi4503."], "wordsB": ["We", "are", "currently", "developing", "two", "clinical", "stage", "investigational", "drugs,", "which", "are", "both", "VDAs", "CA4P", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p32_s0", "idA": "908259_16_item1_p30_s1", "sentA": "Results of the FALCON Study, completed in 2011, which enrolled 63 patients and combined CA4P with both bevacizumab and chemotherapy, showed a numerical improvement in overall response rate for the CA4P group (56.3%) compared to the control group (35.5%), although the results were not statistically significant.", "sentB": "completed in 2011, which enrolled 63 patients and combined CA4P with both bevacizumab and chemotherapy, showed a numerical improvement in ORR for the CA4P group (56.3%) compared to the control group (35.5%), although the results were not statistically significant.", "type": 2, "words": ["<tag1>", "Results", "of", "the", "FALCON", "Study,", "completed", "in", "2011,", "which", "enrolled", "63", "patients", "and", "combined", "CA4P", "with", "both", "bevacizumab", "and", "chemotherapy,", "showed", "a", "numerical", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(56.3%)", "compared", "to", "the", "control", "group", "(35.5%),", "although", "the", "results", "were", "not", "statistically", "significant.", "<tag2>", "completed", "in", "2011,", "which", "enrolled", "63", "patients", "and", "combined", "CA4P", "with", "both", "bevacizumab", "and", "chemotherapy,", "showed", "a", "numerical", "improvement", "in", "ORR", "for", "the", "CA4P", "group", "(56.3%)", "compared", "to", "the", "control", "group", "(35.5%),", "although", "the", "results", "were", "not", "statistically", "significant.", "<tag3>"], "wordsA": ["Results", "of", "the", "FALCON", "Study,", "completed", "in", "2011,", "which", "enrolled", "63", "patients", "and", "combined", "CA4P", "with", "both", "bevacizumab", "and", "chemotherapy,", "showed", "a", "numerical", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(56.3%)", "compared", "to", "the", "control", "group", "(35.5%),", "although", "the", "results", "were", "not", "statistically", "significant."], "wordsB": ["completed", "in", "2011,", "which", "enrolled", "63", "patients", "and", "combined", "CA4P", "with", "both", "bevacizumab", "and", "chemotherapy,", "showed", "a", "numerical", "improvement", "in", "ORR", "for", "the", "CA4P", "group", "(56.3%)", "compared", "to", "the", "control", "group", "(35.5%),", "although", "the", "results", "were", "not", "statistically", "significant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p32_s2", "idA": "908259_16_item1_p30_s2", "sentA": "This clinical trial enrolled chemotherapy-na ve patients, which are patients who have not yet received chemotherapy, which we believe contributed to the high dropout rate among both treatment groups (46.8% and 38.7% for CA4P and control, respectively), making evaluation of progression free survival, the primary endpoint, difficult.", "sentB": "We believe the patients initial exposure to chemotherapy, requiring six cycles in the study, contributed to a high dropout rate among both treatment groups (46.8% and 38.7% for CA4P and control, respectively), making evaluation of PFS, the primary endpoint, difficult.", "type": 2, "words": ["<tag1>", "This", "clinical", "trial", "enrolled", "chemotherapy-na", "ve", "patients,", "which", "are", "patients", "who", "have", "not", "yet", "received", "chemotherapy,", "which", "we", "believe", "contributed", "to", "the", "high", "dropout", "rate", "among", "both", "treatment", "groups", "(46.8%", "and", "38.7%", "for", "CA4P", "and", "control,", "respectively),", "making", "evaluation", "of", "progression", "free", "survival,", "the", "primary", "endpoint,", "difficult.", "<tag2>", "We", "believe", "the", "patients", "initial", "exposure", "to", "chemotherapy,", "requiring", "six", "cycles", "in", "the", "study,", "contributed", "to", "a", "high", "dropout", "rate", "among", "both", "treatment", "groups", "(46.8%", "and", "38.7%", "for", "CA4P", "and", "control,", "respectively),", "making", "evaluation", "of", "PFS,", "the", "primary", "endpoint,", "difficult.", "<tag3>"], "wordsA": ["This", "clinical", "trial", "enrolled", "chemotherapy-na", "ve", "patients,", "which", "are", "patients", "who", "have", "not", "yet", "received", "chemotherapy,", "which", "we", "believe", "contributed", "to", "the", "high", "dropout", "rate", "among", "both", "treatment", "groups", "(46.8%", "and", "38.7%", "for", "CA4P", "and", "control,", "respectively),", "making", "evaluation", "of", "progression", "free", "survival,", "the", "primary", "endpoint,", "difficult."], "wordsB": ["We", "believe", "the", "patients", "initial", "exposure", "to", "chemotherapy,", "requiring", "six", "cycles", "in", "the", "study,", "contributed", "to", "a", "high", "dropout", "rate", "among", "both", "treatment", "groups", "(46.8%", "and", "38.7%", "for", "CA4P", "and", "control,", "respectively),", "making", "evaluation", "of", "PFS,", "the", "primary", "endpoint,", "difficult."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p34_s1", "idA": "908259_16_item1_p30_s5", "sentA": "We believe that this dual mechanism of OXi4503 may result in enhanced anti-tumor activity in certain tumor types.", "sentB": "We believe CA4P s potential enhanced immunologic effect may result in more and/or better clinical responses in certain cancers when combined with immune oncology agents, including in patients who have not experienced a response to therapy with immune oncology agents alone.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "this", "dual", "mechanism", "of", "OXi4503", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types.", "<tag2>", "We", "believe", "CA4P", "s", "potential", "enhanced", "immunologic", "effect", "may", "result", "in", "more", "and/or", "better", "clinical", "responses", "in", "certain", "cancers", "when", "combined", "with", "immune", "oncology", "agents,", "including", "in", "patients", "who", "have", "not", "experienced", "a", "response", "to", "therapy", "with", "immune", "oncology", "agents", "alone.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "dual", "mechanism", "of", "OXi4503", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types."], "wordsB": ["We", "believe", "CA4P", "s", "potential", "enhanced", "immunologic", "effect", "may", "result", "in", "more", "and/or", "better", "clinical", "responses", "in", "certain", "cancers", "when", "combined", "with", "immune", "oncology", "agents,", "including", "in", "patients", "who", "have", "not", "experienced", "a", "response", "to", "therapy", "with", "immune", "oncology", "agents", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p35_s0", "idA": "908259_16_item1_p31_s0", "sentA": "Based on preclinical data, we believe that OXi4503 may be particularly active in hepatocellular carcinoma, melanoma, and leukemias of the myeloid lineage, all of which have relatively high levels of the enzymes that facilitate the conversion of OXi4503 into a metabolite that directly kills tumor cells.", "sentB": "Based on preclinical data, we believe that OXi4503 may be particularly active in certain cancers, including AML, which have relatively high levels of the enzymes that facilitate the conversion of OXi4503 into a metabolite that directly kills tumor cells.", "type": 2, "words": ["<tag1>", "Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "hepatocellular", "carcinoma,", "melanoma,", "and", "leukemias", "of", "the", "myeloid", "lineage,", "all", "of", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "metabolite", "that", "directly", "kills", "tumor", "cells.", "<tag2>", "Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "certain", "cancers,", "including", "AML,", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "metabolite", "that", "directly", "kills", "tumor", "cells.", "<tag3>"], "wordsA": ["Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "hepatocellular", "carcinoma,", "melanoma,", "and", "leukemias", "of", "the", "myeloid", "lineage,", "all", "of", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "metabolite", "that", "directly", "kills", "tumor", "cells."], "wordsB": ["Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "certain", "cancers,", "including", "AML,", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "metabolite", "that", "directly", "kills", "tumor", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p34_s2", "idA": "908259_16_item1_p31_s1", "sentA": "Similar to CA4P, OXi4503 has shown potent anti-tumor activity in preclinical studies of solid tumors and AML, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other anti-proliferative agents.", "sentB": "We have completed several preclinical studies evaluating CA4P in combination with immune oncology agents.", "type": 2, "words": ["<tag1>", "Similar", "to", "CA4P,", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents.", "<tag2>", "We", "have", "completed", "several", "preclinical", "studies", "evaluating", "CA4P", "in", "combination", "with", "immune", "oncology", "agents.", "<tag3>"], "wordsA": ["Similar", "to", "CA4P,", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents."], "wordsB": ["We", "have", "completed", "several", "preclinical", "studies", "evaluating", "CA4P", "in", "combination", "with", "immune", "oncology", "agents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p35_s1", "idA": "908259_16_item1_p31_s1", "sentA": "Similar to CA4P, OXi4503 has shown potent anti-tumor activity in preclinical studies of solid tumors and AML, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other anti-proliferative agents.", "sentB": "OXi4503 has shown potent anti-tumor activity in preclinical studies of solid tumors and AML, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other anti-proliferative agents.", "type": 2, "words": ["<tag1>", "Similar", "to", "CA4P,", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents.", "<tag2>", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents.", "<tag3>"], "wordsA": ["Similar", "to", "CA4P,", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents."], "wordsB": ["OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p36_s0", "idA": "908259_16_item1_p32_s1", "sentA": "AML is characterized by the rapid growth of abnormal white blood cells that pollute bone marrow and interfere with the production of normal blood cells.", "sentB": "Acute Myeloid Leukemia AML is a cancer of the myeloid blood cells, with approximately 10,500 new cases each year in the U.S. AML is characterized by the rapid growth of abnormal white blood cells that pollute bone marrow and interfere with the production of normal blood cells.", "type": 2, "words": ["<tag1>", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells.", "<tag2>", "Acute", "Myeloid", "Leukemia", "AML", "is", "a", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "U.S.", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells.", "<tag3>"], "wordsA": ["AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells."], "wordsB": ["Acute", "Myeloid", "Leukemia", "AML", "is", "a", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "U.S.", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p37_s0", "idA": "908259_16_item1_p33_s0", "sentA": "Prior to October 2015, OXi4503 had been in development in an investigator-sponsored phase 1 clinical trial of patients with AML or MDS, a disorder of the normal blood formation process, being conducted at the University of Florida and with support by The Leukemia Lymphoma Society s Therapy Acceleration Program.", "sentB": "With support from The Leukemia Lymphoma Society s Therapy Acceleration Program, the University of Florida sponsored a phase 1 clinical trial of patients with AML or MDS, a related disorder of the normal blood formation process.", "type": 2, "words": ["<tag1>", "Prior", "to", "October", "2015,", "OXi4503", "had", "been", "in", "development", "in", "an", "investigator-sponsored", "phase", "1", "clinical", "trial", "of", "patients", "with", "AML", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program.", "<tag2>", "With", "support", "from", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program,", "the", "University", "of", "Florida", "sponsored", "a", "phase", "1", "clinical", "trial", "of", "patients", "with", "AML", "or", "MDS,", "a", "related", "disorder", "of", "the", "normal", "blood", "formation", "process.", "<tag3>"], "wordsA": ["Prior", "to", "October", "2015,", "OXi4503", "had", "been", "in", "development", "in", "an", "investigator-sponsored", "phase", "1", "clinical", "trial", "of", "patients", "with", "AML", "or", "MDS,", "a", "disorder", "of", "the", "normal", "blood", "formation", "process,", "being", "conducted", "at", "the", "University", "of", "Florida", "and", "with", "support", "by", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program."], "wordsB": ["With", "support", "from", "The", "Leukemia", "Lymphoma", "Society", "s", "Therapy", "Acceleration", "Program,", "the", "University", "of", "Florida", "sponsored", "a", "phase", "1", "clinical", "trial", "of", "patients", "with", "AML", "or", "MDS,", "a", "related", "disorder", "of", "the", "normal", "blood", "formation", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p38_s0", "idA": "908259_16_item1_p33_s1", "sentA": "This open-label, dose-escalating clinical trial was intended to treat up to 36 patients and evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "sentB": "designed to assess the safety profile, maximum tolerated dose and biologic activity of OXi4503.", "type": 2, "words": ["<tag1>", "This", "open-label,", "dose-escalating", "clinical", "trial", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag2>", "designed", "to", "assess", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503.", "<tag3>"], "wordsA": ["This", "open-label,", "dose-escalating", "clinical", "trial", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "wordsB": ["designed", "to", "assess", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p38_s1", "idA": "908259_16_item1_p33_s3", "sentA": "In October 2015, the investigator-sponsored clinical trial was closed, and we brought the clinical trial under our direct management and expanded the number of sites to four, with the goal of enrolling patients faster than had occurred at a single site.", "sentB": "In October 2015 we closed the investigator-sponsored study and initiated a Mateon-sponsored study, OX1222, prior to the determination of a maximum tolerated dose, in order to bring the clinical trial under our direct management and expand the number of sites enrolling patients.", "type": 2, "words": ["<tag1>", "In", "October", "2015,", "the", "investigator-sponsored", "clinical", "trial", "was", "closed,", "and", "we", "brought", "the", "clinical", "trial", "under", "our", "direct", "management", "and", "expanded", "the", "number", "of", "sites", "to", "four,", "with", "the", "goal", "of", "enrolling", "patients", "faster", "than", "had", "occurred", "at", "a", "single", "site.", "<tag2>", "In", "October", "2015", "we", "closed", "the", "investigator-sponsored", "study", "and", "initiated", "a", "Mateon-sponsored", "study,", "OX1222,", "prior", "to", "the", "determination", "of", "a", "maximum", "tolerated", "dose,", "in", "order", "to", "bring", "the", "clinical", "trial", "under", "our", "direct", "management", "and", "expand", "the", "number", "of", "sites", "enrolling", "patients.", "<tag3>"], "wordsA": ["In", "October", "2015,", "the", "investigator-sponsored", "clinical", "trial", "was", "closed,", "and", "we", "brought", "the", "clinical", "trial", "under", "our", "direct", "management", "and", "expanded", "the", "number", "of", "sites", "to", "four,", "with", "the", "goal", "of", "enrolling", "patients", "faster", "than", "had", "occurred", "at", "a", "single", "site."], "wordsB": ["In", "October", "2015", "we", "closed", "the", "investigator-sponsored", "study", "and", "initiated", "a", "Mateon-sponsored", "study,", "OX1222,", "prior", "to", "the", "determination", "of", "a", "maximum", "tolerated", "dose,", "in", "order", "to", "bring", "the", "clinical", "trial", "under", "our", "direct", "management", "and", "expand", "the", "number", "of", "sites", "enrolling", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p41_s0", "idA": "908259_16_item1_p33_s4", "sentA": "In December 2015, we moved this clinical trial into its second stage, whereby OXi4503 is being used in combination with cytarabine, an FDA-approved drug for the treatment of AML.", "sentB": "In December 2015 we initiated the second stage of OX1222, in which ascending doses of OXi4503 are being used in combination with cytarabine, an FDA-approved drug for the treatment of AML.", "type": 2, "words": ["<tag1>", "In", "December", "2015,", "we", "moved", "this", "clinical", "trial", "into", "its", "second", "stage,", "whereby", "OXi4503", "is", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML.", "<tag2>", "In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["In", "December", "2015,", "we", "moved", "this", "clinical", "trial", "into", "its", "second", "stage,", "whereby", "OXi4503", "is", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML."], "wordsB": ["In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p39_s0", "idA": "908259_16_item1_p34_s0", "sentA": "Data from the investigator-sponsored trial was presented at the December 2013 annual meeting of the American Society of Hematology, or ASH, in New Orleans, Louisiana.", "sentB": "Initial data from UF4503 was presented at the December 2013 annual meeting of the American Society of Hematology, or ASH.", "type": 2, "words": ["<tag1>", "Data", "from", "the", "investigator-sponsored", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH,", "in", "New", "Orleans,", "Louisiana.", "<tag2>", "Initial", "data", "from", "UF4503", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH.", "<tag3>"], "wordsA": ["Data", "from", "the", "investigator-sponsored", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH,", "in", "New", "Orleans,", "Louisiana."], "wordsB": ["Initial", "data", "from", "UF4503", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p42_s0", "idA": "908259_16_item1_p34_s0", "sentA": "Data from the investigator-sponsored trial was presented at the December 2013 annual meeting of the American Society of Hematology, or ASH, in New Orleans, Louisiana.", "sentB": "Data from the first two cohorts of the Mateon-sponsored trial was presented at the December 2016 annual meeting of ASH.", "type": 2, "words": ["<tag1>", "Data", "from", "the", "investigator-sponsored", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH,", "in", "New", "Orleans,", "Louisiana.", "<tag2>", "Data", "from", "the", "first", "two", "cohorts", "of", "the", "Mateon-sponsored", "trial", "was", "presented", "at", "the", "December", "2016", "annual", "meeting", "of", "ASH.", "<tag3>"], "wordsA": ["Data", "from", "the", "investigator-sponsored", "trial", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH,", "in", "New", "Orleans,", "Louisiana."], "wordsB": ["Data", "from", "the", "first", "two", "cohorts", "of", "the", "Mateon-sponsored", "trial", "was", "presented", "at", "the", "December", "2016", "annual", "meeting", "of", "ASH."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p42_s3", "idA": "908259_16_item1_p34_s1", "sentA": "Among the first 13 patients treated at the two lowest dose levels, two patients showed stable disease, one patient had a partial remission and one patient achieved a complete bone marrow response.", "sentB": "In total 2 of 10 (20%) patients achieved a complete remission (CR) on treatment one patient of six (17%) responded in the 3.75 mg/m 2 dose cohort, and one patient of four (25%) responded in the 4.68 mg/m 2 dose cohort.", "type": 2, "words": ["<tag1>", "Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "showed", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response.", "<tag2>", "In", "total", "2", "of", "10", "(20%)", "patients", "achieved", "a", "complete", "remission", "(CR)", "on", "treatment", "one", "patient", "of", "six", "(17%)", "responded", "in", "the", "3.75", "mg/m", "2", "dose", "cohort,", "and", "one", "patient", "of", "four", "(25%)", "responded", "in", "the", "4.68", "mg/m", "2", "dose", "cohort.", "<tag3>"], "wordsA": ["Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "showed", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response."], "wordsB": ["In", "total", "2", "of", "10", "(20%)", "patients", "achieved", "a", "complete", "remission", "(CR)", "on", "treatment", "one", "patient", "of", "six", "(17%)", "responded", "in", "the", "3.75", "mg/m", "2", "dose", "cohort,", "and", "one", "patient", "of", "four", "(25%)", "responded", "in", "the", "4.68", "mg/m", "2", "dose", "cohort."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p44_s2", "idA": "908259_16_item1_p34_s1", "sentA": "Among the first 13 patients treated at the two lowest dose levels, two patients showed stable disease, one patient had a partial remission and one patient achieved a complete bone marrow response.", "sentB": "In the third cohort, one patient (25%) had a CR and one additional patient in the study remained in treatment.", "type": 2, "words": ["<tag1>", "Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "showed", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response.", "<tag2>", "In", "the", "third", "cohort,", "one", "patient", "(25%)", "had", "a", "CR", "and", "one", "additional", "patient", "in", "the", "study", "remained", "in", "treatment.", "<tag3>"], "wordsA": ["Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "showed", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response."], "wordsB": ["In", "the", "third", "cohort,", "one", "patient", "(25%)", "had", "a", "CR", "and", "one", "additional", "patient", "in", "the", "study", "remained", "in", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p40_s0", "idA": "908259_16_item1_p35_s0", "sentA": "that is released when a blood clot breaks up), bone pain, fever, chills and flu-like symptoms.", "sentB": "Side effects included increases in D-dimer (a substance in the blood that is released when a blood clot breaks up), bone pain, fever, chills and flu-like symptoms.", "type": 2, "words": ["<tag1>", "that", "is", "released", "when", "a", "blood", "clot", "breaks", "up),", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms.", "<tag2>", "Side", "effects", "included", "increases", "in", "D-dimer", "(a", "substance", "in", "the", "blood", "that", "is", "released", "when", "a", "blood", "clot", "breaks", "up),", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms.", "<tag3>"], "wordsA": ["that", "is", "released", "when", "a", "blood", "clot", "breaks", "up),", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms."], "wordsB": ["Side", "effects", "included", "increases", "in", "D-dimer", "(a", "substance", "in", "the", "blood", "that", "is", "released", "when", "a", "blood", "clot", "breaks", "up),", "bone", "pain,", "fever,", "chills", "and", "flu-like", "symptoms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p40_s1", "idA": "908259_16_item1_p35_s1", "sentA": "Accordingly, OXi4503 appears to be reasonably well-tolerated based on these results to date in patients with relapsed and refractory AML and MDS.", "sentB": "Accordingly, OXi4503 appeared to be reasonably well-tolerated based on these results in patients with relapsed and refractory AML and MDS.", "type": 2, "words": ["<tag1>", "Accordingly,", "OXi4503", "appears", "to", "be", "reasonably", "well-tolerated", "based", "on", "these", "results", "to", "date", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS.", "<tag2>", "Accordingly,", "OXi4503", "appeared", "to", "be", "reasonably", "well-tolerated", "based", "on", "these", "results", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS.", "<tag3>"], "wordsA": ["Accordingly,", "OXi4503", "appears", "to", "be", "reasonably", "well-tolerated", "based", "on", "these", "results", "to", "date", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS."], "wordsB": ["Accordingly,", "OXi4503", "appeared", "to", "be", "reasonably", "well-tolerated", "based", "on", "these", "results", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p48_s0", "idA": "908259_16_item1_p38_s0", "sentA": "VDAs are drugs that interfere with existing tumor blood vessels.", "sentB": "VDAs are drugs that disrupt existing tumor blood vessels.", "type": 2, "words": ["<tag1>", "VDAs", "are", "drugs", "that", "interfere", "with", "existing", "tumor", "blood", "vessels.", "<tag2>", "VDAs", "are", "drugs", "that", "disrupt", "existing", "tumor", "blood", "vessels.", "<tag3>"], "wordsA": ["VDAs", "are", "drugs", "that", "interfere", "with", "existing", "tumor", "blood", "vessels."], "wordsB": ["VDAs", "are", "drugs", "that", "disrupt", "existing", "tumor", "blood", "vessels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p50_s0", "idA": "908259_16_item1_p39_s2", "sentA": "AAs, on the other hand, act by preventing the formation of new blood vessels to cancer tumors.", "sentB": "formation of new blood vessels to cancer tumors.", "type": 2, "words": ["<tag1>", "AAs,", "on", "the", "other", "hand,", "act", "by", "preventing", "the", "formation", "of", "new", "blood", "vessels", "to", "cancer", "tumors.", "<tag2>", "formation", "of", "new", "blood", "vessels", "to", "cancer", "tumors.", "<tag3>"], "wordsA": ["AAs,", "on", "the", "other", "hand,", "act", "by", "preventing", "the", "formation", "of", "new", "blood", "vessels", "to", "cancer", "tumors."], "wordsB": ["formation", "of", "new", "blood", "vessels", "to", "cancer", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p53_s1", "idA": "908259_16_item1_p39_s3", "sentA": "We believe that our VDA drug candidates and approved AAs are complementary to each other in that one agent destroys existing tumor vasculature and the other prevents new tumor vasculature from forming.", "sentB": "In vitro studies have demonstrated that our VDA drug candidates act in a reversible fashion on tubulin inside newly-formed and growing endothelial cells, such as the vascular endothelial cells comprising tumor vasculature.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "our", "VDA", "drug", "candidates", "and", "approved", "AAs", "are", "complementary", "to", "each", "other", "in", "that", "one", "agent", "destroys", "existing", "tumor", "vasculature", "and", "the", "other", "prevents", "new", "tumor", "vasculature", "from", "forming.", "<tag2>", "In", "vitro", "studies", "have", "demonstrated", "that", "our", "VDA", "drug", "candidates", "act", "in", "a", "reversible", "fashion", "on", "tubulin", "inside", "newly-formed", "and", "growing", "endothelial", "cells,", "such", "as", "the", "vascular", "endothelial", "cells", "comprising", "tumor", "vasculature.", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "VDA", "drug", "candidates", "and", "approved", "AAs", "are", "complementary", "to", "each", "other", "in", "that", "one", "agent", "destroys", "existing", "tumor", "vasculature", "and", "the", "other", "prevents", "new", "tumor", "vasculature", "from", "forming."], "wordsB": ["In", "vitro", "studies", "have", "demonstrated", "that", "our", "VDA", "drug", "candidates", "act", "in", "a", "reversible", "fashion", "on", "tubulin", "inside", "newly-formed", "and", "growing", "endothelial", "cells,", "such", "as", "the", "vascular", "endothelial", "cells", "comprising", "tumor", "vasculature."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p50_s2", "idA": "908259_16_item1_p39_s4", "sentA": "We intend for substantially all of our future CA4P development to be focused on this combination, rather than pursuing CA4P approval as a single therapy.", "sentB": "We intend for substantially all of our future CA4P development to be focused on this combination, rather than pursuing CA4P approval as a monotherapy.", "type": 2, "words": ["<tag1>", "We", "intend", "for", "substantially", "all", "of", "our", "future", "CA4P", "development", "to", "be", "focused", "on", "this", "combination,", "rather", "than", "pursuing", "CA4P", "approval", "as", "a", "single", "therapy.", "<tag2>", "We", "intend", "for", "substantially", "all", "of", "our", "future", "CA4P", "development", "to", "be", "focused", "on", "this", "combination,", "rather", "than", "pursuing", "CA4P", "approval", "as", "a", "monotherapy.", "<tag3>"], "wordsA": ["We", "intend", "for", "substantially", "all", "of", "our", "future", "CA4P", "development", "to", "be", "focused", "on", "this", "combination,", "rather", "than", "pursuing", "CA4P", "approval", "as", "a", "single", "therapy."], "wordsB": ["We", "intend", "for", "substantially", "all", "of", "our", "future", "CA4P", "development", "to", "be", "focused", "on", "this", "combination,", "rather", "than", "pursuing", "CA4P", "approval", "as", "a", "monotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p2_s7", "idA": "908259_16_item1_p39_s7", "sentA": "Several preclinical studies, as well as the results of the phase 2 GOG-0186I clinical trial, have confirmed the potential of this approach.", "sentB": "Our belief in the benefit of this combination is supported by numerous preclinical studies, as well as clinical studies which demonstrate improved progression-free survival and objective response rate, as well as trends in overall survival.", "type": 2, "words": ["<tag1>", "Several", "preclinical", "studies,", "as", "well", "as", "the", "results", "of", "the", "phase", "2", "GOG-0186I", "clinical", "trial,", "have", "confirmed", "the", "potential", "of", "this", "approach.", "<tag2>", "Our", "belief", "in", "the", "benefit", "of", "this", "combination", "is", "supported", "by", "numerous", "preclinical", "studies,", "as", "well", "as", "clinical", "studies", "which", "demonstrate", "improved", "progression-free", "survival", "and", "objective", "response", "rate,", "as", "well", "as", "trends", "in", "overall", "survival.", "<tag3>"], "wordsA": ["Several", "preclinical", "studies,", "as", "well", "as", "the", "results", "of", "the", "phase", "2", "GOG-0186I", "clinical", "trial,", "have", "confirmed", "the", "potential", "of", "this", "approach."], "wordsB": ["Our", "belief", "in", "the", "benefit", "of", "this", "combination", "is", "supported", "by", "numerous", "preclinical", "studies,", "as", "well", "as", "clinical", "studies", "which", "demonstrate", "improved", "progression-free", "survival", "and", "objective", "response", "rate,", "as", "well", "as", "trends", "in", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p3_s1", "idA": "908259_16_item1_p39_s7", "sentA": "Several preclinical studies, as well as the results of the phase 2 GOG-0186I clinical trial, have confirmed the potential of this approach.", "sentB": "Cancer cells on or near the edge of the tumor can receive their blood supply through the tumor vasculature as well as from surrounding, normal vasculature.", "type": 2, "words": ["<tag1>", "Several", "preclinical", "studies,", "as", "well", "as", "the", "results", "of", "the", "phase", "2", "GOG-0186I", "clinical", "trial,", "have", "confirmed", "the", "potential", "of", "this", "approach.", "<tag2>", "Cancer", "cells", "on", "or", "near", "the", "edge", "of", "the", "tumor", "can", "receive", "their", "blood", "supply", "through", "the", "tumor", "vasculature", "as", "well", "as", "from", "surrounding,", "normal", "vasculature.", "<tag3>"], "wordsA": ["Several", "preclinical", "studies,", "as", "well", "as", "the", "results", "of", "the", "phase", "2", "GOG-0186I", "clinical", "trial,", "have", "confirmed", "the", "potential", "of", "this", "approach."], "wordsB": ["Cancer", "cells", "on", "or", "near", "the", "edge", "of", "the", "tumor", "can", "receive", "their", "blood", "supply", "through", "the", "tumor", "vasculature", "as", "well", "as", "from", "surrounding,", "normal", "vasculature."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p5_s2", "idA": "908259_16_item1_p3_s2", "sentA": "Based on the positive results of this clinical trial, we plan to initiate a phase 2/3 clinical trial in platinum-resistant ovarian cancer, which will compare treatment with CA4P, bevacizumab and chemotherapy to treatment with bevacizumab and chemotherapy.", "sentB": "Based on the positive results of this clinical trial, we initiated the FOCUS Study in 2016, a phase 2/3 clinical trial of CA4P in platinum-resistant ovarian cancer, with the goal of determining whether the addition of CA4P improves upon the current standard of care.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "plan", "to", "initiate", "a", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag2>", "Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "initiated", "the", "FOCUS", "Study", "in", "2016,", "a", "phase", "2/3", "clinical", "trial", "of", "CA4P", "in", "platinum-resistant", "ovarian", "cancer,", "with", "the", "goal", "of", "determining", "whether", "the", "addition", "of", "CA4P", "improves", "upon", "the", "current", "standard", "of", "care.", "<tag3>"], "wordsA": ["Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "plan", "to", "initiate", "a", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "wordsB": ["Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "initiated", "the", "FOCUS", "Study", "in", "2016,", "a", "phase", "2/3", "clinical", "trial", "of", "CA4P", "in", "platinum-resistant", "ovarian", "cancer,", "with", "the", "goal", "of", "determining", "whether", "the", "addition", "of", "CA4P", "improves", "upon", "the", "current", "standard", "of", "care."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p6_s1", "idA": "908259_16_item1_p3_s3", "sentA": "CA4P is also being studied in combination with pazopanib (Votrient ) in an on-going phase 1b/2 clinical trial in recurrent ovarian cancer that is sponsored by The Christie Hospital NHS Foundation Trust in the United Kingdom.", "sentB": "CA4P is also being studied in combination with pazopanib (Votrient ) in an on-going phase 2 clinical trial in recurrent ovarian cancer that is sponsored by The Christie Hospital NHS Foundation Trust in the United Kingdom.", "type": 2, "words": ["<tag1>", "CA4P", "is", "also", "being", "studied", "in", "combination", "with", "pazopanib", "(Votrient", ")", "in", "an", "on-going", "phase", "1b/2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "that", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "in", "the", "United", "Kingdom.", "<tag2>", "CA4P", "is", "also", "being", "studied", "in", "combination", "with", "pazopanib", "(Votrient", ")", "in", "an", "on-going", "phase", "2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "that", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "in", "the", "United", "Kingdom.", "<tag3>"], "wordsA": ["CA4P", "is", "also", "being", "studied", "in", "combination", "with", "pazopanib", "(Votrient", ")", "in", "an", "on-going", "phase", "1b/2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "that", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "in", "the", "United", "Kingdom."], "wordsB": ["CA4P", "is", "also", "being", "studied", "in", "combination", "with", "pazopanib", "(Votrient", ")", "in", "an", "on-going", "phase", "2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "that", "is", "sponsored", "by", "The", "Christie", "Hospital", "NHS", "Foundation", "Trust", "in", "the", "United", "Kingdom."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p6_s2", "idA": "908259_16_item1_p3_s4", "sentA": "Our second compound, OXi4503, is being studied in combination with cytarabine in a phase 1/2 clinical trial in the United States in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).", "sentB": "Our second compound, OXi4503, is being studied in combination with cytarabine in an ascending-dose phase 1/2 clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).", "type": 2, "words": ["<tag1>", "Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "a", "phase", "1/2", "clinical", "trial", "in", "the", "United", "States", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag2>", "Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "an", "ascending-dose", "phase", "1/2", "clinical", "trial", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag3>"], "wordsA": ["Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "a", "phase", "1/2", "clinical", "trial", "in", "the", "United", "States", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "wordsB": ["Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "an", "ascending-dose", "phase", "1/2", "clinical", "trial", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p6_s5", "idA": "908259_16_item1_p3_s5", "sentA": "We have been granted orphan drug designation for CA4P for the treatment of ovarian cancer in the United States and the European Union, and for OXi4503 for the treatment of AML in the United States and the European Union.", "sentB": "We have also been granted orphan drug designation for CA4P for the treatment of ovarian cancer in the United States and the European Union, and for OXi4503 for the treatment of AML in the United States and the European Union.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "for", "the", "treatment", "of", "AML", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "We", "have", "also", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "for", "the", "treatment", "of", "AML", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "for", "the", "treatment", "of", "AML", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["We", "have", "also", "been", "granted", "orphan", "drug", "designation", "for", "CA4P", "for", "the", "treatment", "of", "ovarian", "cancer", "in", "the", "United", "States", "and", "the", "European", "Union,", "and", "for", "OXi4503", "for", "the", "treatment", "of", "AML", "in", "the", "United", "States", "and", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p51_s2", "idA": "908259_16_item1_p40_s2", "sentA": "Results from initial human clinical trials conducted by us with combinations of CA4P and bevacizumab provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "sentB": "Results from human clinical trials with combinations of CA4P and bevacizumab provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "type": 2, "words": ["<tag1>", "Results", "from", "initial", "human", "clinical", "trials", "conducted", "by", "us", "with", "combinations", "of", "CA4P", "and", "bevacizumab", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag2>", "Results", "from", "human", "clinical", "trials", "with", "combinations", "of", "CA4P", "and", "bevacizumab", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag3>"], "wordsA": ["Results", "from", "initial", "human", "clinical", "trials", "conducted", "by", "us", "with", "combinations", "of", "CA4P", "and", "bevacizumab", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "wordsB": ["Results", "from", "human", "clinical", "trials", "with", "combinations", "of", "CA4P", "and", "bevacizumab", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p54_s0", "idA": "908259_16_item1_p43_s0", "sentA": "By binding to the tubulin, CA4P is able to collapse the structural framework that normally maintains the cells flat shape.", "sentB": "By binding to the tubulin, CA4P is able to alter the structural framework that normally maintains the cells flat shape.", "type": 2, "words": ["<tag1>", "By", "binding", "to", "the", "tubulin,", "CA4P", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape.", "<tag2>", "By", "binding", "to", "the", "tubulin,", "CA4P", "is", "able", "to", "alter", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape.", "<tag3>"], "wordsA": ["By", "binding", "to", "the", "tubulin,", "CA4P", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape."], "wordsB": ["By", "binding", "to", "the", "tubulin,", "CA4P", "is", "able", "to", "alter", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p54_s1", "idA": "908259_16_item1_p43_s1", "sentA": "When this occurs, the shape of the cells changes from flat to round, initiating a cascade of events resulting in physical blockage of the blood vessels.", "sentB": "When this occurs, the shape of the cells changes from flat to round, resulting in physical blockage of the blood vessels.", "type": 2, "words": ["<tag1>", "When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "initiating", "a", "cascade", "of", "events", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels.", "<tag2>", "When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels.", "<tag3>"], "wordsA": ["When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "initiating", "a", "cascade", "of", "events", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels."], "wordsB": ["When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p54_s3", "idA": "908259_16_item1_p43_s3", "sentA": "The consequence of the blockage is extensive tumor cell death, as demonstrated in animal studies and suggested in imaging studies of human patients treated with CA4P and OXi4503.", "sentB": "The consequence of the blockage is extensive tumor cell death.", "type": 2, "words": ["<tag1>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "CA4P", "and", "OXi4503.", "<tag2>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death.", "<tag3>"], "wordsA": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death,", "as", "demonstrated", "in", "animal", "studies", "and", "suggested", "in", "imaging", "studies", "of", "human", "patients", "treated", "with", "CA4P", "and", "OXi4503."], "wordsB": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p56_s1", "idA": "908259_16_item1_p45_s1", "sentA": "In part because the half-life of the active form of CA4P is relatively short, the effects of CA4P on tubulin are reversible, and CA4P is typically administered no more frequently than once per week.", "sentB": "In part because the half-life of the active form of CA4P is relatively short, the effects of CA4P on tubulin are reversible, and the pharmacodynamic effect lasts for weeks, CA4P is typically administered no more frequently than once per week.", "type": 2, "words": ["<tag1>", "In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week.", "<tag2>", "In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "the", "pharmacodynamic", "effect", "lasts", "for", "weeks,", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week.", "<tag3>"], "wordsA": ["In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week."], "wordsB": ["In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "the", "pharmacodynamic", "effect", "lasts", "for", "weeks,", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p58_s0", "idA": "908259_16_item1_p47_s0", "sentA": "Currently approved AAs generally exert their tumor blood-vessel growth inhibiting effects over days to weeks to months, and as a result can cause a variety of chronic side-effects that are not limited to the immediate period following administration.", "sentB": "months, and as a result can cause a variety of chronic side-effects that are not limited to the immediate period following administration.", "type": 2, "words": ["<tag1>", "Currently", "approved", "AAs", "generally", "exert", "their", "tumor", "blood-vessel", "growth", "inhibiting", "effects", "over", "days", "to", "weeks", "to", "months,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration.", "<tag2>", "months,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration.", "<tag3>"], "wordsA": ["Currently", "approved", "AAs", "generally", "exert", "their", "tumor", "blood-vessel", "growth", "inhibiting", "effects", "over", "days", "to", "weeks", "to", "months,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration."], "wordsB": ["months,", "and", "as", "a", "result", "can", "cause", "a", "variety", "of", "chronic", "side-effects", "that", "are", "not", "limited", "to", "the", "immediate", "period", "following", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p59_s2", "idA": "908259_16_item1_p48_s2", "sentA": "Approximately 10-20% of patients treated with CA4P experience clinically-significant acute blood pressure increases, which are often manageable by controlling underlying hypertension or treating with short-acting anti-hypertensives prior to CA4P infusion.", "sentB": "Incrementally, we have noted that approximately 15-30% more patients treated with CA4P experience clinically-significant acute blood pressure increases compared to control patients.", "type": 2, "words": ["<tag1>", "Approximately", "10-20%", "of", "patients", "treated", "with", "CA4P", "experience", "clinically-significant", "acute", "blood", "pressure", "increases,", "which", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion.", "<tag2>", "Incrementally,", "we", "have", "noted", "that", "approximately", "15-30%", "more", "patients", "treated", "with", "CA4P", "experience", "clinically-significant", "acute", "blood", "pressure", "increases", "compared", "to", "control", "patients.", "<tag3>"], "wordsA": ["Approximately", "10-20%", "of", "patients", "treated", "with", "CA4P", "experience", "clinically-significant", "acute", "blood", "pressure", "increases,", "which", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion."], "wordsB": ["Incrementally,", "we", "have", "noted", "that", "approximately", "15-30%", "more", "patients", "treated", "with", "CA4P", "experience", "clinically-significant", "acute", "blood", "pressure", "increases", "compared", "to", "control", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p59_s3", "idA": "908259_16_item1_p48_s2", "sentA": "Approximately 10-20% of patients treated with CA4P experience clinically-significant acute blood pressure increases, which are often manageable by controlling underlying hypertension or treating with short-acting anti-hypertensives prior to CA4P infusion.", "sentB": "The acute blood pressure increases are often manageable by controlling underlying hypertension or treating with short-acting anti-hypertensives prior to CA4P infusion.", "type": 2, "words": ["<tag1>", "Approximately", "10-20%", "of", "patients", "treated", "with", "CA4P", "experience", "clinically-significant", "acute", "blood", "pressure", "increases,", "which", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion.", "<tag2>", "The", "acute", "blood", "pressure", "increases", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion.", "<tag3>"], "wordsA": ["Approximately", "10-20%", "of", "patients", "treated", "with", "CA4P", "experience", "clinically-significant", "acute", "blood", "pressure", "increases,", "which", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion."], "wordsB": ["The", "acute", "blood", "pressure", "increases", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p7_s0", "idA": "908259_16_item1_p4_s0", "sentA": "CA4P Development Program CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in most solid tumors.", "sentB": "CA4P Development Program CA4P is a reversible tubulin-binding agent that selectively targets endothelial cells, which make up the interior lining of blood vessel walls in most solid tumors.", "type": 2, "words": ["<tag1>", "CA4P", "Development", "Program", "CA4P", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors.", "<tag2>", "CA4P", "Development", "Program", "CA4P", "is", "a", "reversible", "tubulin-binding", "agent", "that", "selectively", "targets", "endothelial", "cells,", "which", "make", "up", "the", "interior", "lining", "of", "blood", "vessel", "walls", "in", "most", "solid", "tumors.", "<tag3>"], "wordsA": ["CA4P", "Development", "Program", "CA4P", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors."], "wordsB": ["CA4P", "Development", "Program", "CA4P", "is", "a", "reversible", "tubulin-binding", "agent", "that", "selectively", "targets", "endothelial", "cells,", "which", "make", "up", "the", "interior", "lining", "of", "blood", "vessel", "walls", "in", "most", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p61_s0", "idA": "908259_16_item1_p50_s1", "sentA": "Our principal focus is to advance the clinical development of our drug candidates, CA4P and OXi4503, and to identify new preclinical candidates that are complementary to our VDAs.", "sentB": "Our primary focus is on advancing the clinical development of our drug candidates CA4P and OXi4503.", "type": 2, "words": ["<tag1>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "of", "our", "drug", "candidates,", "CA4P", "and", "OXi4503,", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag2>", "Our", "primary", "focus", "is", "on", "advancing", "the", "clinical", "development", "of", "our", "drug", "candidates", "CA4P", "and", "OXi4503.", "<tag3>"], "wordsA": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "of", "our", "drug", "candidates,", "CA4P", "and", "OXi4503,", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "wordsB": ["Our", "primary", "focus", "is", "on", "advancing", "the", "clinical", "development", "of", "our", "drug", "candidates", "CA4P", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p61_s1", "idA": "908259_16_item1_p50_s1", "sentA": "Our principal focus is to advance the clinical development of our drug candidates, CA4P and OXi4503, and to identify new preclinical candidates that are complementary to our VDAs.", "sentB": "We are also seeking to find additional potential uses for our clinical candidates and to identify new preclinical candidates that are complementary to our VDAs.", "type": 2, "words": ["<tag1>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "of", "our", "drug", "candidates,", "CA4P", "and", "OXi4503,", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag2>", "We", "are", "also", "seeking", "to", "find", "additional", "potential", "uses", "for", "our", "clinical", "candidates", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag3>"], "wordsA": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "of", "our", "drug", "candidates,", "CA4P", "and", "OXi4503,", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "wordsB": ["We", "are", "also", "seeking", "to", "find", "additional", "potential", "uses", "for", "our", "clinical", "candidates", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p61_s2", "idA": "908259_16_item1_p50_s2", "sentA": "To help advance our strategy, we have established relationships with universities, research organizations and other institutions in these fields.", "sentB": "In order to help achieve these objectives, we have established relationships with universities, research organizations and other institutions in the fields of our interest.", "type": 2, "words": ["<tag1>", "To", "help", "advance", "our", "strategy,", "we", "have", "established", "relationships", "with", "universities,", "research", "organizations", "and", "other", "institutions", "in", "these", "fields.", "<tag2>", "In", "order", "to", "help", "achieve", "these", "objectives,", "we", "have", "established", "relationships", "with", "universities,", "research", "organizations", "and", "other", "institutions", "in", "the", "fields", "of", "our", "interest.", "<tag3>"], "wordsA": ["To", "help", "advance", "our", "strategy,", "we", "have", "established", "relationships", "with", "universities,", "research", "organizations", "and", "other", "institutions", "in", "these", "fields."], "wordsB": ["In", "order", "to", "help", "achieve", "these", "objectives,", "we", "have", "established", "relationships", "with", "universities,", "research", "organizations", "and", "other", "institutions", "in", "the", "fields", "of", "our", "interest."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p61_s3", "idA": "908259_16_item1_p50_s3", "sentA": "We intend to continue to rely on these relationships, rather than expand our in-house research and development staff.", "sentB": "We plan to continue to rely on these external relationships as our programs advance, although the composition of our external relationships may change.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "continue", "to", "rely", "on", "these", "relationships,", "rather", "than", "expand", "our", "in-house", "research", "and", "development", "staff.", "<tag2>", "We", "plan", "to", "continue", "to", "rely", "on", "these", "external", "relationships", "as", "our", "programs", "advance,", "although", "the", "composition", "of", "our", "external", "relationships", "may", "change.", "<tag3>"], "wordsA": ["We", "intend", "to", "continue", "to", "rely", "on", "these", "relationships,", "rather", "than", "expand", "our", "in-house", "research", "and", "development", "staff."], "wordsB": ["We", "plan", "to", "continue", "to", "rely", "on", "these", "external", "relationships", "as", "our", "programs", "advance,", "although", "the", "composition", "of", "our", "external", "relationships", "may", "change."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p113_s3", "idA": "908259_16_item1_p50_s5", "sentA": "Currently, we have collaborative agreements and arrangements with a number of institutions in the United States and abroad, which we utilize to perform the day-to-day activities associated with drug discovery and/or development.", "sentB": "The outcome of the recent Presidential and Congressional elections in the United States could result in significant changes in, and uncertainly with respect to, legislation, regulation and a number of government policies involving matters presently addressed by the ACA.", "type": 2, "words": ["<tag1>", "Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "discovery", "and/or", "development.", "<tag2>", "The", "outcome", "of", "the", "recent", "Presidential", "and", "Congressional", "elections", "in", "the", "United", "States", "could", "result", "in", "significant", "changes", "in,", "and", "uncertainly", "with", "respect", "to,", "legislation,", "regulation", "and", "a", "number", "of", "government", "policies", "involving", "matters", "presently", "addressed", "by", "the", "ACA.", "<tag3>"], "wordsA": ["Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "discovery", "and/or", "development."], "wordsB": ["The", "outcome", "of", "the", "recent", "Presidential", "and", "Congressional", "elections", "in", "the", "United", "States", "could", "result", "in", "significant", "changes", "in,", "and", "uncertainly", "with", "respect", "to,", "legislation,", "regulation", "and", "a", "number", "of", "government", "policies", "involving", "matters", "presently", "addressed", "by", "the", "ACA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p61_s4", "idA": "908259_16_item1_p50_s5", "sentA": "Currently, we have collaborative agreements and arrangements with a number of institutions in the United States and abroad, which we utilize to perform the day-to-day activities associated with drug discovery and/or development.", "sentB": "Currently, we have collaborative agreements and arrangements with a number of institutions which we utilize to perform certain activities associated with drug discovery and drug development.", "type": 2, "words": ["<tag1>", "Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "discovery", "and/or", "development.", "<tag2>", "Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "which", "we", "utilize", "to", "perform", "certain", "activities", "associated", "with", "drug", "discovery", "and", "drug", "development.", "<tag3>"], "wordsA": ["Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "in", "the", "United", "States", "and", "abroad,", "which", "we", "utilize", "to", "perform", "the", "day-to-day", "activities", "associated", "with", "drug", "discovery", "and/or", "development."], "wordsB": ["Currently,", "we", "have", "collaborative", "agreements", "and", "arrangements", "with", "a", "number", "of", "institutions", "which", "we", "utilize", "to", "perform", "certain", "activities", "associated", "with", "drug", "discovery", "and", "drug", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p61_s5", "idA": "908259_16_item1_p50_s6", "sentA": "In 2015, collaborations and agreements were ongoing with a variety of universities and research institutions, including the following:", "sentB": "In 2016, collaborations and agreements were ongoing with several universities and research institutions, including the following:", "type": 2, "words": ["<tag1>", "In", "2015,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "universities", "and", "research", "institutions,", "including", "the", "following:", "<tag2>", "In", "2016,", "collaborations", "and", "agreements", "were", "ongoing", "with", "several", "universities", "and", "research", "institutions,", "including", "the", "following:", "<tag3>"], "wordsA": ["In", "2015,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "universities", "and", "research", "institutions,", "including", "the", "following:"], "wordsB": ["In", "2016,", "collaborations", "and", "agreements", "were", "ongoing", "with", "several", "universities", "and", "research", "institutions,", "including", "the", "following:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p64_s1", "idA": "908259_16_item1_p53_s1", "sentA": "ASU is entitled to single-digit royalty and milestone payments under the license agreement.", "sentB": "ASU is entitled to single-digit royalty payments under the license agreement during the term of the patents licensed from ASU.", "type": 2, "words": ["<tag1>", "ASU", "is", "entitled", "to", "single-digit", "royalty", "and", "milestone", "payments", "under", "the", "license", "agreement.", "<tag2>", "ASU", "is", "entitled", "to", "single-digit", "royalty", "payments", "under", "the", "license", "agreement", "during", "the", "term", "of", "the", "patents", "licensed", "from", "ASU.", "<tag3>"], "wordsA": ["ASU", "is", "entitled", "to", "single-digit", "royalty", "and", "milestone", "payments", "under", "the", "license", "agreement."], "wordsB": ["ASU", "is", "entitled", "to", "single-digit", "royalty", "payments", "under", "the", "license", "agreement", "during", "the", "term", "of", "the", "patents", "licensed", "from", "ASU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p66_s1", "idA": "908259_16_item1_p55_s3", "sentA": "Payments made to ASU to date have amounted to $2,700,000.", "sentB": "License payments made to ASU to date have amounted to $2,700,000, with no further license payments due on the combretastatins we are developing.", "type": 2, "words": ["<tag1>", "Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,700,000.", "<tag2>", "License", "payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,700,000,", "with", "no", "further", "license", "payments", "due", "on", "the", "combretastatins", "we", "are", "developing.", "<tag3>"], "wordsA": ["Payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,700,000."], "wordsB": ["License", "payments", "made", "to", "ASU", "to", "date", "have", "amounted", "to", "$2,700,000,", "with", "no", "further", "license", "payments", "due", "on", "the", "combretastatins", "we", "are", "developing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p66_s4", "idA": "908259_16_item1_p55_s6", "sentA": "In addition, we may terminate the agreement by either (i) determining that filing for regulatory approval is not warranted or economically feasible by the clinical testing date or (ii) by providing two months written notice of our intent to terminate the agreement.", "sentB": "In addition, we may terminate the agreement if we determine that filing for regulatory approval is not warranted or economically feasible or upon two months written notice.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "may", "terminate", "the", "agreement", "by", "either", "(i)", "determining", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "or", "economically", "feasible", "by", "the", "clinical", "testing", "date", "or", "(ii)", "by", "providing", "two", "months", "written", "notice", "of", "our", "intent", "to", "terminate", "the", "agreement.", "<tag2>", "In", "addition,", "we", "may", "terminate", "the", "agreement", "if", "we", "determine", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "or", "economically", "feasible", "or", "upon", "two", "months", "written", "notice.", "<tag3>"], "wordsA": ["In", "addition,", "we", "may", "terminate", "the", "agreement", "by", "either", "(i)", "determining", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "or", "economically", "feasible", "by", "the", "clinical", "testing", "date", "or", "(ii)", "by", "providing", "two", "months", "written", "notice", "of", "our", "intent", "to", "terminate", "the", "agreement."], "wordsB": ["In", "addition,", "we", "may", "terminate", "the", "agreement", "if", "we", "determine", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "or", "economically", "feasible", "or", "upon", "two", "months", "written", "notice."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p69_s0", "idA": "908259_16_item1_p56_s0", "sentA": "Under a sponsored research agreement with Baylor University, we are pursuing discovery and development of additional novel, small-molecule therapeutics for the treatment of cancer, including small-molecule cathepsin-L inhibitors and hypoxia-activated VDAs.", "sentB": "Under a sponsored research agreement with Baylor University, we are pursuing discovery and development of additional novel, small-molecule therapeutics for the treatment of cancer, including small-molecule cathepsin-K inhibitors, cathepsin-L inhibitors and hypoxia-activated VDAs.", "type": 2, "words": ["<tag1>", "Under", "a", "sponsored", "research", "agreement", "with", "Baylor", "University,", "we", "are", "pursuing", "discovery", "and", "development", "of", "additional", "novel,", "small-molecule", "therapeutics", "for", "the", "treatment", "of", "cancer,", "including", "small-molecule", "cathepsin-L", "inhibitors", "and", "hypoxia-activated", "VDAs.", "<tag2>", "Under", "a", "sponsored", "research", "agreement", "with", "Baylor", "University,", "we", "are", "pursuing", "discovery", "and", "development", "of", "additional", "novel,", "small-molecule", "therapeutics", "for", "the", "treatment", "of", "cancer,", "including", "small-molecule", "cathepsin-K", "inhibitors,", "cathepsin-L", "inhibitors", "and", "hypoxia-activated", "VDAs.", "<tag3>"], "wordsA": ["Under", "a", "sponsored", "research", "agreement", "with", "Baylor", "University,", "we", "are", "pursuing", "discovery", "and", "development", "of", "additional", "novel,", "small-molecule", "therapeutics", "for", "the", "treatment", "of", "cancer,", "including", "small-molecule", "cathepsin-L", "inhibitors", "and", "hypoxia-activated", "VDAs."], "wordsB": ["Under", "a", "sponsored", "research", "agreement", "with", "Baylor", "University,", "we", "are", "pursuing", "discovery", "and", "development", "of", "additional", "novel,", "small-molecule", "therapeutics", "for", "the", "treatment", "of", "cancer,", "including", "small-molecule", "cathepsin-K", "inhibitors,", "cathepsin-L", "inhibitors", "and", "hypoxia-activated", "VDAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p71_s1", "idA": "908259_16_item1_p58_s1", "sentA": "We believe that our hypoxia-activated VDAs could serve as line-extension products to fosbretabulin and/or OXi4503.", "sentB": "We believe that our hypoxia-activated VDAs could serve as line-extension products to CA4P and/or OXi4503.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "fosbretabulin", "and/or", "OXi4503.", "<tag2>", "We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "CA4P", "and/or", "OXi4503.", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "fosbretabulin", "and/or", "OXi4503."], "wordsB": ["We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "CA4P", "and/or", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p67_s0", "idA": "908259_16_item1_p58_s12", "sentA": "We also have an exclusive, world-wide, royalty-bearing license from Bristol-Myers Squibb, or BMS, for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, CA4P. Under the BMS license, we have the right to grant sublicenses, and BMS is entitled to low single-digit royalty payments for all commercial sales plus any remuneration we receive for sale of CA4P under named patient or compassionate use programs.", "sentB": "combretastatins, including among others, CA4P. Under the BMS license, we have the right to grant sublicenses, and BMS is entitled to low single-digit royalty payments for all commercial sales plus any remuneration we receive for sale of CA4P under named patient or compassionate use programs.", "type": 2, "words": ["<tag1>", "We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs.", "<tag2>", "combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs.", "<tag3>"], "wordsA": ["We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs."], "wordsB": ["combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p71_s4", "idA": "908259_16_item1_p58_s4", "sentA": "The agreement with Baylor stipulates that low-single-digit royalties will be paid by us should sales be generated through use of Baylor s compounds.", "sentB": "The agreement with Baylor provides for low-single-digit royalties to be paid by us for sales generated through use of Baylor s compounds.", "type": 2, "words": ["<tag1>", "The", "agreement", "with", "Baylor", "stipulates", "that", "low-single-digit", "royalties", "will", "be", "paid", "by", "us", "should", "sales", "be", "generated", "through", "use", "of", "Baylor", "s", "compounds.", "<tag2>", "The", "agreement", "with", "Baylor", "provides", "for", "low-single-digit", "royalties", "to", "be", "paid", "by", "us", "for", "sales", "generated", "through", "use", "of", "Baylor", "s", "compounds.", "<tag3>"], "wordsA": ["The", "agreement", "with", "Baylor", "stipulates", "that", "low-single-digit", "royalties", "will", "be", "paid", "by", "us", "should", "sales", "be", "generated", "through", "use", "of", "Baylor", "s", "compounds."], "wordsB": ["The", "agreement", "with", "Baylor", "provides", "for", "low-single-digit", "royalties", "to", "be", "paid", "by", "us", "for", "sales", "generated", "through", "use", "of", "Baylor", "s", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p68_s0", "idA": "908259_16_item1_p59_s0", "sentA": "preparing, filing, prosecuting and maintaining all patent applications under the BMS license and have a right, but not a duty, of enforcing patents covered by the license.", "sentB": "We bear the costs of preparing, filing, prosecuting and maintaining all patent applications under the BMS license and have a right, but not a duty, of enforcing patents covered by the license.", "type": 2, "words": ["<tag1>", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license.", "<tag2>", "We", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license.", "<tag3>"], "wordsA": ["preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license."], "wordsB": ["We", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p68_s2", "idA": "908259_16_item1_p59_s2", "sentA": "The term of the BMS license shall end upon the expiration of the licensed patents.", "sentB": "The term of the BMS license ends upon the expiration of the licensed patents.", "type": 2, "words": ["<tag1>", "The", "term", "of", "the", "BMS", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents.", "<tag2>", "The", "term", "of", "the", "BMS", "license", "ends", "upon", "the", "expiration", "of", "the", "licensed", "patents.", "<tag3>"], "wordsA": ["The", "term", "of", "the", "BMS", "license", "shall", "end", "upon", "the", "expiration", "of", "the", "licensed", "patents."], "wordsB": ["The", "term", "of", "the", "BMS", "license", "ends", "upon", "the", "expiration", "of", "the", "licensed", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p7_s1", "idA": "908259_16_item1_p5_s0", "sentA": "which obstructs the flow of blood to the tumor and starves the tumor of vital nutrients including oxygen.", "sentB": "CA4P causes these endothelial cells to change shape and detach, which obstructs the flow of blood to the tumor and starves the tumor of vital nutrients and oxygen.", "type": 2, "words": ["<tag1>", "which", "obstructs", "the", "flow", "of", "blood", "to", "the", "tumor", "and", "starves", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen.", "<tag2>", "CA4P", "causes", "these", "endothelial", "cells", "to", "change", "shape", "and", "detach,", "which", "obstructs", "the", "flow", "of", "blood", "to", "the", "tumor", "and", "starves", "the", "tumor", "of", "vital", "nutrients", "and", "oxygen.", "<tag3>"], "wordsA": ["which", "obstructs", "the", "flow", "of", "blood", "to", "the", "tumor", "and", "starves", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen."], "wordsB": ["CA4P", "causes", "these", "endothelial", "cells", "to", "change", "shape", "and", "detach,", "which", "obstructs", "the", "flow", "of", "blood", "to", "the", "tumor", "and", "starves", "the", "tumor", "of", "vital", "nutrients", "and", "oxygen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p7_s2", "idA": "908259_16_item1_p5_s1", "sentA": "This deprivation, also known as tumor hypoxia, results in rapid downstream tumor cell death.", "sentB": "The resultant tumor ischemia leads to rapid downstream tumor cell death.", "type": 2, "words": ["<tag1>", "This", "deprivation,", "also", "known", "as", "tumor", "hypoxia,", "results", "in", "rapid", "downstream", "tumor", "cell", "death.", "<tag2>", "The", "resultant", "tumor", "ischemia", "leads", "to", "rapid", "downstream", "tumor", "cell", "death.", "<tag3>"], "wordsA": ["This", "deprivation,", "also", "known", "as", "tumor", "hypoxia,", "results", "in", "rapid", "downstream", "tumor", "cell", "death."], "wordsB": ["The", "resultant", "tumor", "ischemia", "leads", "to", "rapid", "downstream", "tumor", "cell", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p71_s12", "idA": "908259_16_item1_p60_s0", "sentA": "In June 2012, we secured a royalty-bearing, transferable, worldwide, exclusive license from Angiogene Pharmaceuticals Ltd., or Angiogene, to make, have made, use, import, offer for sale, and sell a vascular disrupting agent, such as CA4P, for treating neuroendocrine tumors and associated symptoms and syndromes.", "sentB": "We previously licensed certain patents related to vascular disrupting agents for treating neuroendocrine tumors and associated symptoms and syndromes from Angiogene Pharmaceuticals Ltd. prior to our termination of the agreement in 2016.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.,", "or", "Angiogene,", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "CA4P,", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes.", "<tag2>", "We", "previously", "licensed", "certain", "patents", "related", "to", "vascular", "disrupting", "agents", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "prior", "to", "our", "termination", "of", "the", "agreement", "in", "2016.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "secured", "a", "royalty-bearing,", "transferable,", "worldwide,", "exclusive", "license", "from", "Angiogene", "Pharmaceuticals", "Ltd.,", "or", "Angiogene,", "to", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale,", "and", "sell", "a", "vascular", "disrupting", "agent,", "such", "as", "CA4P,", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes."], "wordsB": ["We", "previously", "licensed", "certain", "patents", "related", "to", "vascular", "disrupting", "agents", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "prior", "to", "our", "termination", "of", "the", "agreement", "in", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p43_s0", "idA": "908259_16_item1_p60_s3", "sentA": "Milestone payments are due upon initiation of the first clinical trial for a product using Angiogene intellectual property and initiation of the first registration clinical trial for a product using Angiogene intellectual property.", "sentB": "OXi4503 was generally well tolerated in the first two cohorts of the study.", "type": 2, "words": ["<tag1>", "Milestone", "payments", "are", "due", "upon", "initiation", "of", "the", "first", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property", "and", "initiation", "of", "the", "first", "registration", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property.", "<tag2>", "OXi4503", "was", "generally", "well", "tolerated", "in", "the", "first", "two", "cohorts", "of", "the", "study.", "<tag3>"], "wordsA": ["Milestone", "payments", "are", "due", "upon", "initiation", "of", "the", "first", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property", "and", "initiation", "of", "the", "first", "registration", "clinical", "trial", "for", "a", "product", "using", "Angiogene", "intellectual", "property."], "wordsB": ["OXi4503", "was", "generally", "well", "tolerated", "in", "the", "first", "two", "cohorts", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p72_s0", "idA": "908259_16_item1_p62_s0", "sentA": "We are a Delaware corporation, originally incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware, with our principal corporate office in the United States at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 (telephone: (650) 635-7000, fax: (650) 635-7001).", "sentB": "We were originally incorporated in 1988 in New York as OXiGENE, Inc., reincorporating in Delaware in 1992.", "type": 2, "words": ["<tag1>", "We", "are", "a", "Delaware", "corporation,", "originally", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001).", "<tag2>", "We", "were", "originally", "incorporated", "in", "1988", "in", "New", "York", "as", "OXiGENE,", "Inc.,", "reincorporating", "in", "Delaware", "in", "1992.", "<tag3>"], "wordsA": ["We", "are", "a", "Delaware", "corporation,", "originally", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001)."], "wordsB": ["We", "were", "originally", "incorporated", "in", "1988", "in", "New", "York", "as", "OXiGENE,", "Inc.,", "reincorporating", "in", "Delaware", "in", "1992."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p73_s0", "idA": "908259_16_item1_p62_s0", "sentA": "We are a Delaware corporation, originally incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware, with our principal corporate office in the United States at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 (telephone: (650) 635-7000, fax: (650) 635-7001).", "sentB": "Our principal corporate office is in the United States at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 (telephone: (650) 635-7000, fax: (650) 635-7001).", "type": 2, "words": ["<tag1>", "We", "are", "a", "Delaware", "corporation,", "originally", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001).", "<tag2>", "Our", "principal", "corporate", "office", "is", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001).", "<tag3>"], "wordsA": ["We", "are", "a", "Delaware", "corporation,", "originally", "incorporated", "in", "1988", "in", "the", "state", "of", "New", "York", "and", "reincorporated", "in", "1992", "in", "the", "state", "of", "Delaware,", "with", "our", "principal", "corporate", "office", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001)."], "wordsB": ["Our", "principal", "corporate", "office", "is", "in", "the", "United", "States", "at", "701", "Gateway", "Boulevard,", "Suite", "210,", "South", "San", "Francisco,", "California", "94080", "(telephone:", "(650)", "635-7000,", "fax:", "(650)", "635-7001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p73_s1", "idA": "908259_16_item1_p62_s1", "sentA": "Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the Investors Media section of our web site as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the Securities and Exchange Commission.", "sentB": "Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the Investors News section of our web site as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the Securities and Exchange Commission.", "type": 2, "words": ["<tag1>", "Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K,", "and", "all", "amendments", "to", "those", "reports,", "are", "available", "to", "you", "free", "of", "charge", "through", "the", "Investors", "Media", "section", "of", "our", "web", "site", "as", "soon", "as", "reasonably", "practicable", "after", "such", "materials", "have", "been", "electronically", "filed", "with,", "or", "furnished", "to,", "the", "Securities", "and", "Exchange", "Commission.", "<tag2>", "Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K,", "and", "all", "amendments", "to", "those", "reports,", "are", "available", "to", "you", "free", "of", "charge", "through", "the", "Investors", "News", "section", "of", "our", "web", "site", "as", "soon", "as", "reasonably", "practicable", "after", "such", "materials", "have", "been", "electronically", "filed", "with,", "or", "furnished", "to,", "the", "Securities", "and", "Exchange", "Commission.", "<tag3>"], "wordsA": ["Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K,", "and", "all", "amendments", "to", "those", "reports,", "are", "available", "to", "you", "free", "of", "charge", "through", "the", "Investors", "Media", "section", "of", "our", "web", "site", "as", "soon", "as", "reasonably", "practicable", "after", "such", "materials", "have", "been", "electronically", "filed", "with,", "or", "furnished", "to,", "the", "Securities", "and", "Exchange", "Commission."], "wordsB": ["Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K,", "and", "all", "amendments", "to", "those", "reports,", "are", "available", "to", "you", "free", "of", "charge", "through", "the", "Investors", "News", "section", "of", "our", "web", "site", "as", "soon", "as", "reasonably", "practicable", "after", "such", "materials", "have", "been", "electronically", "filed", "with,", "or", "furnished", "to,", "the", "Securities", "and", "Exchange", "Commission."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p7_s3", "idA": "908259_16_item1_p6_s0", "sentA": "Although CA4P acts rapidly, within minutes of infusion, and its circulating half-life is approximately 4 hours, the swelling effect caused by CA4P on the endothelial cells generally lasts for several weeks.", "sentB": "Although CA4P acts quickly, within minutes of infusion, and its circulating half-life is approximately 4 hours, the anti-tumor effects caused by CA4P generally last for several weeks, until tumor regrowth aided by revascularization occurs.", "type": 2, "words": ["<tag1>", "Although", "CA4P", "acts", "rapidly,", "within", "minutes", "of", "infusion,", "and", "its", "circulating", "half-life", "is", "approximately", "4", "hours,", "the", "swelling", "effect", "caused", "by", "CA4P", "on", "the", "endothelial", "cells", "generally", "lasts", "for", "several", "weeks.", "<tag2>", "Although", "CA4P", "acts", "quickly,", "within", "minutes", "of", "infusion,", "and", "its", "circulating", "half-life", "is", "approximately", "4", "hours,", "the", "anti-tumor", "effects", "caused", "by", "CA4P", "generally", "last", "for", "several", "weeks,", "until", "tumor", "regrowth", "aided", "by", "revascularization", "occurs.", "<tag3>"], "wordsA": ["Although", "CA4P", "acts", "rapidly,", "within", "minutes", "of", "infusion,", "and", "its", "circulating", "half-life", "is", "approximately", "4", "hours,", "the", "swelling", "effect", "caused", "by", "CA4P", "on", "the", "endothelial", "cells", "generally", "lasts", "for", "several", "weeks."], "wordsB": ["Although", "CA4P", "acts", "quickly,", "within", "minutes", "of", "infusion,", "and", "its", "circulating", "half-life", "is", "approximately", "4", "hours,", "the", "anti-tumor", "effects", "caused", "by", "CA4P", "generally", "last", "for", "several", "weeks,", "until", "tumor", "regrowth", "aided", "by", "revascularization", "occurs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p86_s0", "idA": "908259_16_item1_p74_s3", "sentA": "The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product.", "sentB": "relevant information are submitted to the FDA as part of an NDA requesting approval to market the product.", "type": 2, "words": ["<tag1>", "The", "results", "of", "product", "development,", "preclinical", "studies", "and", "clinical", "trials,", "along", "with", "descriptions", "of", "the", "manufacturing", "process,", "analytical", "tests", "conducted", "on", "the", "chemistry", "of", "the", "drug,", "proposed", "labeling,", "and", "other", "relevant", "information", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "requesting", "approval", "to", "market", "the", "product.", "<tag2>", "relevant", "information", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "requesting", "approval", "to", "market", "the", "product.", "<tag3>"], "wordsA": ["The", "results", "of", "product", "development,", "preclinical", "studies", "and", "clinical", "trials,", "along", "with", "descriptions", "of", "the", "manufacturing", "process,", "analytical", "tests", "conducted", "on", "the", "chemistry", "of", "the", "drug,", "proposed", "labeling,", "and", "other", "relevant", "information", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "requesting", "approval", "to", "market", "the", "product."], "wordsB": ["relevant", "information", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "requesting", "approval", "to", "market", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p19_s4", "idA": "908259_16_item1_p75_s1", "sentA": "The FDA may request additional information rather than accept an NDA for filing.", "sentB": "The FDA has approved the protocol for FOCUS.", "type": 2, "words": ["<tag1>", "The", "FDA", "may", "request", "additional", "information", "rather", "than", "accept", "an", "NDA", "for", "filing.", "<tag2>", "The", "FDA", "has", "approved", "the", "protocol", "for", "FOCUS.", "<tag3>"], "wordsA": ["The", "FDA", "may", "request", "additional", "information", "rather", "than", "accept", "an", "NDA", "for", "filing."], "wordsB": ["The", "FDA", "has", "approved", "the", "protocol", "for", "FOCUS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p9_s0", "idA": "908259_16_item1_p7_s1", "sentA": "Our primary focus for 2016 will be the development of CA4P for platinum-resistant ovarian cancer.", "sentB": "Ovarian Cancer Our primary focus for 2017 will be the development of CA4P for platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "Our", "primary", "focus", "for", "2016", "will", "be", "the", "development", "of", "CA4P", "for", "platinum-resistant", "ovarian", "cancer.", "<tag2>", "Ovarian", "Cancer", "Our", "primary", "focus", "for", "2017", "will", "be", "the", "development", "of", "CA4P", "for", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Our", "primary", "focus", "for", "2016", "will", "be", "the", "development", "of", "CA4P", "for", "platinum-resistant", "ovarian", "cancer."], "wordsB": ["Ovarian", "Cancer", "Our", "primary", "focus", "for", "2017", "will", "be", "the", "development", "of", "CA4P", "for", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p94_s0", "idA": "908259_16_item1_p81_s2", "sentA": "After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.", "sentB": "therapeutic agent and its potential orphan use are disclosed publicly by the FDA.", "type": 2, "words": ["<tag1>", "After", "the", "FDA", "grants", "orphan", "drug", "designation,", "the", "identity", "of", "the", "therapeutic", "agent", "and", "its", "potential", "orphan", "use", "are", "disclosed", "publicly", "by", "the", "FDA.", "<tag2>", "therapeutic", "agent", "and", "its", "potential", "orphan", "use", "are", "disclosed", "publicly", "by", "the", "FDA.", "<tag3>"], "wordsA": ["After", "the", "FDA", "grants", "orphan", "drug", "designation,", "the", "identity", "of", "the", "therapeutic", "agent", "and", "its", "potential", "orphan", "use", "are", "disclosed", "publicly", "by", "the", "FDA."], "wordsB": ["therapeutic", "agent", "and", "its", "potential", "orphan", "use", "are", "disclosed", "publicly", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p12_s6", "idA": "908259_16_item1_p83_s0", "sentA": "CA4P has been awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers, ovarian cancer and neuroendocrine tumors.", "sentB": "In December 2016, the FDA approved bevacizumab for the treatment of platinum-sensitive ovarian cancer also, which could expand our market opportunity for CA4P, although we are presently not studying CA4P in platinum-sensitive disease.", "type": 2, "words": ["<tag1>", "CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer", "and", "neuroendocrine", "tumors.", "<tag2>", "In", "December", "2016,", "the", "FDA", "approved", "bevacizumab", "for", "the", "treatment", "of", "platinum-sensitive", "ovarian", "cancer", "also,", "which", "could", "expand", "our", "market", "opportunity", "for", "CA4P,", "although", "we", "are", "presently", "not", "studying", "CA4P", "in", "platinum-sensitive", "disease.", "<tag3>"], "wordsA": ["CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer", "and", "neuroendocrine", "tumors."], "wordsB": ["In", "December", "2016,", "the", "FDA", "approved", "bevacizumab", "for", "the", "treatment", "of", "platinum-sensitive", "ovarian", "cancer", "also,", "which", "could", "expand", "our", "market", "opportunity", "for", "CA4P,", "although", "we", "are", "presently", "not", "studying", "CA4P", "in", "platinum-sensitive", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p95_s1", "idA": "908259_16_item1_p83_s0", "sentA": "CA4P has been awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers, ovarian cancer and neuroendocrine tumors.", "sentB": "CA4P has been awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers, ovarian cancer, neuroendocrine tumors and glioma.", "type": 2, "words": ["<tag1>", "CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer", "and", "neuroendocrine", "tumors.", "<tag2>", "CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer,", "neuroendocrine", "tumors", "and", "glioma.", "<tag3>"], "wordsA": ["CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer", "and", "neuroendocrine", "tumors."], "wordsB": ["CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer,", "neuroendocrine", "tumors", "and", "glioma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p99_s0", "idA": "908259_16_item1_p83_s0", "sentA": "CA4P has been awarded orphan drug status by the FDA for the treatment of anaplastic, medullary, Stage IV papillary and Stage IV follicular thyroid cancers, ovarian cancer and neuroendocrine tumors.", "sentB": "CA4P has been awarded Fast Track designation for the treatment of platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer", "and", "neuroendocrine", "tumors.", "<tag2>", "CA4P", "has", "been", "awarded", "Fast", "Track", "designation", "for", "the", "treatment", "of", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["CA4P", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "anaplastic,", "medullary,", "Stage", "IV", "papillary", "and", "Stage", "IV", "follicular", "thyroid", "cancers,", "ovarian", "cancer", "and", "neuroendocrine", "tumors."], "wordsB": ["CA4P", "has", "been", "awarded", "Fast", "Track", "designation", "for", "the", "treatment", "of", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p123_s0", "idA": "908259_16_item1_p83_s1", "sentA": "OXi4503 has been awarded orphan drug status by the FDA for the treatment of acute myelogenous leukemia.", "sentB": "As previously noted, the FDA and European Union have granted CA4P and OXi4503 orphan drug status for certain indications.", "type": 2, "words": ["<tag1>", "OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag2>", "As", "previously", "noted,", "the", "FDA", "and", "European", "Union", "have", "granted", "CA4P", "and", "OXi4503", "orphan", "drug", "status", "for", "certain", "indications.", "<tag3>"], "wordsA": ["OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "wordsB": ["As", "previously", "noted,", "the", "FDA", "and", "European", "Union", "have", "granted", "CA4P", "and", "OXi4503", "orphan", "drug", "status", "for", "certain", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p95_s3", "idA": "908259_16_item1_p83_s2", "sentA": "CA4P has also been awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer, ovarian cancer and gastro-entero-pancreatic neuroendocrine tumors.", "sentB": "CA4P has also been awarded orphan drug status by the European Commission in the European Union for the treatment of anaplastic thyroid cancer, ovarian cancer and neuroendocrine tumors.", "type": 2, "words": ["<tag1>", "CA4P", "has", "also", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer,", "ovarian", "cancer", "and", "gastro-entero-pancreatic", "neuroendocrine", "tumors.", "<tag2>", "CA4P", "has", "also", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer,", "ovarian", "cancer", "and", "neuroendocrine", "tumors.", "<tag3>"], "wordsA": ["CA4P", "has", "also", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer,", "ovarian", "cancer", "and", "gastro-entero-pancreatic", "neuroendocrine", "tumors."], "wordsB": ["CA4P", "has", "also", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "anaplastic", "thyroid", "cancer,", "ovarian", "cancer", "and", "neuroendocrine", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p100_s0", "idA": "908259_16_item1_p87_s0", "sentA": "In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products.", "sentB": "In addition to regulations in the United States, we are subject to a variety of foreign regulations governing clinical trials and if any of our product candidates are approved we will be subject to additional regulations regarding commercial sales and distribution.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "regulations", "in", "the", "United", "States,", "we", "will", "be", "subject", "to", "a", "variety", "of", "foreign", "regulations", "governing", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "products.", "<tag2>", "In", "addition", "to", "regulations", "in", "the", "United", "States,", "we", "are", "subject", "to", "a", "variety", "of", "foreign", "regulations", "governing", "clinical", "trials", "and", "if", "any", "of", "our", "product", "candidates", "are", "approved", "we", "will", "be", "subject", "to", "additional", "regulations", "regarding", "commercial", "sales", "and", "distribution.", "<tag3>"], "wordsA": ["In", "addition", "to", "regulations", "in", "the", "United", "States,", "we", "will", "be", "subject", "to", "a", "variety", "of", "foreign", "regulations", "governing", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "products."], "wordsB": ["In", "addition", "to", "regulations", "in", "the", "United", "States,", "we", "are", "subject", "to", "a", "variety", "of", "foreign", "regulations", "governing", "clinical", "trials", "and", "if", "any", "of", "our", "product", "candidates", "are", "approved", "we", "will", "be", "subject", "to", "additional", "regulations", "regarding", "commercial", "sales", "and", "distribution."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p102_s0", "idA": "908259_16_item1_p88_s1", "sentA": "The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and optional for those medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states.", "sentB": "single marketing authorization that is valid for all European Union member states.", "type": 2, "words": ["<tag1>", "The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag2>", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag3>"], "wordsA": ["The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "wordsB": ["single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p10_s0", "idA": "908259_16_item1_p8_s0", "sentA": "Ovarian Cancer Approximately 22,000 women in the U.S. are diagnosed with ovarian cancer each year.", "sentB": "Approximately 22,000 women in the U.S. are diagnosed with ovarian cancer each year.", "type": 2, "words": ["<tag1>", "Ovarian", "Cancer", "Approximately", "22,000", "women", "in", "the", "U.S.", "are", "diagnosed", "with", "ovarian", "cancer", "each", "year.", "<tag2>", "Approximately", "22,000", "women", "in", "the", "U.S.", "are", "diagnosed", "with", "ovarian", "cancer", "each", "year.", "<tag3>"], "wordsA": ["Ovarian", "Cancer", "Approximately", "22,000", "women", "in", "the", "U.S.", "are", "diagnosed", "with", "ovarian", "cancer", "each", "year."], "wordsB": ["Approximately", "22,000", "women", "in", "the", "U.S.", "are", "diagnosed", "with", "ovarian", "cancer", "each", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p10_s1", "idA": "908259_16_item1_p8_s1", "sentA": "This form of cancer begins in the ovaries and often spreads to the rest of the pelvis and abdomen prior to detection, resulting in a relatively poor prognosis.", "sentB": "This form of cancer is thought to begin in the ovaries and often spreads to the rest of the pelvis and abdomen prior to detection, resulting in a relatively poor prognosis.", "type": 2, "words": ["<tag1>", "This", "form", "of", "cancer", "begins", "in", "the", "ovaries", "and", "often", "spreads", "to", "the", "rest", "of", "the", "pelvis", "and", "abdomen", "prior", "to", "detection,", "resulting", "in", "a", "relatively", "poor", "prognosis.", "<tag2>", "This", "form", "of", "cancer", "is", "thought", "to", "begin", "in", "the", "ovaries", "and", "often", "spreads", "to", "the", "rest", "of", "the", "pelvis", "and", "abdomen", "prior", "to", "detection,", "resulting", "in", "a", "relatively", "poor", "prognosis.", "<tag3>"], "wordsA": ["This", "form", "of", "cancer", "begins", "in", "the", "ovaries", "and", "often", "spreads", "to", "the", "rest", "of", "the", "pelvis", "and", "abdomen", "prior", "to", "detection,", "resulting", "in", "a", "relatively", "poor", "prognosis."], "wordsB": ["This", "form", "of", "cancer", "is", "thought", "to", "begin", "in", "the", "ovaries", "and", "often", "spreads", "to", "the", "rest", "of", "the", "pelvis", "and", "abdomen", "prior", "to", "detection,", "resulting", "in", "a", "relatively", "poor", "prognosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p104_s0", "idA": "908259_16_item1_p90_s0", "sentA": "As in the United States, the European Medicines Agency, or EMA, may grant orphan drug status for specific indications if the request is made before an MAA is made.", "sentB": "As in the United States, the European Medicines Agency, or EMA, may grant orphan drug status for specific indications if the request is made before an MAA is submitted.", "type": 2, "words": ["<tag1>", "As", "in", "the", "United", "States,", "the", "European", "Medicines", "Agency,", "or", "EMA,", "may", "grant", "orphan", "drug", "status", "for", "specific", "indications", "if", "the", "request", "is", "made", "before", "an", "MAA", "is", "made.", "<tag2>", "As", "in", "the", "United", "States,", "the", "European", "Medicines", "Agency,", "or", "EMA,", "may", "grant", "orphan", "drug", "status", "for", "specific", "indications", "if", "the", "request", "is", "made", "before", "an", "MAA", "is", "submitted.", "<tag3>"], "wordsA": ["As", "in", "the", "United", "States,", "the", "European", "Medicines", "Agency,", "or", "EMA,", "may", "grant", "orphan", "drug", "status", "for", "specific", "indications", "if", "the", "request", "is", "made", "before", "an", "MAA", "is", "made."], "wordsB": ["As", "in", "the", "United", "States,", "the", "European", "Medicines", "Agency,", "or", "EMA,", "may", "grant", "orphan", "drug", "status", "for", "specific", "indications", "if", "the", "request", "is", "made", "before", "an", "MAA", "is", "submitted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p123_s1", "idA": "908259_16_item1_p90_s0", "sentA": "As in the United States, the European Medicines Agency, or EMA, may grant orphan drug status for specific indications if the request is made before an MAA is made.", "sentB": "We are also pursuing, and may continue to in the future to pursue, orphan drug status for other product candidates and indications.", "type": 2, "words": ["<tag1>", "As", "in", "the", "United", "States,", "the", "European", "Medicines", "Agency,", "or", "EMA,", "may", "grant", "orphan", "drug", "status", "for", "specific", "indications", "if", "the", "request", "is", "made", "before", "an", "MAA", "is", "made.", "<tag2>", "We", "are", "also", "pursuing,", "and", "may", "continue", "to", "in", "the", "future", "to", "pursue,", "orphan", "drug", "status", "for", "other", "product", "candidates", "and", "indications.", "<tag3>"], "wordsA": ["As", "in", "the", "United", "States,", "the", "European", "Medicines", "Agency,", "or", "EMA,", "may", "grant", "orphan", "drug", "status", "for", "specific", "indications", "if", "the", "request", "is", "made", "before", "an", "MAA", "is", "made."], "wordsB": ["We", "are", "also", "pursuing,", "and", "may", "continue", "to", "in", "the", "future", "to", "pursue,", "orphan", "drug", "status", "for", "other", "product", "candidates", "and", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p114_s1", "idA": "908259_16_item1_p98_s3", "sentA": "We expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of health care costs, including the cost of prescription drugs, while at the same time increasing access to health care services.", "sentB": "We expect that there will continue to be a number of federal and state proposals addressing governmental pricing controls and the growth of health care costs, including the cost of prescription drugs.", "type": 2, "words": ["<tag1>", "We", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "health", "care", "costs,", "including", "the", "cost", "of", "prescription", "drugs,", "while", "at", "the", "same", "time", "increasing", "access", "to", "health", "care", "services.", "<tag2>", "We", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "addressing", "governmental", "pricing", "controls", "and", "the", "growth", "of", "health", "care", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag3>"], "wordsA": ["We", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "health", "care", "costs,", "including", "the", "cost", "of", "prescription", "drugs,", "while", "at", "the", "same", "time", "increasing", "access", "to", "health", "care", "services."], "wordsB": ["We", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "addressing", "governmental", "pricing", "controls", "and", "the", "growth", "of", "health", "care", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p114_s3", "idA": "908259_16_item1_p99_s1", "sentA": "There have been legislative proposals seeking to allow such direct negotiation.", "sentB": "Prior to the 2016 U.S. Presidential and Congressional elections, there were legislative proposals seeking to allow such direct negotiation.", "type": 2, "words": ["<tag1>", "There", "have", "been", "legislative", "proposals", "seeking", "to", "allow", "such", "direct", "negotiation.", "<tag2>", "Prior", "to", "the", "2016", "U.S.", "Presidential", "and", "Congressional", "elections,", "there", "were", "legislative", "proposals", "seeking", "to", "allow", "such", "direct", "negotiation.", "<tag3>"], "wordsA": ["There", "have", "been", "legislative", "proposals", "seeking", "to", "allow", "such", "direct", "negotiation."], "wordsB": ["Prior", "to", "the", "2016", "U.S.", "Presidential", "and", "Congressional", "elections,", "there", "were", "legislative", "proposals", "seeking", "to", "allow", "such", "direct", "negotiation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p114_s4", "idA": "908259_16_item1_p99_s2", "sentA": "It is possible that the adoption of other legislative or regulatory proposals could have a material adverse effect on our business, financial condition and results of operations.", "sentB": "It is possible that the adoption of these or other alternative legislative or regulatory proposals could have a material adverse effect on our business, financial condition and results of operations.", "type": 2, "words": ["<tag1>", "It", "is", "possible", "that", "the", "adoption", "of", "other", "legislative", "or", "regulatory", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations.", "<tag2>", "It", "is", "possible", "that", "the", "adoption", "of", "these", "or", "other", "alternative", "legislative", "or", "regulatory", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations.", "<tag3>"], "wordsA": ["It", "is", "possible", "that", "the", "adoption", "of", "other", "legislative", "or", "regulatory", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations."], "wordsB": ["It", "is", "possible", "that", "the", "adoption", "of", "these", "or", "other", "alternative", "legislative", "or", "regulatory", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p11_s0", "idA": "908259_16_item1_p9_s0", "sentA": "When treating recurrent ovarian cancer, the time between receiving the last dose of platinum-based chemotherapy and disease recurrence is used to help determine the choice of chemotherapy used in the next line of treatment.", "sentB": "When treating recurrent ovarian cancer, the time between receiving the last dose of platinum-based chemotherapy and disease recurrence is used to help determine the choice of therapy used in the next line of treatment.", "type": 2, "words": ["<tag1>", "When", "treating", "recurrent", "ovarian", "cancer,", "the", "time", "between", "receiving", "the", "last", "dose", "of", "platinum-based", "chemotherapy", "and", "disease", "recurrence", "is", "used", "to", "help", "determine", "the", "choice", "of", "chemotherapy", "used", "in", "the", "next", "line", "of", "treatment.", "<tag2>", "When", "treating", "recurrent", "ovarian", "cancer,", "the", "time", "between", "receiving", "the", "last", "dose", "of", "platinum-based", "chemotherapy", "and", "disease", "recurrence", "is", "used", "to", "help", "determine", "the", "choice", "of", "therapy", "used", "in", "the", "next", "line", "of", "treatment.", "<tag3>"], "wordsA": ["When", "treating", "recurrent", "ovarian", "cancer,", "the", "time", "between", "receiving", "the", "last", "dose", "of", "platinum-based", "chemotherapy", "and", "disease", "recurrence", "is", "used", "to", "help", "determine", "the", "choice", "of", "chemotherapy", "used", "in", "the", "next", "line", "of", "treatment."], "wordsB": ["When", "treating", "recurrent", "ovarian", "cancer,", "the", "time", "between", "receiving", "the", "last", "dose", "of", "platinum-based", "chemotherapy", "and", "disease", "recurrence", "is", "used", "to", "help", "determine", "the", "choice", "of", "therapy", "used", "in", "the", "next", "line", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p11_s1", "idA": "908259_16_item1_p9_s1", "sentA": "Patients are said to have platinum-resistant disease if the disease progresses within six months of completing platinum-based chemotherapy.", "sentB": "Patients are considered to have platinum-resistant disease if the cancer progresses within six months of completing platinum-based chemotherapy.", "type": 2, "words": ["<tag1>", "Patients", "are", "said", "to", "have", "platinum-resistant", "disease", "if", "the", "disease", "progresses", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy.", "<tag2>", "Patients", "are", "considered", "to", "have", "platinum-resistant", "disease", "if", "the", "cancer", "progresses", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy.", "<tag3>"], "wordsA": ["Patients", "are", "said", "to", "have", "platinum-resistant", "disease", "if", "the", "disease", "progresses", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy."], "wordsB": ["Patients", "are", "considered", "to", "have", "platinum-resistant", "disease", "if", "the", "cancer", "progresses", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p11_s2", "idA": "908259_16_item1_p9_s2", "sentA": "One quarter of those who relapse after initial treatment, or more than 4,300 women, will have platinum-resistant cancer, the most difficult-to-treat form of the disease.", "sentB": "Approximately 25% of those who relapse after initial treatment, or more than 4,000 women, have platinum-resistant cancer, the most difficult-to-treat form of the disease.", "type": 2, "words": ["<tag1>", "One", "quarter", "of", "those", "who", "relapse", "after", "initial", "treatment,", "or", "more", "than", "4,300", "women,", "will", "have", "platinum-resistant", "cancer,", "the", "most", "difficult-to-treat", "form", "of", "the", "disease.", "<tag2>", "Approximately", "25%", "of", "those", "who", "relapse", "after", "initial", "treatment,", "or", "more", "than", "4,000", "women,", "have", "platinum-resistant", "cancer,", "the", "most", "difficult-to-treat", "form", "of", "the", "disease.", "<tag3>"], "wordsA": ["One", "quarter", "of", "those", "who", "relapse", "after", "initial", "treatment,", "or", "more", "than", "4,300", "women,", "will", "have", "platinum-resistant", "cancer,", "the", "most", "difficult-to-treat", "form", "of", "the", "disease."], "wordsB": ["Approximately", "25%", "of", "those", "who", "relapse", "after", "initial", "treatment,", "or", "more", "than", "4,000", "women,", "have", "platinum-resistant", "cancer,", "the", "most", "difficult-to-treat", "form", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p24_s2", "idA": "908259_16_item1_p9_s3", "sentA": "Additionally, a majority of patients who are not initially platinum-resistant and who may achieve a full remission following first-line therapy will also develop recurrent disease.", "sentB": "In addition, a majority of patients (53%) experienced an improvement in patient-reported quality of life.", "type": 2, "words": ["<tag1>", "Additionally,", "a", "majority", "of", "patients", "who", "are", "not", "initially", "platinum-resistant", "and", "who", "may", "achieve", "a", "full", "remission", "following", "first-line", "therapy", "will", "also", "develop", "recurrent", "disease.", "<tag2>", "In", "addition,", "a", "majority", "of", "patients", "(53%)", "experienced", "an", "improvement", "in", "patient-reported", "quality", "of", "life.", "<tag3>"], "wordsA": ["Additionally,", "a", "majority", "of", "patients", "who", "are", "not", "initially", "platinum-resistant", "and", "who", "may", "achieve", "a", "full", "remission", "following", "first-line", "therapy", "will", "also", "develop", "recurrent", "disease."], "wordsB": ["In", "addition,", "a", "majority", "of", "patients", "(53%)", "experienced", "an", "improvement", "in", "patient-reported", "quality", "of", "life."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p0_s0", "idA": "908259_17_item1_p0_s0", "sentA": "Business Overview We are a biopharmaceutical company focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "Overview We are a clinical stage biopharmaceutical company developing small molecule injectable drugs for the treatment of cancer.", "type": 2, "words": ["<tag1>", "Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "Overview", "We", "are", "a", "clinical", "stage", "biopharmaceutical", "company", "developing", "small", "molecule", "injectable", "drugs", "for", "the", "treatment", "of", "cancer.", "<tag3>"], "wordsA": ["Business", "Overview", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["Overview", "We", "are", "a", "clinical", "stage", "biopharmaceutical", "company", "developing", "small", "molecule", "injectable", "drugs", "for", "the", "treatment", "of", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p0_s1", "idA": "908259_17_item1_p100_s0", "sentA": "In addition to regulations in the United States, we are subject to a variety of foreign regulations governing clinical trials and if any of our product candidates are approved we will be subject to additional regulations regarding commercial sales and distribution.", "sentB": "Our goal is to advance our product candidates into late stage pivotal clinical trials and either sell marketing rights to a larger pharmaceutical company or seek FDA approval ourselves.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "regulations", "in", "the", "United", "States,", "we", "are", "subject", "to", "a", "variety", "of", "foreign", "regulations", "governing", "clinical", "trials", "and", "if", "any", "of", "our", "product", "candidates", "are", "approved", "we", "will", "be", "subject", "to", "additional", "regulations", "regarding", "commercial", "sales", "and", "distribution.", "<tag2>", "Our", "goal", "is", "to", "advance", "our", "product", "candidates", "into", "late", "stage", "pivotal", "clinical", "trials", "and", "either", "sell", "marketing", "rights", "to", "a", "larger", "pharmaceutical", "company", "or", "seek", "FDA", "approval", "ourselves.", "<tag3>"], "wordsA": ["In", "addition", "to", "regulations", "in", "the", "United", "States,", "we", "are", "subject", "to", "a", "variety", "of", "foreign", "regulations", "governing", "clinical", "trials", "and", "if", "any", "of", "our", "product", "candidates", "are", "approved", "we", "will", "be", "subject", "to", "additional", "regulations", "regarding", "commercial", "sales", "and", "distribution."], "wordsB": ["Our", "goal", "is", "to", "advance", "our", "product", "candidates", "into", "late", "stage", "pivotal", "clinical", "trials", "and", "either", "sell", "marketing", "rights", "to", "a", "larger", "pharmaceutical", "company", "or", "seek", "FDA", "approval", "ourselves."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p71_s1", "idA": "908259_17_item1_p100_s1", "sentA": "Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of any product candidate in those countries.", "sentB": "Whether or not we obtain FDA approval to test a product candidate in the United States, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence testing any product candidate in those countries.", "type": 2, "words": ["<tag1>", "Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "clinical", "trials", "or", "marketing", "of", "any", "product", "candidate", "in", "those", "countries.", "<tag2>", "Whether", "or", "not", "we", "obtain", "FDA", "approval", "to", "test", "a", "product", "candidate", "in", "the", "United", "States,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "testing", "any", "product", "candidate", "in", "those", "countries.", "<tag3>"], "wordsA": ["Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "clinical", "trials", "or", "marketing", "of", "any", "product", "candidate", "in", "those", "countries."], "wordsB": ["Whether", "or", "not", "we", "obtain", "FDA", "approval", "to", "test", "a", "product", "candidate", "in", "the", "United", "States,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "testing", "any", "product", "candidate", "in", "those", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p71_s2", "idA": "908259_17_item1_p100_s1", "sentA": "Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of any product candidate in those countries.", "sentB": "Likewise, whether or not we obtain FDA approval to market a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence marketing of any product candidate in those countries.", "type": 2, "words": ["<tag1>", "Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "clinical", "trials", "or", "marketing", "of", "any", "product", "candidate", "in", "those", "countries.", "<tag2>", "Likewise,", "whether", "or", "not", "we", "obtain", "FDA", "approval", "to", "market", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "marketing", "of", "any", "product", "candidate", "in", "those", "countries.", "<tag3>"], "wordsA": ["Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "clinical", "trials", "or", "marketing", "of", "any", "product", "candidate", "in", "those", "countries."], "wordsB": ["Likewise,", "whether", "or", "not", "we", "obtain", "FDA", "approval", "to", "market", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "foreign", "countries", "before", "we", "can", "commence", "marketing", "of", "any", "product", "candidate", "in", "those", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p72_s1", "idA": "908259_17_item1_p102_s0", "sentA": "single marketing authorization that is valid for all European Union member states.", "sentB": "The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and optional for those medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states.", "type": 2, "words": ["<tag1>", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag2>", "The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag3>"], "wordsA": ["single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "wordsB": ["The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p74_s3", "idA": "908259_17_item1_p104_s3", "sentA": "Orphan drugs in the European Union also enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication, unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan designated product.", "sentB": "Orphan drugs in the European Union receive up to ten years of market exclusivity for the approved indication.", "type": 2, "words": ["<tag1>", "Orphan", "drugs", "in", "the", "European", "Union", "also", "enjoy", "economic", "and", "marketing", "benefits,", "including", "up", "to", "ten", "years", "of", "market", "exclusivity", "for", "the", "approved", "indication,", "unless", "another", "applicant", "can", "show", "that", "its", "product", "is", "safer,", "more", "effective", "or", "otherwise", "clinically", "superior", "to", "the", "orphan", "designated", "product.", "<tag2>", "Orphan", "drugs", "in", "the", "European", "Union", "receive", "up", "to", "ten", "years", "of", "market", "exclusivity", "for", "the", "approved", "indication.", "<tag3>"], "wordsA": ["Orphan", "drugs", "in", "the", "European", "Union", "also", "enjoy", "economic", "and", "marketing", "benefits,", "including", "up", "to", "ten", "years", "of", "market", "exclusivity", "for", "the", "approved", "indication,", "unless", "another", "applicant", "can", "show", "that", "its", "product", "is", "safer,", "more", "effective", "or", "otherwise", "clinically", "superior", "to", "the", "orphan", "designated", "product."], "wordsB": ["Orphan", "drugs", "in", "the", "European", "Union", "receive", "up", "to", "ten", "years", "of", "market", "exclusivity", "for", "the", "approved", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p76_s1", "idA": "908259_17_item1_p106_s1", "sentA": "Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue.", "sentB": "Adoption or application of price controls and cost-containment measures could limit our revenue.", "type": 2, "words": ["<tag1>", "Adoption", "of", "price", "controls", "and", "cost-containment", "measures,", "and", "adoption", "of", "more", "restrictive", "policies", "in", "jurisdictions", "with", "existing", "controls", "and", "measures,", "could", "further", "limit", "our", "net", "revenue.", "<tag2>", "Adoption", "or", "application", "of", "price", "controls", "and", "cost-containment", "measures", "could", "limit", "our", "revenue.", "<tag3>"], "wordsA": ["Adoption", "of", "price", "controls", "and", "cost-containment", "measures,", "and", "adoption", "of", "more", "restrictive", "policies", "in", "jurisdictions", "with", "existing", "controls", "and", "measures,", "could", "further", "limit", "our", "net", "revenue."], "wordsB": ["Adoption", "or", "application", "of", "price", "controls", "and", "cost-containment", "measures", "could", "limit", "our", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p76_s2", "idA": "908259_17_item1_p106_s2", "sentA": "If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.", "sentB": "If third-party payors do not consider our products to be cost-effective they may not pay for our products even if we receive approval, or their level of payment may not be sufficient to allow us to sell our products on a profitable basis.", "type": 2, "words": ["<tag1>", "If", "these", "third-party", "payors", "do", "not", "consider", "our", "products", "to", "be", "cost-effective", "compared", "to", "other", "available", "therapies,", "they", "may", "not", "cover", "our", "products", "after", "approval", "as", "a", "benefit", "under", "their", "plans", "or,", "if", "they", "do,", "the", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "on", "a", "profitable", "basis.", "<tag2>", "If", "third-party", "payors", "do", "not", "consider", "our", "products", "to", "be", "cost-effective", "they", "may", "not", "pay", "for", "our", "products", "even", "if", "we", "receive", "approval,", "or", "their", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "on", "a", "profitable", "basis.", "<tag3>"], "wordsA": ["If", "these", "third-party", "payors", "do", "not", "consider", "our", "products", "to", "be", "cost-effective", "compared", "to", "other", "available", "therapies,", "they", "may", "not", "cover", "our", "products", "after", "approval", "as", "a", "benefit", "under", "their", "plans", "or,", "if", "they", "do,", "the", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "on", "a", "profitable", "basis."], "wordsB": ["If", "third-party", "payors", "do", "not", "consider", "our", "products", "to", "be", "cost-effective", "they", "may", "not", "pay", "for", "our", "products", "even", "if", "we", "receive", "approval,", "or", "their", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "on", "a", "profitable", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p80_s0", "idA": "908259_17_item1_p110_s1", "sentA": "The ACA mandated prescription drug coverage as one of ten essential health benefits that most health plans must offer, requiring coverage of at least one drug in every category and class.", "sentB": "The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, the Affordable Care Act or ACA,) mandated prescription drug coverage as one of ten essential health benefits that most health plans must offer, requiring coverage of at least one drug in every category and class.", "type": 2, "words": ["<tag1>", "The", "ACA", "mandated", "prescription", "drug", "coverage", "as", "one", "of", "ten", "essential", "health", "benefits", "that", "most", "health", "plans", "must", "offer,", "requiring", "coverage", "of", "at", "least", "one", "drug", "in", "every", "category", "and", "class.", "<tag2>", "The", "Patient", "Protection", "and", "Affordable", "Care", "Act", "and", "the", "Health", "Care", "and", "Education", "Affordability", "Reconciliation", "Act", "of", "2010", "(collectively,", "the", "Affordable", "Care", "Act", "or", "ACA,)", "mandated", "prescription", "drug", "coverage", "as", "one", "of", "ten", "essential", "health", "benefits", "that", "most", "health", "plans", "must", "offer,", "requiring", "coverage", "of", "at", "least", "one", "drug", "in", "every", "category", "and", "class.", "<tag3>"], "wordsA": ["The", "ACA", "mandated", "prescription", "drug", "coverage", "as", "one", "of", "ten", "essential", "health", "benefits", "that", "most", "health", "plans", "must", "offer,", "requiring", "coverage", "of", "at", "least", "one", "drug", "in", "every", "category", "and", "class."], "wordsB": ["The", "Patient", "Protection", "and", "Affordable", "Care", "Act", "and", "the", "Health", "Care", "and", "Education", "Affordability", "Reconciliation", "Act", "of", "2010", "(collectively,", "the", "Affordable", "Care", "Act", "or", "ACA,)", "mandated", "prescription", "drug", "coverage", "as", "one", "of", "ten", "essential", "health", "benefits", "that", "most", "health", "plans", "must", "offer,", "requiring", "coverage", "of", "at", "least", "one", "drug", "in", "every", "category", "and", "class."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p81_s0", "idA": "908259_17_item1_p114_s0", "sentA": "The U.S. President and certain members of Congress have stated their intent to repeal the ACA and replace it with new laws and regulations.", "sentB": "A number of federal government leaders have expressed their intentions to repeal and replace the ACA.", "type": 2, "words": ["<tag1>", "The", "U.S.", "President", "and", "certain", "members", "of", "Congress", "have", "stated", "their", "intent", "to", "repeal", "the", "ACA", "and", "replace", "it", "with", "new", "laws", "and", "regulations.", "<tag2>", "A", "number", "of", "federal", "government", "leaders", "have", "expressed", "their", "intentions", "to", "repeal", "and", "replace", "the", "ACA.", "<tag3>"], "wordsA": ["The", "U.S.", "President", "and", "certain", "members", "of", "Congress", "have", "stated", "their", "intent", "to", "repeal", "the", "ACA", "and", "replace", "it", "with", "new", "laws", "and", "regulations."], "wordsB": ["A", "number", "of", "federal", "government", "leaders", "have", "expressed", "their", "intentions", "to", "repeal", "and", "replace", "the", "ACA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p9_s0", "idA": "908259_17_item1_p114_s1", "sentA": "We expect that there will continue to be a number of federal and state proposals addressing governmental pricing controls and the growth of health care costs, including the cost of prescription drugs.", "sentB": "Potential to be used in many different cancers: Because CA4P works by obstructing tumor blood flow, it has the potential to be used in any tumor type where there is a large number of blood vessels upon which the growth of the tumor cells depends.", "type": 2, "words": ["<tag1>", "We", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "addressing", "governmental", "pricing", "controls", "and", "the", "growth", "of", "health", "care", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "Potential", "to", "be", "used", "in", "many", "different", "cancers:", "Because", "CA4P", "works", "by", "obstructing", "tumor", "blood", "flow,", "it", "has", "the", "potential", "to", "be", "used", "in", "any", "tumor", "type", "where", "there", "is", "a", "large", "number", "of", "blood", "vessels", "upon", "which", "the", "growth", "of", "the", "tumor", "cells", "depends.", "<tag3>"], "wordsA": ["We", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "addressing", "governmental", "pricing", "controls", "and", "the", "growth", "of", "health", "care", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["Potential", "to", "be", "used", "in", "many", "different", "cancers:", "Because", "CA4P", "works", "by", "obstructing", "tumor", "blood", "flow,", "it", "has", "the", "potential", "to", "be", "used", "in", "any", "tumor", "type", "where", "there", "is", "a", "large", "number", "of", "blood", "vessels", "upon", "which", "the", "growth", "of", "the", "tumor", "cells", "depends."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p81_s2", "idA": "908259_17_item1_p114_s4", "sentA": "It is possible that the adoption of these or other alternative legislative or regulatory proposals could have a material adverse effect on our business, financial condition and results of operations.", "sentB": "As a result, we expect that there will continue to be uncertainty regarding drug product pricing, reimbursement and other factors impacting the revenue we may receive if our product candidates are ultimately approved, which could have a material adverse effect on our business, financial condition and results of operations.", "type": 2, "words": ["<tag1>", "It", "is", "possible", "that", "the", "adoption", "of", "these", "or", "other", "alternative", "legislative", "or", "regulatory", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations.", "<tag2>", "As", "a", "result,", "we", "expect", "that", "there", "will", "continue", "to", "be", "uncertainty", "regarding", "drug", "product", "pricing,", "reimbursement", "and", "other", "factors", "impacting", "the", "revenue", "we", "may", "receive", "if", "our", "product", "candidates", "are", "ultimately", "approved,", "which", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations.", "<tag3>"], "wordsA": ["It", "is", "possible", "that", "the", "adoption", "of", "these", "or", "other", "alternative", "legislative", "or", "regulatory", "proposals", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations."], "wordsB": ["As", "a", "result,", "we", "expect", "that", "there", "will", "continue", "to", "be", "uncertainty", "regarding", "drug", "product", "pricing,", "reimbursement", "and", "other", "factors", "impacting", "the", "revenue", "we", "may", "receive", "if", "our", "product", "candidates", "are", "ultimately", "approved,", "which", "could", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "financial", "condition", "and", "results", "of", "operations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p84_s2", "idA": "908259_17_item1_p117_s2", "sentA": "As of March 30, 2017, we were the exclusive licensee, sole assignee or co-assignee of twenty-one granted U.S. patents, one pending U.S. patent application, and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "sentB": "As of March 30, 2018, we were the exclusive licensee, sole assignee or co-assignee of eighteen granted U.S. patents, three pending U.S. provisional patent applications, and granted patents and/or pending applications in several other major markets, including the European Union, Canada and Japan.", "type": 2, "words": ["<tag1>", "As", "of", "March", "30,", "2017,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-one", "granted", "U.S.", "patents,", "one", "pending", "U.S.", "patent", "application,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag2>", "As", "of", "March", "30,", "2018,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "eighteen", "granted", "U.S.", "patents,", "three", "pending", "U.S.", "provisional", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan.", "<tag3>"], "wordsA": ["As", "of", "March", "30,", "2017,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "twenty-one", "granted", "U.S.", "patents,", "one", "pending", "U.S.", "patent", "application,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "wordsB": ["As", "of", "March", "30,", "2018,", "we", "were", "the", "exclusive", "licensee,", "sole", "assignee", "or", "co-assignee", "of", "eighteen", "granted", "U.S.", "patents,", "three", "pending", "U.S.", "provisional", "patent", "applications,", "and", "granted", "patents", "and/or", "pending", "applications", "in", "several", "other", "major", "markets,", "including", "the", "European", "Union,", "Canada", "and", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p90_s1", "idA": "908259_17_item1_p124_s1", "sentA": "Our competitors include, among others, major pharmaceutical, biopharmaceutical and biotechnology companies, many of which have financial, technical and marketing resources significantly greater than ours.", "sentB": "Our competitors include, among others, major pharmaceutical, biopharmaceutical and biotechnology companies, nearly all of which have financial, technical and marketing resources significantly greater than ours.", "type": 2, "words": ["<tag1>", "Our", "competitors", "include,", "among", "others,", "major", "pharmaceutical,", "biopharmaceutical", "and", "biotechnology", "companies,", "many", "of", "which", "have", "financial,", "technical", "and", "marketing", "resources", "significantly", "greater", "than", "ours.", "<tag2>", "Our", "competitors", "include,", "among", "others,", "major", "pharmaceutical,", "biopharmaceutical", "and", "biotechnology", "companies,", "nearly", "all", "of", "which", "have", "financial,", "technical", "and", "marketing", "resources", "significantly", "greater", "than", "ours.", "<tag3>"], "wordsA": ["Our", "competitors", "include,", "among", "others,", "major", "pharmaceutical,", "biopharmaceutical", "and", "biotechnology", "companies,", "many", "of", "which", "have", "financial,", "technical", "and", "marketing", "resources", "significantly", "greater", "than", "ours."], "wordsB": ["Our", "competitors", "include,", "among", "others,", "major", "pharmaceutical,", "biopharmaceutical", "and", "biotechnology", "companies,", "nearly", "all", "of", "which", "have", "financial,", "technical", "and", "marketing", "resources", "significantly", "greater", "than", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p90_s2", "idA": "908259_17_item1_p124_s2", "sentA": "In addition, many of the small companies that compete with us have also formed collaborative relationships with large, established companies to support research, development, clinical trials and commercialization of products that may be competitive with ours.", "sentB": "In addition, many of the small companies in our industry have also formed collaborative relationships with large, established companies to support research, development and commercialization of products that may be competitive with ours.", "type": 2, "words": ["<tag1>", "In", "addition,", "many", "of", "the", "small", "companies", "that", "compete", "with", "us", "have", "also", "formed", "collaborative", "relationships", "with", "large,", "established", "companies", "to", "support", "research,", "development,", "clinical", "trials", "and", "commercialization", "of", "products", "that", "may", "be", "competitive", "with", "ours.", "<tag2>", "In", "addition,", "many", "of", "the", "small", "companies", "in", "our", "industry", "have", "also", "formed", "collaborative", "relationships", "with", "large,", "established", "companies", "to", "support", "research,", "development", "and", "commercialization", "of", "products", "that", "may", "be", "competitive", "with", "ours.", "<tag3>"], "wordsA": ["In", "addition,", "many", "of", "the", "small", "companies", "that", "compete", "with", "us", "have", "also", "formed", "collaborative", "relationships", "with", "large,", "established", "companies", "to", "support", "research,", "development,", "clinical", "trials", "and", "commercialization", "of", "products", "that", "may", "be", "competitive", "with", "ours."], "wordsB": ["In", "addition,", "many", "of", "the", "small", "companies", "in", "our", "industry", "have", "also", "formed", "collaborative", "relationships", "with", "large,", "established", "companies", "to", "support", "research,", "development", "and", "commercialization", "of", "products", "that", "may", "be", "competitive", "with", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p90_s3", "idA": "908259_17_item1_p124_s3", "sentA": "Academic institutions, governmental agencies and other public and private research organizations are also conducting research activities and seeking patent protection and may commercialize products on their own or through joint ventures or other collaborations.", "sentB": "Academic institutions, governmental agencies and other public and private research organizations are also conducting research activities and patenting new technologies in our line of business and any of these entities may commercialize products that may be competitive with ours.", "type": 2, "words": ["<tag1>", "Academic", "institutions,", "governmental", "agencies", "and", "other", "public", "and", "private", "research", "organizations", "are", "also", "conducting", "research", "activities", "and", "seeking", "patent", "protection", "and", "may", "commercialize", "products", "on", "their", "own", "or", "through", "joint", "ventures", "or", "other", "collaborations.", "<tag2>", "Academic", "institutions,", "governmental", "agencies", "and", "other", "public", "and", "private", "research", "organizations", "are", "also", "conducting", "research", "activities", "and", "patenting", "new", "technologies", "in", "our", "line", "of", "business", "and", "any", "of", "these", "entities", "may", "commercialize", "products", "that", "may", "be", "competitive", "with", "ours.", "<tag3>"], "wordsA": ["Academic", "institutions,", "governmental", "agencies", "and", "other", "public", "and", "private", "research", "organizations", "are", "also", "conducting", "research", "activities", "and", "seeking", "patent", "protection", "and", "may", "commercialize", "products", "on", "their", "own", "or", "through", "joint", "ventures", "or", "other", "collaborations."], "wordsB": ["Academic", "institutions,", "governmental", "agencies", "and", "other", "public", "and", "private", "research", "organizations", "are", "also", "conducting", "research", "activities", "and", "patenting", "new", "technologies", "in", "our", "line", "of", "business", "and", "any", "of", "these", "entities", "may", "commercialize", "products", "that", "may", "be", "competitive", "with", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p90_s8", "idA": "908259_17_item1_p126_s3", "sentA": "EMPLOYEES We expect to continue to maintain a relatively small number of executives and other employees.", "sentB": "We expect to continue to maintain a relatively small number of executives and other employees.", "type": 2, "words": ["<tag1>", "EMPLOYEES", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees.", "<tag2>", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees.", "<tag3>"], "wordsA": ["EMPLOYEES", "We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees."], "wordsB": ["We", "expect", "to", "continue", "to", "maintain", "a", "relatively", "small", "number", "of", "executives", "and", "other", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p90_s6", "idA": "908259_17_item1_p126_s5", "sentA": "As of March 30, 2017, we had a total of 16 full-time employees.", "sentB": "At December 31, 2017 we had five full-time employees.", "type": 2, "words": ["<tag1>", "As", "of", "March", "30,", "2017,", "we", "had", "a", "total", "of", "16", "full-time", "employees.", "<tag2>", "At", "December", "31,", "2017", "we", "had", "five", "full-time", "employees.", "<tag3>"], "wordsA": ["As", "of", "March", "30,", "2017,", "we", "had", "a", "total", "of", "16", "full-time", "employees."], "wordsB": ["At", "December", "31,", "2017", "we", "had", "five", "full-time", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p90_s7", "idA": "908259_17_item1_p126_s5", "sentA": "As of March 30, 2017, we had a total of 16 full-time employees.", "sentB": "As of March 30, 2018, we had two full-time employees.", "type": 2, "words": ["<tag1>", "As", "of", "March", "30,", "2017,", "we", "had", "a", "total", "of", "16", "full-time", "employees.", "<tag2>", "As", "of", "March", "30,", "2018,", "we", "had", "two", "full-time", "employees.", "<tag3>"], "wordsA": ["As", "of", "March", "30,", "2017,", "we", "had", "a", "total", "of", "16", "full-time", "employees."], "wordsB": ["As", "of", "March", "30,", "2018,", "we", "had", "two", "full-time", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p6_s1", "idA": "908259_17_item1_p15_s9", "sentA": "Although the results were stronger for the platinum-resistant patients, the 80 patients who were platinum-sensitive still showed a numerical improvement in PFS for the combination therapy, with a median PFS of 7.6 months for those receiving CA4P plus bevacizumab compared to 6.1 months for those receiving bevacizumab alone, although the results were not statistically significant, with a p-value of 0.139 and a hazard ratio of 0.67.", "sentB": "This large tumor model also showed a survival benefit for the animals receiving combination therapy, with all animals in the combination surviving at the end of the study, compared to none on control and only half the animals receiving immuno-oncology agents alone.", "type": 2, "words": ["<tag1>", "Although", "the", "results", "were", "stronger", "for", "the", "platinum-resistant", "patients,", "the", "80", "patients", "who", "were", "platinum-sensitive", "still", "showed", "a", "numerical", "improvement", "in", "PFS", "for", "the", "combination", "therapy,", "with", "a", "median", "PFS", "of", "7.6", "months", "for", "those", "receiving", "CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67.", "<tag2>", "This", "large", "tumor", "model", "also", "showed", "a", "survival", "benefit", "for", "the", "animals", "receiving", "combination", "therapy,", "with", "all", "animals", "in", "the", "combination", "surviving", "at", "the", "end", "of", "the", "study,", "compared", "to", "none", "on", "control", "and", "only", "half", "the", "animals", "receiving", "immuno-oncology", "agents", "alone.", "<tag3>"], "wordsA": ["Although", "the", "results", "were", "stronger", "for", "the", "platinum-resistant", "patients,", "the", "80", "patients", "who", "were", "platinum-sensitive", "still", "showed", "a", "numerical", "improvement", "in", "PFS", "for", "the", "combination", "therapy,", "with", "a", "median", "PFS", "of", "7.6", "months", "for", "those", "receiving", "CA4P", "plus", "bevacizumab", "compared", "to", "6.1", "months", "for", "those", "receiving", "bevacizumab", "alone,", "although", "the", "results", "were", "not", "statistically", "significant,", "with", "a", "p-value", "of", "0.139", "and", "a", "hazard", "ratio", "of", "0.67."], "wordsB": ["This", "large", "tumor", "model", "also", "showed", "a", "survival", "benefit", "for", "the", "animals", "receiving", "combination", "therapy,", "with", "all", "animals", "in", "the", "combination", "surviving", "at", "the", "end", "of", "the", "study,", "compared", "to", "none", "on", "control", "and", "only", "half", "the", "animals", "receiving", "immuno-oncology", "agents", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p7_s2", "idA": "908259_17_item1_p16_s2", "sentA": "Patients with measurable disease who received the combination of CA4P and bevacizumab achieved a higher objective response rate, or ORR, a secondary endpoint in the clinical trial, measured according to RECIST criteria.", "sentB": "Tumor necrosis with the combination of CA4P and immuno-oncology agents is nearly double the necrosis with only immuno-oncology agents (63.9% compared to 32.8%, control = 25.8%).", "type": 2, "words": ["<tag1>", "Patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria.", "<tag2>", "Tumor", "necrosis", "with", "the", "combination", "of", "CA4P", "and", "immuno-oncology", "agents", "is", "nearly", "double", "the", "necrosis", "with", "only", "immuno-oncology", "agents", "(63.9%", "compared", "to", "32.8%,", "control", "=", "25.8%).", "<tag3>"], "wordsA": ["Patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria."], "wordsB": ["Tumor", "necrosis", "with", "the", "combination", "of", "CA4P", "and", "immuno-oncology", "agents", "is", "nearly", "double", "the", "necrosis", "with", "only", "immuno-oncology", "agents", "(63.9%", "compared", "to", "32.8%,", "control", "=", "25.8%)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p17_s2", "idA": "908259_17_item1_p1_s1", "sentA": "There are over 12 AAs approved in the U.S. for over 15 different oncology indications.", "sentB": "Our Strategy and Development Plan Our primary objective is to advance our investigational drugs for multiple orphan oncology indications.", "type": 2, "words": ["<tag1>", "There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications.", "<tag2>", "Our", "Strategy", "and", "Development", "Plan", "Our", "primary", "objective", "is", "to", "advance", "our", "investigational", "drugs", "for", "multiple", "orphan", "oncology", "indications.", "<tag3>"], "wordsA": ["There", "are", "over", "12", "AAs", "approved", "in", "the", "U.S.", "for", "over", "15", "different", "oncology", "indications."], "wordsB": ["Our", "Strategy", "and", "Development", "Plan", "Our", "primary", "objective", "is", "to", "advance", "our", "investigational", "drugs", "for", "multiple", "orphan", "oncology", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p4_s2", "idA": "908259_17_item1_p21_s2", "sentA": "We believe that using CA4P in combination with pazopanib may provide a clinically active yet potentially better tolerated alternative to the current standard of care, cytotoxic chemotherapy, for relapsed ovarian cancer.", "sentB": "We believe that the existing human safety database for CA4P, which includes over 500 patients, will help expedite the development timeline for advanced cancer.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "using", "CA4P", "in", "combination", "with", "pazopanib", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer.", "<tag2>", "We", "believe", "that", "the", "existing", "human", "safety", "database", "for", "CA4P,", "which", "includes", "over", "500", "patients,", "will", "help", "expedite", "the", "development", "timeline", "for", "advanced", "cancer.", "<tag3>"], "wordsA": ["We", "believe", "that", "using", "CA4P", "in", "combination", "with", "pazopanib", "may", "provide", "a", "clinically", "active", "yet", "potentially", "better", "tolerated", "alternative", "to", "the", "current", "standard", "of", "care,", "cytotoxic", "chemotherapy,", "for", "relapsed", "ovarian", "cancer."], "wordsB": ["We", "believe", "that", "the", "existing", "human", "safety", "database", "for", "CA4P,", "which", "includes", "over", "500", "patients,", "will", "help", "expedite", "the", "development", "timeline", "for", "advanced", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p22_s0", "idA": "908259_17_item1_p22_s0", "sentA": "Approximately 14,000 patients in the U.S. are diagnosed with neuroendocrine tumors, or NETs, each year.", "sentB": "Investigator Sponsored Study in Neuroendocrine Tumors Approximately 14,000 patients in the U.S. are diagnosed with neuroendocrine tumors, or NETs, each year.", "type": 2, "words": ["<tag1>", "Approximately", "14,000", "patients", "in", "the", "U.S.", "are", "diagnosed", "with", "neuroendocrine", "tumors,", "or", "NETs,", "each", "year.", "<tag2>", "Investigator", "Sponsored", "Study", "in", "Neuroendocrine", "Tumors", "Approximately", "14,000", "patients", "in", "the", "U.S.", "are", "diagnosed", "with", "neuroendocrine", "tumors,", "or", "NETs,", "each", "year.", "<tag3>"], "wordsA": ["Approximately", "14,000", "patients", "in", "the", "U.S.", "are", "diagnosed", "with", "neuroendocrine", "tumors,", "or", "NETs,", "each", "year."], "wordsB": ["Investigator", "Sponsored", "Study", "in", "Neuroendocrine", "Tumors", "Approximately", "14,000", "patients", "in", "the", "U.S.", "are", "diagnosed", "with", "neuroendocrine", "tumors,", "or", "NETs,", "each", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p23_s0", "idA": "908259_17_item1_p23_s0", "sentA": "substances including hormones, many of which are biologically active and can result in debilitating symptoms including flushing, diarrhea, weight loss and, less frequently, bronchoconstriction and heart failure.", "sentB": "These tumors can produce increased amounts of vasoactive substances including hormones, many of which are biologically active and can result in debilitating symptoms including flushing, diarrhea, weight loss and, less frequently, bronchoconstriction and heart failure.", "type": 2, "words": ["<tag1>", "substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag2>", "These", "tumors", "can", "produce", "increased", "amounts", "of", "vasoactive", "substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure.", "<tag3>"], "wordsA": ["substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "wordsB": ["These", "tumors", "can", "produce", "increased", "amounts", "of", "vasoactive", "substances", "including", "hormones,", "many", "of", "which", "are", "biologically", "active", "and", "can", "result", "in", "debilitating", "symptoms", "including", "flushing,", "diarrhea,", "weight", "loss", "and,", "less", "frequently,", "bronchoconstriction", "and", "heart", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p20_s0", "idA": "908259_17_item1_p24_s0", "sentA": "We have completed a phase 2 monotherapy clinical trial of CA4P in 18 patients with gastrointestinal or pancreatic NETs and elevated biomarkers.", "sentB": "Initiate clinical trial of CA4P in combination with an immuno-oncology agent:", "type": 2, "words": ["<tag1>", "We", "have", "completed", "a", "phase", "2", "monotherapy", "clinical", "trial", "of", "CA4P", "in", "18", "patients", "with", "gastrointestinal", "or", "pancreatic", "NETs", "and", "elevated", "biomarkers.", "<tag2>", "Initiate", "clinical", "trial", "of", "CA4P", "in", "combination", "with", "an", "immuno-oncology", "agent:", "<tag3>"], "wordsA": ["We", "have", "completed", "a", "phase", "2", "monotherapy", "clinical", "trial", "of", "CA4P", "in", "18", "patients", "with", "gastrointestinal", "or", "pancreatic", "NETs", "and", "elevated", "biomarkers."], "wordsB": ["Initiate", "clinical", "trial", "of", "CA4P", "in", "combination", "with", "an", "immuno-oncology", "agent:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p21_s1", "idA": "908259_17_item1_p25_s1", "sentA": "The partial response and stable disease analyses, as well as other measures from the trial, suggest that CA4P monotherapy has activity in this indication.", "sentB": "We have been in discussions with larger pharmaceutical companies and plan to continue these discussions for both our core programs, as well as other programs, and will seek to complete a transaction once we reach mutual agreement on terms.", "type": 2, "words": ["<tag1>", "The", "partial", "response", "and", "stable", "disease", "analyses,", "as", "well", "as", "other", "measures", "from", "the", "trial,", "suggest", "that", "CA4P", "monotherapy", "has", "activity", "in", "this", "indication.", "<tag2>", "We", "have", "been", "in", "discussions", "with", "larger", "pharmaceutical", "companies", "and", "plan", "to", "continue", "these", "discussions", "for", "both", "our", "core", "programs,", "as", "well", "as", "other", "programs,", "and", "will", "seek", "to", "complete", "a", "transaction", "once", "we", "reach", "mutual", "agreement", "on", "terms.", "<tag3>"], "wordsA": ["The", "partial", "response", "and", "stable", "disease", "analyses,", "as", "well", "as", "other", "measures", "from", "the", "trial,", "suggest", "that", "CA4P", "monotherapy", "has", "activity", "in", "this", "indication."], "wordsB": ["We", "have", "been", "in", "discussions", "with", "larger", "pharmaceutical", "companies", "and", "plan", "to", "continue", "these", "discussions", "for", "both", "our", "core", "programs,", "as", "well", "as", "other", "programs,", "and", "will", "seek", "to", "complete", "a", "transaction", "once", "we", "reach", "mutual", "agreement", "on", "terms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p25_s2", "idA": "908259_17_item1_p25_s2", "sentA": "Based on the evidence of efficacy observed in this trial, plus an understanding of the benefits of VTT combination therapy, a lead investigator in this trial is sponsoring and funding a 20 patient study in NETs using CA4P in combination with everolimus (AFINITOR , marketed by Novartis), an anti-angiogenic agent which is already approved and commonly used in this indication.", "sentB": "Based on the evidence of efficacy observed in this trial, plus an understanding of the benefits of vascular-targeted combination therapy, a lead investigator in this trial is sponsoring and funding a 20 patient study in NETs using CA4P in combination with everolimus (AFINITOR , marketed by Novartis), an anti-angiogenic agent which is already approved and commonly used in this indication.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "evidence", "of", "efficacy", "observed", "in", "this", "trial,", "plus", "an", "understanding", "of", "the", "benefits", "of", "VTT", "combination", "therapy,", "a", "lead", "investigator", "in", "this", "trial", "is", "sponsoring", "and", "funding", "a", "20", "patient", "study", "in", "NETs", "using", "CA4P", "in", "combination", "with", "everolimus", "(AFINITOR", ",", "marketed", "by", "Novartis),", "an", "anti-angiogenic", "agent", "which", "is", "already", "approved", "and", "commonly", "used", "in", "this", "indication.", "<tag2>", "Based", "on", "the", "evidence", "of", "efficacy", "observed", "in", "this", "trial,", "plus", "an", "understanding", "of", "the", "benefits", "of", "vascular-targeted", "combination", "therapy,", "a", "lead", "investigator", "in", "this", "trial", "is", "sponsoring", "and", "funding", "a", "20", "patient", "study", "in", "NETs", "using", "CA4P", "in", "combination", "with", "everolimus", "(AFINITOR", ",", "marketed", "by", "Novartis),", "an", "anti-angiogenic", "agent", "which", "is", "already", "approved", "and", "commonly", "used", "in", "this", "indication.", "<tag3>"], "wordsA": ["Based", "on", "the", "evidence", "of", "efficacy", "observed", "in", "this", "trial,", "plus", "an", "understanding", "of", "the", "benefits", "of", "VTT", "combination", "therapy,", "a", "lead", "investigator", "in", "this", "trial", "is", "sponsoring", "and", "funding", "a", "20", "patient", "study", "in", "NETs", "using", "CA4P", "in", "combination", "with", "everolimus", "(AFINITOR", ",", "marketed", "by", "Novartis),", "an", "anti-angiogenic", "agent", "which", "is", "already", "approved", "and", "commonly", "used", "in", "this", "indication."], "wordsB": ["Based", "on", "the", "evidence", "of", "efficacy", "observed", "in", "this", "trial,", "plus", "an", "understanding", "of", "the", "benefits", "of", "vascular-targeted", "combination", "therapy,", "a", "lead", "investigator", "in", "this", "trial", "is", "sponsoring", "and", "funding", "a", "20", "patient", "study", "in", "NETs", "using", "CA4P", "in", "combination", "with", "everolimus", "(AFINITOR", ",", "marketed", "by", "Novartis),", "an", "anti-angiogenic", "agent", "which", "is", "already", "approved", "and", "commonly", "used", "in", "this", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p26_s1", "idA": "908259_17_item1_p26_s1", "sentA": "Glioblastoma Multiforme We are exploring recurrent glioblastoma multiforme, or GBM, as an additional indication for CA4P because:", "sentB": "We are interested in exploring recurrent glioblastoma multiforme, or GBM, as an additional indication for CA4P because:", "type": 2, "words": ["<tag1>", "Glioblastoma", "Multiforme", "We", "are", "exploring", "recurrent", "glioblastoma", "multiforme,", "or", "GBM,", "as", "an", "additional", "indication", "for", "CA4P", "because:", "<tag2>", "We", "are", "interested", "in", "exploring", "recurrent", "glioblastoma", "multiforme,", "or", "GBM,", "as", "an", "additional", "indication", "for", "CA4P", "because:", "<tag3>"], "wordsA": ["Glioblastoma", "Multiforme", "We", "are", "exploring", "recurrent", "glioblastoma", "multiforme,", "or", "GBM,", "as", "an", "additional", "indication", "for", "CA4P", "because:"], "wordsB": ["We", "are", "interested", "in", "exploring", "recurrent", "glioblastoma", "multiforme,", "or", "GBM,", "as", "an", "additional", "indication", "for", "CA4P", "because:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p18_s4", "idA": "908259_17_item1_p28_s2", "sentA": "However, we currently do not plan to initiate a GBM clinical trial in the near term in order to conserve current resources.", "sentB": "However, we have not enrolled patients beyond the fifth cohort due to our limited cash resources.", "type": 2, "words": ["<tag1>", "However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources.", "<tag2>", "However,", "we", "have", "not", "enrolled", "patients", "beyond", "the", "fifth", "cohort", "due", "to", "our", "limited", "cash", "resources.", "<tag3>"], "wordsA": ["However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources."], "wordsB": ["However,", "we", "have", "not", "enrolled", "patients", "beyond", "the", "fifth", "cohort", "due", "to", "our", "limited", "cash", "resources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p18_s5", "idA": "908259_17_item1_p28_s2", "sentA": "However, we currently do not plan to initiate a GBM clinical trial in the near term in order to conserve current resources.", "sentB": "Subject to securing sufficient funding to continue our operations, we plan to enroll patients into a sixth cohort (12.2 mg/m2) of this trial in order to obtain additional information regarding the safety and efficacy of OXi4503.", "type": 2, "words": ["<tag1>", "However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources.", "<tag2>", "Subject", "to", "securing", "sufficient", "funding", "to", "continue", "our", "operations,", "we", "plan", "to", "enroll", "patients", "into", "a", "sixth", "cohort", "(12.2", "mg/m2)", "of", "this", "trial", "in", "order", "to", "obtain", "additional", "information", "regarding", "the", "safety", "and", "efficacy", "of", "OXi4503.", "<tag3>"], "wordsA": ["However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources."], "wordsB": ["Subject", "to", "securing", "sufficient", "funding", "to", "continue", "our", "operations,", "we", "plan", "to", "enroll", "patients", "into", "a", "sixth", "cohort", "(12.2", "mg/m2)", "of", "this", "trial", "in", "order", "to", "obtain", "additional", "information", "regarding", "the", "safety", "and", "efficacy", "of", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p20_s1", "idA": "908259_17_item1_p28_s2", "sentA": "However, we currently do not plan to initiate a GBM clinical trial in the near term in order to conserve current resources.", "sentB": "Based on preclinical data generated to date and support of two well-known immuno-oncology clinical investigators, we intend to initiate the first human clinical trial combining CA4P and an approved immuno-oncology agent in order to make initial determinations of whether the combination results in improved patient outcomes.", "type": 2, "words": ["<tag1>", "However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources.", "<tag2>", "Based", "on", "preclinical", "data", "generated", "to", "date", "and", "support", "of", "two", "well-known", "immuno-oncology", "clinical", "investigators,", "we", "intend", "to", "initiate", "the", "first", "human", "clinical", "trial", "combining", "CA4P", "and", "an", "approved", "immuno-oncology", "agent", "in", "order", "to", "make", "initial", "determinations", "of", "whether", "the", "combination", "results", "in", "improved", "patient", "outcomes.", "<tag3>"], "wordsA": ["However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources."], "wordsB": ["Based", "on", "preclinical", "data", "generated", "to", "date", "and", "support", "of", "two", "well-known", "immuno-oncology", "clinical", "investigators,", "we", "intend", "to", "initiate", "the", "first", "human", "clinical", "trial", "combining", "CA4P", "and", "an", "approved", "immuno-oncology", "agent", "in", "order", "to", "make", "initial", "determinations", "of", "whether", "the", "combination", "results", "in", "improved", "patient", "outcomes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p4_s0", "idA": "908259_17_item1_p28_s2", "sentA": "However, we currently do not plan to initiate a GBM clinical trial in the near term in order to conserve current resources.", "sentB": "The next step in the process of establishing CA4P as a safe and effective immuno-oncology agent will be to initiate a clinical study in a disease in which immuno-oncology agents are used as standard therapy.", "type": 2, "words": ["<tag1>", "However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources.", "<tag2>", "The", "next", "step", "in", "the", "process", "of", "establishing", "CA4P", "as", "a", "safe", "and", "effective", "immuno-oncology", "agent", "will", "be", "to", "initiate", "a", "clinical", "study", "in", "a", "disease", "in", "which", "immuno-oncology", "agents", "are", "used", "as", "standard", "therapy.", "<tag3>"], "wordsA": ["However,", "we", "currently", "do", "not", "plan", "to", "initiate", "a", "GBM", "clinical", "trial", "in", "the", "near", "term", "in", "order", "to", "conserve", "current", "resources."], "wordsB": ["The", "next", "step", "in", "the", "process", "of", "establishing", "CA4P", "as", "a", "safe", "and", "effective", "immuno-oncology", "agent", "will", "be", "to", "initiate", "a", "clinical", "study", "in", "a", "disease", "in", "which", "immuno-oncology", "agents", "are", "used", "as", "standard", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p0_s2", "idA": "908259_17_item1_p2_s1", "sentA": "We are seeking to realize the full potential of VTTs in oncology by using the combination of VDAs and AAs to treat cancer.", "sentB": "We have two primary programs we are seeking to advance:", "type": 2, "words": ["<tag1>", "We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer.", "<tag2>", "We", "have", "two", "primary", "programs", "we", "are", "seeking", "to", "advance:", "<tag3>"], "wordsA": ["We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer."], "wordsB": ["We", "have", "two", "primary", "programs", "we", "are", "seeking", "to", "advance:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p3_s1", "idA": "908259_17_item1_p2_s2", "sentA": "Our VDAs have been shown to rapidly cut off the blood supply to the tumor, which causes necrosis, or death, of the cancer cells in the interior of the tumor.", "sentB": "This tumor-specific necrosis stimulates the immune system against the tumor.", "type": 2, "words": ["<tag1>", "Our", "VDAs", "have", "been", "shown", "to", "rapidly", "cut", "off", "the", "blood", "supply", "to", "the", "tumor,", "which", "causes", "necrosis,", "or", "death,", "of", "the", "cancer", "cells", "in", "the", "interior", "of", "the", "tumor.", "<tag2>", "This", "tumor-specific", "necrosis", "stimulates", "the", "immune", "system", "against", "the", "tumor.", "<tag3>"], "wordsA": ["Our", "VDAs", "have", "been", "shown", "to", "rapidly", "cut", "off", "the", "blood", "supply", "to", "the", "tumor,", "which", "causes", "necrosis,", "or", "death,", "of", "the", "cancer", "cells", "in", "the", "interior", "of", "the", "tumor."], "wordsB": ["This", "tumor-specific", "necrosis", "stimulates", "the", "immune", "system", "against", "the", "tumor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p3_s0", "idA": "908259_17_item1_p2_s4", "sentA": "If a VDA were given in the absence of an AA, angiogenesis would allow new blood vessels to re-vascularize the tumor, including the interior where the VDA had caused tumor cell necrosis.", "sentB": "CA4P causes rapid and widespread tumor cell necrosis.", "type": 2, "words": ["<tag1>", "If", "a", "VDA", "were", "given", "in", "the", "absence", "of", "an", "AA,", "angiogenesis", "would", "allow", "new", "blood", "vessels", "to", "re-vascularize", "the", "tumor,", "including", "the", "interior", "where", "the", "VDA", "had", "caused", "tumor", "cell", "necrosis.", "<tag2>", "CA4P", "causes", "rapid", "and", "widespread", "tumor", "cell", "necrosis.", "<tag3>"], "wordsA": ["If", "a", "VDA", "were", "given", "in", "the", "absence", "of", "an", "AA,", "angiogenesis", "would", "allow", "new", "blood", "vessels", "to", "re-vascularize", "the", "tumor,", "including", "the", "interior", "where", "the", "VDA", "had", "caused", "tumor", "cell", "necrosis."], "wordsB": ["CA4P", "causes", "rapid", "and", "widespread", "tumor", "cell", "necrosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p12_s1", "idA": "908259_17_item1_p31_s0", "sentA": "NSCLC accounts for most cases of lung cancer, and generally does not respond well to chemotherapy.", "sentB": "Over the past 20 years, no new therapies have consistently improved patient outcomes in this indication when compared to chemotherapy.", "type": 2, "words": ["<tag1>", "NSCLC", "accounts", "for", "most", "cases", "of", "lung", "cancer,", "and", "generally", "does", "not", "respond", "well", "to", "chemotherapy.", "<tag2>", "Over", "the", "past", "20", "years,", "no", "new", "therapies", "have", "consistently", "improved", "patient", "outcomes", "in", "this", "indication", "when", "compared", "to", "chemotherapy.", "<tag3>"], "wordsA": ["NSCLC", "accounts", "for", "most", "cases", "of", "lung", "cancer,", "and", "generally", "does", "not", "respond", "well", "to", "chemotherapy."], "wordsB": ["Over", "the", "past", "20", "years,", "no", "new", "therapies", "have", "consistently", "improved", "patient", "outcomes", "in", "this", "indication", "when", "compared", "to", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p2_s0", "idA": "908259_17_item1_p33_s0", "sentA": "Combination with Immune Oncology Agents Preclinical Research Over the last several years, there have been considerable advances in cancer immunotherapy, which makes use of the immune system to treat cancer.", "sentB": "CA4P as an Immuno-oncology Agent Over the last several years, there have been significant advances in cancer immunotherapy, which makes use of the immune system to treat cancer.", "type": 2, "words": ["<tag1>", "Combination", "with", "Immune", "Oncology", "Agents", "Preclinical", "Research", "Over", "the", "last", "several", "years,", "there", "have", "been", "considerable", "advances", "in", "cancer", "immunotherapy,", "which", "makes", "use", "of", "the", "immune", "system", "to", "treat", "cancer.", "<tag2>", "CA4P", "as", "an", "Immuno-oncology", "Agent", "Over", "the", "last", "several", "years,", "there", "have", "been", "significant", "advances", "in", "cancer", "immunotherapy,", "which", "makes", "use", "of", "the", "immune", "system", "to", "treat", "cancer.", "<tag3>"], "wordsA": ["Combination", "with", "Immune", "Oncology", "Agents", "Preclinical", "Research", "Over", "the", "last", "several", "years,", "there", "have", "been", "considerable", "advances", "in", "cancer", "immunotherapy,", "which", "makes", "use", "of", "the", "immune", "system", "to", "treat", "cancer."], "wordsB": ["CA4P", "as", "an", "Immuno-oncology", "Agent", "Over", "the", "last", "several", "years,", "there", "have", "been", "significant", "advances", "in", "cancer", "immunotherapy,", "which", "makes", "use", "of", "the", "immune", "system", "to", "treat", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p2_s2", "idA": "908259_17_item1_p33_s1", "sentA": "However, these immune oncology agents have significant limitations when used as single agents to treat cancer, since relatively few patients achieve a durable clinical response following treatment.", "sentB": "Despite these advances, current FDA-approved immuno-oncology agents have significant limitations when used alone to treat cancer, since relatively few patients achieve a durable clinical response following treatment.", "type": 2, "words": ["<tag1>", "However,", "these", "immune", "oncology", "agents", "have", "significant", "limitations", "when", "used", "as", "single", "agents", "to", "treat", "cancer,", "since", "relatively", "few", "patients", "achieve", "a", "durable", "clinical", "response", "following", "treatment.", "<tag2>", "Despite", "these", "advances,", "current", "FDA-approved", "immuno-oncology", "agents", "have", "significant", "limitations", "when", "used", "alone", "to", "treat", "cancer,", "since", "relatively", "few", "patients", "achieve", "a", "durable", "clinical", "response", "following", "treatment.", "<tag3>"], "wordsA": ["However,", "these", "immune", "oncology", "agents", "have", "significant", "limitations", "when", "used", "as", "single", "agents", "to", "treat", "cancer,", "since", "relatively", "few", "patients", "achieve", "a", "durable", "clinical", "response", "following", "treatment."], "wordsB": ["Despite", "these", "advances,", "current", "FDA-approved", "immuno-oncology", "agents", "have", "significant", "limitations", "when", "used", "alone", "to", "treat", "cancer,", "since", "relatively", "few", "patients", "achieve", "a", "durable", "clinical", "response", "following", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p3_s2", "idA": "908259_17_item1_p34_s0", "sentA": "Because CA4P causes tumor cell necrosis within hours of its administration, we believe it may in turn release into the circulation tumor antigens that enhance the immune system, and consequently enhance the presence and activity of T-cells within tumors.", "sentB": "Animal models also show that CA4P significantly enhances the presence and activity of cancer-fighting T-cells within tumors, resulting in increased tumor cell death and tumor regressions.", "type": 2, "words": ["<tag1>", "Because", "CA4P", "causes", "tumor", "cell", "necrosis", "within", "hours", "of", "its", "administration,", "we", "believe", "it", "may", "in", "turn", "release", "into", "the", "circulation", "tumor", "antigens", "that", "enhance", "the", "immune", "system,", "and", "consequently", "enhance", "the", "presence", "and", "activity", "of", "T-cells", "within", "tumors.", "<tag2>", "Animal", "models", "also", "show", "that", "CA4P", "significantly", "enhances", "the", "presence", "and", "activity", "of", "cancer-fighting", "T-cells", "within", "tumors,", "resulting", "in", "increased", "tumor", "cell", "death", "and", "tumor", "regressions.", "<tag3>"], "wordsA": ["Because", "CA4P", "causes", "tumor", "cell", "necrosis", "within", "hours", "of", "its", "administration,", "we", "believe", "it", "may", "in", "turn", "release", "into", "the", "circulation", "tumor", "antigens", "that", "enhance", "the", "immune", "system,", "and", "consequently", "enhance", "the", "presence", "and", "activity", "of", "T-cells", "within", "tumors."], "wordsB": ["Animal", "models", "also", "show", "that", "CA4P", "significantly", "enhances", "the", "presence", "and", "activity", "of", "cancer-fighting", "T-cells", "within", "tumors,", "resulting", "in", "increased", "tumor", "cell", "death", "and", "tumor", "regressions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p3_s3", "idA": "908259_17_item1_p34_s1", "sentA": "We believe CA4P s potential enhanced immunologic effect may result in more and/or better clinical responses in certain cancers when combined with immune oncology agents, including in patients who have not experienced a response to therapy with immune oncology agents alone.", "sentB": "Given these data, we believe CA4P may result in more and/or better clinical responses in certain cancers when combined with immuno-oncology agents, including in patients who either have not experienced a response to therapy, or in patients who have initially responded but subsequently progressed after treatment with immuno-oncology agents alone.", "type": 2, "words": ["<tag1>", "We", "believe", "CA4P", "s", "potential", "enhanced", "immunologic", "effect", "may", "result", "in", "more", "and/or", "better", "clinical", "responses", "in", "certain", "cancers", "when", "combined", "with", "immune", "oncology", "agents,", "including", "in", "patients", "who", "have", "not", "experienced", "a", "response", "to", "therapy", "with", "immune", "oncology", "agents", "alone.", "<tag2>", "Given", "these", "data,", "we", "believe", "CA4P", "may", "result", "in", "more", "and/or", "better", "clinical", "responses", "in", "certain", "cancers", "when", "combined", "with", "immuno-oncology", "agents,", "including", "in", "patients", "who", "either", "have", "not", "experienced", "a", "response", "to", "therapy,", "or", "in", "patients", "who", "have", "initially", "responded", "but", "subsequently", "progressed", "after", "treatment", "with", "immuno-oncology", "agents", "alone.", "<tag3>"], "wordsA": ["We", "believe", "CA4P", "s", "potential", "enhanced", "immunologic", "effect", "may", "result", "in", "more", "and/or", "better", "clinical", "responses", "in", "certain", "cancers", "when", "combined", "with", "immune", "oncology", "agents,", "including", "in", "patients", "who", "have", "not", "experienced", "a", "response", "to", "therapy", "with", "immune", "oncology", "agents", "alone."], "wordsB": ["Given", "these", "data,", "we", "believe", "CA4P", "may", "result", "in", "more", "and/or", "better", "clinical", "responses", "in", "certain", "cancers", "when", "combined", "with", "immuno-oncology", "agents,", "including", "in", "patients", "who", "either", "have", "not", "experienced", "a", "response", "to", "therapy,", "or", "in", "patients", "who", "have", "initially", "responded", "but", "subsequently", "progressed", "after", "treatment", "with", "immuno-oncology", "agents", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p17_s5", "idA": "908259_17_item1_p34_s2", "sentA": "We have completed several preclinical studies evaluating CA4P in combination with immune oncology agents.", "sentB": "In our immuno-oncology program, our aim is to obtain our first clinical data of CA4P in combination with immuno-oncology agents.", "type": 2, "words": ["<tag1>", "We", "have", "completed", "several", "preclinical", "studies", "evaluating", "CA4P", "in", "combination", "with", "immune", "oncology", "agents.", "<tag2>", "In", "our", "immuno-oncology", "program,", "our", "aim", "is", "to", "obtain", "our", "first", "clinical", "data", "of", "CA4P", "in", "combination", "with", "immuno-oncology", "agents.", "<tag3>"], "wordsA": ["We", "have", "completed", "several", "preclinical", "studies", "evaluating", "CA4P", "in", "combination", "with", "immune", "oncology", "agents."], "wordsB": ["In", "our", "immuno-oncology", "program,", "our", "aim", "is", "to", "obtain", "our", "first", "clinical", "data", "of", "CA4P", "in", "combination", "with", "immuno-oncology", "agents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p4_s1", "idA": "908259_17_item1_p34_s2", "sentA": "We have completed several preclinical studies evaluating CA4P in combination with immune oncology agents.", "sentB": "This clinical study will evaluate CA4P in combination with currently approved immuno-oncology agents in patients with advanced cancer who have previously failed treatment.", "type": 2, "words": ["<tag1>", "We", "have", "completed", "several", "preclinical", "studies", "evaluating", "CA4P", "in", "combination", "with", "immune", "oncology", "agents.", "<tag2>", "This", "clinical", "study", "will", "evaluate", "CA4P", "in", "combination", "with", "currently", "approved", "immuno-oncology", "agents", "in", "patients", "with", "advanced", "cancer", "who", "have", "previously", "failed", "treatment.", "<tag3>"], "wordsA": ["We", "have", "completed", "several", "preclinical", "studies", "evaluating", "CA4P", "in", "combination", "with", "immune", "oncology", "agents."], "wordsB": ["This", "clinical", "study", "will", "evaluate", "CA4P", "in", "combination", "with", "currently", "approved", "immuno-oncology", "agents", "in", "patients", "with", "advanced", "cancer", "who", "have", "previously", "failed", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p7_s4", "idA": "908259_17_item1_p34_s2", "sentA": "We have completed several preclinical studies evaluating CA4P in combination with immune oncology agents.", "sentB": "We believe CA4P offers the following potential benefits when used in combination with immuno-oncology agents:", "type": 2, "words": ["<tag1>", "We", "have", "completed", "several", "preclinical", "studies", "evaluating", "CA4P", "in", "combination", "with", "immune", "oncology", "agents.", "<tag2>", "We", "believe", "CA4P", "offers", "the", "following", "potential", "benefits", "when", "used", "in", "combination", "with", "immuno-oncology", "agents:", "<tag3>"], "wordsA": ["We", "have", "completed", "several", "preclinical", "studies", "evaluating", "CA4P", "in", "combination", "with", "immune", "oncology", "agents."], "wordsB": ["We", "believe", "CA4P", "offers", "the", "following", "potential", "benefits", "when", "used", "in", "combination", "with", "immuno-oncology", "agents:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p4_s4", "idA": "908259_17_item1_p34_s3", "sentA": "Of these studies, the best results were found combining CA4P with an anti-CTLA4 antibody in an EMT-6 mammary tumor model.", "sentB": "One of these studies combined CA4P with an anti-CTLA4 antibody, an approved and well-known immuno-oncology agent, in an EMT-6 mammary tumor model.", "type": 2, "words": ["<tag1>", "Of", "these", "studies,", "the", "best", "results", "were", "found", "combining", "CA4P", "with", "an", "anti-CTLA4", "antibody", "in", "an", "EMT-6", "mammary", "tumor", "model.", "<tag2>", "One", "of", "these", "studies", "combined", "CA4P", "with", "an", "anti-CTLA4", "antibody,", "an", "approved", "and", "well-known", "immuno-oncology", "agent,", "in", "an", "EMT-6", "mammary", "tumor", "model.", "<tag3>"], "wordsA": ["Of", "these", "studies,", "the", "best", "results", "were", "found", "combining", "CA4P", "with", "an", "anti-CTLA4", "antibody", "in", "an", "EMT-6", "mammary", "tumor", "model."], "wordsB": ["One", "of", "these", "studies", "combined", "CA4P", "with", "an", "anti-CTLA4", "antibody,", "an", "approved", "and", "well-known", "immuno-oncology", "agent,", "in", "an", "EMT-6", "mammary", "tumor", "model."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p5_s0", "idA": "908259_17_item1_p34_s5", "sentA": "Three of four follow-up studies have also indicated that CA4P combined with immune oncology agents can delay tumor growth these studies were conducted in a larger tumor EMT-6 mammary model, a C3H mammary model and a CT26 colon model, providing additional supportive evidence that CA4P may enhance anti-CTLA4 antibody activity, as well as initial evidence that CA4P may enhance anti PD-1 and PD-L1 activity.", "sentB": "Three of four follow-up preclinical studies confirmed that CA4P combined with immuno-oncology agents could delay tumor growth.", "type": 2, "words": ["<tag1>", "Three", "of", "four", "follow-up", "studies", "have", "also", "indicated", "that", "CA4P", "combined", "with", "immune", "oncology", "agents", "can", "delay", "tumor", "growth", "these", "studies", "were", "conducted", "in", "a", "larger", "tumor", "EMT-6", "mammary", "model,", "a", "C3H", "mammary", "model", "and", "a", "CT26", "colon", "model,", "providing", "additional", "supportive", "evidence", "that", "CA4P", "may", "enhance", "anti-CTLA4", "antibody", "activity,", "as", "well", "as", "initial", "evidence", "that", "CA4P", "may", "enhance", "anti", "PD-1", "and", "PD-L1", "activity.", "<tag2>", "Three", "of", "four", "follow-up", "preclinical", "studies", "confirmed", "that", "CA4P", "combined", "with", "immuno-oncology", "agents", "could", "delay", "tumor", "growth.", "<tag3>"], "wordsA": ["Three", "of", "four", "follow-up", "studies", "have", "also", "indicated", "that", "CA4P", "combined", "with", "immune", "oncology", "agents", "can", "delay", "tumor", "growth", "these", "studies", "were", "conducted", "in", "a", "larger", "tumor", "EMT-6", "mammary", "model,", "a", "C3H", "mammary", "model", "and", "a", "CT26", "colon", "model,", "providing", "additional", "supportive", "evidence", "that", "CA4P", "may", "enhance", "anti-CTLA4", "antibody", "activity,", "as", "well", "as", "initial", "evidence", "that", "CA4P", "may", "enhance", "anti", "PD-1", "and", "PD-L1", "activity."], "wordsB": ["Three", "of", "four", "follow-up", "preclinical", "studies", "confirmed", "that", "CA4P", "combined", "with", "immuno-oncology", "agents", "could", "delay", "tumor", "growth."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p5_s1", "idA": "908259_17_item1_p34_s5", "sentA": "Three of four follow-up studies have also indicated that CA4P combined with immune oncology agents can delay tumor growth these studies were conducted in a larger tumor EMT-6 mammary model, a C3H mammary model and a CT26 colon model, providing additional supportive evidence that CA4P may enhance anti-CTLA4 antibody activity, as well as initial evidence that CA4P may enhance anti PD-1 and PD-L1 activity.", "sentB": "These follow-up studies were conducted in a CT26 colon cancer model, a larger tumor EMT-6 mammary cancer model, and a C3H mammary cancer model.", "type": 2, "words": ["<tag1>", "Three", "of", "four", "follow-up", "studies", "have", "also", "indicated", "that", "CA4P", "combined", "with", "immune", "oncology", "agents", "can", "delay", "tumor", "growth", "these", "studies", "were", "conducted", "in", "a", "larger", "tumor", "EMT-6", "mammary", "model,", "a", "C3H", "mammary", "model", "and", "a", "CT26", "colon", "model,", "providing", "additional", "supportive", "evidence", "that", "CA4P", "may", "enhance", "anti-CTLA4", "antibody", "activity,", "as", "well", "as", "initial", "evidence", "that", "CA4P", "may", "enhance", "anti", "PD-1", "and", "PD-L1", "activity.", "<tag2>", "These", "follow-up", "studies", "were", "conducted", "in", "a", "CT26", "colon", "cancer", "model,", "a", "larger", "tumor", "EMT-6", "mammary", "cancer", "model,", "and", "a", "C3H", "mammary", "cancer", "model.", "<tag3>"], "wordsA": ["Three", "of", "four", "follow-up", "studies", "have", "also", "indicated", "that", "CA4P", "combined", "with", "immune", "oncology", "agents", "can", "delay", "tumor", "growth", "these", "studies", "were", "conducted", "in", "a", "larger", "tumor", "EMT-6", "mammary", "model,", "a", "C3H", "mammary", "model", "and", "a", "CT26", "colon", "model,", "providing", "additional", "supportive", "evidence", "that", "CA4P", "may", "enhance", "anti-CTLA4", "antibody", "activity,", "as", "well", "as", "initial", "evidence", "that", "CA4P", "may", "enhance", "anti", "PD-1", "and", "PD-L1", "activity."], "wordsB": ["These", "follow-up", "studies", "were", "conducted", "in", "a", "CT26", "colon", "cancer", "model,", "a", "larger", "tumor", "EMT-6", "mammary", "cancer", "model,", "and", "a", "C3H", "mammary", "cancer", "model."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p14_s3", "idA": "908259_17_item1_p35_s1", "sentA": "OXi4503 has shown potent anti-tumor activity in preclinical studies of solid tumors and AML, and in two clinical studies in advanced solid tumors and liver tumors, both as a single agent and in combination with other anti-proliferative agents.", "sentB": "In early clinical studies, OXi4503 has shown complete responses in high risk patients both as a monotherapy and in combination with cytarabine.", "type": 2, "words": ["<tag1>", "OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents.", "<tag2>", "In", "early", "clinical", "studies,", "OXi4503", "has", "shown", "complete", "responses", "in", "high", "risk", "patients", "both", "as", "a", "monotherapy", "and", "in", "combination", "with", "cytarabine.", "<tag3>"], "wordsA": ["OXi4503", "has", "shown", "potent", "anti-tumor", "activity", "in", "preclinical", "studies", "of", "solid", "tumors", "and", "AML,", "and", "in", "two", "clinical", "studies", "in", "advanced", "solid", "tumors", "and", "liver", "tumors,", "both", "as", "a", "single", "agent", "and", "in", "combination", "with", "other", "anti-proliferative", "agents."], "wordsB": ["In", "early", "clinical", "studies,", "OXi4503", "has", "shown", "complete", "responses", "in", "high", "risk", "patients", "both", "as", "a", "monotherapy", "and", "in", "combination", "with", "cytarabine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p11_s0", "idA": "908259_17_item1_p36_s0", "sentA": "Acute Myeloid Leukemia AML is a cancer of the myeloid blood cells, with approximately 10,500 new cases each year in the U.S. AML is characterized by the rapid growth of abnormal white blood cells that pollute bone marrow and interfere with the production of normal blood cells.", "sentB": "OXi4503 for Acute Myeloid Leukemia Acute myeloid leukemia, or AML, is a cancer of the myeloid blood cells, with approximately 21,000 new cases each year in the U.S. and approximately 10,500 deaths.", "type": 2, "words": ["<tag1>", "Acute", "Myeloid", "Leukemia", "AML", "is", "a", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "U.S.", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells.", "<tag2>", "OXi4503", "for", "Acute", "Myeloid", "Leukemia", "Acute", "myeloid", "leukemia,", "or", "AML,", "is", "a", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "21,000", "new", "cases", "each", "year", "in", "the", "U.S.", "and", "approximately", "10,500", "deaths.", "<tag3>"], "wordsA": ["Acute", "Myeloid", "Leukemia", "AML", "is", "a", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "U.S.", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells."], "wordsB": ["OXi4503", "for", "Acute", "Myeloid", "Leukemia", "Acute", "myeloid", "leukemia,", "or", "AML,", "is", "a", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "21,000", "new", "cases", "each", "year", "in", "the", "U.S.", "and", "approximately", "10,500", "deaths."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p11_s1", "idA": "908259_17_item1_p36_s0", "sentA": "Acute Myeloid Leukemia AML is a cancer of the myeloid blood cells, with approximately 10,500 new cases each year in the U.S. AML is characterized by the rapid growth of abnormal white blood cells that pollute bone marrow and interfere with the production of normal blood cells.", "sentB": "AML is characterized by the rapid growth of abnormal white blood cells that pollute bone marrow and interfere with the production of normal blood cells.", "type": 2, "words": ["<tag1>", "Acute", "Myeloid", "Leukemia", "AML", "is", "a", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "U.S.", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells.", "<tag2>", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells.", "<tag3>"], "wordsA": ["Acute", "Myeloid", "Leukemia", "AML", "is", "a", "cancer", "of", "the", "myeloid", "blood", "cells,", "with", "approximately", "10,500", "new", "cases", "each", "year", "in", "the", "U.S.", "AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells."], "wordsB": ["AML", "is", "characterized", "by", "the", "rapid", "growth", "of", "abnormal", "white", "blood", "cells", "that", "pollute", "bone", "marrow", "and", "interfere", "with", "the", "production", "of", "normal", "blood", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p11_s2", "idA": "908259_17_item1_p36_s1", "sentA": "OXi4503 has been granted orphan drug designation in both the U.S. and the European Union for the treatment of AML.", "sentB": "OXi4503 has been granted orphan drug designation in both the U.S. and the European Union for the treatment of AML, and has received Fast Track designation from the FDA for the treatment of AML.", "type": 2, "words": ["<tag1>", "OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML.", "<tag2>", "OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML,", "and", "has", "received", "Fast", "Track", "designation", "from", "the", "FDA", "for", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML."], "wordsB": ["OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML,", "and", "has", "received", "Fast", "Track", "designation", "from", "the", "FDA", "for", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p14_s2", "idA": "908259_17_item1_p36_s1", "sentA": "OXi4503 has been granted orphan drug designation in both the U.S. and the European Union for the treatment of AML.", "sentB": "In preclinical studies, OXi4503 has been shown to enhance the efficacy of cytarabine, idarubucin, azacitidine, and decitabine, which are each commonly-used chemotherapeutic agents for the treatment of many cancers, including AML.", "type": 2, "words": ["<tag1>", "OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML.", "<tag2>", "In", "preclinical", "studies,", "OXi4503", "has", "been", "shown", "to", "enhance", "the", "efficacy", "of", "cytarabine,", "idarubucin,", "azacitidine,", "and", "decitabine,", "which", "are", "each", "commonly-used", "chemotherapeutic", "agents", "for", "the", "treatment", "of", "many", "cancers,", "including", "AML.", "<tag3>"], "wordsA": ["OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML."], "wordsB": ["In", "preclinical", "studies,", "OXi4503", "has", "been", "shown", "to", "enhance", "the", "efficacy", "of", "cytarabine,", "idarubucin,", "azacitidine,", "and", "decitabine,", "which", "are", "each", "commonly-used", "chemotherapeutic", "agents", "for", "the", "treatment", "of", "many", "cancers,", "including", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p15_s0", "idA": "908259_17_item1_p36_s1", "sentA": "OXi4503 has been granted orphan drug designation in both the U.S. and the European Union for the treatment of AML.", "sentB": "A unique approach for AML: We believe that disrupting bone marrow tumor vessels for the treatment of AML is a new approach for a difficult to treat disease, with few competing clinical programs.", "type": 2, "words": ["<tag1>", "OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML.", "<tag2>", "A", "unique", "approach", "for", "AML:", "We", "believe", "that", "disrupting", "bone", "marrow", "tumor", "vessels", "for", "the", "treatment", "of", "AML", "is", "a", "new", "approach", "for", "a", "difficult", "to", "treat", "disease,", "with", "few", "competing", "clinical", "programs.", "<tag3>"], "wordsA": ["OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML."], "wordsB": ["A", "unique", "approach", "for", "AML:", "We", "believe", "that", "disrupting", "bone", "marrow", "tumor", "vessels", "for", "the", "treatment", "of", "AML", "is", "a", "new", "approach", "for", "a", "difficult", "to", "treat", "disease,", "with", "few", "competing", "clinical", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p17_s3", "idA": "908259_17_item1_p36_s1", "sentA": "OXi4503 has been granted orphan drug designation in both the U.S. and the European Union for the treatment of AML.", "sentB": "We are currently focused on two core programs CA4P as an immuno-oncology agent and OXi4503 for the treatment of AML.", "type": 2, "words": ["<tag1>", "OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML.", "<tag2>", "We", "are", "currently", "focused", "on", "two", "core", "programs", "CA4P", "as", "an", "immuno-oncology", "agent", "and", "OXi4503", "for", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["OXi4503", "has", "been", "granted", "orphan", "drug", "designation", "in", "both", "the", "U.S.", "and", "the", "European", "Union", "for", "the", "treatment", "of", "AML."], "wordsB": ["We", "are", "currently", "focused", "on", "two", "core", "programs", "CA4P", "as", "an", "immuno-oncology", "agent", "and", "OXi4503", "for", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p19_s0", "idA": "908259_17_item1_p38_s0", "sentA": "designed to assess the safety profile, maximum tolerated dose and biologic activity of OXi4503.", "sentB": "we have seen signs of efficacy, we are planning to expand the sixth and future cohorts to approximately 10 patients per cohort in order to better assess the potential efficacy of OXi4503.", "type": 2, "words": ["<tag1>", "designed", "to", "assess", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503.", "<tag2>", "we", "have", "seen", "signs", "of", "efficacy,", "we", "are", "planning", "to", "expand", "the", "sixth", "and", "future", "cohorts", "to", "approximately", "10", "patients", "per", "cohort", "in", "order", "to", "better", "assess", "the", "potential", "efficacy", "of", "OXi4503.", "<tag3>"], "wordsA": ["designed", "to", "assess", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503."], "wordsB": ["we", "have", "seen", "signs", "of", "efficacy,", "we", "are", "planning", "to", "expand", "the", "sixth", "and", "future", "cohorts", "to", "approximately", "10", "patients", "per", "cohort", "in", "order", "to", "better", "assess", "the", "potential", "efficacy", "of", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p7_s0", "idA": "908259_17_item1_p39_s0", "sentA": "Initial data from UF4503 was presented at the December 2013 annual meeting of the American Society of Hematology, or ASH.", "sentB": "Initial data in an MC38 colon cancer model showed that when CA4P is combined with an anti-PD1 antibody there was a 53% reduction in tumor volume at the end of the study, compared with a 16% reduction for CA4P alone and a 15% reduction for the anti-PD1 antibody alone.", "type": 2, "words": ["<tag1>", "Initial", "data", "from", "UF4503", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH.", "<tag2>", "Initial", "data", "in", "an", "MC38", "colon", "cancer", "model", "showed", "that", "when", "CA4P", "is", "combined", "with", "an", "anti-PD1", "antibody", "there", "was", "a", "53%", "reduction", "in", "tumor", "volume", "at", "the", "end", "of", "the", "study,", "compared", "with", "a", "16%", "reduction", "for", "CA4P", "alone", "and", "a", "15%", "reduction", "for", "the", "anti-PD1", "antibody", "alone.", "<tag3>"], "wordsA": ["Initial", "data", "from", "UF4503", "was", "presented", "at", "the", "December", "2013", "annual", "meeting", "of", "the", "American", "Society", "of", "Hematology,", "or", "ASH."], "wordsB": ["Initial", "data", "in", "an", "MC38", "colon", "cancer", "model", "showed", "that", "when", "CA4P", "is", "combined", "with", "an", "anti-PD1", "antibody", "there", "was", "a", "53%", "reduction", "in", "tumor", "volume", "at", "the", "end", "of", "the", "study,", "compared", "with", "a", "16%", "reduction", "for", "CA4P", "alone", "and", "a", "15%", "reduction", "for", "the", "anti-PD1", "antibody", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p12_s3", "idA": "908259_17_item1_p41_s0", "sentA": "In December 2015 we initiated the second stage of OX1222, in which ascending doses of OXi4503 are being used in combination with cytarabine, an FDA-approved drug for the treatment of AML.", "sentB": "We have initiated Study OX1222, a clinical trial using escalating doses of OXi4503 in combination with cytarabine to treat relapsed/ refractory AML.", "type": 2, "words": ["<tag1>", "In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML.", "<tag2>", "We", "have", "initiated", "Study", "OX1222,", "a", "clinical", "trial", "using", "escalating", "doses", "of", "OXi4503", "in", "combination", "with", "cytarabine", "to", "treat", "relapsed/", "refractory", "AML.", "<tag3>"], "wordsA": ["In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML."], "wordsB": ["We", "have", "initiated", "Study", "OX1222,", "a", "clinical", "trial", "using", "escalating", "doses", "of", "OXi4503", "in", "combination", "with", "cytarabine", "to", "treat", "relapsed/", "refractory", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p16_s0", "idA": "908259_17_item1_p41_s0", "sentA": "In December 2015 we initiated the second stage of OX1222, in which ascending doses of OXi4503 are being used in combination with cytarabine, an FDA-approved drug for the treatment of AML.", "sentB": "A safer alternative to high dose chemotherapy: Many patients, especially those that are older, such as those over age 60, cannot tolerate high dose chemotherapy used in the treatment of AML.", "type": 2, "words": ["<tag1>", "In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML.", "<tag2>", "A", "safer", "alternative", "to", "high", "dose", "chemotherapy:", "Many", "patients,", "especially", "those", "that", "are", "older,", "such", "as", "those", "over", "age", "60,", "cannot", "tolerate", "high", "dose", "chemotherapy", "used", "in", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML."], "wordsB": ["A", "safer", "alternative", "to", "high", "dose", "chemotherapy:", "Many", "patients,", "especially", "those", "that", "are", "older,", "such", "as", "those", "over", "age", "60,", "cannot", "tolerate", "high", "dose", "chemotherapy", "used", "in", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p13_s0", "idA": "908259_17_item1_p42_s1", "sentA": "The second cohort enrolled 4 patients, each receiving a dose of 4.68 mg/m 2 of OXi4503 in combination with the same intermediate dose of cytarabine.", "sentB": "highest dose of OXi4503 tested to date, coupled with other partial response data, is a sign of a dose response.", "type": 2, "words": ["<tag1>", "The", "second", "cohort", "enrolled", "4", "patients,", "each", "receiving", "a", "dose", "of", "4.68", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine.", "<tag2>", "highest", "dose", "of", "OXi4503", "tested", "to", "date,", "coupled", "with", "other", "partial", "response", "data,", "is", "a", "sign", "of", "a", "dose", "response.", "<tag3>"], "wordsA": ["The", "second", "cohort", "enrolled", "4", "patients,", "each", "receiving", "a", "dose", "of", "4.68", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine."], "wordsB": ["highest", "dose", "of", "OXi4503", "tested", "to", "date,", "coupled", "with", "other", "partial", "response", "data,", "is", "a", "sign", "of", "a", "dose", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p17_s4", "idA": "908259_17_item1_p42_s1", "sentA": "The second cohort enrolled 4 patients, each receiving a dose of 4.68 mg/m 2 of OXi4503 in combination with the same intermediate dose of cytarabine.", "sentB": "In our AML program, our aim is to obtain clinical data with a dose of OXi4503 higher than the five doses tested to date.", "type": 2, "words": ["<tag1>", "The", "second", "cohort", "enrolled", "4", "patients,", "each", "receiving", "a", "dose", "of", "4.68", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine.", "<tag2>", "In", "our", "AML", "program,", "our", "aim", "is", "to", "obtain", "clinical", "data", "with", "a", "dose", "of", "OXi4503", "higher", "than", "the", "five", "doses", "tested", "to", "date.", "<tag3>"], "wordsA": ["The", "second", "cohort", "enrolled", "4", "patients,", "each", "receiving", "a", "dose", "of", "4.68", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine."], "wordsB": ["In", "our", "AML", "program,", "our", "aim", "is", "to", "obtain", "clinical", "data", "with", "a", "dose", "of", "OXi4503", "higher", "than", "the", "five", "doses", "tested", "to", "date."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p13_s1", "idA": "908259_17_item1_p43_s0", "sentA": "OXi4503 was generally well tolerated in the first two cohorts of the study.", "sentB": "The next patients evaluated will be given 12.2 mg/m2 of OXi4503, a 25% increase compared to the most recently completed fifth cohort of the study.", "type": 2, "words": ["<tag1>", "OXi4503", "was", "generally", "well", "tolerated", "in", "the", "first", "two", "cohorts", "of", "the", "study.", "<tag2>", "The", "next", "patients", "evaluated", "will", "be", "given", "12.2", "mg/m2", "of", "OXi4503,", "a", "25%", "increase", "compared", "to", "the", "most", "recently", "completed", "fifth", "cohort", "of", "the", "study.", "<tag3>"], "wordsA": ["OXi4503", "was", "generally", "well", "tolerated", "in", "the", "first", "two", "cohorts", "of", "the", "study."], "wordsB": ["The", "next", "patients", "evaluated", "will", "be", "given", "12.2", "mg/m2", "of", "OXi4503,", "a", "25%", "increase", "compared", "to", "the", "most", "recently", "completed", "fifth", "cohort", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p29_s0", "idA": "908259_17_item1_p47_s0", "sentA": "According to Cancer Research UK, a non-profit cancer research organization in the United Kingdom, nearly 90% of all cancers are solid tumors that are dependent upon a continually evolving vascular supply for their growth and survival.", "sentB": "According to Cancer Research UK, a non-profit cancer research organization in the United Kingdom, nearly 90% of all cancers are dependent upon a continually evolving vascular supply for their growth and survival.", "type": 2, "words": ["<tag1>", "According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "solid", "tumors", "that", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival.", "<tag2>", "According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival.", "<tag3>"], "wordsA": ["According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "solid", "tumors", "that", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival."], "wordsB": ["According", "to", "Cancer", "Research", "UK,", "a", "non-profit", "cancer", "research", "organization", "in", "the", "United", "Kingdom,", "nearly", "90%", "of", "all", "cancers", "are", "dependent", "upon", "a", "continually", "evolving", "vascular", "supply", "for", "their", "growth", "and", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p29_s1", "idA": "908259_17_item1_p47_s1", "sentA": "VTTs, which include AAs and VDAs, are designed to interfere with a tumor s vascular supply.", "sentB": "Vascular-targeted therapies, such as CA4P and OXi4503, are designed to interfere with a tumor s vascular supply.", "type": 2, "words": ["<tag1>", "VTTs,", "which", "include", "AAs", "and", "VDAs,", "are", "designed", "to", "interfere", "with", "a", "tumor", "s", "vascular", "supply.", "<tag2>", "Vascular-targeted", "therapies,", "such", "as", "CA4P", "and", "OXi4503,", "are", "designed", "to", "interfere", "with", "a", "tumor", "s", "vascular", "supply.", "<tag3>"], "wordsA": ["VTTs,", "which", "include", "AAs", "and", "VDAs,", "are", "designed", "to", "interfere", "with", "a", "tumor", "s", "vascular", "supply."], "wordsB": ["Vascular-targeted", "therapies,", "such", "as", "CA4P", "and", "OXi4503,", "are", "designed", "to", "interfere", "with", "a", "tumor", "s", "vascular", "supply."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p10_s0", "idA": "908259_17_item1_p48_s1", "sentA": "Although a number of VDAs have been in clinical development, to date none have been approved.", "sentB": "A large clinical safety database supports its use in clinical trials: Over 500 patients have been treated with CA4P to date in clinical trials.", "type": 2, "words": ["<tag1>", "Although", "a", "number", "of", "VDAs", "have", "been", "in", "clinical", "development,", "to", "date", "none", "have", "been", "approved.", "<tag2>", "A", "large", "clinical", "safety", "database", "supports", "its", "use", "in", "clinical", "trials:", "Over", "500", "patients", "have", "been", "treated", "with", "CA4P", "to", "date", "in", "clinical", "trials.", "<tag3>"], "wordsA": ["Although", "a", "number", "of", "VDAs", "have", "been", "in", "clinical", "development,", "to", "date", "none", "have", "been", "approved."], "wordsB": ["A", "large", "clinical", "safety", "database", "supports", "its", "use", "in", "clinical", "trials:", "Over", "500", "patients", "have", "been", "treated", "with", "CA4P", "to", "date", "in", "clinical", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p17_s1", "idA": "908259_17_item1_p50_s3", "sentA": "We believe our VDAs are a second generation of VTTs that have the potential to improve upon the efficacy of AAs, the first generation of VTTs.", "sentB": "We believe that OXi4503 has the potential to enhance the effect of many common AML therapies.", "type": 2, "words": ["<tag1>", "We", "believe", "our", "VDAs", "are", "a", "second", "generation", "of", "VTTs", "that", "have", "the", "potential", "to", "improve", "upon", "the", "efficacy", "of", "AAs,", "the", "first", "generation", "of", "VTTs.", "<tag2>", "We", "believe", "that", "OXi4503", "has", "the", "potential", "to", "enhance", "the", "effect", "of", "many", "common", "AML", "therapies.", "<tag3>"], "wordsA": ["We", "believe", "our", "VDAs", "are", "a", "second", "generation", "of", "VTTs", "that", "have", "the", "potential", "to", "improve", "upon", "the", "efficacy", "of", "AAs,", "the", "first", "generation", "of", "VTTs."], "wordsB": ["We", "believe", "that", "OXi4503", "has", "the", "potential", "to", "enhance", "the", "effect", "of", "many", "common", "AML", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p2_s3", "idA": "908259_17_item1_p50_s3", "sentA": "We believe our VDAs are a second generation of VTTs that have the potential to improve upon the efficacy of AAs, the first generation of VTTs.", "sentB": "CA4P has the potential to increase the efficacy of these immuno-oncology agents it has been shown in animal models of several different tumors to improve immune responses that lead to tumor cell death, resulting in increased tumor regressions compared to immune-oncology agents alone.", "type": 2, "words": ["<tag1>", "We", "believe", "our", "VDAs", "are", "a", "second", "generation", "of", "VTTs", "that", "have", "the", "potential", "to", "improve", "upon", "the", "efficacy", "of", "AAs,", "the", "first", "generation", "of", "VTTs.", "<tag2>", "CA4P", "has", "the", "potential", "to", "increase", "the", "efficacy", "of", "these", "immuno-oncology", "agents", "it", "has", "been", "shown", "in", "animal", "models", "of", "several", "different", "tumors", "to", "improve", "immune", "responses", "that", "lead", "to", "tumor", "cell", "death,", "resulting", "in", "increased", "tumor", "regressions", "compared", "to", "immune-oncology", "agents", "alone.", "<tag3>"], "wordsA": ["We", "believe", "our", "VDAs", "are", "a", "second", "generation", "of", "VTTs", "that", "have", "the", "potential", "to", "improve", "upon", "the", "efficacy", "of", "AAs,", "the", "first", "generation", "of", "VTTs."], "wordsB": ["CA4P", "has", "the", "potential", "to", "increase", "the", "efficacy", "of", "these", "immuno-oncology", "agents", "it", "has", "been", "shown", "in", "animal", "models", "of", "several", "different", "tumors", "to", "improve", "immune", "responses", "that", "lead", "to", "tumor", "cell", "death,", "resulting", "in", "increased", "tumor", "regressions", "compared", "to", "immune-oncology", "agents", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p8_s2", "idA": "908259_17_item1_p50_s3", "sentA": "We believe our VDAs are a second generation of VTTs that have the potential to improve upon the efficacy of AAs, the first generation of VTTs.", "sentB": "This is a promising approach for boosting the efficacy of immuno-oncology agents.", "type": 2, "words": ["<tag1>", "We", "believe", "our", "VDAs", "are", "a", "second", "generation", "of", "VTTs", "that", "have", "the", "potential", "to", "improve", "upon", "the", "efficacy", "of", "AAs,", "the", "first", "generation", "of", "VTTs.", "<tag2>", "This", "is", "a", "promising", "approach", "for", "boosting", "the", "efficacy", "of", "immuno-oncology", "agents.", "<tag3>"], "wordsA": ["We", "believe", "our", "VDAs", "are", "a", "second", "generation", "of", "VTTs", "that", "have", "the", "potential", "to", "improve", "upon", "the", "efficacy", "of", "AAs,", "the", "first", "generation", "of", "VTTs."], "wordsB": ["This", "is", "a", "promising", "approach", "for", "boosting", "the", "efficacy", "of", "immuno-oncology", "agents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p29_s2", "idA": "908259_17_item1_p51_s0", "sentA": "As illustrated in the table below, VDA and anti-angiogenic drugs act via different mechanisms to produce complementary biological and anti-vascular effects with mostly non-overlapping side effects.", "sentB": "As illustrated in the table below, there are differences between our vascular targeted therapies and anti-angiogenic drugs which act via a different mechanisms to produce complementary biological and anti-vascular effects.", "type": 2, "words": ["<tag1>", "As", "illustrated", "in", "the", "table", "below,", "VDA", "and", "anti-angiogenic", "drugs", "act", "via", "different", "mechanisms", "to", "produce", "complementary", "biological", "and", "anti-vascular", "effects", "with", "mostly", "non-overlapping", "side", "effects.", "<tag2>", "As", "illustrated", "in", "the", "table", "below,", "there", "are", "differences", "between", "our", "vascular", "targeted", "therapies", "and", "anti-angiogenic", "drugs", "which", "act", "via", "a", "different", "mechanisms", "to", "produce", "complementary", "biological", "and", "anti-vascular", "effects.", "<tag3>"], "wordsA": ["As", "illustrated", "in", "the", "table", "below,", "VDA", "and", "anti-angiogenic", "drugs", "act", "via", "different", "mechanisms", "to", "produce", "complementary", "biological", "and", "anti-vascular", "effects", "with", "mostly", "non-overlapping", "side", "effects."], "wordsB": ["As", "illustrated", "in", "the", "table", "below,", "there", "are", "differences", "between", "our", "vascular", "targeted", "therapies", "and", "anti-angiogenic", "drugs", "which", "act", "via", "a", "different", "mechanisms", "to", "produce", "complementary", "biological", "and", "anti-vascular", "effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p10_s1", "idA": "908259_17_item1_p51_s2", "sentA": "Results from human clinical trials with combinations of CA4P and bevacizumab provide support and initial clinical validation for combining these agents to significantly increase clinical activity without significantly increasing side-effects.", "sentB": "These trials have shown CA4P to be generally well-tolerated, supporting the overall safety of CA4P and the initiation of additional clinical trials in new areas, including in immuno-oncology.", "type": 2, "words": ["<tag1>", "Results", "from", "human", "clinical", "trials", "with", "combinations", "of", "CA4P", "and", "bevacizumab", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects.", "<tag2>", "These", "trials", "have", "shown", "CA4P", "to", "be", "generally", "well-tolerated,", "supporting", "the", "overall", "safety", "of", "CA4P", "and", "the", "initiation", "of", "additional", "clinical", "trials", "in", "new", "areas,", "including", "in", "immuno-oncology.", "<tag3>"], "wordsA": ["Results", "from", "human", "clinical", "trials", "with", "combinations", "of", "CA4P", "and", "bevacizumab", "provide", "support", "and", "initial", "clinical", "validation", "for", "combining", "these", "agents", "to", "significantly", "increase", "clinical", "activity", "without", "significantly", "increasing", "side-effects."], "wordsB": ["These", "trials", "have", "shown", "CA4P", "to", "be", "generally", "well-tolerated,", "supporting", "the", "overall", "safety", "of", "CA4P", "and", "the", "initiation", "of", "additional", "clinical", "trials", "in", "new", "areas,", "including", "in", "immuno-oncology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p31_s0", "idA": "908259_17_item1_p53_s0", "sentA": "Transient acute blood pressure increases; Tumor pain, nausea, vomiting, headache, fatigue; Effects on hematopoiesis and white blood cell counts; In AML similar to solid tumors with more pronounced effects on coagulation and hematopoiesis We believe our VDA drug candidates act on tumor blood vessels via two complementary mechanisms, tubulin depolymerization and disengagement of the junctional protein VE-cadherin, which cause a change in the shape of tumor vascular endothelial cells, tumor vessel occlusion, and the subsequent blockage of blood-flow to the tumor, which deprives the tumor of oxygen and nutrients essential for survival.", "sentB": "Transient acute blood pressure increases; Tumor pain, nausea, vomiting, headache, fatigue; Effects on hematopoiesis and white blood cell counts; In AML similar to solid tumors with more pronounced effects on coagulation and hematopoiesis We believe our drug candidates act on tumor blood vessels via two complementary mechanisms, tubulin depolymerization and disengagement of the junctional protein VE-cadherin, which cause a change in the shape of tumor vascular endothelial cells, tumor vessel occlusion, and the subsequent blockage of blood-flow to the tumor, which deprives the tumor of oxygen and nutrients essential for survival.", "type": 2, "words": ["<tag1>", "Transient", "acute", "blood", "pressure", "increases;", "Tumor", "pain,", "nausea,", "vomiting,", "headache,", "fatigue;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts;", "In", "AML", "similar", "to", "solid", "tumors", "with", "more", "pronounced", "effects", "on", "coagulation", "and", "hematopoiesis", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "a", "change", "in", "the", "shape", "of", "tumor", "vascular", "endothelial", "cells,", "tumor", "vessel", "occlusion,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "the", "tumor", "of", "oxygen", "and", "nutrients", "essential", "for", "survival.", "<tag2>", "Transient", "acute", "blood", "pressure", "increases;", "Tumor", "pain,", "nausea,", "vomiting,", "headache,", "fatigue;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts;", "In", "AML", "similar", "to", "solid", "tumors", "with", "more", "pronounced", "effects", "on", "coagulation", "and", "hematopoiesis", "We", "believe", "our", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "a", "change", "in", "the", "shape", "of", "tumor", "vascular", "endothelial", "cells,", "tumor", "vessel", "occlusion,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "the", "tumor", "of", "oxygen", "and", "nutrients", "essential", "for", "survival.", "<tag3>"], "wordsA": ["Transient", "acute", "blood", "pressure", "increases;", "Tumor", "pain,", "nausea,", "vomiting,", "headache,", "fatigue;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts;", "In", "AML", "similar", "to", "solid", "tumors", "with", "more", "pronounced", "effects", "on", "coagulation", "and", "hematopoiesis", "We", "believe", "our", "VDA", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "a", "change", "in", "the", "shape", "of", "tumor", "vascular", "endothelial", "cells,", "tumor", "vessel", "occlusion,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "the", "tumor", "of", "oxygen", "and", "nutrients", "essential", "for", "survival."], "wordsB": ["Transient", "acute", "blood", "pressure", "increases;", "Tumor", "pain,", "nausea,", "vomiting,", "headache,", "fatigue;", "Effects", "on", "hematopoiesis", "and", "white", "blood", "cell", "counts;", "In", "AML", "similar", "to", "solid", "tumors", "with", "more", "pronounced", "effects", "on", "coagulation", "and", "hematopoiesis", "We", "believe", "our", "drug", "candidates", "act", "on", "tumor", "blood", "vessels", "via", "two", "complementary", "mechanisms,", "tubulin", "depolymerization", "and", "disengagement", "of", "the", "junctional", "protein", "VE-cadherin,", "which", "cause", "a", "change", "in", "the", "shape", "of", "tumor", "vascular", "endothelial", "cells,", "tumor", "vessel", "occlusion,", "and", "the", "subsequent", "blockage", "of", "blood-flow", "to", "the", "tumor,", "which", "deprives", "the", "tumor", "of", "oxygen", "and", "nutrients", "essential", "for", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p31_s1", "idA": "908259_17_item1_p53_s1", "sentA": "In vitro studies have demonstrated that our VDA drug candidates act in a reversible fashion on tubulin inside newly-formed and growing endothelial cells, such as the vascular endothelial cells comprising tumor vasculature.", "sentB": "In vitro studies have demonstrated that our drug candidates act in a reversible fashion on tubulin inside newly-formed and growing endothelial cells, such as the vascular endothelial cells comprising tumor vasculature.", "type": 2, "words": ["<tag1>", "In", "vitro", "studies", "have", "demonstrated", "that", "our", "VDA", "drug", "candidates", "act", "in", "a", "reversible", "fashion", "on", "tubulin", "inside", "newly-formed", "and", "growing", "endothelial", "cells,", "such", "as", "the", "vascular", "endothelial", "cells", "comprising", "tumor", "vasculature.", "<tag2>", "In", "vitro", "studies", "have", "demonstrated", "that", "our", "drug", "candidates", "act", "in", "a", "reversible", "fashion", "on", "tubulin", "inside", "newly-formed", "and", "growing", "endothelial", "cells,", "such", "as", "the", "vascular", "endothelial", "cells", "comprising", "tumor", "vasculature.", "<tag3>"], "wordsA": ["In", "vitro", "studies", "have", "demonstrated", "that", "our", "VDA", "drug", "candidates", "act", "in", "a", "reversible", "fashion", "on", "tubulin", "inside", "newly-formed", "and", "growing", "endothelial", "cells,", "such", "as", "the", "vascular", "endothelial", "cells", "comprising", "tumor", "vasculature."], "wordsB": ["In", "vitro", "studies", "have", "demonstrated", "that", "our", "drug", "candidates", "act", "in", "a", "reversible", "fashion", "on", "tubulin", "inside", "newly-formed", "and", "growing", "endothelial", "cells,", "such", "as", "the", "vascular", "endothelial", "cells", "comprising", "tumor", "vasculature."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p31_s2", "idA": "908259_17_item1_p54_s0", "sentA": "By binding to the tubulin, CA4P is able to alter the structural framework that normally maintains the cells flat shape.", "sentB": "By binding to the tubulin, our candidates are able to alter the structural framework that normally maintains the cells flat shape.", "type": 2, "words": ["<tag1>", "By", "binding", "to", "the", "tubulin,", "CA4P", "is", "able", "to", "alter", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape.", "<tag2>", "By", "binding", "to", "the", "tubulin,", "our", "candidates", "are", "able", "to", "alter", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape.", "<tag3>"], "wordsA": ["By", "binding", "to", "the", "tubulin,", "CA4P", "is", "able", "to", "alter", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape."], "wordsB": ["By", "binding", "to", "the", "tubulin,", "our", "candidates", "are", "able", "to", "alter", "the", "structural", "framework", "that", "normally", "maintains", "the", "cells", "flat", "shape."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p8_s1", "idA": "908259_17_item1_p54_s1", "sentA": "When this occurs, the shape of the cells changes from flat to round, resulting in physical blockage of the blood vessels.", "sentB": "It does this by blocking tumor blood flow after binding to and altering the shape of cells lining the tumor blood vessels, resulting in increased tumor cell death and tumor regressions.", "type": 2, "words": ["<tag1>", "When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels.", "<tag2>", "It", "does", "this", "by", "blocking", "tumor", "blood", "flow", "after", "binding", "to", "and", "altering", "the", "shape", "of", "cells", "lining", "the", "tumor", "blood", "vessels,", "resulting", "in", "increased", "tumor", "cell", "death", "and", "tumor", "regressions.", "<tag3>"], "wordsA": ["When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels."], "wordsB": ["It", "does", "this", "by", "blocking", "tumor", "blood", "flow", "after", "binding", "to", "and", "altering", "the", "shape", "of", "cells", "lining", "the", "tumor", "blood", "vessels,", "resulting", "in", "increased", "tumor", "cell", "death", "and", "tumor", "regressions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p2_s1", "idA": "908259_17_item1_p54_s3", "sentA": "The consequence of the blockage is extensive tumor cell death.", "sentB": "Immuno-oncology agents stimulate the body s immune system to fight cancer cells, resulting in tumor cell death and tumor regressions in patients who otherwise would not have responded to therapy.", "type": 2, "words": ["<tag1>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death.", "<tag2>", "Immuno-oncology", "agents", "stimulate", "the", "body", "s", "immune", "system", "to", "fight", "cancer", "cells,", "resulting", "in", "tumor", "cell", "death", "and", "tumor", "regressions", "in", "patients", "who", "otherwise", "would", "not", "have", "responded", "to", "therapy.", "<tag3>"], "wordsA": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death."], "wordsB": ["Immuno-oncology", "agents", "stimulate", "the", "body", "s", "immune", "system", "to", "fight", "cancer", "cells,", "resulting", "in", "tumor", "cell", "death", "and", "tumor", "regressions", "in", "patients", "who", "otherwise", "would", "not", "have", "responded", "to", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p31_s5", "idA": "908259_17_item1_p54_s3", "sentA": "The consequence of the blockage is extensive tumor cell death.", "sentB": "The consequence of the tumor blood vessel blockage is extensive necrosis (cell death) within the tumor.", "type": 2, "words": ["<tag1>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death.", "<tag2>", "The", "consequence", "of", "the", "tumor", "blood", "vessel", "blockage", "is", "extensive", "necrosis", "(cell", "death)", "within", "the", "tumor.", "<tag3>"], "wordsA": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death."], "wordsB": ["The", "consequence", "of", "the", "tumor", "blood", "vessel", "blockage", "is", "extensive", "necrosis", "(cell", "death)", "within", "the", "tumor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p8_s0", "idA": "908259_17_item1_p54_s3", "sentA": "The consequence of the blockage is extensive tumor cell death.", "sentB": "A promising approach for enhancing the efficacy of immuno-oncology agents: CA4P induces rapid tumor cell death and stimulation of the immune system.", "type": 2, "words": ["<tag1>", "The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death.", "<tag2>", "A", "promising", "approach", "for", "enhancing", "the", "efficacy", "of", "immuno-oncology", "agents:", "CA4P", "induces", "rapid", "tumor", "cell", "death", "and", "stimulation", "of", "the", "immune", "system.", "<tag3>"], "wordsA": ["The", "consequence", "of", "the", "blockage", "is", "extensive", "tumor", "cell", "death."], "wordsB": ["A", "promising", "approach", "for", "enhancing", "the", "efficacy", "of", "immuno-oncology", "agents:", "CA4P", "induces", "rapid", "tumor", "cell", "death", "and", "stimulation", "of", "the", "immune", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p32_s0", "idA": "908259_17_item1_p54_s4", "sentA": "Preclinical research, published in the November 2005 issue of the Journal of Clinical Investigation, showed that CA4P also disrupts the molecular engagement of VE-cadherin, a junctional protein important for endothelial cell survival and function.", "sentB": "Preclinical research, published in the November 2005 issue of the Journal of Clinical Investigation, showed that our drug candidates also disrupt the molecular engagement of VE-cadherin, a junctional protein important for endothelial cell survival and function.", "type": 2, "words": ["<tag1>", "Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "CA4P", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function.", "<tag2>", "Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "our", "drug", "candidates", "also", "disrupt", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function.", "<tag3>"], "wordsA": ["Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "CA4P", "also", "disrupts", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function."], "wordsB": ["Preclinical", "research,", "published", "in", "the", "November", "2005", "issue", "of", "the", "Journal", "of", "Clinical", "Investigation,", "showed", "that", "our", "drug", "candidates", "also", "disrupt", "the", "molecular", "engagement", "of", "VE-cadherin,", "a", "junctional", "protein", "important", "for", "endothelial", "cell", "survival", "and", "function."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p34_s0", "idA": "908259_17_item1_p56_s0", "sentA": "Preclinical and clinical study results indicate that CA4P exerts anti-vascular effects rapidly, within hours of administration, and the half-life of the active form of CA4P in humans is approximately four hours.", "sentB": "Clinical study results and additional preclinical studies indicate that our investigational drugs exert their anti-vascular effects rapidly, within hours of administration, and the half-life of the active form of our drugs in humans is approximately two-four hours.", "type": 2, "words": ["<tag1>", "Preclinical", "and", "clinical", "study", "results", "indicate", "that", "CA4P", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "in", "humans", "is", "approximately", "four", "hours.", "<tag2>", "Clinical", "study", "results", "and", "additional", "preclinical", "studies", "indicate", "that", "our", "investigational", "drugs", "exert", "their", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "our", "drugs", "in", "humans", "is", "approximately", "two-four", "hours.", "<tag3>"], "wordsA": ["Preclinical", "and", "clinical", "study", "results", "indicate", "that", "CA4P", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "in", "humans", "is", "approximately", "four", "hours."], "wordsB": ["Clinical", "study", "results", "and", "additional", "preclinical", "studies", "indicate", "that", "our", "investigational", "drugs", "exert", "their", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "our", "drugs", "in", "humans", "is", "approximately", "two-four", "hours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p34_s1", "idA": "908259_17_item1_p56_s1", "sentA": "In part because the half-life of the active form of CA4P is relatively short, the effects of CA4P on tubulin are reversible, and the pharmacodynamic effect lasts for weeks, CA4P is typically administered no more frequently than once per week.", "sentB": "In part because the half-life is relatively short, the effects on tubulin are reversible.", "type": 2, "words": ["<tag1>", "In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "the", "pharmacodynamic", "effect", "lasts", "for", "weeks,", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week.", "<tag2>", "In", "part", "because", "the", "half-life", "is", "relatively", "short,", "the", "effects", "on", "tubulin", "are", "reversible.", "<tag3>"], "wordsA": ["In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "the", "pharmacodynamic", "effect", "lasts", "for", "weeks,", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week."], "wordsB": ["In", "part", "because", "the", "half-life", "is", "relatively", "short,", "the", "effects", "on", "tubulin", "are", "reversible."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p34_s2", "idA": "908259_17_item1_p56_s1", "sentA": "In part because the half-life of the active form of CA4P is relatively short, the effects of CA4P on tubulin are reversible, and the pharmacodynamic effect lasts for weeks, CA4P is typically administered no more frequently than once per week.", "sentB": "However, the pharmacodynamic effect lasts for weeks, so our agents are typically administered no more frequently than once per week.", "type": 2, "words": ["<tag1>", "In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "the", "pharmacodynamic", "effect", "lasts", "for", "weeks,", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week.", "<tag2>", "However,", "the", "pharmacodynamic", "effect", "lasts", "for", "weeks,", "so", "our", "agents", "are", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week.", "<tag3>"], "wordsA": ["In", "part", "because", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "is", "relatively", "short,", "the", "effects", "of", "CA4P", "on", "tubulin", "are", "reversible,", "and", "the", "pharmacodynamic", "effect", "lasts", "for", "weeks,", "CA4P", "is", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week."], "wordsB": ["However,", "the", "pharmacodynamic", "effect", "lasts", "for", "weeks,", "so", "our", "agents", "are", "typically", "administered", "no", "more", "frequently", "than", "once", "per", "week."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p35_s0", "idA": "908259_17_item1_p57_s0", "sentA": "The side-effects of CA4P are typically transient in nature, limited to the period of time following administration when the active form of CA4P is in the body in significant concentrations.", "sentB": "The side-effects are typically transient in nature, limited to the few hours following administration when the active form is in the body in significant concentrations.", "type": 2, "words": ["<tag1>", "The", "side-effects", "of", "CA4P", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "CA4P", "is", "in", "the", "body", "in", "significant", "concentrations.", "<tag2>", "The", "side-effects", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "few", "hours", "following", "administration", "when", "the", "active", "form", "is", "in", "the", "body", "in", "significant", "concentrations.", "<tag3>"], "wordsA": ["The", "side-effects", "of", "CA4P", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "period", "of", "time", "following", "administration", "when", "the", "active", "form", "of", "CA4P", "is", "in", "the", "body", "in", "significant", "concentrations."], "wordsB": ["The", "side-effects", "are", "typically", "transient", "in", "nature,", "limited", "to", "the", "few", "hours", "following", "administration", "when", "the", "active", "form", "is", "in", "the", "body", "in", "significant", "concentrations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p35_s1", "idA": "908259_17_item1_p59_s0", "sentA": "Side-effects associated with CA4P are generally transient and manageable.", "sentB": "Side-effects associated with our investigational drugs are generally transient and manageable.", "type": 2, "words": ["<tag1>", "Side-effects", "associated", "with", "CA4P", "are", "generally", "transient", "and", "manageable.", "<tag2>", "Side-effects", "associated", "with", "our", "investigational", "drugs", "are", "generally", "transient", "and", "manageable.", "<tag3>"], "wordsA": ["Side-effects", "associated", "with", "CA4P", "are", "generally", "transient", "and", "manageable."], "wordsB": ["Side-effects", "associated", "with", "our", "investigational", "drugs", "are", "generally", "transient", "and", "manageable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p36_s0", "idA": "908259_17_item1_p59_s1", "sentA": "The most frequent CA4P side-effects include acute blood pressure increases, infusion-related side effects such as nausea, vomiting, headache and fatigue, and tumor pain, which is consistent with the drug s mechanism-of-action.", "sentB": "vomiting, headache and fatigue, and tumor pain, which is consistent with the drug s mechanism-of-action.", "type": 2, "words": ["<tag1>", "The", "most", "frequent", "CA4P", "side-effects", "include", "acute", "blood", "pressure", "increases,", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action.", "<tag2>", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action.", "<tag3>"], "wordsA": ["The", "most", "frequent", "CA4P", "side-effects", "include", "acute", "blood", "pressure", "increases,", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action."], "wordsB": ["vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p36_s1", "idA": "908259_17_item1_p59_s3", "sentA": "The acute blood pressure increases are often manageable by controlling underlying hypertension or treating with short-acting anti-hypertensives prior to CA4P infusion.", "sentB": "The acute blood pressure increases are often manageable by controlling underlying hypertension or treating with short-acting anti-hypertensives prior to infusion.", "type": 2, "words": ["<tag1>", "The", "acute", "blood", "pressure", "increases", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion.", "<tag2>", "The", "acute", "blood", "pressure", "increases", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "infusion.", "<tag3>"], "wordsA": ["The", "acute", "blood", "pressure", "increases", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "CA4P", "infusion."], "wordsB": ["The", "acute", "blood", "pressure", "increases", "are", "often", "manageable", "by", "controlling", "underlying", "hypertension", "or", "treating", "with", "short-acting", "anti-hypertensives", "prior", "to", "infusion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p21_s0", "idA": "908259_17_item1_p61_s1", "sentA": "We are also seeking to find additional potential uses for our clinical candidates and to identify new preclinical candidates that are complementary to our VDAs.", "sentB": "Continue to discuss CA4P and OXi4503 collaboration opportunities with larger pharmaceutical companies: We intend to find a partner to acquire the marketing rights to our product candidates and to finance further clinical studies.", "type": 2, "words": ["<tag1>", "We", "are", "also", "seeking", "to", "find", "additional", "potential", "uses", "for", "our", "clinical", "candidates", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag2>", "Continue", "to", "discuss", "CA4P", "and", "OXi4503", "collaboration", "opportunities", "with", "larger", "pharmaceutical", "companies:", "We", "intend", "to", "find", "a", "partner", "to", "acquire", "the", "marketing", "rights", "to", "our", "product", "candidates", "and", "to", "finance", "further", "clinical", "studies.", "<tag3>"], "wordsA": ["We", "are", "also", "seeking", "to", "find", "additional", "potential", "uses", "for", "our", "clinical", "candidates", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "wordsB": ["Continue", "to", "discuss", "CA4P", "and", "OXi4503", "collaboration", "opportunities", "with", "larger", "pharmaceutical", "companies:", "We", "intend", "to", "find", "a", "partner", "to", "acquire", "the", "marketing", "rights", "to", "our", "product", "candidates", "and", "to", "finance", "further", "clinical", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p38_s0", "idA": "908259_17_item1_p62_s0", "sentA": "For rights to CA4P, we have secured a technology license from Arizona State University, or ASU.", "sentB": "Collaborative Research and Development Arrangements We have entered into a technology license from Arizona State University, or ASU, for rights to combretastatins, which includes CA4P and OXi4503.", "type": 2, "words": ["<tag1>", "For", "rights", "to", "CA4P,", "we", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU.", "<tag2>", "Collaborative", "Research", "and", "Development", "Arrangements", "We", "have", "entered", "into", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU,", "for", "rights", "to", "combretastatins,", "which", "includes", "CA4P", "and", "OXi4503.", "<tag3>"], "wordsA": ["For", "rights", "to", "CA4P,", "we", "have", "secured", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU."], "wordsB": ["Collaborative", "Research", "and", "Development", "Arrangements", "We", "have", "entered", "into", "a", "technology", "license", "from", "Arizona", "State", "University,", "or", "ASU,", "for", "rights", "to", "combretastatins,", "which", "includes", "CA4P", "and", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p38_s1", "idA": "908259_17_item1_p62_s1", "sentA": "The ASU license is an exclusive, world-wide, royalty-bearing license for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, CA4P and OXi4503.", "sentB": "The ASU license is an exclusive, world-wide, royalty-bearing license for the commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins.", "type": 2, "words": ["<tag1>", "The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P", "and", "OXi4503.", "<tag2>", "The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "the", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins.", "<tag3>"], "wordsA": ["The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P", "and", "OXi4503."], "wordsB": ["The", "ASU", "license", "is", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "for", "the", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p43_s0", "idA": "908259_17_item1_p67_s0", "sentA": "combretastatins, including among others, CA4P. Under the BMS license, we have the right to grant sublicenses, and BMS is entitled to low single-digit royalty payments for all commercial sales plus any remuneration we receive for sale of CA4P under named patient or compassionate use programs.", "sentB": "We also have an exclusive, world-wide, royalty-bearing license from Bristol-Myers Squibb, or BMS, for commercial development, use and sale of products or services covered by certain patent rights to particular combretastatins, including among others, CA4P. Under the BMS license, we have the right to grant sublicenses, and BMS is entitled to low single-digit royalty payments for all commercial sales plus any remuneration we receive for sale of CA4P under named patient or compassionate use programs.", "type": 2, "words": ["<tag1>", "combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs.", "<tag2>", "We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs.", "<tag3>"], "wordsA": ["combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs."], "wordsB": ["We", "also", "have", "an", "exclusive,", "world-wide,", "royalty-bearing", "license", "from", "Bristol-Myers", "Squibb,", "or", "BMS,", "for", "commercial", "development,", "use", "and", "sale", "of", "products", "or", "services", "covered", "by", "certain", "patent", "rights", "to", "particular", "combretastatins,", "including", "among", "others,", "CA4P.", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses,", "and", "BMS", "is", "entitled", "to", "low", "single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "we", "receive", "for", "sale", "of", "CA4P", "under", "named", "patient", "or", "compassionate", "use", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p7_s3", "idA": "908259_17_item1_p69_s0", "sentA": "Under a sponsored research agreement with Baylor University, we are pursuing discovery and development of additional novel, small-molecule therapeutics for the treatment of cancer, including small-molecule cathepsin-K inhibitors, cathepsin-L inhibitors and hypoxia-activated VDAs.", "sentB": "The overall data from all these studies provides evidence that CA4P may enhance the activity of immuno-oncology agents for the treatment of cancer, including anti-CTLA4 antibodies and anti PD-1 antibodies.", "type": 2, "words": ["<tag1>", "Under", "a", "sponsored", "research", "agreement", "with", "Baylor", "University,", "we", "are", "pursuing", "discovery", "and", "development", "of", "additional", "novel,", "small-molecule", "therapeutics", "for", "the", "treatment", "of", "cancer,", "including", "small-molecule", "cathepsin-K", "inhibitors,", "cathepsin-L", "inhibitors", "and", "hypoxia-activated", "VDAs.", "<tag2>", "The", "overall", "data", "from", "all", "these", "studies", "provides", "evidence", "that", "CA4P", "may", "enhance", "the", "activity", "of", "immuno-oncology", "agents", "for", "the", "treatment", "of", "cancer,", "including", "anti-CTLA4", "antibodies", "and", "anti", "PD-1", "antibodies.", "<tag3>"], "wordsA": ["Under", "a", "sponsored", "research", "agreement", "with", "Baylor", "University,", "we", "are", "pursuing", "discovery", "and", "development", "of", "additional", "novel,", "small-molecule", "therapeutics", "for", "the", "treatment", "of", "cancer,", "including", "small-molecule", "cathepsin-K", "inhibitors,", "cathepsin-L", "inhibitors", "and", "hypoxia-activated", "VDAs."], "wordsB": ["The", "overall", "data", "from", "all", "these", "studies", "provides", "evidence", "that", "CA4P", "may", "enhance", "the", "activity", "of", "immuno-oncology", "agents", "for", "the", "treatment", "of", "cancer,", "including", "anti-CTLA4", "antibodies", "and", "anti", "PD-1", "antibodies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p18_s0", "idA": "908259_17_item1_p6_s2", "sentA": "Our second compound, OXi4503, is being studied in combination with cytarabine in an ascending-dose phase 1/2 clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).", "sentB": "Continue to test OXi4503 in the dose-escalating study OX1222, and obtain data for the next scheduled cohort of the study: We have completed five ascending dose cohorts of OXi4503 in combination with cytarabine in Study OX1222 in patients with relapsed/refractory AML.", "type": 2, "words": ["<tag1>", "Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "an", "ascending-dose", "phase", "1/2", "clinical", "trial", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag2>", "Continue", "to", "test", "OXi4503", "in", "the", "dose-escalating", "study", "OX1222,", "and", "obtain", "data", "for", "the", "next", "scheduled", "cohort", "of", "the", "study:", "We", "have", "completed", "five", "ascending", "dose", "cohorts", "of", "OXi4503", "in", "combination", "with", "cytarabine", "in", "Study", "OX1222", "in", "patients", "with", "relapsed/refractory", "AML.", "<tag3>"], "wordsA": ["Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "an", "ascending-dose", "phase", "1/2", "clinical", "trial", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "wordsB": ["Continue", "to", "test", "OXi4503", "in", "the", "dose-escalating", "study", "OX1222,", "and", "obtain", "data", "for", "the", "next", "scheduled", "cohort", "of", "the", "study:", "We", "have", "completed", "five", "ascending", "dose", "cohorts", "of", "OXi4503", "in", "combination", "with", "cytarabine", "in", "Study", "OX1222", "in", "patients", "with", "relapsed/refractory", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p14_s4", "idA": "908259_17_item1_p71_s1", "sentA": "We believe that our hypoxia-activated VDAs could serve as line-extension products to CA4P and/or OXi4503.", "sentB": "We believe OXi4503 offers the following potential benefits:", "type": 2, "words": ["<tag1>", "We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "CA4P", "and/or", "OXi4503.", "<tag2>", "We", "believe", "OXi4503", "offers", "the", "following", "potential", "benefits:", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "hypoxia-activated", "VDAs", "could", "serve", "as", "line-extension", "products", "to", "CA4P", "and/or", "OXi4503."], "wordsB": ["We", "believe", "OXi4503", "offers", "the", "following", "potential", "benefits:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p4_s3", "idA": "908259_17_item1_p71_s12", "sentA": "We previously licensed certain patents related to vascular disrupting agents for treating neuroendocrine tumors and associated symptoms and syndromes from Angiogene Pharmaceuticals Ltd. prior to our termination of the agreement in 2016.", "sentB": "Our initial immuno-oncology preclinical studies were completed in 2016.", "type": 2, "words": ["<tag1>", "We", "previously", "licensed", "certain", "patents", "related", "to", "vascular", "disrupting", "agents", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "prior", "to", "our", "termination", "of", "the", "agreement", "in", "2016.", "<tag2>", "Our", "initial", "immuno-oncology", "preclinical", "studies", "were", "completed", "in", "2016.", "<tag3>"], "wordsA": ["We", "previously", "licensed", "certain", "patents", "related", "to", "vascular", "disrupting", "agents", "for", "treating", "neuroendocrine", "tumors", "and", "associated", "symptoms", "and", "syndromes", "from", "Angiogene", "Pharmaceuticals", "Ltd.", "prior", "to", "our", "termination", "of", "the", "agreement", "in", "2016."], "wordsB": ["Our", "initial", "immuno-oncology", "preclinical", "studies", "were", "completed", "in", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p46_s2", "idA": "908259_17_item1_p73_s2", "sentA": "Information contained on, or that can be accessed through, our web site is not and shall not be deemed to be a part of this Annual Report on Form 10-K. REGULATORY MATTERS Government Regulation and Product Approval Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing.", "sentB": "Information contained on, or that can be accessed through, our web site is not and shall not be deemed to be a part of this Annual Report on Form 10-K.", "type": 2, "words": ["<tag1>", "Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "web", "site", "is", "not", "and", "shall", "not", "be", "deemed", "to", "be", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag2>", "Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "web", "site", "is", "not", "and", "shall", "not", "be", "deemed", "to", "be", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "<tag3>"], "wordsA": ["Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "web", "site", "is", "not", "and", "shall", "not", "be", "deemed", "to", "be", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "wordsB": ["Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "web", "site", "is", "not", "and", "shall", "not", "be", "deemed", "to", "be", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p47_s0", "idA": "908259_17_item1_p73_s2", "sentA": "Information contained on, or that can be accessed through, our web site is not and shall not be deemed to be a part of this Annual Report on Form 10-K. REGULATORY MATTERS Government Regulation and Product Approval Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing.", "sentB": "REGULATORY MATTERS Government Regulation and Product Approval Government authorities in the United States and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing.", "type": 2, "words": ["<tag1>", "Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "web", "site", "is", "not", "and", "shall", "not", "be", "deemed", "to", "be", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag2>", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag3>"], "wordsA": ["Information", "contained", "on,", "or", "that", "can", "be", "accessed", "through,", "our", "web", "site", "is", "not", "and", "shall", "not", "be", "deemed", "to", "be", "a", "part", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "wordsB": ["REGULATORY", "MATTERS", "Government", "Regulation", "and", "Product", "Approval", "Government", "authorities", "in", "the", "United", "States", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p52_s1", "idA": "908259_17_item1_p78_s1", "sentA": "The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold.", "sentB": "The IND becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold.", "type": 2, "words": ["<tag1>", "The", "IND", "automatically", "becomes", "effective", "30", "days", "after", "receipt", "by", "the", "FDA,", "unless", "the", "FDA,", "within", "the", "30-day", "time", "period,", "places", "the", "clinical", "trial", "on", "a", "clinical", "hold.", "<tag2>", "The", "IND", "becomes", "effective", "30", "days", "after", "receipt", "by", "the", "FDA,", "unless", "the", "FDA,", "within", "the", "30-day", "time", "period,", "places", "the", "clinical", "trial", "on", "a", "clinical", "hold.", "<tag3>"], "wordsA": ["The", "IND", "automatically", "becomes", "effective", "30", "days", "after", "receipt", "by", "the", "FDA,", "unless", "the", "FDA,", "within", "the", "30-day", "time", "period,", "places", "the", "clinical", "trial", "on", "a", "clinical", "hold."], "wordsB": ["The", "IND", "becomes", "effective", "30", "days", "after", "receipt", "by", "the", "FDA,", "unless", "the", "FDA,", "within", "the", "30-day", "time", "period,", "places", "the", "clinical", "trial", "on", "a", "clinical", "hold."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p55_s0", "idA": "908259_17_item1_p80_s0", "sentA": "Phase 1: The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion.", "sentB": "Phase 1: The drug is initially introduced into human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion.", "type": 2, "words": ["<tag1>", "Phase", "1:", "The", "drug", "is", "initially", "introduced", "into", "healthy", "human", "subjects", "and", "tested", "for", "safety,", "dosage", "tolerance,", "absorption,", "metabolism,", "distribution", "and", "excretion.", "<tag2>", "Phase", "1:", "The", "drug", "is", "initially", "introduced", "into", "human", "subjects", "and", "tested", "for", "safety,", "dosage", "tolerance,", "absorption,", "metabolism,", "distribution", "and", "excretion.", "<tag3>"], "wordsA": ["Phase", "1:", "The", "drug", "is", "initially", "introduced", "into", "healthy", "human", "subjects", "and", "tested", "for", "safety,", "dosage", "tolerance,", "absorption,", "metabolism,", "distribution", "and", "excretion."], "wordsB": ["Phase", "1:", "The", "drug", "is", "initially", "introduced", "into", "human", "subjects", "and", "tested", "for", "safety,", "dosage", "tolerance,", "absorption,", "metabolism,", "distribution", "and", "excretion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p57_s0", "idA": "908259_17_item1_p82_s0", "sentA": "Phase 3: Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites.", "sentB": "Phase 3: Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population.", "type": 2, "words": ["<tag1>", "Phase", "3:", "Clinical", "trials", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "trial", "sites.", "<tag2>", "Phase", "3:", "Clinical", "trials", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population.", "<tag3>"], "wordsA": ["Phase", "3:", "Clinical", "trials", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "trial", "sites."], "wordsB": ["Phase", "3:", "Clinical", "trials", "are", "undertaken", "to", "further", "evaluate", "dosage,", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p58_s3", "idA": "908259_17_item1_p86_s0", "sentA": "relevant information are submitted to the FDA as part of an NDA requesting approval to market the product.", "sentB": "The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product.", "type": 2, "words": ["<tag1>", "relevant", "information", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "requesting", "approval", "to", "market", "the", "product.", "<tag2>", "The", "results", "of", "product", "development,", "preclinical", "studies", "and", "clinical", "trials,", "along", "with", "descriptions", "of", "the", "manufacturing", "process,", "analytical", "tests", "conducted", "on", "the", "chemistry", "of", "the", "drug,", "proposed", "labeling,", "and", "other", "relevant", "information", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "requesting", "approval", "to", "market", "the", "product.", "<tag3>"], "wordsA": ["relevant", "information", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "requesting", "approval", "to", "market", "the", "product."], "wordsB": ["The", "results", "of", "product", "development,", "preclinical", "studies", "and", "clinical", "trials,", "along", "with", "descriptions", "of", "the", "manufacturing", "process,", "analytical", "tests", "conducted", "on", "the", "chemistry", "of", "the", "drug,", "proposed", "labeling,", "and", "other", "relevant", "information", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "requesting", "approval", "to", "market", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p59_s0", "idA": "908259_17_item1_p86_s1", "sentA": "The submission of an NDA is subject to the payment of user fees; a waiver of such fees may be obtained under certain limited circumstances, which may include orphan drug status and the first NDA application for a company.", "sentB": "submission of an NDA is subject to the payment of user fees; a waiver of such fees may be obtained under certain limited circumstances, which may include orphan drug status and the first NDA application for a company.", "type": 2, "words": ["<tag1>", "The", "submission", "of", "an", "NDA", "is", "subject", "to", "the", "payment", "of", "user", "fees;", "a", "waiver", "of", "such", "fees", "may", "be", "obtained", "under", "certain", "limited", "circumstances,", "which", "may", "include", "orphan", "drug", "status", "and", "the", "first", "NDA", "application", "for", "a", "company.", "<tag2>", "submission", "of", "an", "NDA", "is", "subject", "to", "the", "payment", "of", "user", "fees;", "a", "waiver", "of", "such", "fees", "may", "be", "obtained", "under", "certain", "limited", "circumstances,", "which", "may", "include", "orphan", "drug", "status", "and", "the", "first", "NDA", "application", "for", "a", "company.", "<tag3>"], "wordsA": ["The", "submission", "of", "an", "NDA", "is", "subject", "to", "the", "payment", "of", "user", "fees;", "a", "waiver", "of", "such", "fees", "may", "be", "obtained", "under", "certain", "limited", "circumstances,", "which", "may", "include", "orphan", "drug", "status", "and", "the", "first", "NDA", "application", "for", "a", "company."], "wordsB": ["submission", "of", "an", "NDA", "is", "subject", "to", "the", "payment", "of", "user", "fees;", "a", "waiver", "of", "such", "fees", "may", "be", "obtained", "under", "certain", "limited", "circumstances,", "which", "may", "include", "orphan", "drug", "status", "and", "the", "first", "NDA", "application", "for", "a", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p81_s1", "idA": "908259_17_item1_p86_s3", "sentA": "The FDA may grant deferrals for submission of data or full or partial waivers.", "sentB": "If full or partial repeal is enacted, many if not all of the provisions of the ACA may no longer apply to prescription drugs.", "type": 2, "words": ["<tag1>", "The", "FDA", "may", "grant", "deferrals", "for", "submission", "of", "data", "or", "full", "or", "partial", "waivers.", "<tag2>", "If", "full", "or", "partial", "repeal", "is", "enacted,", "many", "if", "not", "all", "of", "the", "provisions", "of", "the", "ACA", "may", "no", "longer", "apply", "to", "prescription", "drugs.", "<tag3>"], "wordsA": ["The", "FDA", "may", "grant", "deferrals", "for", "submission", "of", "data", "or", "full", "or", "partial", "waivers."], "wordsB": ["If", "full", "or", "partial", "repeal", "is", "enacted,", "many", "if", "not", "all", "of", "the", "provisions", "of", "the", "ACA", "may", "no", "longer", "apply", "to", "prescription", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p61_s1", "idA": "908259_17_item1_p88_s1", "sentA": "The FDA may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.", "sentB": "The FDA also may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.", "type": 2, "words": ["<tag1>", "The", "FDA", "may", "refer", "the", "NDA", "to", "an", "advisory", "committee", "for", "review,", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions.", "<tag2>", "The", "FDA", "also", "may", "refer", "the", "NDA", "to", "an", "advisory", "committee", "for", "review,", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions.", "<tag3>"], "wordsA": ["The", "FDA", "may", "refer", "the", "NDA", "to", "an", "advisory", "committee", "for", "review,", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions."], "wordsB": ["The", "FDA", "also", "may", "refer", "the", "NDA", "to", "an", "advisory", "committee", "for", "review,", "evaluation", "and", "recommendation", "as", "to", "whether", "the", "application", "should", "be", "approved", "and", "under", "what", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p61_s3", "idA": "908259_17_item1_p88_s3", "sentA": "The approval process is lengthy and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information.", "sentB": "The approval process is lengthy and difficult and the FDA may refuse to approve an NDA at its discretion or the FDA may require additional clinical or other data and information.", "type": 2, "words": ["<tag1>", "The", "approval", "process", "is", "lengthy", "and", "difficult", "and", "the", "FDA", "may", "refuse", "to", "approve", "an", "NDA", "if", "the", "applicable", "regulatory", "criteria", "are", "not", "satisfied", "or", "may", "require", "additional", "clinical", "or", "other", "data", "and", "information.", "<tag2>", "The", "approval", "process", "is", "lengthy", "and", "difficult", "and", "the", "FDA", "may", "refuse", "to", "approve", "an", "NDA", "at", "its", "discretion", "or", "the", "FDA", "may", "require", "additional", "clinical", "or", "other", "data", "and", "information.", "<tag3>"], "wordsA": ["The", "approval", "process", "is", "lengthy", "and", "difficult", "and", "the", "FDA", "may", "refuse", "to", "approve", "an", "NDA", "if", "the", "applicable", "regulatory", "criteria", "are", "not", "satisfied", "or", "may", "require", "additional", "clinical", "or", "other", "data", "and", "information."], "wordsB": ["The", "approval", "process", "is", "lengthy", "and", "difficult", "and", "the", "FDA", "may", "refuse", "to", "approve", "an", "NDA", "at", "its", "discretion", "or", "the", "FDA", "may", "require", "additional", "clinical", "or", "other", "data", "and", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p61_s4", "idA": "908259_17_item1_p88_s4", "sentA": "Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.", "sentB": "Even if such additional data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy its criteria for approval.", "type": 2, "words": ["<tag1>", "Even", "if", "such", "data", "and", "information", "are", "submitted,", "the", "FDA", "may", "ultimately", "decide", "that", "the", "NDA", "does", "not", "satisfy", "the", "criteria", "for", "approval.", "<tag2>", "Even", "if", "such", "additional", "data", "and", "information", "are", "submitted,", "the", "FDA", "may", "ultimately", "decide", "that", "the", "NDA", "does", "not", "satisfy", "its", "criteria", "for", "approval.", "<tag3>"], "wordsA": ["Even", "if", "such", "data", "and", "information", "are", "submitted,", "the", "FDA", "may", "ultimately", "decide", "that", "the", "NDA", "does", "not", "satisfy", "the", "criteria", "for", "approval."], "wordsB": ["Even", "if", "such", "additional", "data", "and", "information", "are", "submitted,", "the", "FDA", "may", "ultimately", "decide", "that", "the", "NDA", "does", "not", "satisfy", "its", "criteria", "for", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p61_s5", "idA": "908259_17_item1_p88_s5", "sentA": "Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data.", "sentB": "Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we or others may interpret the same data.", "type": 2, "words": ["<tag1>", "Data", "obtained", "from", "clinical", "trials", "are", "not", "always", "conclusive,", "and", "the", "FDA", "may", "interpret", "data", "differently", "than", "we", "interpret", "the", "same", "data.", "<tag2>", "Data", "obtained", "from", "clinical", "trials", "are", "not", "always", "conclusive,", "and", "the", "FDA", "may", "interpret", "data", "differently", "than", "we", "or", "others", "may", "interpret", "the", "same", "data.", "<tag3>"], "wordsA": ["Data", "obtained", "from", "clinical", "trials", "are", "not", "always", "conclusive,", "and", "the", "FDA", "may", "interpret", "data", "differently", "than", "we", "interpret", "the", "same", "data."], "wordsB": ["Data", "obtained", "from", "clinical", "trials", "are", "not", "always", "conclusive,", "and", "the", "FDA", "may", "interpret", "data", "differently", "than", "we", "or", "others", "may", "interpret", "the", "same", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p61_s6", "idA": "908259_17_item1_p88_s6", "sentA": "The FDA may issue a complete response letter, which may require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the NDA.", "sentB": "The FDA may issue a complete response letter, which may require additional clinical or other data or impose other conditions that must be met in order to obtain approval of the NDA.", "type": 2, "words": ["<tag1>", "The", "FDA", "may", "issue", "a", "complete", "response", "letter,", "which", "may", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA.", "<tag2>", "The", "FDA", "may", "issue", "a", "complete", "response", "letter,", "which", "may", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "obtain", "approval", "of", "the", "NDA.", "<tag3>"], "wordsA": ["The", "FDA", "may", "issue", "a", "complete", "response", "letter,", "which", "may", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "the", "NDA."], "wordsB": ["The", "FDA", "may", "issue", "a", "complete", "response", "letter,", "which", "may", "require", "additional", "clinical", "or", "other", "data", "or", "impose", "other", "conditions", "that", "must", "be", "met", "in", "order", "to", "obtain", "approval", "of", "the", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p63_s0", "idA": "908259_17_item1_p90_s0", "sentA": "Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured.", "sentB": "Before approving an NDA, the FDA will generally inspect the facility or facilities where the product is manufactured.", "type": 2, "words": ["<tag1>", "Before", "approving", "an", "NDA,", "the", "FDA", "will", "inspect", "the", "facility", "or", "facilities", "where", "the", "product", "is", "manufactured.", "<tag2>", "Before", "approving", "an", "NDA,", "the", "FDA", "will", "generally", "inspect", "the", "facility", "or", "facilities", "where", "the", "product", "is", "manufactured.", "<tag3>"], "wordsA": ["Before", "approving", "an", "NDA,", "the", "FDA", "will", "inspect", "the", "facility", "or", "facilities", "where", "the", "product", "is", "manufactured."], "wordsB": ["Before", "approving", "an", "NDA,", "the", "FDA", "will", "generally", "inspect", "the", "facility", "or", "facilities", "where", "the", "product", "is", "manufactured."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p63_s1", "idA": "908259_17_item1_p90_s1", "sentA": "The FDA will also inspect selected clinical sites that participated in the clinical studies and may inspect the testing facilities that performed the GLP toxicology studies cited in the NDA.", "sentB": "The FDA will also generally inspect selected clinical sites that participated in the clinical studies and may inspect the testing facilities that performed the GLP toxicology studies cited in the NDA.", "type": 2, "words": ["<tag1>", "The", "FDA", "will", "also", "inspect", "selected", "clinical", "sites", "that", "participated", "in", "the", "clinical", "studies", "and", "may", "inspect", "the", "testing", "facilities", "that", "performed", "the", "GLP", "toxicology", "studies", "cited", "in", "the", "NDA.", "<tag2>", "The", "FDA", "will", "also", "generally", "inspect", "selected", "clinical", "sites", "that", "participated", "in", "the", "clinical", "studies", "and", "may", "inspect", "the", "testing", "facilities", "that", "performed", "the", "GLP", "toxicology", "studies", "cited", "in", "the", "NDA.", "<tag3>"], "wordsA": ["The", "FDA", "will", "also", "inspect", "selected", "clinical", "sites", "that", "participated", "in", "the", "clinical", "studies", "and", "may", "inspect", "the", "testing", "facilities", "that", "performed", "the", "GLP", "toxicology", "studies", "cited", "in", "the", "NDA."], "wordsB": ["The", "FDA", "will", "also", "generally", "inspect", "selected", "clinical", "sites", "that", "participated", "in", "the", "clinical", "studies", "and", "may", "inspect", "the", "testing", "facilities", "that", "performed", "the", "GLP", "toxicology", "studies", "cited", "in", "the", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p64_s5", "idA": "908259_17_item1_p92_s0", "sentA": "If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product.", "sentB": "If a product receives regulatory approval, the approval may be limited to specific diseases or patient subpopulations and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product.", "type": 2, "words": ["<tag1>", "If", "a", "product", "receives", "regulatory", "approval,", "the", "approval", "may", "be", "significantly", "limited", "to", "specific", "diseases", "and", "dosages", "or", "the", "indications", "for", "use", "may", "otherwise", "be", "limited,", "which", "could", "restrict", "the", "commercial", "value", "of", "the", "product.", "<tag2>", "If", "a", "product", "receives", "regulatory", "approval,", "the", "approval", "may", "be", "limited", "to", "specific", "diseases", "or", "patient", "subpopulations", "and", "dosages", "or", "the", "indications", "for", "use", "may", "otherwise", "be", "limited,", "which", "could", "restrict", "the", "commercial", "value", "of", "the", "product.", "<tag3>"], "wordsA": ["If", "a", "product", "receives", "regulatory", "approval,", "the", "approval", "may", "be", "significantly", "limited", "to", "specific", "diseases", "and", "dosages", "or", "the", "indications", "for", "use", "may", "otherwise", "be", "limited,", "which", "could", "restrict", "the", "commercial", "value", "of", "the", "product."], "wordsB": ["If", "a", "product", "receives", "regulatory", "approval,", "the", "approval", "may", "be", "limited", "to", "specific", "diseases", "or", "patient", "subpopulations", "and", "dosages", "or", "the", "indications", "for", "use", "may", "otherwise", "be", "limited,", "which", "could", "restrict", "the", "commercial", "value", "of", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p64_s6", "idA": "908259_17_item1_p92_s1", "sentA": "In addition, the FDA may require us to conduct phase 4 testing, which involves clinical trials designed to further assess a drug s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized.", "sentB": "In addition, approval by the FDA may include a requirement for phase 4 testing, which involves clinical trials designed to further assess a drug s safety and effectiveness, and the FDA may require testing and surveillance programs to monitor the safety of approved products which have been commercialized.", "type": 2, "words": ["<tag1>", "In", "addition,", "the", "FDA", "may", "require", "us", "to", "conduct", "phase", "4", "testing,", "which", "involves", "clinical", "trials", "designed", "to", "further", "assess", "a", "drug", "s", "safety", "and", "effectiveness", "after", "NDA", "approval,", "and", "may", "require", "testing", "and", "surveillance", "programs", "to", "monitor", "the", "safety", "of", "approved", "products", "which", "have", "been", "commercialized.", "<tag2>", "In", "addition,", "approval", "by", "the", "FDA", "may", "include", "a", "requirement", "for", "phase", "4", "testing,", "which", "involves", "clinical", "trials", "designed", "to", "further", "assess", "a", "drug", "s", "safety", "and", "effectiveness,", "and", "the", "FDA", "may", "require", "testing", "and", "surveillance", "programs", "to", "monitor", "the", "safety", "of", "approved", "products", "which", "have", "been", "commercialized.", "<tag3>"], "wordsA": ["In", "addition,", "the", "FDA", "may", "require", "us", "to", "conduct", "phase", "4", "testing,", "which", "involves", "clinical", "trials", "designed", "to", "further", "assess", "a", "drug", "s", "safety", "and", "effectiveness", "after", "NDA", "approval,", "and", "may", "require", "testing", "and", "surveillance", "programs", "to", "monitor", "the", "safety", "of", "approved", "products", "which", "have", "been", "commercialized."], "wordsB": ["In", "addition,", "approval", "by", "the", "FDA", "may", "include", "a", "requirement", "for", "phase", "4", "testing,", "which", "involves", "clinical", "trials", "designed", "to", "further", "assess", "a", "drug", "s", "safety", "and", "effectiveness,", "and", "the", "FDA", "may", "require", "testing", "and", "surveillance", "programs", "to", "monitor", "the", "safety", "of", "approved", "products", "which", "have", "been", "commercialized."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p65_s0", "idA": "908259_17_item1_p94_s0", "sentA": "therapeutic agent and its potential orphan use are disclosed publicly by the FDA.", "sentB": "After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.", "type": 2, "words": ["<tag1>", "therapeutic", "agent", "and", "its", "potential", "orphan", "use", "are", "disclosed", "publicly", "by", "the", "FDA.", "<tag2>", "After", "the", "FDA", "grants", "orphan", "drug", "designation,", "the", "identity", "of", "the", "therapeutic", "agent", "and", "its", "potential", "orphan", "use", "are", "disclosed", "publicly", "by", "the", "FDA.", "<tag3>"], "wordsA": ["therapeutic", "agent", "and", "its", "potential", "orphan", "use", "are", "disclosed", "publicly", "by", "the", "FDA."], "wordsB": ["After", "the", "FDA", "grants", "orphan", "drug", "designation,", "the", "identity", "of", "the", "therapeutic", "agent", "and", "its", "potential", "orphan", "use", "are", "disclosed", "publicly", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p65_s3", "idA": "908259_17_item1_p95_s0", "sentA": "In the European Union and Japan, orphan drug exclusivity regulations provide for 10 years of marketing exclusivity for orphan drugs that are approved for the treatment of rare diseases or conditions.", "sentB": "In the European Union and Japan, orphan drug exclusivity regulations provide for 10 years of market exclusivity.", "type": 2, "words": ["<tag1>", "In", "the", "European", "Union", "and", "Japan,", "orphan", "drug", "exclusivity", "regulations", "provide", "for", "10", "years", "of", "marketing", "exclusivity", "for", "orphan", "drugs", "that", "are", "approved", "for", "the", "treatment", "of", "rare", "diseases", "or", "conditions.", "<tag2>", "In", "the", "European", "Union", "and", "Japan,", "orphan", "drug", "exclusivity", "regulations", "provide", "for", "10", "years", "of", "market", "exclusivity.", "<tag3>"], "wordsA": ["In", "the", "European", "Union", "and", "Japan,", "orphan", "drug", "exclusivity", "regulations", "provide", "for", "10", "years", "of", "marketing", "exclusivity", "for", "orphan", "drugs", "that", "are", "approved", "for", "the", "treatment", "of", "rare", "diseases", "or", "conditions."], "wordsB": ["In", "the", "European", "Union", "and", "Japan,", "orphan", "drug", "exclusivity", "regulations", "provide", "for", "10", "years", "of", "market", "exclusivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p14_s1", "idA": "908259_17_item1_p95_s2", "sentA": "OXi4503 has been awarded orphan drug status by the FDA for the treatment of acute myelogenous leukemia.", "sentB": "OXi4503 has also been demonstrated to be cytotoxic itself and kill leukemic cells directly after it has been metabolized by enzymes located within leukemic cells.", "type": 2, "words": ["<tag1>", "OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag2>", "OXi4503", "has", "also", "been", "demonstrated", "to", "be", "cytotoxic", "itself", "and", "kill", "leukemic", "cells", "directly", "after", "it", "has", "been", "metabolized", "by", "enzymes", "located", "within", "leukemic", "cells.", "<tag3>"], "wordsA": ["OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "wordsB": ["OXi4503", "has", "also", "been", "demonstrated", "to", "be", "cytotoxic", "itself", "and", "kill", "leukemic", "cells", "directly", "after", "it", "has", "been", "metabolized", "by", "enzymes", "located", "within", "leukemic", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p70_s0", "idA": "908259_17_item1_p99_s0", "sentA": "CA4P has been awarded Fast Track designation for the treatment of platinum-resistant ovarian cancer.", "sentB": "OXi4503 has been awarded Fast Track designation for the treatment of AML.", "type": 2, "words": ["<tag1>", "CA4P", "has", "been", "awarded", "Fast", "Track", "designation", "for", "the", "treatment", "of", "platinum-resistant", "ovarian", "cancer.", "<tag2>", "OXi4503", "has", "been", "awarded", "Fast", "Track", "designation", "for", "the", "treatment", "of", "AML.", "<tag3>"], "wordsA": ["CA4P", "has", "been", "awarded", "Fast", "Track", "designation", "for", "the", "treatment", "of", "platinum-resistant", "ovarian", "cancer."], "wordsB": ["OXi4503", "has", "been", "awarded", "Fast", "Track", "designation", "for", "the", "treatment", "of", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
